Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT04913857	Effects of SUDOKU Mind Activation & Revitalizing Training on Cognitive Function in People With Mild Cognitive Impairment	SMART	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: 24-week SUDOKU Training Programme|Other: Control Arm (wait-list)	Cantonese version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)|The digit span-forward and backward test|The list learning delayed recall test|Trail-Making Test Part A and B|Memory Inventory for Chinese|The 36-item Chinese version of the Short Form 36 (SF-36)	The University of Hong Kong	All	55 Years and older   (Adult, Older Adult)	Not Applicable	288	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	SMART	January 15, 2020	December 31, 2021	March 31, 2022	June 4, 2021		June 4, 2021	School of Nursing, LKS Faculty of Medicine, Hong Kong, Hong Kong	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/57/NCT04913857/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04913857
2	NCT03906903	Transcranial Magnetic Stimulation and Cognitive Stimulation in Mild Cognitive Impairment	rTMS&MCI	Unknown status	No Results Available	Mild Cognitive Impairment	Device: Repetitive Transcranial Magnetic Stimulation|Behavioral: Cognitive Stimulation	Montreal Cognitive Assessment (MoCA)|Mini Mental State Examination (MMSE)|Attention and Memory Neuropsychological Battery (NEUROPSI)|Changes in Depressive symptoms evaluated by Geriatric Depression Scale (GDS - Yesavage - Brink)|Changes in impulsive behavior evaluated by Barratt Impulsivity Scale (BIS-11)	Universidad Autonoma de Queretaro	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	05-01/02/2018	March 5, 2018	March 30, 2019	August 30, 2019	April 8, 2019		April 16, 2019	Autonomous University of Queretaro, Querétaro City, Querétaro, Mexico		https://ClinicalTrials.gov/show/NCT03906903
3	NCT05515952	Interleaved TMS-fMRI for Hippocampal Stimulation: Modeling Dose-Response Relationship in Amnestic Mild Cognitive Impairment	TMS-fMRI	Not yet recruiting	No Results Available	Mild Cognitive Impairment	Device: Transcranial Magnetic Stimulation|Device: Transcranial Magnetic Stimulation (Low Intensity)	Brain imaging data|Correction rate in memory association recall	University of Arizona|National Institute on Aging (NIA)	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	38	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	R21AG077153	September 2022	March 2024	March 31, 2024	August 25, 2022		August 25, 2022	Bioscience Research Laboratory, Tucson, Arizona, United States		https://ClinicalTrials.gov/show/NCT05515952
4	NCT05041790	A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Drug: Choline Alfoscerate|Drug: Placebo	The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baseline|The proportion of subjects reduced by more than or equal to 0 points for modified ADAS-Cog score at 24 weeks compared to baseline|The proportion of subjects reduced by more than 2 points of modified ADAS-Cog score at 24 to 48 weeks compared to baseline|The proportion of subjects reduced by more than 4 points of modified ADAS-Cog score at 24 to 48 weeks compared to baseline|The change of Modified ADAS-Cog score at 24 to 48 weeks compared to baseline|The proportion of subjects increased by more than or equal to 0 point of K-MMSE-2 score at 24 and 48 weeks compared to baseline|The change of K-MMSE-2 score at 24 to 48 weeks compared to baseline|The change of CDR-SB score at 48 weeks compared to baseline	Chong Kun Dang Pharmaceutical|Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)	All	55 Years and older   (Adult, Older Adult)	Phase 4	418	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	B78_02MCI2003	September 30, 2021	November 30, 2024	November 30, 2024	September 13, 2021		September 20, 2021	Asan Medical Center Institutional Review Board, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05041790
5	NCT05336942	Correlation Between Prognosis of Mild Cognitive Impairment and Hearing Function in Community Elderly		Completed	No Results Available	Mild Cognitive Impairment		Mini-mental state examination (MMSE)|Montreal Cognitive Assessment (MocA)|Pure tone Listening Test (PTA)|Clinical Dementia Rating (CDR)|Auditory brainstem response (ABR)	Tongji University	All	55 Years to 65 Years   (Adult, Older Adult)		90	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	PKJ2019-Y24	November 1, 2020	December 30, 2021	March 30, 2022	April 20, 2022		April 20, 2022	Tongji University, Shanghai, China		https://ClinicalTrials.gov/show/NCT05336942
6	NCT03974087	The Effect of Transcranial Direct Current Stimulation on Visual Attention in Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Device: Transcranial Direct Current Stimulation (tDCS)	Visual-attention task accuracy|Psychological assessment - z-score computed from multiple psychological domains|Magnetic resonance imaging	Masaryk University|St. Anne's University Hospital Brno, Czech Republic	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	NV18-04-00256	February 19, 2020	April 30, 2022	July 30, 2022	June 4, 2019		April 6, 2022	Ceitec, Masaryk University, Brno, Czechia		https://ClinicalTrials.gov/show/NCT03974087
7	NCT03167840	Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment	FallsPACT	Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Physical and Cognitive Training|Behavioral: Physical Training|Behavioral: Cognitive training	Falls Rate|Change in Physiologic Profile Assessment (PPA) score|Change in Falls Risks for Older People in the Community (FROP-Com) Screen score|Change in Global Cognitive Function|Change in Memory Function|Change in Executive Function|Change in Balance|Change in Gait Speed|Change in Muscle Strength	The Hong Kong Polytechnic University|University of Santo Tomas Hospital, Philippines	All	60 Years and older   (Adult, Older Adult)	Not Applicable	95	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	HSEARS20170402001	September 6, 2017	January 31, 2018	August 31, 2018	May 30, 2017		April 27, 2018	University of Santo Tomas, Manila, Metro Manila, Philippines		https://ClinicalTrials.gov/show/NCT03167840
8	NCT03405857	Effects of the Cognitive Enhancing ICT Contents in Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Other: Cognitive rehabilitation program	Change from baseline performance on Digit Span Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Span Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Continuous Performance Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Auditory Continuous Performance Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Trail Making Test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Stroop test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Visual Recognition test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline performance on Auditory Verbal Learning test (Neuropsychological test) at 4 weeks and 8 weeks|Change from baseline score on Korean Version of Geriatric Depression Test Short Form (Depression scale) at 4 weeks and 8 weeks|Change from baseline activity on functional Near-Infrared Spectroscopy (fNIRS) at 4 weeks and 8 weeks	Samsung Medical Center	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2016-01-013-010	May 25, 2016	January 25, 2018	April 7, 2018	January 23, 2018		August 2, 2018	Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03405857
9	NCT02388451	The Benefits of the Use of the Feuerstein Cognitive Training Method on Cognitive Function in Community-dwelling Older Patients With Mild Cognitive Impairment: a Pilot Study		Completed	No Results Available	Mild Cognitive Impairment	Device: Feuerstein Program	Mindstreams Mild Cognitive Impairment Computerized Assessment Battery	Meir Medical Center	All	65 Years and older   (Older Adult)	Not Applicable	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	001	December 2015	July 2017	August 2018	March 17, 2015		January 23, 2019	Yan Press, Beer-Sheva, Israel		https://ClinicalTrials.gov/show/NCT02388451
10	NCT03441152	The Effects of Transcranial Direct Current Stimulation in Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Device: tDCS	Montreal Cognitive Assessment (MoCA)|Digit Span Test|Trial Making Test (TMT)|Riverhead Behavioral Memory Test (3rd edition) (RBMT-3)	The Hong Kong Polytechnic University	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	66	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	HongKongPUPabloRS	July 1, 2017	August 2018	August 2018	February 22, 2018		February 22, 2018	The Hong Kong Polytechnic University, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT03441152
11	NCT04435509	Management of Mild Cognitive Impairment Patients With Greek Mountain Tea - TEAMENTIA	TEAMENTIA	Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: 1000+ Greek Mountain Tea|Other: Mediterranean Diet	Neuropsychological Assessment- Measurements to Assess General Cognitive Function|FUCAS-Measurements to Assess Daily Functionality|Letter & Category Fluency Test- Measurement to Assess Verbal Fluency and Learning|CDR- Measurements to Assess General Cognitive Function|MoCA- Measurements to Assess General Cognitive Function|CANTAB- Measurements to Assess General Cognitive Function|Clock Drawing test- Measurements to Assess General Cognitive Function|Logical Memory test- Measurements to Assess General Cognitive Function|Digit Span Forward & Backward test- Measurements to Assess General Cognitive Function|WAIS-R Digit Symbol- Measurements to Assess General Cognitive Function|TMT part A and B- Measurements to Assess General Cognitive Function|ADASCog-Measurements to Assess Daily Functionality|Functional Rating Scale for Dementia-Measurements to Assess Daily Functionality|Auditory Verbal Learning Test- Measurement to Assess Verbal Fluency and Learning|Boston Naming Test- Measurement to Assess Verbal Fluency and Learning|NeuroImaging|CSF - beta amyloid|CSF TAU-protein|Electroencephalography recording	Aristotle University Of Thessaloniki	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	31c/17-05-17	November 17, 2019	September 30, 2020	May 30, 2021	June 17, 2020		June 17, 2020	Greek Alzheimer's Association and Related Disorders, Thessaloníki, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT04435509
12	NCT04515875	PRIMA Intervention for Adults With Mild Cognitive Impairment and Their Caregivers	PRIMA	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Daily Engagement Meaningful Activity (DEMA)|Behavioral: Information Support (IS)	Life satisfaction|Patient Health Questionnaire-9 Items (PHQ-9)|The General Anxiety Disorder 7-item (GAD-7)|Alzheimer Disease Cooperative Study MCI-Activities of Daily Living Inventory [ADCS-MCI-ADL Scale]|Relationship Assessment Scale (RAS)|Caregiving Outcomes Scale (COS)	Indiana University|National Institute of Nursing Research (NINR)	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	400	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care	IUPREMA0822|1R01NR018162-01A1	December 13, 2021	December 31, 2024	June 30, 2025	August 17, 2020		February 28, 2022	Indiana University Alzhemier Disease Research Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT04515875
13	NCT03938051	Multi-component Exercise on Mild Cognitive Impairment In Elderly Population		Completed	No Results Available	Mild Cognitive Impairment	Other: Experimental group|Other: Control group	Mini mental state examination (MMSE)|Trail making test (TMT) A & B|Montreal cognitive assessment (MoCA)	Riphah International University	All	55 Years and older   (Adult, Older Adult)	Not Applicable	51	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	RiphahIU Hafsah Gul Khattak	January 15, 2019	June 30, 2019	July 12, 2019	May 6, 2019		September 6, 2019	Riphah International University, Islamabad, Federal, Pakistan		https://ClinicalTrials.gov/show/NCT03938051
14	NCT01552265	Shanghai Mild Cognitive Impairment Cohort Study		Completed	No Results Available	Mild Cognitive Impairment		Time to Conversion from MCI to "Probable AD Dementia"|Time to Conversion from MCI to "Possible AD Dementia" or "Probable AD Dementia"|Time to Conversion from MCI to "All-cause Dementia"|Overall survival|Changes in Neuropsychological examinations|Changes in MRI	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Fudan University	All	up to 90 Years   (Child, Adult, Older Adult)		400	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	TRIAD1109	February 2012	February 2017	July 31, 2017	March 13, 2012		April 25, 2018	Department of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT01552265
15	NCT04943003	Study of Neurobiological Predictors of Response to Non-invasive Neurostimulation and Genetic Susceptibility to Dementia in Patients With Amnestic Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Device: Transcranial Direct Current Stimulation (tDCS)	Mini Mental State Examination (MMSE) (T0)|Mini Mental State Examination (MMSE) (T1)|Digit Span Memory Test|Beck Depression Scale II and Beck Anxiety Inventory|Genetic susceptibility (ApoE)|Electroencephalography|Electroencephalography (EEG)|Magnetic Resonance Imaging-MRI	Suellen Marinho Andrade|Federal University of Paraíba	All	65 Years to 85 Years   (Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	tDCS in MCI	August 26, 2021	December 25, 2022	December 25, 2024	June 29, 2021		July 27, 2021	Federal University of Paraíba,Department of Psychology, João Pessoa, Paraíba, Brazil		https://ClinicalTrials.gov/show/NCT04943003
16	NCT01448148	Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Other: Cognitive intervention|Other: Psychosocial intervention	Change in memory measures|generalization of therapeutic gains to everyday life|Change in psychological health measures	Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Laval University	All	55 Years and older   (Adult, Older Adult)	Not Applicable	145	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CRIUGM-002	November 2011	January 2016	January 2016	October 7, 2011		January 27, 2016	Centre de recherche de l'Institut universitaire de geriatrie de Montreal, Montreal, Quebec, Canada|Centre hospitalier Robert-Giffard, Quebec, Canada		https://ClinicalTrials.gov/show/NCT01448148
17	NCT01812213	Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)	NAV4-04	Unknown status	No Results Available	Mild Cognitive Impairment	Drug: [18F]NAV4694	Incidence of Mild Cognitive Impairment Progression to Alzheimer's Disease|Incidence of [18F]NAV4694 PET Positive scans at 18 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 6 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 12 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 18 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 24 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 30 months compared to baseline|Change in Neuro-cognitive Test Battery Scores at 36 months compared to baseline|Change in SUVR scores at 18 months compared to baseline|Incidence of Adverse Events post baseline	Navidea Biopharmaceuticals	All	55 Years to 99 Years   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NAV4-04	March 2013	June 2018	August 2018	March 18, 2013		July 26, 2017	Banner Sun Health Research Institute, Sun City, Arizona, United States|Galiz Research, Hialeah, Florida, United States|Mt. Sinai Wien Center for Alzheimer's Disease, Miami Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|SIU School of Medicine, Springfield, Illinois, United States|McLean Hospital, Belmont, Massachusetts, United States|Qunicy Medical Center, Alzheimer's Disease Center, Quincy, Massachusetts, United States|Neurological Associates of Albany, Albany, New York, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01812213
18	NCT04515563	Effectiveness of Walking Exercise in Improving Cognitive Function in Older Adults With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Stretching exercise|Behavioral: Low-frequency, moderate-intensity walking group|Behavioral: High-frequency, moderate-intensity walking group|Behavioral: Low-frequency, vigorous-intensity walking group|Behavioral: High-frequency, vigorous-intensity walking group	Global cognition-Hong Kong Montreal Cognitive Assessment (HK-MoCA) score|Objective cognitive score|Working memory-Digit Span test|Working memory-Verbal Fluency Test|Executive function-Stroop test|Executive function-Trail Making test|Subjective cognitive report|Remission rate-Chinese Abbreviated Mild Cognitive Impairment Test (CAMCI)|Remission rate-Hong Kong Montreal Cognitive Assessment (HK-MoCA)|VO2max|Body fat mass|Lean mass|Bone mineral density|Habitual sleep|Quality of Life-12-item Short Form Survey (SF-12)|Depression level|Mental health|Anxiety level|Physical activity|Balance performance	The University of Hong Kong	All	50 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	RF-3030059835-007	March 1, 2020	September 1, 2021	September 1, 2021	August 17, 2020		November 11, 2021	Li Kai Shing Faculty of Medicine, Hong Kong, Southern District, Hong Kong		https://ClinicalTrials.gov/show/NCT04515563
19	NCT05029765	Effect of Mediterranean Diet and Probiotics in Adults With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Mediterranean diet|Dietary Supplement: Healthy diet (WHO recommendations)|Dietary Supplement: Placebo|Dietary Supplement: Biopolis-MIX42	Cognitive change|Microbiota pattern|Endotoxemia levels|Change in inflammatory marker|Change in oxidative stress parameters|Neurofunctional change|Modulation of Microbiota-gut-nervous system|Change in cytokine levels|Neuropeptides modulation	Pablo Pérez Martínez|Maimónides Biomedical Research Institute of Córdoba	All	60 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	PI16/01777	January 26, 2017	March 5, 2020	March 5, 2020	September 1, 2021		September 1, 2021	Reina Sofia University Hospital, Cordoba, Spain		https://ClinicalTrials.gov/show/NCT05029765
20	NCT04959383	Exergame Balance Training for Patients With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Other: Low complexity Exergaming group|Other: Moderate complexity Exergaming group|Other: High complexity Exergaming group|Other: Control Group	Stroop test|Trails Test|Digit Span Forward and Backward|Montreal Cognitive Assessment|Alzheimer's disease Assessment Scale|Time Up and Go Test|Mini Brief Balance Evaluation Systems|Smartphone Gait and Balance Application|Force Plate|Gait Speed Assessment|Electroencephalography|Blood Biomarkers|Voice Recording	Riphah International University	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	REC/1954 Aruba Saeed	September 23, 2021	December 30, 2022	December 30, 2022	July 13, 2021		September 30, 2021	Railway General Hospital, Rawalpindi, Pakistan		https://ClinicalTrials.gov/show/NCT04959383
21	NCT03619577	The Effectiveness of Combining Physical Exercise and Cognitive Training for Individuals With Mild Cognitive Impairment		Enrolling by invitation	No Results Available	Mild Cognitive Impairment	Behavioral: Sequential training	Change scores of the Montreal Cognitive Assessment (MoCA)|Change scores of the Stroop test|Change scores of the Dual-task test|Change scores of the Timed up and go (TUG) test|Change scores of the Wechsler Memory Scale (WMS)|Change scores of the Lawton Instrumental Activities of Daily Living Scale (IADL)|Change scores of the Wechsler Adult Intelligence Scale (WAIS)|Change scores of Memory complaint questionnaire|Change scores of Spatial Span Test|Change scores of the short form of the Geriatric Depression Scale (GDS-SF)|Change scores of the Community Integration Questionnaire (CIQ)|Change scores of the Everyday Cognition scales (ECog)-12 items	Chang Gung Memorial Hospital	All	55 Years to 95 Years   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	201711EM006	January 30, 2018	June 2022	June 2022	August 8, 2018		May 17, 2021	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT03619577
22	NCT03362996	Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil - MICOIL	MICOIL	Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil|Combination Product: extra virgin olive oil|Other: mediterranean diet	Neuropsychological Assessment- Measurements to Assess General Cognitive Function|FUCAS-Measurements to Assess Daily Functionality|Letter & Category Fluency Test- Measurement to Assess Verbal Fluency and Learning|CDR- Measurements to Assess General Cognitive Function|MoCA- Measurements to Assess General Cognitive Function|CANTAB- Measurements to Assess General Cognitive Function|Clock Drawing test- Measurements to Assess General Cognitive Function|Logical Memory test- Measurements to Assess General Cognitive Function|Digit Span Forward & Backward test- Measurements to Assess General Cognitive Function|WAIS-R Digit Symbol- Measurements to Assess General Cognitive Function|TMT part A and B- Measurements to Assess General Cognitive Function|ADASCog-Measurements to Assess Daily Functionality|Functional Rating Scale for Dementia-Measurements to Assess Daily Functionality|Auditory Verbal Learning Test- Measurement to Assess Verbal Fluency and Learning|Boston Naming Test- Measurement to Assess Verbal Fluency and Learning|NeuroImaging|CSF - beta amyloid|CSF TAU-protein|Neurophysiology and ERPs|Electroencephalography recording	Greek Alzheimer's Association and Related Disorders	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	25/201614	November 9, 2016	February 15, 2018	May 15, 2019	December 5, 2017		January 8, 2018	Greek Association of Alzheimer's Disease and Related Disordeers, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT03362996
23	NCT04436614	Management of Mild Cognitive Impairment Patients With Aloe and Crocus - BALSAM	BALSAM	Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement: Dietary Supplement:Aloe Vera (simple)|Dietary Supplement: Dietary Supplement:Mediterranean Diet	Neuropsychological Assessment- Measurements to Assess General Cognitive Function.|FUCAS-Measurements to Assess Daily Functionality|Letter & Category Fluency Test- Measurement to Assess Verbal Fluency and Learning|CDR- Measurements to Assess General Cognitive Function|MoCA- Measurements to Assess General Cognitive Function|Clock Drawing test- Measurements to Assess General Cognitive Function|Logical Memory test- Measurements to Assess General Cognitive Function|Digit Span Forward & Backward test- Measurements to Assess General Cognitive Function|WAIS-R Digit Symbol- Measurements to Assess General Cognitive Function|TMT part A and B- Measurements to Assess General Cognitive Function|ADASCog-Measurements to Assess Daily Functionality|Functional Rating Scale for Dementia-Measurements to Assess Daily Functionality|Auditory Verbal Learning Test- Measurement to Assess Verbal Fluency and Learning|NeuroImaging|CSF - beta amyloid|CSF TAU-protein|Electroencephalography recording	Aristotle University Of Thessaloniki	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	31b/17-05-17	December 17, 2017	May 30, 2018	October 30, 2019	June 18, 2020		June 22, 2020	Greek Alzheimer's Association and Related Disorders, Thessaloníki, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT04436614
24	NCT01146717	Aerobic Exercise Training in Mild Cognitive Impairment Study	AETMCI	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Exercise|Behavioral: Balance training	Cognitive function|Cerebrovascular function|Brain tissue volume and white matter integrity	University of Texas Southwestern Medical Center|National Institute on Aging (NIA)	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	032009-065|R01AG033106-01A2	March 2010	September 2016	September 2016	June 17, 2010		February 7, 2020	UT Southwestern ADC/Institute for Exercise and Environmental Medicine, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT01146717
25	NCT03359902	Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation	TVNS MCI	Recruiting	No Results Available	Mild Cognitive Impairment	Device: Transcutaneous vagal nerve stimulation|Device: Sham stimulation	Rey AVLT	University of Florida|Department of Health and Human Services|National Institute on Aging (NIA)	All	60 Years to 89 Years   (Adult, Older Adult)	Not Applicable	250	Other|U.S. Fed|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	IRB201600730 -N-A|R21AG054876	January 1, 2018	May 31, 2022	May 31, 2022	December 2, 2017		August 2, 2021	HealthStreet, Gainesville, Florida, United States|Malcom Randall VA Medical Center, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States		https://ClinicalTrials.gov/show/NCT03359902
26	NCT01927653	Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment		differentiation of MCI using diffusion MRI|Prognosis value of diffusion MRI	Chang Gung Memorial Hospital	All	55 Years to 70 Years   (Adult, Older Adult)		108	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	98-3628B	January 2011	December 2016	February 2017	August 22, 2013		July 18, 2018	ChangGung Memorial Hospital, Linkou, Tao Yuan, Taiwan		https://ClinicalTrials.gov/show/NCT01927653
27	NCT03225482	Cognitive Rehabilitation Therapy for Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Motivationally Enhanced Compensatory Cognitive Training|Behavioral: Goal-focused Supportive Contact	Change in Objective cognitive performance composite z score|Change in Functional capacity performance composite z score|Change in Subjective Everyday Functioning Composite Score (Average total score across Applied Cognition Executive Function and Applied Cognition General Concerns scales)|Change in Everyday Cognition Scale|Change in Cognitive Activity Inventory|Change in CHAMPS Physical Activity Questionnaire for Older Adults|Change in Portland Cognitive Strategies Scale|Change in Fitbit-measured physical activity level|Change in Fitbit-measured sleep efficiency	VA Office of Research and Development|Portland VA Medical Center	All	55 Years and older   (Adult, Older Adult)	Not Applicable	216	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NURD-019-16F|I01CX001592	July 11, 2018	March 31, 2023	December 30, 2023	July 21, 2017		January 20, 2022	VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT03225482
28	NCT00934375	A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment	Drug: Aricept (donepezil hydrochloride)|Drug: placebo	Number of Participants With Treatment-Emergent Adverse Events	Eisai Inc.	All	45 Years to 90 Years   (Adult, Older Adult)	Phase 4	145	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E2020-A001-414	February 2006	September 2007	September 2007	July 8, 2009	July 8, 2009	January 14, 2014	Neurology Neurodiagnostic Lab, LLC, Alabaster, Alabama, United States|Pivotal Research Centers, Peoria, Arizona, United States|Sun Health Research Institute, Sun City, Arizona, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, United States|The Neurology Center, Encinitas, California, United States|Margolin Brain Institute, Fresno, California, United States|Colaborative Neuroscience Network (CNS Network), Garden Grove, California, United States|Nerve Pro Research, Irvine, California, United States|Optimum Health Services, La Mesa, California, United States|Pacific Research Network, San Diego, California, United States|Neurological Research Institute, Santa Monica, California, United States|CA Neuroscience Research, Sherman Oaks, California, United States|Pacific Research Network, Vista, California, United States|Yale University Alzheimers Disease Research Unit School of Medicine Department of Psychiatry, New Haven, Connecticut, United States|North Broward Medical Center Memory Disorder Center, Deerfield Beach, Florida, United States|Neurologic Consultants, Ft. Lauderdale, Florida, United States|Berma Research Group, Hialeah, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Wien Center for Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida, United States|Berma Research Group, Plantation, Florida, United States|The Roskamp Institute, Sarasota, Florida, United States|Comprehensive Neuroscience, Inc., St. Petersburg, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|USF Memory Disorder's Clinic, Tampa, Florida, United States|USF Suncoast Gerontalogy Center, Tampa, Florida, United States|Center for Clinical Trials. L.C., Venice, Florida, United States|Palm Beach Neurology, West Palm Beach, Florida, United States|Lexington Clinic, Lexington, Kentucky, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|St. Louis University - Clinical Trials Unit, St. Louis, Missouri, United States|Comprehensive Neuroscience, Inc, Kenilworth, New Jersey, United States|Neurological Associates of Albany, PC Neurology, Albany, New York, United States|Neurobehavioral Research Inc., Lawrence, New York, United States|New York University School of Medicine Aging and Dementia Research Center, New York, New York, United States|Columbia University, New York, New York, United States|Monroe Community Hospital Program in Neurobehavioral Therapeutics, Rochester, New York, United States|Behavioral Medical Research of Staten Island, Staten Island, New York, United States|The Ohio State University, Columbus, Ohio, United States|Neurology Center of Ohio, Toledo, Ohio, United States|Pahl Pharmaceutical Research, LLC, Oklahoma City, Oklahoma, United States|Summit Research Network(Oregon) Inc., Portland, Oregon, United States|Clinical Trial Specialists, Bala Cynwyd, Pennsylvania, United States|Westmoreland Neurology Associates, Greensburg, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Medical University of South Carolina-Alzheimer's Research, Charleston, South Carolina, United States|The University of Texas Mental Sciences Instittute, Houston, Texas, United States|START Center, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Southwestern Vermont Medical Center - The Memory Clinc, Bennington, Vermont, United States		https://ClinicalTrials.gov/show/NCT00934375
29	NCT05022186	The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Drug: Cannabidiol Oil|Drug: Homotaurine	Changes in Mini Mental State Examination (MMSE) score|Changes in Montreal Cognitive Assessment (MoCA) score|Changes in Functional Cognitive Assessment (FUCAS) score|Changes in Letter & Category Verbal Fluency|Changes in Clinical Dementia Rating Scale score|Changes in ADAS-COG|Changes in Rey Auditory Verbal Learning Test|Changes in Rey Osterrieth Complex Figure|Changes in Functional Rating Scale for Dementia|Changes in Trail Making Test A & B|Changes in Geriatric Depression Scale|Changes in SAST|Changes in Beck Anxiety Inventory|Changes in Rivermead Behavioural Memory Test|Changes in STROOP Test|Changes in Symbol-Digit Test|Changes in BDNF|Changes in MDA|Changes in GFAP|Changes in Tau-protein	Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders	All	65 Years to 85 Years   (Older Adult)	Phase 4	90	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	65/06-02-2021	April 1, 2021	December 20, 2022	December 20, 2022	August 26, 2021		August 26, 2021	Greek Association of Alzheimer's Disease and Related Disorders, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT05022186
30	NCT02512627	Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Cognitive training|Behavioral: Physical exercise	Change scores of Montreal Cognitive Assessment (MoCA)|Change scores of Stroop test|Change scores of Dual-task test|Change scores of Timed up and go (TUG) test|Change scores of the Verbal Fluency Test|Change scores of the Useful Field of View (UFOV)|Change scores of the 30 second chair stand test (CST)|Change scores of the Chinese version of the International Physical Activity Questionnaires (IPAQ)|Change scores of the Barthel Index (BI)|Change scores of the Lawton Instrumental Activities of Daily Living Scale|Change scores of the Disability Assessment for Dementia (DAD)|Change scores of the Quality of Life in Alzheimer's Disease Instrument (QoLAD)|Change scores of the Caregiver Burden Inventory (CBI)|Change scores of the Geriatric Depression Scale (GDS)|Change scores of the Community Integration Questionnaire (CIQ)|Change scores of the ActiGraph GX3 accelerometers Change scores of the ActiGraph|Change scores of evaluating isometric knee flexors and extensors muscle strength|Change scores of using hand dynamometer to measure grip strength of both hand|Change scores of Wechsler Memory Scale - Third Edition (WMS-III)|Change scores of Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)|BDNF val66met genotype	Chang Gung Memorial Hospital	All	20 Years and older   (Adult, Older Adult)	Not Applicable	55	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	103-6651A3	January 30, 2015	January 29, 2018	March 13, 2019	July 31, 2015		July 12, 2019	Baliexcelsior Nursing Home, New Taipei City, Taiwan|Pine nursing home, Taichung, Taiwan|Zhishan community home, Taipei, Taiwan|Bailing clinics and nursing homes, Taipei, Taiwan|Shihlin cum day care center, Taipei, Taiwan|Xihu day care center, Taipei, Taiwan|TaoSheng Nursing home, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan|Chang Gung Memorial Hospital Taoyuan Branch, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02512627
31	NCT03493178	Glutathione in Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Glycine|Dietary Supplement: N-acetylcysteine (NAC)|Dietary Supplement: Alanine	Cognition|Concentrations of Glutathione, cysteine, glycine, glutamic acid|Concentrations of malondialdehyde, F2,F3 isoprostanes|Endothelial function markers sICAM, sVCAM, E-selectin|Endothelial function|Mitochondrial fuel oxidation in fasted and fed states	Baylor College of Medicine|The Methodist Hospital Research Institute	All	55 Years to 85 Years   (Adult, Older Adult)	Early Phase 1	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other	H42035: Glutathione in MCI	April 14, 2018	May 31, 2023	December 31, 2023	April 10, 2018		February 11, 2022	Baylor College of Medicine, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03493178
32	NCT01843283	Meaningful Activity Intervention for Persons With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Daily Enhancement Meaningful Activity (DEMA)|Behavioral: Information Support (IS)	Patient_Depression symptoms: Patient Health Questionnaire Depression Scale (PHQ-9)|Patient_satisfaction with communication: The subscale of Communication and Affective Responsiveness|Patient_Physical Function: Alzheimer disease cooperative study activities of daily living inventory.|Patient_Life satisfaction : Life Satisfaction Index for the Third Age-Short Form|Patient_Satisfaction with program: Satisfaction with Meaningful Activity Program Scale is adapted from the Caregiver Satisfaction Scale|Patient_ Meaningful activities engagement performance and satisfaction: Canadian Occupational Performance Measure & weekly log|Patient_Sense of confidence: Confidence Scale|Caregiver_Depressive Symptoms: PHQ-9|Caregiver_ Caregiver life changes: Caregiving Outcomes Scale|Caregiver_- Satisfaction with program: Satisfaction with Meaningful Activity Program Scale is adapted from the Caregiver Satisfaction Scale	Indiana University	All	21 Years to 95 Years   (Adult, Older Adult)	Phase 1	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	1R21NR013755-01	July 2012	March 2015	May 2016	April 30, 2013		October 25, 2016	Indiana University School of Nursing, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT01843283
33	NCT01962038	A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment		Completed	No Results Available	Amnestic Mild Cognitive Impairment	Behavioral: Combined Aerobic and Resistance Exercise|Behavioral: Stretching Exercises|Behavioral: Cognitive Training	Change from Baseline to 28 weeks in delayed recall of a word list|Change from Baseline to 28 weeks in Delayed Recall of Names-Face Task|Non-Cognitive Outcomes (Depression, Sleep, Quality of Life)	Palo Alto Veterans Institute for Research|U.S. Army Medical Research and Development Command	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	72	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FAI0002AGG	May 2013	July 2017	November 2017	October 14, 2013		April 5, 2018	VA Palo Alto Health Care System, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT01962038
34	NCT04027725	NEUROFEEDBACK TRAINING FOR OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: A PILOT STUDY	NEUROFEEDEL	Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Neurofeedback	Change on Rey Auditory Verbal Learning test|relative power for delta, theta, alpha, sensorimotor and lower beta frequency bands.	Assistance Publique - Hôpitaux de Paris	All	65 Years to 90 Years   (Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	K170908J|2017-A02933-50	November 2019	May 2021	November 2021	July 22, 2019		October 21, 2019	Hopital BROCA, Paris, France		https://ClinicalTrials.gov/show/NCT04027725
35	NCT02670850	Intervention Program for Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Other: Family Caregiver Intervention Program	Caregivers' preparedness was measured by the 10-item Caregiver Preparedness Scale.|Caregivers' competence was measured by the 17-item Competence Scale.|Caregivers' quality of life was measured by the The 36-Item Short Form Health Survey (SF-36).|Caregivers' depressive symptoms was measured by the the Center for Epidemiologic Studies Depression Scale.	Chang Gung Memorial Hospital|Ministry of Science and Technology, Taiwan	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	NSC102-2314-B-182-051-MY3	August 1, 2013	July 31, 2016	July 31, 2016	February 2, 2016		February 3, 2017	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02670850
36	NCT03195816	A Computer-based Cognitive Stimulation in Mild Cognitive Impairment With White Matter Hyperintensities		Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Computerized Cognitive training	Change on Rey Auditory Verbal Learning test|Change on Fazekas scale	Leila DJABELKHIR|Broca Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	LUS3WMH	January 2018	December 2018	March 2019	June 22, 2017		June 22, 2017			https://ClinicalTrials.gov/show/NCT03195816
37	NCT01522404	Effects of Atomoxetine in Mild Cognitive Impairment	ATX-001	Completed	Has Results	Mild Cognitive Impairment	Drug: Atomoxetine|Drug: Placebo	Change in Interleukin 1 (IL 1-alpha) in Cerebrospinal Fluid (CSF) in Subjects With Mild Cognitive Impairment (MCI) Treated With Atomoxetine/Inactive Compound Compared to Subjects Treated With Inactive Compound / Atomoxetine|Change in Mean Level of Thymus-Expressed Chemokine (TECK) in Cerebrospinal Fluid (CSF) in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine|Number of All Adverse Events Among the Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine Compared to the Participants Treated With Placebo/Inactive Compound|Number of Participants That Drop Out of the Study Among the Participants Treated With Atomoxetine When Compared to the Participants Treated With Inactive Compound (Placebo)|Rate of Cerebral Blood Flow in Subjects With Mild Cognitive Impairment MCI Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine|Change in FluoroDeoxyGlucose (FDG) Uptake in Participants With Mild Cognitive Impairment (MCI) Treated With Atomoxetine / Inactive Compound Compared to Participants Treated With Inactive Compound / Atomoxetine	Emory University|National Institute on Aging (NIA)	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	39	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	IRB00054397|5U01AG010483|ATX-001	March 2012	October 31, 2017	June 30, 2018	January 31, 2012	December 5, 2018	July 23, 2019	Emory University School of Medicine, Atlanta, Georgia, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01522404/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01522404
38	NCT02320890	Study of tDCS for Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Device: YBand (YDT-201N)|Device: sham-YBand (YDT-201N)	Change in PET-CT images|Change in Cognitive function|Change in activities of daily living|Change in Geriatric Depression Scale	Incheon St.Mary's Hospital|Ybrain Inc.	All	65 Years to 90 Years   (Older Adult)	Not Applicable	16	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	OC14OISI0045	December 2014	October 2015	October 2015	December 19, 2014		August 8, 2018	Incheon St.Mary's Hospital, Incheon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02320890
39	NCT02180529	The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment		Terminated	No Results Available	Mild Cognitive Impairment (MCI)	Drug: Methylphenidate|Drug: Placebo	cognitive function	Meir Medical Center	All	65 Years and older   (Older Adult)	Not Applicable	16	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MMC0642013	November 2015	June 2020	June 2020	July 2, 2014		February 25, 2021	Clalit Health Service, Beer-Sheva, Israel		https://ClinicalTrials.gov/show/NCT02180529
40	NCT01991405	Memory Aid - Working Memory Training in Patients With Mild Cognitive Impairment.	MCI	Unknown status	No Results Available	Mild Cognitive Impairment	Device: Computerized Working Memory Training.	Working Memory function.|Episodic memory function.	Sorlandet Hospital HF	All	55 Years and older   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MCI Working Memory Training.	August 2013	December 2015	December 2016	November 25, 2013		May 23, 2014	Sorlandet Hospital HF, Arendal, Aust-Agder, Norway		https://ClinicalTrials.gov/show/NCT01991405
41	NCT05327257	iTBS rTMS in Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Device: iTBS rTMS	Clinician Referrals|Participant enrollment|Treatment adherence	Maria I. Lapid, M.D.|Mayo Clinic	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other	21-010661	August 11, 2022	July 2024	July 2024	April 14, 2022		September 2, 2022	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT05327257
42	NCT03765398	VR-CogMoBal Training for Reducing Falls Among Older Adults With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: VR Cognitive-motor-balance training	Change in Movement velocity|Change in end point excursion|Change in maximum excursion|Change in directional control|Change in postural stability during reactive balance control (single and dual-task)|Change in 4 meter walk test|Change in gait parameters|Change of accuracy in letter number sequencing|Change in accuracy of Auditory stroop|Change in dual-task cost|Change in Interference in the reaction time|Change in language fluency|Change in reaction time|Change in paired associated learning|Change in spatial working memory|Change in working memory|Change in episodic memory|Change in accuracy of flanker inhibitory control and attention test|Change in cognitive flexibility and attention|Change in processing speed|Changes in fractional anisotropy|Berg Balance scale|Change in physical activity level (Questionnaires)|Change in physical activity level	University of Illinois at Chicago|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-1257|2P30AG022849-11	November 28, 2018	December 16, 2022	December 16, 2022	December 5, 2018		August 13, 2021	University of Illinois at Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03765398
43	NCT05064007	Sound and Music for Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: A: 40 Hz music|Behavioral: B: 40 Hz sound|Behavioral: C: Preferred music	Change in Cognitive function	Johns Hopkins University	All	65 Years to 95 Years   (Older Adult)	Not Applicable	27	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	IRB00295386	December 5, 2021	October 1, 2023	October 1, 2024	October 1, 2021		January 5, 2022	Johns Hopkins School of Nursing, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT05064007
44	NCT02227966	A Pilot Study of tDCS for Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Device: Yband (YDT-201N)|Device: Sham-Yband (YDT-201N)	Change in Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 13)|Change in questionnaire|Change in Clinician's Interview-Based Impression of Change Plus (CIBIC plus)|Change in tDCS feedback|Change in activities of daily living|Change in Korean version of Geriatric Depression Scale (K-GDS)|Change in cognitive function|Change in Multifactorial Memory Questionnaire (MMQ)	Samsung Medical Center|Ybrain Inc.	All	65 Years to 80 Years   (Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SMC 2014-04-026	September 2014	December 2014	December 2014	August 28, 2014		September 3, 2014	Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02227966
45	NCT03526692	Neurofeedback Training for Older Adults With Mild Cognitive Impairment: a Protocol Study		Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Neurofeedback	Change on attention test, TMTB-TMA|Change on Rey Auditory Verbal Learning Test	Fabienne Marlats|Broca Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	LUS1EEGNF	January 2019	December 2019	February 2020	May 16, 2018		May 18, 2018			https://ClinicalTrials.gov/show/NCT03526692
46	NCT03659643	Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker		Unknown status	No Results Available	Mild Cognitive Impairment	Diagnostic Test: EEG with SPR analysis	Diagnosis of dementia|CERAD ten word test	Jon Snaedal|Ullevaal University Hospital|Karolinska University Hospital|Rigshospitalet, Denmark|Zealand University Hospital|Haukeland University Hospital|Kavli Research Foundation, Bergen Norway|Landspitali University Hospital	All	50 Years to 85 Years   (Adult, Older Adult)		300	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NORD-MCI	January 1, 2018	October 1, 2020	October 1, 2020	September 6, 2018		September 6, 2018	Landspitali University Hospital, Reykjavík, Iceland		https://ClinicalTrials.gov/show/NCT03659643
47	NCT03851198	Early Diagnosis of Patients With Mild Cognitive Impairment Through the Parameterization of Functional Tests.		Unknown status	No Results Available	Mild Cognitive Impairment	Procedure: Standard Care or Usual Clinical Practice	Kinematic analysis by motion sensor|Kinematic analysis by 3D motion capture|Responsiveness|Reliability|Validity|Mini-Mental State Examination (MMSE)|Geriatric Depression Screening Scale (GDSS)|Katz Index|Lawnton & Brody Scale|Cardiopulmonary function|Metabolic parameters|Sonographic parameters	University of Malaga|King's College London	All	60 Years and older   (Adult, Older Adult)	Not Applicable	34	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	IJFA07	April 1, 2020	July 2021	September 2021	February 22, 2019		September 30, 2020	Health Science School , University of Malaga, Malaga, Spain		https://ClinicalTrials.gov/show/NCT03851198
48	NCT02083237	Evaluation of an Intervention for Living With Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Behavioural Intervention Program	Change from baseline in memory strategy knowledge and application|Change from baseline in functional memory skills|Change from baseline in family member coping skills.|Change in mood status from baseline	Baycrest|University of Manitoba	All	Child, Adult, Older Adult	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	REB0650	January 2013	December 2014	April 2015	March 11, 2014		March 11, 2014	Baycrest, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02083237
49	NCT04736355	DAOIB for the Treatment of Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Drug: DAOIB|Drug: Placebo	Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24|Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24|Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24|Change from baseline in Medical Outcomes Study Short-Form-36 (SF-36) score at week 8, 16 and 24|Change from baseline in the composite score of a battery of additional cognitive tests at week 8, 16 and 24	Chang Gung Memorial Hospital	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	201800387A3	January 1, 2020	January 2023	January 2023	February 3, 2021		March 10, 2022	Chang Gung Memorial Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT04736355
50	NCT00903695	MemoryXL Effects on Mild Cognitive Impairment Patients	MemoryXL	Terminated	Has Results	Mild Cognitive Impairment	Drug: Memory XL|Drug: placebo	Differences in Dementia Rating Scale (DRS) at 12 Months From Baseline, by Study Group|Differences in Clinical Dementia Rating Scale (CDR) Over 12 Months, by Study Group|Differences in Clock Drawing Test (CLOX) Scores Over 12 Months, by Study Group|Differences in MiniMental State Exam (MMSE) Scores Over 12 Months, by Study Group|Differences in Neuropsychiatric Inventory (NPI) Scores Over 12 Months, by Study Group|Differences in Activities of Daily Living (ADL) Scores Over 12 Months, by Study Group|Differences in Instrumental Activities of Daily Living (IADL) Scores Over 12 Months, by Study Group|Number of Subjects Who Converted to Early Alzheimer's (Dementia).	University of Oklahoma	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	10	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	14594	June 2009	May 2011	May 2011	May 18, 2009	January 26, 2012	January 26, 2012	Univ. of Okla. Health Sciences Center & VAMC OKC, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States		https://ClinicalTrials.gov/show/NCT00903695
51	NCT04546451	Countervail Cognitive and Cerebral Decline in Mild Cognitive Impairment Patients Using Non-medical Interventions	COPE	Enrolling by invitation	No Results Available	Mild Cognitive Impairment	Behavioral: Music practice|Behavioral: Psychomotor therapy	Cognitive Telephone Screening Instrument (COGTEL)|Individual subtests of the COGTEL|D2-R test|Trail making test|Go/No-Go|International Matrix Test (Oldenburg)|fMRI visual working memory task|Sensorimotor function|Short Version of the Amsterdam Instrumental Activity of the Daily Living Questionnaire (A-IADL-Q(SV))|World Health Organization Quality of Life Instruments - short Version WHOQOL-BREF (WHO 1996)|Emotional regulation questionnaire (ERQ)|Magnetization Prepared 2 Rapid Gradient Echo (MP2RAGE)|Functional MRI (fMRI)|Resting state functional MRI (RS-fMRI)|Diffusion Tensor Imaging (DTI)	School of Health Sciences Geneva|University Hospital, Geneva|University of Geneva, Switzerland|University of Lausanne Hospitals	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	99861	January 1, 2021	July 1, 2022	December 31, 2022	September 14, 2020		November 3, 2021	CHUV: Centre Leenaards Memory Center, Lausanne, Vaud, Switzerland|School of Health Sciences Geneva HES-SO, Geneva, Switzerland		https://ClinicalTrials.gov/show/NCT04546451
52	NCT01358955	Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment	CogMCI	Completed	No Results Available	Mild Cognitive Impairment	Other: group cognitive intervention|Other: Home-based cognitive intervention	Modified Alzheimer's Disease Assessment Scale-Cognitive subscale(ADAS-cog)|story recall test|Digit span forward and backward|Word fluency test|color-word stroop test|Digit symbol test|prospective memory test|Mini-Mental State Examination|CDR-SB|K-AD8|PRMQ|MMQ-Strategy|QOL-AD|Geriatric Depression Scale-short form|Bayer ADL|CGA-NPI|Subjective cognitive assessment	Inha University Hospital|Eisai Inc.	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	293	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CogMCI study	March 2011	January 2013	January 2013	May 24, 2011		August 28, 2013	Korea University Medical College, Ansan, Korea, Republic of|Soonchunhyang University Hospital, Bucheon, Korea, Republic of|Bucheon St. Mary's Hospital, the Catholic University of Korea, Bucheon, Korea, Republic of|Donga University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Daejun Eulji University Hopistal, Daejun, Korea, Republic of|Myongji Hospital, Goyang, Korea, Republic of|NHIC Ilsan Hospital, Goyang, Korea, Republic of|Inha Univeristy Hospital, Incheon, Korea, Republic of|Jeju National University Hospital, Jeju, Korea, Republic of|Maryknoll Hospital, Pusan, Korea, Republic of|Bobath Memorial Hospital, Seongnam, Korea, Republic of|Sungkyunkwan University, Samsung Seoul Hospital, Seoul, Korea, Republic of|Asan Medical Center, Psychiatry, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Konkuk University Medical Cener, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Hyoja Geriatric Hospital, Yongin, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01358955
53	NCT02114580	Brain Plasticity Following Aerobic Exercise in Patient With Mild Cognitive Impairment: Neuroimaging Study		Unknown status	No Results Available	Mild Cognitive Impairment	Other: physical training	functional Magnetic Resonance Imaging|Neuropsychological assessment	Tel-Aviv Sourasky Medical Center	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0051-14-TLV	May 2014	March 2016	March 2016	April 15, 2014		April 15, 2014	Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel		https://ClinicalTrials.gov/show/NCT02114580
54	NCT03987464	Platform-based Mild Cognitive Impairment (MCI) Trial		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Planning for the Future|Behavioral: Enhanced Medical Engagement|Behavioral: Confidence Building and Social Engagement|Behavioral: Physical Intervention|Behavioral: Medical Adherence	Self-Efficacy; general self-efficacy scale (GSES)|Readiness to complete advance directives (ACPES)|Motivations Around Advance Care Planning (ADS)|Long Term Care Planning Behavior Scale (LTCP), planning subscale|Long-Term Supports and Services (LTSS)|World Health Organization Quality-of-Life (WHOQOL), Brief - Psychological and Social Relationship subscale|MCI Test of Knowledge (MCI-ToK)|Long Term Care Planning Behavior Scale (LTCP), health subscale|Technophilia Scale, Technology for health subscale (TTfH)|Technophilia Scale, Comfort with technology subscale (TCwT)|Technophilia Scale, Use of technology subscale (TUoT)|Patient communication pattern scale (PCPS)|Comfort engaging medical professionals (CEMP)|Mindfulness Attention Awareness Scale (MAAS)|Mindfulness Adherence Questionnaire (MAQ)|CHAMPS Physical Activity Questionnaire for Older Adults (CHAMPS), Social engagement subscale.|Social Interaction Anxiety Scale (SIAS)|Crowne-Marlowe Social Desirability (CMSDS)|Memory Situation Questionnaire (MSQ; adapted)|Sickness Impact Profile (SIP) - subscales including body care and movement, mobility, and home management|CHAMPS Physical Activity Questionnaire for Older Adults (CHAMPS), Physical activity subscale|Long Term Care Planning Behavior Scale (LTCP), home modifications item|Short Falls Efficacy Scale (Short FES-I)|36-Item Short Form Survey (SF-36) - physical functioning, pain, energy/fatigue, subscales|Activity|Medication Adherence (MA-MCI)|Medication Adherence (MA-SP)|Concerns about Memory Medications (CaMM)|Motivations around Memory Medications (MMM)|MCI Medication Test of Knowledge (MCI-MToK)	Allison Gibson|University of Kentucky	All	18 Years and older   (Adult, Older Adult)	Not Applicable	38	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	44035	November 1, 2019	December 14, 2021	December 14, 2021	June 17, 2019		February 25, 2022	University of Kentucky, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT03987464
55	NCT05028920	The Study on Nutritional Status of Patients With Mild Cognitive Impairment		Enrolling by invitation	No Results Available	Mild Cognitive Impairment		The dietary quality index: Mediterranean-DASH Intervention for Neurodegenerative Delay diet|Assessment cognitive function only one time: Mini-mental state examination scale, MMSE|Assessment cognitive function only one time:Clinical dementia rating scale, CDR|Lipid profile|Kidney function|Liver function	Taipei Medical University	All	40 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	201900610B0	July 1, 2021	December 31, 2022	December 31, 2022	August 31, 2021		August 31, 2021	Taipei Medical University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT05028920
56	NCT02419183	A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Other: SAMSTAR|Other: RAVLT	Cognitive Evaluation by Self-administered memory screening test with automated reporting (SAMSTAR)|Cognitive Evaluation by Rey Auditory Verbal Learning Test (RAVLT)|Assess the feasibility of SAMSTAR	Janssen Research & Development, LLC	All	55 Years to 84 Years   (Adult, Older Adult)		153	Industry	Observational	Observational Model: Case-Crossover|Time Perspective: Prospective	CR106702|NOPRODALZ0001	May 2015	March 2016	March 2016	April 17, 2015		July 1, 2016	Chapel Hill, North Carolina, United States|Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02419183
57	NCT05470062	Arch Support Effects on Balance and Gait in Older Adults With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Device: arch support insoles (FootDisc)	Change of static standing balance|Change of timed-up-and-go test|Change of 10-m obstacle crossing|Change of functional reach test|Change of Short Physical Performance Battery|Change of gait	National Taipei University of Nursing and Health Sciences	Female	65 Years to 80 Years   (Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CTH-110-2-5-018	July 1, 2022	December 31, 2022	December 31, 2022	July 22, 2022		July 22, 2022	Cardinal Tien Hospital, New Taipei City, Taiwan		https://ClinicalTrials.gov/show/NCT05470062
58	NCT03486704	Telerehabilitation in Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Face to Face VRRS and telerehabilitation|Behavioral: Usual rehabilitation program|Behavioral: FTF VRRS plus unstructured CS|Behavioral: Face to Face VRRS plus active tDCS and telerehabilitation|Behavioral: Face to Face VRRS plus placebo tDCS and telerehabilitation	Change in long term episodic verbal memory|Change in measure of quality of life|Change in dementia severity|Change in global cognition|Change in memory complaints|Change in visual constructional abilities|Change in nonverbal long term memory|Change in visual attention and task switching|Change in naming abilities|Change in non-verbal abstract reasoning|Change in verbal fluency	IRCCS Centro San Giovanni di Dio Fatebenefratelli|IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT)|Fondazione Don Carlo Gnocchi Onlus|IRCCS San Raffaele	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	VR-Rehab-MCI	April 9, 2018	December 31, 2022	January 31, 2023	April 3, 2018		March 31, 2022	IRCCS Centro san Giovanni di Dio, Brescia, BS, Italy		https://ClinicalTrials.gov/show/NCT03486704
59	NCT05468424	Effect of Tablet-Based Games on Executive Functions in Older Adults With Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Other: tablet (iPad or android) based role-playing game|Other: tablet (iPad or android) based word puzzles and image puzzles	response inhibition|attention|verbal short-term memory|spatial short-term memory|working memory|visuospatial working memory|visuospatial rotations|visuospatial processing|deductive reasoning|verbal reasoning|planning|engagement	Queen's University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	42	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	6035589	September 12, 2022	September 2, 2023	September 2, 2023	July 21, 2022		September 13, 2022	Providence Care Hospital, Kingston, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05468424
60	NCT05396248	Improve New Learning and Memory in Individuals With Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Retraining Exercises|Behavioral: Placebo Control Memory Exercises	Verbal list learning|Participation in everyday life|Self-reported depression|Self-reported anxiety|Self-reported quality of life|Self-reported quality of well-being|Functional neuroimaging|Functional memory|Story memory	Kessler Foundation|University of Michigan|Michigan State University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R-1183-22	September 2022	March 2027	March 2027	May 31, 2022		August 17, 2022	University of Michigan, Ann Arbor, Michigan, United States|Kessler Foundation Research Center, West Orange, New Jersey, United States		https://ClinicalTrials.gov/show/NCT05396248
61	NCT01605448	Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Mindfulness Based Stress Reduction (MBSR)	Number of participants with adverse events|Feasibility: 85% completion|Change in fMRI Resting state|Change in Cognition|Change in Measures of "well-being"|Qualitative Improvements	Beth Israel Deaconess Medical Center	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	14	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009P-000411	January 2010	May 2011	January 2012	May 24, 2012		May 24, 2012	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01605448
62	NCT05472415	Effects of Cognicise and Arch Support Insoles in Older Adults With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Other: cognicise|Device: arch support insoles	Change of static standing balance|Change of timed-up-and-go test|Change of 10-m obstacle crossing|Change of functional reach test|Change of Short Physical Performance Battery|Change of gait	National Taipei University of Nursing and Health Sciences	All	55 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	110A-37	July 25, 2022	December 31, 2022	December 31, 2022	July 25, 2022		July 25, 2022	Cheng Hsin General Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT05472415
63	NCT04566900	Neurofeedback to Improve Working Memory in Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Neurofeedback|Other: Placebo	Change in Working Memory accuracy|Durability of Change in Working Memory accuracy|Change in Gamma Band Response|Durability of Gamma Band Response	University of California, San Diego	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	112	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	192022	January 1, 2021	December 30, 2025	March 31, 2026	September 28, 2020		March 17, 2022	University of California at San Diego, La Jolla, California, United States		https://ClinicalTrials.gov/show/NCT04566900
64	NCT04647032	Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation		Completed	No Results Available	Mild Cognitive Impairment	Device: Transcranial alternating current stimulation	Change in Divided Attention|Change in Sustained Attention|Change in Working Memory|Change in Instrumental Activities of Daily Living (IADL)	University of California, San Francisco|National Institute on Aging (NIA)	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	30	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	132026a|R21AG062395	January 11, 2021	December 31, 2021	May 31, 2022	November 30, 2020		August 4, 2022	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04647032
65	NCT05291208	Clinical Trial Through Combined tACS Therapy in Patients With Mild Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Combination Product: Combined tACS and Cognitive Training Program|Behavioral: Traditional Cognitive Training Program	Prefrontal theta oscillation activity.|WAIS-IV Digit Retention subtest. Chilean standard. (Rosas et al., 2015)|Trail Making Test B (TMT-B). Chilean standard. (Arango-Lasprilla et al., 2015)|Parietal theta oscillation activity.	Universidad del Desarrollo	All	60 Years and older   (Adult, Older Adult)	Phase 2	62	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	SA19I0118	January 26, 2022	September 2022	December 2023	March 22, 2022		March 22, 2022	Centro de Investigación del Desarrollo de Cognición y Lenguaje, Faculty of Medicine, Universidad de Valparaíso., Valparaíso, Quinta Región, Chile		https://ClinicalTrials.gov/show/NCT05291208
66	NCT05301868	Multidomain Intervention Via a None-face-to-face Platform in Mild Cognitive Impairment	EXTENDED	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Multidomain intervention	Change of cognition|Change of global cognition|Change of function|Change of subjective memory|Change of depression|Quality of life assessed by the Quality of life-Alzheimer's disease|Change of activities of daily living|Change of nutritional behavior|Change of nutrition|Change of motor function|Sleep quality assessed by the Pittsburgh Sleep Quality Index|Change of motivation	Inha University Hospital	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2022-02-009	April 11, 2022	November 30, 2023	December 31, 2023	March 31, 2022		April 13, 2022	Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Ewha Womans Seoul Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05301868
67	NCT05540613	Tai Chi Versus Conventional Exercise to Improve Cognitive Performance in Older Adults With Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Health Education|Behavioral: Conventional Exercise|Behavioral: Tai Chi	The score of the Montreal Cognitive Assessment (MoCA)|Clinical Dementia Rating|Neurocognitive Test|Subjective Cognitive Performance|Subjective Memory complaints|Subjective Sleep Quality|The Hospital Anxiety and Depression Scale|The 12-Item Short Form Survey|Medication Use|Short Physical Performance Battery (SPPB) Test|Habitual Physical Activity	The University of Hong Kong	All	50 Years and older   (Adult, Older Adult)	Not Applicable	315	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	TC_MCI_RCT	September 2022	July 2024	July 2024	September 14, 2022		September 14, 2022	The University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT05540613
68	NCT01299766	Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment (MCI)	Behavioral: Behavioral Activation (BA)|Behavioral: Supportive Therapy (ST)	Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R)|Change in University of California Performance-based Skills Assessment (UPSA) Score Per Year	Thomas Jefferson University|Dartmouth College|Johns Hopkins University|University of Pennsylvania|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Phase 3	221	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	1R01AG035025	June 21, 2011	December 13, 2016	December 13, 2016	February 18, 2011	November 20, 2018	December 12, 2018	Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01299766
69	NCT05059353	Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Device: Digitally based multidomain intervention	Change from baseline in processing speed|Change from baseline in executive functioning|Change from baseline in mood using the Depression Anxiety Stress Scales (DASS-21) in patients with MCI|Change from baseline in overall cognition in patients with MCI|Change from baseline in QoL	Neuroglee Therapeutics	All	50 Years to 70 Years   (Adult, Older Adult)	Not Applicable	55	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NG-001	November 1, 2021	April 2022	June 2022	September 28, 2021		December 10, 2021	National Neuroscience Institute, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT05059353
70	NCT02592187	A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)	ReMemory-MCI	Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: ReMemory-MCI training|Behavioral: Control intervention	Change in memory after receiving treatment|Change in attention after receiving treatment|Change in working memory after receiving treatment|Change in executive function, set-shifting after receiving treatment|Change in executive function,verbal fluency|Change in executive function, inhibition after receiving treatment|Change in processing speed after receiving treatment|Change in subjective memory complaints after receiving treatment|Change in functional capacity after receiving treatment|Change in depression and anxiety after receiving treatment|Change in quality of life|Change in Neuropsychiatric symptoms|Change in Caregiver Burden|Change in patient's self-esteem|Change in patient and caregiver's perception of social support|Change in neuroplasticiy	Consorci Sanitari de Terrassa|University of Barcelona|Associació Vallès Amics de la Neurologia|Fundació La Marató de TV3	All	65 Years to 90 Years   (Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Fundacio la MaratóTV3 20141510	June 2015	February 2019	February 2019	October 30, 2015		January 11, 2019			https://ClinicalTrials.gov/show/NCT02592187
71	NCT04533204	Mnemonic Strategy Versus Spaced Retrieval Training in Those With Mild Cognitive Impairment	MST training	Completed	Has Results	Mild Cognitive Impairment	Behavioral: mnemonic strategy training|Behavioral: spaced retrieval training	Percent of Correct Object Location Associations Assessed up to 1 Month Post-treatment|Change in Accuracy (vs. Baseline) on Novel Object Location Associations	VA Office of Research and Development	All	Child, Adult, Older Adult	Not Applicable	59	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	B6366-W-1	August 1, 2010	June 30, 2014	July 30, 2014	August 31, 2020	March 23, 2021	March 23, 2021	VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04533204
72	NCT04920123	Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic		Recruiting	No Results Available	Mild Cognitive Impairment	Device: Neuro-World	Montreal Cognitive Assessment (MoCA)|Mini-Mental State Examination (MMSE)|Digit Forward Span (DFS)|Digit Backward Span (DBS)|Geriatric Depression Scale (GDS)|Short Form 36 (SF-36)|Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for mild cognitive impairment patients (ADCS/MCI/ADL24)	University of Massachusetts, Amherst|Rutgers, The State University of New Jersey|Université de Montréal	All	55 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	2585	February 17, 2022	June 30, 2023	June 30, 2023	June 9, 2021		June 23, 2022	University of Massachusetts, Amherst, Amherst, Massachusetts, United States|The State University of New Jersey, Rutgers, Newark, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04920123
73	NCT05023057	Multidomain Interventions Via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment	SUPERBRAIN	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Multidomain intervention	Change of cognition|Change of global cognition|Change of function|Change of subjective memory|Change of depression|Change of quality of life|Change of activities of daily living|Change of nutritional behavior|Change of nutrition|Change of motor function|Change of sleep quality|Change of motivation	Inha University Hospital	All	60 Years to 79 Years   (Adult, Older Adult)	Not Applicable	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	2021-06-040	September 23, 2021	June 2023	July 2023	August 26, 2021		March 31, 2022	Dong-A University Hospital, Busan, Korea, Republic of|Chonnam University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Bobath Memorial Hospital, Seongnam, Korea, Republic of|Ewha Womans Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05023057
74	NCT04490616	TMS Treatment of Social Cognition Skills in Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Other: rTMS treatment	Comparison of Deceptive Box Task score|Comparison of Look-prediction/say-prediction test score|Comparison of Empathy Quotient score|Comparison of Ekman 60 test score|Comparison of Frontal Behavioral Inventory score|Comparison of Look-prediction/say-prediction test|Changes from baseline in Deceptive Box Task Test.|Changes from baseline in Look/say Test|Changes from baseline in Empathy Quotient scale|Changes from baseline in Ekman 60 Test|Changes from baseline in Frontal Behavioral Inventory|Comparison Montreal Cognitive Assessment|Comparison of Geriatric Depression Scale score|Comparison of Euroquol-5 dimensions score	Ospedale Regionale di Lugano	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	32	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	2020-00434/CE 3594	September 15, 2020	May 31, 2024	August 31, 2024	July 29, 2020		July 31, 2020			https://ClinicalTrials.gov/show/NCT04490616
75	NCT04507386	Reducing Sedentary Time in Patients With Mild Cognitive Impairment: The Take a STAND for Health Study		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Take a STAND for health	Sedentary behaviour assessed by ActivPAL™|Physical activity levels assessed by ActiGraph GT3X®|Cognitive performance assessed by the Montreal Cognitive Assessment (MoCA)|Cognitive decline assessed by the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)|Subjective memory complaints assessed by the Memory Complaint Scale (MCS)|Functional impairments in activities of daily living assessed by the Functional Activities Questionnaire (FAQ)|Anxiety symptoms assessed by the Geriatric Anxiety Inventory (GAI)|Depression symptoms assessed by the Geriatric Depression Scale (GDS-15)|Neurocognitive assessment assessed by the Cogstate Research™ (Cogstate, Melbourne, AUS)|Magnetic resonance imaging using the Philips ACHIEVA 3.0 Tesla|Positron emission computed tomography with 18F-fluordesoxyglucose (PET-18FDG) using the Biograph, CTI/Siemens, Knowville, EUA|Assessment of cerebrovascular reactivity to CO2 inhalation|Muscle functional assessed by the Timed Stands Test and the Timed Up-and-Go Test|Handgrip strength assessed by a hand dynamometer|Blood pressure|Fatigue severity assessed by the Fatigue Severity Scale (FSS)|Physical and mental aspects of fatigue assessed by the Chalder Fatigue Scale (CFS)|Subjective sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI)|Daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS)|Quality of life assessed by the SF-36 (Medical Outcomes Study 36 - Short-Form Health Survey)|Food consumption|Insulin sensitivity|Lipid profile|Inflammatory cytokines|Genetic profile for Alzheimer's disease|Oral glucose tolerance test	University of Sao Paulo	All	60 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Take a STAND for Health MCI	August 2020	August 2024	August 2024	August 11, 2020		August 17, 2020			https://ClinicalTrials.gov/show/NCT04507386
76	NCT04426162	Effects of Memory Boot Camp on Brain Function in Adults With Symptoms of Mild Cognitive Impairment (MCI)		Completed	No Results Available	Mild Cognitive Impairment	Other: Multi-domain Intervention	Change in Montreal Cognitive Assessment (MoCA)	Neurocore	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	76	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-127	October 5, 2017	April 24, 2019	April 24, 2019	June 11, 2020		June 11, 2020	Neurocore Brain Performance Center, Boca Raton, Florida, United States|Neurocore Brain Performance Center, Palm Beach Gardens, Florida, United States|Neurocore Brain Performance Center, Grandville, Michigan, United States		https://ClinicalTrials.gov/show/NCT04426162
77	NCT04792528	REACT MCI - Repeated Advanced Cognitive Training in Mild Cognitive Impairment	REACT MCI	Recruiting	No Results Available	Mild Cognitive Impairment	Other: Computerized cognitive training.|Other: Generalized brain training / Active control	Working memory training is superior to active control measured by spatial span backwards at 6 months|Reduced function in the glymphatic system is associated with reduced working memory training effect measured by CT evaluated craniospinal clearance|Working memory training impact quality of life measure in the participants as compared to active control measured by EuroQOL5D-5L after 12 months.|Working memory training prolongs the MCI phase as compared to active controls|The effect of working memory training is dose related measured by spatial span backwards after 6 months|Allelic variations in predefined genetic markes influence training effects after 3 months measured by spatial span backwards.|Workin memory training reduces relatives stress scores as compared to relatives stress scores in the active control group after 12 months|Working memory training reduces QALY associated cost as compared to active controls at 24 months.|Working memory training reduces QALY associated cost as compared to active controls at 48 months.	Susanne Sørensen Hernes|Oslo University Hospital|NKS Olaviken|St. Olavs Hospital|NKS Kloverasen|Barrow Neurological Institute|University of Maryland, College Park|Sorlandet Hospital HF	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	213	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	77084 REACT MCI|Prosjektnr. 2019208	May 15, 2021	April 15, 2026	April 15, 2026	March 11, 2021		June 4, 2021	Sørlandet Sykehus Arendal, Arendal, Norway|NKS Olaviken Alderspsykiatriske sykehus - Hukommelsesklinikk, Bergen, Norway|N.K.S. Kløveråsen, Bodø, Norway|Oslo Universitetssykehus Ullevål, Oslo, Norway|St. Olavs Hospital, Trondheim, Norway		https://ClinicalTrials.gov/show/NCT04792528
78	NCT03819127	Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Drug: Vildagliptin 50 MG Oral Tablet|Drug: Metformin Pill	Evaluation of cognitive decline|Rate of Glycated hemoglobin (%)	University of Catania	All	65 Years and older   (Older Adult)	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	01/2015	January 2015	September 2016	September 2016	January 28, 2019		January 28, 2019			https://ClinicalTrials.gov/show/NCT03819127
79	NCT04723667	Effects of an Empowerment-based Psycho-behavioral Program on Persons With Mild Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: 13-week multimodal intervention|Behavioral: 5-week health education programme	Mild Behavioral Impairment - Checklist (MBI-C)|Kessler Psychological Distress Scale (K10)|Apathy Evaluation Scale (AES-S)|Geriatric Depression Scale - Short Form (GDS-SF)|Hong Kong version of the Montreal Cognitive Assessment (HK-MoCA)|Memory Inventory in Chinese (MIC)|Hong Kong Short Form -12 (HK-SF12)	Chinese University of Hong Kong	All	50 Years to 100 Years   (Adult, Older Adult)	Not Applicable	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	0000	September 1, 2020	July 18, 2021	June 10, 2022	January 26, 2021		January 3, 2022	Rose Lin, Hong Kong, Hong Kong|University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04723667
80	NCT04045483	Virtual Reality Based Cognitive Training Program in Mild Cognitive Impairment	VRMCI	Unknown status	No Results Available	Mild Cognitive Impairment	Other: Virtual reality based cognitive training	Change of Short form of Literacy Independent Cognitive Assessment from baseline at 6 weeks|Change of Mini-Mental State Examination from baseline at 6 weeks|Change of Clinical Dementia Rating Scale-Sum of Boxes from baseline at 6 weeks|Change of Quality of life-Alzheimer's disease from baseline at 6 weeks|Change of Geriatric Depression Scale-15 items from baseline at 6 weeks|Change of Prospective and Retrospective Memory Questionnaire from baseline at 6 weeks|Change of Bayer Activities of Daily Living from baseline at 6 weeks	Inha University Hospital	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2019-04-029	June 7, 2019	February 28, 2020	March 14, 2020	August 5, 2019		August 5, 2019	Inha University Hospital, Incheon, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04045483
81	NCT04248400	Effectiveness of Tai Chi to Improve Cognitive Function in Older Adults With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Other: Tai Chi training|Other: Conventional exercise	The score of the Montreal Cognitive Assessment|30-min delay recall|Trial making test|Stroop test|Verbal fluency|Digit span|n-back test	The University of Hong Kong	All	50 Years and older   (Adult, Older Adult)	Not Applicable	37	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	TCMCI	October 10, 2018	August 3, 2019	February 28, 2020	January 30, 2020		August 25, 2021	The University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04248400
82	NCT04717479	A Scalable Model for Promoting Functioning and Well-Being Among Older Adults With Mild Cognitive Impairment Via Meaningful Social Interactions: Project SPEAK!		Completed	No Results Available	Mild Cognitive Impairment	Other: Intervention (videoconferencing)	The primary outcome will be a measure of participant recruitment.	University of Michigan|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Not Applicable	108	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	1R21AG066644|5R21AG066644-02	March 19, 2021	April 11, 2022	July 25, 2022	January 22, 2021		July 28, 2022	University of Michigan, North Campus Research Complex, Ann Arbor, Michigan, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04717479/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04717479
83	NCT04301960	Effects of Single and Dual Task Training in Individuals With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Other: Single task training|Other: Dual task training	Choice Stepping Reaction Time Test (CSRT)|Stroop Test|Verbal Fluency Test (VFT)|Serial Subtraction Test (SST)|10 Meter Walking Test (10 MWT)|10 Meter Walking Test with Verbal Fluency Test (10 MWT-VFT)|10 Meter Walking Test with Serial Subtraction Test (10 MWT-SST)|Fullerton Advanced Balance (FAB) Scale|D+R Balance Application	Eastern Mediterranean University	All	65 Years to 85 Years   (Older Adult)	Not Applicable	42	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019/23-11	February 16, 2021	June 16, 2021	June 16, 2021	March 10, 2020		June 18, 2021	Eastern Mediterranean University, Famagusta, Eyalet/Yerleşke, Cyprus		https://ClinicalTrials.gov/show/NCT04301960
84	NCT01935219	Improving Performance in Drivers With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Goal Management Training|Behavioral: Processing Speed Training|Behavioral: Brain Health Workshop	Driving Performance|Sustained Attention to Response Task (SART)|D-KEFs Tower Test|Useful Field of View Test (UFOV)|Cognitive Failures Questionnaire|Dysexecutive Questionnaire|Geriatric Depression Scale (GDS-15 item)|Quality of Life: AD (QOL-AD)	Baycrest|Unity Health Toronto|Sunnybrook Health Sciences Centre|Lakehead University|McGill University|University Health Network, Toronto|Michael Garron Hospital|Centre for Addiction and Mental Health	All	55 Years and older   (Adult, Older Adult)	Not Applicable	66	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	CIHR MOP-119580	August 2013	March 2019	March 2019	September 5, 2013		January 21, 2020	Baycrest Health Sciences, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01935219
85	NCT02943187	Multidisciplinary Intervention for Mild Cognitive Impairment	(MCI)	Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Cognitive training|Dietary Supplement: Nutrition	Evidence of overall cognitive function improvement|Evidence of improvement in executive function|Evidence of improvement in cognitive flexibility|Evidence of change in brain function|Evidence of improvement in visual attention|Evidence of improvement in auditory attention	Gibson Institute of Cognitive Research|True Life Medicine	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	5	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GICR-1012	October 2016	December 2018	June 2022	October 24, 2016		July 27, 2021	Gibson Institute of Cognitive Research, Colorado Springs, Colorado, United States		https://ClinicalTrials.gov/show/NCT02943187
86	NCT04000984	Beneficial Effects of Mindfulness-based Training on Neuropsychological Outcomes in Mild Cognitive Impairment	MEDIC	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Mindfulness Based Training (MBT) Program|Behavioral: Cognitive Rehabilitation Training	Change in Attention|Change in Immediate Memory|Change in Delayed Memory|Change in Processing Speed: Colour Trails 1 and 2|Chang in Mindfulness Awareness and Attention Scores|Change in Subjective Quality of Life: Short-Form 36|Change in Subjective measures of Sleep quality: Insomnia Severity Index|Change in Subjective measures of Sleep quality: Pittsburgh Sleep Quality Index Score|Imaging measures (structural): change in orbitofrontal cortex volume|Change in functional imaging measures: Resting state	Singapore General Hospital|Duke-NUS Graduate Medical School	All	45 Years to 75 Years   (Adult, Older Adult)	Not Applicable	81	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2015/3149	January 1, 2016	December 1, 2019	December 1, 2019	June 27, 2019		March 27, 2020	Singapore General Hospital, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04000984
87	NCT03647345	Noninvasive Dual-mode Stimulation Therapy for Neurorehabilitation in Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Device: High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|Device: High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|Device: High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC	Accuracy of 2-back verbal working memory task	Samsung Medical Center	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	21	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2015-01-132-005	April 26, 2015	July 5, 2018	July 5, 2018	August 27, 2018		September 20, 2019	Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03647345
88	NCT03928613	Efficacy of the Cognitive Training Based on Location Information and Activity in People With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: tablet based Cognitive Training based on location information	Change in CERAD-TS1 score|Change in MMSE score|Change in SMCQ score|Change in GDS score	Seoul National University Bundang Hospital|Institute of Information & Communications Technology Planning & Evaluation, Korea	All	60 Years and older   (Adult, Older Adult)	Not Applicable	43	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B-1903-526-301	April 17, 2019	December 31, 2019	February 28, 2020	April 26, 2019		March 18, 2020	Seoul National University Bundang Hospital,, Seongnam-si, Gyeonggi, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03928613
89	NCT03855319	Neurofeedback Improves Cognitive Performance and EEG Activity in Elderly With Mild Cognitive Impairment	Neurofeedel	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: SMR neurofeedback training to MCI	Rey Auditory Verbal Learning test|Relative power for delta, theta, alpha, sensorimotor and lower beta frequency bands.	Fabienne Marlats|Broca Hospital	All	65 Years to 90 Years   (Older Adult)	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	LUS3EEGNF	December 15, 2016	December 15, 2018	December 15, 2018	February 26, 2019		February 28, 2019			https://ClinicalTrials.gov/show/NCT03855319
90	NCT04121156	High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Device: HD-tDCS treatment|Device: sham (placebo) HD-tDCS	Cognitive Abilities Screening Instrument, CASI|Wechsler Memory Scale-third edition (WMS III) - verbal paired associates I and II|Wechsler Memory Scale-third edition (WMS III) - visual reproduction I and II|Wisconsin card sorting test|Frontal assessment battery, FAB|Wechsler adult intelligence scale four edition, WAIS-IV, digit span|Wechsler adult intelligence scale four edition, WAIS-IV, digit symbol coding|Wechsler adult intelligence scale four edition, WAIS-IV, vocabulary|Beck depression inventory (BDI-II)|Beck anxiety inventory (BAI)|Subjective Cognitive Decline Questionnaire (SCD-Q MyCog)	Kaohsiung Veterans General Hospital.	All	65 Years to 85 Years   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	VGHKS-2068	September 30, 2020	August 31, 2022	August 31, 2022	October 9, 2019		December 3, 2020	Department of Psychiatry, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT04121156
91	NCT04346862	Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease		Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Acetyl-L-carnitine hydrochloride 500mg|Drug: Placebo	Interference score using K-CWST(Korean-Color Word Stroop Test)|Montreal Cognitive Assessment Korean(MOCA-K)|Korean Trail Making Test Elderly(K-TMT-e)|EQ-5D|Clinical Global Impression -Improvement (CGI-I)	Hanmi Pharmaceutical Company Limited	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 4	636	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HM-VASCA-401	January 26, 2016	June 30, 2020	June 30, 2020	April 15, 2020		April 21, 2020	Catholic Kwandong University International St. Mary'S Hospital, Incheon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04346862
92	NCT03482167	NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment	Drug: Niagen®|Other: Placebo	Change from baseline in cognitive scores at 12 weeks|Change from baseline in cerebrovascular reactivity at 12 weeks|Change from baseline in total brain blood flow at 12 weeks|Change from baseline in aortic stiffness at 12 weeks|Change from baseline in blood pressure at 12 weeks	University of Delaware|National Institute on Aging (NIA)	All	60 Years to 90 Years   (Adult, Older Adult)	Phase 1|Phase 2	58	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	1079271|K01AG054731	December 1, 2018	December 31, 2023	December 31, 2023	March 29, 2018		August 31, 2022	Neurovascular Aging Laboratory, Newark, Delaware, United States		https://ClinicalTrials.gov/show/NCT03482167
93	NCT03526146	Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)	MCI PLIE	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Behavioral: Preventing Loss of Independence through Exercise (PLIE)	Short Physical Performance Battery (SPPB)|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Change in Default Mode Network (DMN) functional connectivity, as measured by resting state functional Magnetic Resonance Imaging (rs-fMRI) as quantified by 3 Tesla MR imaging.|Change in cerebral perfusion, as measured by arterial spin labeled (ASL) perfusion MRI as quantified by 3 Tesla MR imaging.|Quality of Life Scale in Alzheimer's Disease (QOL-AD)|Change in hippocampal subfield volumes as quantified by 3 Tesla MR imaging	University of California, San Francisco|United States Department of Defense	All	50 Years and older   (Adult, Older Adult)	Not Applicable	33	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	17-23034	August 30, 2018	October 30, 2020	October 30, 2020	May 16, 2018		November 4, 2020	San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03526146
94	NCT03577717	Efficacy of Computerized Cognitive Training in the Elderly With Mild Cognitive Impairment		Terminated	No Results Available	Mild Cognitive Impairment	Other: computerized cognitive training|Other: occupational therapy	Change scores of Quick Mild Cognitive Impairment screen|Change scores of Montreal Cognitive Assessment|Change scores of Contextual Memory Test|Change scores of Color Trail Test|Change scores of Digits Span Tasks-forward and backward|Change scores of Cancellation Test|Change scores of Pattern Comparison|Change scores of Everyday Memory Questionnaire|Change scores of Neuropsychiatric Inventory Questionnaire|Change scores of Brief University of California San Diego (UCSD) Performance-based Skills Assessment|Change scores of Disability Assessment for Dementia Questionnaire (DAD)	Taipei Hospital, Taiwan	All	65 Years and older   (Older Adult)	Not Applicable	7	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	201804	July 13, 2018	February 13, 2019	March 11, 2019	July 5, 2018		February 17, 2020	Taipei Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan		https://ClinicalTrials.gov/show/NCT03577717
95	NCT03857269	Acupoint Massage and Aromatherapy Intervention in Elderly People With Mild Cognitive Impairment in Nursing Institutions		Unknown status	No Results Available	Mild Cognitive Impairment	Other: Acupoint Massage|Other: lavender essential oil|Other: Acupoint Massage and lavender essential oil	Mini-mental State Examination|Wechsler Intelligence Scale|Geriatric depression scale|Pittsburgh sleep quality index	Huan Ding|Nanjing University of Traditional Chinese Medicine	All	60 Years and older   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	KY2019002	December 27, 2018	September 30, 2019	October 30, 2019	February 27, 2019		August 28, 2019	Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT03857269
96	NCT01983930	Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment	Behavioral: Kundalini yoga and meditation|Behavioral: Memory Training	Cognitive Measures - Hopkins Verbal Learning Test (HVLT) Total Recall Score|Clinical Global Impression Scale|Geriatric Depression Scale (GDS)|Change in Functional Magnetic Resonance Imaging (fMRI) Connectivity	University of California, Los Angeles	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	81	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	13-000821	September 2013	May 2016	May 2016	November 14, 2013	October 23, 2018	October 23, 2018	UCLA Semel Institute, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT01983930
97	NCT04191486	Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Drug: T-817MA|Drug: Placebo	The change in the CSF p-tau181 from Baseline to Week 78|The change in the CSF p-tau181 from Baseline to Week 52|The change in the CSF p-tau217 from Baseline to Weeks 52 and 78|The change in the CSF total tau from Baseline to Weeks 52 and 78|The change in the CSF Aβ1-42 from Baseline to Weeks 52 and 78|The change in the CSF Aβ1-40 from Baseline to Weeks 52 and 78|The change in the CSF neurofilament light (NFL) from Baseline to Weeks 52 and 78|The change in the CSF neurogranin from Baseline to Weeks 52 and 78|The change in the CSF YKL-40 from Baseline to Weeks 52 and 78|The change in the CSF Aβ1-42/Aβ1-40 ratio from Baseline to Weeks 52 and 78|The change in the plasma Aβ1-42 from Baseline to Weeks 52 and 78|The change in the plasma Aβ1-40 from Baseline to Weeks 52 and 78|The change in the plasma NFL from Baseline to Weeks 52 and 78|The change in cognitive function assessed by CDR-sb and working memory and attention domain as measured by the CFC from Baseline to Weeks 28, 52 and 78|The change in brain volume (total brain volume (TBV), ventricular volume and hippocampal volume) and cortical thickness measured by vMRI from Baseline to Weeks 52 and 78|The change in alpha/theta ratio measured by the EEG from Baseline to Weeks 52 and 78|Safety as assessed by the occurrence of AEs, clinical laboratory tests, vital signs, physical examinations, ECGs|Population PK analysis of T-817MA with assessment of maximum plasma concentration (Cmax)|Population PK analysis of T-817MA with assessment of minimum plasma concentration (Cmin)|Population PK analysis of T-817MA with assessment of total daily exposure (AUC0-24h)	FUJIFILM Toyama Chemical Co., Ltd.	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	T817MAEU201|2018-003567-66	December 24, 2019	February 2023	March 2023	December 9, 2019		June 29, 2021	FNUSA - Mezinarodni centrum klinickeho vyzkumu, Brno, Czechia|FNHK - Neurologicka klinika, Hradec Králové, Czechia|A-shine, s.r.o., Plzen, Czechia|CLINTRIAL, s.r.o., Prague, Czechia|VESTRACLINICS, s.r.o., Rychnov, Czechia|Klinik für Psychiatrie, Psychosomatik und Psychotherapie Universitätsklinikum Frankfurt, Frankfurt, Germany|Klinik für Neurologie Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Klinik und Poliklinik für Neurologie Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Magdeburg Institut für Kognitive Neurologie und Demenzforschung, Magdeburg, Germany|Institut für Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany|Technische Universität München, München, Germany|Universitätsklinikum Münster Klinik für Allgemeine Neurologie, Münster, Germany|Universitätsmedizin Rostock Zentrum für Nervenheilkunde Klinik für Psychosomatik und Psychotherapeutische Medizin, Rostock, Germany|Universitätsklinikum Ulm Studienzentrum Klinik für Neurologie, Ulm, Germany|Debreceni Egyetem KK, Pszichiátriai Klinika, Budapest, Hungary|Jávorszky Ödön Városi Kórház, Gyógyszertár, Debrecen, Hungary|Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika, Győr, Hungary|Semmelweis Egyetem Neurológiai Klinika Gyógyszertára, C földszint, Vác, Hungary|St. Vincent's University Hospital, Dublin, Ireland|Tallaght University Hospital., Dublin, Ireland|Brain Research Center Den Bosch, 's-Hertogenbosch, Netherlands|Brain Research Center, Amsterdam, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Isala ziekenhuis, Zwolle, Netherlands|Hospital General Universitari d' Elx, Alicante, Spain|Fundació ACE, Barcelona, Spain|Àrea Gestió Documentació Assaigs Clínics-AGDAC Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clínico Universitario Virgen de La Arrixaca, El Palmar, Spain|CAE Oroitu, Getxo, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Victoria Eugenia - Cruz Roja, Sevilla, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|University of Bath, Bath, United Kingdom|Southmead Hospital North Bristol NHS Trust, Bristol, United Kingdom|Glasgow memory Clinic, Glasgow, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Memory Assessment & Research Centre, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT04191486
98	NCT01978353	Memory Training in Patients With Amnestic Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Training|Behavioral: Psychoeducation	Changes in memory measures|Changes in functional magnetic resonance imaging (fMRI)|Changes in perception of memory performance and mood|Changes in memory performance and perception of memory performance over time - follow up	University of Sao Paulo General Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CAAE: 08223513.3.0000.0068|12/51699-1	November 2012	October 2015	October 2015	November 7, 2013		October 26, 2015	University of São Paulo, Faculty of Medicine, Institute and Department of Psychiatry, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT01978353
99	NCT04012346	Modulation of Cognition and Brain Connectivity by Noninvasive Brain Stimulation in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease	LUSTR	Unknown status	No Results Available	Mild Cognitive Impairment	Device: Transcranial magnetic stimulation	Visual-attention task accuracy and reaction times|Resting state measurement	Masaryk University|St. Anne's University Hospital Brno, Czech Republic	All	60 Years and older   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	NV16-31868A	April 30, 2018	December 2019	December 2019	July 9, 2019		July 9, 2019	Ceitec Masaryk University, Brno, Czechia		https://ClinicalTrials.gov/show/NCT04012346
100	NCT03375151	An Examination of the Use of Electrophysiological Brain Monitoring to Direct the Treatment of Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Device: EEG based feedback|Behavioral: Standard practice based feedback|Behavioral: No feedback	Cognitive test grade|Rey Auditory-Verbal Learning Test|Free And Cued Selective Reminding Test|Rivermead Behavioral Memory Test|Clinical Global Impression of Change	Brainmarc Ltd.	All	65 Years to 120 Years   (Older Adult)	Not Applicable	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLD13	February 2018	February 2019	April 2019	December 15, 2017		December 15, 2017			https://ClinicalTrials.gov/show/NCT03375151
101	NCT03265522	Tailored Mediterranean Lifestyle Education in Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: "ThinkMed" resource at baseline|Behavioral: Standard Care Control|Behavioral: "ThinkMed" resource (staged)	Change in Mediterranean Diet Score (MDS) at 6 months|Physical Activity|Anthropometric measurements|Muscle Strength|Geriatric Depression Scale|Functional Assessment (1)|Cognitive Assessment|Barriers to consuming a Mediterranean Diet questionnaire|Blood Sample|Functional Assessment (2)|4-day Food Diary|Change in Lifestyle questionnaire|Dietary Quality of Life questionnaire|Mediterranean Diet Knowledge questionnaire|Rand SF-36 HEALTH SURVEY|Staging Algorithm Questionnaire|Mediterranean Diet self-efficacy questionnaire|Mediterranean diet tolerance questionnaire	Queen's University, Belfast|Wellcome Trust	All	Child, Adult, Older Adult	Not Applicable	15	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	16/NI/0105	May 1, 2017	June 30, 2019	June 30, 2019	August 29, 2017		November 4, 2019	Belfast Health and Social Care Trust, Belfast, United Kingdom		https://ClinicalTrials.gov/show/NCT03265522
102	NCT01888029	Influence of tDCS on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)		Withdrawn	No Results Available	Patients With Mild Cognitive Impairment	Device: transcranial direct current stimulation|Device: sham stimulation	the anodal transcranial direct current stimulation over the primary motor cortex (M1) in patients with mild cognitive impairment (MCI)|Comparison of tDCS-induced changes on central cholinergic activity|Comparison of tDCS-induced changes in learning success|MR elastography|genetic polymorphism, ApoE4	Charite University, Berlin, Germany	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Plasticity in MCI	May 2013	October 2017	December 2017	June 27, 2013		May 14, 2021	Klinik und Poliklinik für Neurologie, Charité Universitätsmedizin Berlin, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01888029
103	NCT01532739	Making Memory Better for Seniors With Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Cognitive training	Change in everyday memory functioning|Change on traditional memory testing|Change in memory perception|Change in mood (i.e., self-report symptoms of depression)|Change in mood (i.e., self-report symptoms of anxiety)|Change in other psychiatric symptoms (informant-report)|Change in quality of life|Change in caregiver burden|Feasibility	Karen Chipman|Nova Scotia Health Research Foundation|Nova Scotia Health Authority	All	Child, Adult, Older Adult	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDHA-RS/2012-227	April 2012	April 2017	April 2017	February 14, 2012		August 9, 2016	Neuropsychology Service, Nova Scotia Hospital, Dartmouth, Nova Scotia, Canada		https://ClinicalTrials.gov/show/NCT01532739
104	NCT02913053	The Effects of an Extensive Exercise Program on the Progression of Mild Cognitive Impairment	NeuroExercise	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Aerobic exercise|Behavioral: Non-aerobic exercise	Cognitive performance|Global cognitive function|Cardiovascular fitness|Physical activity|Health related Quality of Life|Depressive symptoms|Neuroticism-Extraversion-Openness-Five Factor Inventory (NEO-FFI)|Timed up and Go (TUG)|Hand grip strength|30 second chair stand|Epigenetics|Brain imaging	Radboud University Medical Center|German Sport University, Cologne|University of Dublin, Trinity College|University of Bonn|University Hospital, Bonn	All	50 Years and older   (Adult, Older Adult)	Not Applicable	183	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ZonMw733051044|BMBF 01ED1510A|JPND-2014-1	June 2015	November 2018	December 2018	September 23, 2016		November 14, 2019	German Sport University, Cologne, Germany|Trinity College Dublin, Dublin, Ireland|Radboud University Medical Center, Nijmegen, Netherlands		https://ClinicalTrials.gov/show/NCT02913053
105	NCT03319810	Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease		Completed	Has Results	Mild Cognitive Impairment	Biological: Octagam 10%	Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months|Change in Baseline Retinal Amyloid Imaging (RAI) at 3 Months	Sutter Health	All	50 Years to 84 Years   (Adult, Older Adult)	Phase 2	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SIMR_Kile_IVIG POC	January 4, 2018	July 19, 2018	July 19, 2018	October 24, 2017	April 16, 2019	June 25, 2019	Sutter Neuroscience Medical Group, Sacramento, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03319810/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03319810
106	NCT03195803	Cognitive Intervention in Mild Cognitive Impairment With or Without White Matter Hyperintensities		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Computerized Cognitive Stimulation	Rey Auditory Verbal Learning test	Leila DJABELKHIR|Broca Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	51	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	LUS2WMH	October 2015	April 2017	April 2017	June 22, 2017		June 22, 2017			https://ClinicalTrials.gov/show/NCT03195803
107	NCT02737878	Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Aerobic Training|Behavioral: Resistance Training|Behavioral: Balance and Tone Training	Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)|Executive functions as measured by standard neuropsychological and computerized tests|Cardiometabolic risk factors as measured by blood panel|Health related quality of life as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L)|Health related quality of life as measured by the ICE-CAP|Mood as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)|Brain function as measured by functional magnetic resonance imaging (fMRI)|Brain structure as measured by structural magnetic resonance imaging|White matter lesion volume as measured by magnetic resonance imaging|Diffusion tensor imaging as measured by magnetic resonance imaging|Memory as measured by standard neuropsychological and computerized tests|Visualspatial ability as measured by standard neuropsychological and computerized tests|Cardiorespiratory capacity as measured by treadmill test|Mobility as measured by 400-m walk|Cardiometabolic risk as measured by waist to hip ratio|Cardiometabolic risk as measured by body mass index|Cardiometabolic risk as measured by pulse wave velocity (arterial stiffness)|Cortisol levels through saliva samples|Lower body strength as measured by the 30 sec sit-to-stand|Lower body strength as measured by Biodex|Upper body strength as measured by grip strength|Sleep monitoring as measured by Motion Watch actigraphy|Neurotrophic factors as measured by blood|Mobility as measured by Short Physical Performance Battery|Community mobility as measured by the Life Space Questionnaire|Body composition as measured by DXA|Loneliness as measured by the UCLA Loneliness Scale|Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale - 13 items|Sedentary behaviour as measure by the Sedentary Behaviour Questionnaire|Risk of sleep apnea as measured by the STOP Bang Questionnaire|Prospective falls via Monthly Calendars|Social support as measured by Social Provision Scale|Mindfulness as measured by the Mindfulness Attention Awareness Scale|Memory as measured by the Everyday Memory Questionnaire|Sleep as measured by the Pittsburgh Sleep Quality Index|Functional ability as measured by the Lawson IADL|Comorbidities as measured by the Function Comorbidity Index|Mood as measured by the State and Trait Anxiety Inventory|Social network as measured by Lubben Social Network Scale|Physical activity as measured by the CHAMP Questionnaire	University of British Columbia	All	65 Years to 80 Years   (Older Adult)	Not Applicable	216	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	H15-02181	November 13, 2017	December 2022	December 2022	April 14, 2016		September 2, 2022	University of British Columbia, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT02737878
108	NCT03292705	Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment	CogT-PACT	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: PEP|Behavioral: CCI	Attitudes Toward Computers Questionnaire Total score|Useful Field of View|Executive Function|Brief Visuospatial Memory Test|Activities of Daily Living-Prevention Instrument|Everyday Problems for Cognitive Challenged Elderly Test	University of Rochester	All	60 Years and older   (Adult, Older Adult)	Not Applicable	49	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	R21AG054810	October 1, 2017	April 5, 2019	September 1, 2019	September 25, 2017		December 6, 2019	Brickstone/Saint John Meadow, Rochester, New York, United States|River Edge Manor, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT03292705
109	NCT02982642	Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment		Withdrawn	No Results Available	Mild Cognitive Impairment	Drug: 1612 capsule|Drug: Placebos	Change in cognitive scores: Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)|Change from baseline to end of double-blind treatment of rate of dementia conversion from mild cognitive impairment|Change from baseline to end of double-blind treatment of Mini-Mental State Examination(MMSE)|Change from baseline to end of double-blind treatment of Delayed Story Recall test (DSR)|Change from baseline to end of double-blind treatment of Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24)	Dongzhimen Hospital, Beijing	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 4	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Z20055424	January 2017	December 2018	December 2018	December 5, 2016		March 4, 2021	Dongzhimen Hospital ,Beijing University of Chinese Medicine, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02982642
110	NCT03447236	Functional MRI Changes Resulting From the Feuerstein Program in Older People With Mild Cognitive Impairment (MCI)		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Feuerstein Program	Change from baseline functional connectivity|Change from baseline cognitive function	Rambam Health Care Campus|Adolf und Mary Mil-Stiftung|Helen Bader Foundation|Montreal Jewish Community Fund|Rochlin Family Foundation	All	60 Years and older   (Adult, Older Adult)	Not Applicable	28	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	0580-16-RMB	July 4, 2017	June 28, 2019	June 28, 2019	February 27, 2018		September 17, 2019	Rambam Health Care Campus, Haifa, Israel		https://ClinicalTrials.gov/show/NCT03447236
111	NCT02878538	A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment		Withdrawn	No Results Available	Mild Cognitive Impairment	Drug: Deferiprone|Other: Placebo phase	Efficacy of deferiprone therapy on "d" scores in Mild Cognitive Impairment (MCI)|Explore deferiprone's longitudinal effect on "d" and dementia conversion	The University of Texas Health Science Center at San Antonio	All	65 Years to 80 Years   (Older Adult)	Early Phase 1	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other	P30AG044271|HSC20160395H	January 2018	April 2022	April 2023	August 25, 2016		February 6, 2018	University of Texas Health Science Center, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT02878538
112	NCT02301546	Cognitive Training and Practice Effects in Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment	Behavioral: computerized cognitive exercises	Auditory Memory Attention Index	University of Utah|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	197	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	R01AG045163	March 2015	January 28, 2020	February 28, 2020	November 26, 2014	June 9, 2020	June 9, 2020	University of Utah Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02301546/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02301546
113	NCT02491268	A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)		Completed	No Results Available	Mild Cognitive Impairment	Drug: Cilostazol|Drug: Placebo	Change from baseline in Mini Mental State Examination (MMSE)|Conversion from MCI to All-cause Dementia|Cognitive Decline on Clinical dementia rating-sum of boxes (CDR-SB)|Cognitive Decline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) 14|Cognitive Decline on Logical Memory subtest of the Wechsler Memory Scale-Revised (WMS-R)|Functional Decline on Alzheimer's disease Cooperative Study scale for activities of daily living in MCI (ADCS-MCI-ADL)|Hippocampal volume	National Cerebral and Cardiovascular Center	All	55 Years to 84 Years   (Adult, Older Adult)	Phase 2	166	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	TRINEU1321	May 1, 2015	August 14, 2020	December 1, 2020	July 8, 2015		December 4, 2020	National Cerebral and Cardiovascular Center, Suita, Osaka, Japan		https://ClinicalTrials.gov/show/NCT02491268
114	NCT02785315	Cognitive Intervention for Persons With Amnestic Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: rehabilitation & remediation approach|Behavioral: remediation approach	Change from Baseline The Brief University of California San Diego (UCSD) Performance-Based Skills Assessment （Traditional Chinese Version）（UPSA-Brief ) at the 12th and 24th weeks|Change from Baseline Short-form Zarit Caregiver Burden Interview-12 (sCZBI-12) at the 12th and 24th weeks|Change from Baseline Montreal Cognitive Assessment (MoCA) Taiwan Version at the 12th and 24th weeks|Change from Baseline Word Sequence Learning Test at the 12th and 24th weeks|Change from Baseline Minimal-Mental Status Exam (MMSE) at the 12th and 24th weeks|Change from Baseline Miami Prospective Memory Test (MPMT) at the 12th and 24th weeks|Change from Baseline Color Trails Test at the 12th and 24th weeks|Change from Baseline Structure MRI at the 12th and 24th weeks|Change from Baseline PiB-PET and FDG-PET at the 12th and 24th weeks|Change from Baseline amyloid Aβ40, Aβ42 and tau proteins at the 12th and 24th weeks|Change from Baseline The Disability Assessment for Dementia (DAD) at the 12th and 24th weeks|Change from Baseline Quality of Life-Alzheimer's Disease scale (QoL-AD) at the 12th and 24th weeks|Change from Baseline Goal Attainment Scaling (GAS) at the 12th and 24th weeks|Change from Baseline Everyday Memory Questionnaire at the 12th and 24th weeks	National Taiwan University Hospital	All	50 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	201402028RINC	December 16, 2014	November 14, 2017	November 14, 2017	May 27, 2016		March 14, 2019	National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02785315
115	NCT04073628	The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Device: Lighting Intervention	Cognition using the Word Pairs Associates (WPA) Task|Cognition using the Working Memory (WM) Task|Cognition using Implicit Priming Task|Cognition using the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)|Sleep Quality in the MCI Participant using the Pittsburgh Sleep Quality Index (PSQI)|Sleep Quality in the Caregiver using the Pittsburgh Sleep Quality Index (PSQI)|Sleep Spindles using Ambulatory Electroencephalography (EEG)|Slow Oscillation Sleep Activity using Ambulatory Electroencephalography (EEG)|Caregiver Burden using the Zarit Burden Interview (ZBI)|Depression using the Geriatric Depression Scale (GDS)|Quality of Life using the Dementia Quality of Life Instrument (DQoL)|Light Exposure measurement in MCI Participants|Light Exposure in Caregivers|Sleep Efficiency in the MCI Participant|Sleep Efficiency in the Caregiver|Quality of Life using the Quality of Life in Alzheimer's Disease D - QOL-AD|Cognition in the Caregiver using the Word Pairs Associates (WPA) Task|Cognition in the Caregiver using the Working Memory (WM) Task|Cognition using the Montreal Cognitive Assessment (MoCA) tool|Cognition using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) tool|Depression using the Center for Epidemiological Studies Depression Scale (CES-D)	Icahn School of Medicine at Mount Sinai|Rutgers University|National Institute on Aging (NIA)	All	50 Years and older   (Adult, Older Adult)	Not Applicable	240	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	GCO 21-0019|R01AG062288	June 14, 2021	January 2024	April 2024	August 29, 2019		June 24, 2022	Icahn School of Medicine at Mount Sinai, New York, New York, United States|Icahn School of Medicine at Mount Sinai, Troy, New York, United States		https://ClinicalTrials.gov/show/NCT04073628
116	NCT02608840	Auditory Stimulation of Slow Wave Sleep and Memory in Mild Cognitive Impairment and Older Adults		Completed	No Results Available	Mild Cognitive Impairment	Other: Auditory stimulation during sleep|Other: Sham Intervention	Memory performance on a word pair recall|NIH Cognition Toolbox - Composite score	Northwestern University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	23	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STU00200555	July 2015	December 31, 2018	December 31, 2018	November 20, 2015		November 6, 2019	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT02608840
117	NCT02601859	Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Drug: Lithium Carbonate	GSK-3 activity in PBMC isolates	University of Dundee|University of Oxford	All	55 Years and older   (Adult, Older Adult)	Not Applicable	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	2014MH08	August 2016	June 2017	June 2017	November 10, 2015		August 9, 2021			https://ClinicalTrials.gov/show/NCT02601859
118	NCT02559063	Vision-based Speed of Processing Cognitive Training and Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Vision-based speed of processing training|Behavioral: Mental leisure activities	Attention and processing speed test (UFOV)|Cognitive control and working memory (EXAMINER)|instrumental activities of daily living (TIADL)|mean of functional connectivity in default mode network|mean of structural connectivity in default mode network	University of Rochester|National Institute of Nursing Research (NINR)	All	60 Years and older   (Adult, Older Adult)	Not Applicable	84	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	1R01NR015452	January 12, 2016	October 9, 2018	July 1, 2019	September 24, 2015		October 2, 2019	University of Rochester Memory Care Program, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT02559063
119	NCT02420522	Magnetic Brain Stimulation in the Treatment of Mild Cognitive Impairment		Suspended	No Results Available	Mild Cognitive Impairment	Device: Repetitive Transcranial Magnetic Stimulation|Device: Sham Transcranial Magnetic Stimulation	Cognitive changes	University of Manitoba	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	64	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	B2014:134	September 2015	December 2017	December 2021	April 20, 2015		October 8, 2021	St Boniface Hospital, Winnipeg, Manitoba, Canada		https://ClinicalTrials.gov/show/NCT02420522
120	NCT02553603	The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Drug: Growth Hormone Releasing Hormone (GHRH)|Drug: Placebo Growth Hormone Releasing Hormone	Cognitive Function measured by SLUMS|Brain Perfusion measured by fMRI|Brain Morphology measured by MRI|Body composition measured by DEXA|Physical Function measured by 6 minute walking test	The University of Texas Medical Branch, Galveston	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1	22	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	15-0086	July 18, 2017	January 17, 2019	January 17, 2019	September 17, 2015		November 4, 2019	The University of Texas Medical Branch, Galveston, Texas, United States		https://ClinicalTrials.gov/show/NCT02553603
121	NCT02414607	Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment	Biological: Elderberry Juice|Other: Placebo	Visuospatial Problem Solving Battery (VSP)|Clinical Dementia Rating (CDR) Scale|Mini-Mental State Examination (MMSE)|Hopkins Verbal Learning Test (HVLT)|Boston Naming Test (BNT)|Rey Complex Figure Task (Rey)|Anagrams|Instrumental Activities of Daily Living Scale (IADLS)	University of Missouri-Columbia	All	50 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	1211953	September 2016	December 2019	December 2019	April 13, 2015	June 23, 2022	June 23, 2022	University of Missouri Hospital, Columbia, Missouri, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02414607/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02414607/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02414607
122	NCT02110043	Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS		Completed	No Results Available	Mild Cognitive Impairment (MCI)	Device: tDCS|Behavioral: training	Performance in LOCATO task (Visual-spatial learning and memory) after a combination of intensive visual-spatial training and tDCS|long term effects|functional changes: Connectivity|cortical excitability|Quality of Life|memory|affective state|genotyping of learning related polymorphisms	Charite University, Berlin, Germany	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	21	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	LOCATO-MCI-tDCS	March 2014	August 2017	October 2017	April 10, 2014		May 21, 2021	Charite Universitätsmedizin Berlin, Berlin, Germany		https://ClinicalTrials.gov/show/NCT02110043
123	NCT04971096	Relationship Between Gut Microbiome, Probiotics, and Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment (MCI)	Dietary Supplement: PS23 live|Dietary Supplement: PS23 heat-treated|Dietary Supplement: Placebo	Mini-Mental State Examination, MMSE (end point scare-baseline score)/ Baseline score*100% ≥ 12%|Wechsler Memory Scale-III, WMS-III (end point scare-baseline score)/ Baseline score*100% ≥ 12%|Change in Cognitive Abilities Screening Instrument, CASI|Change in Clinical Dementia Rating (CDR)|Change in Insomnia Severity Index, ISI|Change in Geriatric Depression Scale, GDS|Change in Hamilton Anxiety Scale, HAM-A|Change in The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16, QLESQ-16|Change in Visual Analogue Scale for GI symptoms (VAS-GI)|Change in Color Trails Test (CTT)|Change in levels of exploratory blood-based biomarkers for inflammatory and/or oxidative stress changes|Change in Gut microbiome|Change in WAIS-IV	Mackay Memorial Hospital|Bened Biomedical Co., Ltd.	All	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	240	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other	20CT060be	April 1, 2022	February 24, 2024	February 24, 2024	July 21, 2021		July 12, 2022	Mackay Memorial Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT04971096
124	NCT02211560	Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment		Terminated	No Results Available	Mild Cognitive Impairment	Other: Phosphatidylserine|Other: Placebo	Difference in change in the Selective Reminding Test (SRT) between the study groups.|Mini Mental State Examination (MMSE)|Computerized Neurological battery test (NBT)|Transition rate to dementia according to DSM-4 criteria|Mini Sleep Questionnaire (MSQ)|Hamilton Anxiety Rating Scale (HAM-A).|Selective Reminding Test (SRT)	Enzymotec	All	65 Years to 85 Years   (Older Adult)	Not Applicable	97	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	Vayacog_002	September 2014	December 25, 2017	December 25, 2017	August 7, 2014		February 5, 2018	Pharmacology Research Institute, Encino, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|New West Physicians, PC, Golden, Colorado, United States|Miami Jewish Health Systems, Miami, Florida, United States|APG Research LLC, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Memory Enhancement Center of America, Eatontown, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|The Medical Research Network, New York, New York, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Rambam medical center, Israel, Haifa, Israel|Ichilov medical center, Tel-Aviv, Israel		https://ClinicalTrials.gov/show/NCT02211560
125	NCT01425957	Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment		Completed	No Results Available	MILD COGNITIVE IMPAIRMENT	Procedure: Lumbar puncture	Part A: Magnetic Resonance Imagery protocol|Part B: Changes of the hippocampal volume|Part B: Clinical assessment|Part B: Neuropsychology|Part B: Neurophysiology|Part B: Magnetic Resonance Imagery and functional MRI|Part B: Blood drawing|Part B: Actigraphy|Adverse events	Qualissima|European Union	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	229	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	WP5P001|2011-A00985-36	December 2011	August 2015	October 2015	August 30, 2011		November 1, 2015	Université Lille 2, UL2 - Centre d'investigation clinique / Centre de Ressources biologiques 9301 - INSERM - Centre Hospitalier Régional et Universitaire de LILLE, Lille, France|APHM, Hopital de la Timone, Service de Neurologie et Neuropsychologie, Marseille, France|INSERM - CHU Purpan, Toulouse, France|Hospital and Institute of the University of Duisburg and Essen - Department for Psychiatry and Psychotherapy, LVR Hospital Essen, Essen, Germany|University Hospital of Leipzig - Department of Psychiatry, Leipzig, Germany|Aristotle University of Thessaloniki, Greek Association of Alzheimer's disease and related disorders, Thessaloniki, Greece, Thessaloniki, Greece|IRCCS-FBF - Ordine Ospedaliero San Giovanni di Dio, Fatebenefratelli, Istituto di Ricovero e Cura a Carattere Scientifico, Brescia, Provincia Lombardo-Veneta, Italy|Neurofisiologia Clinica IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Padiglione Specialita' piano Fondi, Genoa, Italy|IRCCS Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare di Napoli, Napoli, Italy|Dipartimento di Specialità medico-chirurgiche e Sanità Pubblica, Sezione di Clinica Neurologica, Centro Disturbi della Memoria, Perugia, Italy, Perugia, Italy|Università Cattolica del Sacro Cuore - Policlinico Agostino Gemelli Istituto di Neurologia - Neuropsychological and Neurorehabilitation Unit, Roma, Italy|VUmc Alzheimercentrum, Amsterdam, Netherlands|Institut d'Investigacions Biomèdiques August Pi I Sunyer, IDIBAPS, Barcelona, Catalunya, Spain		https://ClinicalTrials.gov/show/NCT01425957
126	NCT02087618	The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment	KodroSol	Unknown status	No Results Available	Mild Cognitive Impairment	Other: Kodro+|Other: Kodro+D	Compliance with Kodro Solution|Satisfaction with Kodro Solution	Mt. Sinai Medical Center, Miami|Kodro Inc.	All	60 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-05-H-02	March 2014	March 2015	June 2015	March 14, 2014		March 14, 2014	Mount Sinai Medical Center, Miami Beach, Florida, United States		https://ClinicalTrials.gov/show/NCT02087618
127	NCT01669200	Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Other: Medium Chain Triglyceride Oil|Other: Placebo Oil	Improvement in cognitive performance|Serum Ketones	Pennington Biomedical Research Center	All	50 Years and older   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PBRC12024	August 2012	August 2014	October 2014	August 20, 2012		June 9, 2014	Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States		https://ClinicalTrials.gov/show/NCT01669200
128	NCT00285753	Support Groups for Patients With Mild Cognitive Impairment and Their Partners		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: support groups	quality of life: RAND, GDS|caregiver: sense of competence (SCQ), burden of the problems in the Revised Memory and Behavioral Problems (RMBP)|Illness cognitions: Illness Cognitions Questionnaire (ICQ)|marital satisfaction: Maudsley Marital Questionnaire (MMQ)	Radboud University Medical Center|Netherlands Alzheimer Foundation	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	110	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	V-2002-018|CMO-nr: 2003/071	November 2003	October 2007	October 2007	February 2, 2006		May 21, 2008	Rijnstate Ziekenhuis, Arnhem, Gelderland, Netherlands|UMC Sint Radboud, Nijmegen, Gelderland, Netherlands		https://ClinicalTrials.gov/show/NCT00285753
129	NCT01283269	A Rehabilitation Intervention for Amnestic Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Support System|Behavioral: Computer Training	To assess participant adherence to Memory Support System (MSS) use at different levels (6 week, 10 day, or computer activity) of the training intervention. This will be measured by an overall adherence score (Adherence Assessment).|To assess participant adherence to (Memory Support System) MSS use at different levels (6 week, 10 day, or computer activity) of the training intervention. This will be measured by an overall adherence score (Adherence Assessment).|To assess participant adherence to (Memory Support System)MSS use at different levels (6 week, 10 day, or computer activity) of the training intervention. This will be measured by an overall adherence score (Adherence Assessment).	Emory University|Mayo Clinic|National Institute of Nursing Research (NINR)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	128	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	IRB00034934|R01NR012419	October 2010	August 2013	July 2014	January 25, 2011		December 4, 2014	Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Emory University, Atlanta, Georgia, United States|Mayo Clinic-Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT01283269
130	NCT01771211	Impact of Transcranial Direct Current Stimulation on Language Functions in Mild Cognitive Impairment	STIMCI	Completed	No Results Available	Mild Cognitive Impairment	Device: tDCS	Number of correct responses during word-generation tasks (max. 60)|Neural activity during word-generation task assessed by functional magnetic resonance imaging (fMRI)	Charite University, Berlin, Germany|German Research Foundation	All	45 Years to 86 Years   (Adult, Older Adult)	Not Applicable	18	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	FL379101	December 2012	July 2013	July 2013	January 18, 2013		August 22, 2013	Charite University Medicine, Department of Neurology, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01771211
131	NCT01603862	ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)	ThinkingFit	Completed	No Results Available	Mild Cognitive Impairment	Procedure: ThinkingFit programme	Activity Compliance|Cardiovascular fitness measure|Cognitive measures|Measures of quality of life and everyday activities	Dr Thomas Dannhauser|University College, London|North Essex Partnership NHS Foundation Trust	All	40 Years and older   (Adult, Older Adult)	Not Applicable	128	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ThinkingFit 1	January 2010	November 2012	November 2012	May 23, 2012		April 28, 2014	North Essex Partnership Foundation NHS Trust, Harlow, Essex, United Kingdom		https://ClinicalTrials.gov/show/NCT01603862
132	NCT01436552	Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia	FPRMCI	Unknown status	No Results Available	Mild Cognitive Impairment		Occurrence of dementia according to DSM-IV-TR criteria in MCI patients according to their cumulated score of TLE measured by EVVIE.	Centre Hospitalier Esquirol	All	50 Years and older   (Adult, Older Adult)		392	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	B1001104-10	February 2010	February 2012	February 2014	September 19, 2011		September 19, 2011	CH Esquirol, Limoges, France		https://ClinicalTrials.gov/show/NCT01436552
133	NCT01300728	Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment	MCI	Unknown status	Has Results	Mild Cognitive Impairment	Drug: NewGam 10% IVIG|Other: Placebo	Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI|Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD)|Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aβ1-42/CSF P-Tau181P Alzheimer Signature|Mean Cognitive Performance at 12 Months|Mean Cognitive Performance at 24 Months	Sutter Health	All	50 Years to 84 Years   (Adult, Older Adult)	Phase 2	52	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	IVIG-KILE-032010	January 2011	November 2014	December 2019	February 23, 2011	March 31, 2016	October 8, 2019	Sutter Neuroscience Medical Group, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT01300728
134	NCT04063956	COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT		Recruiting	No Results Available	Amnestic Mild Cognitive Impairment	Behavioral: multi-domain internet-based adaptive training program|Behavioral: active-control program	Change in Montreal Cognitive Assessment|Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 11-items version).|Change in brain volume and white matter integrity|Change in brain connectivity|Change in Mini-mental State Examination|Change in memory function|Change in Digit span forward|Change in Digit span backward|Change in Trail Making Test|Change in Boston Naming Test|Change in Activities of Daily Living|Change in Clinical Dementia Rating Scale sum of the boxes|Change in Quality of Life-Alzheimer's Disease (QoL-AD) Scale|Change in Cookie Theft picture description task	Xuanwu Hospital, Beijing|The First Affiliated Hospital of Shanxi Medical University|Shandong Provincial Hospital|First Affiliated Hospital of Zhejiang University|The First Hospital of Jilin University|Beijing Friendship Hospital|First Affiliated Hospital Xi'an Jiaotong University|Wuhan University	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	260	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2019042-XZ1	November 6, 2019	December 2022	December 2022	August 21, 2019		July 13, 2022	Xuanwu Hospital, Capital Medical University, Beijing, China		https://ClinicalTrials.gov/show/NCT04063956
135	NCT00319943	Computer-Based Therapy for Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Procedure: Computer-based training for Mild Cognitive Impairment (MCI)	The study investigates changes in a neuropsychological assessment battery pre-randomization|and upon the completion of training.|Early evaluations will be conducted from brain imaging; specifically, date|obtained via positron emission tomography (PET), magnetoencephalography (MEG),|electroencephalography (EEG), and functional magnetic resonance imaging (fMRI)|studies.	Posit Science Corporation|University of California, San Francisco|University of California, Davis|Stanford University	All	65 Years to 90 Years   (Older Adult)	Phase 1	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	OUT-108-2005	September 2004		July 2006	April 27, 2006		April 27, 2006	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT00319943
136	NCT04185298	mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment	mSIM	Recruiting	No Results Available	Amnestic Mild Cognitive Impairment	Behavioral: mSIM intervention plus activity monitoring|Behavioral: Activity monitoring	Memory Function Composite Score|Functional Abilities|Resting brain-derived neurotrophic factor (BDNF)|Resting norepinephrine (NE)	Jennifer Bramen|National Institutes of Health (NIH)|National Institute on Aging (NIA)|Saint John's Cancer Institute	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	30	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20191298|R21AG061494	October 1, 2019	April 30, 2023	April 30, 2023	December 4, 2019		April 1, 2022	Pacific Brain Health Center, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT04185298
137	NCT01219244	Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: caloric restriction|Behavioral: omega-3 supplementation|Behavioral: resveratrol supplementation|Behavioral: Placebo|Behavioral: 2nd step: intervention + physical / cognitive training|Behavioral: 2nd step: intervention + control	Alzheimer's Disease Assessment Scale - cognitive subscale|Functional/Structural brain changes|Plasma biomarkers	Charite University, Berlin, Germany|German Federal Ministry of Education and Research	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	330	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	nutrition_memory_01	August 2010	July 2016	December 2016	October 13, 2010		July 28, 2017	Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01219244
138	NCT00595582	Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine		Terminated	Has Results	Mild Cognitive Impairment	Dietary Supplement: curcumin + bioperine	Neuropsychological Scores in Patients With MCI or Mild AD.	Louisiana State University Health Sciences Center Shreveport	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LSU#H05-168	May 2005	June 2008	June 2008	January 16, 2008	May 28, 2012	May 28, 2012	Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States		https://ClinicalTrials.gov/show/NCT00595582
139	NCT04810104	Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug	PD-MIND	Not yet recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Drug: AZD0328|Drug: Placebo	Change in Attentional Intensity Index composite factor score from baseline to week 12|Change in Attentional Intensity Index composite factor score from baseline to week 6|Change in Sustained Attention Index composite factor score from baseline to week 6 and week 12|Change in Working Memory Index composite factor score from baseline to week 6 and week 12|Change in Episodic Memory Index composite factor score from baseline to week 6 and week 12|Change in Memory Speed Retrieval Index composite factor score from baseline to week 6 and week 12|Change in MoCA score from screening to week 12|Change in Sustained Attention Index composite factor score from week 12 to week 16|Change in Working Memory Index composite factor score from week 12 to week 16|Change in Episodic Memory Index composite factor score from week 12 to week 16|Change in Memory Speed Retrieval Index composite factor score from week 12 to week 16|Change in MDS-UPDRS Part III motor examination subscale score from baseline to week 12|Change in total score from the Non-Motor Symptom Scale from baseline to week 12|Change in total score from the 39-item Parkinson's Disease Questionnaire from baseline to week 12|Change in MCI-CGIC from baseline to week 12|Change in depression and anxiety subscale scores from the HADS from baseline to week 12|Incidence, nature and severity of AEs and SAEs during treatment period|Incidence of dosage reduction or treatment discontinuation during treatment period|Incidence of clinically significant changes or abnormal electrocardiogram (ECG) assessments, vital sign measurements and clinical laboratory values during treatment period|Changes in whole-brain and regionally specific brain volumes from baseline/screening to week 12|Changes in whole-brain perfusion as well as perfusion in regions of interests (ROIs) from baseline/screening to week 12|Changes in functional resting-state connectivity of the large-scale cognitive brain networks from baseline/screening to week 12	King's College London|Helse Stavanger HF|Michael J. Fox Foundation for Parkinson's Research|Parkinsons Org UK|AstraZeneca|Masaryk University|Norges Parkinsonforbund, Norway|University of Exeter|Stichting Lygature|Innovative Medicines Initiative	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	160	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PD-MIND|2019-002423-15	October 2022	January 2024	April 2024	March 22, 2021		August 17, 2022	Stavanger University Hospital, Stavanger, Norway		https://ClinicalTrials.gov/show/NCT04810104
140	NCT03686839	Feasibility Study of Neurofeedback Training for Older Adults With Mild Cognitive Impairment	Neurofeedel	Completed	No Results Available	Mild Cognitive Impairment, So Stated	Behavioral: SMR neurofeedback training to MCI	Neurofeedback Technology Acceptation Questionnaire	Fabienne Marlats|Broca Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	22	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	LUS2EEGNF	March 3, 2017	June 18, 2018	July 20, 2018	September 27, 2018		September 27, 2018	Anne-Sophie Rigaud, Paris, France		https://ClinicalTrials.gov/show/NCT03686839
141	NCT04430517	Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia		Recruiting	No Results Available	Mild Cognitive Impairment|Mild Alzheimer Disease	Drug: Nicotinamide riboside	Changes in brain NAD+|Changes in brain redox state|Changes in mitochondrial function|Changes in antioxidant glutathione (GSH) levels	Mclean Hospital|National Institute on Aging (NIA)	All	55 Years to 89 Years   (Adult, Older Adult)	Early Phase 1	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	2020P001652|1R01AG066670	March 2, 2022	April 30, 2025	April 30, 2025	June 12, 2020		March 23, 2022	McLean Hospital, Belmont, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04430517
142	NCT03133052	CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)	CTA-MCI	Unknown status	No Results Available	Amnestic Mild Cognitive Impairment	Behavioral: internet-based adaptive cognitive control training program|Behavioral: placebo program	Montreal Cognitive Assessment (MoCA)|Auditory Verbal Learning Test (AVLT)|Gray matter volume|White matter Integrity|Brain response change|Functional connectivity across regions	First Affiliated Hospital of Zhejiang University	All	55 Years and older   (Adult, Older Adult)	Not Applicable	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DTCI-cognitive training	July 9, 2017	November 2019	April 2020	April 28, 2017		February 19, 2019	The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT03133052
143	NCT01782391	Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Patients With Mild Cognitive Impairments		Withdrawn	No Results Available	Mild Cognitive Impairment, So Stated	Device: Stimulation|Device: SHAM	Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS|Amount of Slow wave Sleep, spindels, eeg-correlates, further memory systems	Charite University, Berlin, Germany	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nighttime sleep-tSOS-MCI	April 2013	December 2017	December 2017	February 1, 2013		May 24, 2021	Charite CCM Neurologie Berlin, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01782391
144	NCT01782365	Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment, So Stated	Device: SHAM stimulation|Device: 0,75 Hz stimulation	Retention of declarative memories after 0.75 Hz stimulation during SWS, vs after sham stimulation during SWS|Amount of Slow wave Sleep, spindels, eeg-correlates, further memory systems	Charite University, Berlin, Germany	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	16	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	Nap-tSOS-MCI	August 8, 2013	April 26, 2016	August 30, 2016	February 1, 2013		May 14, 2021	Charite CCM Neurologie Berlin, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01782365
145	NCT04711486	Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease		Completed	No Results Available	Mild Cognitive Impairment Due to Alzheimer's Disease	Drug: Contraloid acetate|Drug: Placebo	Safety: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Safety: Number of Participants with abnormal laboratory values (urinalysis, CBC, Quick, PTT, Creatinine, CK, CRP, ALT, AST)|Safety: Number of Participants with abnormal ECG values|Pharmacokinetics: Peak Plasma Concentration (Cmax)|Pharmacokinetics: The time at which Cmax is observed (Tmax)|Pharmacokinetics: Terminal elimination half-life (t1/2) in plasma	Charite University, Berlin, Germany|Berlin Institute of Health|Federal Agency for Disruptive Innovation - SPRIN-D	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 1	19	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ContraloidAD	December 8, 2020	January 13, 2022	January 13, 2022	January 15, 2021		August 23, 2022	Charité University Medicine, Berlin, Germany		https://ClinicalTrials.gov/show/NCT04711486
146	NCT00544791	The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment	MCI	Unknown status	No Results Available	Mild Cognitive Impairment (MCI)	Drug: melatonin|Drug: placebo like melatonin tablets	a delay in cognitive decline as measured by memory tests|Reduced MCI conversion rate to AD per year	Assaf-Harofeh Medical Center|Neurim Pharmaceuticals Ltd.	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	32/07	October 2007		October 2010	October 16, 2007		October 16, 2007	Memory clinic, 'Asaf Harofeh' medical center, Zerifin, Israel		https://ClinicalTrials.gov/show/NCT00544791
147	NCT00202540	Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients		Terminated	No Results Available	Mild Cognitive Impairment	Drug: S18986	Episodic memory|Other cognitive domains, activities of daily living, global impression of change, MRI, safety.	Institut de Recherches Internationales Servier|Servier	All	55 Years and older   (Adult, Older Adult)	Phase 2	38	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double	CL2-18986-009	June 2005	March 29, 2006	March 29, 2006	September 20, 2005		March 20, 2018	Hôpital la Grave-Casselardit, Toulouse, France		https://ClinicalTrials.gov/show/NCT00202540
148	NCT00040443	Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.		Completed	Has Results	Mild Cognitive Impairment	Drug: CX516|Drug: Placebo	15-Item Word List Delayed Recall	RespireRx	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	175	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CORX-CX516-012.1	April 2002	August 2003	June 2004	June 28, 2002	July 23, 2018	July 23, 2018	Pivotal Research Centers, Peoria, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California at Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Sun Coast Gerontology Center, University of South Florida, Tampa, Florida, United States|Mercy Mayo Clinic, Des Moines, Iowa, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00040443
149	NCT02573740	Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment		Terminated	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: ABT-957|Other: Placebo	Percentage of participants reporting treatment-emergent adverse events|Level of spectrin breakdown product-145 (SBDP-145)	AbbVie	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1	8	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	M13-730	December 2015	June 2016	June 2016	October 12, 2015		July 6, 2021	Site Reference ID/Investigator# 143180, Cypress, California, United States|Site Reference ID/Investigator# 143178, Orlando, Florida, United States|Site Reference ID/Investigator# 149484, The Villages, Florida, United States|Site Reference ID/Investigator# 143181, Marlton, New Jersey, United States|Site Reference ID/Investigator# 143182, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 149481, Dallas, Texas, United States|Site Reference ID/Investigator# 143254, Orem, Utah, United States|Site Reference ID/Investigator# 143179, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 143177, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT02573740
150	NCT04532697	Use of Gou-Teng to Treat Patients With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|White Matter Hyperintensity	Other: Uncaria Rhynchophylla (Gou-Teng)|Other: Placebo	HK-MoCA|Automatic Retinal Image Analysis (ARIA)	Chinese University of Hong Kong	All	65 Years and older   (Older Adult)	Not Applicable	56	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MCI-Gou Teng study	November 24, 2020	March 31, 2022	September 30, 2022	August 31, 2020		August 4, 2021	The Chinese University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04532697
151	NCT05172661	Effects of Physical-Cognitive Training With Different Task Models in Parkinson's Disease With Mild Cognitive Impairment		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Parkinson Disease	Behavioral: Integrated physical-cognitive training|Behavioral: Consecutive physical-cognitive training	Change from baseline dual-task walking performance at 8 weeks|Fall frequency|Change from baseline Montreal Cognitive Assessment (MoCA) score at 8 weeks	National Taiwan University Hospital	All	40 Years and older   (Adult, Older Adult)	Not Applicable	28	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	202109095RINA	November 26, 2021	June 30, 2022	July 31, 2022	December 29, 2021		January 14, 2022	National Taiwan University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT05172661
152	NCT00404014	Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery		Completed	No Results Available	Mild Cognitive Impairment	Drug: AL-208|Drug: Placebo	The primary objective of this study was to compare mild cognitive impairment in the AL-208 group with the placebo group at 14±3 days after coronary artery bypass graft (CABG) surgery.|The safety profile of AL-208 in subjects undergoing CABG surgery|The effect of treatment with AL-208 on postoperative personality changes in subjects undergoing CABG surgery|Concentration of AL-208 in plasma in subjects undergoing CABG surgery	Allon Therapeutics	All	50 Years to 79 Years   (Adult, Older Adult)	Phase 2	234	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AL 208-201	August 2006	June 2008	June 2008	November 27, 2006		October 24, 2012	Physicians Clinical Research Corp., Laguna Hills, California, United States|Sacramento Heart and Vascular Research Center, Sacramento, California, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Piedmont Hospital Research Institute, Atlanta, Georgia, United States|The Atlanta Heart and Vascular Research Group, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Chicago Heart Institute and Vein Clinic, Elk Grove Village, Illinois, United States|Illinois Heart and Vascular Foundation, Hindsdale, Illinois, United States|Indiana/Ohio Heart Cardiothoracic and Vascular Surgeons, Ft. Wayne, Indiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Cardiothoracic Associates, Flint, Michigan, United States|NYU Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Carolina Cardiovascular Surgical Associates, PA, Raleigh, North Carolina, United States|Memory Assessment and Research Services, Wilmington, North Carolina, United States|St. Vincent Mary Medical Center, Toledo, Ohio, United States|Tulsa Clinical Resesarch, LLC, Tulsa, Oklahoma, United States|Consultants in Cardiovascular Diseases Inc., Erie, Pennsylvania, United States|Clinical Research Solutions, PC, Knoxville, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Clinical Cardiovascular Research Center, Dallas, Texas, United States|St. Luke's Episcopal Hospital, Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Cardiac and Thoracic Surgical Associates, Ltd., Mechanicsville, Virginia, United States|Multicare Health Systems, Tacoma, Washington, United States|London health Sciences Centre, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00404014
153	NCT01212692	Effects of Mental Stimulation in Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment (MCI)	Behavioral: mentally stimulating activities	Self-Ordered Pointing Task|Trail-Making|Timed Instrumental Activities of Daily Living|Rey Auditory Verbal Learning Test|Self-ordered pointing task|Clinical Dementia Rating Scale|Digit Symbol Substitution Test|Digit Span|Verbal Fluency Test|Geriatric Depression Scale|Neuropsychiatric Inventory|Recollection Task|N-Back|Rivermead Behavioral Memory Test|Instrumental Activities of Daily Living|Functional Capacities for Activities of Daily Living|Multifactorial Memory Questionnaire	Johns Hopkins University|National Institute on Aging (NIA)	All	50 Years to 100 Years   (Adult, Older Adult)	Phase 2	63	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NA_00039100|R01AG034934	October 2010	June 2014	June 2014	October 1, 2010		December 9, 2015	BPRU, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01212692
154	NCT02085330	Hyperbaric Oxygen Therapy for Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment and Vascular Subcortical Ischemia	Device: Hyperbaric oxygen therapy	Vascular Dementia Assessment Scale cognitive subscale (VADAS-cog)|Daily functioning, autonomy and quality of life|Safety of HBOT in patients with mci	Assaf-Harofeh Medical Center	All	65 Years to 90 Years   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	69/13	March 2014	May 2016	February 2017	March 12, 2014		October 2, 2014	Assaf-Harofeh Medical Center, Zerifin, Israel		https://ClinicalTrials.gov/show/NCT02085330
155	NCT02190019	Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study		Unknown status	No Results Available	Apathy|Mild Cognitive Impairment	Device: Neurostar repetitive transcranial magnetic stimulator	Apathy Evaluation Scale (AES)|Trials making test	Central Arkansas Veterans Healthcare System	All	55 Years to 91 Years   (Adult, Older Adult)	Phase 4	14	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	391721	April 2014	April 2015	July 2016	July 15, 2014		February 10, 2016	Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States		https://ClinicalTrials.gov/show/NCT02190019
156	NCT02987842	Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease		Unknown status	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Device: TruScan Neurofeedback	Memory performance|General cognitive performance improvement|qEEG	Beersheva Mental Health Center	All	50 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BeershevaMHC	December 2016	December 2017	December 2017	December 9, 2016		December 13, 2016	Beer-Sheva Mental Health Center, Beer-Sheva, Israel		https://ClinicalTrials.gov/show/NCT02987842
157	NCT03831061	Cognitive Stimulation in Older With Mild Cognitive Impairment	Cognitive	Completed	No Results Available	Mild Cognitive Impairment|Randomized Controlled Trial	Other: Cognitive stimulation	The Spanish versions of the Mini-Mental State Examination (MEC-35),|The Barthel Index (Barthel)|The scale of Lawton & Brody (Lawton)|The Goldberg questionnaire (EADG)|The abbreviated Yesavage depression scale (GDS-15)	Universidad de Zaragoza	All	65 Years and older   (Older Adult)	Not Applicable	122	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	School of Health Sciences	December 2011	October 2012	December 2016	February 5, 2019		February 5, 2019			https://ClinicalTrials.gov/show/NCT03831061
158	NCT04635085	A Mixed Method Pilot Study for Patients With Mild Cognitive Impairment and Insomnia.		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Insomnia	Behavioral: Empowerment-based Cognitive behavioral therapy for insomnia for MCI	Changes from Baseline in Sleep on the 19 item The Pittsburgh Sleep Quality (PSQI) Index at the 12th week and 3 months|Changes from Baseline in Insomnia Severity on the 7-item The Chinese version of the Insomnia Severity Index (ISI-C)at the 12th week and 3 months|An Actiwatch, which contains an accelerometer (during sleep for a consecutive seven-day period)|Changes from the Cantonese version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)|Changes from the Hong Kong List Learning Test (HKLLT)|the Color Trail Test (CCT)|The Chinese Hong Kong version of the Short Form Health Survey (SF-12)	The University of Hong Kong	All	50 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	HKWC-2020-0029	November 1, 2021	November 30, 2021	March 1, 2022	November 18, 2020		September 29, 2021		"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04635085/Prot_SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04635085/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04635085
159	NCT05483790	The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment|The Cognitive Normal Elderly	Behavioral: multidomain intervention	cognitive function assessed by The Montreal Cognitive Assessment (MoCA)|cognitive function assessed by the Mini-Mental State Examination (MMSE)|MRI--T1-weighted structure imaging|MRI--resting functional MRI (rfMRI) imaging|MRI--diffusion-weighted imaging (DWI).|memory function assessed by AVLT|memory function assessed by LMT|executive function assessed by TMT-A|executive function assessed by DSST|concentration function assessed by DST|quality of life assessed by the Barthel index|quality of life assessed by EQ-5D-5L|quality of life assessed by IADL|quality of life assessed by PSMS|quality of life assessed by SF-36|social support assessed by SSRS|quality of sleep assessed by PSQI|emotion assessed by GDS-15	Huashan Hospital|School of Public Health，Fudan University|Medicine-Mental Health Center of Minhang District|Xinzhuang Community Health Service Center	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	112	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2017YFC1310504	June 1, 2020	December 31, 2024	December 31, 2024	August 2, 2022		August 3, 2022	Huashan Hospital, Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT05483790
160	NCT05320523	Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment		Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Device: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Device: GPi stimulation|Device: NBM stimulation|Device: Sham stimulation	Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events.|Change in Parkinson's Disease - Cognitive Rating Scale (PD-CRS).|Change in Mattis Dementia Rating Scale.|Change in Verbal Fluency Battery.|Change in Trail Making Task.|Change in Stroop Test.|Change in Symbol Digit Modalities Test.|Change in Parkinson's Disease Questionnaire for quality of life (PDQ-39).|Change in Questionnaire of the EuroQol-group (EQ-5D-5L).|Change in Unified Parkinson's Disease Rating Scale section I (UPDRS I).|Change in Unified Parkinson's Disease Rating Scale section II (UPDRS II).|Change in Unified Parkinson's Disease Rating Scale section III (UPDRS III).|Change in Unified Parkinson's Disease Rating Scale section IV (UPDRS IV).|Change in objective assessment of gait measured by a sensor (MobilityLab) that assess step speed.|Change in objective assessment of gait measured by a sensor (MobilityLab) that assess number of steps per minute.|Change in objective assessment of gait measured by a sensor (MobilityLab) that assess distance between heels.|Change in objective assessment of gait measured by a sensor (MobilityLab) that assess balance.|Change in objective assessment of gait measured by Time Up and Go - Test 3 meters (TUG test 3M).|Change in objective assessment of gait measured by Time Up and Go dual task - Test 3 meters (TUG dual task - test 3M).|Change in objective assessment of gait measured by freezing of gait score (FOG score).|Change in New Freezing of Gait Questionnaire (N-FOG).|Change in Falls Efficacy Scale International (FES-I).|Change in Activities-Specific Balance Confidence Scale (ABC scale).|Change in Beck Depression Inventory (BDI).|Change in Beck Anxiety Inventory (BAI).|Change in Starkstein Apathy Scale.|Change in Neuropsychiatric Inventory (NPI).|Change in Ardouin Scale of Behavior in Parkinson's Disease.	University of Sao Paulo General Hospital	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	10	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	38865720.1.0000.0068	July 20, 2021	August 2023	January 2024	April 11, 2022		April 11, 2022	University of São Paulo General Hospital, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT05320523
161	NCT01600469	NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: DAOI-B|Other: Placebo	Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24|Change from baseline in Mini Mental Status Examination at week 8, 16 and 24|Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24|Change from baseline in Verbal learning and memory at week 24|Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24	Chang Gung Memorial Hospital	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	86	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	99-2452A3	January 2012	May 2013	May 2013	May 17, 2012		June 4, 2013	Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT01600469
162	NCT02284906	AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease		Terminated	Has Results	Mild Cognitive Impairment Due to Alzheimer's Disease	Drug: Pioglitazone|Drug: Placebo	Change From Extension Study Baseline in Composite Score of a Broad Cognitive Test Battery at Month 24|Time to Diagnosis of Alzheimer's Disease (AD) Dementia	Takeda	All	65 Years and older   (Older Adult)	Phase 3	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AD-4833/TOMM40_303|U1111-1154-9637|2013-004984-30	February 12, 2015	January 31, 2018	May 8, 2018	November 6, 2014	July 2, 2019	July 2, 2019	Phoenix, Arizona, United States|Sun City, Arizona, United States|San Diego, California, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lake Worth, Florida, United States|Melbourne, Florida, United States|Merritt Island, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elk Grove, Illinois, United States|Iowa City, Iowa, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|New York, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States|North Ryde, New South Wales, Australia|Southport, Queensland, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|Basel, Switzerland|Bristol, Avon, United Kingdom|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Hammersmith, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Blackpool, Lancashire, United Kingdom|Isleworth, Middlesex, United Kingdom|Glasgow, Strathclyde, United Kingdom|Perth, Tayside Region, United Kingdom	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02284906/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02284906/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02284906
163	NCT03191916	Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Mild Cognitive Impairment (tDCS)	tDCS	Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Device: transcranial direct current stimulation|Device: Sham (for transcranial direct current stimulation)	Change in Reaction Time (RT) on contextual cueing computer task|Change in Error Rate on contextual cueing computer task|Multidimensional Fatigue Inventory (MFI)|Center for Epidemiological Studies Depression Scale (CES-D)|McGill Quality of Life (QOL) Scale|Neuropsychological battery (Stroop and Digit Span)|Montreal Cognitive Assessment (MOCA)	Sanford Health	All	Child, Adult, Older Adult	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	SH tDCS Parkinsons	October 19, 2015	August 7, 2023	August 31, 2023	June 19, 2017		November 30, 2021	Sanford Brain & Spine Center, Fargo, North Dakota, United States		https://ClinicalTrials.gov/show/NCT03191916
164	NCT04259047	Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans With Diabetes and Mild Cognitive Impairment: A Randomized Clinical Trial	DREAM	Recruiting	No Results Available	Mild Cognitive Impairment|Diabetes	Behavioral: Diabetes Regulation for Eyesight and Memory|Behavioral: Enhanced Usual Care	Decline in Verbal Memory	Thomas Jefferson University	All	65 Years and older   (Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	R01AG065467	October 25, 2021	January 31, 2025	January 31, 2025	February 6, 2020		December 16, 2021	Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04259047
165	NCT02119546	Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease		Completed	No Results Available	Mild CognitIve Impairment|Alzheimer's Disease	Other: Aerobic exercise|Other: Stretch exercise	Change from baseline in Color Trails Test at week12 and Week24|Change from baseline in walking speed at week12 and Week24	National Taiwan University Hospital	All	45 Years to 85 Years   (Adult, Older Adult)	Not Applicable	19	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	200912126R	May 2010	September 2012	December 2012	April 21, 2014		April 21, 2014	National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02119546
166	NCT04606953	Working Memory Training in Older Adults With Mild Cognitive Impairment : Impacts on Cognition and Ecological Activities	APT-II	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Behavioral: Attention Process Training (APT-II)	Mini Mental State MMSE|Digit span|PASAT (Naegele and Mazza, 2004)|Brown Peterson's Paradigm (Peterson and Peterson, 1959)|Virtual reality memory task|Continious Performance task CPT|Cognitive Failure Questionnaire|Bravo's Scale|APT-II Attention Questionnaire	University of Paris 5 - Rene Descartes|Assistance Publique - Hôpitaux de Paris	All	55 Years and older   (Adult, Older Adult)	Not Applicable	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	APT-II Project	February 1, 2019	July 30, 2021	September 27, 2021	October 28, 2020		September 29, 2021	SABA, Paris, France		https://ClinicalTrials.gov/show/NCT04606953
167	NCT01931566	Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset	TOMMORROW	Terminated	Has Results	Mild Cognitive Impairment Due to Alzheimer's Disease	Drug: Pioglitazone|Drug: Pioglitazone placebo	Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian Participants|Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian Participants|Change From Baseline for Cognitive Decline on Composite Score on the Cognitive Test Battery for Pioglitazone-treated Participants Versus Placebo-treated Participants in the High-risk Stratum|Change From Baseline in Instrumental Activities of Daily Living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) Between Pioglitazone-treated and Placebo-treated Groups of the High-risk Stratum	Takeda|Zinfandel Pharmaceuticals Inc.	All	65 Years to 83 Years   (Older Adult)	Phase 3	3494	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AD-4833/TOMM40_301|2012-003111-58|U1111-1139-0355	August 1, 2013	July 24, 2018	September 6, 2018	August 29, 2013	August 14, 2019	September 16, 2019	Phoenix, Arizona, United States|Sun City, Arizona, United States|Long Beach, California, United States|San Diego, California, United States|San Francisco, California, United States|Delray Beach, Florida, United States|Fort Myers, Florida, United States|Lady Lake, Florida, United States|Lake Worth, Florida, United States|Merritt Island, Florida, United States|Orlando, Florida, United States|Port Orange, Florida, United States|Saint Petersburg, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Elk Grove, Illinois, United States|Iowa City, Iowa, United States|Farmington Hills, Michigan, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Marlton, New Jersey, United States|New York, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Akron, Ohio, United States|Portland, Oregon, United States|Charleston, South Carolina, United States|Cordova, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Middleton, Wisconsin, United States|North Ryde, New South Wales, Australia|Southport, Queensland, Australia|West Heidelberg, Victoria, Australia|Nedlands, Western Australia, Australia|Stuttgart, Baden Wuerttemberg, Germany|Siegen, Nordrhein Westfalen, Germany|Halle, Sachsen Anhalt, Germany|Berlin, Germany|Basel, Switzerland|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Hammersmith, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Salford, Greater Manchester, United Kingdom|Blackpool, Lancashire, United Kingdom|Isleworth, Middlesex, United Kingdom|Glasgow, Strathclyde, United Kingdom|Dundee, Tayside Region, United Kingdom|Perth, Tayside Region, United Kingdom|Bristol, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01931566/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01931566/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01931566
168	NCT04899089	Cognitive Training in Mild Cognitive Impairment	TRAIN-MCI	Recruiting	No Results Available	Insomnia|Mild Cognitive Impairment	Behavioral: Cognitive Training|Behavioral: Trivia Training	Objective Cognition - Computerized Cognitive Tasks|Subjective Cognitive Self-Efficacy. - Cognitive Failures Questionnaire|Subjective Behavioral Sleep- Electronic Daily Sleep Diaries|Subjective Behavioral Sleep- Insomnia Severity Index|Objective Sleep-Watchpat|Physiological Arousal- Heart Rate Variability|Anxiety - State-Trait Anxiety Inventory|Game-related experience- Sessions and duration played|Circadian Rhythm- Morningness-Eveningness Questionnaire|Perceived Stress- Perceived Stress Scale Subjective Arousal- Perceived Stress Scale|Subjective Arousal- Arousal Predisposition Scale|Game Engagement Questionnaire|Mood-Depression-Beck Depression Inventory-II|Alcohol Use - Alcohol Use Disorder Test|Physical Activity - International Physical Activity Questionnaire|Personality - Big Five Inventory|Computer Proficiency- Computer Proficiency Questionnaire	University of Missouri-Columbia	All	60 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other	2053302	July 28, 2021	May 2023	August 2023	May 24, 2021		April 27, 2022	University of Missouri, Columbia, Missouri, United States		https://ClinicalTrials.gov/show/NCT04899089
169	NCT05495087	Intermittent Hypoxia Training: A Novel Therapy for Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Memory Impairment	Device: IHT Treatment|Other: Sham-IHT Control	Overall Cognitive Function|Attention and Short-term Memory|Cognitive Function|Visual Orientation and Executive Function|Neurotoxic Protein|Neuroprotective Protein|Cerebral Vascular Function|Brain Morphology	University of North Texas Health Science Center|University of Texas Southwestern Medical Center|National Institute on Aging (NIA)	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	66	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	R01AG076675	August 15, 2022	April 30, 2025	April 30, 2025	August 10, 2022		August 10, 2022			https://ClinicalTrials.gov/show/NCT05495087
170	NCT00422981	Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment, So Stated	Drug: AL-108|Drug: Placebo	Change from baseline to Week 12 on the Composite Memory Variable|Changes in the Composite Memory Variable from baseline to weeks 4, 8, and 16|Changes in test battery individual items from baseline to endpoints (weeks 4, 8, 12, and 16).	Allon Therapeutics	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	144	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AL-108-211	January 2007	January 2008	January 2008	January 17, 2007		October 24, 2012	Pivotal Research, Peoria, Arizona, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Synergy Research, National City, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Meridien Research, Brooksville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Meridien Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Clinical Research Center of Indian River Medical Center, Vero Beach, Florida, United States|Comprehensive Neuroscience, Hoffman Estates, Illinois, United States|The Memory Enhancement Center of America, Long Branch, New Jersey, United States|SPRI Clinical trials, Brooklyn, New York, United States|Memory Assessment and Research Services, Wilmington, North Carolina, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Senior Adults Speciality Research, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT00422981
171	NCT03839576	Motor Signature, Falls Risk, and Home-Based Interventions in Older Adults With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|Fall	Behavioral: Exercise|Behavioral: Computerized training	cognitive functions|mobility|balance|falls|depressive symptoms|fear of falling	Taipei Medical University|National Science Council, Taiwan	All	65 Years to 100 Years   (Older Adult)	Not Applicable	228	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	MOST106-2314-B-038-046	February 15, 2019	July 31, 2021	July 31, 2021	February 15, 2019		April 1, 2021	Taipei Medical University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03839576
172	NCT02706210	Magnetic Resonance Imaging-based Comparative Research in Different Mild Cognitive Impairment Subtype		Unknown status	No Results Available	Mild Cognitive Impairment		fractional anisotropy (FA)|axial diffusivity (AxD)|radial diffusivity (RD)	Mudanjiang Medical University|National Natural Science Foundation of China	All	45 Years to 80 Years   (Adult, Older Adult)		160	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	MudanjiangMU	September 2015	June 2017	December 2018	March 11, 2016		March 1, 2017	Department of Neurology, Hongqi Hospital of Mudanjiang Medical Universiy, Mudanjiang, Heilongjiang, China		https://ClinicalTrials.gov/show/NCT02706210
173	NCT04583215	Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment	PAS-MCI	Recruiting	No Results Available	Mild Cognitive Impairment|Memory Impairment	Device: Paired Associative Stimulation (PAS)	PAS-Long-term-potentiation (PAS-LTP)|Change in PAS-Long-term-potentiation (PAS-LTP)|N-Back Performance|Change in N-Back Performance|Executive Function Composite Measure|Change in Executive Function Composite Measure	Centre for Addiction and Mental Health	All	60 Years and older   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	050/2019	October 12, 2020	February 1, 2025	April 1, 2025	October 12, 2020		August 11, 2022	Centre for Addiction and Mental Health, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04583215
174	NCT01482351	Mild Cognitive Impairment and Obstructive Sleep Apnea	MEMORIES	Completed	Has Results	Obstructive Sleep Apnea|Mild Cognitive Impairment	Behavioral: CPAP adherence intervention|Behavioral: Attention control intervention	Hopkins Verbal Learning Test-Revised (HVLT-R)|Digit Symbol Subtest (DS)|Mini Mental State Evaluation Exam (MMSE)|Stroop Color and Word Test (SCW)|The Psychomotor Vigilance Task (PVT)|Epworth Sleepiness Scale [ESS]|Functional Outcomes Sleep Questionnaire (FOSQ)|Everyday Function Outcome: Everyday Cognition (E-Cog)|Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)|Clinical Dementia Rating Scale (CDR)	George Mason University|National Institute on Aging (NIA)|University of Pennsylvania	All	55 Years to 89 Years   (Adult, Older Adult)	Not Applicable	54	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	7584|R01AG034682-01A2	September 2012	December 2014	December 2014	November 30, 2011	January 29, 2019	March 6, 2019	Abington Memorial Hospital, Abington, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|George Mason University, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT01482351
175	NCT04736017	Auditory Slow Wave Enhancement in Parkinson Disease and Mild Cognitive Impairment	PDMCI-TS	Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Device: TSB Axo	Difference in objective EDS|Difference in verbal episodic memory performance|Subjective EDS|Sustained attention|Vigilance|Subjective nocturnal sleep quality|Executive Function and attention|Plasma biomarkers|Subjective sleep quality|Subjective mood|Subjective momentary sleepiness|Digital biomarkers|Sleep intensity|Depressive symptoms|Verbal episodic and visuospatial memory function|Quality of life (VAS)|Motor symptoms|Focused motor assessment|Overnight memory consolidation|Overnight restoration inhibitory control|Overnight restoration working memory|Overnight restoration vigilance	University of Zurich	All	18 Years and older   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	PDMCI-TS	April 1, 2021	March 31, 2024	March 31, 2024	February 3, 2021		April 12, 2022	University Hospital Zurich, Neurology department, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04736017
176	NCT03542474	Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease		Completed	Has Results	Parkinson Disease|Mild Cognitive Impairment	Behavioral: High Intensity Endurance Exercise	Mean Change in Cognitive Function|6 Month Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score|6 Month Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Motor Experiences of Daily Living)|6 Month Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Non Motor Experiences of Daily Living Score|6 Month Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Motor Complications Score|6 Month Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Motor (Part III) Score|6 Month Change in Sleep Quality Evaluated by the Epworth Sleepiness Scale (ESS)|6 Month Change in Sleep Quality Evaluated by the Pittsburg Sleep Quality Index (PSQI)|6 Month Change in Fatigue Evaluated by the Fatigue Severity Scale|6 Month Change in Mood Evaluated by the Hamilton Depression Scale (HAM-D)|6 Month Change in Quality of Life Evaluated by the Parkinson Disease Neuro Quality of Life (Neuro-QOL)|6 Month Change in Quality of Life Evaluated by the Parkinson Disease Questionnaire 39 (PDQ-39)|The Boston Naming Test|Verbal Fluency Test|Benton Judgement of Line Orientation Test|Intersecting Pentagon Copying Test|Mini Balance Evaluation Systems Test|Timed Up and Go Test (TUG)|Six Minute Walk Test|Activities Specific Balance Confidence Scale|New Freezing of Gait Questionnaire|6 Month Change in Hippocampus Volumes on Structural MRI|6 Month Change in Microstructural Integrity of White Matter Pathways on Diffusion Tensor Imaging|6 Month Change in Functional Connectivity Among Brain Networks on Resting State fMRI|6 Month Change in Salivary Cortisol Levels|6 Month Change in Soluble Inflammatory Biomarkers in Plasma|6 Month Change in Peripheral Levels of Neurotrophic Factors in Plasma	Northwestern University|Rush University Medical Center|Shirley Ryan AbilityLab	All	40 Years to 85 Years   (Adult, Older Adult)	Not Applicable	8	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STU00202794	May 15, 2017	November 5, 2018	August 31, 2019	May 31, 2018	July 14, 2020	July 14, 2020	Northwestern University, Chicago, Illinois, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03542474/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03542474
177	NCT04070703	Tai Ji Quan and Cognitive Function in Older Adults With Mild Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: The Go for Exercise & Healthy Aging Project	Montreal Cognitive Assessment|gait under a dual-task condition - walking with no cognitive task, walking with a concurrent cognitive task|Clinical Dementia Rating|Paper-and-pencil domain-specific cognitive battery tests|Computerized cognitive battery tests|Physical performance - Functional Reach; Short Physical Performance Battery	Oregon Research Institute	All	65 Years to 95 Years   (Older Adult)	Not Applicable	332	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	AG059546	October 15, 2019	June 2023	December 2023	August 28, 2019		July 18, 2022	Oregon Research Institute, Eugene, Oregon, United States		https://ClinicalTrials.gov/show/NCT04070703
178	NCT01496222	The Montreal Cognitive Assessment as a Screening Tool for Preoperative Mild Cognitive Impairment in Geriatric Patients	MoCA	Unknown status	No Results Available	Mild Cognitive Impairment		Incidence of mild cognitive impairment in preoperative geriatric patients|Relationship between mild cognitive impairment and drug used preoperatively in geriatric patients	Mahidol University	All	65 Years and older   (Older Adult)		582	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	460/2554(EC2)	January 2012	October 2015	April 2016	December 21, 2011		March 16, 2016	Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand		https://ClinicalTrials.gov/show/NCT01496222
179	NCT03895346	Mental Training for Adults With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment|Aging	Behavioral: Mindfulness|Behavioral: Brain Games and Puzzles	Recruitment feasibility|Retention|Adherence to study protocol	Massachusetts General Hospital	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	22	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2018P002574	April 10, 2019	March 30, 2020	December 31, 2021	March 29, 2019		September 15, 2022	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03895346
180	NCT05215717	Hypnosis for Sleep Quality for Individuals With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|Poor Quality Sleep	Behavioral: Self-Administered Hypnosis|Behavioral: Self-Administered White Noise Hypnosis	Daily At-home Self-Hypnosis Practice Log|Program Rating Scale|Treatment Satisfaction Scale|Wrist Actigraphy - Objective Sleep Duration|Pittsburgh Sleep Quality Index|Daily Sleep Diaries|Epworth Sleepiness Scale|Sleep Environment Questionnaire|Attitudes Toward Hypnosis Scale|Insomnia Severity Index|Perceived Stress Scale|PROMIS Cognitive Function - Short Form|Pain Visual Analog Scale|Motivation Scale	Baylor University|National Center for Complementary and Integrative Health (NCCIH)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	3R01AT009384-05S1	February 22, 2022	August 31, 2022	August 31, 2022	January 31, 2022		March 15, 2022	Baylor University, Waco, Texas, United States		https://ClinicalTrials.gov/show/NCT05215717
181	NCT04795466	Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Biological: Canakinumab|Other: Placebo	Change from baseline in cognition as measured by the Neuropsychological Test Battery (NTB) total score|Number of participants who experience adverse events and serious adverse events|Change from baseline in microglia activation as measured by Positron-Emission Tomography-Translocator Protein 18kDa - microglia activation|Change from baseline in neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) total score|Change from baseline in function (activities of daily living) as measured by the Everyday Cognition (eCog) total score|Change from baseline in memory as measured by the total Neuropsychological Test Battery memory composite score and change from baseline in executive function as measured by the total Neuropsychological Test Battery executive function composite score|Change from baseline in pharmacokinetic concentrations and immunogenetic anti-agent antibody levels in serum and/or plasma and/or cerebrospinal fluid	Novartis Pharmaceuticals|Novartis	All	45 Years to 90 Years   (Adult, Older Adult)	Phase 2	90	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CADPT06A12201	October 28, 2021	January 22, 2024	January 22, 2024	March 12, 2021		April 15, 2022	Novartis Investigative Site, Charlestown, Massachusetts, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Fairfax, Virginia, United States|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT04795466
182	NCT05411822	Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Device: Lighting Intervention Blue light|Device: Lighting Intervention Green light	Change in melatonin levels	Icahn School of Medicine at Mount Sinai	All	55 Years and older   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	GCO 21-0400	September 28, 2021	June 2023	August 2023	June 9, 2022		June 9, 2022	Light and Health Research Center at Mount Sinai, Menands, New York, United States		https://ClinicalTrials.gov/show/NCT05411822
183	NCT01429623	A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment|Dementia	Drug: ladostigil hemitartrate|Drug: Placebo	Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo|Change in Geriatric Depression Scale for Ladostigil Versus Placebo Population|Change in Neuropsychiatric Test Battery for Ladostigil Versus Placebo Population|Change in Disability Assessment in Dementia for Ladostigil Versus Placebo Population	Avraham Pharmaceuticals Ltd	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CO17730|2011-004187-30	February 2012	July 2016	September 2016	September 7, 2011	June 15, 2017	June 15, 2017	Medizinische Universitat Graz, Abteilung fur Neurologie, Graz, Austria|Landeskrankenhaus Hall, Memory Klinik, Hall in Tirol, Austria|Privatordination Rainer, Wien, Austria|Studienambulanz St. Joseph Krankenhaus Berlin, Emovis GmbH, Berlin, Germany|Otto-von-Guericke-Universitat, Universitatsklinik fur Neurologie und fur Stereotaktische, Magdeburg, Germany|Studienzentrum Nordwest, Westerstede, Germany|Department of Geriatrics and Memory Clinic, Mental Health Center, Israel, Beersheva, Israel|Cognitive Neurology Unit, Rambam Health Care Campus, Haifa, Israel|Cognitive Clinic, Department of Geriatrics, Carmel Medical Center, Haifa, Israel|Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, PO Box 24035, Jerusalem, Israel|Memory Clinic, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Center for Memory and Attention Disorders, Department of Neurology, Sourasky Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT01429623
184	NCT03923712	Exercise, Brain, Cognition, OMICs, Molecular Markers and Functionality in People at Risk of Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Dementia	Behavioral: Supervised Exercise Programme	Assessed changes from Baseline Neuroimaging Markers of Brain Structures (thickness in mm; volumes in mm)|Assessed changes from Baseline Neuroimaging Markers of Brain Function (level of activity in percentage)|Assessed changes from Baseline Cognitive Status|Assessed changes from Baseline OMICs Analysis|Assessed changes from Baseline Molecular Makers|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Muscle-skeletal|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Cardiorespiratory fitness|Assessed changes from Baseline Physical Health Parameters on Functional capacity:Agility-motor coordination|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Flexibility|Assessed changes from Baseline Physical Health Parameters on Functional capacity: Handgrip strength|Assessed changes from Baseline Incremental Exercise test:|Assessed changes from Baseline Physical Health by the Scale of instrumental activities of the daily life of Lawton and Brody|Assessed changes from Baseline Physical Health of hemodynamic status|Assessed changes from Baseline Physical Health of Body Composition: Weight|Assessed changes from Baseline Physical Health of Body Composition:Height|Assessed changes from Baseline Physical Health of Body Composition: Waist Circumference|Assessed changes from Baseline Physical Health of Body Composition: Body mass index|Assessed changes from Baseline Physical Health of Body Composition: Total body fluids|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile: Glucose.|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:Total cholesterol|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:HDL cholesterol|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile: LDL Cholesterol|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:triglycerides|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:Apolipoprotein B|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile:Insulin|Assessed changes from Baseline Blood Sample of the Cardio-metabolic Risk Factors Profile: HOMA|Assessed changes from Baseline Blood Sample of the Antioxidant Capacity|Assessed changes from Baseline Blood Sample of the Neurotrophic Factor Derived from the Brain (neurotransmitter)|Assessed of Baseline levels for Cerebrospinal fluid:|Assessed changes from Baseline Quality of life as assessed through the quality of life questionnaire related to health (Short-Form Health Survey 36 -SF36)|Assessed changes from Baseline of Depression using the Geriatric Depression Scale (GDS)|Assessed changes from Baseline of Sociodemographic Characteristics: Age.|Assessed changes from Baseline of Sociodemographic Characteristics.Sex.|Assessed changes from Baseline of Sociodemographic Characteristics.Marital Status.|Assessed changes from Baseline of Sociodemographic Characteristics.Educational level and socio-economic status.|Assessed changes from Baseline of Sociodemographic Characteristics.Family history of dementia.|Assessed changes from Baseline of Sociodemographic Characteristics.Medication.|Assessed changes from Baseline of Sociodemographic Characteristics. Other pathologies.	University of Cadiz|Centro de Excelencia en Metabolómica y Bioanálisis (CEMBIO)|Servicio Central de Neuroimagen de la Universidad Pablo de Olavide|Consejería de Salud y Bienestar Social, Andalucía	All	65 Years to 75 Years   (Older Adult)	Not Applicable	98	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	DEP2016-76123-R|PI-0002-2017	January 15, 2018	December 31, 2020	December 31, 2020	April 23, 2019		April 27, 2021	University of Cádiz, Cadiz, Spain		https://ClinicalTrials.gov/show/NCT03923712
185	NCT04748354	Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment		Recruiting	No Results Available	Hip Fractures|Mild Cognitive Impairment	Behavioral: Otago Exercise Program|Other: Usual Care	Change in Physiological Profile Assessment|Change in Short Physical Performance Batter|Change in Usual Gait Speed|Change in Life Space Assessment|Change in NIH Cognitive Toolbox|Change in Digit Symbol Substitute Test|Change in Center for Epidemiological Studies Depression Scale|Change in Positive and Negative Affect Scale|Change in EQ-5D-5L|Change in ICE-CAP|Change in Physical Activity for the Elderly|Health Resource Utilization|Total Number of Prospective Falls|Change in Activities Specific Balance Confidence|Change in PROMIS Sleep Disturbance	University of British Columbia|Amgen	All	65 Years and older   (Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	H19-03812	May 3, 2021	December 31, 2022	December 31, 2022	February 10, 2021		August 31, 2022	University of British Columbia, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT04748354
186	NCT01519271	Mild Cognitive Impairment in Parkinson's Disease		Completed	Has Results	Parkinson's Disease|Mild Cognitive Impairment	Drug: Exelon Patch (rivastigmine transdermal system)|Drug: Placebo Patches	Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC)|Montreal Cognitive Assessment (MoCA)	University of Pennsylvania	All	40 Years to 85 Years   (Adult, Older Adult)	Phase 4	28	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	813803	December 2011	June 2014	June 2014	January 26, 2012	April 7, 2017	April 7, 2017	University of Pennsylvania, Ralston House, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01519271
187	NCT04663256	Effects of Cognitive Stimulation in Older People With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment|Older People	Other: Cognitive stimulation group	MMSE (mini-mental state examination)|Yesavage Geriatric Depression Scale Adjetivo 1 relating to old people, especially with regard to their healthcare. a geriatric hospital Sustantivo 1 an old person, especially one receiving special care. a rest home for geriatrics.|Hamilton Scale for Anxiety.|SF-36 (The Short Form-36 Health Survey)	University of Jaén	All	70 Years and older   (Older Adult)	Not Applicable	85	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	University of Jaén_2020	January 11, 2021	April 5, 2021	April 12, 2021	December 10, 2020		May 26, 2022	U.E.D. Virgen de la Capilla, Jaén, Spain		https://ClinicalTrials.gov/show/NCT04663256
188	NCT01451749	Efficacy and Safety Study of Shenwu Capsule		Completed	Has Results	Mild Cognitive Impairment	Drug: Shenwu Capsule|Drug: Donepezil	Change in Cognitive Scores: Alzheimer Disease Assessment Scale-cognitive. Subscale (ADAS-cog)|Change in Memory Scores: The Delayed Story Recall (DSR) Test From the Adult Memory and Information Processing Battery (AMIPB)|Change in Functional Scores: Instrumental Activities of Daily Living (IADL).	North China Pharmaceutical Group Corporation	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 3	324	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SFDA2001ZL116-SW|NorthChinaPGC	September 2008	May 2009	May 2010	October 14, 2011	October 10, 2014	October 10, 2014	Dongzhimen Hospital,BUCM, Beijing, China		https://ClinicalTrials.gov/show/NCT01451749
189	NCT02503501	Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease		Terminated	Has Results	Mild Cognitive Impairment|Alzheimer's Disease (AD)	Drug: Insulin glulisine|Drug: Placebo	Change in Cognition as Measured by the Alzheimer's Disease Assessment Scale - Cognitive 13 (ADAS-Cog 13)|Change in Functional Performance as Measured by the Clinical Dementia Rating (CDR) Scale|Change in Functional Performance as Measured by the Functional Activities Questionnaire (FAQ)	HealthPartners Institute	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	49	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IN-INSUL-MCI-AD	September 28, 2015	February 11, 2019	February 15, 2019	July 21, 2015	April 9, 2020	April 9, 2020	HealthPartners Riverside, Minneapolis, Minnesota, United States|HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02503501/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02503501
190	NCT04522739	Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease	STAND	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Drug: Spironolactone|Drug: Placebo	Count of Adverse Events|Attrition rate|Change in Trail Making Test Part A Score|Change in Trail Making Test Part B Score|Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall Score|Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall Score|Change in Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index Score|Change in Digit Span Test Score	Emory University|Alzheimer's Association	All	50 Years and older   (Adult, Older Adult)	Phase 4	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	STUDY00000124	September 6, 2022	September 2023	September 2023	August 21, 2020		September 8, 2022	Emory Clinic at Executive Park, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT04522739
191	NCT04085107	The Moderating Roles of Social Support, Coping Resources and Personality and Mediating Role of Self-esteem on the Impact of Cognitive Deficit on Neuropsychiatric Symptoms Among Persons With Mild Cognitive Impairment: A Mixed-method Sequential Explanatory Design		Completed	No Results Available	Mild Cognitive Impairment|Behavioral Symptoms	Behavioral: Face-to-face interviews	Chinese Version of the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Hong Kong Chinese version of Montreal Cognitive Assessment (HK-MoCA)|Chinese version of Chinese version of Mild Behavioural Impairment -Checklist|Chinese version of Simplified Coping Scale Questionnaire (SCSQ)|Chinese version of Multidimensional Scale of Perceived Social Support (MSPSS-C)|Chinese version of the neuroticism subscale of NEO Personality Inventory (NEO-PI)|Rosenberg self-esteem scale (RSES)	Chinese University of Hong Kong	All	18 Years and older   (Adult, Older Adult)		152	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	00000	March 29, 2020	December 29, 2020	December 29, 2020	September 11, 2019		January 20, 2021	University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04085107
192	NCT04364191	Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment	MBSI-I	Recruiting	No Results Available	Mild Cognitive Impairment|Insomnia	Behavioral: Multicomponent Behavioral Sleep Intervention for Insomnia|Behavioral: Active Control	Sleep latency|health related quality of life (HRQOL)|Wake after sleep onset (WASO)|Total sleep time (TST)|Sleep efficiency (SE)|Self- reported insomnia symptoms|self-reported sleep quality	University of Pennsylvania	All	55 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	832826	May 13, 2021	July 2022	July 2022	April 28, 2020		June 9, 2021	University of Pennsylvania, Philadelphia, Pennsylvania, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04364191/Prot_SAP_002.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04364191/ICF_003.pdf	https://ClinicalTrials.gov/show/NCT04364191
193	NCT05058950	An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging	Intuition	Recruiting	No Results Available	Mild Cognitive Impairment|Normal Aging		Sensitivity and Specificity of the Classifier in Distinguishing Between Individuals With and Without MCI|Correlation Between the Cognitive Wellness Score and the Neuropsychological Testing Battery Score|Sensitivity and Specificity of the Classifier in Predicting Between Individuals Who Do and Do Not Develop MCI	Biogen|Apple Inc.	All	21 Years to 86 Years   (Adult, Older Adult)		23000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	285PI401	September 20, 2021	December 31, 2024	December 31, 2024	September 28, 2021		June 2, 2022	Virtual App-Based Study, Cambridge, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT05058950
194	NCT02020564	Speed of Processing Training to Improve Cognition in Traumatic Brain Injury and Mild Cognitive Impairment		Active, not recruiting	No Results Available	Traumatic Brain Injury|Mild Cognitive Impairment	Behavioral: Speed of Processing Training|Behavioral: Placebo Control	Symbol-Digit Modalities Test|TBI Quality of Life, Depression scale|Perceived Deficits Questionnaire|TBI Quality of Life, Total Score	Kessler Foundation	All	18 Years to 59 Years   (Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R-755-12	December 12, 2012	December 30, 2022	December 30, 2022	December 25, 2013		September 30, 2021	Kessler Foundation, East Hanover, New Jersey, United States		https://ClinicalTrials.gov/show/NCT02020564
195	NCT02953964	Memory Encoding Strategies for People With Mild Cognitive Impairments		Completed	No Results Available	Mild Cognitive Impairment|Mild Dementia	Other: Behavioral: perceptual-based memory encoding training|Other: Behavioral: semantic-based memory encoding training|Other: Behavioral: Cognitive stimulation group (control group)	Change in Disability Assessment for Dementia|Change in Instrumental Activities of Daily Living Scale|Change in Cognistat|Change in Digit Span Test|Change in Consortium to Establish a Registry for Alzheimer's Disease	University of Western Sydney	All	60 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	Memory encoding	May 2010	October 2015	October 2015	November 3, 2016		November 3, 2016	Western Sydney University, Penrith, New South Wales, Australia|The Hong Kong Polytechnic University, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT02953964
196	NCT04184037	iMeditate at Home for Older Adults With Mild Cognitive Impairment and Caregivers		Terminated	No Results Available	Mild Cognitive Impairment|Caregivers	Behavioral: Mindfulness meditation delivered via a mobile app	Change in the Perceived Stress Scale (PSS-10) score|Recruitment rate|Total number of meditation sessions|Change in breath counting accuracy|Change in the Mindfulness Attention and Awareness Scale (MAAS) score|Change in the Beck Depression Inventory (BDI-II) score|Change in the Brief Symptom Inventory (BSI) score|Change in the Warwick Edinburgh Mental Well-being Scale (WEMWBS) score|Change in the quality of life (WHO-Quality of Life BREF) score|Change in the Sleep Disturbance score|Change in the Multifactorial Memory Questionnaire (MMQ)-Ability scale score|Change in the Multifactorial Memory Questionnaire (MMQ)-Satisfaction scale score|Change in the Conor-Davidson Resilience Scale (CD-RISC) score|10-item Burden Scale for Family Caregivers (BSFC-s)|Average hours of technical support per person|Change in visual working memory|Change in visual attention|Change in event-related potentials in the auditory oddball task|Toronto Mindfulness Scale (TMS)|Change in the Credibility/Expectancy Questionnaire Score|Retention rate|Mean duration of meditation sessions|Study acceptability score|Change in EEG features during meditation|Change in resting state EEG features with eyes open|Change in resting state EEG features with eyes closed	Baycrest|Center for Aging and Brain Health Innovation|InteraXon, Inc.	All	20 Years to 90 Years   (Adult, Older Adult)	Not Applicable	9	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	REB #18-34	November 15, 2019	March 30, 2020	March 30, 2020	December 3, 2019		March 2, 2022	Baycrest, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04184037
197	NCT03232047	Computerized Cognitive Training for MCI		Unknown status	No Results Available	Mild Cognitive Impairment	Device: Combined executive function and memory training	Composite working memory z score|cognitive test package (CTP)|Self evaluated memory ability|Brain Functional Imaging|Electrical activity of the brain|Brain structural imaging|cerebral blood flow|Mood|BDNF level|Composite of overall cognition z scores	Peking University	All	60 Years to 89 Years   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	Z161100000516001	August 1, 2017	December 1, 2019	December 31, 2019	July 27, 2017		March 21, 2019	Peking University Institute of Mental Health(Six Hospital), Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03232047
198	NCT05469009	Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease 1	Drug: Aducanumab|Device: Exablate Model 4000 Type 2	Treatment intervention related adverse events|Treatment intervention related serious adverse events|Beta-Amyloid plaques within the brain|Cognitive performance (ADAS COG 11)|Cognitive performance (MMSE)	Ali Rezai|InSightec|West Virginia University	All	50 Years to 85 Years   (Adult, Older Adult)	Early Phase 1	5	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	2110449196	July 14, 2022	July 2029	July 2029	July 21, 2022		August 19, 2022	West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia, United States		https://ClinicalTrials.gov/show/NCT05469009
199	NCT04771845	Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease		Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: Transcranial Magnetic Stimulation	Controlled Oral Word Association Test|Boston 30-item naming test|Wechsler Adult Intelligence Scale III|Wechsler Memory Scale III|Buschke Selective Reminding Test, 12 item|Buschke Selective Reminding Test, 12 item, 15 minute|Rosen Drawing Test|Processing speed|Mini-mental status examination	The New York Memory Services	All	Child, Adult, Older Adult		73	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	20-0812	May 1, 2008	May 30, 2020	May 30, 2020	February 25, 2021		February 25, 2021			https://ClinicalTrials.gov/show/NCT04771845
200	NCT03911765	Effect of Digital Cognitive Training on the Functionality of Older Adults With Mild Cognitive Impairment (MCI)		Unknown status	No Results Available	Mild Cognitive Impairment|Aging	Behavioral: digital cognitive training	Performance in everyday living score change|Functional status score change	Universidade Federal do Rio de Janeiro	All	65 Years and older   (Older Adult)	Phase 1	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	17976113.1.0000.5257	January 2, 2019	July 1, 2019	December 2, 2019	April 11, 2019		April 17, 2019	Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil		https://ClinicalTrials.gov/show/NCT03911765
201	NCT04929990	The Effect of Respiratory Muscle Training for Patients With COPD and Mild Cognitive Impairment		Completed	No Results Available	Chronic Obstructive Pulmonary Disease|Mild Cognitive Impairment	Behavioral: Respiratory muscle training	MMSE|Diaphragmatic thickness fraction|chronic obstructive pulmonary disease assessment test (CAT)|diffusing capacity of the lung for carbon monoxide (DLCO)|dead space fraction (Vd/Vt)|the distance walked in 6 minutes|Diaphragmatic excursion|forced vital capacity|forced expiratory volume in 1 second|forced expiratory volume in 1 second divided by forced vital capacity|DLCO divided by alveolar volume (VA)|modified Medical Research Council (mMRC)|minute ventilation to carbon dioxide output (VE/VCO2) slope|the change of oxygen saturation in 6 minutes walking test|the change of Borg scale in 6 minutes walking test	Taichung Veterans General Hospital	All	Child, Adult, Older Adult	Not Applicable	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CF18259A	August 7, 2018	April 6, 2021	June 2, 2021	June 18, 2021		June 18, 2021	Taichung Veterans General Hospital, Taichung, Taiwan		https://ClinicalTrials.gov/show/NCT04929990
202	NCT04491578	An Advance Care Planning Programme for Persons With Early Stage Dementia or Mild Cognitive Impairment in the Community		Enrolling by invitation	No Results Available	Dementia Mild|Mild Cognitive Impairment	Behavioral: ACP programme "Have a Say"	Change in advance care planning engagement|Change in dyadic concordance of end-of-life care preferences	Hong Kong Metropolitan University|Chinese University of Hong Kong|Food and Health Bureau, Hong Kong	All	55 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	HMRF 03180198	January 9, 2021	August 31, 2022	October 31, 2022	July 29, 2020		September 16, 2022	HKSKH Lok Man Alice Kwok Integrated Service Centre, Kowloon, Hong Kong|Hong Kong Christian Service, Kowloon, Hong Kong|Yang Memorial Methodist Social Service Choi Hung Community Centre for Senior Citizens, Kowloon, Hong Kong|Jockey Club Centre for Positive Ageing, Sha Tin, Hong Kong|The Neighbourhood Advice- Action Council Ma On Shan Neighbourhood Elderly Centre, Sha Tin, Hong Kong|The Neighbourhood Advice-Action Council Sham Shui Po District Elderly Community Centre, Sham Shui Po, Hong Kong|The Neighbourhood Advice-Action Council Tuen Mun District Integrated Services Centre for the Elderly, Tuen Mun, Hong Kong|Yau On Lutheran Centre for the Elderly, Tuen Mun, Hong Kong|HKSKH Chuk Yuen Canon Martin District Elderly Community Centre, Wong Tai Sin, Hong Kong|Pentecostal Church of Hong Kong Ltd.Choi Wan Neighbourhood Elderly Centre, Wong Tai Sin, Hong Kong		https://ClinicalTrials.gov/show/NCT04491578
203	NCT02155946	Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease	Device: Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit	Face-name Memory Test Performance|Object Location Association Memory Test Performance - Cued Recall Condition|fMRI Betaweight Change|Prose Memory|MMQ - Strategy Subscale|Spatial Navigation	VA Office of Research and Development	All	50 Years to 88 Years   (Adult, Older Adult)	Not Applicable	107	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	N1534-R	December 1, 2014	February 28, 2021	March 31, 2021	June 4, 2014	September 1, 2022	September 1, 2022	VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02155946/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02155946/SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02155946/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT02155946
204	NCT04507815	tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: Active Transcranial Direct Current Stimulation (tDCS)|Device: Sham Transcranial Direct Current Stimulation (tDCS)	Change in Brief Test of Adult Cognition by Telephone (BTACT)	Minneapolis Veterans Affairs Medical Center	All	60 Years and older   (Adult, Older Adult)	Not Applicable	50	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	VAM-20-00623	September 24, 2020	March 2022	September 2022	August 11, 2020		September 5, 2021	Minneapolis VA Health Care System, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04507815
205	NCT05078437	Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia	AMOR-KY	Recruiting	No Results Available	Dementia|Mild Cognitive Impairment	Behavioral: Medication therapy management	Change in medication use|Participant satisfaction|Connectivity issues|Deprescribing assessments|Caregiver assessment|Cognitive function	Daniela Moga|National Institute on Aging (NIA)|Northern California Institute of Research and Education|University of Kentucky	All	60 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	69305|R24AG064025	October 14, 2021	July 2023	July 2023	October 14, 2021		June 27, 2022	University of Kentucky, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT05078437
206	NCT01464515	Efficiency of Deep Transcranial Magnetic Stimulation on Patients With Mild Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Device: H-Coil Deep TMS|Device: SHAM Coil TMS	Mindstreams|CDR - Clinical Dementia Rating	Brainsway	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 1	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	P-0021	January 2021	January 2021	January 2021	November 3, 2011		July 14, 2020	Ichilov Hospital, Neurological Department, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT01464515
207	NCT05104463	A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease		Recruiting	No Results Available	Mild Cognitive Impairment|Dementia	Drug: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107	Treatment-emergent adverse events|Vital Signs|Electrocardiograms (ECGs)|Change from Baseline in CANTAB Reaction Time Task|Change from Baseline in CANTAB Rapid Visual Information Processing|Change from Baseline in CANTAB Verbal Recognition Memory|Change from Baseline in CANTAB Adaptive Tracking Task|Change from Baseline in CANTAB Paired Associates Learning Test|Change from Baseline in CANTAB Stop Signal Task|Change from Baseline in Negative Emotional Bias in the Facial Expression Recognition Task (FERT)	CuraSen Therapeutics, Inc.	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CST2032/CST107-CLIN-015	April 12, 2022	November 2022	December 2022	November 3, 2021		July 22, 2022	CuraSen Investigational Site, Scottsdale, Arizona, United States|CuraSen Investigational Site, Boca Raton, Florida, United States|CuraSen Investigational Site, Boynton Beach, Florida, United States|CuraSen Investigational Site, Bradenton, Florida, United States|CuraSen Investigational Site, Lady Lake, Florida, United States|CuraSen Investigational Site, Miami, Florida, United States|CuraSen Investigational Site, Winter Park, Florida, United States|CuraSen Investigational Site, Cincinnati, Ohio, United States|CuraSen Investigational Site, Round Rock, Texas, United States|CuraSen Investigational Site, Stafford, Texas, United States|CuraSen Investigational Site, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT05104463
208	NCT04065854	Promoting Activity, Independence and Stability in Early Dementia and Mild Cognitive Impairment	PrAISED2	Unknown status	No Results Available	Dementia|Mild Cognitive Impairment	Behavioral: Intervention	Disability Assessment in Dementia (DAD)|Nottingham Extended ADL Scale|Falls Rate|Quality of Life|Mood or 'Affect'|Physical activity|Cognition|Time to first fall|Rate of fractures and injurious falls|Rate of hospital and care home admissions, and days spent in hospital|Carer strain|Carer health-related quality of life|Personality	Nottingham University Hospitals NHS Trust|National Institute for Health Research, United Kingdom	All	65 Years and older   (Older Adult)	Not Applicable	368	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17HC006	October 1, 2018	March 31, 2021	March 13, 2022	August 22, 2019		August 22, 2019	Derbyshire Healthcare NHS Foundation Trust, Derby, Derbyshire, United Kingdom|Lincolnshire Partnership NHS Foundation Trust, Lincoln, Lincolnshire, United Kingdom|Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, Notts, United Kingdom|RICE - Research Institute for the Care of Older People, Bath, Somerset, United Kingdom		https://ClinicalTrials.gov/show/NCT04065854
209	NCT04023032	Efficacy of a Multicomponent Cognitive Intervention in Adults With Subjective Cognitive Decline and Mild Cognitive Impairments		Completed	No Results Available	Mild Cognitive Impairment|Subjective Cognitive Decline	Behavioral: multicomponent cognitive intervention	Change from Baseline the Brief University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA-Brief ) (Traditional Chinese Version) at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Activities of Daily Living Questionnaire at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Contextual Memory Test (CMT) at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Miami Prospective Memory Test (MPMT) at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Everyday Memory Questionnaire (EMQ) at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Cognitive Failure Questionnaire (CFQ) at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Word Sequence Learning Test at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Wechsler Memory Scale-3rd ed. (WMS-III) Logical Memory (LM) subtest at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Wechsler Memory Scale-3rd ed. (WMS-III) Family Pictures (FP) subtest at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Color Trails Test at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the Geriatric Depression Scale-Short Form (GDS-S) at 16 weeks, 32 weeks, and 48 weeks|Change from Baseline the State-Trait Anxiety Inventory-Situation (STAI-S) at 16 weeks, 32 weeks, and 48 weeks	National Taiwan University Hospital	All	50 Years and older   (Adult, Older Adult)	Not Applicable	28	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201805012RINA	January 2, 2019	August 29, 2021	August 29, 2021	July 17, 2019		September 1, 2021	National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT04023032
210	NCT02051270	Cognitive Impairment and Balance in Elderly		Completed	No Results Available	Mild Cognitive Impairment	Other: Descriptive study	Dynamic balance|Cognitive impairment|Attention|Cognitive flexibility	Universidad de Granada	All	65 Years and older   (Older Adult)		82	Other	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	DF0050UG	January 2014	April 2015	May 2015	January 31, 2014		November 2, 2016	Faculty of health Sciences. University of Granada, Granada, Spain		https://ClinicalTrials.gov/show/NCT02051270
211	NCT03486938	Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease	HOPE4MCI	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Prodromal Alzheimer's Disease	Drug: Placebo Oral Tablet|Drug: AGB101 220 mg tablet	CDR-SB|MMSE|FAQ	AgeneBio|National Institute on Aging (NIA)	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	164	Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AGB101 MCD|R56AG055416|R01AG048349|R01AG061091	January 15, 2019	December 5, 2022	January 15, 2023	April 3, 2018		July 13, 2022	Banner Alzheimer's Institute, Phoenix, Arizona, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Excell Research Inc, Oceanside, California, United States|The Mile High Research Center, Denver, Colorado, United States|Boynton Beach Medical Research Institite, Boynton Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Miami Jewish Health, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|IMIC Research, Palmetto Bay, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Brain Matters Research, Stuart, Florida, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Memory Center/Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Global Medical Institutes LLC; Princeton Medical Institute, Princeton, New Jersey, United States|Neurology Specialist of Monmouth County, PA, West Long Branch, New Jersey, United States|Neurological Associates of Albany PC, Albany, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Clinical Biotechnology Research Institute at RSFH, Charleston, South Carolina, United States|Toronto Memory Program, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03486938
212	NCT03430401	Computer-based Cognitive Rehabilitation Program for Older People With Mild Cognitive Impairment and Mild Dementia		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Mild Dementia	Behavioral: Perceptual-based memory encoding|Behavioral: Semantic-based memory encoding|Behavioral: Cognitive stimulation	Disability Assessment for Dementia - Change from baseline after the intervention|Lawton and Brody Instrumental Activities of Daily Living Scale - Change from baseline after the intervention|Color Trails Test - Change from baseline after the intervention|Repeatable Battery for the Assessment of Neuropsychological Status - Change from baseline after the intervention|Behavior Rating Inventory of Executive Function - Change from baseline after the intervention	University of Western Sydney	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	UWesternSydney	August 1, 2018	August 31, 2022	July 1, 2023	February 12, 2018		August 31, 2022	Western Sydney University, Penrith, New South Wales, Australia		https://ClinicalTrials.gov/show/NCT03430401
213	NCT03363516	1-hour Post-load Hyperglycemia and Mild Cognitive Impairment		Unknown status	No Results Available	Glucose Metabolism Disorders|Mild Cognitive Impairment	Diagnostic Test: Cerebral 3 Tesla MRI	Evidence of early neuropsychological and/or cerebral morphological/functional alterations of MCI in cases	Maria Perticone|University Magna Graecia	All	55 Years and older   (Adult, Older Adult)		30	Other	Observational	Observational Model: Other|Time Perspective: Prospective	UNICZ01	October 2016	September 2018	September 2018	December 6, 2017		December 7, 2017	University Magna Graecia of Catanzaro - Department of Medical and Surgical Sciences - Internal Medicine and Geriatrics Units, Catanzaro, Italy		https://ClinicalTrials.gov/show/NCT03363516
214	NCT01608256	Driving Ability Among People With Mild Cognitive Impairment	MCI	Unknown status	No Results Available	Mild Cognitive Impairment			Tel Aviv University	All	50 Years to 70 Years   (Adult, Older Adult)		60	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	ק0012012	June 2012	July 2013	June 2014	May 31, 2012		May 31, 2012	Sherotw breot Clalit, Hedera, Israel		https://ClinicalTrials.gov/show/NCT01608256
215	NCT03507192	Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.		Unknown status	No Results Available	Mild Cognitive Impairment|Alzheimer Dementia	Device: Muscle relaxation using full body massage machine	cortical thickiness in 3D MRI|functional connectivity in functional MRI	Samsung Medical Center	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2017-05-135	September 25, 2017	December 31, 2019	December 31, 2019	April 24, 2018		March 14, 2019	Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03507192
216	NCT03983655	Effect of High Frequency/Low Intensity Transcranial Magnetic Stimulation in Cognitive Traits of an Elderly Population of Subjects With Mild Cognitive Impairment and Mild Dementia.		Terminated	No Results Available	Mild Cognitive Impairment|Mild Dementia	Device: High Frequency Low Intensity TMS	Proportion of patients suffering any kind of adverse effect|Change from baseline of total Katz Index of Independence in Activities of Daily Living at 3 months|Change from baseline of total Katz Index of Independence in Activities of Daily Living at 6 months|Change from baseline of total Lawton Instrumental Activities of Daily Living Scale at 3 months|Change from baseline of total Lawton Instrumental Activities of Daily Living Scale at 6 months|Change from baseline of total Geriatric Depression Scale at 3 months|Change from baseline of total Geriatric Depression Scale at 6 months|Change from baseline of total Montreal Cognitive Assessment at 3 months|Change from baseline of total Montreal Cognitive Assessment at 6 monts|Change from baseline of total Frontal Asessment Battery at 3 monts|Change from baseline Frontal Asessment Battery at 6 monts|Change from baseline ADAS-COG at 6 monts	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Actipulse Neuroscience	All	65 Years and older   (Older Adult)	Not Applicable	37	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Device Feasibility	GER-2962-19-20-1	May 17, 2019	May 17, 2020	August 1, 2020	June 12, 2019		August 12, 2021	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT03983655
217	NCT05448768	Cognitive Effects and Potential Mechanisms of TBS in Subjects With MCI		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Device: TBS for Amyloid-positive MCI|Device: TBS for Amyloid-negative MCI	Mini-Mental State Examination ( MMSE )|Montreal Cognitive Assessment|The standard uptake values changes of FDG-PET	Chang Gung Memorial Hospital	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202102037A3A0	July 8, 2022	June 30, 2025	June 30, 2025	July 7, 2022		July 7, 2022			https://ClinicalTrials.gov/show/NCT05448768
218	NCT02982603	Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment|Herbal Medicine Allergy	Drug: Qinggongshoutao Bolus|Drug: Ginkgo Biloba Extract 761|Drug: Placebos	Change from baseline to end of double-blind treatment of Alzheimer Disease Assessment Scale-cognitive subscale|Change from baseline to end of double-blind treatment of rate of conversion to dementia|Mini-Mental State Examination(MMSE)|Change from baseline to end of double-blind treatment of Delayed Story Recall test (DSR)|Change from baseline to end of double-blind treatment of Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24)	Dongzhimen Hospital, Beijing	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 4	350	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Z12020286	May 2015	December 2017	December 2017	December 5, 2016		October 23, 2018	Dongzhimen Hospital ,Beijing University of Chinese Medicine, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02982603
219	NCT02502253	BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)	BDPP	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Drug: grape seed polyphenolic extract, resveratrol	Assessment of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Confirm brain penetrance of BDPP by measuring levels of BDPP constituents in cerebrospinal fluid (CSF).|Evaluate BDPP effect on mood with Neuropsychiatric Inventory and Cornell Scale for Depression in Dementia.|Evaluate BDPP effect on cognition with measures of memory, executive function, and attention measures (composite)	Johns Hopkins University|Icahn School of Medicine at Mount Sinai	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 1	14	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	IRB00062802	June 2015	June 1, 2022	June 1, 2022	July 20, 2015		July 22, 2022	Johns Hopkins University, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02502253
220	NCT01286389	Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition		Completed	No Results Available	Mild Cognitive Impairment|Obesity	Other: medical care|Behavioral: caloric restriction	Neuropsychological test performance|Diagnosis of dementia|Weight loss|plasma biomarkers|Genotyping apolipoprotein E|Charlson comorbidity index|International physical activity questionnaire- short version (IPAQ)|Evaluation of Food Consumption|SPPB- Short physical performance battery|Blood pressure	University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo	All	60 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	0706/10 CAPPesq	January 2011	May 2013	October 2014	January 31, 2011		November 5, 2014	Hospital das Clínicas - Faculdade de Medicina da USP, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT01286389
221	NCT03514875	Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients		Withdrawn	No Results Available	Alzheimer Disease, Early Onset|Mild Cognitive Impairment	Dietary Supplement: MitoQ|Dietary Supplement: Placebo	Carotid artery blood flow|Oxidative Stress|Cerebrovascular Oxygenation|Brain Electrical Activity|Endothelial Function	University of Nebraska	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	088-18	November 11, 2019	January 1, 2024	October 1, 2024	May 2, 2018		July 8, 2022	The University of Nebraska at Omaha, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT03514875
222	NCT05313529	Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial		Recruiting	No Results Available	Type 2 Diabetes Mellitus|Mild Cognitive Impairment	Drug: Liraglutide|Drug: Empagliflozin|Drug: Linagliptin	Change of cognitive function|Change of other cognitive function|Change of olfactory brain activation by fMRI|Olfactory threshold test|Change of metabolism	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Wuxi People's Hospital|The First Affiliated Hospital with Nanjing Medical University	All	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	324	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZZ2022	September 20, 2022	August 31, 2026	August 31, 2027	April 6, 2022		September 10, 2022	Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China|Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China|Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China		https://ClinicalTrials.gov/show/NCT05313529
223	NCT01028053	Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease		Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease	Drug: Flutemetamol (18F) Injection	Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.|The of Normal and Abnormal Subjects Who Convert to Probable Alzheimer's Disease (pAD) Within the Follow up Period.	GE Healthcare|Medpace, Inc.|i3 Statprobe|i3 Research|Quintiles, Inc.	All	60 Years and older   (Adult, Older Adult)	Phase 3	365	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	GE-067-005	December 2009	January 2014	January 2014	December 9, 2009	September 11, 2014	September 11, 2014	GE Healthcare, Princeton, New Jersey, United States		https://ClinicalTrials.gov/show/NCT01028053
224	NCT03815292	Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke		Completed	Has Results	Mild Cognitive Impairment|Ischemic Stroke	Drug: MMH-MAP|Drug: Placebo	Percentage of Patients With Improved Cognitive Function (The Montreal Cognitive Assessment Test Total Score of the Baseline +1 or More)	Materia Medica Holding	All	45 Years to 80 Years   (Adult, Older Adult)	Phase 3	276	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MMH-MAP-001	October 19, 2018	January 27, 2020	January 27, 2020	January 24, 2019	February 23, 2021	February 23, 2021	Arkhangelsk Regional Clinical Hospital, Arkhangel'sk, Russian Federation|Belgorod Regional Clinical Hospital of St. Joseph, Belgorod, Russian Federation|Non-State Healthcare Institution "Divisional Hospital at the Bryansk-2 station of the open joint-stock company Russian Railways", Bryansk, Russian Federation|Bryansk Regional Hospital № 1, Bryansk, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "Kazan Medical University" of the Ministry of Healthcare of the Russian Federation, Kazan, Russian Federation|Scientific-Research Institute - Regional Clinical Hospital №1 named after Professor S.V. Ochapovsky, Krasnodar, Russian Federation|The State Budget Health Care institution of Moscow the City "City clinical hospital No. 12 of the Administration of Health Care of Moscow City", Moscow, Russian Federation|State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital No. 1 named after. N.I. Pirogov Moscow Department of Health, Moscow, Russian Federation|City Clinical Hospital named after SI. Spasokokukotsky Department of Health of Moscow, Moscow, Russian Federation|City Clinical Hospital №5 of Nizhny Novgorod region of Nizhny Novgorod, Nizhny Novgorod, Russian Federation|Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation|State budgetary institution of public health services of the Nizhniy Novgorod region "Nizhegorod Regional Clinical Hospital named after NA Semashko", Nizhny Novgorod, Russian Federation|Pyatigorsk City Clinical Hospital № 2, Pyatigorsk, Russian Federation|Ryazan State Medical University named after academician I.P. Pavlov, Ryazan', Russian Federation|St. Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine, Saint Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|State budgetary institution of health care of the Samara region "Samara City Clinical Hospital № 1 named after NI Pirogov", Samara, Russian Federation|Republican Clinical Hospital №4, Saransk, Russian Federation|Saratov State Medical University named after V. I. Razumovsky, Saratov, Russian Federation|St. Petersburg State Budgetary Institution "City Hospital No. 40 in the Kurortny District", Sestroretsk, Russian Federation|Smolensk State Medical University, Smolensk, Russian Federation|State budgetary institution of health care of the Tver region "Regional Clinical Treatment and Rehabilitation Center", Tver, Russian Federation|State Healthcare Institution Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russian Federation|State budgetary health care institution of the Vladimir region "Regional Clinical Hospital", Vladimir, Russian Federation|Volgograd State Medical University, Volgograd, Russian Federation|Voronezh Regional Clinical Hospital № 1, Voronezh, Russian Federation|Vsevolozhsk Clinical Interdistrict Hospital, Vsevolozhsk, Russian Federation|State Institution of Health of the Yaroslavl Region Clinical Hospital No. 8, Yaroslavl, Russian Federation	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03815292/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03815292
225	NCT02637089	Longitudinal Study of Mild Cognitive Impairment in Parkinson's Disease	PD-MCI	Recruiting	No Results Available	Parkinson's Disease|Mild Cognitive Impairment		Identify which structures in the brain exhibit the highest structural changes and / or BOLD changes correlated to the Z-scores of the neuropsychological assessments|Change from baseline in Z-scores of different neuropsychological assessments|Change in Cognitive Ability measured as BOLD fMRI sequence|Change in Executive Functioning measured as BOLD fMRI sequence|Measure changes in the volume of subcortical structures in the brain|Measure changes in cortical thickness in the brain|Measure structural changes in the brain|Analyze DNA for following genes: COMT, DAT1, MAPT, ApoE, GBA, CHNRA4|Measure level of biomarkers: Aß-amyloid in blood through fluorescence spectroscopy|Measure psychiatric changes with the Mild Behavioural Impairment-Checklist (MBI-C)	University of Calgary|Canadian Institutes of Health Research (CIHR)|Natural Sciences and Engineering Research Council, Canada|Montreal Neurological Institute and Hospital|McGill University	All	60 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	REB14-2463	March 28, 2016	December 2023	December 2023	December 22, 2015		November 2, 2020	University of Calgary, Department of Clinical Neurosciences, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT02637089
226	NCT01724151	Effects of Exercise Training in Patients With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease		Walking speed of participants	National Taiwan University Hospital	All	45 Years and older   (Adult, Older Adult)		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	200812152R	April 2009	October 2009	April 2012	November 9, 2012		April 22, 2014	National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01724151
227	NCT02924194	Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease		Terminated	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Device: stimulation ON|Device: stimulation OFF	Evaluate safety of DBS-nbM|Stability or improvement of cognitive symptoms	St. Joseph's Hospital and Medical Center, Phoenix|Barrow Neurological Foundation	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	3	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PHX-16-0141-30-06	September 2016	April 15, 2021	April 15, 2021	October 5, 2016		September 21, 2021	St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States		https://ClinicalTrials.gov/show/NCT02924194
228	NCT05383053	Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients		Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: NeuroAI	Explore predictive values(Clinical Sensitivity, %)|Explore predictive values(Clinical Specificity, %)|Explore predictive values(AUC of ROC Curve (Area Under the Curve of Receiver Operating Characteristic Curve))|Explore predictive values(Accuracy, %)	Neurozen Inc.|Chonnam National University Hospital|Chosun University Hospital	All	50 Years and older   (Adult, Older Adult)		227	Industry|Other	Observational	Observational Model: Other|Time Perspective: Retrospective	CNUH-2022-108	July 22, 2022	August 10, 2022	September 8, 2022	May 19, 2022		September 16, 2022	Chonnam National University Hospital, Gwangju, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05383053
229	NCT01061489	Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment (MCI)|Mild Alzheimer's Disease	Other: auditory discrimination training|Other: physical movement training	Change in global cognition|electrophysiological, MRI, blood and liquor correlates	University of Konstanz|University of Ulm	All	55 Years and older   (Adult, Older Adult)	Not Applicable	65	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	WIN-Kol-09	August 2009	March 2013	March 2013	February 3, 2010		July 14, 2016	University of Konstanz, Konstanz, Germany|University of Ulm, Memory Clinic, Ulm, Germany		https://ClinicalTrials.gov/show/NCT01061489
230	NCT01924312	Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease	MCI/CVD	Completed	No Results Available	Cerebrovascular Disease|Mild Cognitive Impairment	Behavioral: Heart Health Intervention	California Verbal Learning Test- Delayed Recall|Brain T2 hyperintensity volume on MRI|Montreal Cognitive Assessment (MOCA)|Total brain volume	Gregory Jicha, 323-5550|University of Kentucky	All	55 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	R01NR141892|12-0837-F2L	May 2013	June 30, 2018	June 30, 2019	August 16, 2013		October 9, 2019	University of Kentucky, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT01924312
231	NCT03446508	Investigating HD-tDCS in Improving Word Finding and Memory Retrieval in Individuals With MCI		Withdrawn	No Results Available	Mild Cognitive Impairment	Device: Active frontal|Device: Active parietal|Device: Sham	Memory retrieval/word finding assessment.|Electroencephalography (EEG).	The University of Texas at Dallas	All	40 Years to 90 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science	18-21	November 18, 2017	January 25, 2022	January 25, 2022	February 26, 2018		February 8, 2022	University of Texas at Dallas, Richardson, Texas, United States		https://ClinicalTrials.gov/show/NCT03446508
232	NCT05113446	MDD(Mild Cognitive Impairment Delirium Dementia) Cohort		Recruiting	No Results Available	Delirium|Mild Cognitive Impairment|Dementia	Diagnostic Test: Delirium assessment using S-CAM	Delirium incidence in participants with mild cognitive impairment|Dementia conversion rate and transition period in participants with mild cognitive impairment|Risk factors affecting participants' delirium|Mortality|hospital length of stay|healthcare costs	Keimyung University Dongsan Medical Center	All	65 Years and older   (Older Adult)		163	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2019R1I1A3A0106056112	July 1, 2021	October 31, 2022	December 31, 2025	November 9, 2021		August 1, 2022	Yangsan Seoul long-term care (LTC) facilities, Daegu, Gyeongsangnam-do,, Korea, Republic of|Gunsan Chamsarang long-term care (LTC) facilities, Daegu, Jeollabuk-do, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05113446
233	NCT01072812	Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment		Terminated	No Results Available	Alzheimer's Disease|Amnestic Mild Cognitive Impairment	Drug: Posiphen® tartrate capsules	Pharmacokinetics|Pharmacodynamics|Biomarkers|Safety	Annovis Bio Inc.	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 1	5	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QR 12001	February 2010	July 2010	July 2010	February 22, 2010		April 22, 2015	CEDRA Clinical Research, LLC, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT01072812
234	NCT02240459	A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment		Completed	No Results Available	Overactive Bladder|Mild Cognitive Impairment	Drug: fesoterodine 4mg|Drug: Oxybutynin|Drug: placebo|Drug: fesoterodine 8mg	continuity of attention|cognitive function	University of Alberta|Pfizer	All	75 Years and older   (Older Adult)	Phase 2	47	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	FES-COG 1808	August 2016	January 31, 2020	January 31, 2020	September 15, 2014		February 19, 2020	Division of Geriatric Medicine, Clinical Sciences Building, University of Alberta Hosp, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT02240459
235	NCT05332522	Computerized Memory Enhancing Treatment in MCI	COMET	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Neuroplasticity-based Computerized Cognitive Remediation	Evaluate completion rates of nCCR|Evaluate visit frequency throughout nCCR treatment|Evaluate visit duration throughout nCCR treatment	Vanderbilt University Medical Center	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	212375	August 9, 2022	December 31, 2023	December 31, 2023	April 18, 2022		August 12, 2022	Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT05332522
236	NCT00243451	Early Detection of Mild Cognitive Impairment in Individual Patients		Completed	No Results Available	Mild Cognitive Impairment|Mild Alzheimer's Disease	Other: PET scan & fMRI	Determine if the Cognitive Decline Index will discriminate subtle lesions earlier than the standard analysis of the Nuclear Medicine physician.|Determine if sensitivity, specificity, receiver-operator characteristics, and predictive value of our method are appropriate for translation into a clinically useful tool.	Louisiana State University Health Sciences Center Shreveport	All	55 Years to 85 Years   (Adult, Older Adult)		34	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	LSUHSC H04-049	September 2003	July 2011	July 2011	October 24, 2005		September 7, 2011	Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States		https://ClinicalTrials.gov/show/NCT00243451
237	NCT02552329	Effects of Tai Chi Exercise on Cognition and Serum Biomarkers of Individuals With MCI	MCI-TaiChi	Completed	No Results Available	Mild Cognitive Impairment	Other: Tai Chi exercise	Change from baseline in cognitive functions at 6 months|Change from baseline in serum biomarkers at 6 months|Change from baseline in fall risk at 6 months|Change from baseline in quality of life at 6 months|Change from baseline in cognitive functions at 3 months|Change from baseline in fall risk at 3 months	Chiang Mai University	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	66	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Chiang Mai University	December 2013	March 2016	July 2016	September 17, 2015		July 28, 2016	Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Maung, Chiang Mai, Thailand		https://ClinicalTrials.gov/show/NCT02552329
238	NCT04788238	Dual-Task Zumba Gold for Improving the Cognition of Older Adults With MCI		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Dual-Task Zumba Gold	Changes in Montreal Cognitive Assessment score (from baseline to 18 weeks follow-up)|Changes in Trail Making Test Part A (from baseline to 18 weeks follow-up)|Changes in Trail Making Test Part B (from baseline to 18 weeks follow-up)|Changes in Digit Span test (from baseline to 18 weeks follow-up)|Changes in the MoCA-Memory Index score (from baseline to 18 weeks follow-up)|Changes in quality of life using Perceived Well-Being Scale (from baseline to 18 weeks follow-up)|Changes in mood using Geriatric Depression Scale-Short Form (from baseline to 18 weeks follow-up)|Changes in functional mobility using Short Physical Performance Battery (from baseline to 18 weeks follow-up)|Changes in blood pressure (from baseline to 18 weeks follow-up)|Changes in body-mass index (from baseline to 18 weeks follow-up)|Changes in waist circumference (from baseline to 18 weeks follow-up)	The Hong Kong Polytechnic University	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	HSEARS20200717002	March 29, 2021	October 15, 2021	August 31, 2022	March 9, 2021		February 4, 2022	Municipality of Plaridel, Plaridel, Bulacan, Philippines	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04788238/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04788238
239	NCT01482013	Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease		Terminated	No Results Available	Mild Alzheimer's Disease|Mild Cognitive Impairment	Drug: HPP854|Drug: Placebo	Number of Participant Adverse Events|Evaluation of participant plasma HPP854 concentrations|Change in cerebrospinal fluid concentration of Amyloid-Beta	High Point Pharmaceuticals, LLC.	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 1	7	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	HPP854-104	October 2011	March 2012	March 2012	November 30, 2011		August 30, 2012	Elite Research Institute, Miami, Florida, United States|Duke Clinical Research Unit, Durham, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01482013
240	NCT02462135	Protocol of Virtual Interactive Memory-Training Program		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Virtual interactive memory training|Behavioral: Passive information activities	Change in objective memory performance as measured by the Chinese version of the Wechsler Memory Scale-III (WMS-III).|Change in subjective memory complaints as measured by the Multifactorial Memory Questionnaire (MMQ).	Ministry of Science and Technology, Taiwan	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	201301045	March 2014	December 2017	December 2017	June 3, 2015		December 15, 2017	Residential care facilities, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02462135
241	NCT05318703	Virtual Exercise For Older Adults With Mild Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: tai ji quan|Behavioral: Stretching	(a) Total number of intervention sessions taught by instructors over the course of study (recorded by a class check sheet) and (b) total number of classes attended by participants over the course of intervention as recorded by class attendance sheet|number of dropouts from the intervention and study as assessed by a study recording sheet|Number of participants expressing intervention program satisfaction as assessed by a self-report survey|Change in global cognitive function assessed by Montreal Cognitive Assessment|Change in attention and working memory as assessed by Digit Span - forward and backward|Change in dual-task cost as assessed by Timed Up and Go with a cognitive task|Change in executive function as assessed by Trail Making B|Change in executive function as assessed by Category Fluency for Animals|Change in cognitive functioning assessed by Everyday Cognition|Change in physical performance as measured by Timed Up and Go test|change in leg strength as assessed by 30-second chair stand test|Change in balance using a 4-stage balance test|Change in depression as assessed by Geriatric Depression scale|Change in physical activity as assessed by International Physical Activity Questionnaire|Change in quality of life as assessed by EuroQol (EQ-5D-3L)	Oregon Research Institute	All	65 Years to 95 Years   (Older Adult)	Not Applicable	69	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	AG059546-02S1	August 19, 2020	August 30, 2022	October 30, 2022	April 8, 2022		July 18, 2022	Oregon Research Institute, Eugene, Oregon, United States		https://ClinicalTrials.gov/show/NCT05318703
242	NCT01661673	Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Drug: EVP-0962|Drug: Placebo	The number of adverse experiences reported by subjects and/or observed by investigator and repeated clinical evaluations of physical examinations, vital signs, 12-lead ECG (electrocardiogram), and lab tests (hematology, chemistry, urinalysis)|To measure the rate of synthesis of Amyloid Beta in cerebral spinal fluid of healthy subjects|To measure the concentration of Amyloid Beta in cerebral spinal fluid|To measure the rate of synthesis of Amyloid Beta and steady-state levels in the cerebral spinal fluid in MCI or early Alzheimer's disease patients|To determine single-and repeat-dose EVP-0962 pharmacokinetics in cerebral spinal fluid and plasma	FORUM Pharmaceuticals Inc|Parexel	All	45 Years to 85 Years   (Adult, Older Adult)	Phase 2	52	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EVP-0962-002	November 2012	October 2013		August 9, 2012		January 13, 2014	Glendale Adventist Medical Center, Glendale, California, United States		https://ClinicalTrials.gov/show/NCT01661673
243	NCT01662882	A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)		Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: florbetapir (18F)	Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR	Avid Radiopharmaceuticals|Eli Lilly and Company	All	50 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	48	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18F-AV-45-J05|I6E-AV-AVBB	October 2012	February 2013	February 2013	August 13, 2012	September 19, 2013	September 19, 2013	Research Site, Kobe, Japan|Research Site, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT01662882
244	NCT00736996	Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)	POEM	Completed	Has Results	Mild Cognitive Impairment	Drug: Pioglitazone|Drug: Placebo|Behavioral: Endurance Exercise Training	Change in Cognitive Performance|Change in Insulin Resistance|Change in Peak Oxygen Uptake (VO2 Peak)	University of Colorado, Denver|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Phase 2	78	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	07-1215|R01AG028746	November 2008	December 2013	December 2013	August 18, 2008	January 15, 2016	January 15, 2016	University of Colorado, Denver, Denver, Colorado, United States		https://ClinicalTrials.gov/show/NCT00736996
245	NCT02409238	Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study	IRMCI	Unknown status	No Results Available	Mild Cognitive Impairment|Insulin Resistance|Diabetes Mellitus, Type 2	Drug: Metformin|Behavioral: Intensive Lifestyle Intervention|Behavioral: Standard LIfestyle Recommendation	Primary efficacy endpoint (Cerebral Glucose Metabolic Rate)|Primary cognitive endpoint (Neuropsychological Performance)|Secondary clinical endpoints Subjective Memory and Cognitive Complaint (SMCC|Secondary clinical endpoints Basic Activities of Daily Liver (ADL)|Secondary clinical endpoints Cognitive Instrumental Activities of Daily Living Scale|Secondary clinical endpoints Global Clinical Dementia Rating Sum of Boxes|Secondary clinical endpoints Mini-Mental State Examination|Secondary clinical endpoints Montreal Cognitive Assessment scale|Secondary adherence endpoints fasting plasma insulin|Secondary adherence endpoints Homeostatic Model Assessment (HOMA)|Secondary adherence endpoints Lifestyle Intervention (Change in Weight)|Secondary adherence endpoints Body Mass Index|Secondary adherence endpoints Waist Circumference|Secondary adherence endpoints Fasting plasma glucose|Secondary adherence endpoints Glycated Hemoglobin (HbA1c)|Secondary adherence endpoints Fasting Lipids	SingHealth Polyclinics|National University, Singapore|Singapore General Hospital|Changi General Hospital|National University Hospital, Singapore|Singapore Clinical Research Institute|Agency for Science, Technology and Research|Khoo Teck Puat Hospital|Duke-NUS Graduate Medical School	All	55 Years and older   (Adult, Older Adult)	Phase 4	360	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCI-LM 3	April 2015	December 2017		April 6, 2015		March 31, 2016	SingHealth Polyclinics - Marine Parade Polyclinic, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02409238
246	NCT00620191	Metformin in Amnestic Mild Cognitive Impairment	MCI	Completed	Has Results	Mild Cognitive Impairment	Drug: Metformin|Drug: Placebo	Change in Total Recall Score in the Selective Reminding Test|Change in Score of the Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog)|Change in Relative Glucose Uptake (rCMRg) in the Posterior Cingulate-precuneus.	Columbia University|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	AAAC7231|R01AG026413|270901	June 1, 2008	February 2012	February 2012	February 21, 2008	October 23, 2020	October 23, 2020	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00620191
247	NCT05399888	A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into the Cerebrospinal Fluid of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age	CELIA	Recruiting	No Results Available	Mild Cognitive Impairment Due to Alzheimer's Disease|Alzheimer's Disease Dementia	Drug: BIIB080|Drug: BIIB080-matching placebo	Dose-response in Change From Baseline to Week 76 on the CDR-SB|Change From Baseline to Week 76 on the CDR-SB|Change From Baseline to Week 76 on the Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI)|Change From Baseline to Week 76 on the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog 13)|Change From Baseline to Week 76 on the Mini Mental State Examination (MMSE)|Change From Baseline to Week 76 on the Modified Integrated Alzheimer's Disease Rating Scale (iADRS)|Change From Baseline to Week 76 on the Alzheimer's Disease Composite Score (ADCOMS)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Biogen	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	735	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	247AD201|2021-006036-13	August 19, 2022	December 14, 2026	December 14, 2026	June 1, 2022		August 19, 2022	K2 Medical Research, LLC, Maitland, Florida, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT05399888
248	NCT01823666	Predicting the Conversion From Mild Cognitive Impairment to Dementia	PCMCItoD	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Dementia, Vascular		Rate of conversion to dementia|Mini-Mental State Examination|Immediate and delayed story recall|Clock Drawing Test(CDT)|Boston Naming Test|Verbal Category Fluency Test(animals)|Trail Making Test(TMT)|Hopkins Verbal Learning Test(HVLT)	Dongzhimen Hospital, Beijing	All	40 Years to 85 Years   (Adult, Older Adult)		250	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Z11107056811043	September 2012	August 2014	September 2014	April 4, 2013		August 23, 2021	Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT01823666
249	NCT02332525	The Influence of Oral Vibrational Stimulation on Cognitive Function of Elderly Individuals	OVSCF	Unknown status	No Results Available	Mild Cognitive Impairment	Device: Oral Vibrational Stimulation	cognitive function|quantitative electroencephalography (QEEG) and event-related potentials (ERPs)|functional magnetic resonance imaging (fMRI)|masticatory ability|salivary secretion	Seoul National University Bundang Hospital	All	50 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B-1407-260-006	January 2015	December 2015	December 2016	January 6, 2015		January 6, 2015			https://ClinicalTrials.gov/show/NCT02332525
250	NCT03581929	Efficacy of MEMORMAX in Subjects With MCI	ABO-MEMO	Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Memormax|Other: Placebo	Memormax efficacy on global cognitive performance (FCRST).|Memormax efficacy on global cognitive performance (ACE-R).|Effect of Memormax on global cognitive performance across the entire population (FCRST)|Effect of Memormax on global cognitive performance across the entire population (ACE-R)|variations of the main parameters of cognitive performance (MMSE)|variations of the main parameters of cognitive performance (Digit Span)|variations of the main parameters of cognitive performance (Trail Making)|variations of the main parameters of cognitive performance (Babcock)|variations of the main parameters of cognitive performance (Rey Test)|variations of the main parameters of cognitive performance (Raven Test)|variations of the main parameters of cognitive performance (Token Test)|variations of the main parameters of cognitive performance (Verbal Fluency)|variations of the main parameters of cognitive performance (NEPSY-II)|variations of the main parameters of cognitive performance (NPI)|variations of the main parameters of cognitive performance (GDS)|variations of the main parameters of cognitive performance (Cognitive Reserve Index)|variations of physical performance (BIA)|variations of physical performance (hand grip)|variations of physical performance ( timed up and go)|variations of physical performance (SPPB)|variations of physical performance (Frailty index)|variations of physical performance (ADL)|variations of physical performance (IADL)|variations of modification of biochemical parameters of inflammation.|variations of modification of oxidative stress conditions parameters.|variations of changes in the microbiota (bacteria subpopulations)|variations of changes in the microbiota (SCFA)|Safety and Tolerability (Adverse Events)	Aboca Spa Societa' Agricola|Latis S.r.l.	All	55 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	MEMORMAX	November 20, 2017	December 19, 2019	December 19, 2019	July 10, 2018		July 29, 2020	S.C. di Geriatria Ospedale S. Maria della Misericordia, Perugia, Italy		https://ClinicalTrials.gov/show/NCT03581929
251	NCT03805620	Effects of Combined Physical-cognitive Training on Cognitive Function in MCI		Completed	No Results Available	Mild Cognitive Impairment	Other: Combined physical-cognitive training|Other: Physical training|Other: Cognitive training	change from baseline Alzheimer's Disease Assessment- cognitive subscale at 3 months|change from baseline Rey auditory verbal learning score at 3 months|change from baseline Trail Making B-A score at 3 months|change from baseline brain-derived neurotrophic factor level at 3 months|change from baseline Digit Span score at 3 months|change from baseline stepping response time at 3 months|change from baseline time to complete Timed Up and Go at 3 months|change from baseline physiological profile assessment score at 3 months|change from baseline mitochondrial oxygen consumption rate at 3 months|change from baseline mitochondrial reactive oxygen species (ROS) level at 3 months	Chiang Mai University	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	AMS-CMU	March 18, 2019	January 15, 2021	June 28, 2021	January 15, 2019		July 26, 2021	Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand		https://ClinicalTrials.gov/show/NCT03805620
252	NCT03872375	Calorie Restriction and Brain Function in Mild Cognitive Impairment	5-2CR	Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Meal-Replacement Therapy|Behavioral: Dietary Counseling	Body Weight|Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)|Functional Magnetic Resonance Imaging memory task activation|Functional Magnetic Resonance Imaging executive function task activation|Cerebral blood flow|Neural network functional connectivity|Mini-Mental State Examination|NIH EXAMINER Dysexecutive Errors Composite Score|California Verbal Learning Test|Digit Span - Forward and Backward	Iowa State University|National Institute on Aging (NIA)	All	70 Years to 85 Years   (Older Adult)	Not Applicable	96	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	201612732|R00AG047282	May 8, 2019	December 31, 2021	December 31, 2021	March 13, 2019		March 31, 2022	Nutrition and Wellness Research Center, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States		https://ClinicalTrials.gov/show/NCT03872375
253	NCT00702143	A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)		Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: florbetapir F 18	Qualitative Amyloid Image Assessment|Mean Cortical to Cerebellum SUVR|Proportion of Positive Florbetapir-PET Scans	Avid Radiopharmaceuticals	All	50 Years and older   (Adult, Older Adult)	Phase 2	184	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	18F-AV-45-A05	June 2008	December 2008	December 2008	June 20, 2008	May 3, 2012	May 10, 2012	Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Bennington, Vermont, United States		https://ClinicalTrials.gov/show/NCT00702143
254	NCT05289804	Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Memory Impairment|Memory Disorders in Old Age	Device: NITESGON|Drug: Lidocaine / Prilocaine Topical Cream|Device: C5/C6 stimulation|Device: Sham NITESGON	Word association task performance immediately after NITEGON/sham|Word association task performance at 7 days|Word association task performance at 28 days|EEG gamma oscillations	University of Dublin, Trinity College|Alzheimer's Association	All	50 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	SPREC102021-23|AARG-21-848486	September 1, 2022	March 31, 2025	December 31, 2025	March 21, 2022		May 18, 2022			https://ClinicalTrials.gov/show/NCT05289804
255	NCT03913637	Facilitating Optimal Routines in Aging	ForAging	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Strategy Training|Other: Enhanced Usual Care	Change in disability	University of Pittsburgh|National Institutes of Health (NIH)|National Institute on Aging (NIA)	All	60 Years and older   (Adult, Older Adult)	Not Applicable	150	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY19120012|R01AG056351	July 31, 2019	June 1, 2023	June 1, 2023	April 12, 2019		July 19, 2022	University of Pittsburgh, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03913637
256	NCT04990362	Effects of Pomegranate Seed Oil and Mediterranean Diet on MCI		Recruiting	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Pomegranate oil, Mediterranean Diet|Dietary Supplement: Mediterranean Diet	Neuropsychological Assessment|FUCAS|Letter & Category Fluency Test|CDR|MoCA|CANTAB|Clock Drawing test|Logical Memory test|Digit Span Forward & Backward test|WAIS-R Digit Symbol|TMT part A and B|ADASCog|Functional Rating Scale for Dementia|Auditory Verbal Learning Test|Boston Naming Test|Fullerton Functional Test	Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	69/5-6-2021	July 1, 2021	December 31, 2022	December 31, 2022	August 4, 2021		August 27, 2021	Alzheimer Hellas, Thessaloníki, Thessaloniki, Greece		https://ClinicalTrials.gov/show/NCT04990362
257	NCT04710030	Valacyclovir for Mild Cognitive Impairment	VALMCI	Recruiting	No Results Available	Mild Cognitive Impairment|Herpes Simplex 1|Herpes Simplex 2	Drug: Valacyclovir hydrochloride 500mg caplet|Drug: Placebo sugar pill caplet	Change in accumulation of amyloid plaque (18F-Florbetapir PET) from Screening or Week 0 to Week 52.|Change in Alzheimer's Disease Cooperative Study- Preclinical Alzheimer Cognitive Composite (PAAC) cognitive composite score from Week 0 to Week 52.|Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-PI (ADCS-ADL-PI) score from Week 0 to Week 52.	New York State Psychiatric Institute|Alzheimer's Association	All	50 Years to 95 Years   (Adult, Older Adult)	Phase 2	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	8089	February 1, 2021	February 1, 2023	December 31, 2023	January 14, 2021		April 29, 2022	New York State Psychiatric Institute, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04710030
258	NCT05270408	Noninvasive Brain Stimulation in Mild Cognitive Impairment and Dementia		Enrolling by invitation	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Dementia	Device: Active Transcranial direct current stimulation (STARStim 8)|Device: Sham Transcranial direct current stimulation (STARStim 8)	Change in Score on the Rey Auditory Verbal Learning Test (RAVLT)	University of Texas Southwestern Medical Center	All	50 Years and older   (Adult, Older Adult)	Not Applicable	500	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	STU-2021-0974	August 8, 2022	January 2026	January 2027	March 8, 2022		August 24, 2022	UT Southwestern Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT05270408
259	NCT02940457	Cognitive Ability Training for Seniors With Mild Cognitive Impairment	MICE	Withdrawn	No Results Available	Mild Cognitive Impairment	Device: Verum tDCS|Device: Sham tDCS	Brain activation measured with NIRS|Reaction times, errors and number of generated words in neuropsychological tasks|T1 weighted magnetic resonance Imaging (MRI) of the brain|Blood sampling	Wuerzburg University Hospital	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Wuerzburg165/16	November 1, 2017	December 2020	December 2020	October 21, 2016		May 26, 2020	University Hospital, Wuerzburg, Germany		https://ClinicalTrials.gov/show/NCT02940457
260	NCT04059705	Dual-task Training for Function in MCI		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Dual-Task Training	Change in Motor Function from baseline to 12 weeks|Change in Attention from baseline to 12 weeks|Change in Exercise Self Efficacy from baseline to 12 weeks|Outcome Expectations for Exercise from baseline to 12 weeks	State University of New York at Buffalo	All	65 Years and older   (Older Adult)	Not Applicable	24	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	STUDY00003525	June 4, 2022	January 4, 2023	January 15, 2023	August 16, 2019		May 13, 2022			https://ClinicalTrials.gov/show/NCT04059705
261	NCT00785759	Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers	ALZ201	Completed	No Results Available	Alzheimer's Disease|Amnestic Mild Cognitive Impairment	Drug: AH110690 (18F) Injection	Examine the efficacy and determine visual assessment of raised [18F] brain uptake for separating subjects with probable Alzheimer's Disease from healthy volunteers and assigning amnestic mild cognitive impairment cases to an AD or HV category.|Examine the efficacy and parameters of brain [18F] uptake for separating 25 subjects with probable AD from 25 HV, assigning 20 amnestic MCI cases to an AD or HV category by measuring ranges of regional cerebral to cerebellum tracer uptake ratios.	GE Healthcare|i3 Statprobe|Medpace, Inc.|Hvidovre University Hospital	All	25 Years and older   (Adult, Older Adult)	Phase 2	78	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ALZ201	September 2008	March 2009	December 2009	November 5, 2008		December 7, 2009	GE Healthcare, Oslo, Norway		https://ClinicalTrials.gov/show/NCT00785759
262	NCT02001441	UCLA Fitness and Memory Study of Activity In Mild Cognitive Impairment (AIM)	AIM	Completed	No Results Available	Mild Cognitive Impairment		Activity level correlation with hippocampal thickness|Activity level correlation with memory performance	University of California, Los Angeles	All	60 Years to 89 Years   (Adult, Older Adult)		35	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	13-000781|UL1TR000124	August 2013	August 2015	August 2015	December 4, 2013		May 2, 2018	UCLA Longevity Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT02001441
263	NCT01845636	Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil		Completed	Has Results	Mild Cognitive Impairment	Drug: Donepezil|Drug: Atropine	Selective Reminding Test (SRT)|Total Number of Errors Measured Using the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog)|Clinician's Interview Based Impression of Change Plus Caregiver Input (CIBIC-plus)	New York State Psychiatric Institute|United States Department of Defense	All	55 Years to 95 Years   (Adult, Older Adult)	Phase 4	41	Other|U.S. Fed	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6577|W81XWH-12-0142	August 2012	March 2016	March 2016	May 3, 2013	March 13, 2018	July 9, 2018	New York State Psychiatric Institute, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01845636
264	NCT02310620	Computer Games to Prevent Mild Cognitive Impairment and Dementia		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Cognitive training	Conversion to Mild Cognitive Impairment (?CI) (Proportion of participants who develop MCI after 3 years)|Conversion to dementia (Proportion of participants who develop dementia after 3 years)	Semmelweis University	All	50 Years and older   (Adult, Older Adult)	Not Applicable	109	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	M3W2012	December 2012	December 2017	December 2017	December 8, 2014		November 17, 2021	Department of Psychiatry and Psychotherapy, Budapest, Hungary		https://ClinicalTrials.gov/show/NCT02310620
265	NCT03448445	A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting	CONCORDE	Completed	No Results Available	Mild Cognitive Impairment	Other: Usual care setting	Rate of Alzheimer's Disease (AD) conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI|Mean change from Baseline in Seoul Neuropsychological Screening Battery-Dementia Version scores|Mean change from Baseline in Clinical Dementia Rating (CDR) Sum of Boxes scores|Mean change from Baseline in the CDR-Global Score|Mean change from Baseline in Geriatric Depression Scale scores|Mean change from Baseline in the volume of the whole brain according to Baseline demographics|Mean change from Baseline in other structural magnetic resonance imaging (MRI) measures according to Baseline demographics|Mean change from Baseline in the volume of the hippocampus according to Baseline demographics	Eisai Korea Inc.|Eisai Inc.	All	55 Years to 89 Years   (Adult, Older Adult)		201	Industry	Observational	Observational Model: Case-Control|Time Perspective: Prospective	E0000-M082-603	June 22, 2018	August 10, 2021	August 10, 2021	February 28, 2018		October 6, 2021	Eisai Trial site_12, Anyang, Korea, Republic of|Eisai Trial site_11, Busan, Korea, Republic of|Eisai Trial site_15, Busan, Korea, Republic of|Eisai Trial site_08, Changwon, Korea, Republic of|Eisai Trial site_09, Daegu, Korea, Republic of|Eisai Trial site_05, Daejeon, Korea, Republic of|Eisai Trial site_03, Gachon, Korea, Republic of|Eisai Trial site_07, Guri, Korea, Republic of|Eisai Trial site_10, Gwangju, Korea, Republic of|Eisai Trial site_16, Jeju, Korea, Republic of|Eisai Trial site_01, Seoul, Korea, Republic of|Eisai Trial site_02, Seoul, Korea, Republic of|Eisai Trial site_04, Seoul, Korea, Republic of|Eisai Trial site_06, Seoul, Korea, Republic of|Eisai Trial site_13, Seoul, Korea, Republic of|Eisai Trial site_14, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03448445
266	NCT02755792	Calligraphy Writing for Cognitive and Emotional Enhancement Among Older MCI People	CALLI-MCI	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Calligraphy Training|Behavioral: iPad Training	Change in Digit span backward test (DSB) from baseline, after end of training, and 6-month follow-up.|Color Trails Test (CTT)|Symbol-digit Modalities Test (SDMT)|Heart rate and heart rate variability.|Blood pressure.|Geriatric Depression Scale - Short Form (GDS-SF)|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)	The Hong Kong Polytechnic University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	99	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Calligraphy-MCI	July 2012	December 2015	April 2016	April 29, 2016		April 29, 2016	The Hong Kong Polytechnic University, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT02755792
267	NCT02596906	Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment	Device: tDCS|Device: Sham tDCS	Change From Baseline in California Verbal Learning Task Score|Regional Brain Blood Flow Change Immediately After 1 Month of Cognitive Training and tDCS Brain Stimulation	The University of Texas at Dallas	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	22	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CBH-MCI-tDCS	January 2016	January 2018	January 2018	November 4, 2015	December 11, 2020	January 7, 2021	UTD Center for BrainHealth, Dallas, Texas, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02596906/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02596906
268	NCT02239003	NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Drug: DAOIB|Drug: Placebo	Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24|Change from baseline in speed of processing (Category Fluency) at week 24|Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24|Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24|Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24	Chang Gung Memorial Hospital	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	103-3642C	January 2012	October 2017	December 2017	September 12, 2014		January 24, 2018	Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT02239003
269	NCT04206670	In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment		Completed	Has Results	Dementia|Mild Cognitive Impairment|Alzheimer Disease	Device: In-Home Technology System and Questionnaires|Device: Waiting Control In-Home Technology System and Questionnaires	3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)|6 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D)|3 Months Assessment for Zarit Burden Interview-Short Form|6 Months Assessment for Zarit Burden Interview-Short Form|3 Months Assessment for Beck Anxiety Inventory (BAI)|6 Months Assessment for Beck Anxiety Inventory (BAI)|3 Months Assessment for Satisfaction With Life Scale|6 Months Assessment for Satisfaction With Life Scale	University of California, Berkeley|People Power Company|National Institute on Aging (NIA)|University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Not Applicable	216	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care	R44AG059458-03|R44AG059458	March 10, 2020	December 8, 2021	December 8, 2021	December 20, 2019	May 10, 2022	May 10, 2022	University of California, Berkeley, Berkeley, California, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04206670/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04206670/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT04206670
270	NCT05380739	Memory Training and Neural Plasticity	WMTrain	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Working Memory Training	Gains in WM training task performance|Changes in brain activation within the WM network|Changes in criterion (fMRI) WM task performance|Changes in functional connectivity within and between canonical brain networks	University of Michigan	All	60 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HUM00199574	April 7, 2022	December 1, 2022	February 28, 2023	May 19, 2022		May 19, 2022	University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT05380739
271	NCT03711396	ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment	ENACT-aMCI	Completed	Has Results	Mild Cognitive Impairment	Behavioral: Advance Care Planning Group Visits	Change in Readiness to Engage in ACP (ACP Engagement Scale)|Change in Readiness to Engage in ACP (ACP Engagement Score) - Care Partner Reported	University of Colorado, Denver	All	65 Years and older   (Older Adult)	Not Applicable	26	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	18-1459	February 1, 2019	October 31, 2020	January 15, 2021	October 18, 2018	November 22, 2021	November 22, 2021	UCHealth, Aurora, Colorado, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03711396/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03711396/SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03711396/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT03711396
272	NCT02551419	Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET (Positron Emission Tomography)	BENEFIC	Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: ketogenic drink|Dietary Supplement: placebo	Change in global ketone (11C-AcAc) uptake in grey matter|Change in plasma ketone|Change in global brain FDG uptake in grey matter (CMR-G)|Change in regional CMR-A|regional brain volumes by vMRI|Change in cognitive status - episodic memory|Change in cognitive status- language domain|Change in cognitive status - executive function|Change in cognitive status - processing speed|Blood metabolite profile triglycerides|Blood metabolite profile Glucose|Blood metabolite profile cholesterol|Derived cerebral metabolic rate of total ketones|Pharmacokinetic ketone response (phase 2)	Université de Sherbrooke|Alzheimer's Association	All	55 Years and older   (Adult, Older Adult)	Not Applicable	82	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	2015-509	June 2015	December 2019	December 2019	September 16, 2015		March 26, 2020	Research Center on Aging, Sherbrooke, Quebec, Canada	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02551419/SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02551419
273	NCT05423912	The Couple in Control		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Couple in Control Intervention	Changes in Care Partner Self Assessment of their Caregiver competency (Pearlin's Competence Scale)|Changes in Feasibility of the intervention as determined through qualitative interviews|Changes Impact of the intervention on stress (10-item Perceived Stress Scale)|Changes to Center for Epidemiological Studies - Depression Scale (CESD)|Changes in Dyadic Relationship Scale	Emory University|National Institute on Aging (NIA)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	48	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	STUDY00003645|P30AG064200	October 1, 2022	May 2024	May 2024	June 21, 2022		July 28, 2022	Executive Park, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT05423912
274	NCT01594541	A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients		Unknown status	No Results Available	Mild Cognitive Impairment		Change from Baseline in Levels of Homocysteine Over Time|To evaluate the safety and tolerability of Cerefolin NAC® based on adverse events, discontinuation due to intolerability and compliance.|Examine the demographics, medical co-morbidities present and affective and cognitive characteristics of the group of patients demonstrating hyperhomocysteinemia compared with the group without hyperhomocysteinemia in a dementia population.	Pamlab, Inc.|Clionsky Neuro Systems Inc.	All	55 Years to 89 Years   (Adult, Older Adult)		700	Industry	Observational	Time Perspective: Retrospective	NAC-004	January 2013	August 2013	April 2014	May 9, 2012		March 24, 2014	Clionsky Neuro Systems, Inc., Springfield, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01594541
275	NCT02480738	Effectiveness of Computerized Cognitive Training in the Elderly With Cognitive Impairment	CoCoTA	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Computerized Cognitive Training Apparatus	Clinical improvement in the follow-up neuropsychological tests|Cortical thickness changes between baseline and follow-up volumetric MRI|White matter integrities changes between baseline and follow-up diffusion tensor imaging|Spectral ratio changes between baseline and follow-up EEG|local activation pattern changes between baseline and follow-up Fludeoxyglucose PET	Seoul National University Bundang Hospital	All	51 Years to 70 Years   (Adult, Older Adult)	Not Applicable	26	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10035434	June 2012	April 2013	July 2013	June 24, 2015		May 20, 2019			https://ClinicalTrials.gov/show/NCT02480738
276	NCT01653431	Transcranial Direct Current Stimulation to Enhance Cognition in Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment	Device: Transcranial direct current stimulation	California Verbal Learning Test II	The University of New South Wales	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 1|Phase 2	68	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	HC12381	January 2013	November 2018	November 1, 2019	July 31, 2012		February 7, 2020	Black Dog Institute, Sydney, New South Wales, Australia		https://ClinicalTrials.gov/show/NCT01653431
277	NCT02741804	Lifestyle Intervention Program for Cognitive Impairment		Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: BBH-1001 Brain Health Supplement|Other: Lifestyle Intervention|Dietary Supplement: Brain Health Placebo	Change in retinal amyloid burden, as measured by retinal amyloid scan.|Change in Neuropsychology|Diagnosis of Dementia|Change in Neuroimaging|Change in Lab Results|Change in Vascular Risk Factors	Cedars-Sinai Medical Center	All	55 Years and older   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	41387	May 2016	May 2019	May 2019	April 18, 2016		June 27, 2016	Cedars-Sinai Medical Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT02741804
278	NCT05158595	Exer-game Balance Training on Dementia		Recruiting	No Results Available	Mild Cognitive Impairment	Other: Exergaming low intensity group|Other: Exergaming moderate intensity group|Other: Exergaming high intensity group|Other: control group exergaming	DEMENTIA QUALITY OF LIFE QUESTIONAIRRE (DEMQOL)|General Self Efficacy scale|2 Minute Walk test (2MWT)	Riphah International University	All	55 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	REC/01032/Sehar	August 15, 2021	May 2022	May 2022	December 15, 2021		May 4, 2022	Railway General Hospital, Rawalpindi, Punjab, Pakistan		https://ClinicalTrials.gov/show/NCT05158595
279	NCT04964011	Board Game Intervention to Improve Cognitive and Daily Functioning		Completed	No Results Available	Mild Cognitive Impairment	Other: Board game intervention	Saint Louis University Mental Status Exam (SLUMSE)|Contextual Memory Test (CMT)|Trail Making Test part-A (TMT-A)|Instrumental activities of daily living (IADL)	Yang Shang-Yu|National Cheng Kung University	All	65 Years to 88 Years   (Older Adult)	Not Applicable	68	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research	CRREC-108-141	January 3, 2020	January 22, 2020	June 30, 2020	July 15, 2021		July 15, 2021	Asia Univeraity, Taichung, WuFeng, Taiwan		https://ClinicalTrials.gov/show/NCT04964011
280	NCT01573611	Impact of Grape Consumption on Brain Metabolism and Cognitive Function		Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder	Change from baseline in neuropsychological (cognitive, functional) test results|Change from baseline in regional cerebral metabolism	University of California, Los Angeles	All	65 Years and older   (Older Adult)	Phase 1	12	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	11002966	April 2012	April 2013	November 2014	April 9, 2012		December 4, 2014	UCLA Medical Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT01573611
281	NCT03855475	Aging Brain Structure and Memory in Response to Exercise		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Aerobic exercise|Behavioral: Stretching	Change in brain mechanical properties|Change in relational memory performance|Change in cardiorespiratory fitness	University of Delaware|Christiana Care Health Services|University of Illinois at Urbana-Champaign	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science	1256861	March 1, 2019	December 31, 2023	March 31, 2024	February 26, 2019		April 28, 2021	University of Delaware, Newark, Delaware, United States		https://ClinicalTrials.gov/show/NCT03855475
282	NCT04928690	Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping	EARS	Not yet recruiting	No Results Available	Alzheimer Disease|Alzheimer's Disease (Incl Subtypes)|Mild Cognitive Impairment		Area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms using speech recordings as input.|The sensitivity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The specificity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The sensitivity of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The specificity of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The AUC of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The sensitivity of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The specificity of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The AUC of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The sensitivity of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The specificity of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The Cohen's kappa of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The AUC of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|For each classifier/regressor in outcome 1-16, the correlation between the AUC/CIA and each age group, gender and speech-to-reverberation modulation energy ratio group, as measured by the Kendall rank correlation coefficient.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		140	Industry	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	NOV-0120	June 20, 2021	August 15, 2021	August 30, 2022	June 16, 2021		June 16, 2021			https://ClinicalTrials.gov/show/NCT04928690
283	NCT01525368	Outcome Predictors of a Cognitive Intervention in aMCI	OutPreC MCI	Completed	No Results Available	Amnestic Mild Cognitive Impairment	Behavioral: cognitive intervention	Change in California Verbal Learning Test|Change in overall cognition (ADAScog)|Change in Face-Name Learning Test|Change in appraisal of quality of life (SF-36)|Change in neurofunctional MRT (resting state fMRI)|Change in depression scores (Beck Depression Inventory)|Change in working memory (Digit Span)|Change in attention (Trail Making Test)|Change in executive functions (Stroop Test)|Change in neurostructural MRI (diffusion tensor imaging)	Ludwig-Maximilians - University of Munich	All	Child, Adult, Older Adult		110	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	cogT002	September 2010	July 2014	July 2014	February 2, 2012		November 13, 2014	Institute for Stroke and Dementia Research, Campus Grosshadern, Ludwig-Maximilian University, Munich, Germany		https://ClinicalTrials.gov/show/NCT01525368
284	NCT03195829	Feasibility Study of a Computerized Cognitive Stimulation	PSCogStim	Completed	No Results Available	Mild Cognitive Impairment, So Stated	Behavioral: Computerized Cognitive Stimulation|Behavioral: Multimedia-based internet	GROBER-BUSCHKE TEST|Technologies Acceptation Questionnaire	Leila DJABELKHIR|Broca Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	LUSAGE	December 2015	July 2016	July 2016	June 22, 2017		June 22, 2017			https://ClinicalTrials.gov/show/NCT03195829
285	NCT04503096	Plasticity Using Stimulation and Habit: A Pilot Open-label rTMS Study for MCI	PUSH-Pilot	Recruiting	No Results Available	Mild Cognitive Impairment	Device: High-dose accelerated rTMS	Presence of clinically significant structural brain change on T1- and T2-weighted Magnetic Resonance Imaging (MRI)|Change from Baseline global cognition, as measured by the Montreal Cognitive Assessment (MoCA)|Change in the review of systems criteria compared to baseline|Patient perception of treatment acceptability|Retention rate|Change from Baseline depression, as measured by the Hamilton Depression Rating Scale (HAM-D)|Change from Baseline depression, as measured by the Geriatric Depression Scale (GDS)	Medical University of South Carolina|National Center of Neuromodulation for Rehabilitation	All	65 Years to 85 Years   (Older Adult)	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00100536	April 1, 2021	September 30, 2022	September 30, 2022	August 7, 2020		March 10, 2022	Medical University of South Carolina, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT04503096
286	NCT02878486	Intervention to Reduce Sedentary Time	ReST-MCI	Completed	Has Results	Mild Cognitive Impairment	Device: Jawbone Up|Behavioral: Physical Activity Education|Device: ActivPAL	Change in Average Daily Sitting Time|Number of Sitting Bouts Greater Than 30 Min|Change in Glucose Levels Area Under the Curve in Response to Mixed Meal Tolerance Test|Change in Insulin Levels Area Under the Curve Based on a Mixed Meal Tolerance Test	University of Kansas Medical Center	All	Child, Adult, Older Adult	Not Applicable	6	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	STUDY00003981	August 2016	January 2018	January 2018	August 25, 2016	July 29, 2019	July 29, 2019	University of Kansas Medical Center, Kansas City, Kansas, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02878486/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02878486
287	NCT04678453	Safety of SNK01 in Subjects With Mild Cognitive Impairment (MCI) and Alzheimer's Disease	ASK-AD	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Neuro-Degenerative Disease	Biological: SNK01	To determine the safety profile of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.|To determine the tolerability of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.|To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of SNK01 monotherapy.|To assess preliminary efficacy of SNK01 measured by Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-Cog).|To assess preliminary efficacy of SNK01 measured by Mini-Mental Status Exam (MMSE).|To assess preliminary efficacy of SNK01 measured by Clinical Dementia Rating Scale: Sum of Boxes (CDR-SB).|To assess preliminary efficacy of SNK01 measured by Alzheimer's Disease Composite Score (ADCOMS).|To assess preliminary efficacy of SNK01 measured by cerebrospinal fluid (CSF) biomarkers: amyloid beta 42, T-tau and P-tau.	NKGen Biotech, Inc.	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1	21	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SNK01-MX04	January 6, 2021	December 2022	December 2023	December 22, 2020		July 28, 2022	Hospital Angeles Tijuana, Tijuana, Baja California, Mexico		https://ClinicalTrials.gov/show/NCT04678453
288	NCT01688128	Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)	U-SMART	Completed	No Results Available	Mild Cognitive Impairment	Device: Phase I U-SMART (4 wks)|Other: Washout (2 wks)|Device: Phase II U-SMART (4 wks)	Change in the Word List Test (memory, recall, recognition) of the CERAD Neuropsychological Assessment Battery before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Subjective Memory Complaints Questionnaire (SMCQ) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Geriatric Depression Scale (GDS) before and after phase I intervention and before and after phase II intervention (crossover part of the study)|Change in the Mini-Mental State Examination before and after phase I intervention and before and after phase II intervention (crossover part of the study)	Seoul National University Bundang Hospital|KT Corporation	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 3	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E-1207/162-001	August 2012	December 2015	December 2015	September 19, 2012		April 20, 2016	Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01688128
289	NCT04135742	Effects of tACS Combined With CCT for Patients With MCI		Enrolling by invitation	No Results Available	Mild Cognitive Impairment	Device: Transcranial Alternating Current Stimulation|Behavioral: Cognitive Training	Change from baseline RBANS, Color Word Stroop Test (CWST),Visual Reasoning and Trails Making Task.|Neuroimage change from baseline Magnetic Resonance Imaging (MRI)|changes in Gamma oscillation intensity (40-80 Hz) over DLPFC|Changes from baseline RBANS|Changes from baseline Color Word Stroop Test (CWST)|Changes from baseline Visual Reasoning|Changes from baseline Trails Making Task|Changes from baseline Geriatric Depression Scale (GDS)|Changes from baseline in Geriatric Anxiety Inventory (GAI)|Neuroimage changes from baseline Magnetic Resonance Imaging (MRI)|Side-effects of tACS	Shanghai Mental Health Center|Yangpu District Central Hospital Affiliated to Tongji University	All	60 Years to 95 Years   (Adult, Older Adult)	Not Applicable	195	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2019-24R	November 11, 2019	September 30, 2023	December 30, 2023	October 23, 2019		May 6, 2022	Shanghai Mental Health Center, Shanghai, Shanghai, China|Yangpu District Central Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT04135742
290	NCT01628653	Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training	U-SMART	Completed	No Results Available	Mild Cognitive Impairment	Device: U-SMART	the five-point Likert scales for satisfaction and compliance|Word List Memory Test of the CERAD Neuropsychological Assessment Battery|Mini-Mental State Examination (MMSE)	Seoul National University Bundang Hospital|KT Corporation	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 1	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	06-2011-084	June 2011	February 2012	February 2012	June 27, 2012		June 27, 2012	Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01628653
291	NCT00842920	Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients	SIMaMCI	Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Simvastatin 60 mg|Drug: Placebo|Drug: Simvastatin 20 mg	Change in CDR-SOB at 24 months of treatment|Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score|Change in Free and Cued Selective Reminding Test (FCSRT) score|Length of conversion-free interval, starting at the time of randomization, with conversion being defined as an increase of the CDR score beyond 0.5	Charite University, Berlin, Germany|German Federal Ministry of Education and Research	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 4	520	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	EudraCT 2008-002226-11|BMBF grant, 01KG0822	December 2008	August 31, 2020	February 28, 2021	February 12, 2009		January 27, 2020	Department of Psychiatry and Psychotherapy, Charité-CBF, Berlin, Germany|Department of Psychiatry and Psychotherapy, University Bonn, Bonn, Germany|Department of Psychiatry and Psychotherapy, University Erlangen, Erlangen, Germany|Department of Psychiatry and Psychotherapy, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany|Center for Geriatrics and Gerontology, University Freiburg, Freiburg, Germany|Department of Psychiatry and Psychotherapy, Medical University Goettingen, Göttingen, Germany|Department for Psychiatry, Psychotherapy and Psychosomatic; Martin-Luther-University Halle-Wittenberg, Halle, Germany|Department of Psychiatry, University Hospital Heidelberg, Heidelberg, Germany|Department of Gerontopsychiatry, Central Institut of Mental Health, University Heidelberg, Mannheim, Germany|Department of Psychiatry and Psychotherapy, LMU I, Munich, Germany|Institute for Stroke and Dementia Research, LMU, Munich, Germany|Department of Psychiatry and Psychotherapy, University Rostock, Rostock, Germany|Neurologische Universitätsklinik Ulm, Ulm, Germany		https://ClinicalTrials.gov/show/NCT00842920
292	NCT02720445	Memory Improvement Through Nicotine Dosing (MIND) Study	MIND	Recruiting	No Results Available	Mild Cognitive Impairment	Drug: Nicotine Transdermal Patch|Drug: Placebo Patch	Change from Baseline of the Conners Continuous Performance Task (CPT) to Month 25|Change from Baseline in Mild Cognitive Impairment - Clinical Global Impression of Change (MCI-CGIC) to Month 25|Change from Baseline in Cogstate Brief Battery (CBB) to Month 25|Change in Baseline in New York University (NYU) Paragraph Recall to Month 25|Change from Baseline in Clinical Dementia Rating Scale (CDR) - Sum of Boxes (SOB) to Month 25|Change in Baseline in Geriatric Depression Scale (GDS) to Month 25|Change in Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) to Month 25|Change from Baseline in Older Adult Self Report (OASR) / Older Adult Behavior Checklist (OABCL) to Month 25	University of Southern California|National Institute on Aging (NIA)|Vanderbilt University|Alzheimer's Therapeutic Research Institute	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2	380	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ATRI-002-NIC|R01AG047992|131918	January 13, 2017	July 2023	July 2023	March 25, 2016		August 10, 2022	Perseverance Research Center, Scottsdale, Arizona, United States|Central Arkansas Veterans Healthcare System, North Little Rock, Arkansas, United States|USC Rancho Los Amigos, Downey, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Sharp Neurocognitive Research Center, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Nuvance Health Medical Practice Ct, Inc.; Associated Neurologists, PC, Danbury, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Augusta University Movement and Memory Disorders, Augusta, Georgia, United States|Velocity Clinical Research - Boise, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Cypress Medical Research Center, Wichita, Kansas, United States|Acadia Hospital, Bangor, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Donald S. Marks, MD, PC, Plymouth, Massachusetts, United States|Bronson Lakeview Hospital, Kalamazoo, Michigan, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|University at Buffalo (UBMD), Buffalo, New York, United States|Velocity Clinical Research - Syracuse, East Syracuse, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Integrative Clinical Trials, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rapid Medical Research, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Central States Research (formerly Tulsa Clinical Research), Tulsa, Oklahoma, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|LeHigh Valley Hospital, Allentown, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Glenn Biggs Institute at the University of Texas Health, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington / VA Puget Sound, Seattle, Washington, United States|University of Washington Memory and Brain Wellness Center, Seattle, Washington, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02720445
293	NCT03379519	Protocol of Multi-domain Attention Training		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Multi-domain Attention Training (MAT)|Behavioral: Passive information activities (PIA)	Change in attention as measured by the Digit Span Task (DS).|Change in attention as measured by the Trail Making Test (TMT).	Ministry of Science and Technology, Taiwan	All	Child, Adult, Older Adult	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	N201602069	August 1, 2016	May 31, 2019	December 31, 2019	December 20, 2017		February 20, 2020			https://ClinicalTrials.gov/show/NCT03379519
294	NCT03263247	Cognitive Training in Patients With MCI Using fMRI		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Training|Behavioral: Psychoeducation|Behavioral: Alphabet search	Changes in functional magnetic resonance imaging (fMRI)|Changes in memory and language measures|Changes in perception of memory performance	São Paulo State University|Ricardo Nitrini|Sonia Brucki|Maira Okada de Oliveira|Edson Amaro Junior|Maria da Graca M Martin|Rodolfo dos Anjos|Camila Carneiro Pedroza|Ana Carolina Cruz|Aline Gisele Gonçalves|Leticia Nery Celino de Souza Pak|Letícia Ferreira da Mota|Paulo Rodrigo Bazán|Isabella Maria Bello Avolio	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	MCI cognitive training	January 2, 2017	December 31, 2022	December 31, 2023	August 28, 2017		May 10, 2022	University of Sao Paulo, São Paulo, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT03263247
295	NCT03522389	Effect of Action Observation Training on Gait Variables and Global Cognitive Functions		Unknown status	No Results Available	Mild Cognitive Impairment	Procedure: AOT with gait training|Procedure: Gait training|Other: Education	Changed score of stride time variability in single-task condition|Changed score of stride time variability in dual -task condition|Changed score of gait velocity in single-task condition|Changed score of gait velocity in dual -task condition|Changed score of MoCA	Mahidol University	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	39	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	MU-CIRB 2018/001.0301	May 15, 2018	January 31, 2019	January 31, 2019	May 11, 2018		May 16, 2018			https://ClinicalTrials.gov/show/NCT03522389
296	NCT03404765	Effects of Tai Chi on Cognition, I-ADLs, and HRQOL in Older People With MCI		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Tai Chi	Change from baseline C-MMSE score at four months|Change from baseline IADL-CV score at four months|Change from baseline SF-12 score at four months	Chinese University of Hong Kong	All	60 Years and older   (Adult, Older Adult)	Not Applicable	160	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CREC.Ref,No:2015.348	December 15, 2015	September 1, 2016	September 1, 2016	January 19, 2018		January 19, 2018	The Chinese University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT03404765
297	NCT01044758	Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)		Completed	Has Results	Mild Cognitive Impairment (MCI)	Drug: Levetiracetam 62.5mg|Drug: Levetiracetam 125mg|Drug: Levetiracetam 250mg|Drug: Placebo	Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI|Behavioral Performance as Assessed in the Functional Magnetic Resonance Imaging (fMRI) Memory Task	Johns Hopkins University|National Institute on Aging (NIA)	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	96	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	NA_00030573|RC2AG036419	December 2009	July 2012	July 2012	January 8, 2010	August 21, 2017	August 21, 2017	Johns Hopkins University School of Medicine, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01044758
298	NCT04382365	Use of an Internet-Based Insomnia Intervention to Prevent Cognitive Decline in Adults With Mild Cognitive Impairment	SHUTi OASIS	Completed	No Results Available	Mild Cognitive Impairment|Cognitive Impairment|Insomnia	Other: Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness	Increase in Sleep Duration|Impact on Psychological Distress|Impact on Overall Health|Impact on Sleep Pattern	University of Virginia	All	55 Years and older   (Adult, Older Adult)	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	IRB-HSR #20990	December 5, 2018	May 28, 2020	May 28, 2020	May 11, 2020		April 27, 2021	University Of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT04382365
299	NCT02483754	Application and Revision of Montreal Cognitive Assessment in Chinese Retirees	ARMOCA	Completed	No Results Available	Mild Cognitive Impairment		MCI occurrence rate	Xijing Hospital	All	60 Years and older   (Adult, Older Adult)		304	Other	Observational	Observational Model: Other|Time Perspective: Cross-Sectional		January 2011	August 2011	March 2014	June 29, 2015		January 26, 2017			https://ClinicalTrials.gov/show/NCT02483754
300	NCT02955277	The Effectiveness of TECH: Tablet Enhancement of Cognition and Health	TECH	Unknown status	No Results Available	Mild Cognitive Impairment	Other: TECH: Tablet Enhancement of Cognition and Health	The Montreal Cognitive Assessment|WebNeuro|The Tower of Hanoi (ToH) task	Assuta Hospital Systems	All	65 Years and older   (Older Adult)	Not Applicable	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2016009-1	November 2016	June 2020	August 2020	November 4, 2016		April 9, 2020	Maccabi Healthcare Services, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT02955277
301	NCT02774083	Cognitive Training Using Feuerstein Instrumental Enrichment	Feuerstein	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Feuerstein Program|Behavioral: Adler Program	Change from baseline cognitive function	Rambam Health Care Campus|Adolf und Mary Mil-Stiftung|Helen Bader Foundation|Montreal Jewish Community Fund|Rochlin Family Foundation	All	60 Years and older   (Adult, Older Adult)	Not Applicable	26	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention	RMC_TD_23/2015	September 3, 2015	May 31, 2016	May 31, 2016	May 17, 2016		September 24, 2019	Beit Yona, Beersheba, Israel|Ramat Tamir Retirement Home, Jerusalem, Israel|Beit Tovei Hair, Jerusalem, Israel|Bayit Balev Beit Ildan, Qiryat Moẕqin, Israel|Bayit Balev Tel Aviv, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT02774083
302	NCT04078178	Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment		Active, not recruiting	No Results Available	Cognition Disorders in Old Age|Mild Cognitive Impairment|Cognitive Decline	Dietary Supplement: Niagen	The effect of Niagen vs PBO on RBANS.	Steven E Arnold|Massachusetts General Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	39	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	2019P002668	October 30, 2020	September 30, 2022	September 30, 2022	September 4, 2019		April 11, 2022	Alzheimer's Clinical and Translational Research Unit, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04078178
303	NCT00297414	An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine		Completed	No Results Available	Mild Cognitive Impairment	Other: No intervention	To evaluate vital status of patients enrolled in 3 galantamine studies	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	Child, Adult, Older Adult		1083	Industry	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	CR004240|GAL-COG-3002	June 2004	January 2005	January 2005	February 28, 2006		April 12, 2012	Tucson, Arizona, United States|Laguna Woods, California, United States|Northridge, California, United States|Oceanside, California, United States|Paramount, California, United States|San Diego, California, United States|San Francisco, California, United States|Hamden, Connecticut, United States|Hartford, Connecticut, United States|New Haven, Connecticut, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Oscala F, Florida, United States|Saint Petersburg, Florida, United States|St. Petersburg, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Paducah, Kentucky, United States|Glen Burnie, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Pittsfield, Massachusetts, United States|Farmington Hills, Michigan, United States|Kalamazoo, Michigan, United States|Clementon, New Jersey, United States|Ridgewood, New Jersey, United States|Summit, New Jersey, United States|Albany, New York, United States|Bronx, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|E Providence, Rhode Island, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Wichita Falls, Texas, United States|Bennington, Vermont, United States|Richmond, Virginia, United States|Tacoma, Washington, United States|Middleton, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Adelaide, Australia|Christchurch Nz, Australia|Hornsby Streets, Australia|Kew, Australia|Parkville, Australia|Perth, Australia|Randwick, Australia|Woodville, Australia|Graz N/A, Austria|Innsbruck, Austria|Wien, Austria|Aalst, Belgium|Antwerpen, Belgium|Hasselt, Belgium|Jumet, Belgium|Leuven, Belgium|Liege, Belgium|Merksem, Belgium|Reet, Belgium|Roeselare, Belgium|Wilrijk, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|North York, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Pointe-Claire, Quebec, Canada|Quebec City, Quebec, Canada|Verdun, Quebec, Canada|Saskatoon, Saskatchewan, Canada|London N/A, Canada|Montreal N/A, Canada|North York, Canada|T2n, Canada|Chomutov N/A, Czech Republic|Dobrany N/A, Czech Republic|Hluboká Nad Vltavou, Czech Republic|Kolín 2, Czech Republic|Opava, Czech Republic|Praha 8 N/A, Czech Republic|Rennes Cedex, Czech Republic|Usti Nad Labem N/A, Czech Republic|Helsinki, Finland|Kuopio N/A, Finland|Toulouse, France|Berlin, Germany|Frankfurt Am Main, Germany|Mannheim, Germany|München, Germany|Nürnberg, Germany|Ulm, Germany|Haifa, Israel|Petach Tikya, Israel|Ramat Gan, Israel|Tel Aviv, Israel|'S-Hertogenbosch, Netherlands|Alkmaar, Netherlands|Amsterdam, Netherlands|Breda, Netherlands|Maastricht, Netherlands|Gdansk, Poland|Katowice Poland, Poland|Lodz N/A, Poland|Mosina Poland, Poland|Poznan N/A, Poland|Poznan Poland, Poland|Warszawa, Poland|Barakaldo Vizcaya S/N, Spain|Barcelona N/A, Spain|Madrid, Spain|Terrasa Barcelona N/A, Spain|Linköping, Sweden|Lund N/A, Sweden|Malmö, Sweden|Mölndal N/A, Sweden|Piteå, Sweden|Stockholm, Sweden|Umeå, Sweden|Bradford, United Kingdom|Bristol, United Kingdom|Clydebank, United Kingdom|New Milton, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom		https://ClinicalTrials.gov/show/NCT00297414
304	NCT03590327	Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment	TAMCI	Recruiting	No Results Available	Apathy|Mild Cognitive Impairment|Transcranial Magnetic Stimulation	Device: Transcranial Magnetic Stimulation	Change in Apathy Evaluation Scale Score|Change in Modified Mini Mental State Examination Score|Change in Conner's Continuous Performance Test Commission Error percentage	VA Office of Research and Development|Central Arkansas Veterans Healthcare System|University of Arkansas	All	55 Years and older   (Adult, Older Adult)	Not Applicable	125	U.S. Fed|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	D2638-R|1115904	November 1, 2018	September 30, 2023	September 30, 2023	July 18, 2018		July 15, 2020	Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, United States		https://ClinicalTrials.gov/show/NCT03590327
305	NCT02121457	Brazil Nuts Effects on Selenium Status and Cognitive Performance		Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Brazil nut|Dietary Supplement: selenium	Selenium level in plasma and erythrocyte|cognitive performance	University of Sao Paulo	All	60 Years and older   (Adult, Older Adult)	Not Applicable	31	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Doutorado-2014	May 2011	August 2012	August 2012	April 23, 2014		April 23, 2014	University Of são Paulo, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT02121457
306	NCT05380180	Enhancing Quality of Life for Older Adults With and Without Mild Cognitive Impairment (MCI) Through Social Engagement Over Video Technology		Recruiting	No Results Available	Aging|Mild Cognitive Impairment|Aging Well	Other: OneClick Social Engagement Intervention|Other: OneClick Social Engagement Intervention Extension	Change in Social Isolation Measured by Friendship Scale|Change in Loneliness Measured by University of California - Los Angeles (UCLA) Loneliness Scale|Change in Quality of Life Measured by Quality of Life in Alzheimer's Disease|Change in Social Network Measured by Lubben Social Network Index|Change in Social Activity Measured by Social Activity Frequency	University of Illinois at Urbana-Champaign	All	65 Years and older   (Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other	22212	May 15, 2022	April 30, 2023	September 30, 2023	May 18, 2022		May 18, 2022	University of Illinois, Urbana Champaign, Champaign, Illinois, United States|CJE Senior Living, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT05380180
307	NCT02033850	Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II	RehAtt	Completed	Has Results	Mild Cognitive Impairment	Behavioral: Attention Process Training-II	Functionality in Activities of Daily Living (Changes in Scores Approach)|Quality of Life (Changes in Scores Approach)|Quality of Life (Clinically Significance Approach)|Cognitive Performance (Changes in Scores Approach)|Cognitive Performance TMT-A, TMT-B, Stroop (Changes in Scores Approach)|Cognitive Performance Verbal Fluency (Changes in Scores Approach)|Cognitive Performance (Clinically Significance Approach)|Transition to Dementia|Cognitive Plasticity	Azienda Ospedaliero-Universitaria Careggi|Ministero della Salute, Italy	All	18 Years and older   (Adult, Older Adult)	Not Applicable	46	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	RF-2010-2321706	November 2012	April 2016	April 2016	January 13, 2014	June 6, 2019	June 6, 2019	Stroke Unit and Neurology, VAS-COG clinic, Firenze, Italy		https://ClinicalTrials.gov/show/NCT02033850
308	NCT05159661	Intelligent Digital Tools for Screening of Brain Connectivity and Dementia Risk Estimation in People Affected by Mild Cognitive Impairment	AI-Mind	Recruiting	No Results Available	Cognitive Dysfunction|Dementia|Mild Cognitive Impairment		AI-Mind Connector with estimated specificity and sensitivity value > 0.9|AI-Mind Predictor with estimated specificity and sensitivity value > 0.9.|Clinical utility of Digital Cognitive Test compared to classical Neuropsychological test|M/EEG connectivity measures	Oslo University Hospital|Aalto University|Accelopment AG|Alzheimer Europe|BrainSymph AS|Det Norske Veritas|Helsinki University Central Hospital|IRCCS San Raffaele Roma|Lurtis Rules S.L.|Neuroconnect Srl|Oslo Metropolitan University|Radboud University Medical Center|Tallinna Ülikool|Universidad Complutense de Madrid|Catholic University of the Sacred Heart	All	60 Years to 75 Years   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Other|Time Perspective: Prospective	204084	December 2021	January 2025	February 2026	December 16, 2021		December 16, 2021	Helsinki University Hospital, Helsinki, Finland|Università Cattolica del Sacro Cuore Campus di Roma, Roma, Italy|Scientific Institute for Research, Hospitalization and Healthcare, Roma, Italy|Oslo University Hospital, Oslo, Norway|Universidad Complutense de Madrid, Madrid, Spain		https://ClinicalTrials.gov/show/NCT05159661
309	NCT02326038	Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study		Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Methylphenidate	Verbal Learning Test Immediate Recall|Verbal Learning Test Delayed Recall|Verbal Learning Test Recognition|Amplitude of the N400 and P600 event-related potential (ERP) components|Performance on visual and auditory N-back test|Performance on a sustained attention to response task (SART)|Performance on a motor task|Amplitude of ERP components during the visual and auditory N-back test|Amplitude of ERP components during SART	Maastricht University Medical Center|Orbis Medical Centre	All	60 Years to 80 Years   (Adult, Older Adult)	Phase 4	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	14T111|2014-003117-28	November 2014	December 2015	December 2015	December 25, 2014		December 25, 2014	Orbis Medical Centre, Sittard-Geleen, Limburg, Netherlands		https://ClinicalTrials.gov/show/NCT02326038
310	NCT03851523	Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Subjective Cognitive Decline	Other: No intervention	Subjective Cognitive Decline Questionnaire (my-Cog)|Subjective Cognitive Decline Questionnaire (their-Cog)	Barcelonabeta Brain Research Center, Pasqual Maragall Foundation	All	45 Years and older   (Adult, Older Adult)		400	Other	Observational	Observational Model: Other|Time Perspective: Prospective	ALFAcognition/BBRC2017	February 12, 2018	December 31, 2022	December 31, 2023	February 22, 2019		June 9, 2021	Barcelonabeta Brain Research Center, Barcelona, Catalonia, Spain		https://ClinicalTrials.gov/show/NCT03851523
311	NCT04504630	Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury		Recruiting	No Results Available	Amnestic Mild Cognitive Impairment|Traumatic Brain Injury|Mild Traumatic Brain Injury	Device: High Definition Transcranial Direct Current Stimulation|Device: Sham HD-tDCS	Mean change from baseline in episodic memory functioning immediately following the last HD-tDCS session and at 3-month follow-up	University of Texas Southwestern Medical Center|U.S. Army Medical Research and Development Command	All	50 Years and older   (Adult, Older Adult)	Not Applicable	24	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	STU-2019-1769	December 5, 2020	January 31, 2023	August 31, 2023	August 7, 2020		December 14, 2021	University of Texas Southwestern Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT04504630
312	NCT03903211	Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease		Recruiting	No Results Available	Cognitively Normal|Mild Cognitive Impairment|Alzheimer Disease	Drug: [18F]PI-2620	Cross-sectional PI-2620 uptake measured by standard uptake value ratio (SUVR)|Changes of PI-2620 uptake over time measured by standard uptake value ratios (SUVR)|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and indices of structural MRI	Jae Seung Kim|Asan Medical Center	All	40 Years to 85 Years   (Adult, Older Adult)	Phase 2	72	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PI-18002	April 9, 2019	February 28, 2021	February 28, 2021	April 4, 2019		December 14, 2020	Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03903211
313	NCT00958867	EXCEL: Exercise for Cognition and Everyday Living for Seniors With Memory Complaints		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Exercise program (AT)|Behavioral: Exercise training (RT)|Behavioral: Exercise training (S & R; control)	Cognitive performance after 3 and 6 months of training|Everyday problem-solving ability after 3 and 6 months of exercise training, brain function after 6 months of training and physical function after 3 and 6 months of training	University of British Columbia|Pacific Alzheimer Research Foundation	Female	70 Years and older   (Older Adult)	Not Applicable	86	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	H09-00365	August 2009	August 2009	March 2010	August 13, 2009		October 4, 2017	Centre for Hip Health Mobility, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT00958867
314	NCT05534958	UK Validation of the Automated "AcceXible" Speech Analysis Software		Recruiting	No Results Available	Mild Cognitive Impairment and Dementia	Device: Accexible	Diagnostic performance of Accexible's digital screening battery|Correlation of Accexible's test battery with the ACE III	Accexible|Cornwall Partnership NHS Foundation Trust	All	55 Years to 90 Years   (Adult, Older Adult)		248	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	AcceXible-Healthy,MCI,Dementia	August 1, 2022	December 31, 2023	December 31, 2023	September 10, 2022		September 10, 2022	Cornwall Partnership NHS Foundation Trust, Cornwell, United Kingdom		https://ClinicalTrials.gov/show/NCT05534958
315	NCT02386670	Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)	PACt-MD	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Major Depressive Disorder, Recurrent, In Remission|Major Depressive Disorder, Single Episode, in Full Remission	Other: tDCS + CR|Other: sham tDCS + sham CR	Change in cognitive scores over time|Percentage of subjects who remain free of MCI or dementia over time	Centre for Addiction and Mental Health|Brain Canada|Applied Health Research Centre|Queen's University|Baycrest Centre for Geriatric Care|Unity Health Toronto|Sunnybrook Health Sciences Centre|University Health Network, Toronto	All	60 Years and older   (Adult, Older Adult)	Not Applicable	375	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	041-2014	January 2015	June 2022	December 2022	March 12, 2015		April 22, 2021	Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Heath Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada	"Study Protocol: Version 20", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02386670/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT02386670
316	NCT01561820	Mild Cognitive Impairment, Buddy Supported Exercise/ My Buddy Study		Completed	No Results Available	Mild Cognitive Impairment|Cognitive Disorders	Behavioral: 5-month aerobic exercise intervention	Adherence (number of sessions attended and exercise duration in targeted heart rate zone)|Change in score on Digit Symbol Coding Test|Change in 400m walk time (from randomization to 5 months)|Change in Trail Making Test part B score|change in memory, measured by Rey AVLT delayed recall score, at 5 months	Wake Forest University|Wake Forest University Health Sciences	All	60 Years and older   (Adult, Older Adult)	Not Applicable	15	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	IRB00018495	November 2011	December 2012	December 2012	March 23, 2012		September 26, 2019	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01561820
317	NCT00220467	Cognitive Effects of Aerobic Exercise for MCI Adults		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Aerobic exercise	Change in cognitive scores|Change in insulin sensitivity|Change in biomarkers associated with Alzheimer's disease progression|Correlation between cognitive scores, insulin sensitivity, & biomarkers	Seattle Institute for Biomedical and Clinical Research|Alzheimer's Association	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment	RDIS 0008|ALZ ASSOC BL18 (SIBCR)	January 2005	April 2008	May 2008	September 22, 2005		July 30, 2008	Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States|Veterans Affairs Puget Sound Health Care System, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT00220467
318	NCT02545062	MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes		Unknown status	No Results Available	Diabetes Mellitus Type 1|Diabetes Mellitus Type 2|Mild Cognitive Impairment	Other: MoCa test	The differences between the MoCa test score in diabetics and in a control group of non diabetics|The relation between the MoCa test score and glycemic control, in terms of HA1C value, in the past year before recruitment|The relation between the MoCa test score and the presence of microvascular complications, retinopathy, polyneuropathy and nephropathy|The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease	Clalit Health Services	All	20 Years to 55 Years   (Adult)	Not Applicable	170	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	DM- MOCA- 1	May 2014	August 2016	August 2016	September 9, 2015		September 11, 2015	Viviana Ostrovsky, Nes Tziona, Israel		https://ClinicalTrials.gov/show/NCT02545062
319	NCT03991195	Intervention of Intestinal Microorganism in Mild Cognitive Impairment		Completed	No Results Available	Gut Microbiota|Mild Cognitive Impairment|Dementia, Alzheimer Type|Neuroimaging	Dietary Supplement: Probiotic supplemented intervention|Dietary Supplement: Placebo	Improvement of Montreal cognitive assessment (MoCA)|Improvement of Auditory Verbal Learning Test (AVLT)|Changes of intestinal microbial flora diversity|Structural MRI-based brain network changes|Functional MRI-based brain network changes|FNIRS-based brain network changes	XuanwuH 2|First Hospital of Tsinghua University|Beijing Normal University|Xuanwu Hospital, Beijing	All	55 Years and older   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	HanYingsc	August 31, 2019	December 31, 2021	March 31, 2022	June 19, 2019		July 13, 2022	Department of Neurolgy, Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03991195
320	NCT02614131	A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)		Terminated	Has Results	Healthy|Alzheimer's Disease|Mild Cognitive Impairment	Drug: LY2599666|Drug: Solanezumab|Drug: Placebo SC|Drug: Placebo IV	Number of Participants With One or More Serious Adverse Event (SAE) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 Part A|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2599666 Part B|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-∞) of LY2599666 Part A|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to 168 Hours (AUC 0-168) of LY2599666 Part B|Plasma Amyloid Beta1-40 (Aβ1-40 ) Concentration Part A|Plasma Amyloid Beta (Aβ1-40 and Aβ1-42) Concentration Part B	Eli Lilly and Company	All	20 Years and older   (Adult, Older Adult)	Phase 1	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	15491|I2L-MC-ALCA	December 2015	December 2016	December 2016	November 25, 2015	September 23, 2019	June 17, 2020	Parexel Early Phase Unit at Glendale, Glendale, California, United States|CRI Lifetree, Marlton, New Jersey, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Kobe, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan		https://ClinicalTrials.gov/show/NCT02614131
321	NCT02656498	[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease		Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Neurodegenerative Diseases	Drug: [18F]THK-5351	Cross-sectional [18F]THK-5351 Imaging Results|Assess the rate of change of tau deposition as measured by [18F]THK-5351 uptake (SUVR) over time|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and neuropsychiatric test scores|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of structural MRI|Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of functional MRI|Correlation between standard uptake value ratios (SUVR) and distribution of [18F]THK-5351 positron emission computed tomography and amyloid positron emission computed tomography	Jae Seung Kim|Korea Health Industry Development Institute|Samsung Medical Center|Asan Medical Center	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 2	135	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	THK-15002	January 11, 2016	December 31, 2019	December 31, 2019	January 15, 2016		December 14, 2020	Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02656498
322	NCT01602198	Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients		Terminated	Has Results	Mild Cognitive Disorder|Mild Cognitive Impairment	Drug: Exelon [rivastigmine] transdermal patch|Drug: Placebo transdermal patch	Change in BOLD Response on Functional Magnetic Resonance Imaging (fMRI)	The Cleveland Clinic	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	1	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)	AG022304	June 2011	January 2013	January 2013	May 18, 2012	February 28, 2017	February 28, 2017	Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT01602198
323	NCT01220622	Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes	NICE	Unknown status	No Results Available	Stroke|Mild Cognitive Impairment	Drug: Nimodipine|Drug: Placebo	Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 6 months in the ITT population|Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with MoCA and FAB at 6 months in the ITT population|The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 6 months|Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with ADAS-cog and MMSE at 3 months in the ITT population|Assess the effect of nimodipine on the cognitive function after acute cerebral ischemia with MoCA and FAB at 3 months in the ITT population|The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 1 month|The prevalence of possible vascular dementia diagnosed by NINDS-AIREN criteria at 3 months	Ministry of Science and Technology of the People´s Republic of China	All	30 Years to 80 Years   (Adult, Older Adult)	Phase 4	656	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	BSP-SOP-040	October 2010	April 2012	July 2012	October 14, 2010		October 14, 2010	Beijing Tian Tan Hospital, Capital Medical University, Beijing, China		https://ClinicalTrials.gov/show/NCT01220622
324	NCT04636541	Goal Management Training for Parkinson Disease Mild Cognitive Impairment		Completed	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Behavioral: Goal Management Training|Behavioral: Psychoeducation	Raw score Change from baseline DEX (self rated) to 3 weeks after beginning of intervention|Raw score Change from baseline DEX (self rated) to 1 week post test|Raw score Change from baseline DEX (self rated) to 4 weeks post test|Raw score Change from baseline DEX (self rated) to 12 weeks post test|Raw score Change from baseline DEX (caregiver rated) to 3 weeks after the beginning of intervention|Raw score Change from baseline DEX (caregiver rated) to 1 week post test|Raw score Change from baseline DEX (caregiver rated) to 4 weeks post test|Raw score Change from baseline DEX (caregiver rated) to 12 weeks post test|Raw score Change from baseline Zoo Map Test to 1 week post test|Raw score Change from baseline Zoo Map Test to 4 weeks post test|Raw score Change from baseline Zoo Map Test to 12 weeks post test|Raw score Change from baseline Parkinson Disease Questionnaire (39 items; PDQ-39) to 3 weeks after the beginning of intervention|Raw score Change from baseline PDQ-39 to 1 week post-test|Raw score Change from baseline PDQ-39 to 4 weeks post-test|Raw score Change from baseline PDQ-39 to 12 weeks post-test|Mean Change from baseline Dementia Rating Scale, 2nd edition (DRS-II) to 1 week post-test|Mean Change from baseline Dementia Rating Scale, 2nd edition (DRS-II) to 4 weeks post-test|Mean Change from baseline Dementia Rating Scale, 2nd edition (DRS-II) to 12 weeks post-test|Raw score Change from baseline Zarit Burden Interview (12 items) to 3 weeks after the beginning of intervention|Raw score Change from baseline Zarit Burden Interview (12 items) to 1 week post-test|Raw score Change from baseline Zarit Burden Interview (12 items) to 4 weeks post-test|Raw score Change from baseline Zarit Burden Interview (12 items) to 12 week post-test|Raw score Change from baseline Neuropsychiatric Inventory, 12 items to 3 weeks after the beginning of intervention (mid-point)|Raw score Change from baseline Neuropsychiatric Inventory, 12 items to 1 week post-test|Raw score Change from baseline Neuropsychiatric Inventory, 12 items to 4 weeks post-test|Raw score Change from baseline Neuropsychiatric Inventory, 12 items to 12 weeks post-test|Raw score Change from baseline Apathy Evaluation Scale (AES) to 3 weeks after the beginning of intervention (mid-point)|Raw score Change from baseline Apathy Evaluation Scale (AES) to 1 week post-test|Raw score Change from baseline Apathy Evaluation Scale (AES) to 4 weeks post-test|Raw score Change from baseline Apathy Evaluation Scale (AES) to 12 weeks post-test	Laval University	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	12	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care	AGiguère-Rancourt	April 30, 2018	July 20, 2019	July 20, 2019	November 19, 2020		November 19, 2020	School of Psychology, Québec, Canada		https://ClinicalTrials.gov/show/NCT04636541
325	NCT03834402	INTERCEPTOR Project: From MCI to Dementia	INTERCEPTOR	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease		MCI converting to AD|PREDICTING BIOMARKERS	Catholic University of the Sacred Heart|Ministry of Health, Italy|Agenzia Italiana del Farmaco	All	50 Years to 85 Years   (Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2251	May 1, 2019	October 1, 2019	December 31, 2023	February 8, 2019		August 3, 2021	Policlinico Agostino Gemelli, Rome, Italy		https://ClinicalTrials.gov/show/NCT03834402
326	NCT02221622	Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD	Allo	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Drug: Allopregnanolone injection (intravenous solution)|Drug: Placebo injection (intravenous solution)	Safety profile: Adverse events|Safety profile: Clinical laboratory measurements|Safety profile: ARIA|Safety profile: Physical and neurological examination|Tolerability - Maximum tolerated dose (MTD)|Pharmacokinetic profile after single and multiple doses: Maximum Concentration (Cmax)|Pharmacokinetic profile after single and multiple doses: time attain to Cmax (Tmax)|Pharmacokinetic profile after single and multiple doses: Area under the curve (AUC)|Pharmacokinetic profile after single and multiple doses: Drug Clearance (CL)|Pharmacokinetic profile after single and multiple doses: apparent volume of distribution at steady state (Vss)|Cognitive tests (ADAS-Cog; MMSE/MoCA; ADCS-CGIC; CogState)|Brain MRI volumetrics	University of Southern California|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Phase 1	24	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AlloPhase1|1UF1AG046148	August 2014	February 2018	February 2018	August 20, 2014		July 5, 2019	University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT02221622
327	NCT04044183	Managing Pain and Cognitions in Older Adults With Mild Cognitive Impairment or Memory Related Problems and Chronic Pain		Unknown status	No Results Available	Chronic Pain|Mild Cognitive Impairment|Older Adults|Physical Activity	Behavioral: Active Brains 1|Behavioral: Active Brains 2	Change in Client Satisfaction Questionnaire 3-Item (CSQ-3)|Adherence to DMD (digital monitoring device)|Adherence to Homework|Therapist Adherence to Session|Feasibility of Quantitative Measures|Rescue (Non-Narcotic) Analgesic Use|Narcotic Analgesic Use|Credibility and Expectancy Questionnaire (CEQ)|Montreal Cognitive Assessment (MoCA)|Godin Leisure-Time Exercise Questionnaire|Measure of Current Status (MOCS-A)|The Measurement of Everyday Cognition (eCog)|Numerical Rating Scale|The Cognitive and Affective Mindfulness Scale - Revised (CAMS-R)|WHO Disability Assessment Schedule 2.0|The Gratitude Questionnaire (GQ-6)|PROMIS Physical Function|PROMIS Emotional Support|PROMIS Depression|PROMIS Anxiety|Pain Catastrophizing Scale (PCS)|UCLA Loneliness Scale|Pain Self Efficacy Questionnaire (PSEQ)|The Pittsburgh Sleep Quality Index (PSQI)|Tampa Kinesiophobia Scale|Chronic Pain Acceptance Questionnaire|Self-Compassion Scale (SCS)|Demographics|Additional Exit Interview Questions	Massachusetts General Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2018P002152	September 15, 2019	December 2020	December 2020	August 5, 2019		September 23, 2020	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04044183
328	NCT00446485	Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency		Completed	No Results Available	Mild Cognitive Impairment|Cerebrovascular Insufficiency	Drug: Ginkgo biloba standardized extract 24/6|Drug: Ginkgo Biloba standardized extract 24/6|Drug: placebo	Changes of MDRS|Changes of VFT|Changes of CGI|Changes of SCAG|Changes of MMSE|Changes of TCD, and color Doppler of carotid arteries|Changes of platelets, hematocrit, prothrombin time, and activated partial tromboplastin time|Changes of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides|Safety will be assessed according to occurrence of adverse events during the trial	Milsing d.o.o.	All	50 Years and older   (Adult, Older Adult)	Phase 4	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MIL-001	May 2007	April 2010	April 2010	March 13, 2007		September 28, 2015	University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29, Zagreb, Croatia		https://ClinicalTrials.gov/show/NCT00446485
329	NCT04407351	Develop Novel Phototherapy for Health Care of Patients With Sleep Disorder, Mild Cognitive Impairment, or Dementia		Completed	No Results Available	Dementia|Sleep Disorder|Mild Cognitive Impairment|Phototherapy	Device: Green LED light|Device: Red LED light (placebo)	Laser Doppler blood flow analysis (perfusion unit (PU))|Hydration|Transepidermal water loss|Sebum	Kaohsiung Medical University	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	51	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care	MOST106-3111-Y-043001	May 1, 2017	April 30, 2020	May 7, 2020	May 29, 2020		May 29, 2020	Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan		https://ClinicalTrials.gov/show/NCT04407351
330	NCT01548287	A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment|Mild Alzheimer's Disease	Drug: AZD5213|Other: Placebo	Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Latency to Persistent Sleep After 4 Weeks of Treatment, Based on PSG Measurements.|Change From Baseline in Night Total Sleep Time After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Latency of Persistent Sleep After 4 Weeks of Treatment, Based on Actigraphy Recording.|Change From Baseline in Sleep Efficiency After 4 Weeks of Treatment, Based on Actigraphy Recording.	AstraZeneca	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	164	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	D3030C00005	April 2012	January 2013	January 2013	March 8, 2012	December 5, 2016	February 7, 2017	Research Site, Phoenix, Arizona, United States|Research Site, Indio, California, United States|Research Site, Lomita, California, United States|Research Site, San Francisco, California, United States|Research Site, Delray Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01548287
331	NCT01819623	Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment		Withdrawn	No Results Available	Mild Cognitive Impairment	Other: Non-pharmacological therapy	Cognitive function|Cognitive function six months after completing intervention|Depressive symptoms	National Institute of Medical Sciences and Nutrition, Salvador Zubiran	All	60 Years and older   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	GER-830-13/14-1		March 2014		March 27, 2013		April 22, 2015	National Institue of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico		https://ClinicalTrials.gov/show/NCT01819623
332	NCT02061345	PET Imaging in MCI Following ADT for PCa		Suspended	No Results Available	Prostate Cancer|Mild Cognitive Impairment		PET biomarker uptake|PET biomarker volume of distribution	Imperial College London	Male	50 Years to 80 Years   (Adult, Older Adult)		12	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	13HH0558	April 2014	December 2016	December 2016	February 12, 2014		August 15, 2016	Imperial College Healthcare NHS Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02061345
333	NCT02590874	The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment	DEMO	Completed	No Results Available	Mild Cognitive Impairment|Depression	Drug: Duloxetine|Drug: Placebo	Change in scores for the Repeatable Battery for Neuropsychological Status (RBANS) from baseline to 16 weeks.|Evaluation of the relative dominance of the verbal-reading system from baseline at 16 weeks through the Stroop Color and Word Test	University of North Texas Health Science Center	All	50 Years and older   (Adult, Older Adult)	Phase 4	19	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care	UNTHSC IRB#2015-128	January 2016	July 2017	October 2018	October 29, 2015		October 11, 2018	University of North Texas Health Science Center, Fort Worth, Texas, United States		https://ClinicalTrials.gov/show/NCT02590874
334	NCT05310890	Long Term Prospective Study of Tai Chi Intervention to Prevent MCI From Conversion to Dementia	TIME	Not yet recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Tai chi training|Behavioral: Group activity	Incidence of MCI converted to Alzheimer's disease.|The global cognitive function of MCI patients.|Memory|Attention|Executive function|Language|Working memory test|Visual spatial ability|Change from baseline in MMSE score|Change from baseline in MoCA score|Change from baseline in CDR score|Activities of daily living|Anxiety|Depression|Sleep|Brain activity|Neurodegeneration in brain structures|Gut microbiota|Blood biomarkers	Ruijin Hospital|Zhangjiagang Aoyang Hospital of Jiangsu Province	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	206	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	TIME study	September 2022	September 2026	September 2026	April 5, 2022		August 1, 2022			https://ClinicalTrials.gov/show/NCT05310890
335	NCT05331560	Transcranial Pulse Stimulation Open-label Self-controlled Trial For Mild Neurocognitive Disorder		Recruiting	No Results Available	Mild Neurocognitive Disorder	Device: Transcranial Pulse Stimulation (TPS)	Change in Global Cognition|Changes in Verbal Fluency|Change in Working Memory|Change in Executive Functioning|Change in Attention|Change in Depressive Symptoms|Change in Daily Functioning|Change in Apathy|Change in Adverse Effects and Risk Indicators|Changes in Brain Regional Volume Differences and White Matter Hyperintensities (WMH)|Change in Brain Functional Connectivity|Change in Brain-Derived Neurotrophic Factor (BDNF)	The University of Hong Kong|Storz Medical AG	All	60 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW20-024	January 20, 2020	January 20, 2023	July 30, 2024	April 15, 2022		April 15, 2022	The Hong Kong Jockey Club Building for Interdisciplinary Research, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT05331560
336	NCT03545152	Non-pharmacological Interventions on Cognitive Functions in Older People With Mild Cognitive Impairment		Completed	No Results Available	Mild Cognitive Impairment|TTM|Physical Activity|Cognitive Rehabilitation	Behavioral: Exercise|Behavioral: Cognitive training|Behavioral: New life-style	Mini-Mental State Examination|The Alzheimer's Questionnaire|Taiwan version of Prospectiv and Retrospective Memory Questionaire (PRMQ)|Mobility|Depressive symptoms|Quality of life	Tzu-Ting Huang|Chang Gung Memorial Hospital	All	65 Years and older   (Older Adult)	Not Applicable	192	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	103-7443B	August 1, 2015	July 31, 2018	July 31, 2018	June 4, 2018		June 14, 2019			https://ClinicalTrials.gov/show/NCT03545152
337	NCT05200897	Transdermal Trigeminal Electrical Neuromodulation on Mild Cognitive Impairment With Insomnia		Recruiting	No Results Available	Insomnia|Alzheimer Disease|Mild Cognitive Impairment|Amyloid	Device: Transdermal trigeminal electrical neuromodulation(Cefaly)	Changes from Baseline Pittsburgh sleep quality index(PSQI) at 3 months|Changes from Baseline Insomnia severity index(ISI) at 3 months|Changes from Baseline Epworth sleepiness scale(ESS) at 3 months|Changes from Baseline Total time in bed(TIB) at 3 months|Changes from Baseline Total sleep time(TST) at 3 months|Changes from Baseline Sleep efficiency(SE) at 3 months|Changes from Baseline Proportion of stage 1 sleep(N1, %) at 3 months|Changes from Baseline Proportion of stage 2 sleep(N2, %) at 3 months|Changes from Baseline Proportion of stage 3 sleep(N3, %) at 3 months|Changes from Baseline Proportion of REM sleep(R, %) at 3 months|Changes from Baseline REM sleep latency(REML) at 3 months|Changes from Baseline Sleep latency(SL) at 3 months|Changes from Baseline Apnea-hypopnea index(AHI) at 3 months|Changes from Baseline Limb movement index(LMI) at 3 months|Changes from Baseline Periodic limb movement index(PLMI) at 3 months|Changes from Baseline Cortical thickness changes at 3 months|Changes from Baseline Functional connectivity measure at 3 months|Changes from Baseline Fractional anisotropy at 3 months|Changes from Baseline Mean diffusivity at 3 months|Changes from Baseline Verbal fluency at 3 months|Changes from Baseline Boston naming test at 3 months|Changes from Baseline Mini-mental status examination at 3 months|Changes from Baseline Word list recall at 3 months|Changes from Baseline Word list recognition at 3 months|Changes from Baseline Constructional recall at 3 months	Saint Vincent's Hospital, Korea	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	VC21DNSI0029	November 3, 2021	May 31, 2023	May 31, 2023	January 21, 2022		January 21, 2022	St.Vincent's Hospital, the Catholic University of Korea, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05200897
338	NCT00746005	Efficacy of Fish Oil Supplementation on Cognition in MCI Patients and the Influence of the APOE4 Allele		Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: fish oil|Dietary Supplement: placebo, sunflower oil	cognitive performance|blood flow-velocity in the middle cerebral arteries (assessed with TCD) and cortical tissue oxygenation, cerebral autoregulation, cerebral blood volume (assessed with NIRS	Wageningen University|Radboud University Medical Center	All	Child, Adult, Older Adult	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2008/112	October 2008	January 2011	January 2011	September 3, 2008		January 12, 2011	Ziekenhuis Gelderse Vallei, Ede, Gelderland, Netherlands|Radboud University Medical Center, Nijmegen, Gelderland, Netherlands		https://ClinicalTrials.gov/show/NCT00746005
339	NCT02312843	Piedmont Aging, Cognition & Exercise Study-2	PACE-2	Completed	No Results Available	Mild Cognitive Impairment|Prediabetes	Behavioral: Exercise/Aerobic|Behavioral: Exercise/Stretching	Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen|Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise	Wake Forest University|American Diabetes Association|Wake Forest University Health Sciences	All	50 Years to 89 Years   (Adult, Older Adult)	Not Applicable	33	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	IRB00022598	March 2013	April 2017	April 2017	December 9, 2014		August 15, 2018	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02312843
340	NCT03962959	Enhancement of Hippocampal Plasticity Using Repetitive Transcranial Magnetic Stimulation		Recruiting	No Results Available	Mild Cognitive Impairment	Device: TBS	Brain imaging data|NACC Neuropsychological batteries|Correction rate in memory association recall|Specimen sample	University of Arizona|National Institute on Aging (NIA)	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	1812171968|R01AG062543	October 21, 2020	December 31, 2024	June 30, 2025	May 24, 2019		July 14, 2022	Bioscience Research Laboratory, Tucson, Arizona, United States		https://ClinicalTrials.gov/show/NCT03962959
341	NCT04912245	A Telehealth Advance Care Planning Intervention in Those With Mild Cognitive Impairment or Unrecognized Dementia	ACP	Completed	No Results Available	Advance Care Planning|Telemedicine|Mild Cognitive Impairment|Unrecognized Dementia|Dementia	Behavioral: Telehealth visit	Proportion of Patient/Care partner agreeing to participate|Proportion of Telehealth Advance Care Planning (ACP) completed|Number of Advance Care Planning (ACP) discussions documented|Number of times Advance Care Planning (ACP) billing codes are used|Quality of Advance Care Planning (ACP) Discussion	Wake Forest University Health Sciences|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	152	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB00074429|U54AG063546	July 13, 2021	May 9, 2022	May 9, 2022	June 3, 2021		July 27, 2022	Geriatric Medicine-Plaza 1 Davie, Bermuda Run, North Carolina, United States|Wake Forest Health Network Family Medicine Conover, Conover, North Carolina, United States|WFHN Family Medicine-Premier, High Point, North Carolina, United States|Wake Forest Health Network Internal Medicine, Jamestown, North Carolina, United States|WFBIK Geriatric Medicine-Kernersville, Kernersville, North Carolina, United States|WFHN Family Medicine-Thomasville, Thomasville, North Carolina, United States|Geriatric Medicine- Sticht Center, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04912245
342	NCT05009524	The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI)	iPACES	Recruiting	No Results Available	MCI|Mild Cognitive Impairment|Alzheimer Disease|Dementia	Device: iPACES (interactive Physical and Cognitive Exercise System)|Device: PACE (Physical and Cognitive Exercise)	executive function|everyday function|biomarker	iPACES LLC|Pacific Brain Health Center|1st Playable Productions|Adirondack Neuropsychological Associates|Albany Medical College	All	50 Years and older   (Adult, Older Adult)	Not Applicable	120	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIA1R44AG071063	August 23, 2021	May 31, 2022	August 31, 2022	August 17, 2021		November 22, 2021	remote trial conducted via video-conference/mail in-home all locations in the continental USA, Clifton Park, New York, United States		https://ClinicalTrials.gov/show/NCT05009524
343	NCT05077826	Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease	MEMORI	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: North Coast Medical Activadose II	Learning Task Performance	The Mind Research Network	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	21-203	October 7, 2021	April 30, 2023	April 30, 2023	October 14, 2021		August 26, 2022	Mind Research Network, Albuquerque, New Mexico, United States		https://ClinicalTrials.gov/show/NCT05077826
344	NCT04148391	NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)		Recruiting	No Results Available	Mild Cognitive Impairment|Mild Dementia|Parkinson Disease|Lewy Body Disease	Drug: Placebo Oral Capsule|Drug: NYX-458	Change from baseline in physical examination|Rates of adverse events and serious adverse events|Rates of early termination due to adverse events|Change from baseline in vital signs, clinical laboratory values, and electrocardiogram results|Change from baseline dissociative effects, psychosis, and hallucinatory symptoms as measured by the Neuropsychiatric Inventory (NPI-12)|Change from baseline in suicidal ideation and behavior as measured by the Sheehan Suicidality Tracking Scale (S-STS)|Change from baseline in motor complications as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 4|Change in total score of the Sheehan Suicidality Tracking Scale (S-STS)|Change from baseline in the One Back test|Change from baseline in the Two Back test|Change from baseline in the Groton Maze Learning Test|Change from baseline in the Identification Test|Change from baseline in the International Shopping List Test|Change from baseline on Continuous Paired Associate Learning Test	Aptinyx|CogState Ltd.|Worldwide Clinical Trials	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NYX-458-2006	November 14, 2019	December 30, 2022	December 30, 2022	November 1, 2019		September 9, 2022	Aptinyx Clinical Site, Scottsdale, Arizona, United States|Aptinyx Clinical Site, Fresno, California, United States|Aptinyx Clinical Site, Simi Valley, California, United States|Aptinyx Clinical Site, Boca Raton, Florida, United States|Aptinyx Clinical Site, Bradenton, Florida, United States|Aptinyx Clinical Site, Miami Lakes, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx Clinical Site, Port Charlotte, Florida, United States|Aptinyx Clinical Site, Port Orange, Florida, United States|Aptinyx Clinical Site, Sunrise, Florida, United States|Aptinyx Clinical Site, Decatur, Georgia, United States|Aptinyx Clinical Site, Farmington Hills, Michigan, United States|Aptinyx Clinical Site, Golden Valley, Minnesota, United States|Aptinyx Clinical Site, Toms River, New Jersey, United States|Aptinyx Clinical Site, Poughkeepsie, New York, United States|Aptinyx Clinical Site, Asheville, North Carolina, United States|Aptinyx Clinical Site, Dayton, Ohio, United States|Aptinyx Clinical Site, Tulsa, Oklahoma, United States|Aptinyx Clinical Site, Round Rock, Texas, United States|Aptinyx Clinical Site, Sugar Land, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States|Aptinyx Clinical Site, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT04148391
345	NCT00643266	Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment		Completed	No Results Available	Amnestic Mild Cognitive Impairment|Aging	Behavioral: Recollection Training|Behavioral: Control	Recollection estimates|Brain activation as assessed by functional magnetic resonance imaging|Transfer to other recollection-dependent task and to subjective memory measures	Baycrest	All	65 Years to 90 Years   (Older Adult)	Not Applicable	91	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science	RecollectionTraining|CIHR MOP 67015|ASC 08 95	February 2008	August 2013	August 2013	March 26, 2008		November 16, 2018	Baycrest, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00643266
346	NCT03347084	Deep Brain Stimulation With LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease	LIFUP	Recruiting	No Results Available	Brain Imaging|Mild Cognitive Impairment|Alzheimer Disease|Deep Brain Stimulation	Device: Excitation|Device: Inhibition	Change from baseline in fMRI brain scan to 40 minutes.|Change from baseline in Hopkins Verbal Learning Test-Revised45 (HVLT-R)|Change from baseline in Brief Visual Memory Test-Revised|Change from baseline in Geriatric Anxiety Inventory (GAI)	University of California, Los Angeles	All	55 Years and older   (Adult, Older Adult)	Not Applicable	8	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Device Feasibility	16-001314	November 10, 2018	March 2023	March 2023	November 20, 2017		September 6, 2022	UCLA Semel Institute, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03347084
347	NCT02350738	Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia		Completed	No Results Available	Mild Cognitive Impairment|Dementia, Mild	Other: Period I MCET (8 wks)|Other: Washout (4 wks)|Other: Period II MCET (8 wks)	Change in the Mini-Mental State Examination for dementia screening before and after period I and before and after period II intervention (crossover part of the study)|Change in the Korean version of Alzheimer's Disease Assessment Scale -cognitive subscale of Korean version (ADAS-KCog) before and after period I and before and after period II intervention (crossover part of the study)|Change in the Disability Assessment for Dementia (DAD-K) before and after period I and before and after period II intervention (crossover part of the study)|Change in the Revised Memory and Behavior Problems Checklist (RMBPC) before and after period I and before and after period II intervention (crossover part of the study)|Change in the Quality of Life-AD (QoL-AD) of patients before and after period I and before and after period II intervention (crossover part of the study)|Change in the Quality of Life-AD (QoL-AD) of caregivers before and after period I and before and after period II intervention (crossover part of the study)	Ki Woong Kim|Ministry of Health & Welfare, Korea|Seoul National University Bundang Hospital	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 3	64	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	SeoulNUBH	February 2014	June 2015	June 2015	January 30, 2015		July 28, 2015	Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02350738
348	NCT04123314	Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease		Recruiting	No Results Available	Depressive Symptoms|Depression|Alzheimer Disease|Mild Cognitive Impairment	Drug: Psilocybin	Change in Cornell Scale for Depression in Dementia (CSDD) score|Change in Quality of Life Alzheimer's Disease (QOL-AD) scale score	Johns Hopkins University	All	18 Years to 85 Years   (Adult, Older Adult)	Early Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00175915	March 24, 2021	December 30, 2023	December 30, 2023	October 10, 2019		March 24, 2022	Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04123314
349	NCT02574182	Study of Motor Representations in Healthy Subjects and Amnestic MCI	IRMARCHE	Completed	No Results Available	Mild Cognitive Impairment	Radiation: Brain MRI	Review and compare mapping cerebral activation in brain MRI|Review and compare mapping brain activation in healthy subjects and MCI MRI in imagination alone walking.|Study of differences in terms of activation of brain mapping|study of functional connectivity of sensorimotor cortex obtained by fMRI resting in the subject MCI.|study of the potential effects on muscle activation, and autonomic nervous system	University Hospital, Angers	All	18 Years and older   (Adult, Older Adult)		97	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	CHU PROMOTEUR 2014/32	February 24, 2015	May 13, 2017	May 13, 2017	October 12, 2015		July 12, 2021	University Hospital Angers, Angers, Pays De La Loire, France		https://ClinicalTrials.gov/show/NCT02574182
350	NCT04996654	Feasibility of a Novel Exergame-Based Training Concept for Older Adults With Mild Neurocognitive Disorder		Completed	No Results Available	Mild Neurocognitive Disorder	Behavioral: Exergame|Behavioral: Usual Care	Feasibility - recruitment (relative)|Feasibility - recruitment (absolute)|Feasibility - adherence|Feasibility - compliance|Feasibility - attrition|Usability|Acceptance - enjoyment|Acceptance - motivation|Acceptance - perceived usefulness|Changes in Global Cognition|Changes in Learning and Memory - Part 1|Changes in Learning and Memory - Part 2|Changes in Complex Attention - Part 1|Changes in Complex Attention - Part 2|Changes in Complex Attention - Part 3|Changes in Executive Function - Part 1|Changes in Executive Function - Part 2|Changes in Executive Function - Part 3|Changes in Executive Function - Part 4|Changes in Perceptual-Motor Function|Changes in Brain Functional Connectivity|Changes in Spatiotemporal Gait Parameters|Changes in vagally-mediated Heart Rate Variability (HRV)|Changes in Psychosocial Factors - Part 1|Changes in Psychosocial Factors - Part 2	Eling DeBruin|Swiss Federal Institute of Technology	All	50 Years and older   (Adult, Older Adult)	Not Applicable	18	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	EK 2021-N-79	July 12, 2021	June 21, 2022	June 21, 2022	August 9, 2021		June 27, 2022	ETH Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04996654
351	NCT04666077	Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)		Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Behavioral: Home-based MT through Supervised, Supported Singing (H3S)|Behavioral: Individualized Music Therapy (IMT)|Other: Attention Control (AtCon)	Mini Mental Status Exam (MMSE)|Neuropsychiatric Inventory (NPI)|Activities of Daily Living (ADCS-ADL)|Clinician's Global Impression of Change (ADCS-CGIC)|The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)|Zarit Burden Interview	Icahn School of Medicine at Mount Sinai	All	55 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	GCO 19-0243(0002)	July 25, 2019	January 31, 2023	January 31, 2024	December 14, 2020		December 14, 2020	Louis Armstrong Center for Music and Medicine, Mount Sinai Beth Israel, New York, New York, United States|Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04666077
352	NCT01998711	Impact of a Memory Group for Older Adults Reporting Memory Difficulties		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Behavioral: Memory group	Neuropsychological measures of memory and attention|Self-report on memory performance in everyday activities|Self-report on use of memory strategies|Informant report on memory performance in everyday activities|Informant report on use of strategies|Assessment of psychological wellbeing	Bayside Health	All	Child, Adult, Older Adult	Not Applicable	62	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)	156/04	October 2004	November 2007	November 2007	December 2, 2013		December 2, 2013	Caulfield General Medical Centre, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT01998711
353	NCT03676881	Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease		Unknown status	No Results Available	Alzheimer Disease|Dementia|Neuropathology|Mild Cognitive Impairment	Device: Computerized cognitive battery: Cognigram (CG)|Device: The NeuroCatch™ Platform (NCP)	CG scores (accuracy and reaction speed)|MoCA scores|ERP´s amplitudes for Auditory sensation (N100)|ERP´s amplitude for Cognitive processing (N400)|ERP´s amplitude for Basic Attention (P300)|ERP´s latency for Auditory sensation (N100)|ERP´s latency for Cognitive processing (N400)|ERP´s latency for Basic Attention (P300)|Longitudinal changes in CG scores|Longitudinal changes in MoCA scores|Longitudinal change in Mini-mental state examination (MMSE)|Longitudinal change in FAQ|Longitudinal change in GPCOG scores|Longitudinal change in Rey-Osterrieth Complex Figure test (RCFT)|Longitudinal change in Hopkins Verbal Learning test (HVLT-R)|Longitudinal change in Trail Making Tests A and B|Longitudinal change in Semantic Verbal Fluency test (animals).|Longitudinal change in ERP´s amplitudes for Auditory sensation (N100)|Longitudinal change in ERP´s amplitudes for Cognitive processing (N400)|Longitudinal change in ERP´s amplitudes for Basic Attention (P300)|Longitudinal change in ERP´s latencies for Auditory sensation (N100)|Longitudinal change in ERP´s latencies for Cognitive processing (N400)|Longitudinal change in ERP´s latencies for Basic Attention (P300)	Bruyere Research Institute	All	60 Years and older   (Adult, Older Adult)		36	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	M16-17-032)	September 4, 2018	December 2021	December 2021	September 19, 2018		January 14, 2020	Bruyere Research Institute, Ottawa, Ontario, Canada	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03676881/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03676881/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03676881
354	NCT00582855	Effect of AQW051 in Patients With Memory Impairment		Terminated	No Results Available	Mild Alzheimer's Disease|Amnestic Mild Cognitive Impairment	Drug: AQW051|Drug: Placebo	Validated computerized cognitive assessment scores|Validated computerized cognitive assessment scores, the different scores from the Alzheimer's Disease Assessment Score-cognitive subscale (ADAS-Cog), Quality of Life-Alzheimer disease scale and the Disability Assessment for Dementia scale	Novartis Pharmaceuticals|Novartis	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	54	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CAQW051A2104	December 2007	February 2009		December 28, 2007		April 19, 2016	Novartis Investigator Site, Halifax, Canada|Novartis Investigator Site, Montreal, Canada|Novartis Investigator Site, Toronto, Canada|Novartis Investigator Site, Bloemfontein, South Africa|Novartis Investigator Site, George, South Africa|Novartis Investigator Site, Port Elizabeth, South Africa|Novartis Investigator Site, Blackpool, United Kingdom|Novartis Investigator Site, Epping, United Kingdom|Novartis Investigator Site, Glasgow, United Kingdom|Novartis Investigator Site, Manchester, United Kingdom|Novartis Investigator Site, Southampton, United Kingdom|Novartis Investigator Site, Swindon, United Kingdom		https://ClinicalTrials.gov/show/NCT00582855
355	NCT01046292	Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI		Completed	No Results Available	Mild Cognitive Impairment	Drug: Ginkgo biloba	gait speed|cycle time variability	University Hospital, Basel, Switzerland	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 4	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	GBE LI 1370	January 2010	February 2015	October 2015	January 11, 2010		October 14, 2015	Basel University Hospital, Basel Mobility Center, Basel, Basel-Stadt, Switzerland		https://ClinicalTrials.gov/show/NCT01046292
356	NCT05387057	Effectiveness of a Novel Exergame-Based Training Concept for Older Adults With Mild Neurocognitive Disorder		Recruiting	No Results Available	Mild Neurocognitive Disorder	Behavioral: Exergame training according to the 'Brain-IT' exergame-based training concept|Behavioral: Usual Care	Changes in Global Cognition|Changes in Learning and Memory - Part 1|Changes in Learning and Memory - Part 2|Changes in Complex Attention - Part 1|Changes in Complex Attention - Part 2|Changes in Executive Function - Part 1|Changes in Executive Function - Part 2|Changes in Executive Function - Part 3|Changes in Visuospatial Skills|Changes in Brain Structure and Function - Part 1 (Grey Matter Volumes)|Changes in Brain Structure and Function - Part 2 (White Matter Volumes)|Changes in Brain Structure and Function - Part 3 (Mean diffusivity)|Changes in Brain Structure and Function - Part 4 (Fractional Anisotropy)|Changes in Brain Structure and Function - Part 5 (Functional Connectivity Maps at rest)|Changes in Brain Structure and Function - Part 6 (Functional Connectivity Maps during an episodic memory-task)|Changes in Spatiotemporal Gait Parameters - Part 1 (single-task gait speed at preferred walking speed)|Changes in Spatiotemporal Gait Parameters - Part 2 (stride duration)|Changes in Spatiotemporal Gait Parameters - Part 3 (stride length)|Changes in Spatiotemporal Gait Parameters - Part 4 (stance phase duration)|Changes in Spatiotemporal Gait Parameters - Part 5 (swing time)|Changes in Spatiotemporal Gait Parameters - Part 6 (single support time)|Changes in Spatiotemporal Gait Parameters - Part 6 (double support time)|Changes in Instrumental Activities of Daily Living (IADL)|Changes in Psychosocial Factors - Part 1 (Quality of Life)|Changes in Psychosocial Factors - Part 2 (Symptoms of Depression)|Changes in vagally-mediated Heart Rate Variability (HRV)	Eling DeBruin|Swiss Federal Institute of Technology	All	Child, Adult, Older Adult	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	BASEC Nr. 2022-00386	June 22, 2022	December 2023	December 2023	May 24, 2022		June 28, 2022	ETH Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT05387057
357	NCT04689776	The Effectiveness of Dual Task Training in Elderly With Cognitive Decline		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Dual-Task Training	Change scores of the Montreal Cognitive Assessment (MoCA)|Change scores of Mini-Mental State Exam (MMSE)|Change scores of the Stroop test|Change scores of the Timed up and go (TUG) test|Change scores of the Dual-task test|Change scores of the Wechsler Adult Intelligence Scale (WAIS)|Change scores of the Lawton Instrumental Activities of Daily Living Scale (IADL)|Change scores of the Wechsler Memory Scale (WMS)|Change scores of the Community Integration Questionnaire (CIQ)|Change scores of Geriatric Depression Scale (GDS)|Change scores of the Everyday Cognition scales (ECog)-12 items	Chang Gung Memorial Hospital	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	201912EM016	September 16, 2020	January 1, 2023	January 1, 2023	December 30, 2020		July 5, 2022	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT04689776
358	NCT05050812	The Grounded Brain: How Sleeping Grounded Affects Memory and Perceptions		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Chronic Inflammation	Device: grounding mat	Baseline Psychomotor Function Score|Week 1 Psychomotor Function Score|Week 2 Psychomotor Function Score|Week 3 Psychomotor Function Score|Change from Baseline to Week 3 Psychomotor Function Score|Baseline Attention Score|Week 1 Attention Score|Week 2 Attention Score|Week 3 Attention Score|Change from Baseline to Week 3 Attention Score|Baseline Visual Learning Score|Week 1 Visual Learning Score|Week 2 Visual Learning Score|Week 3 Visual Learning Score|Change from Baseline to Week 3 Visual Learning Score|Baseline Working Memory Score|Week 1 Working Memory Score|Week 2 Working Memory Score|Week 3 Working Memory Score|Change from Baseline to Week 3 Working Memory Score|Baseline Sleep Quality Score|Week 1 Sleep Quality Score|Week 2 Sleep Quality Score|Week 3 Sleep Quality Score|Change from Baseline to Week 3 Sleep Quality Score|Baseline Pain Score|Week 1 Pain Score|Week 2 Pain Score|Week 3 Pain Score|Change from Baseline to Week 3 Pain Score|Baseline Mood Score|Week 1 Mood Score|Week 2 Mood Score|Week 3 Mood Score|Change from Baseline to Week 3 Mood Score|Baseline Overall Well-Being Score|Week 1 Overall Well-Being Score|Week 2 Overall Well-Being Score|Week 3 Overall Well-Being Score|Change from Baseline to Week 3 Overall Well-Being Score|Correlation of Change in Psychomotor Function Score and Sleep Quality Score from Baseline to Week 3|Correlation of Change in Psychomotor Function Score and Pain Score from Baseline to Week 3|Correlation of Change in Psychomotor Function Score and Mood Score from Baseline to Week 3|Correlation of Change in Psychomotor Function Score and Overall Well-Being Score from Baseline to Week 3|Correlation of Change in Attention Score and Sleep Quality Score from Baseline to Week 3|Correlation of Change in Attention Score and Pain Score from Baseline to Week 3|Correlation of Change in Attention Score and Mood Score from Baseline to Week 3|Correlation of Change in Attention Score and Overall Well-Being Score from Baseline to Week 3|Correlation of Change in Visual Learning Score and Sleep Quality Score from Baseline to Week 3|Correlation of Change in Visual Learning Score and Pain Score from Baseline to Week 3|Correlation of Change in Visual Learning Score and Mood Score from Baseline to Week 3|Correlation of Change in Visual Learning Score and Overall Well-Being Score from Baseline to Week 3|Correlation of Change in Working Memory Score and Sleep Quality Score from Baseline to Week 3|Correlation of Change in Working Memory Score and Pain Score from Baseline to Week 3|Correlation of Change in Working Memory Score and Mood Score from Baseline to Week 3|Correlation of Change in Working Memory Score and Overall Well-Being Score from Baseline to Week 3	California Institute of Integral Studies	All	55 Years and older   (Adult, Older Adult)	Not Applicable	8	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	PFJ001	September 2021	November 2021	December 2021	September 21, 2021		September 24, 2021			https://ClinicalTrials.gov/show/NCT05050812
359	NCT02353884	Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease		the accuracy of a predictable classifier from MCI to AD based on Multi-Modality MRI characteristics of MCI patients.|characteristic changes of brain structure in progressive MCI|characteristic changes of anatomical connectivity in progressing MCI|characteristic changes of functional connectivity in progressing MCI	XuanwuH 2|Xuanwu Hospital, Beijing	All	55 Years to 75 Years   (Adult, Older Adult)		150	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	hanying3	January 2010	December 2011	December 2012	February 3, 2015		February 3, 2015	Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02353884
360	NCT04884529	Virtual Chair Yoga for Older Adults and Caregivers: Randomized Controlled Trial		Completed	No Results Available	Dementia|Mild Cognitive Impairment	Behavioral: Chair-yoga program	Changes in perceived stress scores as measured by the Perceived Stress Scale (PSS) for treatment group versus control group|Changes in loneliness scores as measured by the 3-item UCLA Loneliness Scale for treatment group versus control group	Lady Davis Institute	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2021-2761	September 1, 2021	December 30, 2021	March 30, 2022	May 13, 2021		April 6, 2022	Institute of Community and Family Psychiatry, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04884529
361	NCT02848404	Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Device: Categorical Language Fluency Smartphone Application	Application usage log|Subjective Memory Complaint Questionnaire|Geriatric Depression Scale|Korean version of MMSE for dementia screening	Seoul National University Bundang Hospital|Seoul National University|Ministry of Science, ICT and Future Planning	All	55 Years and older   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2010-0028631	June 2016	December 2016	February 2017	July 28, 2016		March 25, 2020			https://ClinicalTrials.gov/show/NCT02848404
362	NCT01553929	Physical Training and Cognitive Activity on the Mild Cognitive Impairment (MCI) Patient	EPAC-M	Terminated	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Other: Physical Training and cognitive activity (EPC group)|Other: Physical training (EP group)|Other: control group	effectiveness of physical training|Cognitive improvement	Centre Hospitalier Universitaire de Nice	All	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	5	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	11-AOI-03	March 2012	March 2012	January 2015	March 14, 2012		August 14, 2015	CHU de Nice, Nice, France		https://ClinicalTrials.gov/show/NCT01553929
363	NCT03641404	Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline		Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: ergothioneine|Dietary Supplement: placebo	Change in Singapore Modified - Mini Mental State Examination Scores (Cognitive function assessment)|Change in Clinical Dementia Rating Scale (Cognitive function assessment)|Change in Rey Auditory Verbal Learning Test scores (Cognitive function assessment)|Change in Digit Span (Cognitive function assessments)|Change in Block Design Test scores (Cognitive function assessment)|Change in Symbol Digit Modality Test scores (Cognitive function assessment)|Change in Boston Naming Test scores (Cognitive function assessment)|Change in Colour Trials Test (Cognitive function assessments)|Changes in brain structure (reduction in grey and white matter atrophy)|Changes in brain structure (Reduction in hippocampal atrophy)|Changes in biomarkers of oxidative damage|Changes in inflammation cytokines|Change in Geriatric Depression Scale (Neuropsycological assessment)|Change in Geriatric Anxiety Inventory (Neuropsycological assessment)	National University Hospital, Singapore|National University, Singapore|National University Health System, Singapore	All	60 Years to 90 Years   (Adult, Older Adult)	Phase 3	106	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2017/00982	August 2018	June 2021	December 2021	August 22, 2018		August 22, 2018	National University Cancer Institute, Singapore, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT03641404
364	NCT04350801	Home-based Cognitive Monitoring in MCI		Unknown status	No Results Available	Mild Cognitive Impairment	Diagnostic Test: home-based cognitive monitoring	home-based cognitive monitoring score|Hippocampal atrophy grade|Number of lacunes|Number of microbleeds	Asan Medical Center	All	50 Years and older   (Adult, Older Adult)		40	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Hom-based cognitive monitoring	December 1, 2019	November 1, 2020	December 30, 2020	April 17, 2020		April 20, 2020	Uijeongbu St. Mary's hospital, Uijeongbu, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04350801
365	NCT03824639	Exercise Training to Improve Cognitive Function		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Structured exercise|Behavioral: Health Education	Wechsler Logical Memory Task|Rey-Osterrieth Complex Figure Test	VA Office of Research and Development	All	50 Years and older   (Adult, Older Adult)	Phase 3	60	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	E2545-P	April 23, 2019	May 31, 2022	July 31, 2022	January 31, 2019		August 23, 2022	VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03824639/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT03824639
366	NCT05275153	Effectiveness of a Home-Based Cognitive Rehabilitation Program in Patients With MCI		Completed	No Results Available	Cognitive Impairment|Mild Cognitive Impairment	Other: Home based cognitive rehabilitation program	Change of the Korean-Montreal cognitive assessment(MoCA) score|Change of the semantic verbal emory test (SVLT) score|Change of the Digit Span Test (DST) score|Change of the category word fluency test (CWFT) score|Change of the phonemic word fluency test (PWFT) score|Change of the geriatric depression scale (GDS) score	Pusan National University Yangsan Hospital|Woorisoft	All	55 Years and older   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	02-2019-018	April 22, 2020	June 30, 2021	August 2, 2021	March 11, 2022		March 11, 2022	Pusan national university Yangsan Hospital, Gyeongsang, Yangsan, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05275153
367	NCT03061474	Nicotinamide as an Early Alzheimer's Disease Treatment	NEAT	Active, not recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Nicotinamide|Drug: Placebo Comparator	Change in p-tau 231|Change in p-tau 181|Change in total tau	University of California, Irvine	All	50 Years and older   (Adult, Older Adult)	Phase 2	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	2016-3246	July 12, 2017	August 30, 2022	August 30, 2022	February 23, 2017		November 16, 2021	University of California, Irvine, Irvine, California, United States|University of California, Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03061474
368	NCT03119051	Shanghai Non-pharmacological Intervention of Mild Cognitive Impairment	SIMPLE	Unknown status	No Results Available	Cognitive Dysfunction	Behavioral: Online cognitive training|Behavioral: Cognitive training plus physical exercise	Incidence of AD|The global cognitive function of MCI patients|Memory|Attention|Executive functions|Language|Visual spatial ability and visual memory|Activities of daily living|Structural MRI|Gut microbiota	Ruijin Hospital|RenJi Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Huashan Hospital	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	RuijinHSH	May 15, 2017	March 2021	May 2021	April 18, 2017		August 17, 2020	Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03119051
369	NCT01099332	Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease		Unknown status	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Other: Gastro-retentive zinc cysteine tablet|Other: Tablet identical physically to active comparator containing some lactose	Biometal levels will be measured in serum by atomic absorption spectrometry|Serum zinc levels after oral administration of two different zinc-containing compounds and placebo will be determined by atomic absorption spectrometry|Comparison of mental status functions at baseline, 3 and 6 months in active comparator versus placebo groups.	Adeona Pharmaceuticals	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 1|Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CopperProof-2	November 2009	January 2011	January 2011	April 7, 2010		January 28, 2011	Neuroscience Research Unit, Clearwater, Florida, United States|ATIT Neurology, Holiday, Florida, United States|The Cottages, Port Richey, Florida, United States		https://ClinicalTrials.gov/show/NCT01099332
370	NCT00446394	Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)		Completed	No Results Available	Mild Cognitive Impairment|Dementia	Behavioral: Resources and Activities for Life Long Independence (RALLI)|Behavioral: Social Walking program (SW)	Changes in cognitive status|Changes in health, affective, and functional status	University of Washington	All	70 Years and older   (Older Adult)	Not Applicable	181	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	30692-J|2R01AG014777|IA0100|06-3067-C	June 2007	October 2012	October 2012	March 12, 2007		October 19, 2012	Northwest Research Group on Aging, Department of Psychosocial and Community Health, University of Washington School of Nursing, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00446394
371	NCT05036304	Supporting Aging Through Green Exercise (SAGE)	SAGE	Not yet recruiting	No Results Available	Mild Cognitive Impairment|Aging	Other: Aerobic Exercise Indoors|Other: Aerobic Exercise Outdoors	Change in List Sorting Performance|Change in Digits Span Forwards and Backwards|Change in NIH Toolbox Cognitive Battery Performance|Change in Digit Symbol Substitute Test|Change in the Short Physical Performance Battery|Change in Timed Up and Go Test|Change in State-Trait Anxiety Inventory|Change in Centre for Epidemiological Studies Depression Scale|Change in Blood Pressure|Change in sensor measured sleep|Change in sensor measured physical activity|Change in Physical Activity Scale for the Elderly|Change in Pittsburgh Sleep Quality Index|Change in ICEpop CAPability measure for Older people (ICECAP-O)|5-level EuroQoL 5-dimension (EQ-5D-5L) questionnaire	University of British Columbia	All	65 Years to 80 Years   (Older Adult)	Not Applicable	68	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	H21-00406	October 15, 2022	October 31, 2024	October 31, 2024	September 5, 2021		September 16, 2021			https://ClinicalTrials.gov/show/NCT05036304
372	NCT04301544	Filipino Multicomponent Intervention to Maintain Cognitive Performance in High Risk Population (FINOMAIN)	FINOMAIN	Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: INDAK (Improving Neurocognition through Dance and Kinesthetics)|Behavioral: Nutrition Counseling|Behavioral: Standardized Vascular Care	Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Score|Change from baseline in Mnemonic Similarity Task score|Change from baseline in Executive Function Composite score|Change from baseline in Magnetic Resonance Imaging (MRI)|Change from baseline in Brief Geriatric Depression Scale (GDS) score|Change from baseline in Change in EuroQoL - Visual Analog Scale (EQVAS) rating|Change from baseline in Change in Berg Balance Scale (BBS) score	St. Luke's Medical Center, Philippines|Nanyang Technological University|Icahn School of Medicine at Mount Sinai|University of Copenhagen	All	60 Years and older   (Adult, Older Adult)	Not Applicable	72	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	CT-18146|PITAHC-IDxxx	May 28, 2019	September 30, 2021	December 30, 2021	March 10, 2020		December 31, 2020	Institute for Neurosciences, St. Luke's Medical Center, Quezon, Metro Manila, Philippines		https://ClinicalTrials.gov/show/NCT04301544
373	NCT03113461	MCI: CPAP Treatment of OSA (Memories2)	MCI:OSA	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Sleep Apnea, Obstructive	Device: CPAP	Digit Symbol-Coding test|Clinical Dementia Rating Scale	University of Pennsylvania|National Institute on Aging (NIA)	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	327	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	PD10057866|R01AG054435	October 15, 2017	December 31, 2022	July 1, 2025	April 13, 2017		September 2, 2022	Washington University in St. Louis, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas at Austin, Austin, Texas, United States|University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT03113461
374	NCT00628017	Preliminary Study of Fish Oil and Dementia		Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Dietary Supplement: omega-3 polyunsaturated fatty acids ( EPA+DHA)	the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus)|the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog)|Mini Mental Status Examination (MMSE) scores|17-item Hamilton Depression Scale (HDRS)|adverse events	Taipei City Psychiatric Center, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	46	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	DOH-92-TD-1095	January 2003	March 2005	March 2005	March 4, 2008		March 4, 2008	Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT00628017
375	NCT04525144	EGb 761 in the Syndrome of MCI With Concomitant CVD		Recruiting	No Results Available	Mild Cognitive Impairment|Cerebrovascular Disease	Drug: Tebonin Forte	Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog 13)|Clinical Dementia Rating Sum of Boxes Scores (CDR-SOB)|Visual Cognitive Assessment Tool (VCAT)|Mild Behavioural Impairment Checklist (MBI-C)	National Neuroscience Institute|Dr. Willmar Schwabe GmbH & Co. KG	All	45 Years to 85 Years   (Adult, Older Adult)	Phase 2	134	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	EGB-MCI	October 26, 2020	January 2022	February 2023	August 25, 2020		March 4, 2021	National Neuroscience Institute, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04525144
376	NCT05209035	Evaluation of Trazodone in OSA-MCI		Recruiting	No Results Available	Mild Cognitive Impairment|Obstructive Sleep Apnea	Drug: Trazodone|Other: Placebo	sST2|Clinical Dementia Rating Score	Chinese University of Hong Kong|Hong Kong University of Science and Technology	All	60 Years to 80 Years   (Adult, Older Adult)	Phase 4	124	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2021.038	May 10, 2022	December 31, 2024	December 31, 2026	January 26, 2022		July 20, 2022	The Chinese University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT05209035
377	NCT03927586	Evolving Methods of Hybrid Exercise-cognition Approach to Promote Health-related Conditions for the Elderly With MCI		Recruiting	No Results Available	Mild Cognitive Impairment|Stroke	Other: cognitive training|Other: physical exercise training	Change scores of Montreal Cognitive Assessment (MoCA)|Change scores of Verbal fluency test|Change scores of Wechsler Memory Scale - Third Edition (WMS-III)|Change scores of Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)|Change scores of Useful Field of View (UFOV)|Change scores of Stroop Color-Word test|Change scores of Dual-task test|Change scores of Timed up and go (TUG)|Change scores of Sit-to-stand test|Change scores of International Physical Activity Questionnaires (IPAQ)|Change scores of Mobility level|Change scores of Lower extremity muscle strength|Change scores of Grip strength|Change scores of the Barthel Index (BI)|Change scores of Lawton Instrumental Activities of Daily Living Scale (Lawton IADL)|Change scores of the Disability Assessment for Dementia (DAD)|Change scores of the Quality of Life in Alzheimer's Disease Instrument (QoLAD)|Change scores of Community Integration Questionnaire (CIQ)|Change scores of Caregiver Burden Inventory (CBI)|Change scores of Short form of Geriatric Depression Scale (GDS)|Change scores of serum BDNF level	Chang Gung Memorial Hospital	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	201600262A3	April 10, 2018	December 2021	December 2021	April 25, 2019		June 21, 2021	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT03927586
378	NCT03896308	Reliability of Chinese Version of Verbal Learning Test and Selective Reminding Test		Unknown status	No Results Available	Mild Cognitive Impairment|Test-retest Reliability		Chinese Version of Verbal Learning Test|Chinese Version of Selective Reminding Test	National Yang Ming University	All	50 Years to 100 Years   (Adult, Older Adult)		30	Other	Observational	Observational Model: Other|Time Perspective: Prospective	YM108036E	May 25, 2019	February 28, 2020	March 19, 2020	March 29, 2019		August 6, 2019	National Yang-Ming University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03896308
379	NCT03875326	Stimulation to Improve Memory	STIM	Recruiting	No Results Available	Mild Cognitive Impairment|Dementia of Alzheimer Type	Device: 1 mA HD-tDCS|Device: 2 mA HD-tDCS|Device: 3 mA HD-tDCS|Device: Sham	Change in Lateral Temporal Cortex Connectivity|Self-Report of Contentment with Memory|Self-Report of Memory Mistakes|Self-Report of Memory Strategies Used|Change in Memory Functioning|Change in Overall Fluid Cognitive Abilities|Cumulative Working Memory Effects of HD-tDCS across daily sessions|Cumulative Memory Accuracy Effects of HD-tDCS across daily sessions|Cumulative Memory Reaction Time Effects of HD-tDCS across daily sessions|Tolerability of HD-tDCS|Effectiveness of Blinding of HD-tDCS	University of Michigan|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Not Applicable	240	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HUM00146180|1R01AG058724	April 1, 2019	September 1, 2024	October 1, 2024	March 14, 2019		March 3, 2022	University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT03875326
380	NCT03331796	Noninvasive Brain Stimulation for Mild Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Mild Neurocognitive Disorder|Cognitive Decline|Mental Deterioration|Cognitive Dysfunction|Memory Decline|Memory Loss|Memory Impairment	Device: Active rTMS (Bilateral DLPFC)|Device: Active rTMS (Bilateral LPC)|Device: Placebo rTMS (Inactive)	Change from Baseline in memory score, as measured by the California Verbal Learning Test-II (CVLT-II)|Change from Baseline in memory score, as measured by the California Verbal Learning Test (CVLT-II) Trials 1-5 Total raw score|Change from Baseline in depressive symptoms, as measured by the Geriatric Depression Scale (GDS)|Change from Baseline in everyday functional outcomes, as measured by the Everyday Cognition (ECog) Questionnaire|Change from Baseline in global cognition, as measured by the Montreal Cognitive Assessment (MoCA)|Change from Baseline in CVLT-II Semantic clustering|Change from Baseline in CVLT-II Short-delay free recall|Change from Baseline in visuospatial memory, as measured by the Brief Visuospatial Memory Test-Revised (BVMT-R)|Change from Baseline in language function, as measured by Category Fluency (CF)|Change from Baseline in language function, as measured by 42-item Boston Naming Test (BNT)|Change from Baseline in visuoconstructional function, as measured by the Rey-Osterrieth Complex Figure (ROCF), Copy score|Change from Baseline in speed of processing, as measured by Trail making|Change from Baseline in attention, as measured by the Attentional Network Test (ANT)|Change from Baseline in brain functional connectivity|Change from Baseline in levels of brain-derived neurotrophic factor (BDNF)	Palo Alto Veterans Institute for Research|National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	99	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TAY0003AGG|R01AG055526	May 16, 2018	December 31, 2022	April 30, 2023	November 6, 2017		July 7, 2022	VA Palo Alto Health Care System, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT03331796
381	NCT04513106	Promoting ACP in Persons With MCI and Early Stage Dementia and Their Family Caregivers in Community Care Setting: a Feasibility RCT		Completed	No Results Available	Dementia Mild|Mild Cognitive Impairment	Behavioral: ACP programme "Have a Say"|Behavioral: Attention-control health talks	Change in advance care planning engagement|Change in dyadic concordance of end-of-life care preferences	Hong Kong Metropolitan University|Chinese University of Hong Kong|The British Council in Hong Kong	All	55 Years and older   (Adult, Older Adult)	Not Applicable	36	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	SIRCP R6303	September 9, 2019	April 30, 2020	April 30, 2020	August 14, 2020		January 20, 2022	Hong Kong Family Welfare Society Kowloon City Centre for Active Ageing, Kowloon, Hong Kong|Hong Kong Sheng Kung Hui Chuk Yuen Canon Martin District Elderly Community Centre, Kowloon, Hong Kong|Hong Kong Sheng Kung Hui Lok Man Alice Kwok Integrated Service Centre, Kowloon, Hong Kong|Yang Memorial Methodist Social Service Choi Hung Community Centre for Senior Citizens, Kowloon, Hong Kong|Mrs. Wong Tung Yuen District Elderly Community Centre, Yuen Long, Hong Kong		https://ClinicalTrials.gov/show/NCT04513106
382	NCT02113345	The Relationship Between Metamemory and Memory in Old Age	M&Mresearch	Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Metamemory Cognitive Intervention	Objective Memory Measures|Subjective Memory Measures	The University of Hong Kong	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	082010Deb	April 2014	March 2016	March 2016	April 14, 2014		April 14, 2014	Research Site, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT02113345
383	NCT05375513	SYNchronizing, Exercises and Remedies to GaIn Cognition@Home	SYN2	Not yet recruiting	No Results Available	Mild Cognitive Impairment	Other: PMI@Home|Other: Brain Health Pro	Change in global cognition assessed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) with 13 items (ADASCog-13)|Change in Anthropometric Measures|Change in Rated Perceived Exertion-Borg Scale|Change in Canadian Diet History Questionnaire|Change in Cardiovascular Risk Factors, Aging, and Incidence of Dementia|Changes in the CCNA Gait Assessments results-Walking performance|Changes in Clinical Dementia Rating scores|Changes in Cognitive Expectancy Questionnaire|Changes in Digit Symbol Modalities Test - Oral Version (mental processing speed)|Changes in Eating Pattern Self-Assessment|Changes in Fall Occurrence|Changes in Generalized Anxiety Disorder (GAD-7)|Change in Geriatric Depression Scale (GDS-30)|Change in Health Utility Index (HUI-3)|Changes in Health Resource Utilization Questionnaire (HRUQ)|Changes in Insomnia Severity Index|Changes in International Physical Activity Questionnaire scores|Changes in the Lawton-Brody Instrumental Activities of Daily Living (IADL) scale|Changes in the Mediterranean Diet Assessment|Changes in global cognitive function using Montreal Cognitive Assessment(MoCA)|Changes in the Oral Trail Making Test - Attention Shifting capabilities/executive functions using|Changes in Quality of Life Questionnaire (SF-36)|Changes in Rey Auditory Verbal Learning Test (RAVLT)-Episodic memory|Changes in Stroop test scores - Inhibitory cognitive capabilities	Lawson Health Research Institute	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	275	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	3948	June 1, 2022	November 30, 2023	December 30, 2024	May 16, 2022		May 16, 2022	St. Joseph's Health Care London, Parkwood Hospital, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05375513
384	NCT01658228	Combination Treatment Study for Memory Impairment and Depression	DEP-CI	Completed	Has Results	Depression|Mild Cognitive Impairment	Drug: Donepezil|Drug: Placebo|Drug: Citalopram|Drug: Venlafaxine	Selective Reminding Test (SRT) Total Recall|Selective Reminding Test (SRT) Delayed Recall|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)	New York State Psychiatric Institute|National Institute on Aging (NIA)	All	55 Years to 95 Years   (Adult, Older Adult)	Phase 4	86	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	#6459|R01AG040093-01	September 2011	January 2016	January 2016	August 6, 2012	October 17, 2017	October 17, 2017	New York State Psychiatric Institute, New York, New York, United States|Duke University, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01658228
385	NCT04263519	A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.		Withdrawn	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: Tacrolimus	CSF biomarkers of target engagement, AD pathology, and neurodegeneration|Blood biomarkers of target engagement, AD pathology, and neurodegeneration.|Structural neuroimaging of Hippocampal volume.|Functional neuroimaging of default mode network connectivity.|Electroencephalograms (EEG) spectral power|Montreal Cognitive Assessment (MoCA)|Neuropsychiatric Inventory Questionnaire (NPIQ)|Functional Activities Questionnaire (FAQ)|Repeated Battery for the Assessment of Neuropsychological Status	Massachusetts General Hospital	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019P003904	December 1, 2021	December 1, 2022	January 1, 2023	February 10, 2020		September 27, 2021			https://ClinicalTrials.gov/show/NCT04263519
386	NCT02089555	African American Alzheimer's Progression Markers - CSF and Neuro-Imaging	A3PM	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Procedure: Lumbar puncture|Procedure: Blood draw|Procedure: Magnetic Resonance Imaging (MRI)	CSF endothelial marker levels|CSF Alzheimer's biomarker levels|MRI evidence of small vessel disease|MRI evidence of brain atrophy	Emory University|National Institute on Aging (NIA)	All	60 Years to 85 Years   (Adult, Older Adult)		135	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	IRB00066145|R21AG043885	September 2013	June 2016	June 2016	March 18, 2014		June 23, 2016	Emory University, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT02089555
387	NCT02237560	The Aerobic & Cognitive Exercise Study	ACES	Completed	No Results Available	Mild Cognitive Impairment|Healthy	Behavioral: Cybercycle-Game|Behavioral: Cybercyle-Tour|Behavioral: Game Only	Change from baseline in executive function at 6-months|Change in weight|Change in mood|Change from baseline in executive function at 3-months|Change from baseline in executive function at 1-year follow-up	Union College, New York|National Institute on Aging (NIA)	All	50 Years and older   (Adult, Older Adult)	Not Applicable	111	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	HS13083|R15AG042109-01A1	September 2014	July 2017	July 2017	September 11, 2014		May 3, 2018	Albany Medical Center, Albany, New York, United States|Sidney Albert Albany Jewish Community Center, Albany, New York, United States|Stratton VA Medical Center, Albany, New York, United States|Hawthorne Ridge, East Greenbush, New York, United States|Guilderland YMCA, Guilderland, New York, United States|Glen Eddy, Niskayuna, New York, United States|Coburg Village, Rexford, New York, United States|Prestwick Chase, Saratoga Springs, New York, United States|Kingsway Parkland GardenApartments, Schenectady, New York, United States|Schaffer Heights, Schenectady, New York, United States|Sunnyview Rehabilitation Center, Schenectady, New York, United States|Beverwyck, Slingerlands, New York, United States		https://ClinicalTrials.gov/show/NCT02237560
388	NCT03919669	A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking		Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: All Subjects	Change in [18F]MK-6240 uptake|Correlate the changes in [18F]MK-6240 uptake and changes in clinical cognitive assessments by Mini-Mental Status Exam (MMSE)|Correlate the changes in [18F]MK-6240 uptake and changes in clinical cognitive assessments by Clinical Dementia Rating Scale (CDR).|Correlate the changes in [18F]MK-6240 uptake and changes in clinical cognitive assessments by Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)|Change in the Cross-sectional comparison of [18F]MK-6240 uptake	University of Wisconsin, Madison|Cerveau Technologies, Inc.	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	32	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2018-1348|A534255|SMPH/MEDICINE/GER-AD DEV|Protocol Version 8/26/2021	April 2, 2019	May 19, 2022	May 19, 2022	April 18, 2019		July 15, 2022	University of Wisconsin-Madison, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03919669
389	NCT03461276	Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Biological: ABvac40|Biological: Placebo	Incidence of treatment-emergent adverse events [safety and tolerability]|Immune response	Araclon Biotech S.L.	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 2	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	AB1601	February 8, 2018	December 2021	December 2022	March 12, 2018		January 20, 2021	Hôpital François Mitterrand, Dijon, Bourgogne, France|CHU de Montpellier, Montpellier, France|Centre de Recherche Clinique du Gérontopôle, Toulouse, France|San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|Hospital Mutua de Terrasa, Terrassa, Barcelona, Spain|Hospital Universitario Donosti, San Sebastian, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Ramón y Cajal, Colmenar Viejo, Madrid, Spain|CUN - Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Cae Oroitu, Algorta, Vizcaya, Spain|Hospital General Universitario de Alicante, Alicante, Spain|BarcelonaBeta Brain Research Center (BBRC), Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Fundació ACE, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital U. de Burgos, Burgos, Spain|Hospital Santa Maria de Lleida, Lleida, Spain|Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Karolinska Universitetssjukhuset, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT03461276
390	NCT05040217	A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment		Recruiting	No Results Available	Alzheimer's Disease	Genetic: AAV2-BDNF Gene Therapy|Biological: AAV2-BDNF Gene Therapy	Safety as assessed by mumber of participants with treatment-related adverse events assessed on MRI scan|Memory change tested on Ray Auditory Verbal Learning Task|Memory change tested on Benson Complex Figure Draw and Memory|Efficacy on PET scan reflected by change in fluorodeoxyglucose (FDG) PET scan|Change in Biomarkers including CSF amyloid, tau and neurofilament|Memory change tested on mini-mental status examination (MMSE)|Memory tested on Alzheimer's Disease Assessment Scale, Cognitive component (ADAS-Cog)	Mark Tuszynski|Case Western Reserve University|Ohio State University|University of California, San Diego	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCSD-BDNF1	March 1, 2021	March 1, 2023	March 1, 2025	September 10, 2021		September 10, 2021	University of California - San Diego, San Diego, California, United States|Case Western Reserve University, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT05040217
391	NCT04121208	MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease	MICAD	Not yet recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: JNJ-40346527|Other: Placebo	Placebo-controlled change from baseline in cerebrospinal fluid (CSF) protein marker concentration levels.|Placebo-controlled change from baseline in CSF and blood biomarker concentration levels|Placebo-controlled change from baseline in amount of CSF extracellular vesicles and cell population.|Measurement of plasma/CSF JNJ-40346527 levels|Measurement of cerebrospinal fluid (CSF) protein marker concentration levels following different JNJ-40346527 doses|Occurrence of adverse events during the study	University of Oxford|Janssen Pharmaceutica	All	50 Years to 99 Years   (Adult, Older Adult)	Phase 1	54	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other	40346527ALZ1001|2018-004149-17	November 2020	December 2021	December 2021	October 9, 2019		October 28, 2020	Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom|South London and Maudsley Hospital NHS Foundation Trust, London, United Kingdom|Oxford Health NHS Trust, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT04121208
392	NCT02928211	Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations		Unknown status	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Device: Sapphire II|Drug: Aftobetin-HCl|Radiation: Positron Emission Tomography	Paired pre-ligand and post ligand fluorescent uptake values (FUV)|Determination of success (yes or no)|The overall diagnostic precision for each combination of Aftobetin-HCl administrations and Fluorescent Uptake Value (FUV)|Estimates of sensitivity and specificity of MCI and mild AD subjects compared to cognitively normal subjects|Safety of Sapphire II procedure as determined by instances of Adverse Events|Characterization of maximal fluorescence after 1, or potentially 3, ointment administrations|Intra-class correlation of the repeatability of the Sapphire II measurements to verify the system's reliability for reproducible results|Correlation of FUV to PET amyloid status	Cognoptix, Inc.	All	25 Years to 90 Years   (Adult, Older Adult)	Phase 1	105	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PRT-0036	July 2016	December 2018	January 2019	October 10, 2016		August 22, 2018	Neurology Research Institute, West Palm Beach, Florida, United States		https://ClinicalTrials.gov/show/NCT02928211
393	NCT01767909	The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)		Completed	Has Results	Amnestic Mild Cognitive Impairment|Alzheimer's Disease	Drug: Insulin (Humulin® R U-100)|Drug: Placebo	Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12)|Change in Memory Composite as Measured by Story Recall (Immediate Paragraph Recall and Delayed Paragraph Recall) and Free and Cued Selective Reminding Test (FCSRT)|Change in Daily Functioning as Measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI)|Change in Cognitive Deficit as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Change in Hippocampal and Entorhinal Atrophy as Measured by Magnetic Resonance Imaging (MRI)|Change in CSF Biomarkers of AD	University of Southern California|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute|Wake Forest University Health Sciences	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2|Phase 3	240	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ADC-046-INI|RF1AG041845	January 8, 2014	December 11, 2018	December 11, 2018	January 15, 2013	May 18, 2020	May 18, 2020	Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Baylor College of Medicine, Houston, Texas, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/09/NCT01767909/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/09/NCT01767909/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01767909
394	NCT03521089	Cathodal tDCS in MCI: A Randomized, Double-Blind, Sham-Controlled Pilot Study		Completed	Has Results	Mild Cognitive Impairment|Cognitive Impairment|Neurocognitive Dysfunction	Device: Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001	Change in Flanker Inhibitory Control and Attention Test Scores|Change in Picture Vocabulary Test Scores|Change in List Sorting Working Memory Test Scores|Change in Dimensional Change Card Sort Test|Change in Pattern Comparison Processing Speed Test Scores|Change in Picture Sequence Memory Test v2.1 Score|Change in Oral Reading Recognition Test Score	Mayo Clinic	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	16	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	16-007478	February 20, 2018	May 31, 2019	May 31, 2019	May 11, 2018	March 25, 2020	March 25, 2020	Mayo Clinic in Arizona, Scottsdale, Arizona, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03521089/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03521089
395	NCT00777010	Energy Metabolism and Cognitive Aging		Completed	No Results Available	Mild Cognitive Impairment	Other: Ketogenic diet|Other: Healthy high carbohydrate diet	improvement in memory testing|correlation between diet, metabolic factors, memory performance, and cerebral activation	University of Cincinnati	All	50 Years and older   (Adult, Older Adult)	Not Applicable	62	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	04-09-17-01	September 1, 2008	December 31, 2016	March 15, 2017	October 22, 2008		March 24, 2017	University of Cincinnati, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT00777010
396	NCT02951598	A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)	GERAS-US	Active, not recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: Florbetapir F 18 PET Scan	Mean Economic Cost Associated with Amyloid Positive AD|Healthcare Resource Use by AD Cohort|Mean Economic Cost by AD Cohort|Bath Assessment of Subjective Quality of Life in Dementia (BASQID)|Mini-Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14)|Neuropsychiatric Inventory (NPI)|Functional Activities Questionnaire (FAQ)|Cognitive Function Inventory (CFI)|Zarit Burden Interview (ZBI)|Percentage of Participants with a Change in Living Situation|Time to Transition Across Stages of AD|Desire to Institutionalize Scale (DTI)	Eli Lilly and Company	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	1400	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	16466|H8A-US-B004	October 29, 2016	January 30, 2021	April 28, 2023	November 1, 2016		June 10, 2021	California Pharmaceutical Research Institute, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Sun Valley Research Center, Imperial, California, United States|Global Clinical Trials, Irvine, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Pacific Clinical Studies, Inc, Los Alamitos, California, United States|California Neurological Services, Inc., Panorama City, California, United States|Havana Research Institute, Pasadena, California, United States|Clinical Innovations, Inc., Riverside, California, United States|Breakthrough Clinical Trials, San Bernardino, California, United States|HB Clinical Trials, Santa Ana, California, United States|Ventura Clinical Trials, Ventura, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Visionary Investigators Network, Aventura, Florida, United States|Research Alliance, Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Infinite Clinical Research, Doral, Florida, United States|International Research Partners, LLC., Doral, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|South Florida Clinical Trials, Hialeah, Florida, United States|Van Buren Medical, Hollywood, Florida, United States|Clinical Research of Homestead, Homestead, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Universal Neurological Care, Jacksonville, Florida, United States|Sunrise Medical Research, Lauderdale Lakes, Florida, United States|Empire Clinical Research, Miami Lakes, Florida, United States|Biomed Research Institute, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Florida International Research Center, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Genoma Research Group, Inc., Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Combined Research Orlando Phase I-IV LLC, Orlando, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Asclepes Research Centers Florida, Weeki Wachee, Florida, United States|Doctors Clinical Research, Atlanta, Georgia, United States|American Health Network, Franklin, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|Heartland Research Associates, Newton, Kansas, United States|Baptist Health Medical Group, Lexington, Kentucky, United States|NeuroMedical Clinic of Central Louisiana, Alexandria, Louisiana, United States|St. Agnes Medical Group, Catonsville, Maryland, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Psych Care Consultants Research, Saint Louis, Missouri, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Healthwise Medical Associates, PC, Brooklyn, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Adirondack Medical Center, Lake Placid, New York, United States|Mid Hudson Medical Research, PLLC, New Windsor, New York, United States|Onsite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Onsite Clinical Solutions, LLC, Charlotte, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Coastal Carolina Healthcare, P.A., New Bern, North Carolina, United States|Dayton Center for Neurological Disorders, Centerville, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Family Practice Center of Wooster, Wooster, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Clinical Research Solutions, P.C., Knoxville, Tennessee, United States|Lakeside Life Center, Carrollton, Texas, United States|Univ Of Texas Southwestern at Dallas Childrens Med Ctr, Dallas, Texas, United States|The Clinical Research Group, Frisco, Texas, United States|Dallas Clinical Research, Greenville, Texas, United States|Highlands Medical Associates, P.A., Highlands, Texas, United States|University Hills Clinical Research, Irving, Texas, United States|North Pointe Psychiatry, Lewisville, Texas, United States|Premier Clinical Research, Spokane, Washington, United States		https://ClinicalTrials.gov/show/NCT02951598
397	NCT02997007	Neural Correlates of Repeated tDCS		Unknown status	No Results Available	Mild Cognitive Impairment	Device: active tDCS|Device: sham tDCS	neural changes after multi-session tDCS|network changes after multi-session tDCS|Task performance changes after multi-session tDCS	Maastricht University Medical Center	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	NL57751.068.16	May 2, 2017	December 2018	December 2018	December 19, 2016		March 26, 2018	Maastricht University, Maastricht, Limburg, Netherlands		https://ClinicalTrials.gov/show/NCT02997007
398	NCT03243214	Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease	PD-MCI-TMS	Completed	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Device: TMS|Device: Sham-TMS	TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition|Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation|Change in executive functioning measured as BOLD fMRI sequence|Change in levels of biomarkers of interest (alpha-synuclein and BDNF) in serum after TMS stimulation compared to baseline.|Genotyping	University of Calgary|Montreal Neurological Institute and Hospital|McGill University|Canadian Institutes of Health Research (CIHR)	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	41	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	REB15-1689	October 24, 2016	February 14, 2020	February 14, 2020	August 8, 2017		October 19, 2020	University of Calgary, Department of Clinical Neurosciences, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT03243214
399	NCT05033912	A Study of CST-2032 in Subjects With Cognitive Impairment		Withdrawn	No Results Available	Mild Cognitive Impairment (MCI)|Parkinson Disease (PD)	Drug: CST-2032, matching placebo for CST-2032, CST-107	Treatment-Emergent Adverse Events|Vital Signs|Electrocardiograms (ECGs)|Change from Baseline in CANTAB Reaction Time Task|Change from Baseline in CANTAB Paired Associates Learning Test|Change from Baseline in CANTAB Verbal Recognition Memory|Change from Baseline in CANTAB Rapid Visual Information Processing|Change from Baseline in CANTAB Adaptive Tracking Task|Change from Baseline in Verbal Fluency Test|Change from Baseline in ASL MRI scans of the brain	CuraSen Therapeutics, Inc.	All	45 Years to 75 Years   (Adult, Older Adult)	Phase 1	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CST2032-CLIN-007	October 2021	March 2022	May 2022	September 5, 2021		October 28, 2021			https://ClinicalTrials.gov/show/NCT05033912
400	NCT04182477	Age and Number of Previous Anesthesia on the Development of Mild Cognitive Decline (MCI)	MCI	Unknown status	No Results Available	Mild Cognitive Impairment	Diagnostic Test: Montreal Cognitive Assessment	Incidence of Mild cognitive impairment (MCI)in patients enrolled for Cardiac Surgery	University of Padova|Eleonora Maran|Alessandro de Laurenzis	All	18 Years to 99 Years   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	ZivagoMCI	January 7, 2019	February 28, 2020	February 28, 2020	December 2, 2019		February 6, 2020	Azienda Ospedaliera di Padova, Padova, Italy		https://ClinicalTrials.gov/show/NCT04182477
401	NCT02380573	Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease	MB2	Active, not recruiting	No Results Available	Mild Cognitive Impairment|MCI|Aging|Alzheimer's Disease|AD	Drug: Methylene Blue|Drug: FD&C Blue # 2|Drug: Phenazopyridine hydrochloride	Working memory task|Working memory task response|Episodic memory task|Episodic memory task response|Sustained attention task|Sustained attention task reaction time|Neuropsychological battery composite score|Cerebral blood flow measures	The University of Texas Health Science Center at San Antonio|Texas Alzheimer's Research and Care Consortium (TARCC)	All	45 Years to 89 Years   (Adult, Older Adult)	Phase 2	117	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HSC20150410H	July 2015	April 21, 2022	July 2023	March 5, 2015		August 26, 2022	Research Imaging Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT02380573
402	NCT01691976	Mild Cognitive Impairment in Men Following Androgen Deprivation		Withdrawn	No Results Available	Prostate Cancer	Drug: Oestrogen Patches|Drug: LHRHa	Objective evaluation of mild cognitive impairment on parietal fMRI signals|Objective evaluation of mild cognitive impairment on non-parietal fMRI signals|Electroencephalographic evaluation of mild cognitive impairment|Subjective evaluation of mild cognitive impairment by CANTAB|Subjective evaluation of mild cognitive impairment by ADAS-cog	Imperial College London	Male	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	CRO2017	October 2012	December 2013	December 2013	September 25, 2012		November 20, 2020	Imperial College Healthcare NHS Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01691976
403	NCT04705220	Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome	EPICURO	Recruiting	No Results Available	Mild Cognitive Impairment	Dietary Supplement: MERIVA® Tablets|Other: Placebo Tablets	Change from Baseline of Mini-Mental State Examination (MMSE) Test|Change from Baseline of Montreal Cognitive Assessment (MOCA) Test|Change from Baseline of Rey's Auditory Verbal Learning Test (RAVLT) Test|Change from Baseline of Trail Making Test (TMT) Test|Change from Baseline of Multiple Features Target Cancellation (MFTC) Test|Change from Baseline of Phonological and Semantic Verbal Fluidity (FVS) Test|Change from Baseline of Geriatric Depression Scale (GDS) Test|Change from Baseline of Neuro-Psychiatric Inventory (NPI) Test|Change from Baseline of Basic Activities of Daily Living (BADL) Test|Change from Baseline of Instrumental Activities of Daily Living (IADL) Test|Change from Baseline of Stroop Test - Short Version|Change from Baseline of Bioelectrical Impedance (BIA) Assessment|Change from Baseline of Metabolism Parameters measured in Blood|Change from Baseline of Lipid and Immune Profile measured in Blood|Change from Baseline of Brain-Derived Neurotrophic Factor (BDNF) and p66Shc Gene Expression measured in Blood|Rate and Characterization of Adverse Events occurred to Subjects	Indena S.p.A|Istituto Superiore di Sanità|Sintesi Research Srl	All	60 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other	CUR-01-2019	April 8, 2022	September 18, 2023	September 18, 2023	January 12, 2021		September 10, 2022	S.C. di Endocrinologia e Diabetologia, Policlinico Universitario "Agostino Gemelli", Roma, Italy		https://ClinicalTrials.gov/show/NCT04705220
404	NCT04296565	Water-based Activity to Enhance Recall in Veterans	WATER-Vet	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Usual Care|Behavioral: WATER+CT	Cognitive Function Composite Score (ADAS-Cog-Exe)|Peak VO2	VA Office of Research and Development	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 4	130	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	E3143-R|1I01RX003143-01A2	January 3, 2022	March 31, 2025	June 30, 2025	March 5, 2020		January 20, 2022	VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT04296565
405	NCT01103453	Change in Executive Function and IADL Using a Virtual Supermarket Environment Among People With MCI	EF-VAPS	Unknown status	No Results Available	Mild Cognitive Impairment|Lack of Physical Activity	Behavioral: Virtual Action Planning Supermarket (VAP-S) Software	Improvement in executive functions by means of comparison to the results on the NexAde® computerized test.|Improved performance in IADL, both generally and especially in shopping task.	Carmel Medical Center	All	60 Years to 90 Years   (Adult, Older Adult)	Phase 1	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CMC090105CTIL	November 2010	November 2011	May 2012	April 14, 2010		July 21, 2011	Cognitive Clinic, Carmel Medical Center, Haifa, Israel		https://ClinicalTrials.gov/show/NCT01103453
406	NCT01708005	DIetary Supplements, Executive funcTions and Vitamin D (DIET-D)	DIET-D	Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Lecitone®Se-Vitamin D3|Drug: Placebo	Change in executive performance|Change in other executive scores|Change in posture|Between-group comparison of compliance to treatment|Change in gait|Between-group comparison of tolerance	University Hospital, Angers|Nantes University Hospital|NUTRISANTE	All	60 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2012-A00453-40	November 2012	November 2014	November 2014	October 16, 2012		October 16, 2012	University Hospital, Angers, France		https://ClinicalTrials.gov/show/NCT01708005
407	NCT01902004	Brain Aging and Treatment Response in Geriatric Depression		Completed	Has Results	Mild Cognitive Impairment (MCI)|Depression	Drug: Escitalopram|Drug: Memantine|Drug: Placebo	Change in Hamilton Depression Rating Scale|Change in Montgomery Asberg Depression Rating Scale|Change in Cognitive Domain Scores	University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	60 Years and older   (Adult, Older Adult)	Phase 4	115	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R-01 MH097892|R01MH097892	October 2013	January 23, 2019	January 23, 2019	July 17, 2013	October 15, 2019	October 15, 2019	UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01902004/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01902004
408	NCT02959502	Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Dementia|Transcranial Direct Current Stimulation|tDCS	Other: Receive tDCS+CR|Other: Facilitate tDCS + CR	Feasibility of training a facilitator (caregiver) to facilitate the administration of CR+tDCS to their "patient" partner as indicated by a positive response in the Perceived Competence Scale at 24 months from study baseline.|Assess change in Quality of Life Scale scores among patients between baseline and at the end of the 8-week course.|Measure the change in Quality of Life Scale scores among facilitators between baseline and at the end of the 8-week course.|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among patients between baseline and at the end of the 8-week course|Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among facilitators between baseline and at the end of the 8-week course	Centre for Addiction and Mental Health|CAMH Foundation	All	60 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	069/2016	October 31, 2016	December 2022	December 2022	November 9, 2016		January 14, 2022	Centre for Addiction and Mental Health, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02959502
409	NCT01621646	The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly		Completed	No Results Available	Mild Cognitive Impairment	Other: eggs or egg whites	cognition|inflammation	Tufts University	All	50 Years and older   (Adult, Older Adult)	Not Applicable	44	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	001	July 2012	August 2015	August 2015	June 18, 2012		September 1, 2017	Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01621646
410	NCT04146818	Study of the Effects of Adapted Tango and Multidimensional Intervention in pREvention of Dementia in agiNG (STRENGTH)	STRENGTH	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Adapted Tango Dancing|Behavioral: Control	change in overall cognition|change in cognitive status|change in level of cognitive impairment|change in depressive symptoms|change in functional status|change in functional performance|change in social supports|change in the physical performance|change in psychological well being|change in quality of life|change in genetic biomarkers|change in trace elements	Istituto Nazionale di Ricovero e Cura per Anziani|Ministry of Health, Italy	All	60 Years and older   (Adult, Older Adult)	Not Applicable	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	INRCA_04_2019|GR-2016-02363041	September 19, 2019	November 2022	November 2022	October 31, 2019		June 24, 2020	Cinzia Giuli, Fermo, Italy		https://ClinicalTrials.gov/show/NCT04146818
411	NCT03654911	Sustainable Method for Alzheimer's Prediction		Completed	No Results Available	Alzheimer Disease|Amnestic-Mild Cognitive Impairment	Diagnostic Test: EEG|Genetic: ApoE	Biomarkers: EEG|Biomarker: ApoE4|Biomarker: Accuracy of digital classifier	Catholic University of the Sacred Heart	All	18 Years and older   (Adult, Older Adult)		150	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	ROSSINI_MSD_ID1764	April 11, 2018	June 28, 2019	January 31, 2020	August 31, 2018		July 22, 2020	Fondazione Policlinico A.Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy		https://ClinicalTrials.gov/show/NCT03654911
412	NCT00857506	Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)		Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: florbetapir F 18	Change in ADAS-Cog for MCI Subjects|Cognitive Decline in MCI Subjects|Change in ADAS-Cog in CN and AD Subjects|Cognitive Decline in CN and AD Subjects|Covariate Adjusted Psychometric Score Change|Correlation of Change in ADAS-Cog and SUVR	Avid Radiopharmaceuticals	All	50 Years and older   (Adult, Older Adult)	Phase 2	152	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	18F-AV-45-A11	January 2009	December 2011	December 2011	March 6, 2009	March 28, 2013	March 28, 2013	Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, Brooksville, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00857506
413	NCT03185208	Lithium As a Treatment to Prevent Impairment of Cognition in Elders	LATTICE	Active, not recruiting	No Results Available	Mild Cognitive Impairment	Drug: Lithium Carbonate|Drug: Placebo oral capsule	Change from baseline cognitive testing measures over 2 years|Change from baseline biomarker values over 2 years|Change from baseline brain volume values over 2 years as measured by structural imaging (7T MRI)|Change from baseline brain integrity measures over 2 years as measured by structural imaging (7T MRI)|Change from baseline cerebrospinal phospho tau levels over 2 years	Ariel Gildengers, MD|National Institute on Aging (NIA)|University of Pittsburgh	All	60 Years and older   (Adult, Older Adult)	Phase 4	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	PRO17030527|R01AG055389-01	September 1, 2017	May 31, 2024	May 31, 2024	June 14, 2017		June 7, 2022	University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03185208
414	NCT05514756	VINCI-AD: An Investigation of Transcutaneous Vagus Nerve Stimulation in Mild Cognitive Impairment.		Recruiting	No Results Available	Mild Cognitive Impairment|Neurocardiogenic Syncope|Memory Impairment|Inflammatory Response|Alzheimer Disease	Device: Active t-VNS|Device: Sham t-VNS|Other: Baseline assessments	Effect of acute t-VNS on associative memory in participants with MCI|Effect of acute t-VNS on orthostatic challenge in participants with MCI|Effect of acute t-VNS on heart rate variability in participants with MCI|Effect of acute t-VNS on inhibitory control in participants with MCI|Effect of acute t-VNS on spatial navigation in participants with MCI|Effect of acute t-VNS on serum and plasma chemokines and cytokines in participants with MCI|Acceptability of t-VNS device in participants with MCI|Utility of t-VNS device in participants with MCI	Tallaght University Hospital	All	Child, Adult, Older Adult	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	VINCI-AD	June 1, 2022	June 2023	June 2023	August 24, 2022		August 24, 2022	Tallaght University Hospital, Dublin, Ireland		https://ClinicalTrials.gov/show/NCT05514756
415	NCT03205709	Cognitive Training and Neuroplasticity in Mild Cognitive Impairment	CogTraining	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Memory Disorders|Memory Impairment|Cognitive Impairment|Cognitive Disorder|Cognitive Decline	Other: Computerized Cognitive Training|Other: Crossword Puzzles	Change overtime in the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)|Neuropsychological Testing Composite Score|Change overtime in Pfeffer Functional Activities Questionnaire (FAQ)|UPSA|Change overtime in the Neurocognitive Performance Test	New York State Psychiatric Institute|Duke University|Queens College, The City University of New York	All	55 Years to 95 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	7395	November 29, 2017	July 31, 2023	July 31, 2023	July 2, 2017		April 22, 2022	New York State Psychiatric Institute, New York, New York, United States|Duke University, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03205709
416	NCT03361410	Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year		Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder	Regional Cerebral Metabolism|Changes in neuropsychological performance measures|Changes in neuropsychological performance measures: Mini-Mental State Examination|Changes in neuropsychological performance measures: Wechsler Adult Intelligence Scale (WAIS-III) Digit Span|Changes in neuropsychological performance measures: Trail Making Test Part B|Changes in neuropsychological performance measures: Functional Activities Questionnaire|Changes in neuropsychological performance measures: Verbal Memory|Changes in neuropsychological performance measures: Non-Verbal Memory|Changes in neuropsychological performance measures: Verbal Function|Changes in neuropsychological performance measures: Stroop Interference|Changes in neuropsychological performance measures: Problem Solving|Changes in neuropsychological performance measures: Visual Spatial Processing	University of California, Los Angeles|California Table Grape Commission	All	65 Years to 85 Years   (Older Adult)	Phase 2	32	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	17-001290	November 18, 2017	January 2021	January 2021	December 4, 2017		September 26, 2019	University of California, Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03361410
417	NCT04658654	Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients	ROMEMA	Recruiting	No Results Available	Mild Cognitive Impairment|Mild Dementia|Amnestic Mild Cognitive Disorder	Drug: Roflumilast|Drug: Placebo oral tablet	Verbal Learning Test (VLT) (15 words)|Alzheimer's disease Assessment Scale- Cognitive Sub-scale (ADAS-Cog scale)|Mini Mental State Examination (MMSE)|Pattern Separation Task|Trail-Making Test (TMT)|Letter Digit Substitution Test (LDST)|Hospital Anxiety and Depression Scale (HADS)|Alzheimer's disease co-operative study activities of daily living (ADCS-ADL) scale|Neuropsychiatric Inventory (NPI)|QoL-AD|EuroQol|Boston Naming Task	Maastricht University Medical Center	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	81	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	72476	November 19, 2021	October 2023	October 2023	December 8, 2020		April 21, 2022	University of Maastricht, Faculty of Psychology and Neuropsychology, Maastricht, Netherlands		https://ClinicalTrials.gov/show/NCT04658654
418	NCT03121118	Return of Amyloid Imaging Results (RAISR Study)	RAISR	Completed	No Results Available	Mild Cognitive Impairment	Other: Scan Opportunity	Understanding of mild cognitive impairment as a potential precursor to dementia--knowledge|Understanding of mild cognitive impairment as a potential precursor to dementia-Coherence|Perceived efficacy to cope with mild cognitive impairment as a potential precursor to dementia	University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)		82	Other	Observational	Observational Model: Other|Time Perspective: Prospective	PRO13100338	September 17, 2014	September 30, 2019	May 31, 2020	April 19, 2017		November 19, 2020			https://ClinicalTrials.gov/show/NCT03121118
419	NCT02614092	Water-based Activity to Enhance Recall in Veterans	WATER-VET	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Water-based Activity + Cognitive Training	Retention and Recruitment Rates|Change in Delayed Recall of a Word List|Participant Adherence to Protocol|Appropriateness of Inclusion and Exclusion Criteria	VA Office of Research and Development	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	101	U.S. Fed	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E1884-P|12I1-RX001884-01A1	January 1, 2016	April 30, 2020	November 30, 2020	November 25, 2015		February 25, 2021	VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT02614092
420	NCT02390453	Cognitive and Aerobic Resilience for the Brain	CARB	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Combined Cognitive and Physical|Behavioral: Cognitive|Behavioral: Physical|Behavioral: Control	Executive Cognitive Function Composite Score as Measured by Individually-Administered Tests of Psychomotor Speed, Complex Sequencing, and List Learning	Indiana University|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	201	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	R01AG045157|1R01AG045157-01A1	January 2015	October 25, 2019	October 25, 2019	March 17, 2015		June 25, 2021	Indiana University, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT02390453
421	NCT01886586	Retaining Cognition While Avoiding Late-Life Depression	RECALL	Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Problem Solving Therapy|Behavioral: Problem Solving Therapy + Exercise|Other: Enhanced Usual Care	Incidence of depression or anxiety disorders|Change in cognitive function measured by RBANS and DKEFS	University of Pittsburgh|National Institute of Mental Health (NIMH)	All	60 Years and older   (Adult, Older Adult)	Not Applicable	94	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	10110050	July 2011	June 2016	July 2016	June 26, 2013		November 14, 2017	UPMC Late-Life Evaluation and Treatment Center, Pittsburgh, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01886586
422	NCT02082418	Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly		Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Alpha-lactalbumin|Dietary Supplement: Whey|Dietary Supplement: Casein	Net whole-body protein synthesis|Citrulline rate of appearance|Skeletal and respiratory muscle strength|Cognitive function and mood|Protein digestion after feeding|Arginine turnover rate|Whole body collagen breakdown rate|Tryptophan turnover rate|Insulin response to feeding|Fat-free mass|Myofibrillar protein breakdown rate|Glycine rate of appearance|Taurine turnover rate	Texas A&M University	All	55 Years and older   (Adult, Older Adult)	Not Applicable	59	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2014-0065	March 2014	February 2020	February 2021	March 10, 2014		April 11, 2019	Texas A&M University, College Station, Texas, United States		https://ClinicalTrials.gov/show/NCT02082418
423	NCT01434667	Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV		Completed	Has Results	Mild Cognitive Impairment	Behavioral: APOE genotype and Alzheimer's disease risk disclosure|Behavioral: Alzheimer's disease risk disclosure	Geriatric Depression Scale|Mini State Trait Anxiety Inventory|Impact of Event Scale (IES)|Psychological Impact of Test Disclosure (IGT-AD)|Recall and Comprehension of Risk Information|Participant Satisfaction|User Ratings of Risk Assessment Experience|Health Behavior and Insurance Changes|Insurance and Advance Planning Changes|Participation in Alzheimer's Disease-related Research After Receiving the Alzheimer's Disease Risk Estimate.	Brigham and Women's Hospital|National Human Genome Research Institute (NHGRI)|University of Michigan|University of Pennsylvania|Howard University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	146	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	R01HG002213	January 2010	July 2014	July 2014	September 15, 2011	October 23, 2018	October 23, 2018	Howard University, Washington, District of Columbia, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01434667
424	NCT01641328	Cognitive Activation Therapy for MCI: A Randomized Control Study	FarbMCI2012	Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Cogntive Activation Training|Behavioral: Waitlist Control / Home-based training	Processing Speed|Memory|Executive Function|Attention / Working Memory|Mood and Well-being|Daily Function	Rotman Research Institute at Baycrest|Roy Hintsa	All	50 Years and older   (Adult, Older Adult)	Phase 1	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RRI_Farb_001	October 2012	March 2013	July 2013	July 16, 2012		July 16, 2012	Baycrest, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01641328
425	NCT01292382	Effects of rTMS on the Cognition of Elderly With Mild Memory Complaints	TMSMemOld	Unknown status	No Results Available	Mild Cognitive Impairment	Device: Repetitive transcranial magnetic stimulation	Repetitive transcranial magnetic stimulation improves memory in elderly with memory complaints|Repetitive transcranial magnetic stimulation improves global cognition of elderly with memory complaints	University of Sao Paulo General Hospital	All	60 Years to 74 Years   (Adult, Older Adult)	Not Applicable	34	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	rTMSCogOld	November 2010	November 2010	July 2012	February 9, 2011		April 21, 2011	University of Sao Paulo General Hospital, Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT01292382
426	NCT01811381	Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease		Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Curcumin|Behavioral: aerobic yoga|Behavioral: non aerobic yoga|Dietary Supplement: Placebo	Curcumin effects (first six month period) or curcumin and aerobic yoga effects (second six month period) on the changes in the levels of blood biomarkers for Mild Cognitive Impairment relative to baseline or relative to placebo or non-aerobic yoga.|Changes in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) glucose metabolism neuroimaging after supplementation compared to baseline and compared to placebo|Curcumin effects on changes in Neuropsychological parameters compared to baseline and to placebo (first six month period) and in combination with aerobic yoga, compared to baseline and to non-aerobic yoga with curcumin or aerobic yoga with supplement|Number of Participants with Adverse Events	VA Office of Research and Development	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	80	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	E0669-I|VA_RX00069	January 20, 2014	March 16, 2020	December 31, 2020	March 14, 2013		September 17, 2020	VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT01811381
427	NCT03721705	Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type		Completed	Has Results	Alzheimer Disease|Cognitive Dysfunction|Mild Cognitive Impairment|Mild Dementia|Cognitive Decline|Dementia, Alzheimer Type	Device: Renew NCP-5	Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks.|Number of Participants With Treatment Related Adverse Events as Assessed by MedDRA.|Number of Participants With Treatment Related Serious Adverse Events as Assessed by MedDRA.	Renew Research, LLC|Navitas Clinical Research, Inc|ClinEdge, LLC	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 3	190	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	RenewTM NCP-5-1001	November 12, 2018	March 23, 2021	March 23, 2021	October 26, 2018	April 19, 2022	May 11, 2022	Xenoscience, Phoenix, Arizona, United States|Irvine Clinical Research, Irvine, California, United States|Charter Research, Lady Lake, Florida, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|iResearch Atlanta, Atlanta, Georgia, United States|iResearch Savannah, Savannah, Georgia, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cardiovascular Advantages, LLC, Baton Rouge, Louisiana, United States|Neuro-Behavioral Clinical Research, Canton, Ohio, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|St. James's Hospital, Dublin, Ireland|National University Hospital, Singapore, Singapore	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03721705/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03721705/SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03721705/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT03721705
428	NCT05159557	In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables		Recruiting	No Results Available	Dementia|Mild Cognitive Impairment|Alzheimer Disease	Device: In-Home Technology System|Device: Limited In-Home Technology	Change from Baseline to 3 Months in Center for Epidemiological Studies Depression Scale (CES-D)|Change from 3 Months to 6 Months in Center for Epidemiological Studies Depression Scale (CES-D)|Change from Baseline to 3 Months in Zarit Burden Interview-Short Form|Change from 3 Months to 6 Months in Zarit Burden Interview-Short Form|Change from Baseline to 3 Months in Beck Anxiety Inventory (BAI)|Change from 3 Months to 6 Months in Beck Anxiety Inventory (BAI)|Change from Baseline to 3 Months in Satisfaction with Life Scale|Change from 3 Months to 6 Months in Satisfaction with Life Scale|Change from Baseline to 3 Months in Revised Functional Limitations Battery|Change from 3 Months to 6 Months in Revised Functional Limitations Battery	University of California, Berkeley|People Power Company|National Institute on Aging (NIA)|University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care	1247267250000-4|2SB1AG059458-04A1	October 1, 2022	June 30, 2023	July 31, 2023	December 16, 2021		August 19, 2022	University of California, Berkeley, Berkeley, California, United States		https://ClinicalTrials.gov/show/NCT05159557
429	NCT05159596	In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Spanish Language Homes		Recruiting	No Results Available	Dementia|Mild Cognitive Impairment|Alzheimer Disease	Device: In-Home Technology System|Device: Limited In-Home Technology	Change from Baseline to 3 Months in Center for Epidemiological Studies Depression Scale (CES-D)|Change from 3 Months to 6 Months in Center for Epidemiological Studies Depression Scale (CES-D)|Change from Baseline to 3 Months in Zarit Burden Interview-Short Form|Change from 3 Months to 6 Months in Zarit Burden Interview-Short Form|Change from Baseline to 3 Months in Beck Anxiety Inventory (BAI)|Change from 3 Months to 6 Months in Beck Anxiety Inventory (BAI)|Change from Baseline to 3 Months in Satisfaction with Life Scale|Change from 3 Months to 6 Months in Satisfaction with Life Scale|Change from Baseline to 3 Months in Revised Functional Limitations Battery|Change from 3 Months to 6 Months in Revised Functional Limitations Battery	University of California, Berkeley|People Power Company|National Institute on Aging (NIA)|University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care	1247267250000-2|2SB1AG059458-04A1	September 1, 2022	June 30, 2023	June 30, 2023	December 16, 2021		August 19, 2022	University of California, Berkeley, Berkeley, California, United States		https://ClinicalTrials.gov/show/NCT05159596
430	NCT03313895	The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: ACT|Behavioral: Cycling Only|Behavioral: Cognitive Training Only|Behavioral: Stretching and Mental Stimulating Activities	Cognition|AD-signature cortical thickness|Functional connectivity|Aerobic fitness|Conversion to Alzheimer's diseae	Arizona State University|University of Rochester|Mayo Clinic|University of St Thomas|University of Minnesota	All	65 Years and older   (Older Adult)	Not Applicable	128	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	STUDY00001135	July 5, 2018	May 31, 2022	May 31, 2022	October 18, 2017		June 9, 2021	Arizona State University, Phoenix, Arizona, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Rochester, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT03313895
431	NCT05503641	Cognitive and Psychomotor Stimulation in the Physical and Cognitive Function in the Functional Capacity of Older Adults		Recruiting	No Results Available	Mild Cognitive Impairment	Other: Cognitive and psychomotor stimulation	Tinetti Scale|Handgrip Strength|MMSE (mini-mental state examination)|TUG test (Timed Up and Go test)|The Lawton & Brody scale|The Barthel Index|BMI (Body Mass Index)|Body Weight|Height	University of Jaén	All	65 Years and older   (Older Adult)	Not Applicable	98	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	- University of Jaén	September 15, 2022	December 5, 2022	December 12, 2022	August 17, 2022		August 17, 2022	U.E.D. Virgen de la Capilla, Jaén, Spain		https://ClinicalTrials.gov/show/NCT05503641
432	NCT05408689	Effects of Transcutaneous Electrical Nerve Stimulation (TENS) to Improve the Cognitive Functions in Older Adults		Recruiting	No Results Available	Mild Cognitive Impairment	Device: T1 TENS|Device: Concha TENS|Device: Control	Montreal cognitive assessment (MoCA)|Digit Span Test|Visual Memory Span Test|Stroop Color and Word Test|Face Recognition Test|Picture Recognition Test|Berg Balance Scale (BBS)|10 Meter Walking Test (10MWT)|6 Minutes Walking Test (6MWT)|Time Up and Go Test (TUG)|Community Integration Measure|Limit of Stability (LOS)-Reaction Time|Limit of Stability (LOS)-Movement Velocity|Limit of Stability (LOS)-Endpoint Excursion|Limit of Stability (LOS)-Maximum Excursion|Limit of Stability (LOS)-Directional Control	The Hong Kong Polytechnic University	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2022_TVNS	May 23, 2022	May 23, 2023	May 23, 2023	June 7, 2022		June 7, 2022	The Hong Kong Polytechnic University, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT05408689
433	NCT04997681	SYNchronizing Exercises, Remedies in Gait and Cognition at Home (SYNERGIC@Home)	SYNERGIC@Hom	Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Combined Aerobic Exercise and Resistance Training (AE + RT)|Behavioral: Cognitive Training (NeuropeakTM)|Behavioral: Control Cognitive Training of Website Searching and Video Watching (WS+V)|Behavioral: Control Balance and Toning Exercise Training (BAT)	Intervention Adherence|Intervention Preference|Recruitment Rate|Retention Rate|Assessment Tolerability|Trial Experience|Adverse Events|Height|Data Loss|Weight|Sex|Age|Change in Hip Circumference|Change in Neck Circumference|Change in waist circumference|Change in blood pressure|Change in heart rate|Change in Medications|Chronic Diseases|Change in fall history|Change in Health Status and Self-Perception|Change in Constant Fatigue|Change in Falls and Balance|Change in Vision|Change in Hearing|Change in Nutrition|Change in Sleep|Change in Mayo Fluctuation Scale|Change in Telephone Cognitive Screen (TCogS)|Change in Clinical Dementia Rating Scale (CDR)|Change in remote version of the Montreal Cognitive Assessment (MoCA)|Change in Lawton-Brody Instrumental Activities of Daily Living (IADL) scale|Change in ADAS-Cog Immediate Word Recall|Change in ADAS-Cog Delayed Word Recall|Change in ADAS-Cog Orientation|Change in Cognitive Functional Composite 2 (CFC-2)|Functional Activities Questionnaire|Change in Oral Trail Making Test (TMT) A|Change in Oral Trail Making Test (TMT) B|Change in 15-item Boston Naming Test (BNT)|Change in Logical Memory I|Change in Logical Memory II|Change in ADAS-Cog Word Recognition|Change in The Delis-Kaplan Executive Function System (DKEFS) phonemic fluency test|Change in The Delis-Kaplan Executive Function System (DKEFS) semantic fluency test|Change in Digit Span Backward Test|Change in Oral version of the Digit Symbol Modalities Test|Change in 18-item Pittsburgh Sleep Quality Index (PSQI-18)|Change in Work and Sleep Diary (WSD)|Change in 14-item Mediterranean Diet Assessment (MDA-14)|Change in Eating Pattern Self-Assessment|Change in Questionnaire for Vitamin D intake|Change in Physical Activity Scale for the Elderly (PASE)|Change in Life Space Questionnaire (LSQ)|Change in Clinical Frailty Scale (CFS)|Change in Short Form quality of life questionnaire (SF-36)|COVID-19 Questionnaire|Change in Generalized Anxiety Disorder 7 (GAD 7)|Change in Geriatric Depression Scale (GDS-30)|Short Test of Functional Health Literacy in Adults (STOFHLA)|Change in Functional Assessment of Currently Employed Technology Scale (FACETS)|Change in seated dual task|Change in single-task gait|Change in dual-task gait|Change in Sit to Stand Test (STST) performance|Biomarkers of Alzhiemer's Disease and Related Diseases	University of New Brunswick|Horizon Health Network|Réseau de Santé Vitalité Health Network|Universite de Moncton|University of Western Ontario, Canada	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	64	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	SYNH001	July 28, 2021	January 2023	October 2023	August 10, 2021		December 28, 2021	The University of New Brunswick, Fredericton, New Brunswick, Canada		https://ClinicalTrials.gov/show/NCT04997681
434	NCT03233646	OCTA in Mild Cognitive Impairment and Alzheimer's Disease		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Retinal Vascular|Parkinson Disease|Multiple Sclerosis|Huntington Disease|Neuro-Degenerative Disease	Device: Retinal Imaging	Foveal avascular zone|Vessel Density|Choroidal Thickness	Duke University|University of Edinburgh	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	Pro00082598	July 20, 2017	December 31, 2022	December 31, 2022	July 28, 2017		September 27, 2021	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03233646
435	NCT04967378	Homebound Elderly People Psychotherapeutic Intervention	HEPPI	Completed	No Results Available	Mild Cognitive Impairment|Depressive Symptoms|Anxiety State	Behavioral: HEPPI	Feasibility of HEPPI program|Acceptability of HEPPI program|Changes in General Cognitive Function|Changes in Verbal Memory|Changes in Episodic Memory|Changes in Sustained Attention|Changes in Depressive Symptomatology|Changes in Anxious Symptomatology|Changes in Subjective Memory Complaints|Changes in Quality of Life|Changes in Functional Capacity	University of Coimbra|Foundation for Science and Technology (FCT)	All	65 Years and older   (Older Adult)	Not Applicable	51	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	HEPPI-CINEICC|SFRH/BD/146170/2019	June 1, 2020	August 31, 2021	December 31, 2021	July 19, 2021		June 8, 2022	Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Coimbra, Portugal		https://ClinicalTrials.gov/show/NCT04967378
436	NCT03773185	A Comparative Study of Brain Structure and Amyloid Load in MCI Patients		Withdrawn	No Results Available	Mild Cognitive Impairment		Amyloid load	Chinese University of Hong Kong	All	65 Years to 85 Years   (Older Adult)		0	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	2018.454	December 15, 2018	July 31, 2020	July 31, 2020	December 12, 2018		October 21, 2021	The Chinese University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT03773185
437	NCT01872858	Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)		Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Aspirin|Drug: Cilostazol	changes in cognitive function|Number of Participants with Incident cerebral vascular event|Changes of peripheral inflammatory markers level|The progression of cerebral white matter lesion and lacunar infarction|changes in MRI-diffused tension image(DTI)	Huashan Hospital	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	jianhuifu2013	November 2010	November 2012	November 2015	June 7, 2013		June 7, 2013	Dept. of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT01872858
438	NCT05253365	French Memory Support System: A Pilot Study		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Support System	Adherence to French Memory Support System Intervention|Center for Epidemiologic Studies Depression Scale|Everyday Cognition questionnaire.|Functional Assessment Questionnaire|Quality of Life in Alzheimer Disease|State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project|Chronic Disease Self-efficacy Scale|Caregiver Burden Inventory Short-Form	Bruyere Research Institute|Ottawa Hospital Research Institute	All	50 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	M16-21-035	March 3, 2022	January 31, 2023	March 31, 2023	February 23, 2022		May 3, 2022	Bruyere Research Institute, Ottawa, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05253365
439	NCT05030948	A Physical Activity Intervention to Promote Cognitive Health, Cardiovascular Health and Sleep in Older Latinos		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Tiempo Juntos Intervention	Change from Baseline Physical Activity Frequency at 3 months|Change from Baseline Physical Activity Frequency at 6 months|Change from Baseline Physical Activity Frequency at 12 months|Change from Baseline Physical Activity Intensity at 3 months|Change from Baseline Physical Activity Intensity at 6 months|Change from Baseline Physical Activity Intensity at 12 months|Change from Baseline Physical Activity Duration at 3 months|Change from Baseline Physical Activity Duration at 6 months|Change from Baseline Physical Activity Duration at 12 months	University of Pennsylvania|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Not Applicable	216	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	844561|1R01AG070351-01	August 27, 2021	December 31, 2023	December 31, 2024	September 1, 2021		September 23, 2021	University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT05030948
440	NCT02854085	Art Therapy and Music Reminiscence Activity in the Prevention of Cognitive Decline		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Art Therapy|Behavioral: Music Reminiscence Activity	Neuropsychological Test: Change from baseline in Rey Auditory Verbal Learning Test scores at 3 months and 9 months|Neuropsychological Test: Change from baseline in Digit Span Task scores at 3 months and 9 months|Neuropsychological Test: Change from baseline in Colour Trails Test scores at 3 months and 9 months|Neuropsychological Test: Change from baseline in Block Design Test scores at 3 months and 9 months|Change from baseline fMRI scan at 3 months|Change from baseline telomere lengths at 3 months and 9 months	National University, Singapore	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	68	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	B-16-095	July 2016	April 2017	May 2017	August 3, 2016		January 26, 2018	Training and Research Academy, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02854085
441	NCT05108246	Home-Based Dual-Task Training for Older Adults		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Dual-Task Exercise Training	Change in Cognitive Function (Interference inhibition and attention)|Change in Cognitive Function (Task-switching and attention)|Change in Walking Ability, Lower-Body Strength, and Balance|Change in Dual-Task Performance	State University of New York at Buffalo	All	65 Years and older   (Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00004857	January 25, 2022	October 28, 2022	December 31, 2022	November 4, 2021		April 1, 2022	University at Buffalo, SUNY, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT05108246
442	NCT05015478	Rhythmic Light Therapy for Alzheimer's Disease Patients		Recruiting	No Results Available	Mild Cognitive Impairment	Device: Tailored Rhythmic Lighting Intervention|Device: Placebo Rhythmic Lighting Intervention	Electroencephalography (EEG) power at 40 hertz (Hz)|Subjective Sleepiness using the Karolinska Sleepiness Scale (KSS)|Cognition using a working memory task	Icahn School of Medicine at Mount Sinai	All	55 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	GCO 21-0378-01	January 10, 2022	January 2023	January 2023	August 20, 2021		July 14, 2022	Light and Health Research Center, Menands, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT05015478
443	NCT04683835	Evaluation of Cognitive State in Senior Subjects Using Neurosteer EEG System		Recruiting	No Results Available	Mild Cognitive Impairment	Device: Neurosteer Aurora system	Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE) and the Neurosteer Technology.|Reproducibility of the pilot study results.|Inter-patient variability between two consecutive measurement sessions.|Differentiation between subjects who are at risk for cognitive decline and cognitively healthy subjects.	Neurosteer Ltd.	All	50 Years and older   (Adult, Older Adult)		60	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	092020	October 15, 2020	July 1, 2021	July 1, 2021	December 24, 2020		December 24, 2020	Dorot - Netanya Geriatric Medical Center, Netanya, Israel		https://ClinicalTrials.gov/show/NCT04683835
444	NCT04848155	Measuring the Impact of a Socially Assistive Robot		Active, not recruiting	No Results Available	Mild Cognitive Impairment	Other: socially assistive robot	Change from baseline Active Engagement at month 6|Change from baseline Loneliness at month 6|Change from baseline Physical functioning at month 6|Change from baseline Cognitive functioning at month 6|Change from baseline Participation level at month 6	University Ghent	All	65 Years and older   (Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	B6702020000244	October 12, 2020	December 31, 2021	December 31, 2021	April 19, 2021		November 22, 2021	Ghent University, Ghent, Belgium		https://ClinicalTrials.gov/show/NCT04848155
445	NCT05159583	In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes		Recruiting	No Results Available	Dementia|Mild Cognitive Impairment|Alzheimer Disease	Device: In-Home Technology System|Device: Limited In-Home Technology	Change from Baseline to 3 Months in Center for Epidemiological Studies Depression Scale (CES-D)|Change from 3 Months to 6 Months in Center for Epidemiological Studies Depression Scale (CES-D)|Change from Baseline to 3 Months in Zarit Burden Interview-Short Form|Change from 3 Months to 6 Months in Zarit Burden Interview-Short Form|Change from Baseline to 3 Months in Beck Anxiety Inventory (BAI)|Change from 3 Months to 6 Months in Beck Anxiety Inventory (BAI)|Change from Baseline to 3 Months in Satisfaction with Life Scale|Change from 3 Months to 6 Months in Satisfaction with Life Scale|Change from Baseline to 3 Months in Revised Functional Limitations Battery|Change from 3 Months to 6 Months in Revised Functional Limitations Battery	University of California, Berkeley|People Power Company|National Institute on Aging (NIA)|University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care	1247267250000-1|2SB1AG059458-04A1	September 1, 2022	June 30, 2023	June 30, 2023	December 16, 2021		August 18, 2022	University of California, Berkeley, Berkeley, California, United States		https://ClinicalTrials.gov/show/NCT05159583
446	NCT04765137	Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in MCI		Recruiting	No Results Available	Mild Cognitive Impairment	Drug: Atorvastatin Oral Tablet	Change of MRI whole brain cerebrovascular reactivity (wbCVR)|Change in plasma exosomes|Change in cognitive function (global neurocognitive measure)|Change in cognitive function (domain-specific neurocognitive measure)	Johns Hopkins University	All	60 Years to 95 Years   (Adult, Older Adult)	Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00256402	May 21, 2021	October 31, 2022	December 31, 2022	February 21, 2021		December 13, 2021	Johns Hopkins University, Bayview Medical Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04765137
447	NCT04539132	Maintaining Independence and Quality of Life in Aging Adults Through Targeted Cognitive Training		Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: ABI Wellness Program	Montreal Cognitive Assessment|Memory Alteration Test|Mild Cognitive Impairment Questionnaire|Neuro-QOL|Qualitative Interviews	Kwantlen Polytechnic University|Centre for Aging and Brain Health Innovation|ABI Wellness Inc|Watson Centre Society for Brain Health	All	65 Years and older   (Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	103298	September 1, 2020	August 31, 2021	October 31, 2021	September 4, 2020		September 4, 2020			https://ClinicalTrials.gov/show/NCT04539132
448	NCT05016219	Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Device: Circadian-Effective Light|Device: Rhythmic Light|Device: Placebo Light|Device: Placebo Rhythmic Light	Cognition using the Montreal Cognitive Assessment (MoCA)|Cognition using a working memory task|Cognition using a word pair associates task|Cognition using an implicit priming task|Cognition using the Alzheimer's Disease Assessment Scale - Cognitive Subscale|Urine Melatonin Biomarker|Light Exposure using a Daysimeter|Sleep Quantity using Actigraphy|Sleep Quality using the Pittsburgh Sleep Quality Index (PSQI)|Quality of Life using the Dementia Quality of Life Instrument	Icahn School of Medicine at Mount Sinai	All	55 Years and older   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	GCO 21-0378-02	January 2023	December 31, 2025	December 2026	August 23, 2021		June 16, 2022	Light and Health Research Center, Menands, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT05016219
449	NCT04646499	Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory		Completed	No Results Available	Mild Cognitive Impairment	Device: Transcranial alternating current stimulation	Side effects|Drop out|Beta amyloid load|Memory: Recall|Memory: Paired Associates|Memory: Fluency|Change in tau	University of California, San Francisco|National Institute on Aging (NIA)	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	13	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	131887a|R21AG060335	January 18, 2021	December 31, 2021	May 31, 2022	November 30, 2020		August 4, 2022	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT04646499
450	NCT02537080	The Effect of Nimodipine on the Postoperative Cognitive Dysfunction		Terminated	No Results Available	Mild Cognitive Impairment	Drug: Nimodipine group|Drug: Control group	Change in cognitive behavior	University Hospital Hradec Kralove	All	60 Years and older   (Adult, Older Adult)	Not Applicable	15	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	201508-S22P	September 2015	December 2017	December 2017	September 1, 2015		October 1, 2019	University Hospital, Hradec Kralove, Czechia		https://ClinicalTrials.gov/show/NCT02537080
451	NCT02536885	The Effect of Blood Pressure on the Postoperative Cognitive Dysfunction		Completed	No Results Available	Mild Cognitive Impairment	Procedure: Liberal group|Procedure: Restrictive group	Change in cognitive behavior	University Hospital Hradec Kralove	All	60 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	201508-S21P	September 2015	June 2018	July 2018	September 1, 2015		August 22, 2018	University Hospital Hradec Kralove, Hradec Kralove, Czechia		https://ClinicalTrials.gov/show/NCT02536885
452	NCT04464538	Reducing Sedentary Behaviour and Cognition in Older People		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: WALC-R|Other: Information leaflet	Acceptability of intervention assessed by semi-structured interviews|Recruitment rate|Completeness of intervention|Adverse event rate|Device measured sedentary behaviour|Self reported sedentary behaviour assessed using the Sedentary Behaviour Questionnaire|Verbal fluency assessed using the Controlled and Oral Word Association Test (COWAT)|Perceived quality of life using the EuroQol five-dimension questionnaire (EQ-5D)|Pre-morbid intelligence	Anglia Ruskin University|Cambridgeshire and Peterborough NHS Foundation Trust	All	50 Years and older   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	IRAS280073	October 20, 2020	August 31, 2021	October 1, 2021	July 9, 2020		March 2, 2022	The Queen Elizabeth Hospital NHS Foundation Trust, King's Lynn, United Kingdom		https://ClinicalTrials.gov/show/NCT04464538
453	NCT04522791	Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)		Recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: RFB|Behavioral: VSOP|Behavioral: IR	change of ANS flexibility at 2 months from baseline|change of ANS flexibility at 8 months from baseline|change of ANS flexibility at 14 months from baseline|change of cognition at 2 months from baseline|change of cognition at 8 months from baseline|change of cognition at 14 months from baseline|change of instrumental activities of daily living function (IADL) at 2 months from baseline|change of instrumental activities of daily living function (IADL) at 8 months from baseline|change of instrumental activities of daily living function (IADL) at 14 months from baseline	University of Rochester	All	60 Years to 89 Years   (Adult, Older Adult)	Phase 2	114	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	STUDY00004727	August 18, 2020	December 1, 2024	May 31, 2025	August 21, 2020		September 8, 2022	Feng Lin, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT04522791
454	NCT04446481	Neurofeedback to Aid Vets' Memory	TUNe	Recruiting	No Results Available	Mild Cognitive Impairment	Device: Neurofeedback	EEG alpha band|memory-related potentials|California Verbal Learning Test	VA Office of Research and Development	All	60 Years and older   (Adult, Older Adult)	Not Applicable	50	U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N3173-P|RX-003173|JIA-20-003-HE	February 5, 2022	September 30, 2022	September 30, 2022	June 25, 2020		March 17, 2022	Lexington VA Medical Center, Lexington, KY, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT04446481
455	NCT04251130	Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI		Recruiting	No Results Available	Mild Cognitive Impairment	Drug: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine	Correlation between PI-2620 SUVR and MTL subregion thickness|Interaction between PI-2620 SUVR and amyloid status prediction of MTL subregion thickness|Correlation between longitudinal PI-2620 SUVR and MTL subregion thickness|Interaction between longitudinal PI-2620 SUVR and amyloid status for prediction of MTL subregion thickness	University of Pennsylvania|National Institutes of Health (NIH)	All	60 Years and older   (Adult, Older Adult)	Phase 2	150	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	833864	March 11, 2020	January 2025	January 2026	January 31, 2020		April 15, 2022	University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04251130
456	NCT04549155	Network-guided TMS in Early Alzheimer's Disease	NetTMS	Recruiting	No Results Available	Mild Cognitive Impairment	Device: Transcranial Magnetic Stimulation	Change in Episodic Memory Task Performance (accuracy and response time)|Change in neurovascular reactivity, as measured by resting-state fluctuations in activity (RSFA)|Change in structural connectivity, as measured by fractional anisotropy (FA)	Duke University|National Institute on Aging (NIA)	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	40	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Pro00106545	March 8, 2022	November 2022	December 2022	September 16, 2020		June 6, 2022	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04549155
457	NCT04176406	Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)	MCI_Sub	Terminated	Has Results	Mild Cognitive Impairment	Device: rTMS|Device: Sham rTMS	Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Accuracy (in Percentage)|Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Reaction Times (ms)	Duke University|National Institute on Aging (NIA)	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	10	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science	Pro00065334_1	November 25, 2019	February 27, 2020	February 27, 2020	November 25, 2019	January 11, 2021	January 27, 2021	Duke University Medical Center, Durham, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/06/NCT04176406/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04176406
458	NCT03954340	BestBrain Evaluation of Cognitive Memory & Executive-Function	BECOME	Active, not recruiting	No Results Available	Mild Cognitive Impairment	Device: iRemember Neurofeedback (NFB)	Improvement to Memory|Improvement to Executive Functions|Improvement to Every Day Functionality	BestBrain Ltd.	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	140	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CIP001	December 11, 2019	June 2021	June 2021	May 17, 2019		October 22, 2020	Clalit Health Services, Be'er Sheva, Israel		https://ClinicalTrials.gov/show/NCT03954340
459	NCT04077320	Neurological Changes With a Memory Self-efficacy Training Protocol		Unknown status	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Self-Efficacy Training|Behavioral: General Education	Neurological bio-markers: Regional activation|Neurological bio-markers: Default mode network|Story Recall - Trained memory performance task|List Recall - Trained memory performance tasks|Face-Name Pairs - Trained memory performance tasks|RAVLT - Untrained memory performance tasks|Visual Spatial Learning Task - Untrained memory performance tasks|Digit Span Task - Untrained memory performance tasks|Face-Scene Pairs - Untrained memory performance tasks	Western University, Canada|Western BrainsCAN	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	52	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	BSCAN1920	January 2020	December 2020	December 2020	September 4, 2019		September 9, 2019	Community, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04077320
460	NCT03883308	The Influence of Multi-domain Cognitive Training on Large-scale Structural and Functional Brain Networks in MCI		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Multi-domain cognitive training|Behavioral: Cross-word puzzle training	Executive function composite score|Executive function network connectivity|Memory function composite score|Medial temporal network connectivity|White matter integrity in memory circuit	Stanford University|National Institute on Aging (NIA)	All	65 Years to 85 Years   (Older Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	120954|5K25AG050759	October 30, 2017	September 30, 2020	December 1, 2020	March 20, 2019		May 5, 2021	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT03883308
461	NCT04111640	Computerized Cognitive Training in Neurodegenerative Diseases (NDD2019)	NDD2019	Unknown status	No Results Available	Mild Cognitive Impairment	Other: CoRe software|Other: Control Group	Change in Global cognitive functioning measured by Mini-Mental State Examination (MMSE)|Change in Global cognitive functioning measured by Montreal Overall Cognitive Assessment (MoCA)|Change in Memory|Change in executive functions|Change in Mood (assessed by Beck Depression Inventory - BDI)|Change in Quality of life (assessed by Short Form-36 Health Survey - SF-36)|Change in The evolution of cognitive profile (assessed by Clinical Dementia Rating Scale - CDR)	IRCCS National Neurological Institute "C. Mondino" Foundation	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	NDD2019	March 15, 2017	December 15, 2020	December 15, 2020	October 1, 2019		October 1, 2019	Struttura Semplice Neuropsicologia Clinica/ Centro UVA, Pavia, Italy		https://ClinicalTrials.gov/show/NCT04111640
462	NCT04020744	Real-time fMRI Neurofeedback in Patients With MCI		Recruiting	No Results Available	Mild Cognitive Impairment	Other: real-time fMRI based neurofeedback from the hippocampus|Other: real-time fMRI based neurofeedback from another brain area	Rate of change in hippocampal activity during a memory task|Rate of change in memory performance|Rate of change from in memory performance (behavioural)	University of Bern|University of Zurich	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	84	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	1163	July 1, 2020	December 31, 2022	June 30, 2023	July 16, 2019		May 17, 2022	SITEM (Swiss Institute for Translational and Entrepreneurial Medicine), Bern, Switzerland|University of Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04020744
463	NCT02570451	Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older		Completed	No Results Available	Mild Cognitive Impairment	Other: Patient Survey|Other: Mini Cog|Other: Independent Activities of Daily Living Score Sheet|Other: Activities of Daily Living Score Sheet|Other: Geriatric Depression Scale Short Form|Other: Confusion Assessment Method (CAM)|Other: RAND 36-Item Short Form Health Survey|Other: Grip Strength	Discharge location (defined home vs. other than home) on day of patient discharge from hospital|Patient score on the confusion assessment method postoperative days 1-3|Number of newly diagnosed health complications following surgery|Readmission Rate|Emergency Room Admit|Mortality	Brigham and Women's Hospital|Anesthesia Patient Safety Foundation	All	65 Years and older   (Older Adult)		711	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2013P001214B	September 2014	August 2015	August 2020	October 7, 2015		April 15, 2021	Weiner Center for Preoperative Evaluation, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02570451
464	NCT04277767	The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease		Not yet recruiting	No Results Available	Mild Cognitive Impairment	Diagnostic Test: observational	OCT retinal and choroidal thickness|Retinal Photography vascular caliber|functional connection strength in the brain network	Zhongshan Ophthalmic Center, Sun Yat-sen University	All	50 Years to 70 Years   (Adult, Older Adult)		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	AD2020	September 1, 2022	February 1, 2023	July 1, 2023	February 20, 2020		April 1, 2021	Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04277767
465	NCT03933085	Spanish Translation and Cultural Adaptation of the Memory Support System		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Memory Support System (MSS)	Change from Baseline Memory Support System (MSS) adherence at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Memory functional ability at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Self-efficacy at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Mood at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Anxiety at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Quality of Life at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline General Functional Ability at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Caregiver Burden at 2 weeks after intervention start and at 2-month follow-up|Change from Baseline Medication Management Skills at 2 weeks after intervention start and at 2-month follow-up	Mayo Clinic	All	50 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-008125	March 6, 2019	February 28, 2020	July 31, 2021	May 1, 2019		November 1, 2021	Mayo Clinic, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT03933085
466	NCT03453554	Evaluating a Digital Memory Notebook App to Improve Functional Independence		Unknown status	No Results Available	Mild Cognitive Impairment	Other: Digital Notebook app|Other: Smart Home Prompting	Digital Memory Notebook Use|Quality of Life|Activities of Daily Living|Caregiver Burden|Coping self-efficacy|Cognitive functioning	Washington State University|United States Department of Defense	All	40 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	AZ150096	August 1, 2018	August 30, 2021	August 30, 2021	March 5, 2018		October 9, 2018	Washington State University - Pullman, Pullman, Washington, United States		https://ClinicalTrials.gov/show/NCT03453554
467	NCT01659398	Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients		Completed	No Results Available	Mild Cognitive Impairment	Device: External Counterpulsation (EECP)	Change in Cognitive Function|Change in Ophthalmic blood flow (OBF)|Change in Blood Viscosity|Cholesterol composition of the blood	Patrick Moriarty, MD, FACP, FACC|University of Kansas Medical Center	All	18 Years to 85 Years   (Adult, Older Adult)	Early Phase 1	8	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13106	June 2012	October 2014	October 2014	August 7, 2012		January 13, 2016	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT01659398
468	NCT03887741	Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression		Enrolling by invitation	No Results Available	Mild Cognitive Impairment	Biological: Plasmapheresis|Biological: Plasma infusion	Adverse events	Mayo Clinic	All	50 Years to 75 Years   (Adult, Older Adult)	Phase 1	9	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-007034	September 15, 2021	December 2022	December 2022	March 25, 2019		October 21, 2021	Mayo Clinic in Florida, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT03887741
469	NCT04229186	Pilot Study About Extra Virgin Olive Oil "Coratina" in Mild Cognitive Impairment and Alzheimer's Disease Patients	EVOCAD	Unknown status	No Results Available	Neurodegenerative Diseases	Dietary Supplement: EVOO-C|Dietary Supplement: ROO	Evaluate the change of cerebral performance after olive oil supplementation.|Evaluate the change of nutritional parameters after olive oil supplementation|Evaluate the change of neurodegenerative biomarkers after olive oil supplementation.|Evaluate the change of optic nerve and macula thickness after olive oil supplementation.|Evaluate the change of cortical thickness with brain MRI after olive oil supplementation.|Evaluate the change of brain amyloid plaque load (BAPL) after olive oil supplementation.	University of Bari Aldo Moro|Med & Food and Schena Foundation	All	50 Years to 70 Years   (Adult, Older Adult)	Not Applicable	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	5752	January 2020	January 2021	January 2022	January 18, 2020		January 18, 2020			https://ClinicalTrials.gov/show/NCT04229186
470	NCT04098666	Metformin in Alzheimer's Dementia Prevention	MAP	Recruiting	No Results Available	Mild Cognitive Impairment	Drug: Placebo oral tablet|Drug: extended release metformin	Free and Cued Selective Reminding Test (FCSRT)|Alzheimer's Disease Cooperative Study Preclinical Alzheimer's Cognitive Composite (PACC-ADCS)|Cortical Thickness|White matter hyper intensity volume (WMH)|Brain amyloid|Brain Tau|plasma amyloid|plasma tau|plasma neurofilament light	Columbia University|Johns Hopkins University|National Institute on Aging (NIA)|University of Rochester|University of Iowa|Boston University|Wake Forest University|Rush University|Pennington Biomedical Research Center|University of Miami|Emory University|Georgetown University|NYU Langone Health|University of California, Berkeley|The University of Texas Health Science Center at San Antonio|University of Washington	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2|Phase 3	370	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	AAAS6912|R01AG062624	March 22, 2021	March 31, 2026	April 30, 2026	September 23, 2019		August 31, 2022	Georgetown University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Boston University, Boston, Massachusetts, United States|New York University Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|The University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT04098666
471	NCT02094729	A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease	Drug: BAN2401 2.5 mg/kg|Drug: BAN2401 5 mg/kg|Drug: BAN2401 10 mg/kg|Drug: Placebo	Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetics of BAN2401: Maximum Concentration (Cmax)|Pharmacokinetics of BAN2401: time attain to Cmax (tmax)|Pharmacokinetics of BAN2401: Area under the curve (AUC)|Pharmacokinetics of BAN2401: Drug Clearance (CL)|Pharmacokinetics of BAN2401: apparent volume of distribution at steady state (Vss)|Investigation of the effect of repeated intravenous infusions of BAN2401 on the immunogenicity and CSF biomarkers|Investigation of the effect of apolipoprotein allele4 (ApoE4) on the safety, tolerability and pharmacodynamic (PD) response of repeated intravenous infusions of BAN2401	Eisai Co., Ltd.|Eisai Inc.	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 1	26	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	BAN2401-J081-104	September 2013	March 2015	May 2015	March 24, 2014		June 8, 2015	Kobe, Hyogo, Japan|Sendai, Miyagi, Japan|Kurashiki, Okayama, Japan|Koto-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT02094729
472	NCT01817101	Dietary Supplement for the Prevention of Cognitive Decline in a Very Elderly Population.		Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Omega-3 fatty acid supplementation	Mini Mental State Examination|Short Portable Mental Status Questionnaire (SPMSQ)|Verbal fluency test|Clock-drawing test	Clinica Universidad de Navarra, Universidad de Navarra	All	75 Years and older   (Older Adult)	Not Applicable	170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	DIET	January 2012	October 2015	December 2015	March 22, 2013		July 17, 2015	Amma Argaray, Pamplona, Navarra, Spain|AMMA Mutilva, Pamplona, Navarra, Spain|AMMA Oblatas, Pamplona, Navarra, Spain		https://ClinicalTrials.gov/show/NCT01817101
473	NCT03663387	PET Measures of CSF Clearance in Preclinical Alzheimer's Disease		Recruiting	No Results Available	Mild Cognitive Impairment		Percent change in brain amyloid|Percent change in cortical ribbon thickness	Weill Medical College of Cornell University|National Institute on Aging (NIA)	All	20 Years to 100 Years   (Adult, Older Adult)		70	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	1804019181|1RF1AG057570-01	July 30, 2018	August 31, 2022	August 31, 2022	September 10, 2018		May 5, 2022	Weill Cornell Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03663387
474	NCT03112902	Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance		Terminated	Has Results	Mild Cognitive Impairment	Device: Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance	Change in Electro-encephalogram (EEG) Power of Slow Wave Oscillations|Change in Declarative Memory Encoding|Change in Procedural Memory Encoding *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Sleep Architecture as Measured by Minutes in Each Stage of Sleep *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Fast and Slow Spindle Numbers During Sleep *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Slow Wave Coherence *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Slow Wave Power *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Sleep Architecture as Measured by Self Reported Sleep Timing *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Hospital Anxiety and Depression Scale (HADS) *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Clinical Global Impression of Change (CGIC) *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Battery of Working Memory Tasks *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Battery of Attention Tasks *No Processing of Data Occurred to Provide Information About This Outcome Measure.|Change in Battery of Visuospatial Processing Tasks *No Processing of Data Occurred to Provide Information About This Outcome Measure.	University of Colorado, Denver	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	24	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Other	16-1875	March 7, 2018	May 4, 2021	May 4, 2021	April 13, 2017	July 21, 2021	December 17, 2021	University of Colorado AMC, Aurora, Colorado, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03112902/Prot_002.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03112902/SAP_003.pdf	https://ClinicalTrials.gov/show/NCT03112902
475	NCT03093896	The Effect of Consumption of Almonds and Snack Mix Daily for 6 Months on Cognitive Function in Older Adults		Completed	No Results Available	Mild Cognitive Impairment	Dietary Supplement: snack mix|Dietary Supplement: almonds, 1.5 oz|Dietary Supplement: almonds, 3 oz	executive function executive function assessed by test administered via CANTAB (www.cambridgecognition.com)|attention assessed by test administered via CANTAB (www.cambridgecognition.com)|visual memory assessed by test administered via CANTAB (www.cambridgecognition.com)|inflammation - serum C-reactive protein as measured by ELISA kit|inflammation - serum IL6 as measured by ELISA kit|inflammation - serum IL12 as measured by ELISA kit|inflammation - serum ICAM as measured by ELISA kit|plasma fatty acids|plasma alpha-tocopherol|plasma magnesium|fatty acids in red blood cells|oxidative stress - aminothiols|oxidative stress - isoprostanes|oxidative stress - superoxide dismutase|oxidative stress - glutathione peroxidase|oxidative stress - glutathione reductase|total serum cholesterol|serum low density lipoprotein|serum high density lipoprotein|serum very low density lipoprotein	Tufts University	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention	003	April 2016	September 2018	May 2019	March 28, 2017		March 20, 2020	Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03093896
476	NCT04012398	Validation of the German Version of the Amsterdam Instrumental Activities of Daily Living Questionnaire®		Completed	No Results Available	Mild Cognitive Impairment|Mild Dementia	Diagnostic Test: Amsterdam IADL Questionnaire short, German version	Amsterdam IADL Questionnaire short German version|Change from baseline on the Amsterdam IADL Questionnaire short German version at two to four weeks|Mini Mental State Examination|Cumulative Dementia Rating|Lawton Brody Instrumental Activities of Daily Living Scale|Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) short|Depression im Alter Scale (DIA-S)	Zurich University of Applied Sciences	All	60 Years and older   (Adult, Older Adult)		96	Other	Observational	Observational Model: Other|Time Perspective: Cross-Sectional	A-IADL-G Validation	February 1, 2018	July 30, 2019	September 30, 2019	July 9, 2019		October 30, 2019	Memory Clinic, Geriatrische Klinik St.Gallen, Saint Gallen, Switzerland		https://ClinicalTrials.gov/show/NCT04012398
477	NCT03388242	Protein and microRNA Markers for Early Detection of Alzheimer's Disease		Unknown status	No Results Available	Mild Cognitive Impairment	Other: No intervention	Fold changes of microRNAs in the blood of Patients with MCI over control people.|Fold changes of proteins in the blood of Patients with MCI over control people.	Sun Yat-sen University	All	30 Years to 80 Years   (Adult, Older Adult)		120	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	SYSEC-KY-060	December 7, 2017	March 30, 2020	March 30, 2020	January 2, 2018		January 3, 2019	Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT03388242
478	NCT02902692	Mindfulness for Older Adults With Cognitive Concerns		Unknown status	No Results Available	Mild Cognitive Impairment	Other: Brief Mindfulness	Test of Everyday Attention|Hospital Anxiety Depression Scale (HADS)|Penn State Worry Questionnaire|Short Form Health Survey|The Trail Making Test Parts A&B|Digit Span Task|Letter-Number Sequencing Task|The Cognitive Failures Questionnaire|The Five Facet Mindfulness Questionnaire (FFMQ)|Ruminative Response Scale of the Response Styles Questionnaire|Self-Compassion Scale Short-Form|CORE-10|Discharge Satisfaction Questionnaire	King's College London	All	50 Years and older   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	16/LO/0223	April 2016	March 2017	May 2017	September 16, 2016		September 16, 2016	South London and Maudsely NHS Memory Services, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02902692
479	NCT02587338	Cognitive Ability Training in Seniors	CATS	Completed	No Results Available	Mild Cognitive Impairment	Device: Verum tDCS|Device: Sham tDCS	Neuropsychological performance in neuropsychological tests|Brain activation measured with NIRS	Wuerzburg University Hospital	All	60 Years to 70 Years   (Adult, Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Wuerzburg22/15	May 2015	April 2017	December 2017	October 27, 2015		April 10, 2018	University hospital, Wuerzburg, Germany		https://ClinicalTrials.gov/show/NCT02587338
480	NCT02864069	Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI	CBI	Completed	Has Results	Mild Cognitive Impairment	Behavioral: Walking Intervention|Behavioral: Cognitive Training Intervention|Behavioral: Combined Intervention	Rivermead Behavioral Memory Test|Everyday Cognition Scale|Older Peoples Quality of Life Questionnaire	University of California, San Diego|Alzheimer's Association	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	52	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	NPSASA-14-321959	September 2014	October 2018	October 2018	August 11, 2016	January 18, 2020	January 18, 2020	UCSD, La Jolla, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02864069/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02864069
481	NCT02982252	Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 2)		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: CoPILOT	Change in Power-mobility Indoor Driving Assessment (PIDA)|Change in Wheelchair Skills Test Questionnaire (WST-P-Q)|Change in Wheelchair-use Confidence Scale (WheelCon-P )|Change in Health Utility Index Mark 3 (HUI3)|Change in The Wheelchair Outcome Measure (WhOM)|The Wheeling While Talking Test	University of British Columbia|Networks of Centres of Excellence of Canada|Alzheimer Society of Canada|Canadian Institutes of Health Research (CIHR)|Promobilia Foundation|Rick Hansen Foundation	All	60 Years and older   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	H14-01702 (Phase 2)	October 2016	October 1, 2019	October 1, 2019	December 5, 2016		October 9, 2019	GF Strong Rehabilitation Centre, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT02982252
482	NCT01492335	Cognitive Assessment of Elderly Primary Care Patients		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Cognitive Report|Behavioral: Treatment As Usual	Scores on a comprehensive battery of neuropsychological tests.	University of Pittsburgh	All	65 Years and older   (Older Adult)	Not Applicable	524	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	PCP-AG023129	January 2006	October 2011	August 2012	December 14, 2011		January 14, 2016	University of Pittsburgh, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01492335
483	NCT03130036	Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease	AcAc PET	Recruiting	No Results Available	Mild Cognitive Impairment	Other: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan	Brain biodistribution of [11C]AcAc|Brain biodistribution of [18F]FDG -	Wake Forest University Health Sciences	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science	IRB00033365	June 9, 2015	February 2024	February 2026	April 26, 2017		January 13, 2022	Wake Forest School of Medicine, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03130036
484	NCT02808676	SYNchronizing Exercises, Remedies in GaIt and Cognition	SYNERGIC	Terminated	No Results Available	Mild Cognitive Impairment	Dietary Supplement: Vitamin D3|Other: Exercises (E)|Other: Cognitive Training (CT)|Other: placebo D3|Other: control cognitive training|Other: Placebo exercise	Change in global cognition assessed using the ADASCog(13 and Plus modalities).|Change in cognition assessed as the CCNA Cognitive Battery.|Change in gait velocity (cm/s).|Change in gait variability (%CoV).|Brain structure (sMRI)|Brain function (fMRI)|Changes in BDNF serum levels|Combined Score of Cognition and Functionality (Pooled Index)|Changes in serum levels Interleukin 1.|Changes in serum levels Interleukin 6.|Changes in serum High Sensitive C reactive protein (CRP).|Changes in serum levels of VEGF receptor 1.	Lawson Health Research Institute	All	60 Years and older   (Adult, Older Adult)	Not Applicable	176	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	107670	July 14, 2016	November 24, 2020	November 24, 2020	June 22, 2016		October 8, 2021	University of British Columbia, Vancouver, British Columbia, Canada|St. Joseph's Health Care London, Parkwood Hospital, London, Ontario, Canada|University of Waterloo, Waterloo, Ontario, Canada|Wilfrid Laurier University, Waterloo, Ontario, Canada|Université de Montréal, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02808676
485	NCT02811744	11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation		Terminated	No Results Available	Mild Cognitive Impairment	Drug: 11C-acetate	Evaluate whether 11C-acetate uptake is increased in amyloid positive Mild Cognitive Impairment (MCI) subjects compared to amyloid negative healthy controls|Correlate 11C-acetate uptake to areas of greater amyloid plaque burden quantified on Amyloid PET/CT|Compare 11C-acetate in areas of mildly elevated PET SUVR to areas with high or sub-threshold amyloid burden|Correlate 11C-acetate uptake to levels of inflammatory markers in CSF	University of Pennsylvania	All	65 Years and older   (Older Adult)	Phase 2	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	824822	January 2017	February 28, 2022	February 28, 2022	June 23, 2016		April 18, 2022	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02811744
486	NCT02616679	Cognitive Detection of Preclinical AD: Validation Using Biomarkers		Completed	No Results Available	Mild Cognitive Impairment		Correlation of composite score on cognitive tests with biomarkers|Presence of ApoE allele	NYU Langone Health|Janssen Scientific Affairs, LLC	All	60 Years to 85 Years   (Adult, Older Adult)		81	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	13-00706	January 5, 2016	August 12, 2020	August 12, 2020	November 30, 2015		January 15, 2021	NYU Langone Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02616679
487	NCT02681354	Dual Task Training in Elderly Using the BioRescue		Completed	No Results Available	Mild Cognitive Impairment	Other: Biorescue training	Static balance|Dynamic Balance|instrumented timed Up-and-Go test while dual-tasking|"stops walking while talking" test|fall incidence|cognitive function	Hasselt University	All	65 Years and older   (Older Adult)	Not Applicable	21	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)	2015-PFE-JSP-01	November 2015	January 2016	June 2016	February 12, 2016		June 14, 2016	Hasselt University, Diepenbeek, Belgium|Woon- en zorgcentrum Sint Elisabeth, Hasselt, Belgium		https://ClinicalTrials.gov/show/NCT02681354
488	NCT02588209	Cognitive Screening and Cognitive Training in Seniors		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Strategic Memory Advanced Reasoning Training|Behavioral: Brain Health Workshop	Improvement in memory or thinking after brain training|Measures changes in brain wave activity	The University of Texas at Dallas	All	50 Years and older   (Adult, Older Adult)	Not Applicable	71	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RGK11-52	January 2012	June 2015	December 2017	October 27, 2015		January 28, 2022	UTD Center for BrainHealth, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT02588209
489	NCT02564809	Cognitive Brain Training in Older Adults		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Fit Brains Training|Behavioral: Exercise + Fit Brains Training|Behavioral: Balanced And Tone	Change from baseline in episodic memory as measured with the Rey Auditory Verbal Learning Test (RAVLT) at 8 weeks and 1-year follow-up|Change from baseline in response inhibition as measured with the stroop test at 8 weeks and 1-year follow-up|Change from baseline in set shifting as measured with the Trailmaking A and B test at 8 weeks and 1-year follow-up|Change from baseline in working memory as measured with the digits forward and backward test at 8 weeks and 1-year follow-up|Change from baseline in functional capacity as measured by the 6-Minute Walk Test at 8 weeks and 1-year follow-up|Change from baseline in mobility as measured by the Short Physical Performance Battery (SPPB) at 8 weeks|Change from baseline in brain structure as measured by structural MRI at 8 weeks|Change from baseline in brain function as measured by resting state functional MRI at 8 weeks	University of British Columbia|Mitacs	All	65 Years to 85 Years   (Older Adult)	Not Applicable	123	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	H14-02438	January 2016	September 2018	September 2018	October 1, 2015		May 9, 2019	Djavad Mowafaghian Centre for Brain Health & Centre for Hip Health and Mobility, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT02564809
490	NCT02957227	Diagnosis of Alzheimer's Disease Using Event Related Potentials		Recruiting	No Results Available	Mild Cognitive Impairment	Device: No intervention is part of this study but patients use an EEG device during observational data collection.	Change in memory disorder diagnosis|EEG peak amplitude and latency|Cortical, quantitative MRI volume measurements|Amyloid PET tracer uptake, Standardardized Uptake Value ratios (SUVRs)|Mini mental status exam scores|Test of Memory and Malingering (TOMM) scores	VA Boston Healthcare System	All	50 Years to 100 Years   (Adult, Older Adult)		170	U.S. Fed	Observational	Observational Model: Case-Control|Time Perspective: Prospective	5I01CX000736-02-COG|5I01CX000736-02	July 2016	July 2023	July 2023	November 6, 2016		September 10, 2022	VA Boston Healthcare, Jamaica Plain, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02957227
491	NCT05321498	Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation		Not yet recruiting	No Results Available	Mild Cognitive Impairment (MCI)|Alzheimer Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Tauopathies|Neurodegenerative Diseases|Mental Disorders	Drug: XPro1595|Drug: Placebo	Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)|Change in Mean Computer-based Cognitive Assessment (Cogstate) Composite score from Screening to Week 12|Change in myelin content|Change in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid)|Change in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)|Change in Imaging (MRI) Neuroinflammation|Change in imaging markers of brain quality|Change in apparent fiber density (AFD)|Change in non-cognitive behavioral symptoms|Change in brain activity|Change in speech and language|Change in Alzheimer's Disease Cooperative Study - Mild Cognitive Impairment Activities of Daily Living (ADCS-MCI ADL)|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)|Number of participants who experience adverse events and serious adverse events	Inmune Bio, Inc.	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	XPro1595-AD-03	September 2022	January 26, 2023	January 26, 2023	April 11, 2022		August 17, 2022			https://ClinicalTrials.gov/show/NCT05321498
492	NCT02608021	Neurotrack Test Validation Protocol		Completed	No Results Available	Mild Cognitive Impairment		Presence of eye fixation assessed by a point of gaze continually remaining within 1 degree of visual angle for a period of 100 milliseconds or more.|Eye tracking data - Total looking time|Eye tracking data - Total number of fixations|Eye tracking data - Percentage looking time|Correlation of MRI data with VPC task score	NYU Langone Health|Neurotrack Technologies, Inc.	All	60 Years to 85 Years   (Adult, Older Adult)		81	Other|Industry	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	14-00586	October 1, 2015	October 2018	October 17, 2018	November 18, 2015		December 20, 2019	NYU Langone Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02608021
493	NCT02572323	Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons		Recruiting	No Results Available	Mild Cognitive Impairment	Drug: Tesamorelin	Neurocognitive performance|Biomarkers of visceral adipose tissue (VAT)-related inflammation and immune activation, metabolic parameters, and neuronal integrity	University of California, San Diego|University of Southern California|PalmTree Clinical Research Inc.|University of California, San Francisco	All	40 Years and older   (Adult, Older Adult)	Phase 2	100	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	R01AG048650	February 15, 2017	May 2023	May 2023	October 8, 2015		July 8, 2022	Keck School of Medicine of the University of Southern California, Los Angeles, California, United States|PalmTree, Palm Springs, California, United States|HIV Neurobehavioral Research Program (HNRP), San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT02572323
494	NCT02646982	Candesartan's Effects on Alzheimer's Disease And Related Biomarkers	CEDAR	Completed	No Results Available	Mild Cognitive Impairment	Drug: Placebo|Drug: Candesartan	Number of hypotensive episodes|Number of participants with symptoms of hypotension|Number of participants with elevated serum creatinine|Number of participants with hyperkalemia|Number of participants discontinuing the study medication|Change in Cerebrospinal Fluid (CSF) Tau Levels|Change in Pulse Wave Velocity (PWV)|Change in Augmentation Index (AI)|Change in Brain Perfusion|Change in Hippocampal Volume|Change in Vasoreactivity|Global Standardized Uptake Value Ratio (SUVR) of (11)C-Pittsburgh compound B (PiB)|Global Standardized Uptake Value Ratio (SUVR) of [18F]T807|Change in Clinical Dementia Rating (CDR) Score|Change in EXAMINER Assessment Phonemic Fluency Score|Change in EXAMINER Assessment Category Fluency Score|Change in Hopkins Verbal Learning Test (HVLT) Delayed Recall Score|Change in Trail Making Test (TMT) Part B|Change in Trail Making Test (TMT) Part B - A	Emory University|National Institute on Aging (NIA)	All	50 Years and older   (Adult, Older Adult)	Phase 2	77	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00084574|R01AG049752	June 30, 2016	August 17, 2020	August 17, 2020	January 6, 2016		February 18, 2022	Emory University, Atlanta, Georgia, United States|Wesley Woods Center, Atlanta, Georgia, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02646982/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02646982/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT02646982
495	NCT02614365	Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach	GEMSII	Active, not recruiting	No Results Available	Mild Cognitive Impairment	Behavioral: Aerobic exercise|Behavioral: Stretch exercise	Neuropsychological assessments|Brain MRI-derived regions of interest assessed by change in regions of interest brain volume|Cardiovascular disease-related markers and biomarkers assessed by change in lipids (mg/dl)|Cardiovascular disease-related markers and biomarkers assessed by change in Nuclear Magnetic Resonance Spectroscopy measured lipids concentrations (nml/L)|Cardiovascular disease-related markers and biomarkers assessed by change in cytokines' levels (pg/ml)|Alzheimer's disease-related markers and biomarkers assessed by change in serum levels of Tau (ng/L) and Abeta (ng/L)|Alzheimer's disease-related markers and biomarkers assessed by change in CSF levels of Tau (ng/L) and Abeta (ng/L)|Cardiovascular disease and Alzheimer's disease-related gene-environment interactions.|Alzheimer's disease-related markers and biomarkers and their gene-environment interactions.|Number of participants enrolled|Number of participants accepting of spinal tap procedure	Howard University|University of Southern California|University of California, San Diego	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	07-MED-41E	July 2014	April 2022	December 2022	November 25, 2015		March 2, 2021	Howard University Clinical Research Unit, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT02614365
496	NCT02317250	Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II		Withdrawn	No Results Available	Mild Cognitive Impairment	Procedure: Amyloid imaging|Procedure: FDG-PET	Rate of change from baseline in neuropsychological (cognitive,functional) test results|Utilization of healthcare resources|FDG-PET and amyloid imaging results, compared with working diagnoses made before and after time of imaging|Rates of prescription of AD-specific therapies	University of California, Los Angeles|Centers for Medicare and Medicaid Services	All	65 Years and older   (Older Adult)	Phase 3	0	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic	11-00815-02	June 2018	October 2022	December 2022	December 15, 2014		October 15, 2018			https://ClinicalTrials.gov/show/NCT02317250
497	NCT05149742	Deafness and Cognition in Middle-aged Adults	SURDICOG	Recruiting	No Results Available	Mild Cognitive Impairment in Middle-aged Adults	Behavioral: Cognitive and audiometry evaluation	Evaluation of Mini Mental State Examination to access cognitive impairment in patients with severe to profound hearing loss compare to subjects with normal hearing|Evaluation of Trail making tests (TMT) A et B to evaluate executive functions in patients with severe to profound hearing loss compare to subjects with normal hearing|Evaluation of "Fluences verbales sémantique et phonémique" to evaluate linguistic skills in patients with severe to profound hearing loss compare to subjects with normal hearing|Evaluation of 16-item Free and Cue Selective Recall Test (RLRI/16) to evaluate episodic memory in patients with severe to profound hearing loss compare to subjects with normal hearing|Evaluation of Digit Symbol Substitution Test to evaluate psychomotor speed and executive functions, executive functions in patients with severe to profound hearing loss compare to subjects with normal hearing|Evaluation of Instrumental activities of daily living scale to evaluate the level of dependence of dependence of the subjects in patients with severe to profound hearing loss compare to subjects with normal hearing|Evaluation of Cognitive Complaint Questionnaire to evaluate Cognitive assessment in patients with severe to profound hearing loss compare to subjects with normal hearing|Type of MCI|Impact of the severity of the hearing loss on presence and severity of cognitive disorders	Assistance Publique - Hôpitaux de Paris	All	45 Years to 64 Years   (Adult)	Not Applicable	180	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	APHP 210439	May 24, 2022	November 24, 2025	November 24, 2025	December 8, 2021		June 8, 2022	Centre de Recherche en Audiologie (CReA) - Groupe Hospitalier Pitié-Salpêtrière, Paris, France		https://ClinicalTrials.gov/show/NCT05149742
498	NCT02225964	Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD		Completed	No Results Available	Mild Cognitive Impairment		the conversion of aMCI patients with APOEε4 to AD	XuanwuH 2|Xuanwu Hospital, Beijing	All	Child, Adult, Older Adult		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	XuanwuH 2	January 2014	December 2017	December 2018	August 26, 2014		July 2, 2020	Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02225964
499	NCT02023645	The Effects of a Carotenoid Intervention on Cognitive Function		Unknown status	No Results Available	Mild Cognitive Impairment	Dietary Supplement: active supplement|Other: placebo	macular pigment optical density|serum carotenoid levels|reaction time|executive function|short-term memory|visual attention	University of Georgia|Abbott Nutrition|DSM Nutritional Products, Inc.	All	18 Years to 95 Years   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	2012-10516	January 2012	September 2015	December 2015	December 30, 2013		May 27, 2015	The University of Georgia, Athens, Georgia, United States		https://ClinicalTrials.gov/show/NCT02023645
500	NCT01808235	Oral Health Intervention Pilot Study for Individuals With Memory Problems		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: Oral Health Intervention	Change in oral health|Changes in subjects' self-efficacy	Duke University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Pro00039035	July 2012	February 3, 2017	February 3, 2017	March 11, 2013		March 30, 2017	Duke University, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01808235
501	NCT04835909	Board Games Among Mild Cognitive Impairment Patients Experience (GAME Project)	GAME-Project	Recruiting	No Results Available	Cognitive Impairment, Mild	Behavioral: Modern board and card games group|Behavioral: Paper and pencil tasks group	Change in cognitive impairment from baseline to post intervention|Change in visuoconstruction, immediate memory and long-term memory from baseline to post intervention|Change in verbal long-term memory from baseline to post intervention|Change in verbal short-term memory from baseline to post intervention|Change in verbal working memory from baseline to post intervention|Change in visuospatial short-term memory from baseline to post intervention|Change in visuospatial working memory from baseline to post intervention|Change in visuospatial processing from baseline to post intervention|Change in flexibility from baseline to post intervention|Change in inhibition from baseline to post intervention|Change in phonemic and semantic fluency from baseline to post intervention|Change in neuropsychiatric symptoms from baseline to post intervention|Change in psychological well-being from baseline to post intervention|Change in depressive symptoms from baseline to post intervention	Brain In Game scientific-technical service|University Hospital of Santa Maria, Lleida	All	60 Years and older   (Adult, Older Adult)	Not Applicable	112	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	NCT2021UTC	February 16, 2021	March 2024	March 2024	April 8, 2021		April 8, 2021	Faculty of Education, Psychology and Social Work; University of Lleida, Lleida, Spain|Cognitive disorders unity, Santa Maria's University Hospital, GSS, Lleida, Spain		https://ClinicalTrials.gov/show/NCT04835909
502	NCT02074215	Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease	Other: Aerobic exercises|Other: Stretch exercise	Changes of Memory and executive function related neuropsychological test|Changes of muscle strength of upper and lower extremity and walking speed	National Taiwan University Hospital	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	19	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	201012136RB	March 2011	December 2012	December 2013	February 28, 2014		February 28, 2014	National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02074215
503	NCT01620567	Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults		Completed	Has Results	Mild Cognitive Impairment	Other: avocado|Other: potato or chickpea	Cognition|Inflammation	Tufts University	All	50 Years and older   (Adult, Older Adult)	Not Applicable	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	002	August 2012	August 2014	August 2014	June 15, 2012	July 19, 2019	July 19, 2019	Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01620567
504	NCT02176629	Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease	MeMO-RV2	Completed	No Results Available	MCI|Alzheimer's Disease	Other: Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|Other: Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)	Evaluate the acceptability of the RV|Evaluate the motivation of subjects (interest, cognition) is greater in the virtual environment during the VR experience compared to a conventional cognitive stimulation activity (CSC).	Centre Hospitalier Universitaire de Nice	All	60 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)	14-PP-03	August 2014	February 2015	February 2015	June 27, 2014		September 1, 2015	Institut Claude Pompidou, Nice, France		https://ClinicalTrials.gov/show/NCT02176629
505	NCT01201616	The Effects of Diet on Mood, Cognition and Appetite		Completed	No Results Available	Mild Cognitive Impairment	Other: High Fat Low Carbohydrate Diet|Other: Low fat High Carbohydrate Diet	Clear-headedness|Reaction time	University of Nottingham|Mars, Inc.	Female	18 Years to 45 Years   (Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	RIS030426a	July 2010	December 2012	March 2013	September 14, 2010		March 27, 2018	University of Nottingham, Nottingham, Notts, United Kingdom		https://ClinicalTrials.gov/show/NCT01201616
506	NCT00714571	Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)		Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease|Traumatic Brain Injury	Behavioral: Mnemonic strategy training (MST)|Behavioral: Repeated exposure (XP)|Behavioral: Subtracting Cues training	Memory Test Accuracy on Trained Stimuli	VA Office of Research and Development|Emory University	All	18 Years to 88 Years   (Adult, Older Adult)	Phase 1	82	U.S. Fed|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment	B6366-W	July 2008	September 2014	September 2014	July 14, 2008	January 4, 2017	January 4, 2017	Atlanta VA Medical and Rehab Center, Decatur, Decatur, Georgia, United States		https://ClinicalTrials.gov/show/NCT00714571
507	NCT05108922	A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Drug: Donanemab|Drug: Aducanumab	Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on donanemab versus aducanumab|Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Subpopulation (Superiority) on donanemab versus aducanumab|Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab|Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Noninferiority) on donanemab 6 months versus aducanumab 12 months|Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Noninferiority) donanemab 6 months versus aducanumab 18 months|Time to Reach Complete Amyloid Plaque Clearance on donanemab versus aducanumab|Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) donanemab versus aducanumab|Mean Percent Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab|Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan (Superiority) on donanemab versus aducanumab|Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab|Mean Absolute Change from Baseline in Brain Amyloid Plaque on Florbetapir F18 PET Scan in the Intermediate Tau Subpopulation (Superiority) on donanemab versus aducanumab|Change from Baseline in Brain Amyloid Plaque Reduction on Florbetapir F18 PET Scan (Superiority) donanemab 6 months versus aducanumab 12 months	Eli Lilly and Company	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18369|I5T-MC-AACN	November 16, 2021	August 30, 2022	July 2, 2024	November 5, 2021		September 7, 2022	Neurology Center of North Orange County, Fullerton, California, United States|Irvine Clinical Research, Irvine, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Charter Research - Lady Lake, Lady Lake, Florida, United States|ClinCloud - Maitland, Maitland, Florida, United States|ClinCloud - Viera, Melbourne, Florida, United States|Merritt Island Medical Research, LLC, Merritt Island, Florida, United States|Optimus U Corporation, Miami, Florida, United States|Brainstorm Research, Miami, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Conquest Research, Winter Park, Florida, United States|Columbus Memory Center, PC, Columbus, Georgia, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|Donald S. Marks M.D., P.C., Plymouth, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Abington Neurological Associates, Ltd., Abington, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Kerwin Medical Center, Dallas, Texas, United States|National Clinical Research, Inc, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT05108922
508	NCT04498195	Walking on Cognitive Function in Individuals With Mild Cognitive Impairment: A Pilot Project		Completed	No Results Available	Cognitive Impairment, Mild	Behavioral: increased exercise and physical activity	Whether increasing the number of daily steps among older adults with mild cognitive impairment would improve their cognitive functioning.	Samuel Merritt University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	17	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	SMUIRB#19-013	January 7, 2019	October 31, 2019	December 6, 2019	August 4, 2020		August 4, 2020	Sutter Medical Neuroscience, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT04498195
509	NCT00091468	Nicotine Treatment of Mild Cognitive Impairment (MCI)		Unknown status	No Results Available	Age-Related Memory Disorders	Drug: Transdermal nicotine patch|Drug: Placebo transdermal patch	Safety of transdermal nicotine patch|Change in cognitive performance|Change in global functioning	National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 1	75	NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IA0060|R01AG022462-02	September 2003	July 2008	July 2008	October 14, 2004		January 15, 2008	Georgetown University Medical Center, Department of Neurology, Washington, District of Columbia, United States|Duke University, Duke Health Center at Morreene Road, Durham, North Carolina, United States|University of Vermont College of Medicine, Burlington, Vermont, United States		https://ClinicalTrials.gov/show/NCT00091468
510	NCT00609427	Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study		Completed	No Results Available	Mild Cognitive Impairment	Behavioral: MEMO programme (Inst Universitaire de Geriatrie, Montreal)|Behavioral: External memory aids training	Rey Auditory Verbal Learning Test|Wechsler Memory Scale - Logical Memory|Face-name associations test|Multifactorial Memory Questionnaire - Ability subscale|Rivermead Behavioural Memory Test|FAS test (non-memory)|Category fluency (non-memory test)|Victoria Stroop Test (non-memory test)|Digit Span (non-memory test)|Multifactorial Memory Questionnaire - Strategies and Contentment subscales	McGill University Health Centre/Research Institute of the McGill University Health Centre	All	65 Years to 90 Years   (Older Adult)	Phase 1	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PSY-07-015	May 2008	May 2010	May 2010	February 7, 2008		June 2, 2010	McGill University Health Centre, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00609427
511	NCT00134953	Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment		Terminated	No Results Available	Cognitive Symptoms	Drug: Rivastigmine	16 week's treatment with rivastigmine on alertness, memory, attention, cognitive flexibility, orientation and language in patients with mild cognitive impairment|Safety of 16 week's treatment with rivastigmine in patients with mild cognitive impairment	Novartis	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	CENA713BDE05	January 2003		May 2004	August 25, 2005		December 17, 2007			https://ClinicalTrials.gov/show/NCT00134953
512	NCT05537363	Agility Training and Its Relations in Elderly Adults With and Without MCI		Not yet recruiting	No Results Available	Elderly Adults|Mild Cognitive Impairment|Healthy	Other: Health education|Other: Multicomponent training|Other: Agility training	Agility Challenge for the Elderly (ACE)|Fall history and fear of falls|Quality of life (QOL)|Brain activation|Montreal Cognitive Assessment (MoCA)|Mental set shifting|Working memory|Selective attention and inhibition|Motor Function	National Taiwan University Hospital	All	20 Years to 100 Years   (Adult, Older Adult)	Not Applicable	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	202112236RINB	September 10, 2022	October 31, 2025	December 31, 2025	September 13, 2022		September 13, 2022			https://ClinicalTrials.gov/show/NCT05537363
513	NCT00306124	Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment		Unknown status	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Healthy	Drug: Levodopa	Cognitive performance assessed by neuropsychological tests and learning paradigms under placebo and levodopa in healthy subjects and patients with dementia or Mild Cognitive Impairment.|Brain activity pattern during learning under levodopa as compared to placebo in healthy subjects.|Long-term stability of learning performance after 1 month in healthy subjects.	University Hospital Muenster	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 4	120	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment	LL_001 Project on Dementia/MCI	January 2006		March 2008	March 22, 2006		October 25, 2007	University of Muenster, Department of Neurology, Muenster, North-Rhine Westphalia, Germany		https://ClinicalTrials.gov/show/NCT00306124
514	NCT02279316	Move for Your Mind - Pilot Trial	MFYM - P	Completed	No Results Available	Mild Cognitive Impairment|Mild Dementia|Fall Prevention	Drug: Vi-De 3|Other: Jaques-Dalcroze eurhythmics|Other: Home exercise program	Rate of falls (any falls, low trauma falls, injurious falls) during 12 month follow-up|Number of participants who fell at least once during 12 months of follow up|Gait variability (stride time, stride length and gait speed)|Cognitive function|Alertness|Quality of life	University of Zurich|Waid City Hospital, Zurich	All	65 Years and older   (Older Adult)	Not Applicable	19	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention	SNCTP000000580	October 2014	September 2016	September 2016	October 31, 2014		November 17, 2016	Centre on Aging and Mobility, University of Zurich, Waid City Hospital, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT02279316
515	NCT00242593	Rosiglitazone Effects on Cognition for Adults in Later Life	RECALL	Unknown status	No Results Available	Mild Cognitive Impairment	Drug: Rosiglitazone	Cognitive measures: delayed list recall, Stroop Interference test|Biological outcomes: plasma insulin, IDE, AB40, AB42, inflammatory cytokines, and F2-isoprostanes|MRI outcome: Whole brain and medial temporal lobe atrophy rate|Cognitive measures: ADAS-cog total score, story recall verbal fluency, paired associate learning, SOPT, rating scales	University of Washington|National Institute on Aging (NIA)|GlaxoSmithKline	All	55 Years and older   (Adult, Older Adult)	Phase 2	120	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IA0087|1R01AG025502-01A1	June 2006	December 2011	December 2011	October 20, 2005		August 5, 2011	Banner Alzheimer Institute, Phoenix, Arizona, United States|UCLA Alzheimer's Disease Center, Los Angeles, California, United States|University of Washington/VA Puget Sound Health Care System, Seattle/Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT00242593
516	NCT02955719	CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia	CCI	Completed	No Results Available	Depression|Anxiety|Mild Cognitive Impairment	Drug: Sertraline|Drug: Venlafaxine|Other: CBT/Psychological Therapy|Other: Psychiatric Consultation|Other: Lifestyle Intervention Resources	Change in anxiety/depression/quality of life (QOL) scores among participants in the ICP and comparison groups|Acceptability and perceived utility of the ICP|Feasibility of the ICP|Adjustments made for the adoption of the ICP in primary care teams|Barriers to implementation of the ICP and the key elements to initiate, sustain and spread the ICP|Changes in the primary care providers' knowledge of, and ability to recognize and manage, depression, anxiety, and MCI in older adults.|Time-to-treatment initiation among those in the ICP arm versus those in the comparison arm.|Specific Aim 3a: To assess the impact of the ICP on the rates of diagnoses/detection among older patients with anxiety, depression, or MCI compared to before ICP implementation.|Specific Aim 3b: To assess the impact of ICP on rates of diagnoses/detection among patients of the same age cohort as our target ICP population, but not in our study sample.	Centre for Addiction and Mental Health|McMaster University	All	60 Years to 65 Years   (Adult, Older Adult)	Not Applicable	145	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	019/2016	March 30, 2016	July 16, 2020	July 16, 2020	November 4, 2016		January 7, 2021	Centre for Addiction and Mental Health, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02955719
517	NCT01937221	Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease		Completed	No Results Available	Mild Cognitive Impairment|Mild to Moderate Cognitive Impairment	Other: spectral-domain optical coherence tomography (SD-OCT)	Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score|NFL/GCL abnormality score|Drusen/plaque score|Total drusen area	Duke University|Duke Institute for Brain Sciences|Alzheimer's Association|Duke-NUS Graduate Medical School	All	55 Years and older   (Adult, Older Adult)		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	Pro00047227	September 2013	July 2017	July 2017	September 9, 2013		January 31, 2019	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01937221
518	NCT05144516	Cancer and Mild Cognitive Impairment Dyadic Intervention		Not yet recruiting	No Results Available	Cancer|Cognitive Impairment	Behavioral: Behavioral: COPE +	Number of completed sessions as measured by enrollment log|Number of participants who are satisfied with the intervention as measured by a score of 24 or greater on the CSQ-8|Change in Distress as measured by the DASS-21|Change in Quality of Life as measured by the FACT-G|Change in Communication Patterns as measured by the CPQ-SF|Change in Relationship Satisfaction as measured by the Mutuality Scale of the Family Care Inventory	Duke University	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	144	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00109148	October 1, 2022	September 30, 2027	September 30, 2027	December 3, 2021		May 24, 2022	Duke University, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT05144516
519	NCT00236431	A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment		Completed	No Results Available	Dementia|Alzheimer Disease	Drug: Galantamine hydrobromide	Memory and cognition (ADAS-COG/MCI and CDR-SB scores), global functional skills and overall severity of dementia (the CDR-SB and the overall Clinical Dementia Rating) measured at 12 and 24 months.|Digit Symbol Coding and Alzheimer's Disease Cooperative Study-ADL scale (MCI version) at 12 and 24 months. Safety assessment (reports of adverse events, laboratory values, results of physical examinations, and electrocardiograms) throughout the study.	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	50 Years and older   (Adult, Older Adult)	Phase 3	1063	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	CR002014	May 2001		December 2003	October 12, 2005		June 8, 2011			https://ClinicalTrials.gov/show/NCT00236431
520	NCT02814526	Exercise in Adults With Mild Memory Problems	EXERT	Completed	No Results Available	Mild Cognitive Impairment|Cognitive Decline|Memory Impairment	Behavioral: Aerobic exercise|Behavioral: Stretching/balance/range of motion exercise	Cognitive function composite score (ADAS-Cog-Exec)|Cognitive function composite score (ADAS-Cog-Exec) in a subset of participants who completed 12 months of the study prior to the COVID-19 pandemic score (ADAS-Cog-Exec)|Executive Function and Episodic Memory composite scores|Volumetric and arterial spin labeling magnetic resonance imaging (MRI)|AD biomarkers in CSF and blood	Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|Wake Forest University	All	65 Years to 89 Years   (Older Adult)	Not Applicable	296	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ADC-041-EX|U19AG010483-22	September 13, 2016	December 31, 2021	January 28, 2022	June 27, 2016		July 11, 2022	University of California, Irvine, Irvine, California, United States|VAPAHCS / Stanford University School of Medicine, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Great Lakes Clinical Trials (Andersonville), Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02814526/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02814526/SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02814526/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT02814526
521	NCT04317612	Effect of Nordic Berries on Cognitive Function, Cardiometabolic Risk Markers and Gut Microbiota in Adults With Mild Cognitive Impairment	MINDBERRY	Recruiting	No Results Available	Cognitive Impairment, Mild|Memory Impairment	Other: Active berry product|Other: Reference product	CANTAB - Paired Associate Learning test (PAL28)|Episodic memory (test verbal recognition memory (VRM) (free-, immediate- and delayed recall)|Attention, psychomotor speed and executive function (Trail making test (TMT) A and B)|Selective attention and processing speed (Stroop color-word test)|Verbal fluency (letter "S" word fluency test)|Behavior and quality of life (AES, Apathy evaluation score (self))|Behavior and quality of life (Apathy evaluation score (informant))|EuroQol five dimension (EQ-5D) life quality score.|Hospital Anxiety Depression (HAD) Score.|Systolic blood pressure|Diastolic blood pressure|Heart rate|Body weight|BMI|Body fat composition|Waist-to-hip ratio|Fasting glucose (mM)|Fasting insulin|HOMA-IR|Lipid metabolism: total cholesterol mg/dl|Lipid metabolism: LDL-cholesterol mg/dl|Lipid metabolism: HDL-cholesterol mg/dl|Lipid metabolism: triglycerides mg/dl|Lipid metabolism: apolipoprotein B/ apolipoprotein A1 ratio|Lipid metabolism: oxLDL|Liver function: alanine aminotransferase (ALAT) (ukat/L)|Inflammation: hsCRP (mg/L)|Inflammation: plasma serum amyloid A (mg/L)|Inflammation: IL-6 ng/L|Inflammation: TNFalfa ng/L|Inflammation: IL-12 ng/L|Inflammation: IL-15 ng/L|Inflammation: MCP-1 ng/L|Inflammation: sVCAM-1 (ukat/L)|Inflammation: IFN-g|Biomarker related to cognitive function: BDNF|PAL scores (PALTEA)|VRM scores	Region Skane|Lund University|Berry Lab	All	55 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	Mindberry2020	June 3, 2020	June 1, 2022	August 1, 2022	March 23, 2020		January 26, 2022	Cognitve medicine, Ängelholm, Sweden|Cognitive medicine, Ängelholm, Sweden		https://ClinicalTrials.gov/show/NCT04317612
522	NCT04826315	Cancer and Mild Cognitive Impairment a Patient-Caregiver Behavioral Intervention		Withdrawn	No Results Available	Cancer|Cognitive Impairment	Behavioral: COPE +	Number of completed sessions as measured by enrollment log|Number of participants who are satisfied with the intervention as measured by a score of 24 or greater on the CSQ-8|Change in Distress as measured by the DASS-21|Change in Quality of Life as measured by the FACT-G|Change in Communication Patterns as measured by the CPQ-SF|Change in Relationship Satisfaction as measured by the Mutuality Scale of the Family Care Inventory	Duke University	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00107680	January 15, 2022	November 30, 2026	November 30, 2026	April 1, 2021		January 19, 2022	Duke University, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04826315
523	NCT01816308	Cognitive Impairment in Atrial Fibrillation	DIAL-F	Recruiting	No Results Available	Atrial Fibrillation|Mild Cognitive Impairment|Dementia		improvement or no-worsening in MoCA score assessed at baseline and 2 year follow-up|Correlation between MoCA score and physical activity, social support, anxiety and depression	Texas Cardiac Arrhythmia Research Foundation	All	50 Years to 75 Years   (Adult, Older Adult)		888	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	TCAI_DIAL-F	July 2014	June 2020	December 2022	March 22, 2013		September 9, 2019	Texas Cardiac Arrhythmia Institute, St. david's Medical Center, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT01816308
524	NCT01745198	Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease|Alzheimer's Disease Related Disorders		Change in rate of cognitive decline as measured by the Memory Performance Index (MPI)|Change in rate of cognitive decline as measured by the MCI Screen|Change in rate of cognitive decline as measured by The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Drawings|Change in rate of cognitive decline as measured by Trails A & B|Rate of atrophy of hippocampal volume|Rate of atrophy in cortical volume|Rate of atrophy in ventricular volume|Change in rate of cognitive decline as measured by Functional Assessment Staging Test (FAST)	Pamlab, Inc.|The Shankle Clinic|Hoag Memorial Hospital Presbyterian	All	18 Years and older   (Adult, Older Adult)		121	Industry|Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	NAC-002c	December 2012	March 2014	June 2014	December 10, 2012		April 28, 2015	Hoag Memorial Hospital, Newport Beach, California, United States		https://ClinicalTrials.gov/show/NCT01745198
525	NCT04051918	Robot-assisted Cognitive Training for Lonely Older Adults With Mild Cognitive Impairment (MCI)	MCI	Recruiting	No Results Available	Cognitive Change|Cognitive Impairment, Mild|Aging	Behavioral: Piano Training	Verbal Memory Test|Visual Memory Test|Non-Verbal Reasoning Test|Shifting Attention Test|Stroop Test|Continuous Performance Test|Symbol Digit Coding Test|Technology Acceptance - TAM3|DeJong Loneliness Scale|NASA TLX	University of Georgia|Applied Universal Dynamics, Corp.|Van Robotics, Inc.	All	65 Years and older   (Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	PROJECT00000940	October 7, 2021	August 31, 2023	August 31, 2023	August 9, 2019		November 9, 2021	University of Georgia, Athens, Georgia, United States		https://ClinicalTrials.gov/show/NCT04051918
526	NCT05153941	Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures	DNS	Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment		ADL using selected RMTs|Neuropsychological assessment like the Clinical Dementia Rating (CDR) scale|Neuropsychological assessment like Altoida, Inc. Neuro Motor Index (NMI) medical device|Demographics, medical history, physical status, life-habits, and medication from the analysis of neuropsychological assessments.|Demographics, medical history, physical status, life-habits, and medication from the analysis of biomarker measurements.|Demographics, medical history, physical status, life-habits, and medication from the analysis of RMTs|Demographics, medical history, physical status, life-habits, and medication from the analysis of Altoida NMI medical device.	Altoida|Eisai Co., Ltd.|Ionian University	All	50 Years and older   (Adult, Older Adult)		3500	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	4151/19-10-2021	January 31, 2022	January 31, 2029	January 31, 2030	December 10, 2021		February 11, 2022	Nikaia Ag Panteleimon Hospital, Athens, Greece		https://ClinicalTrials.gov/show/NCT05153941
527	NCT03120741	Dementia Patient's Behavior Evaluation Using Noninvasive Ambient Sensor		Unknown status	No Results Available	Mild Cognitive Impairment, Dementia		The relationship between moving pattern change and dementia.|The relationship between daily routine change and dementia.|The relationship between sleeping time change and dementia.	National Taiwan University Hospital	All	65 Years to 100 Years   (Older Adult)		35	Other	Observational	Observational Model: Case-Control|Time Perspective: Other	201608004RINB	May 2017	August 2018	August 2018	April 19, 2017		April 19, 2017	National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03120741
528	NCT03043573	Problem Adaptation Therapy for Mild Cognitive Impairment and Depression	PATH-MCI	Recruiting	No Results Available	Cognitive Impairment|Depression	Behavioral: PATH-MCI|Behavioral: Supportive Therapy	Change in Global Cognition assessed by RBANS|Change in disability function assessed with WHODAS-II|Change in Depression assessed by MADRS|Change in Episodic Memory assessed by subscale of RBANS|Change in Executive Function assessed by Trail Making Test	Weill Medical College of Cornell University|Johns Hopkins University|Montefiore Medical Center|National Institute on Aging (NIA)	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	80	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	1603017114|1R01AG050514	July 1, 2017	July 31, 2022	July 31, 2022	February 6, 2017		December 21, 2021	Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medicine, New York, New York, United States|Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York, United States		https://ClinicalTrials.gov/show/NCT03043573
529	NCT04555941	The Effects of Intermittent Theta Burst Stimulation in MCI and Early AD		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Cognitive Decline	Device: intermittent theta burst stimulation	Changes from baseline in scores of any tests of the Neuropsychological Battery|Brain MRI	Taipei Medical University Shuang Ho Hospital	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	N202003022	October 5, 2020	July 31, 2021	July 31, 2021	September 21, 2020		October 8, 2020	Shuang Ho Hospital, New Taipei City, Taiwan		https://ClinicalTrials.gov/show/NCT04555941
530	NCT03880240	Gamma Induction for Alzheimer's Disease		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: Transcranial Alternating Current Stimulation (tACS)|Other: Sham Transcranial Alternating Current Stimulation	PET amyloid burden|PET tau deposition|Incidence of Treatment-Emergent Adverse Events|Change in Gamma activity|Alzheimer's Disease Assessment Scale -Cog Score|Follow-up Amyloid PET burden|Follow-up Cognitive Evaluation	Massachusetts General Hospital|Beth Israel Deaconess Medical Center|National Institutes of Health (NIH)|National Institute on Aging (NIA)	All	45 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	55	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2019P000092|R01AG060981	August 5, 2019	November 2023	November 2023	March 19, 2019		August 19, 2022	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03880240
531	NCT04685590	Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study	SToMP-AD	Recruiting	No Results Available	Alzheimer Disease, Early Onset|Mild Cognitive Impairment	Drug: Dasatinib + Quercetin|Other: Placebo Capsules	Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group|Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score|Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood|Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood|Change in cellular senescence blood marker T cells in blood|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope|Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope|Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology	Wake Forest University Health Sciences|The University of Texas Health Science Center at San Antonio	All	65 Years and older   (Older Adult)	Phase 2	48	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00067429	December 22, 2021	January 2027	January 2032	December 28, 2020		January 24, 2022	Wake Forest Health Sciences, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04685590
532	NCT01801943	Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment		Unknown status	No Results Available	Cognitive Impairment	Behavioral: Cognitive Remediation Therapy Group|Behavioral: Walking Intervention (WI) Group|Behavioral: Combination Group|Behavioral: Healthy Living Group	Effects of interventions on cognition|Effects of interventions on gait	Pennington Biomedical Research Center	All	65 Years to 85 Years   (Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)	WalkCog-MCI	February 2013	April 2015	May 2015	March 1, 2013		June 9, 2014	Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States		https://ClinicalTrials.gov/show/NCT01801943
533	NCT03448055	Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health		Recruiting	No Results Available	Mild Cognitive Impairment (MCI)	Dietary Supplement: Immunocal	Change in GSH levels in the brain|Change in plasma GSH:GSSG ratios measured by HPLC|Evaluation of neuropsychological and cognitive functions	Immunotec Inc.	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	MCI-IMM15	February 5, 2018	November 25, 2022	November 25, 2023	February 27, 2018		February 10, 2021	Memory Clinic/Jewish General Hospital, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT03448055
534	NCT00908999	Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)		Completed	No Results Available	Anosognosia|Alzheimer's Disease|Mild Cognitive Impairment			University of Wisconsin, Madison	All	60 Years to 90 Years   (Adult, Older Adult)		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	HSC-2008-0090	April 2008	September 2011	September 2011	May 27, 2009		September 29, 2011	William S Middleton VA Hospital GRECC, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00908999
535	NCT03138018	Aging Stereotypes and Prodromal Alzheimer's Disease	AGING	Recruiting	No Results Available	Mild Cognitive Impairment (MCI)	Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)	Neuropsychological tests|Neuroimaging biomarkers of neurodegeneration|Physiological stress|Self-report questionnaires|Heart rate variability (thin elasticized heart rate transmitter belt),|Skin conductance (wristwatch)|Salivary biomarkers	Assistance Publique Hopitaux De Marseille	All	50 Years and older   (Adult, Older Adult)	Not Applicable	260	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic	2016-45|IDRCB Number	July 6, 2018	July 1, 2023	July 1, 2023	May 3, 2017		July 26, 2018	Assistance Publique Hôpitaux de Marseille, Marseille, France		https://ClinicalTrials.gov/show/NCT03138018
536	NCT03937908	Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment		Terminated	Has Results	Cognitive Impairment|Elderly	Drug: 2g Centella asiatica water extract product|Drug: 4g Centella asiatica water extract product	Peak Plasma Concentration of Centella Asiatica Bioactive Compounds (Cmax)|Time of Maximum Concentration (Tmax)|Half-life (t1/2)|Area Under the Curve (AUC) of the Concentration vs Time Profiles of Known Bioactives From Centella Asiatica|Total Urinary Excretion|NRF2 Expression	Oregon Health and Science University|National Center for Complementary and Integrative Health (NCCIH)	All	65 Years to 85 Years   (Older Adult)	Early Phase 1	5	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening	STUDY00017985|R61AT009628	October 31, 2019	December 21, 2020	December 21, 2020	May 6, 2019	May 4, 2022	May 4, 2022	Oregon Health and Science University Department of Neurology, Portland, Oregon, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03937908/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03937908
537	NCT02225314	Computer-based Cognitive Training for Individuals With Parkinson's Disease		Completed	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Behavioral: Brain Fitness|Behavioral: InSight|Behavioral: Active Control	Percent Accuracy on Cognitive Training Quizzes|Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39)|California Verbal Learning Test-II Long Delay Free Recall Scaled Score Change Over 3 Months	Virginia Commonwealth University	All	21 Years to 90 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADWilliams2012-647173	April 2012	October 2015	December 2015	August 26, 2014		January 8, 2016	Virginia Commonwealth University Parkinson's and Movement Disorders Center, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT02225314
538	NCT04742465	ARIADE : Augmented Reality for Improving Autonomy in Dementia	ARIADE	Completed	No Results Available	Alzheimer or Mild Cognitive Impairment	Other: Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.	Destination|Event of an endangerment|6-minute walking test|Senior Technology Acceptance|Personality	Rennes University Hospital|INRIA, Hybrid team|Ecole Centrale Nantes, laboratoire Ambiances, Architectures, Urbanités - UMR 1563 CNRS-ECN-ENSAN-ENSAG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	19	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	35RC20_8889_ARIADE|2021-A00062-39	June 7, 2021	June 25, 2021	June 25, 2021	February 8, 2021		July 7, 2021	Rennes University Hospital, Rennes, France		https://ClinicalTrials.gov/show/NCT04742465
539	NCT03811184	Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen	MemScreen	Unknown status	No Results Available	Cognitive Impairment|Alzheimer Disease	Diagnostic Test: MemScreen	Ability to detect patients with mild cognitive impairment.	MemScreen	All	40 Years and older   (Adult, Older Adult)		400	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	2018-A02672-53	January 17, 2019	March 2020	June 2020	January 22, 2019		August 15, 2019	Centre Neurologie Cognitive Hôpital Fernand Widal, Paris, France		https://ClinicalTrials.gov/show/NCT03811184
540	NCT02174562	Improving Medication Adherence in Older African Americans With Diabetes		Completed	Has Results	Type 2 Diabetes|Mild Cognitive Impairment	Behavioral: Primary Care-Occupational Therapy|Behavioral: Enhanced Usual Care	Percent of Participants With Improvement in Hemoglobin A1c by 0.5%"|Adherence as Measured By Percentage of Doses Taken as Prescribed	Thomas Jefferson University|Johns Hopkins University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	101	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	R01DK102609-01	July 2014	December 2019	December 2019	June 25, 2014	June 16, 2020	August 10, 2020	Thomas Jefferson University, Philadelphia, Pennsylvania, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02174562/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02174562
541	NCT04246164	A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Memory Disorders|Memory Loss	Device: HD-tDCS combined with CT|Device: sham HD-tDCS combined with CT	Treatment completion rates|Recruitment rate	Medical College of Wisconsin	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	8	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PRO00035757	January 25, 2021	August 2022	August 2022	January 29, 2020		November 19, 2021	The Medical College of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT04246164
542	NCT04901494	SSRI's and the Rate of Progression From MCI to Dementia		Recruiting	No Results Available	Mild Cognitive Impairment|Dementia|Alzheimer Disease	Drug: SSRI	SSRI rate of progression to dementia|SSRI and acetylcholinesterase inhibitor use progression to dementia|Rate of conversion from MCI to dementia and the other factors	Ohio State University	All	50 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	2020H0375	September 1, 2021	July 1, 2022	July 1, 2022	May 25, 2021		September 9, 2021	The Ohio State University, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT04901494
543	NCT04721093	Effects of Photobiomodulation on Changes in Cognitive Function and rCBF in MCI		Completed	No Results Available	Regional Cerebral Blood Flow|Mild Cognitive Impairment|Cognitive Function	Device: Photobiomodulation device	Korean Version of Montreal Cognitive Assessment(MoCA) score change|Single photon emission computed tomography(SPECT) z-score change|The verbal learning test(VLT) score change|The trail making test(TMT) score change|Boston naming test(BNT) score change|Rey complex figure test(RCFT)-'copy' score change|Rey complex figure test(RCFT)-'Immediate Recall' score change	Pusan National University Yangsan Hospital	All	55 Years and older   (Adult, Older Adult)	Not Applicable	14	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	03-2018-006	December 12, 2019	April 30, 2020	June 30, 2020	January 22, 2021		January 22, 2021	Pusan national university Yangsan Hospital, Gyeongsang, Yangsan, Korea, Republic of		https://ClinicalTrials.gov/show/NCT04721093
544	NCT04240665	The Digital Memory Notebook	DMN	Enrolling by invitation	No Results Available	Prodromal Alzheimer's Disease|Mild Cognitive Impairment|Subjective Cognitive Complaints	Behavioral: Digital Memory Notebook (DMN) Application	Real-time data extracted from the DMN Application|Participant Questionnaire Outcomes	University of California, Davis	All	60 Years and older   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	1454000	November 11, 2020	January 31, 2023	June 30, 2023	January 27, 2020		February 21, 2022	Alzheimer's Disease Center, University of California, Davis, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT04240665
545	NCT03755362	Dental Carotid Cognitive Study		Terminated	No Results Available	Carotid Stenosis|Mild Cognitive Impairment|Periodontitis	Procedure: Standard Treatment|Procedure: Intensive Treatment	Changes in performance on Montreal Cognitive Assessment (MoCA)|Presence of oral bacteria in saliva and dental plaque samples|Presence of bacteria in stool samples|Systemic inflammation|Change from baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR)|Changes in performance on Wechsler Adult Intelligence Scale (WAIS)-III Digit Span subtest|Changes in performance on Hopkins Verbal Learning Test|Changes in performance on Brief Visuospatial Memory test|Changes in performance on Trail Making Test (A+B)|Changes in performance on Controlled Oral Word Association Test|Changes in performance on Boston Naming Test|Changes in performance on Modified Wisconsin Card Sorting Test|Changes in performance on Grooved Pegboard Test|Changes in Composite Cognitive Function Score	University of Maryland, Baltimore|University of Maryland, College Park|Baltimore VA Medical Center	All	60 Years to 100 Years   (Adult, Older Adult)	Not Applicable	26	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	HP-00082777	April 8, 2019	February 21, 2021	February 25, 2021	November 28, 2018		July 23, 2021	University of Maryland - Administrative Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03755362
546	NCT04482036	The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study	MOMENT	Terminated	No Results Available	Alzheimer Disease|Mild Memory Disturbance|Mild Cognitive Impairment	Other: Mobile Phone Application Assessments|Other: Standard Assessments	Feasibility of the BrainCare Notes (BCN) app - Caregiver Completion Rate of the Neuropsychiatric Interview Questionnaire (NPI-Q) at 3 months|Feasibility of the BrainCare Notes (BCN) app - Caregiver Completion Rate of the Neuropsychiatric Interview Questionnaire (NPI-Q) at 6 months|Feasibility of the BrainCare Notes (BCN) app - Survey Burden Mean at 3 months|Feasibility of the BrainCare Notes (BCN) app - Survey Burden Mean at 6 months|Usability of the BrainCare Notes (BCN) app - System Usability Scale Results at 3 months|Usability of the BrainCare Notes (BCN) app - System Usability Scale Results at 6 months|Change in Behavioral and Psychological Symptoms of Dementia Ratings at 3 months|Change in Behavioral and Psychological Symptoms of Dementia Ratings at 6 months|Change in Caregiver Distress at 3 months|Change in Caregiver Distress at 6 months	Indiana University|National Institute on Aging (NIA)	All	18 Years to 120 Years   (Adult, Older Adult)	Not Applicable	20	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	1907055854|1K23AG059914-01A1	October 23, 2020	October 4, 2021	October 4, 2021	July 22, 2020		June 10, 2022	Eskenazi Health, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT04482036
547	NCT04804241	Senicapoc in Alzheimer's Disease	Senicapoc	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Drug: Senicapoc|Other: Placebo Tablet	Change from Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog 13) score|Change from Baseline to Week 52 in levels of Cerebrospinal fluid (CSF) biomarkers: IL-1β, IL-6, TNF-α, MCP-1, and IL-10|Change from Baseline to Week 52 in levels of serum biomarkers: IL-6, TNF-α, MCP-1, and IL-10 and high sensitivity C-Reactive protein|Change from Screening in the Clinical Dementia Rating (CDR) sum of boxes score|Change from Baseline in the Everyday Cognition (ECog) score|Change from Screening in Montreal Cognitive Assessment (MoCA) score|Change from Baseline to Week 52 in Spanish English Neuropsychological Assessment Scales (SENAS) memory score|Change from Baseline to Week 52 in Spanish English Neuropsychological Assessment Scales (SENAS) executive composite score|Change from Baseline in Bushcke Cued Selective Reminding Task (CSRT) score|Change from Baseline in Trails B score|Change from Baseline in Verbal fluency (semantic) score|Change from Baseline in Verbal fluency (letter) score|Change from Baseline to Week 52 in Brain MRI measures of total grey matter.|Change from Baseline to Week 52 in Brain MRI measures of total brain volume.|Change from Baseline to Week 52 in Brain MRI measures of white matter hyperintensities.|Change from Baseline to Week 52 in total grey matter florbetaben binding on amyloid Positron Emission Tomography (PET)|Change from Baseline in Cognitive Event Related Potential (ERP) measures of P600 word repetition.|Change from Baseline in Cognitive Event Related Potential (ERP) measures of alpha suppression effect.|Change from Baseline in Cognitive Event Related Potential (ERP) measures of anti-coupling between early theta and late alpha/beta activity.	University of California, Davis	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	55	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	945869	March 18, 2022	December 2024	June 2025	March 18, 2021		March 25, 2022	University of California, Davis Alzheimer's Disease Center, Sacramento, California, United States|UC Davis Alzheimer's Disease Center East Bay, Walnut Creek, California, United States		https://ClinicalTrials.gov/show/NCT04804241
548	NCT04376671	Quantitative EEG Markers in Mild Cognitive Impairment in Epilepsy		Completed	No Results Available	Epilepsy	Device: Electroencephalography	Mini-mental state examination (MMSE)|Montreal cognitive assessment (MoCA)	Mansoura University Hospital	All	Child, Adult, Older Adult		90	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	Mansoura University 15	March 1, 2019	February 1, 2020	March 1, 2020	May 6, 2020		May 6, 2020	Mansoura University Hospital, Mansoura, Egypt		https://ClinicalTrials.gov/show/NCT04376671
549	NCT03980392	South Korean Study to Prevent Cognitive Impairment and Protect Brain Health Through Lifestyle Intervention	SUPERBRAIN	Completed	No Results Available	Mild Cognitive Impairment|Aged	Other: Multidomain intervention program	retention rate (percent) of the participants|compliance (percent)|Change of cognition|Change of global cognition|Change of function|Change of depression|Change of subjective memory complaints|Change of memory complaints|Change of prospective memory|Change of Quality of life (QOL)|Change of activities of daily livings (ADL)|Change of nutritional status|Change of nutrition|Change of balance|Change of physical activity|Change of motivation|Adverse event (number of participants)	Inha University Hospital|Korea Health Industry Development Institute	All	60 Years to 79 Years   (Adult, Older Adult)	Not Applicable	152	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	HI18C0479	May 29, 2019	February 14, 2020	February 25, 2020	June 10, 2019		March 4, 2021	Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha Univeristy Hospital, Incheon, Korea, Republic of|Dong-A University Hospital, Pusan, Korea, Republic of|Bobath Memorial Hospital, Seongnam, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03980392
550	NCT04505735	Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment		Enrolling by invitation	No Results Available	Alzheimer Disease|Healthy Aging	Drug: 11C-PiB	Amyloid burden	University of Colorado, Denver	All	50 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	16-2064	November 22, 2016	November 2024	November 2024	August 10, 2020		January 13, 2022	University of Colorado, Denver, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT04505735
551	NCT02813070	Comparison of PET Amyloid Imaging in Japanese and Western Subjects		Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease|Healthy	Drug: [18F] Flutemetamol	Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese Readers|Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Japanese Readers	GE Healthcare	All	25 Years and older   (Adult, Older Adult)	Phase 2	70	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	GE067-017	October 2012	May 2013	May 2013	June 24, 2016	June 5, 2017	June 5, 2017			https://ClinicalTrials.gov/show/NCT02813070
552	NCT03644043	Evidence Amyloid Scan EEG Study	EASES	Unknown status	No Results Available	Alzheimer Disease|Dementia Frontal|Mild Cognitive Impairment	Device: EEG scan	Patient meeting Appropriate Use Criteria (AUC) with EEG brain scan - P300 and P50 will be measured for correlation between P300 and P50 with amyloid deposition.	Metabolic Therapy Inc.|Institute of Asian American Adult Development	All	60 Years and older   (Adult, Older Adult)		2000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	1R02TCR0072518	July 20, 2018	November 15, 2020	November 30, 2020	August 23, 2018		August 23, 2018	Translational Cognitive Research, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03644043
553	NCT01497652	A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy	RECOGNIZE	Completed	No Results Available	Parkinson's Disease	Drug: Rasagiline/Placebo|Drug: Rasagiline	Montreal Cognitive Assessment	Georgetown University|Teva Neuroscience, Inc.	All	40 Years and older   (Adult, Older Adult)	Phase 4	34	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IIT-TN-067	January 2012	March 2015	March 2015	December 22, 2011		December 16, 2015	Georgetown University Hospital, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT01497652
554	NCT04602624	A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)		Completed	No Results Available	Alzheimer Disease|Cognitive Dysfunction|Mild Dementia	Drug: SAGE-718	Number of Participants With Treatment-Emergent Adverse Events (TEAE)|Percentage of Participants With Clinically Significant Changes in Vital Signs Measurements|Percentage of Participants With Clinically Significant Changes in Laboratory Assessments|Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements|Percentage of Participants With Change From Baseline Responses on the Columbia Suicide Severity Rating Scale (C-SSRS)	Sage Therapeutics	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	26	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	718-CNA-201	February 2, 2021	September 21, 2021	September 21, 2021	October 26, 2020		January 21, 2022	Sage Investigational Site, Phoenix, Arizona, United States|Sage Investigational Site, Redlands, California, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Saint Petersburg, Florida, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Decatur, Georgia, United States|Sage Investigational Site, Gaithersburg, Maryland, United States|Sage Investigational Site, Farmington Hills, Michigan, United States|Sage Investigational Site, Omaha, Nebraska, United States|Sage Investigational Site, North Canton, Ohio, United States		https://ClinicalTrials.gov/show/NCT04602624
555	NCT02322021	Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease		Terminated	Has Results	Alzheimer Disease|Dementia, Alzheimer Type	Drug: E2609|Drug: Placebo	Core Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Core Phase: Number of Participants With Serious Adverse Events (SAEs)|Core Phase: Number of Participants With Treatment Emergent Markedly Abnormal Laboratory Safety Test Values|Core Phase: Number of Participants With Markedly Abnormal Vital Sign Values|Core Phase: Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings|Extension Phase: Number of Participants With TEAEs and SAEs|Extension Phase: Number of Participants With Markedly Abnormal Vital Sign Values|Extension Phase: Number of Participants With Markedly Abnormal ECG Findings|Extension Phase: Number of Participants With Treatment Emergent Markedly Abnormal Laboratory Safety Test Values|Extension Phase: Number of Participants With Abnormal Magnetic Resonance Imaging (MRI) Findings|Core Phase: Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid (A) Beta(1-x) and Abeta(1-42) After 1 Month and 18 Months of Treatment|Core Phase: Mean Concentration of Elenbecestat in CSF|Core Phase: Mean Concentration of Elenbecestat in Plasma|Extension Phase: Change From Extension Phase Baseline in the Mini-Mental State Examination (MMSE) Scores|Extension Phase: Change From Extension Phase Baseline in the Functional Assessment Questionnaire (FAQ) Score|Extension Phase: Percent Change From Extension Phase Baseline in Plasma Amyloid (A) Beta(1-x) Measurements at Months 12 and 24|Extension Phase: Percent Change From Extension Phase Baseline in Total Hippocampal Volume at Month 24|Extension Phase: Percent Change From Extension Phase Baseline in Left and Right Hippocampal Volume at Month 24|Extension Phase: Percent Change From Extension Phase Baseline in Whole Brain Volume at Month 24|Extension Phase: Percent Change From Extension Phase Baseline in Total Ventricular Volume at Month 24	Eisai Inc.|Biogen	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	70	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	E2609-G000-202|2014-002723-94	November 26, 2014	December 20, 2019	December 20, 2019	December 22, 2014	March 5, 2021	March 5, 2021	Bellflower, California, United States|Costa Mesa, California, United States|Glendale, California, United States|Irvine, California, United States|Aventura, Florida, United States|Boca Raton, Florida, United States|Brooksville, Florida, United States|Lake Worth, Florida, United States|Orlando, Florida, United States|Port Charlotte, Florida, United States|Atlanta, Georgia, United States|Savannah, Georgia, United States|Wichita, Kansas, United States|Kalamazoo, Michigan, United States|Mount Arlington, New Jersey, United States|Scotch Plains, New Jersey, United States|Charlotte, North Carolina, United States|Dayton, Ohio, United States|Port Royal, South Carolina, United States|Dallas, Texas, United States|San Antonio, Texas, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02322021/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02322021/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02322021
556	NCT03383549	Cognitive and Physical Home-rehabilitation by Information and Communications Technology. Games for Older Adults Active Life (GOAL)	GOAL	Completed	No Results Available	Cognitive Dysfunction|Mild Cognitive Impairment|Vascular Cognitive Impairment	Other: Tele-rehabilitation	Comparison between the cognitive ability measured at the end of the treatment (time point 2 months) and at the screening time point|Maintenance or improvement of the physical activity|Copy and Recall of Rey's Figure|Verbal fluency task|Stroop Test|Serious Game test	Fondazione Don Carlo Gnocchi Onlus|Consorzio di Bioingeneria e Informatica Medica|University of Florence|Gutenberg Srl	All	65 Years to 80 Years   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	DongnocchiGOAL	January 1, 2018	October 30, 2018	June 30, 2019	December 26, 2017		January 29, 2020	Rehabilitation Centre IRCCS Don Carlo Gnocchi Foundation, Florence, Italy		https://ClinicalTrials.gov/show/NCT03383549
557	NCT04558164	Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment		Recruiting	No Results Available	Cognitive Dysfunction|Memory Disorders in Old Age	Device: Active Theta Burst Stimulation|Device: Sham Theta Burst Stimulation	Verbal recall performance change|Object recognition memory performance change|Associative memory performance change|Resting state fMRI functional connectivity|EEG activity	University of California, Los Angeles|National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	70	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	20-001417|R01AG068317	January 26, 2021	June 30, 2024	June 30, 2025	September 22, 2020		April 15, 2022	University of California Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04558164
558	NCT05504811	FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease		Not yet recruiting	No Results Available	Mild Cognitive Impairment (MCI) or Mild Dementia Due to Alzheimer's Disease	Device: FitMi AD|Other: Conventional exercise program	Change in Functional Reach Test|Change in Timed Up and Go test|Change in 30 second chair stand test|Visual Analog Pain Scale|Global Physical Activity Questionnaire|Geriatric Depression Scale|Pittsburgh Sleep Quality Index|Duration of exercise performed	Flint Rehabilitation Devices, LLC|Rancho Research Institute, Inc.	All	50 Years and older   (Adult, Older Adult)	Phase 1	30	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2R44AG063651-02	September 2022	May 2023	August 2023	August 17, 2022		August 17, 2022	Rancho Research Institute, Inc, Downey, California, United States		https://ClinicalTrials.gov/show/NCT05504811
559	NCT04804618	Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease		Not yet recruiting	No Results Available	Alzheimer Disease, Early Onset|Protein; Disease		Changes in the protein expression profile of urine and saliva|Change of the cognitive function every year|Changes in plasma protein expression profile every year|Variation characteristics of gut microbiome every year	Guangzhou University of Traditional Chinese Medicine|Guangzhou Cadre Health Management Center	All	55 Years and older   (Adult, Older Adult)		650	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	AD2020	April 1, 2021	April 30, 2026	April 30, 2026	March 18, 2021		March 18, 2021			https://ClinicalTrials.gov/show/NCT04804618
560	NCT00236574	A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment		Completed	No Results Available	Dementia|Alzheimer Disease	Drug: Galantamine hydrobromide	Memory and cognition (ADAS-cog/MCI and CDR-SB scores) at 12 months and Global functional skills and the overall severity of dementia (the CDR-SB and the overall CDR) at 24 months.|Brain atrophy assessed by MRI, Digit Symbol Coding, Alzheimer's Disease Cooperative Study-ADL scale(MCI version) at 24 months. Safety evaluations (adverse event reports, vital signs, laboratory tests, physical examination, electrocardiograms) throughout.	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	50 Years and older   (Adult, Older Adult)	Phase 3	974	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	CR003145	May 2001		November 2003	October 12, 2005		June 8, 2011			https://ClinicalTrials.gov/show/NCT00236574
561	NCT04571112	GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment	2T-DBS	Unknown status	No Results Available	Parkinson Disease|Memory Disorders	Device: NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)	Change in cognition after GPi/NBM DBS|Change in motor function (UPDRS)GPi/NBM DBS|To assess the occurrence of adverse events from GPi/NBM DBS and occurrence of adverse events.|To assess the impact on health-related quality-of-life and various non-motor symptoms of PD|To use neuroimaging biomarkers (MEG and FDG-PET) to examine localized effects of NBM stimulation	University of Toronto	All	Child, Adult, Older Adult	Not Applicable	6	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	17-5400-B	December 4, 2017	October 1, 2020	October 1, 2020	September 30, 2020		September 30, 2020	Toronto Western Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04571112
562	NCT05380284	Senior Driving Simulation Training for Subjective Cognitive Decline and Mild Cognitive Impairment	SDST	Not yet recruiting	No Results Available	MCI|Subjective Cognitive Decline|Healthy Aging	Other: Senior Driving Simulation Training|Other: Waiting list control	Mental set shifting, measured by Wisconsin Card Sorting Test|Change from Baseline Mental set shifting, measured by Wisconsin Card Sorting Test at 3 months|Change from Baseline Mental set shifting, measured by Wisconsin Card Sorting Test at 6 months|Change from Baseline Mental set shifting, measured by Wisconsin Card Sorting Test at 12 months|Working memory, measured by Digit span test|Change from Baseline Working memory, measured by Digit span test at 3 months|Change from Baseline Working memory, measured by Digit span test at 6 months|Change from Baseline Working memory, measured by Digit span test at 12 months|Inhibition, measured by the Stroop Color and Word Test|Change from Baseline Inhibition, measured by the Stroop Color and Word Test at 3 months|Change from Baseline Inhibition, measured by the Stroop Color and Word Test at 6 months|Change from Baseline Inhibition, measured by the Stroop Color and Word Test at 12 months|Cognitive function measured by Montreal Cognitive Assessment|Cognitive function measured by Cognitive Change Index(C-CCI)|Change from Baseline cognitive function by Montreal Cognitive Assessment at 3 months|Change from Baseline cognitive function by Montreal Cognitive Assessment at 6 months|Change from Baseline cognitive function by Montreal Cognitive Assessment at 12 months|Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 3 months|Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 6 months|Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 12 months|EEG|Change from Baseline EEG at 3 months|Change from Baseline EEG at 6 months|Change from Baseline EEG at 12 months|Visual awareness measured by CANTAB|Visual awareness measured by trail making test|Change from Baseline visual awareness by CANTAB at 3 months|Change from Baseline visual awareness by CANTAB at 6 months|Change from Baseline visual awareness by CANTAB at 12 months|Change from Baseline visual awareness by trail making test at 3 months|Change from Baseline visual awareness by trail making test at 6 months|Change from Baseline visual awareness by trail making test at 12 months|simulator sickness|Usability|Acceptance	Taipei Medical University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	N202002083	June 1, 2022	June 1, 2022	May 31, 2023	May 18, 2022		May 18, 2022			https://ClinicalTrials.gov/show/NCT05380284
563	NCT05173363	Influence of Square-stepping Exercise on Brain Activation, Cognitive Function and Physical Performance in Frail Elders With MCI		Not yet recruiting	No Results Available	Frailty|Mild Cognitive Impairment		Brain activity|SSE performance|Montreal Cognitive Assessment|Trail making test|Stroop color and word test|Digit span test|Timed up and go test|Berg balance scale|Five times sit to stand test	National Yang Ming University	All	65 Years to 90 Years   (Older Adult)		30	Other	Observational	Observational Model: Other|Time Perspective: Cross-Sectional	YM110152F	February 28, 2022	December 31, 2023	December 31, 2023	December 29, 2021		December 29, 2021	National Yang Ming Chiao Tung University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT05173363
564	NCT01870518	Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI	DBS	Terminated	No Results Available	Parkinson's Disease|Mild Cognitive Impairment|Dementia	Device: Bilateral GPi DBS|Device: Bilateral STN DBS	Neurocognitive Function|Functional motor improvements	St. Joseph's Hospital and Medical Center, Phoenix	All	21 Years and older   (Adult, Older Adult)	Not Applicable	13	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	13BN006	April 2013	February 2016	February 2016	June 6, 2013		February 10, 2016	Barrow Neurological Institute / St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States		https://ClinicalTrials.gov/show/NCT01870518
565	NCT04416841	Tai Chi Chuan as Rehabilitation Program for Mild Cognitive Impairment in Type 2 Diabetes Mellitus Patients		Unknown status	No Results Available	Diabetes Mellitus, Type 2|Cognitive Dysfunction	Behavioral: Tai Chi Chuan|Behavioral: Fitness Walking|Behavioral: Standard Diabetic Care Education	Change in Global cognition-Montreal Cognitive Assessment Between Baseline and 24 Weeks|Change in Memory function-Wechsler Memory Scale Between Baseline and 24 Weeks|Change in Global cognition-Montreal Cognitive Assessment from baseline to 12, 36 Weeks|Change in Memory function-Wechsler Memory Scale from baseline to 12, 36 Weeks|Change in Digital Symbol test from baseline to 12, 24, 36 weeks|Change in Trial Making Test part B from baseline to 12, 24, 36 weeks|Change in Stroop color word test from baseline to 12, 24, 36 weeks|Change in Boston naming test from baseline to 12, 24, 36 weeks|Change in Rey-Osterrieth complex graphics test from baseline to 12, 24, 36 weeks|Change in Multi-task balance test-Time up and go test; Time up and go test + cognitive task;Time up and go test + motor task;Time up and go test + cognitive task + motor task from baseline to 12, 24, 36 weeks|Change in Balance function-Functional reach test from baseline to 12, 24, 36 weeks|Change in Balance function-One leg stance test from baseline to 12, 24, 36 weeks|Change in Grip strength from baseline to 12, 24, 36 weeks|Change in Five times sit-to-stand test from baseline to 12, 24, 36 weeks|Change in Sensation function from baseline to 12, 24, 36 weeks|Change in Fall efficiency-Modified Falls Efficacy Scale from baseline to 12, 24, 36 weeks|Change in Quality of life-Medical Outcomes Study 36-item Short-Form Health Survey from baseline to 12, 24, 36 weeks	Jing Tao|Second Affiliated Hospital of Heilongjiang University of Chinese Medicine|Bao'an District People's Hospital of Shenzhen|Xiyuan Hospital of China Academy of Chinese Medical Sciences|Peking University|University of Electronic Science and Technology of China|Fujian University of Traditional Chinese Medicine	All	60 Years and older   (Adult, Older Adult)	Not Applicable	327	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	FujianUTCM	June 3, 2020	January 15, 2021	April 20, 2021	June 4, 2020		July 29, 2020	Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China		https://ClinicalTrials.gov/show/NCT04416841
566	NCT01436188	A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease		Completed	No Results Available	Healthy|Alzheimer Disease	Procedure: Standard CSR sampling procedure|Procedure: Alternate frequency CSR sampling procedure|Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen|Procedure: Alternative lower frequency CSR sampling procedure	Measurement of CSF proteins|The number of volunteers with adverse events	Janssen Research & Development, LLC	All	50 Years to 90 Years   (Adult, Older Adult)	Early Phase 1	5	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)	CR100658|NOCOMPOUNDEDI0001|2011-003525-94	September 2011		June 2013	September 19, 2011		March 18, 2014	Antwerp, Belgium|Groningen, Netherlands|Leiden, Netherlands		https://ClinicalTrials.gov/show/NCT01436188
567	NCT03601000	Efficacy Study of Yi-Zhi-An-Shen Granules For Older Adults With Amnestic Mild Cognitive Impairment		Completed	No Results Available	Cognitive Dysfunction	Drug: Yi-Zhi-An-Shen|Drug: Placebo	Change from Baseline in Alzheimer´s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score|Change from Baseline in the Mini Mental Status Examination (MMSE)|Change from Baseline in the Montreal Cognitive Assessment (MoCA)|Change from Baseline in the Clinical Dementia Rating Scale (CDR)|Change from Baseline in the Activity of Daily Living (ADL)|Change from Baseline in the Pittsburgh sleep quality index (PSQI)|Differences between patients with aMCI and individuals with normal cognition in gut microbiome.	Chengdu University of Traditional Chinese Medicine	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 1|Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	ChengduUTCM-WWB-201801	April 21, 2018	April 30, 2019	September 12, 2019	July 26, 2018		September 19, 2019	Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China|Welfare Institution of Emei Civil Administration, Leshan, Sichuan, China	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03601000/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03601000
568	NCT04476017	A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)		Completed	No Results Available	Parkinson Disease|Cognitive Dysfunction	Drug: SAGE-718	Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants With Clinically Significant Changes in Vital Sign Measurements|Percentage of Participants With Clinically Significant Changes in Laboratory Assessments|Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements|Percentage of Participants With Change in Baseline for Responses on the Columbia Suicide Severity Rating Scale (C-SSRS)	Sage Therapeutics	All	50 Years to 75 Years   (Adult, Older Adult)	Phase 2	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	718-CNP-201	September 11, 2020	March 25, 2022	March 25, 2022	July 17, 2020		April 25, 2022	Sage Investigational Site, Phoenix, Arizona, United States|Sage Investigational Site, Long Beach, California, United States|Sage Investigational Site, Boca Raton, Florida, United States|Sage Investigational Site, Port Charlotte, Florida, United States|Sage Investigational Site, Saint Petersburg, Florida, United States|Sage Investigational Site, West Palm Beach, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Chicago, Illinois, United States|Sage Investigational Site, Gaithersburg, Maryland, United States|Sage Investigational Site, Omaha, Nebraska, United States|Sage Investigational Site, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04476017
569	NCT04956549	Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)	RAATE-MCI	Recruiting	No Results Available	Dementia of Alzheimer Type	Behavioral: Physical activity program|Behavioral: Successful Aging	Change in executive function|Change in episodic memory|Change in cognitive status|Change in glucose|Change in time spent in physical activity|Change in cardiorespiratory fitness|Change in physical function-NIH Toolbox|Change in telomere length|Change in weight|Change in brain structure|Changes in brain function|Change in lipoproteins|APOE genotype|Change in physical activity|Change in systolic blood pressure|Change in diastolic blood pressure|Change in mood|Change in height|Change in physical function-SPPB	Pennington Biomedical Research Center|National Institute on Aging (NIA)	All	60 Years and older   (Adult, Older Adult)	Not Applicable	144	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	PBRC_2020_013|R01AG067765-01	June 1, 2021	May 2025	May 31, 2026	July 9, 2021		March 3, 2022	Pennington Biomedical Research, Baton Rouge, Louisiana, United States		https://ClinicalTrials.gov/show/NCT04956549
570	NCT05472727	Comparison of Physical Fitness, Walking Speed, Reaction Time In Older Adults With and Without Mild Cognitive Impairment		Not yet recruiting	No Results Available	Reaction Time|Physical Fitness	Other: reaction time test|Other: Physical fitness test	reaction time|physical fitness	Dokuz Eylul University	All	65 Years and older   (Older Adult)		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	6987-GOA	August 1, 2022	January 1, 2023	May 1, 2023	July 25, 2022		July 25, 2022			https://ClinicalTrials.gov/show/NCT05472727
571	NCT02214342	Virtual Reality Based Balance Training in People With Mild Cognitive Impairment		Completed	No Results Available	Distorted; Balance|Motor Deficit|Cognitive Deficit	Other: Balance Training	Postural Balance|Gait performance|Cognitive status|Fear of falling|User experience|Depressive signs	University of Arizona|Banner Health	All	Child, Adult, Older Adult	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1401199972	July 2014	September 2014	September 2014	August 12, 2014		December 16, 2014	Banner Sun Health Research Institute, Sun City, Arizona, United States		https://ClinicalTrials.gov/show/NCT02214342
572	NCT03946254	Effect of Strength Training on Executive Functions in Elderly People With Mild Cognitive Impairment	Executive-19	Unknown status	No Results Available	Strength Training|Executive Function	Other: Effect of strength training on executive functions in elderly people with mild cognitive impairment.	Baseline of Inhibitory control|Mean Change from Baseline in Inhibitory control|Inhibitory control in the follow-up phase|Baseline of general cognition|Mean Change from Baseline in General cognition|General cognition in the follow-up phase|Baseline of physical condition|Mean Change from Baseline in Physical condition|Physical condition in the follow-up phase|Baseline of physical condition variante|Mean Change from Baseline in Physical condition variante|Physical condition variante in the follow-up phase|Baseline of blood test|Mean Change from Baseline in Blood test|Baseline of strength|Mean Change from Baseline in Strength|Strength in the follow-up phase|Baseline of cognitive flexibility|Mean Change from Baseline in cognitive flexibility|cognitive flexibility in the follow-up phase|Baseline of cognitive flexibility variante|Mean Change from Baseline in cognitive flexibility variante|cognitive flexibility variante in the follow-up phase|Baseline of working memory|Mean Change from Baseline in working memory|Working memory in the follow-up phase	University of Seville	All	60 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	University of seville	September 1, 2019	March 15, 2020	June 15, 2020	May 10, 2019		May 10, 2019	Education Faculty, Seville, Spain		https://ClinicalTrials.gov/show/NCT03946254
573	NCT04891887	Diabetes Mellitus and microRNA as Risk Factors for Mild Cognitive Impairment: Impact of Life Style Modification		Completed	No Results Available	Diabetes Mellitus, Type 2	Behavioral: Health education program	HbA1c|Cognitive function|Depression|Health related quality of life|Malondialdehyde|Glutathione Reductase|Glutathione Peroxidase|Total serum cholesterol|LDL|HDL|Triglycerides|Fasting blood glucose|Healthy dietary intake|Physical activities|Social activity|Mental activity|Trail Making Test|Medication compliance|Hypoglycemic attacks|Body weight	National Research Centre, Egypt|Science and Technology Development Fund (STDF)	All	40 Years to 65 Years   (Adult, Older Adult)	Not Applicable	163	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	15026	February 2016	June 2019	June 2019	May 19, 2021		May 19, 2021	National Research Centre, Giza, Egypt		https://ClinicalTrials.gov/show/NCT04891887
574	NCT00000173	Memory Impairment Study (Mild Cognitive Impairment Study)		Completed	No Results Available	Alzheimer Disease	Drug: Donepezil|Drug: Vitamin E		National Institute on Aging (NIA)|Alzheimer's Disease Cooperative Study (ADCS)	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 3		NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	IA0011|3U01AG010483-08S2	March 1999	January 2004	January 2004	November 1, 1999		December 11, 2009	Barrow Neurological Group, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UC Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|East Bay Institute, Martinez, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|Affiliated Research Instiute, San Diego, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Baumel-Eisner Neuromedical Institute, Boca Raton, Boca Raton, Florida, United States|Baumel-Eisner Neuromedical Institute, Ft. Lauderdale, Ft. Lauderdale, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami Beach, Florida, United States|Baumel-Eisner Neuromedical Institute, MiamiBeach, Miami Beach, Florida, United States|University of Miami, Port Charlotte, Florida, United States|University of South Florida, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta VA Medical Center, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memory Disorders Institute, Lakehurst, New Jersey, United States|Princeton Biomedical Research, PA, Princeton, New Jersey, United States|ClinSearch, Inc., Summit, New Jersey, United States|Princeton Biomedical - Toms River, Toms River, New Jersey, United States|Alzheimer's Research Corp., West Long Branch, New Jersey, United States|Univ. of New Mexico, Albuquerque, New Mexico, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Stony Brook, Stony Brook, New York, United States|Burke Medical Research Institute, White Plains, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|MCP Hahnemann, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brown University, Pawtucket, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Southwestern Vermont Medical Center, Bennington, Vermont, United States|Clinical Neuroscience Research Unit, Burlington, Vermont, United States|University of Washington, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Fredericton Medical Clinic, Fredericton, New Brunswick, Canada|Geriatric Medicine Research Group, Halifax, Nova Scotia, Canada|St. Joseph's Health Center, London, Ontario, Canada|Elizabeth Bruyere Centre, Ottawa, Ontario, Canada|Sunnybrook Health Science Center, Toronto, Ontario, Canada|Jewish General Hospital Memory Clinic, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Verdun, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00000173
575	NCT03912571	Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment		Completed	No Results Available	Sleep Disorder	Diagnostic Test: Structural 3T MRI|Diagnostic Test: MRI Based Perfusion Imaging|Diagnostic Test: VR-CO2 MRI Scans	Decreased cerebral blood flow (CBF)|Measure of vasoreactivity to CO2 (VRCO2)|Increase in cortical AB plaque burden	NYU Langone Health	All	55 Years to 90 Years   (Adult, Older Adult)		28	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	12-00041	November 13, 2011	September 2019	September 2019	April 11, 2019		September 5, 2021	NYU Langone Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03912571
576	NCT05466422	A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)		Not yet recruiting	No Results Available	Alzheimer Disease	Biological: MK-2214|Drug: Placebo	Number of Participants Who Experience At Least One Adverse Event (AE)|Number of Participants Who Discontinue Study Treatment Due to an AE|Serum Area Under the Concentration-Time Curve of MK-2214 from Time 0 to 28 Hours (AUC0-28) After First and Third Dose|Serum Maximum Concentration (Cmax) of MK-2214 After First and Third Dose|Serum Time to Maximum Concentration (Tmax) of MK-2214 After First and Third Dose|Serum Apparent Terminal Half-Life (t1/2) of MK-2214 After First and Third Dose|Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85 (C85d)|Percentage change from baseline to Day 29 in free phospho-tau in CSF|Percentage change from baseline to Day 85 in free phospho-tau in CSF	Merck Sharp & Dohme LLC	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 1	48	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2214-002|MK-2214-002	September 16, 2022	August 30, 2024	August 30, 2024	July 20, 2022		September 6, 2022			https://ClinicalTrials.gov/show/NCT05466422
577	NCT01953601	Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)	APECS	Terminated	Has Results	Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease	Drug: Verubecestat 12 mg (Parts 1 and 2)|Drug: Verubecestat 40 mg (Parts 1 and 2)|Other: Placebo (Part 1)	Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104|Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130|Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia|Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment|Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104|Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104|Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104	Merck Sharp & Dohme LLC	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	1454	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	8931-019|2012-005542-38|142502|MK-8931-019	November 5, 2013	April 17, 2018	April 17, 2018	October 1, 2013	May 17, 2019	May 17, 2019		"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01953601/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01953601
578	NCT03811847	A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.		Completed	No Results Available	Alzheimer Dementia	Drug: Methylphenidate Extended Release Oral Capsule|Other: Placebo	Feasibility of a virtual multicrossover randomized control trial design as measured my completion rates and medication compliance.|Feasibility of a virtual multicrossover randomized control trial design determined by qualitative participant feedback.|Cognition as measured by the Repeatable Battery for the Assessment Neuropsychological Status-Update (RBANS)|Cognition as measured by daily, home-based brain games (Lumosity, Lumos Labs, Inc.)|Sleep and activity as measured by Fitbit Charge 3	Massachusetts General Hospital	All	55 Years to 95 Years   (Adult, Older Adult)	Phase 4	8	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	2018P003099	November 1, 2019	August 30, 2021	August 30, 2021	January 22, 2019		February 2, 2022	Massachusetts General Hospital, Clinical Translational Research Unit, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03811847
579	NCT05404802	Therapeutic Effectiveness of PARO Companion Robot for Elderly With Mild Cognitive Impairment/Dementia in Elderly Residential Setting: A Quasi-experimental Study		Recruiting	No Results Available	Technology	Device: Experimental group intervention|Device: Control group intervention	10 week change in neuropsychiatric symptoms after participating in 10-week PARO training program|10 week change in loneliness after participating in 10-week PARO training program|Change in feelings of stress and anxiety as indicated by pulse rate after participating in PARO training session|Change in feelings of stress and anxiety as indicated by oxygen saturation after participating in PARO training session|Qualitative Measure: Observed emotions|Qualitative Measure: Observed engagement|Qualitative Measure: Observed engagement (compliance)|14 week change in neuropsychiatric symptoms after participating in 10-week PARO training program|14 week change in loneliness after participating in 10-week PARO training program|Change in quality of life after participating in 10-week PARO training program|Change in sleep quality after participating in 10-week PARO training program|Change in cognitive functions after participating in 10-week PARO training program|Qualitative Measure: Perceived feelings, satisfaction and acceptance on companion robot by the participants|Qualitative Measure: Perceived feelings, satisfaction and acceptance on companion robot by the PARO facilitators	The University of Hong Kong|Haven of Hope Hospital|The Social Innovation and Entrepreneurship Development Fund, Hong Kong	All	Child, Adult, Older Adult	Not Applicable	57	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	HKU_robot_protocol_v3	June 20, 2022	October 2022	October 2022	June 3, 2022		June 27, 2022	Haven of Hope Hang Hau Care and Attention Home for Severely Disabled, Hong Kong, Hong Kong|Haven of Hope Woo Ping Care & Attention Home, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT05404802
580	NCT03274817	A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol		Terminated	No Results Available	Alzheimer Disease	Drug: Escitalopram Pill|Drug: Venlafaxine Pill|Drug: Placebo Oral Tablet	Z-score for the hippocampal region of interest in the theta band|Multivariate Z score for overall theta abnormality in the frontal and parieto-temporal regions;|Probability of deterioration from logistic regression predictive of future decline;|Z-score coherence (synchrony) between right central and parietal regions across all bands;|Mean frequency across the total EEG brain spectrum.|Metabolic reduction in the hippocampal formation (a region including the hippocampal subiculum and the entorhinal cortex) assessed bilaterally.|Brief Cognitive Rating Scale Axes I to V total scores|The Mini-Mental State Examination (MMSE) total scores|MAC-Q total score	NYU Langone Health	All	60 Years to 80 Years   (Adult, Older Adult)	Phase 1	5	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention	09-0228	June 18, 2009	September 25, 2019	September 25, 2019	September 7, 2017		June 2, 2020	New York University School of Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03274817
581	NCT02874300	Promoting Activity, Independence and Stability in Early Dementia	PrAISED	Completed	No Results Available	Dementia MCI (Mild Cognitive Impairment)	Other: High intensity supervision arm|Other: Moderate intensity supervision arm	Disability Assessment in Dementia (Gelinas and Gauthier, 1994)|Falls (defined as 'unintentionally coming to rest on the ground or at a lower level, however caused')	Nottingham University Hospitals NHS Trust|National Institute for Health Research, United Kingdom	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	16HC001	September 2016	March 31, 2018	March 26, 2019	August 22, 2016		May 22, 2019			https://ClinicalTrials.gov/show/NCT02874300
582	NCT03819699	Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD		Terminated	No Results Available	Alzheimer Disease	Drug: Lu AF20513|Biological: booster vaccine	AUC|Cmax|Titre response|Amyloid load	H. Lundbeck A/S	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 1	3	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18086A	December 12, 2018	June 27, 2019	June 27, 2019	January 28, 2019		February 21, 2020	University of Eastern Finland, Brain Research Unit (FI002), Kuopio, Finland|Clinical Research Services Turku Oy (FI001), Turku, Finland|Karolinska University Hospital, Huddinge (SE001), Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT03819699
583	NCT03019536	A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease		Completed	No Results Available	Alzheimer Disease	Drug: LY3303560 - IV|Drug: Placebo - IV|Drug: Florbetapir F 18|Drug: Flortaucipir F18	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Serum Concentration (Cmax) of LY3303560|Pharmacokinetics: Area Under the Serum Concentration Time Curve During the Dosing Interval (AUC) of LY3303560	Eli Lilly and Company	All	50 Years and older   (Adult, Older Adult)	Phase 1	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	16452|I8G-MC-LMDD|2016-002102-39	January 31, 2017	June 5, 2019	June 5, 2019	January 12, 2017		July 5, 2019	Bioclinica, Melbourne, Florida, United States|Bioclinica, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Bioclinica, The Villages, Florida, United States|Princeton Medical Institute, Princeton, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bunkyo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kurume, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bath, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom		https://ClinicalTrials.gov/show/NCT03019536
584	NCT05079464	Exercise as a Primer for Brain Stimulation in Vascular Cognitive Impairment No Dementia (VCIND)	EXPRESS-V	Recruiting	No Results Available	Vascular Cognitive Impairment|Mild Cognitive Impairment	Other: tDCS|Other: Exercise|Other: Sham stimulation|Other: Treatment as usual	Montreal Cognitive Assessment - Global Cognition|Cognitive domains|Behavioural measures	Sunnybrook Health Sciences Centre	All	50 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	3348	November 22, 2021	September 2023	September 2024	October 15, 2021		February 28, 2022	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05079464
585	NCT03784183	Neuropsychological and Neurophysiological Effects of Cognitive Stimulation in Patients With Alzheimer's Disease and Mild Cognitive Impairment		Unknown status	No Results Available	Alzheimer Disease	Other: Cognitive Stimulation (CS)	Change in global cognition as assessed by Mini Mental State Examination|Change in dementia severity as assessed by Clinical Dementia Rating Scale|Change in frontal functions as assessed by Frontal Assessment Battery|Change in verbal memory as assessed by Rey Auditory Verbal Learning Test|Change in attention as assessed by Visual Search Test|Change in visuospatial functions as assessed by Clock Drawing Test|Change in naming as assessed by Boston Naming Test|Change in synaptic plasticity as assessed by Paired Associative Stimulation|Change in blinking as assessed by Blink Rate Evaluation	University of Roma La Sapienza	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	126	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	BSP-2018	September 27, 2018	October 1, 2020	October 1, 2020	December 21, 2018		December 21, 2018	Department of Human Neuroscience, Sapienza University of Rome, Rome, Italy		https://ClinicalTrials.gov/show/NCT03784183
586	NCT04182529	Photo Neuro-Modulation Therapy to Adults		Unknown status	No Results Available	Photo Neuro-Modulation Therapy, Mild Cognitive Impairment	Device: Photoneuromodulation therapy|Other: Sham	N-Back Test (cognitive test battery)|Category Fluency Test|The Hong Kong List Learning Test|The Chinese Version of the Mattis Dementia Rating Scale|NIRS Recording|EEG Recordings	Chinese University of Hong Kong	All	40 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017.354	October 31, 2017	June 2020	July 2020	December 2, 2019		December 2, 2019	Neuropsychology Laboratory, Department of Psychology, The Chinese University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04182529
587	NCT02667496	Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease		Withdrawn	No Results Available	Dementia Alzheimer's Type	Drug: Sargramostim GZ402664|Drug: Placebo|Drug: Florbetapir F18	Change from baseline in standardized uptake value ratio as measured by PET using florbetapir F18 (Amyvid)|Number of patients experiencing treatment-emergent adverse events (TEAEs)|Change from baseline in CSF analysis|MRI to assess for emergence of amyloid related imaging abnormalities (ARIA)|Measurement of antidrug antibody levels	Sanofi|National Institute on Aging (NIA)	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 2	0	Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ACT14019|U1111-1163-0793|1UF1AG046143	November 2016	March 31, 2017	March 31, 2017	January 29, 2016		April 7, 2017	Investigational Site Number 840001, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02667496
588	NCT01238458	Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers	[18F]AV-45	Unknown status	No Results Available	Alzheimer's Disease	Drug: [18F]AV-45 PET amyloid binding imaging	To expand the safety database of [18F]AV-45 PET imaging	Chang Gung Memorial Hospital	All	50 Years and older   (Adult, Older Adult)	Phase 2	150	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	98-1852A	November 2009	November 2011	June 2013	November 10, 2010		September 28, 2012			https://ClinicalTrials.gov/show/NCT01238458
589	NCT01561430	Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease		Terminated	Has Results	Alzheimer's Disease	Drug: LY2886721|Drug: Placebo	Change From Baseline to 12 Weeks in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations|Change From Baseline to 26 Weeks in CSF Aβ1-40 and Aβ1-42 Concentrations|Change From Baseline in Plasma Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations|Change From Baseline to 26 Weeks in Neuropsychological Test Battery (NTB)|Change From Baseline to 26 Weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Change From Baseline to 26 Weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Change From Baseline to 26 Weeks in Mini Mental State Examination (MMSE)|Change From Baseline in Cerebrospinal Fluid (CSF) Tau and Phosphorylated Tau (Ptau)-181 Concentrations	Eli Lilly and Company	All	55 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	70	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	13735|I4O-MC-BACC|2011-005217-37	March 2012	August 2013	August 2013	March 23, 2012	May 18, 2018	May 18, 2018	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Long Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delray Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quincy, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monroe, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sant Cugal Del Valles, Spain		https://ClinicalTrials.gov/show/NCT01561430
590	NCT04463797	Effects of Square-stepping Exercise on Frailty and Cognitive Function in Elderly With Frailty and MCI		Recruiting	No Results Available	Frailty|Mild Cognitive Impairment	Other: Square-stepping exercise|Other: Stretching and strengthening	Fried frailty criteria|The Montreal Cognitive Assessment|Frailty reverse rate|MCI reverse rate|Digit Span Test|Trail Making Test|Timed Up and Go Test|6-minute walk test|Lower extremity strength|Brain activation	National Yang Ming University	All	65 Years to 90 Years   (Older Adult)	Not Applicable	28	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	YM109044F	August 15, 2020	May 31, 2022	July 31, 2022	July 9, 2020		November 22, 2021	National Yang-Ming University, Taipei, Beitou District, Taiwan		https://ClinicalTrials.gov/show/NCT04463797
591	NCT02423200	Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD		Completed	Has Results	Alzheimer's Disease	Drug: VX-745	Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines|Severe or Serious Adverse Events|Maximal CSF VX-745 Concentration|Episodic Memory Function	EIP Pharma Inc	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 2	16	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EIP14-745-303	April 2015	September 2016	November 2016	April 22, 2015	April 3, 2018	April 3, 2018	Parexel International, Glendale, California, United States		https://ClinicalTrials.gov/show/NCT02423200
592	NCT03639987	A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities	EVOLVE	Terminated	Has Results	Cognitive Dysfunction|Alzheimer's Disease	Drug: Aducanumab|Drug: Placebo	Number of Participants With Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA)|Number of Participants With ARIA by Severity as Obtained on Magnetic Resonance Imaging (MRI)|Time to Onset of ARIA as Obtained on MRI|Time to Resolution of ARIA as Obtained on MRI|Number of Participants With Symptomatic ARIA by Severity|Time to Onset of Symptomatic ARIA|Time to Resolution of Symptomatic ARIA|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline in the Montreal Cognitive Assessment (MoCA) at Week 54|Number of Participants With Aducanumab Concentration in Serum|Number of Participants With Antiaducanumab Antibodies in Serum	Biogen	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	52	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	221AD205|2018-002102-31	December 20, 2018	July 30, 2019	July 30, 2019	August 21, 2018	September 16, 2021	September 16, 2021	Banner Alzheimer's Institute, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Pacific Research Network, Inc, San Diego, California, United States|California Neuroscience Research Medical Group Inc., Sherman Oaks, California, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Bioclinica Orlando, Orlando, Florida, United States|Bioclinica Orlando, The Villages, Florida, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|Josephson, Wallack, Munshower Neurology, P.C., Indianapolis, Indiana, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Senior Adult Specialty Research, Austin, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03639987/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03639987/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03639987
593	NCT01138111	Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients		Completed	Has Results	Alzheimer Disease|Amyloid Beta-Protein	Drug: Florbetaben (BAY94-9172)	Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake|Number of Normal and Abnormal Scans in Patients With MCI Progressing to AD and Those Who do Not Progress Based on a Threshold of Neocortical SUVR=1.4|Number and Proportion of Normal and Abnormal Scans Based on Brain ß-amyloid Plaque Load (BAPL) in Subjects With MCI Converting to AD and Those Who do Not Progress|Sensitivity/Specificity/Negative Predictive Value (NPV)/Positive Predictive Value (PPV) at Baseline, 12, and 24 Months in the Detection of Significant Brain ß-amyloid Plaque Load in Patients With MCI Progressing to AD Compared to Those Who do Not Progress	Life Molecular Imaging SA	All	60 Years and older   (Adult, Older Adult)	Phase 1	45	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	312043	June 2008	December 2011	December 2011	June 7, 2010	June 25, 2014	June 25, 2014	Heidelberg, Victoria, Australia		https://ClinicalTrials.gov/show/NCT01138111
594	NCT00293176	The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)		Completed	No Results Available	Memory Loss	Drug: Donepezil Hydrochloride|Drug: Placebo	Assessment of cognitive and global function in subjects with MCI.|Behavioral, global and cognitive outcomes; Neuroimaging	Eisai Inc.|Pfizer	All	45 Years to 90 Years   (Adult, Older Adult)	Phase 4	821	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	E2020-A001-412	December 2003	March 2007	March 2007	February 17, 2006		April 1, 2011	Albaster, Alabama, United States|Mesa, Arizona, United States|Peoria, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Fresno, California, United States|Garden Grove, California, United States|Irvine, California, United States|San Francisco, California, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Boynton Beach, Florida, United States|Fort Meyers, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Melbourne, Florida, United States|North Miami, Florida, United States|Ocala, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Venice, Florida, United States|West Palm Beach, Florida, United States|Snellville, Georgia, United States|Chicago, Illinois, United States|Elkhart, Indiana, United States|New Orleans, Louisiana, United States|Farmington Hills, Michigan, United States|Kalamazoo, Michigan, United States|Las Vegas, Nevada, United States|Kenilworth, New Jersey, United States|Long Branch, New Jersey, United States|Albany, New York, United States|Lexington, New York, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|No. Charleston, North Carolina, United States|Centerville, Ohio, United States|Cleveland, Ohio, United States|Toledo, Ohio, United States|Medford, Oregon, United States|Portland, Oregon, United States|Greensberg, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Madison, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00293176
595	NCT02769065	Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants		Terminated	Has Results	Alzheimer Disease|Healthy Volunteers	Drug: TAK-071|Drug: Donepezil|Drug: TAK-071 Placebo|Drug: Donepezil Placebo	Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) Parameters at Least Once Post-dose|Tmax: Time of First Occurrence of Cmax for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants|Tmax: Time of First Occurrence of Cmax for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 21]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 1]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 8]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Non-Japanese Participants [Day 28]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 1]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 8]|Tmax: Time of First Occurrence of Cmax for TAK-071 MRD Japanese Participants [Day 28]|Tmax: Time of First Occurrence of Cmax for TAK-071 Relative Bioavailability and Food Effect|Tmax: Time of First Occurrence of Cmax for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|Cmax: Maximum Observed Plasma Concentration for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants|Cmax: Maximum Observed Plasma Concentration for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 21]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 1]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 8]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Non-Japanese Participants [Day 28]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 1]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 8]|Cmax: Maximum Observed Plasma Concentration for TAK-071 MRD Japanese Participants [Day 28]|Cmax: Maximum Observed Plasma Concentration for TAK-071 Relative Bioavailability and Food Effect|Cmax: Maximum Observed Plasma Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Single-Rising Dose (SRD) Non-Japanese Participants|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 Multiple-Rising Dose (MRD) Non-Japanese Participants [Day 1]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 21]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 1]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 8]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Non-Japanese Participants [Day 28]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 1]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 8]|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 MRD Japanese Participants [Day 28]|AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071 Relative Bioavailability and Food Effect|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants|AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese Participants|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Japanese Participants|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 MRD Non-Japanese|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 Relative Bioavailability and Food Effect|AUClast: Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants|Terminal Disposition Phase Half-life (t1/2z) for TAK-071 Relative Bioavailability and Food Effect|Terminal Disposition Phase Half-life (t1/2z) for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants|CL/F: Apparent Clearance After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect|CL/F: Apparent Clearance After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071+Donepezil|Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants|Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 Relative Bioavailability and Food Effect|Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-071 SRD Non-Japanese Participants TAK-071 + Donepezil|Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Non-Japanese Participants|Accumulation Ratio Based on AUCτ (Rac[AUC]) for TAK-071 MRD Japanese Participants|Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Non-Japanese Participants|Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 MRD Japanese Participants|AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants|AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants|AEt: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants|Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 SRD Non-Japanese Participants|Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Non-Japanese Participants|Fet: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t for TAK-071 MRD Japanese Participants|CLR: Renal Clearance for TAK-071 SRD Non-Japanese Participants|CLR: Renal Clearance for TAK-071 MRD Non-Japanese Participants|CLR: Renal Clearance for TAK-071 MRD Japanese Participants|CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071|CSF AUC(0-12): Area Under the CSF Concentration-time Curve From Time 0 to 12 Hours for TAK-071|CSF AUC(0-36): Area Under the CSF Concentration-time Curve From Time 0 to 36 Hours for TAK-071|Ratio of CSF AUC(0-12) to the Plasma AUC(0-12) for TAK-071|Ratio of CSF AUC(0-36) to the Plasma AUC(0-36) for TAK-071|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Donepezil MRD Non-Japanese Participants|Cmax: Maximum Observed Plasma Concentration for Donepezil MRD Non-Japanese Participants|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for Donepezil|Ratio of Geometric Mean of Cmax for Donepezil After 21 Daily Doses of TAK-071|Ratio of Geometric Mean of AUC(0-24) for Donepezil After 21 Daily Doses of TAK-071	Takeda	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 1	179	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	TAK-071-1001|U1111-1176-7435	May 5, 2016	June 8, 2017	June 8, 2017	May 11, 2016	June 10, 2019	June 10, 2019	Glendale, California, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02769065/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02769065/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02769065
596	NCT04572477	The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome		Recruiting	No Results Available	Post-stroke Dementia, Vascular Mild Cognitive Impairment	Drug: [18F]THK-5351|Drug: [18F]AV-45	Imaging positive and negative conditions|Chi-square test will be performed to analyze dementia conversion rate.	Chang Gung Memorial Hospital	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	430	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	201601675A0	June 1, 2017	May 31, 2022	May 31, 2023	October 1, 2020		October 5, 2021	Department of Neurology, Chang-Gung memorial Hospital, Taoyuan, Guishan, Taiwan		https://ClinicalTrials.gov/show/NCT04572477
597	NCT01723670	Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment	CT05	Withdrawn	No Results Available	Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: Placebo	To determine the effects on change from baseline on brain atrophy|To determine the presence of other biomarkers of neuronal degeneration	CERESPIR	All	45 Years to 64 Years   (Adult)	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CCD-1109-PR-0072	December 2012	March 2016	March 2016	November 8, 2012		February 10, 2015			https://ClinicalTrials.gov/show/NCT01723670
598	NCT01600859	Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)		Completed	No Results Available	Alzheimer's Disease	Drug: E2609|Drug: Placebo for E2609	Percent change from baseline in cerebrospinal fluid amyloid-beta levels|Incidence of adverse events	Eisai Inc.	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 1	65	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	E2609-A001-101	July 2012	September 2013	October 2013	May 17, 2012		December 30, 2016	Glendale, California, United States|Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01600859
599	NCT02309723	Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.		Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Device: Beta amyloid imaging	Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss|Likelihood of Recommending a Medication Indicated for Alzheimer's Disease|Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures	Tufts Medical Center|GE Healthcare	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	315	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CEVR-2013-001	September 2013	September 2013	November 2013	December 5, 2014	April 10, 2017	April 10, 2017	Tufts Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02309723
600	NCT00567060	Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)		Completed	No Results Available	Memory Disorders	Drug: Piracetam	Cognitive Battery Composite Score over a 52-week period|safety of piracetam for 12 months	UCB Pharma	All	50 Years to 89 Years   (Adult, Older Adult)	Not Applicable	676	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	N01001	May 2000	January 2004	January 2004	December 4, 2007		December 16, 2013			https://ClinicalTrials.gov/show/NCT00567060
601	NCT04692974	Cognitive Frailty in Older Adults: The Role of Technology in Physical Activity Enhancement		Recruiting	No Results Available	Mild Cognitive Impairment|Frailty	Device: Mobile phone application and smart watch	Mean Change from Baseline in frailty screening scores on the FRAIL questionnaire at 3 and 6 months|Mean Change from Baseline in physical frailty as measured by physical performance tests at 3 months and 6 months|Mean Change from Baseline in cognitive scores as measured on the Neurocognitive Assessment test battery at 3 and 6 months|Mean Change from Baseline in Steps Taken measured by the smart watch at 3 months and 6 months|Mean Change from Baseline in moderate exercise measured by the smart watch at 3 months and 6 months|Mean Change from Baseline in levels of physical activity measured by the "International Physical Activity Questionnaire" at 3 months and 6 months	National University, Singapore|Sengkang General Hospital	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	H-20-038	December 15, 2020	August 2021	August 2021	January 5, 2021		April 19, 2021	Hannah Senior Activity Center, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04692974
602	NCT04739423	A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders	CLIN-011	Active, not recruiting	No Results Available	Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia	Drug: CST-103, CST-107, matching placebo	Change from Baseline in Negative Emotional Bias in the Facial Expression Recognition Task (FERT)|Change from Baseline in Cognitive Fluctuations|Change from Baseline in CANTAB Cognitive Assessments|Digital wearable device (BioStamp)	CuraSen Therapeutics, Inc.	All	40 Years to 80 Years   (Adult, Older Adult)	Phase 2	41	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CST103/CST107-CLIN-011	June 28, 2021	July 2022	August 2022	February 4, 2021		June 2, 2022	The University of Sydney, Sydney, New South Wales, Australia|Wesley Medical Research Ltd, Brisbane, Queensland, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|NZBRI, Christchurch, New Zealand|MAC, Tankersley, Barnsley, United Kingdom|MAC, Blackpool, Lancashire, United Kingdom|MAC, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT04739423
603	NCT02621424	Repetitive Transcranial Magnetic Stimulation for Dementia	rTMS for demen	Active, not recruiting	Has Results	Dementia|Mild Cognitive Impairment	Device: RTMS|Device: sham	Changes From Baseline CVLT Scores After Treatment and 4 Month Later|Changes in Boston Naming After Treatment|Changes in Plasma BDNF Levels After Treatment|Changes in Animal Fluency After Treatment and 4 Months Later|Changes in Trail Making B Test Score After Treatment and 4 Months Later|Brief Visual Memory Test (BVMT)|Montreal Cognitive Assessment (MoCA)	VA Office of Research and Development	All	55 Years to 99 Years   (Adult, Older Adult)	Not Applicable	32	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	E1889-P|RX14-009	January 1, 2016	February 28, 2019	October 31, 2022	December 3, 2015	May 27, 2020	December 15, 2021	VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02621424/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02621424/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02621424
604	NCT01479855	Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type	ALZ-vit	Unknown status	No Results Available	Mild Cognitive Impairment|Alzheimers Disease		Vitamin A|Vitamin B1|Vitamin B6|Vitamin B12|Vitamin C|Vitamin E|Cognitive function	Oslo University Hospital|South Eastern Area Health Service	All	Child, Adult, Older Adult		180	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	2011/698 (REK)|Other Identifier	January 2012	December 2013	December 2013	November 28, 2011		November 27, 2013	OsloUH, Ullevål, Oslo, Norway		https://ClinicalTrials.gov/show/NCT01479855
605	NCT00240695	A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment		Completed	No Results Available	Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases	Drug: galantamine hydrobromide	Incidence of adverse events; Changes in laboratory tests, ECGs, and physical examinations|Change in CDR, ADAS-Cog/MCI version, CDR-SB and SF-36 scores from baseline to end of treatment; resource use; time to conversion to dementia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	50 Years and older   (Adult, Older Adult)	Phase 3	724	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CR005947	May 2003		May 2004	October 18, 2005		May 18, 2011			https://ClinicalTrials.gov/show/NCT00240695
606	NCT01672827	Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images		Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: [18F]Flutemetamol	Summary of Sensitivity of the Blinded Visual PET Image Interpretations Without Anatomic Images.|Summary of Specificity of Blinded Visual PET Image Interpretations Without Anatomic Images.|Inter-Reader Agreement of PET Images Without Anatomic Images	GE Healthcare	All	18 Years and older   (Adult, Older Adult)	Phase 3	276	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	GE-067-021	July 2012	August 2012	August 2012	August 27, 2012	December 19, 2013	January 24, 2014			https://ClinicalTrials.gov/show/NCT01672827
607	NCT01636596	Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease		Withdrawn	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Insulin LISPRO	cerebral glucose metabolism|cognition|general clinical improvement|basal metabolism	Louisiana State University Health Sciences Center Shreveport|Acuity Center	All	50 Years to 95 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H12-166	September 2013	January 2015	January 2015	July 10, 2012		March 13, 2014	LSUHSC Shrevport Psychopharmacology Research Clinic, Shreveport, Louisiana, United States		https://ClinicalTrials.gov/show/NCT01636596
608	NCT01602393	Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase	CT04 POLEP	Completed	No Results Available	Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x	Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment	Chiesi Farmaceutici S.p.A.|Chiesi USA, Inc.	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2	51	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCD-1014-PR-0053 POLEP|2010-024270-19	May 2012	October 2013	October 2013	May 21, 2012		February 6, 2014	Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy		https://ClinicalTrials.gov/show/NCT01602393
609	NCT02942888	The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition	NAD	Completed	No Results Available	Mild Cognitive Impairment|NAD	Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Sugar Pill	Change in Cognitive Assessment - Montreal Cognitive Assessment (MoCA) - from baseline at 10 weeks|Change in cerebral blood flow from baseline at 10 weeks|Change in plasma NAD from baseline at 10 weeks|Change in Physical Performance - Short Physical Performance Battery (SPPB) - from baseline at 10 weeks|Change in Physical Performance - Instrumental Activities of Daily Living (IADLs) - from baseline at 10 weeks|Change in endothelial function from baseline at 10 weeks|Change in Cognitive Assessment - Geriatric Depression Scale (GDS) - from baseline at 10 weeks|Change in Cognitive Assessment - Geriatric Anxiety Scale (GAS) - from baseline at 10 weeks|Change in Cognitive Assessment - Clock Drawing Task Protocol (CLOX) - from baseline at 10 weeks|Change in Cognitive Assessment - Executive Interview (EXIT) - from baseline at 10 weeks|Change in Cognitive Assessment - Test of Auditory Processing Skills (TAPS) - from baseline at 10 weeks|Change in Physical Performance - Grip Strength - from baseline at 10 weeks	The University of Texas Health Science Center at San Antonio|University of Texas|South Texas Veterans Health Care System	All	65 Years and older   (Older Adult)	Not Applicable	46	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	HSC20160350H	November 30, 2017	August 31, 2019	August 16, 2021	October 24, 2016		September 2, 2021	South Texas Veterans Healthcare System (STVHCS), San Antonio, Texas, United States|University of Texas Health San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT02942888
610	NCT01595646	Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)	SL120	Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Saline|Drug: Insulin detemir|Drug: Insulin	Verbal Memory Composite|Cerebral Spinal Fluid (CSF) Biomarkers of AD|Cerebral Spinal Fluid (CSF) Biomarkers of AD TTau-P181/Abeta42 Ratio|Functional Ability|The Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer's Disease Cooperative Study (ADCS)] - MCI Revision	Wake Forest University Health Sciences|Alzheimer's Association	All	50 Years to 89 Years   (Adult, Older Adult)	Phase 2	37	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00023230|ZEN-10-173646US	November 2011	March 12, 2015	March 12, 2015	May 10, 2012	February 1, 2018	November 17, 2020	Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States|VA Puget Sound Health Care System - American Lake Division, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT01595646
611	NCT02778438	A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits	REINVENT	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease		Change in Mini Mental State Examination|Change in Clinical Dementia Rating Sum of Boxes|Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale|Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version)	Quintiles, Inc.|Biogen	All	50 Years to 85 Years   (Adult, Older Adult)		30	Industry	Observational	Observational Model: Case-Crossover|Time Perspective: Prospective	REI-001	February 2016	August 2016	August 2016	May 19, 2016		September 27, 2016	Clinical Research Advantage, Inc / Neurological Physicians of Arizona, Inc, Gilbert, Arizona, United States		https://ClinicalTrials.gov/show/NCT02778438
612	NCT03670615	Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia	EXPRESS	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Other: tDCS|Other: Exercise|Other: Exercise Education|Other: Sham tDCS	Change in global cognitive function: The Montreal Cognitive Assessment (MoCA) Total Scores|Changes in concentration of blood biomarkers of brain plasticity	Sunnybrook Health Sciences Centre	All	50 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	075-2018	November 28, 2018	November 2022	February 2023	September 13, 2018		February 28, 2022	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03670615
613	NCT01421056	Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)		Completed	No Results Available	Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x	Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment	Chiesi Farmaceutici S.p.A.|Chiesi USA, Inc.	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2	74	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCD-1014-PR-0053 OLEP|2010-024270-19	July 2011	November 2012	November 2012	August 22, 2011		February 6, 2014	Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinica Santa Maria, Div Neurologia, Castellanza, Italy|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy		https://ClinicalTrials.gov/show/NCT01421056
614	NCT00934531	Donepezil and the Risk of Falls in Seniors With Cognitive Impairment		Completed	No Results Available	Falls|Gait|Balance|Mild Cognitive Impairment (MCI)	Drug: Donepezil	Improvements in gait performance (Combined outcome: increase in gait velocity-cm/second- and/or reduction in gait variability assessed as standard deviation (SD) and coefficient of variation (CoV).|Improvement in: 1. Balance confidence 2. Balance sway 3. Attention 4. Executive function 5. Reduction of number of Falls.	Lawson Health Research Institute	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	R-09-427|16086	September 2009	January 2019	January 2019	July 8, 2009		January 7, 2019	St. Joseph's Health Care London, Parkwood Hospital, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00934531
615	NCT04318639	The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder		Completed	No Results Available	Alcohol Use Disorder|Mild Cognitive Impairment	Combination Product: Donepazil	Clinical Global Index of AUD recovery|Global Composite T-Score of MCI related neurocognitive measures.	VA Connecticut Healthcare System	All	21 Years to 80 Years   (Adult, Older Adult)	Phase 2|Phase 3	15	U.S. Fed	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MB0020	August 17, 2018	December 31, 2019	December 31, 2019	March 24, 2020		March 24, 2020	VA Connecticut Healthcare System, West Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04318639
616	NCT01793493	Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia (Allena-Mente).	Allena-Mente	Completed	No Results Available	Mild Cognitive Impairment|Healthy Subjects With Family History for Dementia	Other: Cognitive stimulation|Other: Sanitary education	Long-term change from Baseline in Mini Mental State Examination (MMSE)|Change from Baseline in Mini Mental State Examination at 2-weeks after the intervention|Change from Baseline in Montreal Cognitive Assessment (MoCA) at 2-weeks after the intervention|Change from Baseline in Corsi test at 2-weeks after the intervention|Change from Baseline in Walking While Talking Dual Task at 2-weeks after the intervention	Fondazione Golgi Cenci|Alzheimer Federation Italy|Camillo Golgi Geriatric Institute|University of Pavia|Mario Negri Institute for Pharmacological Research	All	70 Years to 75 Years   (Older Adult)	Phase 2	121	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	02	March 2011	March 2015	June 2015	February 15, 2013		August 17, 2015	Golgi Cenci Foundation, Abbiategrasso, Milan, Italy		https://ClinicalTrials.gov/show/NCT01793493
617	NCT04938349	Dual Task Perturbation Training for OAwMCI		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Old Age; Debility	Behavioral: Dual task perturbation training	Change in Stability gain or loss|Change in Limb support gain or loss|Change in laboratory-induced falls|Change in postural stability during reactive balance control (single and dual-task) on treadmill slips|Change in postural stability during reactive balance control (single and dual-task) on overground slips|Change in walking step length|Change in walking cadence|Change in walking stride length|Change of accuracy in letter number sequencing|Change in accuracy of Visual clock test|Change in dual-task cost|Change in visuomotor task|Fractional anisotropy|Gray matter volume|Functional connectivity Z score|Perceived task load|Balance evaluation Systems test|Berg Balance scale|Cognitive Timed up and Go test|Muscle Strength|Range of Motion|Fukuda step test|Head thrust test|Postural Sway|Change in physical activity level (Questionnaires)	University of Illinois at Chicago|National Institute on Aging (NIA)|Roybal Predoctoral pilot grant	All	55 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-0478|R01AG073152	June 9, 2021	June 9, 2022	October 30, 2022	June 24, 2021		September 27, 2021	University of Illinois at Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04938349
618	NCT03653234	TV-based Service to Support People Living With Mild Dementia or Mild Cognitive Impariment	TV-AssistDem	Completed	No Results Available	Mild Cognitive Impairment|Mild Dementia	Device: TV-based Assistive Integrated Service	Change from baseline quality of life in people with mild cognitive impairment or mild dementia at 6 and 12 months.|Change from baseline quality of life in informal caregivers at 6 and 12 months.|Change from baseline burden in informal caregivers at 6 and 12 months.|Change from baseline treatment adherence in people with mild cognitive impairment or mild dementia at 6 and 12 months.|Change from baseline treatment compliance in people with mild cognitive impairment or mild dementia at 6 and 12 months.|Change from baseline functional decline in people with mild cognitive impairment or mild dementia at 6 and 12 months.|Change from baseline healthcare costs at 12 months	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Îngrijiri la domiciliu, Romania|Consiglio Nazionale delle Ricerche, Italy|Institut multidisciplinaire de science de données, Italy|Asociación de Familiares de Personas con Alzheimer y otras Demencias de Málaga, Spain|Smart Health TV Solution, Spain|Istituto di Scienze e Tecnologie della Cognizione, Switzerland|MEDEA, Italy	All	60 Years and older   (Adult, Older Adult)	Not Applicable	404	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	TV-AssistDem (AAL-2016-024)	April 1, 2019	August 31, 2020	December 31, 2020	August 31, 2018		May 14, 2021	Îngrijiri La Domiciliu, Brașov, Romania|Instituto de Investigacion Biomedica de Malaga-IBIMA, Málaga, Spain		https://ClinicalTrials.gov/show/NCT03653234
619	NCT05151562	Music Therapy for Patients With Alzheimer's Disease		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Behavioral: Virtual Music Therapy	Change in autobiographical memory level as assessed by Autobiographical Memory Test (AMT)|Change in scores on neuropsychiatric symptom level as assessed by Neuropsychiatric Inventory Questionnaire (NPI-Q) (caregivers)|Change in cortical activation as assessed by Blood Oxygen Level Dependent (BOLD) on functional magnetic resonance imaging (fMRI)|Change in cognition as assessed by the Montreal Cognitive Assessment (MoCA)|Change in quality of life as assessed by the Quality of Life for Alzheimer's Disease (QoL-AD)|Change in nostalgia level as assessed by Southampton Nostalgia Scale (SNS)|Change in anxiety level as assessed by State-Trait Anxiety Inventory (STAI)|Change in depression level as assessed by Geriatric Depression Scale (GDS)|Change in score/statement on music therapy experiences as assessed by the structured interview reporting form	Johns Hopkins University	All	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00274248	July 18, 2022	April 2024	June 2024	December 9, 2021		July 25, 2022	Johns Hopkins School of Medicine, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT05151562
620	NCT05370118	Improving Physical Activity With Cognitive Impairment		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Caregiver Burnout	Behavioral: Telerehabilitation physical activity behavioral (TPAB) intervention	TPAB intervention Participant Retention|TPAB Intervention Attendance|TPAB Intervention Acceptability|TPAB Intervention Safety|Feasibility of the TPAB Intervention (Semi-Structured Interviews)|Daily step count change	Creighton University|National Institutes of Health (NIH)	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2002895	October 2022	June 2023	June 2023	May 11, 2022		September 7, 2022			https://ClinicalTrials.gov/show/NCT05370118
621	NCT02864303	Use of Saliva for Alzheimer's Disease Diagnosis	SalivALZ	Terminated	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Other: Saliva samples	Aβ40 and Aβ42|Neuropsychologic tests|ApoE polymorphism	University Hospital, Montpellier	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	88	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	8835	June 21, 2012	October 11, 2018	October 11, 2018	August 12, 2016		December 28, 2021	CHRU, Montpellier, France		https://ClinicalTrials.gov/show/NCT02864303
622	NCT04311736	Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults	Exergames	Unknown status	No Results Available	Mild Cognitive Impairment|Exercise Training	Behavioral: Exergame|Behavioral: Cycling|Behavioral: Stretching	Episodic Memory|Executive Function|Global Cognition|Aerobic Fitness	Moai Technologies LLC|University of Minnesota	All	65 Years and older   (Older Adult)	Not Applicable	96	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention	EXERGAMES2	October 1, 2019	October 1, 2021	October 1, 2021	March 17, 2020		March 17, 2020	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04311736
623	NCT02525198	The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial	CANN	Unknown status	No Results Available	Mild Cognitive Impairment|Subjective Memory Impairment	Dietary Supplement: fatty acid/flavonoid blend|Dietary Supplement: Placebo	Number of false positive responses during the picture recognition task of the CDR Computerized Cognitive Assessment System|Hippocampal volume|Gut microflora speciation and metabolism|Association between baseline APOE status and number of false positive responses during the picture recognition task of the CDR Computerized Cognitive Assessment System|Circulating biomarkers of cognition|Circulating biomarkers of cardiovascular health|Language ability on the Boston Naming Test|Visuospatial ability on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Figure Copy test|Attention ability on the Digit Span task|Executive function on the Trail Making Task|Cerebrovascular blood flow|Measurement of blood brain barrier permeability	University of East Anglia|Swinburne University of Technology|University of Illinois at Chicago	All	55 Years and older   (Adult, Older Adult)	Not Applicable	240	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R21647	August 2015	April 2018	April 2019	August 17, 2015		November 18, 2016	Beckman Institute, University of Illinois, Urbana, Illinois, United States|Centre for Human Psychopharmacology, Swinburne Univerity of Technology, Melbourne, Victoria, Australia|Department of Nutrition, University of East Anglia, Norwich, Norfolk, United Kingdom		https://ClinicalTrials.gov/show/NCT02525198
624	NCT03319173	Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation		Completed	Has Results	Mild Cognitive Impairment|Metabolic Syndrome	Behavioral: Dietary intervention	MoCA (Montreal Cognitive Assessment)|NMR Lipoprofile Particle Size - Small LDL-P|NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45|Fasting Triglycerides|Triglyceride/HDL Ratio|Fasting Insulin|Fasting Glucose|HOMA-IR|HgA1c|Weight|Body Fat Mass (BFM)|VLDL|SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)|SAM (S-adenosylmethionine)|SAH (S-adenosylhomocysteine)|Adenosine	Bristlecone Health, Inc.|University of Minnesota	All	35 Years to 80 Years   (Adult, Older Adult)	Not Applicable	98	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Bristlecone-001	October 15, 2017	September 30, 2018	September 30, 2018	October 24, 2017	November 12, 2019	November 12, 2019	Bristlecone Health, Inc., Maple Grove, Minnesota, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03319173/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03319173/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03319173
625	NCT03503669	Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Behavioral: Memory Training|Behavioral: Kundalini yoga and meditation	Change in Hopkins Verbal Learning Test (HVLT) total recall score|Change in Memory Functioning Questionnaire (MFQ) Scale|Change in Medical Outcomes Study Short Form 36-Item Health Survey (SF-36)	University of California, Los Angeles|Alzheimer's Research and Prevention Foundation	Female	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	17-001876	May 1, 2018	January 8, 2021	February 1, 2021	April 20, 2018		March 2, 2022	UCLA Semel Institute, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03503669
626	NCT03836950	rTMS to Improve Cognition in Parkinson's	TMSCogReP	Recruiting	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Device: MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)	change in NIH sponsored Executive Abilities: Measures and Instruments for neurobehavioral evaluation and re-search (NIH-EXAMINER) executive composite score	VA Office of Research and Development	All	50 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	166	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	N2938-W|IK2RX002938	April 1, 2020	June 26, 2024	June 16, 2025	February 11, 2019		October 28, 2021	Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States		https://ClinicalTrials.gov/show/NCT03836950
627	NCT05380297	Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild Impairment or Dementia in Primary Care		Recruiting	No Results Available	Mild Cognitive Impairment|Dementia	Device: Speech analysis	Vocal biomarkers to assess pre-post variability of normal, MCI and dementia at both point of the study.|Correlation between standard cognitive test (MMSE) and linguistic variables obtained by vocal biomarkers.	Accexible	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	248	Industry	Interventional	Allocation: N/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PS2020056	March 1, 2020	July 2022	December 2022	May 18, 2022		May 18, 2022	País Vasco, País Vasco, Spain		https://ClinicalTrials.gov/show/NCT05380297
628	NCT02521818	Dietary Treatments for Cognitive Impairment in Older Adults		Completed	No Results Available	Mild Cognitive Impairment|Probable Alzheimer's Disease	Other: Modified Atkins Diet|Other: NIA Diet for Seniors	Feasibility for MAD Group|Feasibility for Control Group|Efficacy for Cognition|Efficacy for Function	Johns Hopkins University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	38	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRB00066092	August 2015	July 1, 2019	July 1, 2019	August 13, 2015		September 6, 2019	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02521818
629	NCT05016960	Sleep-SMART for Veterans	Sleep-SMART	Recruiting	No Results Available	Insomnia|Mild Cognitive Impairment	Behavioral: Sleep-SMART	Feasibility of Intervention Measure (FIM)|Client Satisfaction Questionnaire (CSQ-8)|Telehealth Usability Questionnaire (TUQ)|Acceptability of Intervention Measure (AIM)|Intervention Appropriateness Measure (IAM)|WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)|Independent Living Skills Survey (ILSS)|Quality of Life Inventory (QOLI)|Quality of Life in Neurological Disorders (Neuro-QOL) cognition scale|Everyday Cognition Scale (ECoG)|Insomnia Severity Index (ISI)|Pittsburgh Sleep Quality Index (PSQI)|Hopkins Verbal Learning Test-Revised|Brief Visuospatial Memory Test-Revised|Wechsler Adult Intelligence Scale-IV (WAIS-IV) Digit Span|Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test	VA Office of Research and Development	All	60 Years and older   (Adult, Older Adult)	Not Applicable	31	U.S. Fed	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	D3721-P	January 4, 2022	June 30, 2023	September 30, 2023	August 23, 2021		January 14, 2022	VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT05016960
630	NCT05340218	Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Dementia	Other: Speech analysis	Pre-post variability of normal, MCI and dementia at both points of the study.|Correlation between cognitive tests and language variables obtained by the platform.	Accexible	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	300	Industry	Interventional	Allocation: N/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18/475-E	January 1, 2019	December 1, 2019	December 31, 2022	April 22, 2022		April 22, 2022	Centro de Prevención de Deterioro Cognitivo, Madrid, Spain		https://ClinicalTrials.gov/show/NCT05340218
631	NCT03736434	Brain Connections and Blood Pressure		Completed	No Results Available	Hypertension|Mild Cognitive Impairment	Behavioral: Mindfulness and DASH Diet Education|Behavioral: Education group	Change in Resting State Network|Change in Systolic and Diastolic Blood Pressure	Ohio State University	All	65 Years and older   (Older Adult)	Not Applicable	38	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	2018H0136	August 23, 2018	January 17, 2020	March 25, 2020	November 9, 2018		December 19, 2020	The Ohio State University College of Nursing, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03736434
632	NCT04950998	Smartphone App to Improve Physical Activity in Older Adults With MCI/Mild Dementia		Completed	No Results Available	Sedentary Lifestyle|Dementia, Mild|Mild Cognitive Impairment|Memory and Thinking Problems	Behavioral: Moving Up - A	Change from baseline in objective physical activity, as measured using ActivPAL|Change from baseline in objective sedentary activity, as measured using ActivPAL|App usability measured using the User Version of the Mobile Application Rating Scale (uMARS)|User experience, as measured through interview and diary	University of Southern California|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	30	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	HS-19-00444|3R21AG052838-02S1	December 5, 2021	April 25, 2022	April 25, 2022	July 6, 2021		June 15, 2022	University of Southern California, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04950998
633	NCT04866979	Applying Non-invasive Brain Stimulation in Alzheimer's Rehabilitation	StimoLaMente	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: Experimental: Continuous TBS (cTBS)|Device: Intermittent TBS (iTBS)|Behavioral: Cognitive training (CT).|Device: Sham Stimulation (shamTBS)	Face-name associative memory performance - Measure of Memory Recall|Mini-Mental State Evaluation (MMSE) Score - Non-Trained Measure of Global Function|TMS evoked potentials - TEP: Analysis of cortical excitability and inhibition changes induced in the state of excitability/inhibition of brain circuits following the TMS impulse.|Connectivity Index - Connectivity evoked by TMS: cortico-cortical connectivity analysis|TMS evoked oscillations: changes induced by TMS and its influence on intrinsic oscillatory activity|Raven's Colored Progressive Matrices: Evaluation of abstract non-verbal reasoning|Digit Span: Evaluation of short and long term memory (verbal)|Spatial Span: Evaluation of short and long term memory (visuospatial)|Prose Memory:Evaluation of short and long term memory|Free And Cued Selective Reminding Test: Evaluation of short and long term memory|Deferred re-enactment of the Complex Figure by Rey Osterrieth: Long term memory evaluation|Token Test: Evaluation of linguistic production|Semantic fluency and Phonemic fluency|Multiple Features Cancellation task: Evaluation of attention and executive function "MFCT"|Trail Making test (for A, B and B-A conditions): Evaluation of attention and executive function|Stroop test Error and Time: Evaluation of attention and executive function|Attentional Matrices: Evaluation of attention and executive function|Copy of Rey's Complex Figure: Evaluation of practical and visual-constructive skills|Geriatric Depression Scale, GDS:Evaluation of depressive symptoms in the elderly|Questionnaire of Identification of Deficits (QID): Evaluation on quality of life and identification of deficit questionnaire for the patient and caregiver|Clinical Insight Rating Scale, (CIRS): Evaluation of awareness of deficits and disease|Jefferson Scale: Evaluation of the patient's perception of empathy	Università degli Studi di Trento	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	UStudidiTrento	April 6, 2021	January 31, 2023	January 31, 2023	April 30, 2021		May 19, 2022	Centro Interdipartimentale Mente/Cervello - CIMeC, Rovereto, Trento, Italy	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04866979/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT04866979
634	NCT01600404	Effects of Antimuscarinics on Cognition in Spinal Cord Injury		Completed	No Results Available	Mild Cognitive Impairment|Spinal Cord Injuries	Drug: antimuscarinic treatment	d2 Test|International Spinal Cord Injury Pain Basic Data Set|Beck Depression Inventory Score|patient characteristics|type of neurologic lower urinary tract dysfunction|Stroop Test|California Verbal Learning Test|Verbal Fluency Test according to Thurstone|visuospatial performance|divided attention	Swiss Paraplegic Centre Nottwil	All	18 Years to 65 Years   (Adult, Older Adult)		32	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2011-25	December 2011	November 2015	November 2015	May 17, 2012		November 17, 2015	Swiss Paraplegic Centre, Nottwil, LU, Switzerland		https://ClinicalTrials.gov/show/NCT01600404
635	NCT04474379	Everyday Memory Impairment in PD-related Cognitive Decline	PMT2	Enrolling by invitation	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Behavioral: Strategy Training (Time- and Event- Based)	Change in Virtual Week Computer-based Memory Test performance after 5-weeks and 12-month post-intervention.|Change in The Prospective and Retrospective Memory Questionnaire scores after 5-weeks, 3-months, 6-months, and 12-month post-intervention.|Change in Bangor Goal Setting Interview goal attainment after 5-weeks and 12-month post-intervention.	Washington University School of Medicine	All	50 Years and older   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	202007054	November 29, 2021	September 1, 2026	September 1, 2026	July 16, 2020		January 12, 2022	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04474379
636	NCT01463384	Minocycline in Patients With Alzheimer's Disease		Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease	Drug: Minocycline	Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).|Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)	Huntington Medical Research Institutes	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2	13	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LKW-AB34	September 2011	October 2012	October 2012	November 1, 2011	September 25, 2014	September 25, 2014	Huntington Medical Research Institutes, Pasadena, California, United States		https://ClinicalTrials.gov/show/NCT01463384
637	NCT04082611	The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition	PREVENTION	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Behavioral: Data-Driven Clinical Recommendations|Behavioral: Coached Data-Driven Clinical Recommendations	NIH ToolBox Cognition Function Battery - Cognitive Function Composite Score|RAVLT (Rey's Auditory Verbal Learning Test) score|Hippocampal Volume|Blood Urine Nitrogen	Saint John's Cancer Institute|Institute for Systems Biology|St. Joseph's Healthcare Foundation	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	20190583	July 12, 2019	May 2023	May 2023	September 9, 2019		June 14, 2022	Pacific Brain Health Center, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT04082611
638	NCT01778946	Nicotine Treatment of Cognitive Decline in Down Syndrome		Completed	Has Results	Down Syndrome|Mild Cognitive Impairment	Drug: Low Dose Nicotine (7mg)|Drug: Moderate Dose Nicotine (14mg)	Tolerability of Nicotine Intervention|Cognitive Improvement - Simple Response Time|Exploratory - Event-Related Potentials|Cognitive Improvement - Continuous Performance Test|Cognitive Improvement - Buschke Selective Reminding Task|Cognitive Improvement - Critical Flicker Fusion Task	Vanderbilt University Medical Center	All	25 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	7	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	121759	April 2013	February 2021	February 2021	January 29, 2013	May 10, 2022	May 10, 2022	Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01778946/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01778946/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT01778946
639	NCT05004688	A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD		Recruiting	No Results Available	Mild Cognitive Impairment|Mild Dementia|Moderate Dementia|Alzheimer Disease	Biological: Biological/Vaccine: Bacillus Calmette-Guerin (BCG)	Blood biomarkers of pharmacodynamic response- cytokines|CSF biomarkers of pharmacodynamic response- cytokines|Blood biomarkers of AD pathology-ATN|CSF biomarkers of AD pathology-ATN|Cognitive Measures (RBANS)	Steven E Arnold|Massachusetts General Hospital	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	2021P002577	March 25, 2022	October 1, 2023	October 1, 2023	August 13, 2021		July 12, 2022	Alzheimer's Clinical and Translational Research Unit, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT05004688
640	NCT03165396	Appropriate Compatibility of Propofol and Sevoflurane for Orthopaedic Surgery of Patients With MCI	MCI	Unknown status	No Results Available	Cognitive Impairment, Mild	Drug: Propofol|Drug: Sevoflurane	Evidence of clinically cognitive function decline ：Apolipoprotein J（ApoJ）|Evidence of clinically cognitive function decline ：Soluble CD14（sCD14）|Mini mental Examination(MMSE)|Montreal Cognitive Assessment（MoCA)	The Third Central Clinical College of Tianjin Medical University	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention	szxlcyj-chen	November 10, 2016	August 1, 2018	November 1, 2018	May 24, 2017		May 25, 2018	Third Central Hospital of Tianjin, Tianjin, Tianjin, China		https://ClinicalTrials.gov/show/NCT03165396
641	NCT00850928	Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids		Completed	No Results Available	Postoperative Cognitive Dysfunction|Mild Cognitive Impairment		To examine the effect of surgery on the progression of AD in a population at high risk for this disease through measures of Amyloid Beta levels (AB40 and AB42). levels|To determine whether major surgery induces an increase in plasma Aβ40 and Aβ42.|To determine whether the pattern of plasma inflammatory markers is different in patients with MCI compared to patients without MCI.|To determine whether the Apolipoprotein E genotype correlates with POCD.|To examine the relationship between plasma levels of Aβ40 / Aβ42 and subject performance on neurocognitive testing.|To establish a correlation between preoperative mild cognitive impaired (MCI) and post operative cognitive decline ( POCD) using neurocognitive testing.	NYU Langone Health	All	65 Years and older   (Older Adult)		41	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	H08-658	December 2008	January 2011	January 2011	February 25, 2009		March 17, 2016	NYU School of Medicine, New York City, New York, United States		https://ClinicalTrials.gov/show/NCT00850928
642	NCT03722316	Nature Video to Improve Older Adult Health: A Feasibility Study.		Terminated	No Results Available	Mild Dementia|Mild Cognitive Impairment	Other: Immersive Nature Video|Other: Neutral Video	Percent of Participants Retained|Recruitment rate|Frequency and type of implementation barriers|Number of discussion questions used during group discussion|Momentary affective state|Working memory|Heart rate variability|Skin conductance activity|Quality of social communication	University of Southern California|Front Porch Center for Innovation and Wellbeing	All	65 Years and older   (Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NatureFeasibility2018	January 14, 2019	October 1, 2019	February 3, 2022	October 26, 2018		April 4, 2022	Front Porch Center for Innovation and Wellbeing, Glendale, California, United States|University of Southern California, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03722316
643	NCT05534607	Natives Engaged in Alzheimers Research - 'Ike Kupuna	NEAR	Recruiting	No Results Available	Mild Cognitive Impairment|Subjective Cognitive Impairment	Behavioral: Ola Mau i ka Hula	Change in participants' systolic blood pressure at each time frame from baseline|Change in participants' Hemoglobin A1c at each time frame from baseline|Change in participants' total cholesterol at each time frame from baseline|Change in participants' body mass index at each time frame from baseline|Change in participants' Cognitive Change Index score at each time frame from baseline|Change in participants' Number Symbol Coding Test score at each time frame from baseline|Change in participants' overall Cognivue score at each time frame from baseline|Change in participants' overall Quick Dementia Rating System score at each time frame from baseline	University of Hawaii	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	192	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	'Ike Kupuna	September 15, 2022	April 30, 2025	April 30, 2026	September 9, 2022		September 9, 2022	Kula No Na Po'e, Honolulu, Hawaii, United States|Kokua Kalihi Valley, Honolulu, Hawaii, United States|Hui No Ke Ola Pono, Wailuku, Hawaii, United States		https://ClinicalTrials.gov/show/NCT05534607
644	NCT03095170	Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder	PEACEOFMND	Terminated	No Results Available	Mild Cognitive Impairment|Memory Disorders|Mild Dementia|Impaired Cognition|Mild Cognitive Disorder|Amnestic Disorder|Dementia and Amnestic Conditions|Poor Short-term Memory|Memory Impairment|Mild Neurocognitive Disorder	Behavioral: Computerized brain fitness training|Behavioral: Yoga|Behavioral: Wellness Education|Behavioral: Support Group (patient and partner)|Behavioral: Cognitive Rehabilitation	Resting State Magnetic Resonance Imaging (MRI)|Diffusion Tensor Imaging (DTI)	University of Florida|Mayo Clinic|Tallahassee Memorial HealthCare|Florida Department of Health	All	21 Years and older   (Adult, Older Adult)	Not Applicable	5	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB201700004|7AZA1|9AZ15|IRB201900522|OCR21041	March 23, 2017	March 21, 2022	March 21, 2022	March 29, 2017		July 6, 2022	University of Florida, Gainesville, Florida, United States		https://ClinicalTrials.gov/show/NCT03095170
645	NCT05198726	Speed of Processing (SoP) Training Plus α-tACS	aMCIUp	Recruiting	No Results Available	Cognitive Dysfunction|Mild Cognitive Impairment|tACS|Cognitive Training	Device: alpha tACS|Behavioral: Speed of Processing Training	Useful Field of View Test (UFOV)|Useful Field of View (UFOV)|Executive Composite Score from the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH EXAMINER)|EEG power in the alpha band|P300 Event related potential - A|P300 Event related potential - L	Portucalense University|Aveiro University|University of Coimbra	All	65 Years and older   (Older Adult)	Not Applicable	327	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	UPT01	April 19, 2022	December 2024	June 2025	January 20, 2022		April 20, 2022	Portucalense University, Porto, Portugal		https://ClinicalTrials.gov/show/NCT05198726
646	NCT04199767	SNIFF Multi-Device Study 2		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Cognitive Impairment	Drug: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Drug: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)	CSF insulin levels|Auditory-Verbal Learning Test (AVLT)	Wake Forest University Health Sciences	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00062612	July 16, 2020	October 2022	October 2023	December 16, 2019		November 4, 2021	Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04199767
647	NCT03528486	Interventions to Attenuate Cognitive Decline: Keys to Staying Sharp		Completed	No Results Available	Mild Cognitive Impairment|Age-related Cognitive Decline	Behavioral: Music Training I	Cognition|Central Auditory Processing|Everyday Function	University of South Florida	All	60 Years and older   (Adult, Older Adult)	Not Applicable	268	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	32335	January 29, 2018	August 30, 2021	December 30, 2021	May 17, 2018		July 14, 2022	University of South Florida, Tampa, Florida, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03528486/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03528486
648	NCT03857321	Study of Nasal Insulin to Fight Forgetfulness - Device Study		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Cognitive Impairment	Drug: Insulin|Other: Placebo|Device: intranasal nebulizer-like device	CSF insulin levels|The Auditory-Verbal Learning Test (AVLT)|CSF Levels of AB42|CSF Levels of total tau|CSF Levels phospho-tau 181	Wake Forest University Health Sciences	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	21	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00055429	April 12, 2019	August 2024	August 2025	February 27, 2019		February 11, 2022	Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03857321
649	NCT01646333	A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease		Completed	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Behavioral: Memory and Problem-Solving Intervention|Behavioral: Supportive Therapy	California Verbal Learning Test-II Long Delay Free Recall Scaled Score Change Over 10 Weeks|Linear Analog Scale Assessment Overall Well Being Raw Score Change Over 10 Weeks	Virginia Commonwealth University|Michael J. Fox Foundation for Parkinson's Research	All	18 Years and older   (Adult, Older Adult)	Not Applicable	32	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PT107964	July 2012	October 2015	December 2015	July 20, 2012		January 8, 2016	VCU Parkinson's and Movement Disorders Center, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT01646333
650	NCT04262674	Non-invasive, Wearable Multi-parameter System for the Early Prediction of Cognitive Decline and Dementia in Older Adults		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Healthy Aging	Other: Cognitive-motor training	Electroencephalography (EEG)|Gait speed analysis with inertial sensors|Gait variability analysis with inertial sensors|Heart rate variability (HRV) indices SDNN and RMSSD with two-lead electrocardiogram chest belt|Heart rate variability (HRV) index HF power with two-lead electrocardiogram chest belt|Body temperature (T) with temperature sensors (thermistors)|Cognitive performance with neuropsychological tests|Core body temperature (Tc) with telemetric gastrointestinal temperature pill	Empa, Swiss Federal Laboratories for Materials Science and Technology|Geriatrische Klinik St. Gallen|ETH Zurich	All	65 Years and older   (Older Adult)	Not Applicable	82	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	5213.00187	September 23, 2019	May 2021	July 2021	February 10, 2020		February 4, 2021	Empa, St.Gallen, SG, Switzerland		https://ClinicalTrials.gov/show/NCT04262674
651	NCT01315639	New Biomarker for Alzheimer's Disease Diagnostic	BALTAZAR	Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Biological: biomarkers, MRI and CSF	Mean concentration of plasma AB peptides|plasma levels of Tau protein|Mean concentration of biomarker|MRI|Transcriptomics biomarkers|Bace peptide|TACE/ADAM17|Cathepsin|sAPPβ|Ratio of CSF sAPPβ and CSF sAPPα|Ratio of plasma Aβ and plasma Tau|Plasma Tau|MRI biomarkers	Assistance Publique - Hôpitaux de Paris	All	45 Years and older   (Adult, Older Adult)	Not Applicable	1067	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	P081205	September 3, 2010	February 26, 2015	March 16, 2018	March 15, 2011		November 22, 2021	APHP, Hôpital Broca, Paris, France		https://ClinicalTrials.gov/show/NCT01315639
652	NCT03752294	A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.		Unknown status	No Results Available	Mild Cognitive Impairment|Mild Alzheimer's Disease	Drug: Dabigatran|Drug: Placebo - Cap	Evaluate dabigatran efficacy in MCI and mild AD population using changes in targeted plasma and CSF biomarker levels at 9 and 21 months|Demonstrate a reduction in decline of cognitive function related to physical functioning in placebo arm after crossing over to 12-months of active treatment|Changes in cognitive performance in placebo arm after cross-over to open-label treatment phase|Safety and tolerability of dabigatran in experimental population (MCI and mild AD populations) based on reported serious and adverse events|Evaluation of cognitive performance in placebo arm after cross-over to open-label treatment phase	University of Rhode Island|Alzheimer's Drug Discovery Foundation|Boehringer Ingelheim	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 1	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	RIN001-001	November 2018	November 2021	December 2021	November 23, 2018		November 23, 2018			https://ClinicalTrials.gov/show/NCT03752294
653	NCT03581643	Validation of the Montreal Cognitive Assessment in Patients With Mild and Major Neurocognitive Disorder	MoCA-Valid	Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment		Montreal Cognitive Assessment (MoCA) total score|Mini-Mental State Examination (MMSE) total score|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)	Andreas Monsch|University Hospital, Basel, Switzerland	All	65 Years and older   (Older Adult)		430	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	MoCA-Valid	March 6, 2017	May 8, 2018	May 8, 2018	July 10, 2018		July 10, 2018	Memory Clinic, University Center for Medicine of Aging, Felix Platter Hospital Basel, Basel, BS, Switzerland		https://ClinicalTrials.gov/show/NCT03581643
654	NCT05298501	Assessing Performance on Speech Tasks Via Crowdsourced Participants	AMYWEB	Recruiting	No Results Available	Cognitive Impairment|Mild Cognitive Impairment	Other: No intervention/exposure	Age, sex, and education adjusted normative scores for the Automatic Story Recall Task (ASRT) test variants derived via linear regression analysis.|Normative data will be derived for shorter variants of the ASRT test battery derived via linear regression analysis.|Age, sex, and education adjusted normative scores for the category fluency task performance derived via linear regression analysis.|Age, sex, and education adjusted normative scores for the letter fluency task performance derived via linear regression analysis.|The effect of demographic differences on task performance will be evaluated via linear regression analysis.|Demographic and cultural biases will be examined via group or pairwise comparison of transcription error rate and scoring errors on a simple reading task.|Performance differences in parallel ASRT variant tasks will be examined via task-wise comparison.|Area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between the MCI sample and the normative sample using as input the speech elicited during cognitive tasks.|Area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between depressed and non-depressed participants using as input the speech elicited during cognitive tasks.|The agreement between the PHQ-8 and the corresponding regression model predicting depressive symptomatology from speech data elicited during tasks will be evaluated.	Novoic Limited	All	18 Years and older   (Adult, Older Adult)		8000	Industry	Observational	Observational Model: Other|Time Perspective: Cross-Sectional	NOV-0300	April 5, 2022	November 2022	November 2022	March 28, 2022		April 15, 2022	Novoic Ltd, London, United Kingdom		https://ClinicalTrials.gov/show/NCT05298501
655	NCT03877783	DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes	DEMAND	Active, not recruiting	No Results Available	Type 2 Diabetes Mellitus|Mild Cognitive Impairment	Dietary Supplement: mediterranean diet|Behavioral: individualized fitness program|Other: recommended modified pharmacological treatment	inclusion rate|adherence rate|retention rate|Metabolic change|Memory function	Umeå University	All	65 Years and older   (Older Adult)	Not Applicable	10	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	DEMAND pilot	October 19, 2020	March 31, 2022	June 30, 2023	March 18, 2019		March 26, 2021	Umeå University, Umeå, Västerbotten, Sweden		https://ClinicalTrials.gov/show/NCT03877783
656	NCT02921477	Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Dementia	Drug: bosutinib	Number of patients who are discontinued due to tolerability issues related to treatment	Neurological Associates of West Los Angeles|Pfizer	All	45 Years to 89 Years   (Adult, Older Adult)	Phase 1	71	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	062016	September 2016	December 31, 2023	December 31, 2025	October 3, 2016		March 2, 2021	Neurological Associates of West LA, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT02921477
657	NCT05460468	Neuromodulation of Memory in Aging	TMS-AD	Not yet recruiting	No Results Available	Mild Cognitive Impairment|MCI	Device: Transcranial Magnetic Stimulation	Working Memory Task|Functional network connectivity|Vascular density (VAD)|EEG-based connectivity|Montreal Cognitive Assessment (MoCA)|National Institutes of Health (NIH) Toolbox Cognitive Battery|Hopkins Verbal Learning Test (HVLT-2)|Brief Visuospatial Memory Test (BVMT-R)|Number Span Forwards/ Backwards|Category & Phonemic Verbal Fluency|Trail Making Test	Duke University|National Institute on Aging (NIA)	All	60 Years to 75 Years   (Adult, Older Adult)	Not Applicable	150	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Pro00110872	October 1, 2022	June 30, 2027	June 30, 2027	July 15, 2022		July 15, 2022			https://ClinicalTrials.gov/show/NCT05460468
658	NCT05235113	Remote Game-based Exercise Program for Cognitive and Motor Function Improvement		Recruiting	No Results Available	Mild Cognitive Impairment|Dementia	Device: Tele-Exergame Platform|Device: No Tele-Exergame Platform	Change in Balance|Change in Gait speed|Change in Cognitive Function|Change in Fear of Falling|Change in Physical Activity|Change in Quality of Life	Baylor College of Medicine	All	65 Years and older   (Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care	H-44913	December 22, 2021	December 31, 2024	March 21, 2026	February 11, 2022		March 11, 2022	Baylor College of Medicine, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT05235113
659	NCT05217849	Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION)	MOTION	Recruiting	No Results Available	Mild Cognitive Impairment|Subjective Memory Decline	Behavioral: Tai Chi|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|Behavioral: Health and Wellness Education	Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Scores|Change in Default Mode Network (DMN) functional connectivity|Change in Auditory Memory scores|Change in Attention/Executive Function Cognitive Domain Scores|Change in Verbal Fluency scores|Change in Processing Speed Scores|Change in Mobility|Change in Salience Network functional connectivity|Change in Language Network functional connectivity	University of California, San Francisco|San Francisco VA Health Care System|University of California, Los Angeles|United States Department of Defense	All	55 Years and older   (Adult, Older Adult)	Not Applicable	80	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	21-33507	February 15, 2022	December 31, 2025	June 30, 2026	February 1, 2022		March 8, 2022	VA Health Care System, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT05217849
660	NCT03630419	Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Dietary Supplement: Mito-Food Plan|Other: Cellular Repair Therapy	Change in inflammation as measured through bioimpedance analysis from baseline to week 12|Change in Mini Mental State Exam (MMSE) from Baseline to Week 12|Change in Montreal Cognitive Assessment (MoCA) from Baseline to Week 12|Change in Quality of Life in Alzheimer's Disease (QOL-AD) from Baseline to Week 12	Perseverance Research Center, LLC|Cerulean Advanced Fitness and Wellness	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 1|Phase 2	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Mito-01	February 10, 2018	July 28, 2018	July 28, 2018	August 14, 2018		October 2, 2018	Perseverance Research Center, LLC, Scottsdale, Arizona, United States		https://ClinicalTrials.gov/show/NCT03630419
661	NCT04986787	Novel, Individualized Brain Stimulation, Network-based Approaches to Improve Cognition	NiBS-iCog	Recruiting	No Results Available	Mild Cognitive Impairment|Healthy Aging	Device: tACS|Device: TMS	Working memory performance|The reproducibility of the outcomes of this proof-of-concept brain stimulation in MCI between centers|The neural underpinning of NIBS-induced changes quantified by s/fMRI and network-based analytical approaches.|The neural underpinning of NIBS-induced changes quantified by EEG.|Transfer of the acquired WM abilities during the intervention into a daily-life relevant scenario as assessed by The Virtual Supermarket Shopping Task.	Masaryk University|Swiss Federal Institute of Technology	All	60 Years and older   (Adult, Older Adult)	Not Applicable	160	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	GF21-13462L	September 1, 2021	April 30, 2022	December 31, 2023	August 3, 2021		September 2, 2021	Ceitec Masaryk University, Brno, Czechia		https://ClinicalTrials.gov/show/NCT04986787
662	NCT03883633	Reversal of Cognitive Decline (ReCODE) Study	RECODE	Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Behavioral: ReCODE Protocol	Changes in short-time memory function|Changes in cognitive function|Perceived changes in capability assessed by input from care giver or family member	QuesGen Systems Inc	All	45 Years to 76 Years   (Adult, Older Adult)		30	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	RECODE-1018	June 30, 2019	December 31, 2020	December 31, 2020	March 21, 2019		January 22, 2021	Ann Hathaway MD, San Rafael, California, United States|Bay Area Wellness, Walnut Creek, California, United States|Northwest Memory Center, Ashland, Oregon, United States		https://ClinicalTrials.gov/show/NCT03883633
663	NCT04818255	STIM+: PET Biomarker Education & Disclosure	STIM+	Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Dementia; Alzheimer's Type (Etiology)	Behavioral: PET Biomarker Disclosure	Interest in PET Biomarker Disclosure|Percent of individuals demonstrating disclosure decision-making capacity|Change in Positive and Negative Affect Scale - Short Form (PANAS-SF) Positive Subscale Score|Change in Positive and Negative Affect Scale - Short Form (PANAS-SF) Negative Subscale Score|Change in Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Distress Score|Change in Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Positive Emotions Score|Change in Stigma Scale for Chronic Illness (SSCI-8) Total Score|Change in Self-Efficacy for Managing Chronic Disease Scale (SECD) Total Score|Change in Future Time Perspectives Scale (FTP) Average Score|Participant Comprehension/Recall of Results Percent Correct Score: Immediately Following Disclosure|Change in Participant Comprehension/Recall of Results Percent Correct Score	University of Michigan|National Institute on Aging (NIA)	All	50 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	HUM00188109|R01AG058724	December 10, 2020	December 31, 2023	December 31, 2023	March 26, 2021		March 3, 2022	University of Michigan Medical School, Department of Psychiatry, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04818255
664	NCT04679441	A Novel Computer-Based Functional Skills Assessment and Training Program		Recruiting	No Results Available	Mild Cognitive Impairment|Healthy Aging	Device: The Computerized Functional Skills Assessment and Training Program|Device: Brain HQ Double Decision	Time to completion on each Task of the the CFAST|Performance on the Brief Assessment of Cognition App|Performance on The Virtual Reality Functional Capacity Assessment Task|EMA measurement of real world activities	i-Function, Inc.	All	60 Years to 100 Years   (Adult, Older Adult)	Phase 2	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	iFunction Phase 2	August 1, 2021	March 31, 2023	May 31, 2023	December 22, 2020		August 27, 2021	Ifunction at University of Miami, Miami, Florida, United States|Weill Cornell Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04679441
665	NCT05172128	Effect of Blueberry Supplementation on Alzheimer's Biomarkers		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Dietary Supplement: lyophilized blueberry supplement	Change in blood Neurofilament light (NfL) levels as measured by blood biomarker assay|Change in blood glial fibrillary acidic protein (GFAP) levels as measured by blood biomarker assay|Change in blood Amyloid beta 40/42 as measured by blood biomarker assay|Change in p-tau 181 as measured by blood biomarker assay|Change in blood interleukin-6 (IL-6) levels as measured by blood biomarker assay|Change in tumor necrosis factor (TNF-alpha) levels as measured by blood biomarker assay	Duke University|U.S. Highbush Blueberry Council	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Pro00108907	February 21, 2022	December 31, 2023	December 31, 2023	December 29, 2021		February 23, 2022	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT05172128
666	NCT04820335	Promoting Independence With Compensatory Cognitive Rehabilitation		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Behavioral: Structured External Memory Aid Treatment (SEMAT)	Changes in Memory Based Everyday Function|Changes in Memory Based Compensation|Changes in Everyday Strategy Use|Changes in Cognitive Abilities|Changes in Quality of Life|Changes in Executive Functioning Skills|Changes in Self Efficacy|Maintained Changes in Memory Based Everyday Function|Maintained Changes in Memory Based Compensation|Maintained Changes in Everyday Strategy Use	University of Delaware	All	60 Years to 90 Years   (Adult, Older Adult)	Phase 1	65	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	K23AG070185	January 5, 2022	August 2024	December 2025	March 29, 2021		May 20, 2022	University of Delaware, Newark, Delaware, United States		https://ClinicalTrials.gov/show/NCT04820335
667	NCT04983368	A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers	XanaMIA-DR	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Drug: Xanamem® 5 mg|Drug: Placebo|Drug: Xanamem® 10 mg	Short-term efficacy: Assessment of changes of different doses of Xanamem® on cognition.|Assessment of safety and tolerability of different Xanamem® doses by the occurrence of Treatment-Emergent Adverse Events (TEAEs).|Short-term efficacy of different doses of Xanamem® on cognition	Actinogen Medical|Avance Clinical	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	107	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ACW0005	June 30, 2021	February 11, 2022	February 11, 2022	July 30, 2021		April 8, 2022	Paratus Clinical Research Canberra, Bruce, Australian Capital Territory, Australia|Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia|Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia|Paratus Clinical Research Brisbane, Albion, Queensland, Australia|USC Clinical Trials, Sippy Downs, Queensland, Australia		https://ClinicalTrials.gov/show/NCT04983368
668	NCT04507126	A Pilot Study of the Effects of Bacillus Calmette-Guérin (BCG) Immunization on Cerebrospinal Fluid and Blood-based Biomarkers in Older Adults.		Completed	No Results Available	Mild Cognitive Impairment|Healthy	Biological: Bacillus Calmette-Guerin (BCG)	CSF biomarkers of pharmacodynamic response- cytokines|CSF biomarkers of AD pathology-ATN|Blood biomarkers of pharmacodynamic response- cytokines|Blood biomarkers of AD pathology|Cognitive Measures (RBANS)	Massachusetts General Hospital	All	55 Years to 80 Years   (Adult, Older Adult)	Early Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	2020P002042	March 1, 2021	April 1, 2022	April 1, 2022	August 11, 2020		August 24, 2022	Clinical Translational Research Unit, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04507126
669	NCT05240664	Effects of An ACP Programme for Older People With Early Dementia		Completed	No Results Available	Dementia, Mild|Mild Cognitive Impairment	Behavioral: Have A Say Programme|Behavioral: Attention-control health talks	Change in advance care planning engagement|Change in dyadic concordance of preference on end-of-life care|change in depression|Change in caregivers' stress	Hong Kong Metropolitan University|Chinese University of Hong Kong	All	55 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	CREC 2019.438	January 9, 2021	August 31, 2021	August 31, 2021	February 15, 2022		March 2, 2022	HKSKH Lok Man Alice Kwok Integrated Service Centre, Kowloon, Hong Kong|Hong Kong Christian Service, Kowloon, Hong Kong|Hong Kong Sheng Kung Hui Chuk Yuen Canon Martin District Elderly Community Centre, Kowloon, Hong Kong|Yang Memorial Methodist Social Service Choi Hung Community Centre for Senior Citizens, Kowloon, Hong Kong|Jockey Club Centre for Positive Ageing, Sha Tin, Hong Kong|Yau On Lutheran Centre for the Elderly, Tuen Mun, Hong Kong		https://ClinicalTrials.gov/show/NCT05240664
670	NCT04629495	Rapamycin - Effects on Alzheimer's and Cognitive Health	REACH	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Drug: Rapamycin|Other: Placebo	Number of adverse events|Change in glucose level|Change in albumin|Change in carbon dioxide or bicarbonate (CO2)|Change in calcium|Central nervous system penetration of rapamycin|Change in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5)|Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB)|Change in Functional status|Change in Neuropsychiatric symptoms|Change in Gait Speed|Change in Grip Strength|Change in CSF amyloid beta|Change in cerebral glucose metabolism|Change in Brain Volumetry	The University of Texas Health Science Center at San Antonio	All	55 Years to 89 Years   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HSC20200763H	August 11, 2021	December 2023	August 2024	November 16, 2020		September 17, 2021	Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT04629495
671	NCT04309500	SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting	SHARE(D)	Completed	No Results Available	Mild Cognitive Impairment|Healthy Aging	Behavioral: Personalized DAT Risk Disclosure Protocol	Comprehension/Recall of Results - Personal Information Score (Immediate) - PARTICIPANT|Comprehension/Recall of Results - Personal Information Score (Immediate) - CO-PARTICIPANTS|Comprehension/Recall of Results - Personal Information Score (1-week Follow-Up) - PARTICIPANTS|Comprehension/Recall of Results - Personal Information Score (1-week Follow-Up) - CO-PARTICIPANTS|Comprehension/Recall of Results - Personal Information Score (6-week Follow-Up) - PARTICIPANTS|Comprehension/Recall of Results - Personal Information Score (6-week Follow-Up) - CO-PARTICIPANTS|Comprehension/Recall of Results - Meaning of Risk Information Score (Immediate) - PARTICIPANTS|Comprehension/Recall of Results - Meaning of Risk Information Score (Immediate) - CO-PARTICIPANTS|Comprehension/Recall of Results - Meaning of Risk Information Score (1-week Follow-Up) - PARTICIPANTS|Comprehension/Recall of Results - Meaning of Risk Information Score (1-week Follow-Up) - CO-PARTICIPANTS|Comprehension/Recall of Results - Meaning of Risk Information Score (6-week Follow-Up) - PARTICIPANTS|Comprehension/Recall of Results - Meaning of Risk Information Score (6-week Follow-Up) - CO-PARTICIPANTS|Geriatric Depression Scale - Short Form (GDS-15; Immediate) - PARTICIPANTS|Geriatric Depression Scale - Short Form (GDS-15; Immediate) - CO-PARTICIPANTS|Geriatric Depression Scale - Short Form (GDS-15; 1-week Follow-Up) - PARTICIPANTS|Geriatric Depression Scale - Short Form (GDS-15; 1-week Follow-Up) - CO-PARTICIPANTS|Geriatric Depression Scale - Short Form (GDS-15; 6-week Follow-Up) - PARTICIPANTS|Geriatric Depression Scale - Short Form (GDS-15; 6-week Follow-Up) - CO-PARTICIPANTS|Beck Anxiety Inventory (BAI; Immediate) - PARTICIPANTS|Beck Anxiety Inventory (BAI; Immediate) - CO-PARTICIPANTS|Beck Anxiety Inventory (BAI; 1-week follow-up) - PARTICIPANTS|Beck Anxiety Inventory (BAI; 1-week follow-up) - CO-PARTICIPANTS|Beck Anxiety Inventory (BAI; 6-week Follow-Up) - PARTICIPANTS|Beck Anxiety Inventory (BAI; 6-week Follow-Up) - CO-PARTICIPANTS|The Impact of Genetic Testing for AD (IGT-AD; Immediate) - PARTICIPANTS|The Impact of Genetic Testing for AD (IGT-AD; Immediate) - CO-PARTICIPANTS|The Impact of Genetic Testing for AD (IGT-AD; 1-week Follow-Up) - PARTICIPANTS|The Impact of Genetic Testing for AD (IGT-AD; 1-week Follow-Up) - CO-PARTICIPANTS|The Impact of Genetic Testing for AD (IGT-AD; 6-week Follow-Up) - PARTICIPANTS|The Impact of Genetic Testing for AD (IGT-AD; 6-week Follow-Up) - CO-PARTICIPANTS	University of Michigan|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	20	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HUM00178869	May 20, 2021	January 31, 2022	January 31, 2022	March 16, 2020		May 12, 2022	University of Michigan Medical School, Department of Psychiatry, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04309500
672	NCT04785300	ALSENLITE: Senolytics for Alzheimer's Disease		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Drug: Dasatinib|Drug: Quercetin	Safety and Tolerability of 11 week of intermittent D+Q treatment	James L. Kirkland, MD, PhD|Mayo Clinic	All	55 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-003394	July 6, 2022	December 2023	December 2023	March 5, 2021		September 10, 2022	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04785300
673	NCT04784416	Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Device: Active tPBM-2.0|Device: Sham tPBM-2.0|Drug: 18F-MK-6240	Change in Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS) Total Scale Index Score.|Addenbrooke's Cognitive Examination (ACE-III) Score|Letter Comparison Test Score|Pattern Comparison Test Score|Stroop Color and Word Test (SCWT)|Difference in Score Between Trail Making Test-A (TMT-A) and Trail Making Test-B (TMT-B)|TMT-B T-Score|Face-Name Associative Memory Exam (FNAME-12) Score|Letter Number Sequencing Score|Change in Systemic Assessment for Treatment Emergent Events - Specific Inquiry (SAFTEE-SI) Score	NYU Langone Health|Alzheimer's Association|National Institutes of Health (NIH)|LiteCure LLC	All	65 Years to 85 Years   (Older Adult)	Phase 2	125	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	20-00865	April 27, 2021	June 30, 2025	November 30, 2025	March 5, 2021		June 30, 2022	Massachusetts General Hospital, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|Nathan Kline Institute, Orangeburg, New York, United States		https://ClinicalTrials.gov/show/NCT04784416
674	NCT00297271	Prospective Research in Memory Clinics (PRIME)		Completed	No Results Available	Dementia|Mild Cognitive Impairment	Other: Current treatment practice of each participating physician	The primary objective of the study is to analyse the epidemiology and treatment outcomes of mild cognitive impairment and dementia under conditions of routine clinical practice|Change From Baseline in Clinical Dementia Rating Scale (total and overall score)|Mini Mental State Examination (total score)|The Alzheimer's Disease Assessment Scale (cognitive total score)|The Clock Drawing Test (total score)|Frontal Assessment Battery (total score)|Functional Autonomy Measurement System (total score and subscores)|Neuropsychiatric Inventory (total score, total distress to caregivers score, and total number of behaviors)|Zarit caregiver burden interview (total score)|Resource Utilization	Janssen-Cilag Pty Ltd	All	Child, Adult, Older Adult		970	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	CR004819|GALDEM4007	August 2005	August 2011	August 2011	February 28, 2006		December 2, 2013	Chermside N/A, Australia|Fremantle, Australia|Geelong, Australia|Heidelberg, Australia|Hornsby, Australia|Kew, Australia|Newcastle, Australia|Randwick, Australia|Woodville, Australia		https://ClinicalTrials.gov/show/NCT00297271
675	NCT04614376	Alzheimer's and Blood Glucose Levels		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease		Blood Glucose Levels	Bio Conscious Technologies Inc.	All	50 Years and older   (Adult, Older Adult)		100	Industry	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	BCT_AD_001	November 2020	August 2021	March 2022	November 4, 2020		November 4, 2020	Bio Conscious Technologies Inc., Vancouver, British Columbia, Canada	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04614376/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04614376
676	NCT04099524	CogT BEEM Study (a tDCS Study)		Completed	No Results Available	Mild Cognitive Impairment|Neuropsychiatric Syndrome	Device: tDCS	Change of NPS-shared neural circuit|Change of informant-rated NPS	University of Rochester	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science	STUDY00003664	December 6, 2019	January 19, 2022	January 19, 2022	September 23, 2019		June 10, 2022	Cabin, Ur, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT04099524
677	NCT01727622	Arterial Spin Labeling (ASL) MRI for Cognitive Decline		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Drug: FDG-PET|Other: ASL-MRI|Procedure: Lumbar Puncture	Composite region of interest (ROI) measure of cerebral blood flow (CBF) measured by ASL MRI versus composite ROI measure of cerebral metabolism measured by FDG PET|Prediction of longitudinal change in hippocampal volume|Prediction of longitudinal change in clinical status (i.e. progression to Alzheimer's Disease)	University of Pennsylvania|National Institute on Aging (NIA)	All	55 Years to 89 Years   (Adult, Older Adult)		102	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	815471|5R01AG040271	August 2012	May 11, 2018	May 31, 2018	November 16, 2012		September 28, 2020	Penn Memory Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01727622
678	NCT04385797	Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia	CONNECTDEM	Unknown status	No Results Available	Mild Cognitive Impairment|Dementia	Other: Telephone interview	Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.|Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.|Change on caregiver burden prior to, during and after confinement.|Change on healthcare and social support services access prior to, during and after confinement.|Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	All	55 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Other	CONNECT DEM	May 4, 2020	December 31, 2020	December 31, 2020	May 13, 2020		December 4, 2020	Instituto de Investigacion Biomedica de Malaga-IBIMA, Málaga, Spain		https://ClinicalTrials.gov/show/NCT04385797
679	NCT03372317	Tau PET in Imaging and Cognition: Healthy Adults From 55-90		Recruiting	No Results Available	Mild Cognitive Impairment|Aging	Drug: 18F-MK-6240	Total number of individuals with tau present|Cognition|Functional imaging (fMRI)	Yaakov Stern|National Institute on Aging (NIA)|Columbia University	All	55 Years to 90 Years   (Adult, Older Adult)		105	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	AAAR6959|2RF1AG038465-06	June 1, 2018	January 2023	December 2023	December 13, 2017		February 11, 2022	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03372317
680	NCT03574207	Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities		Recruiting	No Results Available	Mild Cognitive Impairment|Memory Loss	Device: Transcranial magnetic stimulation	Changes in memory performance measured with the number of studied face-word associations recalled|Changes in intrinsic functional connectivity between the target brain region stimulated with rTMS and other brain regions.	University of Nebraska|National Institute of General Medical Sciences (NIGMS)	All	19 Years and older   (Adult, Older Adult)	Early Phase 1	70	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science	096-18-FB	January 1, 2019	December 2022	December 2023	June 29, 2018		January 26, 2022	University of Nebraska Medical Center, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT03574207
681	NCT03587012	Brain Fitness APP for Cognitive Enhancement		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Dementia	Other: Brain fitness app|Other: Brain fitness app with tACS	Change in Wechsler Memory Scale (WMS IV)|Change in Egocentric Spatial Orientation|Change in MONTGOMERY ASBERG DEPRESSION RATING SCALE (MADRS)	University of Manitoba	All	20 Years to 95 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B2018:029GB	June 20, 2018	December 2021	December 2021	July 16, 2018		February 24, 2021	Riverview Health Center, Winnipeg, Manitoba, Canada		https://ClinicalTrials.gov/show/NCT03587012
682	NCT04131491	Epilepsy in Alzheimer's Disease: Effect on Disease Progression	EADP	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease	Procedure: Lumbar puncture	Prevalence, expressed as percentage, of subclinical epileptiform activity in MCI due to AD patients, compared to healthy controls.|Odds ratio for conversion to clinical AD when comparing MCI patients with and without subclinical signs of epilepsy at the baseline evaluation.	Universitair Ziekenhuis Brussel	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	UZB-NEU-001	February 12, 2020	September 30, 2023	September 30, 2023	October 18, 2019		October 7, 2021	UZ Brussel, Brussels, Jette, Belgium		https://ClinicalTrials.gov/show/NCT04131491
683	NCT03839563	Temporal Relations and Exercise Interventions of Various Gait and Cognitive Domains in Older Adults		Recruiting	No Results Available	Fallers|Mild Cognitive Impairment	Behavioral: Exercise	Gait characteristics|Global cognition|Serum levels of BDNF|Serum levels of IGF-1|Serum levels of VEGF|Tinetti balance|Mobility|Muscle strength|Falls|Depressive symptoms|Fear of falling	Taipei Medical University|National Health Research Institutes, Taiwan	All	65 Years to 100 Years   (Older Adult)	Not Applicable	189	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	NHRI-EX108-10804PI	February 15, 2019	December 31, 2023	December 31, 2023	February 15, 2019		April 1, 2021	Taipei Medical University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03839563
684	NCT04265378	Cognitive Training and Brain Stimulation in Prodromal Alzheimer's Disease	AD-Stim	Recruiting	No Results Available	Subjective Cognitive Decline|Mild Cognitive Impairment	Device: anodal tDCS|Behavioral: Intensive cognitive training	Working memory training performance (Letter Updating task)|Working memory training performance (Markov task)|Transfer outcomes: numerical n-back task (% correct)|Transfer outcomes: AVLT (auditory verbal learning test) (sum of correctly recalled items trials 1-5)|Transfer outcomes: Wiener Matrices Test (no. correct)|Long-term outcomes: Letter Updating task (no. of correctly recalled lists)|Long-term outcomes: Markov decision making task (% optimal actions)|Long-term outcomes: numerical n-back task (% correct)|Long-term outcomes: AVLT (auditory verbal learning test) (sum of correctly recalled items trials 1-5)|Long-term outcomes: Wiener Matrices Test (no. correct)|Neural correlates: Structural neural correlates of tDCS effect|Neural correlates: Functional neural correlates of tDCS effect	University Medicine Greifswald	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	46	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	AD-Stim	May 1, 2019	June 2022	December 2022	February 11, 2020		February 4, 2022	University Medicine Greifswald, Greifswald, Germany	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04265378/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT04265378
685	NCT03136679	Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease	BVB	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease		Discovery of novel biomarkers that will lead to the early detection of Alzheimer's disease.	Baylor Research Institute	All	40 Years and older   (Adult, Older Adult)		220	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	017-039	March 22, 2017	April 30, 2022	December 31, 2022	May 2, 2017		October 7, 2019	Baylor AT&T Memory Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT03136679
686	NCT03081546	Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease		Completed	No Results Available	Mild Cognitive Impairment|Healthy Controls		University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA)|Medication Management Ability Assessment|Lawton iADL (instrumental activities of daily living) scale	University of Colorado, Denver|Alzheimer's Association	All	55 Years to 85 Years   (Adult, Older Adult)		41	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	16-1954	May 4, 2017	September 1, 2018	September 1, 2018	March 16, 2017		August 9, 2021	University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT03081546
687	NCT05538507	Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: smart soup|Drug: Donepezil|Drug: Memantine|Drug: Placebo	Changes of cognitive screening|Changes of comprehensive cognitive assessment|Changes in the degree of dementia|Changes in behavior|Changes in Psychiatric symptoms|Changes of daily living skills|Changes in health status|Tau and Beta-amyloid biomarkers in CSF and plasma|Magnetic resonance imaging and Electroencephalogram（EEG）|Oxidative stress markers in blood|Alterations of neurotransmitters in the blood	Peking Union Medical College Hospital|Tongji University	All	40 Years to 90 Years   (Adult, Older Adult)	Phase 2	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	Smart Soup	June 1, 2022	June 2024	June 2024	September 14, 2022		September 14, 2022	Peking Union Medical College Hospital, Beijing, China		https://ClinicalTrials.gov/show/NCT05538507
688	NCT04984681	Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV Supplement		Recruiting	No Results Available	HIV Infections|Mild Cognitive Impairment	Behavioral: Mindfulness|Other: Usual Care	Feasibility of the mindfulness intervention in women with mild cognitive impairment|Acceptability|Neurocognitive Function|Medication Adherence|Perceived Stress|Mental Distress	University of Alabama at Birmingham	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	K23AT010567S|K23AT010567	March 2, 2022	November 1, 2022	July 31, 2023	July 30, 2021		June 10, 2022	UAB School of Nursing, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT04984681
689	NCT05469360	Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants		Not yet recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: NIO752|Drug: Matching placebo	Change in cerebrospinal total tau from baseline to Day 85|Number of adverse events and serious adverse events|Concentration of NIO752 in cerebrospinal fluid (CSF)|Cmax, Ctrough in plasma|Tmax in blood plasma|AUC-last in blood plasma|AUC-inf in blood plasma	Novartis Pharmaceuticals|Novartis	All	30 Years to 74 Years   (Adult, Older Adult)	Phase 1	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CNIO752B12201|2022-000921-26	September 9, 2022	November 22, 2023	November 22, 2023	July 21, 2022		July 21, 2022			https://ClinicalTrials.gov/show/NCT05469360
690	NCT02544074	Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)	eSAGE	Active, not recruiting	Has Results	Mild Cognitive Impairment|Dementia	Behavioral: neuropsychological testing|Behavioral: eSAGE testing	eSAGE Score Compared to the Sum of the Neuropsychological Measures.|eSAGE Score Compared to the Paper SAGE Score|eSAGE Score Compared to the Mini-Mental State Examination (MMSE) Score|eSAGE Score Compared to the Montreal Cognitive Assessment (MoCA) Score|eSAGE Score Compared to the Boston Naming Test Score|eSAGE Score Compared to the Wisconsin Card Sort Task (WCST) Score|eSAGE Score Compared to the Hopkins Verbal Learning Test (HVLT) Score|eSAGE Score Compare to the FAS Verbal Fluency Task Score|eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Letter-number Score|eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Block Design Score	Ohio State University|Brain Test, Inc.	All	50 Years and older   (Adult, Older Adult)		69	Other|Industry	Observational	Observational Model: Other|Time Perspective: Prospective	2014H0039	January 2015	December 1, 2022	December 12, 2022	September 9, 2015	November 6, 2017	May 26, 2022	The Ohio State University, Columbus, Ohio, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02544074/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02544074
691	NCT05229978	Engagement 2.0 Forms of Consent for Data (re-)Use	ENGAGE	Recruiting	No Results Available	Alzheimer Disease, Early Onset|Mild Cognitive Impairment	Other: Showing an existing Dynamic Consent (computer interface) as prompt	Qualitative data: interpretations / opinions / needs / thoughts / feelings with regard to clinical data usage and dynamic consent.	Universitair Ziekenhuis Brussel	All	18 Years and older   (Adult, Older Adult)		18	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Engage 2.0	June 2022	July 2022	September 2022	February 8, 2022		May 24, 2022	Universitair Ziekenhuis Brussel (UZB), Jette, Brussel, Belgium		https://ClinicalTrials.gov/show/NCT05229978
692	NCT02774720	Centre- Versus Home-based Exercise for MCI and Early Dementia	CHIME	Completed	No Results Available	Mild Cognitive Impairment|Dementia	Behavioral: Centre-based exercise|Behavioral: Home-based exercise	Achievement of Physical Activity|Change in physical activity|Cost-effectiveness	University of Waterloo|Alzheimer's Association	All	50 Years and older   (Adult, Older Adult)	Not Applicable	44	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	20687	September 2016	March 2019	March 2019	May 17, 2016		May 29, 2019	Sunnybrook Research Institute, Toronto, Ontario, Canada|University of Waterloo, Waterloo, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02774720
693	NCT05138263	Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's disease2 (KBASE2)	KBASE2	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment		Amount of brain amyloid deposition|Amount of brain tau deposition|Change of brain amyloid deposition|Change of brain tau deposition|Change of CERAD total score|Change of cortical thickness	Seoul National University Hospital|National Institute on Aging (NIA)	All	20 Years to 90 Years   (Adult, Older Adult)		640	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	KBASE02|U01AG072177	January 1, 2022	June 2026	June 2026	November 30, 2021		May 9, 2022	Seoul National University Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05138263
694	NCT04482660	Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population		Enrolling by invitation	No Results Available	Healthy|Mild Cognitive Impairment	Procedure: Positron emission tomography with 18F-RO6958948	Prevalence of cerebral tau positivity|tau accumulation and spreading	Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Hoffmann-La Roche|Hospital Clinic of Barcelona	All	45 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	tau-PET/BBRC2019	March 29, 2021	March 31, 2024	March 31, 2025	July 22, 2020		September 16, 2021	BarcelonaBeta Brain Research Center, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04482660
695	NCT04253587	Wayfinding Intervention in High-Fidelity Long-Term Memory	LABYR	Completed	No Results Available	Long-Term Memory Decline|Mild Cognitive Impairment	Device: LabyrinthVR|Device: Placebo Games|Device: Coherence|Device: Tablet	MDT change in mnemonic discrimination|WALK change in recall|Changes in volumetric-based brain morphometry associated with training-induced changes in mnemonic discrimination|Changes in task-based cortical functional connectivity associated with training-induced changes in mnemonic discrimination|Remote Cognitive Module (RCM)|Test of Visual Attention change in top-down control	University of California, San Francisco	All	62 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science	19-27586-A	October 1, 2019	December 15, 2021	December 15, 2021	February 5, 2020		May 17, 2022	UCSF Mission Bay, San Francisco, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04253587/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT04253587
696	NCT02984540	Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease	BEAM	Completed	No Results Available	Mild Cognitive Impairment|Insulin Resistance	Other: Low-Carbohydrate Diet|Other: Low-Fat Diet	Change in spinal fluid levels of biomarkers associated with Alzheimer's disease|Change in memory composite score|Change in insulin sensitivity|change in 11C acetoacetate PET uptake	Wake Forest University Health Sciences	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	IRB00029992	February 2015	April 3, 2017	April 3, 2017	December 7, 2016		August 4, 2020	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02984540
697	NCT04730635	Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)		Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Donepezil|Drug: Placebo	Percentage Change From Baseline in Correct Responses on the One Card Learning (OCL) Task to Week 8|Percentage Change From Baseline in the Overall Standard Deviation (sd) in Average OCL Task (Arcsine Square Root Transformed) to Week 8|Percentage of Correct Responses on the OCL Task	Merck Sharp & Dohme LLC	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1	36	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	0000-413|MK-0000-413	March 23, 2021	January 31, 2023	February 14, 2023	January 29, 2021		August 2, 2022	Collaborative Neuroscience Network ( Site 0010), Long Beach, California, United States|MD Clinical ( Site 0013), Hallandale Beach, Florida, United States|Charter Research - Lady Lake ( Site 0025), Lady Lake, Florida, United States|iResearch Atlanta ( Site 0005), Decatur, Georgia, United States|iResearch Savannah ( Site 0023), Savannah, Georgia, United States|Pennington Biomedical Research Center ( Site 0006), Baton Rouge, Louisiana, United States|Insight Clinical Trials ( Site 0020), Beachwood, Ohio, United States|North Texas Clinical Trials - Fort Worth - West Rosedale ( Site 0022), Fort Worth, Texas, United States|Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031), Adelaide, South Australia, Australia|Austin Health ( Site 0030), Heidelberg, Victoria, Australia		https://ClinicalTrials.gov/show/NCT04730635
698	NCT05377060	Disclosing Dementia Risk Based on Plasma Phosphorylated Tau		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Behavioral: Plasma p-tau risk disclosure|Behavioral: Standard risk disclosure	Geriatric Depression Scale|Geriatric Depression Scale - 6-month follow-up|Geriatric Anxiety Scale|Geriatric Anxiety Scale - 6-month follow-up|Beck Hopelessness Scale|Beck Hopelessness Scale - 6-month follow-up|Impact of Events Scale|Immediate Comprehension|Long-term Comprehension	Vanderbilt University Medical Center	All	60 Years and older   (Adult, Older Adult)	Not Applicable	44	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	220449	September 1, 2022	May 31, 2024	May 31, 2024	May 17, 2022		September 16, 2022	Vanderbilt University Medical Center, Nashville, Illinois, United States		https://ClinicalTrials.gov/show/NCT05377060
699	NCT03025334	tDCS on Parkinson's Disease Cognition	tDCS-PD-fMRI	Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Device: High-definition transcranial direct current stimulation	cognitive performance in neuropsychological tests	University of Manitoba|Parkinson Society Canada	All	40 Years and older   (Adult, Older Adult)	Not Applicable	36	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	B2016:052	March 22, 2017	August 2023	August 2024	January 19, 2017		April 12, 2022	University of Manitoba, Winnipeg, Manitoba, Canada		https://ClinicalTrials.gov/show/NCT03025334
700	NCT04240561	Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia		Recruiting	No Results Available	Hearing Loss, Sensorineural|Dementia of Alzheimer Type|Amnestic Mild Cognitive Impairment	Device: High level of signal manipulation|Device: Low level of signal manipulation	Change In Speech Intelligibility (%Correct)|Change in Conversation Analysis of Communication Breakdown	Northwestern University|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	20	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	STU00211218|3R01DC012289-08S1	July 1, 2021	March 30, 2022	September 30, 2022	January 27, 2020		September 2, 2021	Northwestern University, Chicago, Illinois, United States|Northwestern University, Evanston, Illinois, United States		https://ClinicalTrials.gov/show/NCT04240561
701	NCT00474513	An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.		Completed	No Results Available	Mild Cognitive Impairment|Dementia	Drug: GSK239512	Receptor occupancy in the brain after receiving a dose of GSK239512, measured using calculations from PET images at 4 hours and 24 hours post dose|Safety of drug and concentration of GSK239512 in the blood at various timepoints. Using vital signs and ECG, clinical laboratory assessments and PK sampling.	GlaxoSmithKline	Male	35 Years to 49 Years   (Adult)	Phase 1	5	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H3B106026	March 2007	March 2008	March 2008	May 17, 2007		June 4, 2012	GSK Investigational Site, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00474513
702	NCT02353845	Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease		number of participants correctly classified by the support vector machine (SVM) classifier for the aMCI diagnosis|number of participants correctly predicted by the SVM classifier for predicting conversion from aMCI to AD|regional cerebral metabolism (CMgl) measured by FDG-PET|changed regional cerebral blood flow measured by FDG-PET	XuanwuH 2|Xuanwu Hospital, Beijing	All	Child, Adult, Older Adult		297	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	hanying2	November 2013	October 2015	August 2016	February 3, 2015		August 23, 2016	Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02353845
703	NCT04992975	Brain Iron Toxicity and Neurodegeneration - A 7T MRI Study	BITaN	Enrolling by invitation	No Results Available	Prodromal Alzheimer's Disease|Mild Cognitive Impairment	Other: MRI at 7T	Quantitative Susceptibility Mapping, QSM (from 7T MRI data) to hippocampal subfield volume loss at 1 year|cross-sectional and longitudinal changes in QSM in the hippocampal subfields|neuropsychological measures in relation to QSM and volume loss in hippocampal subfields	Nottingham University Hospitals NHS Trust	All	18 Years to 75 Years   (Adult, Older Adult)		40	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	19NS038	August 2021	January 2023	September 2023	August 6, 2021		August 6, 2021	Nottingham University Hospitals NHS Trust, Nottingham, East Midland, United Kingdom		https://ClinicalTrials.gov/show/NCT04992975
704	NCT05364307	Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)		Not yet recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Memory Loss|Memory Disorders|Memory Impairment	Other: Prescreener database	Determine number of patients eligible for therapeutic Alzheimer's Disease clinical trial	Global Alzheimer's Platform Foundation	All	50 Years to 90 Years   (Adult, Older Adult)		3000	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Apheleia-001	June 2022	June 2024	December 2024	May 6, 2022		May 11, 2022			https://ClinicalTrials.gov/show/NCT05364307
705	NCT02452619	MRI Brain Changes Induced by Hyperbaric Oxygen Therapy in Brain Injury Patients		Unknown status	No Results Available	Hyperbaric Oxygen Therapy|Mild Cognitive Impairment	Other: Hyperbaric oxygen therapy	Perfusion MRI changes|Microstructure changes (DTI)	Assaf-Harofeh Medical Center	All	18 Years and older   (Adult, Older Adult)		30	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	0030-15-ASF	March 2015	June 2017	June 2017	May 22, 2015		October 25, 2016	Assaf-Harofeh Medical Center, Zerifin,, Israel|Assaf-Harofeh Medical Center, Zerifin, Israel		https://ClinicalTrials.gov/show/NCT02452619
706	NCT04103255	High Frequency and Intensive Prevention Program		Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment	Other: High frequency and intensive prevention program	The Reliable Change Index in in Mini Mental Status (MMS; Folstein et al., 1975)|The Reliable Change Index in Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005)|The Reliable Change Index in the Semantic (Morris et al., 1989) and the Phonemic (Thurstone, 1948) fluency|The Reliable Change Index in the Five-Point Test (Regard, Strauss, & Knapp, 1982)|The Reliable Change Index in the Trail Making Test (TMT; Reitan, 1958)|The Reliable Change Index in the Stroop Test (Stroop, 1935)|The Reliable Change Index in Modified Wisconsin Card Sorting Test (mWCST; Nelson, 1976)|The Reliable Change Index in California Verbal Learning Test (CVLT; Delis, Kramer, Ober, & Kaplan, 1987)|The Reliable Change Index in Digit Span and the Corsi Block Test (Härtig et al., 2000)|The Reliable Change Index in the 15-item version of the Boston Naming Test (Kaplan et al., 1978)|Apathy Evaluation Scale (AES; Marin, Biedrzycki, & Firinciogullari, 1991; German version: Lueken et al., 2006)|The Reliable Change Index in Beck Depression Inventory (Beck et al. Arch Gen Psychiatry 1961)|The Reliable Change Index in Beck Angst Inventory (BAI; Ehlers & Margraf, 2007)|The Reliable Change Index in Parkinson's disease fatigue scale (PFS; Brown, Dittner, Findley, & Wessely, 2005)|The Reliable Change Index in the PDQ-39|The Reliable Change Index in Barratt-Impulsiveness-Scale|NEO-FFI-30 (Körner et al., 2008)|The locus of Control Scale (The IE-4 scale) ( Julian B. Rotter et al., 1966)|The Reliable Change Index in AST - Apraxia Screen of TULIA|The Reliable Change Index in Rey-Osterrieth complex figure, Copy (Duley et al., 1993)|Electroencephalogram (EEG)|Near-infrared spectroscopy|The Reliable Change Index in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part I + UPDRS Part II +UPDRS Part III +UPDRS Part IV|Non Motor Symptom Assessment Scale for Parkinson's disease|The SEIQoL-DW ((Schedule for the Evaluation of Individual Quality of Life - Direct Weighting)	University Hospital, Basel, Switzerland|Parkinson Schweiz	All	18 Years to 86 Years   (Adult, Older Adult)	Not Applicable	6	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	BSL prevention program	July 10, 2020	November 1, 2021	February 2022	September 25, 2019		May 6, 2021	University Hospital Basel, Basel, Switzerland		https://ClinicalTrials.gov/show/NCT04103255
707	NCT05433883	The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness	OSA	Enrolling by invitation	No Results Available	Obstructive Sleep Apnea of Adult|Mild Cognitive Impairment	Procedure: sleep surgery	polysomnography|Mini-Mental State Examination|peripheral blood sample for plasma Aβ42, Aβ40, Aβ42/Aβ40, Tau, NfL|amyloid deposit (18F-florbetapir PET)|Taiwan smell identification test	Chang Gung Memorial Hospital	All	50 Years and older   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Hsueh-Yu Li	November 3, 2020	October 2022	October 2022	June 27, 2022		June 27, 2022	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT05433883
708	NCT04120766	Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging	SMArT-HS	Recruiting	No Results Available	Dementia|Mild Cognitive Impairment	Drug: Nicorandil|Drug: Placebo	Frequency of subjects by arm that experience treatment-related adverse events at week 96|Hippocampal volume (CC)	Gregory Jicha, MD, PhD|National Institute on Aging (NIA)|University of Kentucky	All	75 Years and older   (Older Adult)	Phase 2	64	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	NIA 1R01AG061111|1R01AG061111	December 1, 2021	November 1, 2024	November 20, 2024	October 9, 2019		January 11, 2022	University of Kentucky, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT04120766
709	NCT03836963	Cognitive Rehab for Parkinson's		Recruiting	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Behavioral: cognitive training|Behavioral: active control cognitive training|Behavioral: memory strategy training	change in NIH sponsored Executive Abilities: Measures and Instruments for neurobehavioral evaluation and re-search (NIH-EXAMINER) executive composite score	VA Office of Research and Development	All	50 Years and older   (Adult, Older Adult)	Not Applicable	45	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	N3015-P|RX003015	January 27, 2020	October 1, 2022	October 3, 2022	February 11, 2019		October 20, 2021	Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States		https://ClinicalTrials.gov/show/NCT03836963
710	NCT03408509	Cognitive Training to Promote Brain Health: Implementation and Engagement		Unknown status	No Results Available	Aging|Mild Cognitive Impairment	Behavioral: Computerized cognitive training	Engagement|Individual gains on the computerized exercises|Quantitative measure of motivation with the computerized training exercise|Qualitative motivation with the computerized training exercise|Training adherence (dichotomic variable)	Universidade Federal do Rio de Janeiro|University of Dublin, Trinity College|Global Brain health Institute	All	Child, Adult, Older Adult	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	GBHI_ALZ-18-544160	January 12, 2018	December 31, 2019	December 31, 2019	January 24, 2018		January 26, 2018	St James Hospital, Dublin, Ireland		https://ClinicalTrials.gov/show/NCT03408509
711	NCT04468347	Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease		Completed	Has Results	Alzheimer Disease|Mild Cognitive Impairment	Drug: Flortaucipir F18|Procedure: Brain PET scan	Flortaucipir PET Imaging (Quantitative)|Number of Participants With Advanced AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status|Number of Participants With AD Pattern Flortaucipir PET Scan and Relationship to Cognitive Status	Avid Radiopharmaceuticals	All	60 Years and older   (Adult, Older Adult)	Phase 1	89	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18F-AV-1451-A08	October 2014	February 2018	February 2018	July 13, 2020	September 25, 2020	September 25, 2020		"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04468347/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/47/NCT04468347/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT04468347
712	NCT03960476	Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults		Active, not recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Behavioral: PlanYourLifespan.org	Change in long-term care plan decision-making|Participant utilization of long-term care services|Number of participants that implement any of their long-term care plans|Participant long-term care goal concordance	Northwestern University|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Not Applicable	293	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	R01AG058777|1R01AG058777-01A1	January 13, 2020	August 30, 2023	February 29, 2024	May 23, 2019		January 21, 2022	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03960476
713	NCT01958437	Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation		Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease	Device: Transcranial direct current stimulation (tDCS)	Accuracy in Centimeters From Target Location for Allocentric|Hippocampal BOLD Signal During Task-based fMRI|Dorsal Attention Network Connectivity During Resting-state fMRI|Egocentric	VA Office of Research and Development	All	50 Years to 88 Years   (Adult, Older Adult)	Not Applicable	44	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	C1381-P	October 1, 2013	March 23, 2017	March 24, 2017	October 9, 2013	August 31, 2018	August 31, 2018	Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/37/NCT01958437/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01958437
714	NCT03370224	Application of the Modified Story Memory Technique (mSMT)© to Aging		Active, not recruiting	No Results Available	Aging|Mild Cognitive Impairment	Behavioral: Memory retraining exercises|Behavioral: Placebo control memory exercises	Change in scores on standardized neuropsychological tests of memory using the California Verbal Learning Test|Change in scores on self-report of emotional functioning, measured via the Chicago multiscale depression inventory|Change in scores on self-report of memory functioning, measured via questionnaire by the Memory Functioning Questionnaire|Change in scores on self-report of quality of life, measured via the SF-12	Kessler Foundation	All	65 Years and older   (Older Adult)	Not Applicable	33	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	R-990-17	November 1, 2017	November 1, 2022	November 1, 2022	December 12, 2017		March 15, 2022	Kessler Foundation, East Hanover, New Jersey, United States		https://ClinicalTrials.gov/show/NCT03370224
715	NCT03740178	Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)		Unknown status	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: MK-4334|Drug: Placebo to MK-4334|Drug: Donepepzil	Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing Study Treatment due to an Adverse Event|Plasma Steady State Concentration at 24 Hours (C24) of MK-4334|Plasma Steady State Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-4334|Plasma Steady State Maximum Concentration (Cmax) of MK-4334|Plasma Steady State Apparent Half-Life (t1/2) of MK-4334|Plasma Steady State Time to Maximum Concentration (Tmax) of MK-4334|Plasma Steady State Apparent Clearance (CL/F) of MK-4334|Plasma Steady State Apparent Volume of Distribution (Vz/F) of MK-4334	Merck Sharp & Dohme LLC	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1	12	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4334-005|MK-4334-005	September 27, 2019	February 28, 2020	February 28, 2020	November 14, 2018		May 3, 2019			https://ClinicalTrials.gov/show/NCT03740178
716	NCT03649724	The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's	LUCINDA	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: Placebo|Drug: Eligard 22.5Mg Suspension for Injection	Percent change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog-11)|Percent change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Alzheimer Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC+)|Percent change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Percent change in Burden Inventory|Percent change in Neuropsychiatric Inventory (NPI)|Change in Brain Magnetic Resonance Imaging (MRI) biomarkers	Weill Medical College of Cornell University|National Institute on Aging (NIA)|Tolmar Pharmaceuticals	Female	65 Years to 120 Years   (Older Adult)	Phase 2	180	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	19-05020209|R01AG057681-01A1	November 27, 2020	February 2025	February 2026	August 28, 2018		August 2, 2022	University of Miami Miller School of Medicine, Boca Raton, Florida, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03649724/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03649724
717	NCT03560960	Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease	DTAD	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Drug: Pramlintide challenge test	Plasma Aβ and t-tau changes|Plasma inflammatory changes|Plasma metabolic changes in blood|Change in MMSE|Change in CDR|Change in NAB|Change in WMS-III Logical Memory|Change in CLOX paradigm|Change in Trailmaking Test Part B|Change in Controlled Oral Word Association Test	Boston University|National Institute on Aging (NIA)	All	60 Years to 90 Years   (Adult, Older Adult)	Early Phase 1	240	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	H-37432|1R01AG059424-01	February 4, 2020	July 2023	July 2023	June 19, 2018		January 31, 2022	Indiana University Alzheimer Disease Center, Indianapolis, Indiana, United States|BU Alzheimer Disease Center, Boston, Massachusetts, United States|Memory Center VA Boston Healthcare, Jamaica Plain, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03560960
718	NCT03472664	Brain Energy for Amyloid Transformation in Alzheimer's Disease Study	BEAT-AD	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Other: low carbohydrate/high fat diet|Other: low fat/high carbohydrate diet	Cerebrospinal Fluid (CSF) Abeta42|CSF abeta42/ptau ratio|Preclinical Alzheimer Cognitive Composite (PACC)|Cerebral Blood Flow Measure with Arterial Spin Labeling (ASL) MRI	Wake Forest University Health Sciences|National Institute on Aging (NIA)	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	120	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00049474|1R01AG055122-01	July 16, 2018	April 2025	April 2026	March 21, 2018		June 1, 2022	Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03472664
719	NCT03466736	Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects	APPE	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Diagnostic Test: [18F]flutemetamol PET scan	short-term practice effects	University of Utah|National Institutes of Health (NIH)	All	65 Years and older   (Older Adult)		210	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	R01AG055428	September 1, 2018	April 30, 2022	April 30, 2022	March 15, 2018		March 10, 2021	University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03466736
720	NCT02851173	Cognitive Enhancement Through Transcranial Laser Therapy	LLLT	Completed	No Results Available	Healthy Participants|Mild Cognitive Impairment	Device: LLLT|Device: Placebo	Psychomotor vigilance task (PVT)|BOLD response to working memory task (2 back task)|Working memory (2 back task)	University of Texas at Austin	All	45 Years and older   (Adult, Older Adult)	Phase 2	99	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2015-09-0018	February 21, 2016	April 30, 2020	April 30, 2020	August 1, 2016		May 18, 2021	University of Texas at Austin, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT02851173
721	NCT02871921	Internet-based Conversational Engagement Clinical Trial	I-CONECT	Completed	No Results Available	Aging|Mild Cognitive Impairment	Behavioral: Conversational Engagement	Intervention Efficacy for High Dose : Global Cognitive Function|Intervention Efficacy for High Dose: Language-based executive function|Intervention Efficacy for High Dose: learning function|Intervention Efficacy for High Dose: Memory function|Intervention Efficacy for High Dose: objectively assessed IADL (Instrumental Activities of Daily Living) functions	Oregon Health and Science University|University of Michigan|National Institute on Aging (NIA)|Wayne State University|Emory University	All	75 Years and older   (Older Adult)	Not Applicable	186	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	STUDY00015937|R56AG056102|R01AG051628|R01AG056102	June 1, 2018	August 31, 2021	August 31, 2021	August 18, 2016		September 23, 2021	University of Michigan, Ann Arbor, Michigan, United States|Oregon Health & Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT02871921
722	NCT01571427	Conversations as a Means to Delay the Onset of Alzheimer's Disease	conversation	Completed	Has Results	Mild Cognitive Impairment|Cognitive Change	Behavioral: Active social engagement group|Behavioral: Control group	Changes in Global Cognitive Function Using Mini Mental State Examination Score (Post-study Test Score - Baseline Test Score)|Changes in Category Fluency (Animals) Test Scores (Post-study Test Score - Baseline Test Score)|Changes in Verbal Fluency Letter Test Scores (Post-study Test Score - Baseline Test Score)|Changes in the Consortium to Establish a Registry for Alzheimer's Disease Word List Immediate Recall (Post-study Test Score - Baseline Test Score)|Changes in the Consortium to Establish a Registry for Alzheimer's Disease Word List Delayed Recall (Post-study Test Score - Baseline Test Score)|Changes in Trail Making Test A Scores (Post-study Test Score - Baseline Test Score)|Changes in Trail Making Test B Scores (Post-study Test Score - Baseline Test Score)|Changes in the Stroop Color and Word Test (Stroop Test C) Scores (Post-study Test Scores - Baseline Test Scores)|Changes in Cogstate Computerized Test: Detection Test (Post-study Test Score - Baseline Test Score)|Changes in Cogstate One Back Accuracy (Post-study Test Score - Baseline Test Score)|Changes in Cogstate Two Back Accuracy (Post-study Test Score - Baseline Test Score)|Changes in CAMCI Total Score (Post-study Test Score - Baseline Test Score)	Oregon Health and Science University|National Institute on Aging (NIA)	All	70 Years and older   (Older Adult)	Early Phase 1	83	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	socialengagementR01|R01AG033581	February 2012	September 2013	September 2013	April 5, 2012	April 24, 2019	February 5, 2020	Oregon Health & Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT01571427
723	NCT03687710	The Comparative Effectiveness Dementia & Alzheimer's Registry	CEDAR	Active, not recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Behavioral: Multidomain precision medicine intervention	Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months|Change from Baseline in Cognitive Aging Composite (CAC) every 6 months|Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months|Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months|Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months|Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.|Change from Baseline in Cholesterol Biomarkers at 18 months|Change from Baseline in Inflammatory Biomarkers at 18 months|Change from Baseline in Metabolism Biomarkers at 18 months|Change from Baseline in Homocysteine at 18 months|Change from Baseline in Vitamin D at 18 months	Weill Medical College of Cornell University	All	18 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	1408015423	February 16, 2015	June 30, 2026	June 30, 2026	September 27, 2018		October 29, 2021			https://ClinicalTrials.gov/show/NCT03687710
724	NCT03089827	Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease		Enrolling by invitation	No Results Available	Alzheimer Disease|Mild Cognitive Impairment		Amyloid deposition	Wake Forest University Health Sciences	All	55 Years and older   (Adult, Older Adult)		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB00027675	May 21, 2014	April 2025	April 2028	March 24, 2017		May 3, 2022	Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03089827
725	NCT03030365	Orientation in AD Patients: PET-MR Study		Unknown status	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Device: Siemens "Biograph mMR" PET-MR (3T)	Orientation performance|Cortical atrophy|Functional connectivity analysis|Mental-orientation evoked fMRI activity|[18]F-fluorodeoxyglucose (FDG) uptake	Assuta Medical Center|Hadassah Medical Organization	All	50 Years to 79 Years   (Adult, Older Adult)		30	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	AssutaMC	February 15, 2017	February 15, 2019	February 15, 2020	January 25, 2017		January 25, 2017			https://ClinicalTrials.gov/show/NCT03030365
726	NCT02559700	Online Brain Training Intervention for Over 50s		Completed	No Results Available	Dementia|Mild Cognitive Impairment	Behavioral: Brain training programme	Change in reasoning ability as measured by the Baddeley Grammatical Reasoning|Change in visual memory and learning as measured by the Paired Associate Learning Test|Change in reaction time as measured by the Simple and Choice Reaction Test|Change in spatial working memory as measured by the Spatial Working Memory Test|Change in ability to complete day-to-day activities as measured by the Instrumental Activities of Daily Living scale (part of the Home Care Minimum Dataset)	King's College London|Alzheimer's Society|Imperial College London	All	50 Years to 110 Years   (Adult, Older Adult)	Not Applicable	4387	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	188008	November 2015	March 31, 2018	March 31, 2019	September 24, 2015		November 7, 2019			https://ClinicalTrials.gov/show/NCT02559700
727	NCT02701855	Retina Microvascular Remodeling and Cognitive Function In Hypertension	EYEBRAIN	Unknown status	No Results Available	Hypertension|Mild Cognitive Impairment	Behavioral: Cognitive tests|Biological: Blood test|Radiation: Brain and aorta RMI|Other: Adaptative optics	Relationships between retina micro-vascular remodeling and cognitive function in hypertensive patients.|• Associations between cognitive function and proximal aortic stiffness indices estimated from MRI images.|• Associations between retina arteriolar remodelling and cerebrovascular lesions (infarcts, lacuna, and white matter lesions) quantified from MRI images.|• Associations between retina arteriolar remodelling and neurodegenerative lesions (hippocampus atrophy) quantified from MRI images.|• Associations between proximal aortic stiffness and cerebrovascular lesions (infarcts, lacuna, and white matter lesions) quantified from MRI images.|• Associations between proximal aortic stiffness and neurodegenerative lesions (hippocampus atrophy) quantified from MRI images.|• Associations between retina arteriolar remodelling and proximal aortic stiffness indices.	Institute of Cardiometabolism and Nutrition, France|Fondation de Recherche sur l'Hypertension Artérielle	All	65 Years and older   (Older Adult)		160	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	14DRM_EYEBRAIN	October 2014	September 2017	December 2017	March 8, 2016		March 8, 2016	Unité de prévention des maladies cardiovasculaires Pôle Cardiologie/Métabolisme Hôpital Pitié-Salpétriêre, APHP, 83 bd de l'hôpital,, Paris, France		https://ClinicalTrials.gov/show/NCT02701855
728	NCT02597504	Development of a Neurocognitive Screening Test		Unknown status	No Results Available	Brain Concussion|Mild Cognitive Impairment	Other: Pen and paper neuropsychological test|Device: Quick Test	Reliability will be established through a test-retest to establish results should be stable over time|Validity established through correlation studies with well-known measures of memory and processing speed and ANOVA.	ImPACT Applications, Inc.	All	6 Years to 75 Years   (Child, Adult, Older Adult)	Not Applicable	1600	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	QPR-15-44	October 2015	September 2019	December 2020	November 5, 2015		October 2, 2019	FastMed Urgent Care, Scottsdale, Arizona, United States|University of Arkansas, Fayetteville, Arkansas, United States|Head First, Crofton, Maryland, United States|Jim Gyurke, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02597504
729	NCT01078636	Alzheimer's Disease Neuroimaging Initiative Grand Opportunity	ADNI-GO	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease		Rate of Decline as measured by: Cognitive tests, Activities of Daily Living, and CDR Sum of Boxes|Rate of conversion will be evaluated among all four groups|Rate of volume change of whole brain, hippocampus, and other structural MRI measures|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV-45|Group differences for each imaging and biomarker measurement|Correlations among biomarkers and biomarker change|Subgroups analyses: APOE genotype, low CSF Aβ42, positive amyloid imaging with 18F-AV-45	Alzheimer's Disease Cooperative Study (ADCS)|Northern California Institute of Research and Education|National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)		342	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	IA0175|1RC2AG036535-01	April 2010	October 2012	October 2012	March 2, 2010		September 16, 2014	University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, Irvine - BIC, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Martinez, California, United States|Stanford University, Palo Alto, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, St. Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRBC), Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Group, Amherst, New York, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory & Aging Program, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas SWMC, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Vancouver, British Columbia, Canada|Saint Joseph's Hospital, Hamilton, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT01078636
730	NCT02462161	Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart	SNIFF-Quick	Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Insulin aspart|Drug: Placebo	Change in cognition|Cerebral spinal fluid (CSF) and blood amyloid-beta, tau protein, and inflammatory markers|MRI measure of cortical thickness in Alzheimer's disease (AD) -vulnerable regions	Wake Forest University Health Sciences|National Institute on Aging (NIA)|General Electric	All	50 Years to 89 Years   (Adult, Older Adult)	Phase 1	24	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00026106|5P50AG005136-30	March 20, 2015	April 16, 2019	April 16, 2019	June 3, 2015		May 12, 2020	Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02462161/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT02462161
731	NCT00979446	Passport to Brain Wellness in Sedentary Adults		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Behavioral: Guided|Behavioral: Self-directed	We will use this pilot to determine the feasibility of carrying out a full-scale randomized trial to test the efficacy of our intervention.	HealthPartners Institute	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	63	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	03-024S2|3R01AG023410-05S2	June 2008	May 2009	August 2009	September 18, 2009		September 18, 2009	HealthPartners Research Foundation, Bloomington, Minnesota, United States		https://ClinicalTrials.gov/show/NCT00979446
732	NCT01984164	CAndesartan vs LIsinopril Effects on the BRain	CALIBREX	Completed	Has Results	Hypertension|Mild Cognitive Impairment	Drug: Candesartan|Drug: Lisinopril	Executive Function|NINDS-initiated EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or "EXAMINER" Tool Box.|Memory|Language|Attention Measured Using Digit Span Backward|White Matter Lesion Volume|Cerebral Perfusion|Attention Measured Using Digit Span Forward	Emory University|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Phase 2	176	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	IRB00070087|R01AG042127	August 20, 2014	December 3, 2018	December 3, 2018	November 14, 2013	February 21, 2021	February 21, 2021	Emory Univeristy, Atlanta, Georgia, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01984164/ICF_000.pdf|"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01984164/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01984164
733	NCT02048605	Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease	CBT	Unknown status	No Results Available	Parkinson's Disease|Mild Cognitive Impairment	Behavioral: Psycho-social CBT based training|Behavioral: Unspecific group training	Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SeiQol-DW)|Scale for the assessment of management of daily living (Alltagsbewältigungsskala: A-B-S)	University Hospital, Basel, Switzerland|Parkinson Schweiz|Bangerter-Rhyner Foundation|AbbVie	All	45 Years to 95 Years   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BSLTraining2	February 2014	January 2016	January 2021	January 29, 2014		September 21, 2020	University Hospital Basel, Basel, Switzerland		https://ClinicalTrials.gov/show/NCT02048605
734	NCT02137460	Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease	KBASE	Active, not recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment		The amount of brain amyloid deposition|Group difference for each clinical, neuropsychological, structural and functional neuroimaging, tau imaging, genetic, biochemical measures|Change of brain amyloid deposition|Change of clinical, neuropsychological measures|Change of structural and functional neuroimaging measures|Change of biochemical measures|Chage of tau imaging measures	Seoul National University Hospital|Ministry of Science and ICT, Republic of Korea	All	20 Years to 90 Years   (Adult, Older Adult)		920	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	KBASE01|NRF-2013M3C7A1072998|NRF-2013M3C7A1069644|NRF-2014M3C7A1046042|NRF-2014M3C7A1046037	May 2014	June 2022	June 2022	May 13, 2014		May 9, 2022	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02137460
735	NCT02423122	A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)		Completed	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: VX-745	Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET|Number of 11C-PiB Responders|Wechsler Memory Scale (WMS) Immediate Recall Composite|Wechsler Memory Scale (WMS) Delayed Recall Composite	EIP Pharma Inc	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 2	16	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	EIP-VX00-745-302	April 2015	July 2016	September 2016	April 22, 2015	June 14, 2019	June 14, 2019	Alzheimer Research Center, VU Medical Center, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT02423122
736	NCT00539305	Hormone and Information Processing Study	HIP	Completed	Has Results	Mild Cognitive Impairment|Alzheimer's Disease	Drug: testosterone gel|Drug: placebo gel	Behavioral & Mood Measure: Profile of Mood States (POMS)|Cognitive Changes Measured by Neuropsychological Tests: Rey Auditory Verbal Learning Test|Geriatric Depression Scale (GDS)|Short-Form Health Survey (SF-36)	University of Washington|National Institute on Aging (NIA)|Solvay Pharmaceuticals	Male	60 Years to 90 Years   (Adult, Older Adult)	Phase 3	22	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	29975-A|R01AG027156|1R01AG027156-01A2	July 2009	July 2011	May 2012	October 4, 2007	July 14, 2014	July 14, 2014	VA Puget Sound Health Care Systems, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00539305
737	NCT01874418	Biomarker Study to Diagnose Alzheimer's Disease	ADAM	Unknown status	No Results Available	Alzheimer Disease|Mild Cognitive Impairment	Other: Biomarker	Oligomeric beta-amyloid 42 in serum|Total tau concentration in CSF|Phosphorylated tau concentration in CSF|Monomeric beta-amyloid 42 in CSF	Seoul National University Hospital	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ADAM	March 2012	February 2015	February 2015	June 11, 2013		June 11, 2013	Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01874418
738	NCT00546767	Home-Based Assessment for Alzheimer Disease Prevention	HBA	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Behavioral: Mail and Live Phone|Behavioral: Interactive Voice Response (IVR)|Behavioral: Home-based Computer Kiosk|Behavioral: Traditional Evaluation Instruments	Feasibility Data -- the number of subjects recruited, screened, enrolled, and retained|Efficiency Data -- staff time required to successfully complete data collection|Transition from cognitive health to impairment|Method-Specific Adherence, including medication adherence|Rate of change in domains of assessment|Research blood samples|Safety Assessments: symptom checklist and adverse event checklist	Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)	All	75 Years and older   (Older Adult)	Not Applicable	640	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	IA0123|1RC2AG036535|ADC-030-HBA	September 2007	June 2013	June 2013	October 19, 2007		September 16, 2014	University of Alabama at Birmingham, Birmingham, Alabama, United States|Sun Health Reseach Institute, Sun City, Arizona, United States|University of California, Irvine Institute for Brain Aging and Dementia, Irvine, California, United States|University of California-San Diego ADRC/Neurosciences, La Jolla, California, United States|University of California, Davis, Martinez, California, United States|Stanford University / PAIRE, Palo Alto, California, United States|Yale University Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Mayo Clinic Jacksonville Neurology, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|University of South Florida, Suncoast Alzheimer's & Gerontology Center, Tampa, Florida, United States|Northwestern University Cognitive Neurology & Alzheimer's Disease, Chicago, Illinois, United States|Rush Alzheimer's Disease Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston University Alzheimer's Disease Clinical and Research Program, Boston, Massachusetts, United States|University of Michigan Psychiatry - Neuropsychology, Ann Arbor, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|New York University Aging and Dementia Research Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Neurological Care of CNY, Syracuse, New York, United States|Wake Forest University Gerontology and Geriatric Medicine, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania Geriatrics, Philadelphia, Pennsylvania, United States|University of Utah Center for Alzheimer's Care, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT00546767
739	NCT00438568	SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)	SNIFF 120	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease	Drug: Regular Insulin|Drug: Placebo	Changes in cognition|glucose metabolism|plasma biological markers|CSF biological markers|cerebral glucose metabolism	University of Washington|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Phase 2	173	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	30579-B|5R01AG027415|1R01AG027415-01	June 2006	December 2011	December 2011	February 22, 2007		September 14, 2012	Veterans Administration Puget Sound Health Care System, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00438568
740	NCT01547169	Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days	SNIFF-LONG 21	Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Placebo Comparator|Drug: insulin detemir	Verbal Memory Composite|Neuropsychological Test of Executive Function 1|Glucose Tolerance|Functional Ability|Plasma biomarkers of AD|Neuropsychological Test of Executive Functioning 2|Neuropsychological Tests of Visual Working Memory	University of Washington|National Institute on Aging (NIA)	All	50 Years to 89 Years   (Adult, Older Adult)	Phase 2	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	39683-A|2P50AG005136-27	March 2011	December 2012	December 2012	March 7, 2012		December 18, 2012	VA Puget Sound Health Care System, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT01547169
741	NCT01325259	FluoroAv45 Imaging Research-in Alzheimer's Disease	FAIR-AD	Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Other: neuropsychologic assessment|Radiation: [18F]AV-45 PET|Radiation: 18-FDG PET|Other: MRI	Standard Uptake Value Ratios (SUVr)	University Hospital, Tours	All	60 Years and older   (Adult, Older Adult)	Phase 2	54	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	PHRN08-VC / FAIR AD	April 2009	December 2011	December 2013	March 29, 2011		February 8, 2016	university hospital of CAEN, Caen, France|University Hospital of Lille, Lille, France|University Hospital of Toulouse, Toulouse, France|University Hospital of Tours, Tours, France		https://ClinicalTrials.gov/show/NCT01325259
742	NCT01320527	A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment	Dietary Supplement: Nutriceutical formulation|Other: Placebo	cognitive improvement or maintenance of cognitive performance|behavioral/psychotic symptoms	University of Massachusetts, Worcester|University of Massachusetts, Lowell|Alzheimer's Association	All	40 Years and older   (Adult, Older Adult)	Phase 2	135	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	05-1350|IIRG-08-91737	August 2008	April 2012	April 2012	March 22, 2011		March 3, 2016	Naples Medical Center, Naples, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Rivercourt Residences, Groton, Massachusetts, United States|Mary Immaculate Residential, Lawrence, Massachusetts, United States|D'Youville Senior Care, Lowell, Massachusetts, United States|Neurocognitive Institute, Mt. Arlington, New Jersey, United States|Advanced Memory Dynamics, Layton, Utah, United States		https://ClinicalTrials.gov/show/NCT01320527
743	NCT01255163	A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease		Terminated	Has Results	Alzheimer's Disease|Mild Cognitive Impairment	Drug: Exendin-4 SC|Drug: Placebo SC	Number of Participants With Incidence of Nausea|Mini Mental State Examination (MMSE)|Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog70)|Clinical Dementia Rating (CDR) Global Score|Clinical Dementia Rating (CDR) Sum of Boxes|Cerebrospinal Fluid (CSF) Total Tau|Cerebrospinal Fluid phospho181-tau (CSF p181-tau)|Cerebrospinal Fluid Amyloid-beta 42 (CSF Abeta42)|Body Mass Index (BMI)	National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)	All	60 Years and older   (Adult, Older Adult)	Phase 2	57	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	100423|10-AG-0423	November 21, 2010	November 18, 2016	November 18, 2016	December 7, 2010	February 22, 2018	February 22, 2018	National Institute on Aging, Clinical Research Unit, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01255163
744	NCT01642420	Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression	DEMPROG	Unknown status	No Results Available	Alzheimers Disease|Mild Cognitive Impairment		Conversion from Mild Cognitive Impairment to Alzheimers disease	Zealand University Hospital|Rigshospitalet, Denmark	All	50 Years to 90 Years   (Adult, Older Adult)		115	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	DEMPROG 2012	April 2012	February 2017	February 2017	July 17, 2012		September 13, 2012	Neurologisk Afd, Roskilde Sygehus, Roskilde, Denmark		https://ClinicalTrials.gov/show/NCT01642420
745	NCT04588649	The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke		Completed	No Results Available	Post-stroke Dementia|Vascular Mild Cognitive Impairment	Drug: THK-5351|Drug: AV-45	CDR score of cognition deteriorating group and stable group|Imaging positive and negative conditions	Chang Gung Memorial Hospital	All	50 Years and older   (Adult, Older Adult)	Phase 2	181	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	103-7584A	January 4, 2016	March 29, 2016	December 31, 2019	October 19, 2020		October 5, 2021	Department of Neurology, Chang-Gung memorial Hospital, Taoyuan, Guishan, Taiwan		https://ClinicalTrials.gov/show/NCT04588649
746	NCT00902499	Evolution of Memory Related Activity		Unknown status	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment			National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)		160	NIH	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	IA0159|5R01AG027435-04	May 2006	May 2011	May 2011	May 15, 2009		July 26, 2010	Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00902499
747	NCT04103463	Interactive Stepping Exercise on Memory		Unknown status	No Results Available	Amnestic Mild Cognitive Impairment|Interactive Stepping Exercise|Memory|Cognitive Function|Executive Function	Other: Interactive stepping exercise|Other: Home exercise	Chinese version verbal learning test|Selective reminding test|Wechsler Memory Scale-III|Logic memory test|Montreal Cognitive Assessment|Trail making test|Stroop test|Executive Interview	National Yang Ming University	All	50 Years to 100 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	YM108072F	October 1, 2019	December 31, 2020	July 31, 2021	September 25, 2019		September 25, 2019			https://ClinicalTrials.gov/show/NCT04103463
748	NCT05258058	Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment		Recruiting	No Results Available	Cognitive Dysfunction	Behavioral: Memory and Adaptation Training-Geriatrics	MAAT-G Feasibility|Qualitative assessment of feasibility|Change in cognitive function|Usability	Allison Magnuson|University of Rochester	All	65 Years and older   (Older Adult)	Not Applicable	35	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	UCCS19102- Part 2	December 10, 2021	March 1, 2023	March 1, 2023	February 28, 2022		February 28, 2022	University of Rochester, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT05258058
749	NCT00585572	Wisconsin Brain Donor Program	WBDP	Enrolling by invitation	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment			University of Wisconsin, Madison|University of Washington|National Institute on Aging (NIA)	All	18 Years and older   (Adult, Older Adult)		9999	Other|NIH	Observational	Observational Model: Other|Time Perspective: Other	H-2010-0037|2014-1484|A534255|GERIATRICS AND ADULT|2RF1AG027161-11A1|1P30AG062715-01	March 2007	August 2026	August 2026	January 3, 2008		September 14, 2022	University of Wisconsin Madison, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00585572
750	NCT00257712	SMART: Somatotrophics, Memory, and Aging Research Trial		Completed	No Results Available	Aging|Mild Cognitive Impairment	Drug: TH9507 human growth hormone releasing hormone (GHRH)	Change in declarative memory, including total recall scores on three tests of memory and on dual task response time (RT), a test of executive function.|Changes in other areas of cognitive function, including other tests of executive function, tests of lexical access, and tests of cognitive and perceptual-motor processing speed.	University of Washington|National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 2	151	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	28287-K|R01AG025515|R01AG025525-01A1	February 2006	December 2011	December 2011	November 23, 2005		December 19, 2013	University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00257712
751	NCT04498650	A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD	VIVIAD	Recruiting	No Results Available	Early Alzheimers Disease|Mild Cognitive Impairment Due to AD	Drug: PQ912|Drug: Placebo	Primary safety: The proportion of participants who experience any Adverse Event (AE), Serious Adverse Event (SAE), Adverse Event of Interest (AE-I)|Primary efficacy: within-participant linear change with time of the combinded z-score for cognition compared between active arm and placebo.|Secondary efficacy: The within-participant linear change from baseline to week 48 in quantitative EEG (global relative theta wave power), compared between active and placebo.|Secondary efficacy: The within-participant linear change with time in overall cognition as measured by the CogState Brief Battery (CBB) Z-score compared between active arm and placebo	Vivoryon Therapeutics N.V.|Nordic Bioscience A/S|Amsterdam UMC, location VUmc	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	250	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	PBD-01180|2019-003532-23	July 6, 2020	May 2023	July 2023	August 4, 2020		August 10, 2022	Sanos Clinics, Ganderup, Denmark|Sanos Clinics, Herlev, Denmark|Sanos Clinics, Vejle, Denmark|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Schleswig-Holstein (UKSH), Klinik für Neurologie, Kiel, Germany|Universitätsklinikum Magdeburg / Institut für Kognitive Neurologie und Demenzforschung, Magdeburg, Germany|Institut für Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany|Klinikum rechts der Isar der TU München / Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster / Klinik für Allgemeine Neurologie, Münster, Germany|Klinik für Neurologie Universitätsklinikum Ulm, Ulm, Germany|Brain Research Center, Amsterdam, Netherlands|Brain Research Center, Den Bosch, Netherlands|Brain Research Center Zwolle, Zwolle, Netherlands|Neurology (Memory Unit) - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Fundació ACE, Barcelona, Spain|Unidad de Neurociencias. Hospital Victoria Eugenia, Seville, Spain		https://ClinicalTrials.gov/show/NCT04498650
752	NCT00249080	Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease		Completed	No Results Available	Neurodegenerative Diseases|Mild Cognitive Impairment			Albany Medical College|United States Department of Defense	All	18 Years and older   (Adult, Older Adult)		182	Other|U.S. Fed	Observational	Observational Model: Cohort|Time Perspective: Prospective	AMC-IRB-1599|A-13214	June 2005		August 2007	November 7, 2005		August 24, 2009			https://ClinicalTrials.gov/show/NCT00249080
753	NCT00544856	Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease|Cognitive Impairment	Behavioral: complex cognitive training	cognition: MMSE, ADAS-cog.|quality of life	Ludwig-Maximilians - University of Munich	All	55 Years to 95 Years   (Adult, Older Adult)	Not Applicable	39	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	cogT001	October 2007	October 2008	October 2008	October 16, 2007		January 29, 2009			https://ClinicalTrials.gov/show/NCT00544856
754	NCT05417555	Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI	LIFUP-MCI	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Amnestic Mild Cognitive Disorder|Deep Brain Stimulation	Device: Low-Intensity Focused Ultrasound Pulsation (LIFUP)	Change in Perfusion Arterial Spin Labeling (ASL) fMRI Signal throughout Brain|Changes in BOLD-related functional connectivity from baseline in fMRI brain scan to 40 minutes.|Change in Brief Visual Memory Test Scores|Change in Verbal Learning Test Scores|Post-hoc biomarker analysis of APOE-4 status as a predictor of tFUS efficacy|Post-hoc biomarker analysis of plasma AB42/40 ratio as a predictor of tFUS efficacy|Post-hoc biomarker analysis of plasma ptau as a predictor of tFUS efficacy	University of California, Los Angeles|National Institute on Aging (NIA)	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	144	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	IRB#21-000995|1R01AG073480-01	September 1, 2022	July 31, 2026	July 31, 2026	June 14, 2022		September 6, 2022	UCLA Semel Institute for Neuroscience and Behavior, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT05417555
755	NCT03652012	Probing Cortical Excitability and Cognitive Function With TMS		Active, not recruiting	No Results Available	Cognitive Dysfunction	Device: Transcranial Magnetic Stimulation (TMS)	Cortical Excitability: Resting Motor Threshold (RMT). Measured with EMG, Resting Motor Threshold is the minimum amount of stimulation intensity over the motor hotspot that elicits a motor evoked response.|Cortical Excitability: Stimulus Response Curve. Measured with EMG, this measures motor response to various intensities of magnetic pulse stimuli|Cortical Excitability: Cortical Silent Period. Measured with EMG, this is a direct measure of cortical inhibition.|Baseline Functional Magnetic Resonance Imaging (fMRI) to observe functional activation of brain networks prior to intervention.|Post Functional Magnetic Resonance Imaging (fMRI) to observe functional activation of brain networks immediately following intervention.	University of Arizona	All	60 Years to 75 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	1707654427	April 3, 2018	October 31, 2021	October 31, 2021	August 29, 2018		April 30, 2021	University of Arizona, Tucson, Arizona, United States		https://ClinicalTrials.gov/show/NCT03652012
756	NCT02562989	[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)		Completed	Has Results	Alzheimer's Disease|Amnestic Mild Cognitive Impairment	Drug: [18F]MK-6240, ~185 MBq|Drug: [18F]MK-6240, ~160 MBq	Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-6240|Organ Effective Dose of [18F]MK-6240|Standardized Uptake Value Ratio (SUVR) of [18F]MK-6240 in Brain Regions of Interest|Intra-subject Test-Retest (T-RT) Variability of Standardized Uptake Value Ratio (SUVR) in Brain Regions of Interest	Merck Sharp & Dohme LLC	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 1	13	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	6240-001|2015-001659-58|MK-6240-001	October 19, 2015	December 27, 2016	December 27, 2016	September 29, 2015	July 23, 2018	September 18, 2018			https://ClinicalTrials.gov/show/NCT02562989
757	NCT01732653	A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults	VTIME	Completed	No Results Available	Elderly Adults|Parkinson|Mild Cognitive Disorder	Other: TT+VR|Other: TT alone	Falls rate|Gait|Cognitive function|Balance and mobility|Quality of life	Tel-Aviv Sourasky Medical Center|Newcastle University|University Medical Center Nijmegen|Universita degli Studi di Genova|KU Leuven	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	302	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	TASMC-12-NG-0505-CTIL|VTIME	November 2012	April 2015	December 2015	November 26, 2012		April 19, 2016	Department of Rehabilitation Sciences, Katholieke Universiteit Leuven, Leuven, Belgium|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Department of Neurosciences Universita Degli Studi Di Genova, Italy, Genova, Italy|Department of Geriatric Medicine and Neurology, Radboud University Nijmegen Medical Center The Netherlands, Nijmegen, Netherlands|Institute for Aging and Health, University of Newcastle, UK, Newcastle, United Kingdom		https://ClinicalTrials.gov/show/NCT01732653
758	NCT01684293	Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study		Completed	No Results Available	Mild Cognitive Impairment, So Stated|Cocaine Use Disorder	Behavioral: Occupational therapy-based cognitive rehabilitation|Behavioral: Psychoeducation/games	Change in cognitive impairment	University of California, San Francisco|San Francisco Veterans Affairs Medical Center	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	50	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	5K23DA034883-02	July 2013	March 31, 2019	March 31, 2019	September 12, 2012		July 1, 2019	University of California, San Francisco & San Francisco Veterans Affairs Medical Center, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT01684293
759	NCT01383161	18-Month Study of Memory Effects of Curcumin	Curcumin	Completed	Has Results	Age-associated Cognitive Impairment|Mild Cognitive Impairment (MCI)	Drug: Curcumin|Other: Placebo	Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Recall|Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Delay|Change From Baseline on Buschke Selective Reminding Task, Consistent Long-Term Retrieval|Change From Baseline on Buschke Selective Reminding Task, Total Score|Change From Baseline to 18 Months on Trail Making Test, Part A|Change From Baseline to 18 Months on Beck Depression Inventory (BDI)	University of California, Los Angeles	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	46	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	11-001740|IND 112714	March 2012	April 2017	April 2017	June 28, 2011	March 19, 2018	March 3, 2020	UCLA Longevity Center, Los Angeles, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/61/NCT01383161/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01383161
760	NCT02854033	Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol	ADNI3	Recruiting	No Results Available	Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)		Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)|Rate of change in cognition as measured by the Logical Memory Test I and II|Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE)|Rate of change in cognition as measured by the Cogstate Brief Battery (CBB)|Rate of change in cognition as measured by the American National Adult Reading Test (ANART)|Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA)|Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test|Rate of change in cognition as measured by the Trail Making Test: A and B|Change in tau deposition as measured by 18F-AV-1451|Change in amyloid deposition as measured by Florbetapir|Change in amyloid deposition as measured by Florbetaben|Rate of conversion to MCI or dementia due to AD|Rates of change of glucose metabolism (FDG-PET)|Change in Cerebral Spinal Fluid (CSF) Tau Biomarkers|Change in brain structure using magnetic resonance imaging (MRI)	University of Southern California|Northern California Institute of Research and Education|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute	All	55 Years to 90 Years   (Adult, Older Adult)		2000	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	ATRI-001|U01AG024904	October 2016	July 2022	July 2022	August 3, 2016		June 21, 2022	University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|Long Beach VA Neuropsychiatric Research Program, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|University of California, Davis, Walnut Creek, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Fairway, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Albany Medical College, Albany, New York, United States|Dent Neurologic Institute, Buffalo, New York, United States|New York University Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas, Southwestern MC at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Clinic for AD & Related, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|St. Joseph's Health Center - Cognitive Neurology, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Jewish General Hospital Memory Clinic, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02854033
761	NCT05187117	CAPABLE Family Pilot - Adapting CAPABLE for Older Adults With Mild Cognitive Impairment (MCI)/Early Stage Dementia and Their Care Partners		Recruiting	No Results Available	Dementia, Mild|Mild Cognitive Impairment|Disability Physical|Impairment, Cognitive|Caregiver Burden|Quality of Life|Depression	Behavioral: CAPABLE Family - Open Label Pilot|Behavioral: CAPABLE Family - Randomized Control Trial	Change in Function as assessed by the Katz Index of Independence in Activities of Daily Living|Change in Function as assessed by Lawton & Brody's assessment of Instrumental Activities of Daily Living Scale|Change in Pain as assessed by the Brief Pain Inventory (Short Form)|Change in Depression as assessed by the Patient Health Questionnaire Depression Scale (PHQ-8)|Change in caregiving burden as assessed by the Perceived Change Index Scale|Change in Perceived Change in Function Scale Score|Satisfaction at midpoint of intervention assessed by qualitative questions|Satisfaction at endpoint of intervention as assessed by qualitative questions|Level of Cognitive Impairment for eligibility as assessed by the Montreal Cognitive Assessment (MoCA) Blind/Telephone	Johns Hopkins University|National Institute on Disability, Independent Living, and Rehabilitation Research|The Rita and Alex Hillman Foundation	All	60 Years and older   (Adult, Older Adult)	Not Applicable	80	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	IRB00290674	March 9, 2022	April 1, 2023	April 1, 2023	January 11, 2022		August 10, 2022	Johns Hopkins School of Nursing, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT05187117
762	NCT05282550	Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone	REST	Not yet recruiting	No Results Available	AMCI - Amnestic Mild Cognitive Impairment|Sleep Disturbance	Drug: Trazodone|Drug: Placebo	Change in total sleep duration between the treatment arms|Change in Slow Wave Sleep (SWS) duration between the treatment arms|Change in SWS intensity between the treatment arms|Change in sleep onset latency between the treatment arms|Change in sleep fragmentation between the treatment arms|Change in self reported sleep measure Pittsburgh Sleep Quality Index (PSQI) between treatment arms|Change in self reported sleep measure Epworth Sleepiness Score (ESS) between treatment arms|Change in memory performance between treatment arms|Change in hippocampal activation on Function Magnetic Resonance Imaging (fMRI) measures during memory functioning between treatment arms	Johns Hopkins University|National Institute on Aging (NIA)	All	55 Years and older   (Adult, Older Adult)	Phase 2	100	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00301426|R01AG071522	October 1, 2022	March 2027	May 2028	March 16, 2022		August 10, 2022	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT05282550
763	NCT01421420	Alzheimer's Disease Core Center	ADCC	Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Memory Disorders		Neuropsychological Test Scores|Neurological Exam|Brain Tissue	University of Arizona|Banner Health|Barrow Neurological Foundation|Mayo Clinic|National Institute on Aging (NIA)|National Institutes of Health (NIH)	All	50 Years and older   (Adult, Older Adult)		900	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	P30AG019610	July 2001	December 2024	July 2025	August 22, 2011		June 12, 2015	University of Arizona, University Medical Center, Tucson, Arizona, United States		https://ClinicalTrials.gov/show/NCT01421420
764	NCT02098824	Symptomatic Treatment of Vascular Cognitive Impairment	STREAM-VCI	Unknown status	No Results Available	Mild Cognitive Impairment (Vascular)|Mild Cognitive Disorder (Vascular)|Vascular Dementia	Drug: Galantamine|Drug: Methylphenidate|Drug: Placebo	Change on performance on executive function and on memory after active challenge|Change on performance on other Neurocart tests after active challenge	Amsterdam UMC, location VUmc	All	Child, Adult, Older Adult	Phase 2|Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)	NL45933.029.13	February 2014	December 2016	July 2017	March 28, 2014		May 2, 2016	VU University Medical Center, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT02098824
765	NCT05273125	MOBility Disorders Assessment in Patients With Mild COGnitive Disorders	COG-MOB	Not yet recruiting	No Results Available	Cognitive Dysfunction	Behavioral: Gait disorders and falls risk assessment	Existence of at least one fall|Comparison between the fall schedule given and kept by the patient and / or his main caregiver and the collection of anamnestic data on the occurrence of falls|Patients enrollment rate|Satisfaction rate of caregivers assessed by a specific questionnaire (Likert)|Rate of multifallers allowing the comparison of the same variables as those used for the main objective between fallers, non-fallers and multifallers|Rate of serious falls allowing the comparison of the same variables in the subgroup of patients who had had at least one serious fall|Timeframe until conversion to major cognitive impairment according to the criteria of NIA-AA of 2011	University Hospital, Lille	All	65 Years and older   (Older Adult)		417	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020_55|2021-A00637-34	July 2022	July 2025	July 2025	March 10, 2022		March 10, 2022			https://ClinicalTrials.gov/show/NCT05273125
766	NCT04754906	Analysis of Motor Skills in the Elderly: the Role of Cognitive Abilities for Imagining and Planning Movement.	Vieillissement	Recruiting	No Results Available	Mild Cognitive Disorder	Other: Sequence 1|Other: Sequence 2|Other: Sequence 3|Other: Sequence 4|Other: Sequence 5	Sequence 1: symmetry ratio of the finger speed profile|Sequence 2 : perception bias (error in degrees of angle) of dynamic subjective visual vericality|Sequence 3 : activation time of the focal muscles in relation to the postural muscles|Sequence 4: temporal congruence between the duration of a movement realized and imagined|Sequence 5: speed achieved after the mental training sessions|Sequence 5: accuracy achieved after the mental training sessions	Centre Hospitalier Universitaire Dijon	All	18 Years and older   (Adult, Older Adult)		684	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	MANCKOUNDIA 2018	January 25, 2021	September 2023	September 2023	February 15, 2021		February 15, 2021	Chu Dijon Bourgogne, Dijon, France		https://ClinicalTrials.gov/show/NCT04754906
767	NCT05245903	Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside	Emerald-NRAD	Not yet recruiting	No Results Available	Alzheimer Disease|Dementia Alzheimers|Dementia|Cognitive Impairment|Mild Cognitive Impairment|Neurodegenerative Diseases|Neurocognitive Disorders|Neurocognitive Dysfunction|Cognitive Dysfunction|Mental Disorder	Device: Emerald Device Monitoring	Sleep efficiency|Longitudinal time series of gait speed measurements|Diurnal rhythm	Mclean Hospital|National Institute on Aging (NIA)	All	18 Years to 89 Years   (Adult, Older Adult)		40	Other|NIH	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	2021P003275	May 2022	April 30, 2025	April 30, 2025	February 18, 2022		February 18, 2022			https://ClinicalTrials.gov/show/NCT05245903
768	NCT04934423	Analysis of Inflammatory Predictors and Gene Expression in Patients With Mild Cognitive Impairment		Not yet recruiting	No Results Available	Cognitive Decline	Device: Direct Current Transcranial Stimulation - tDCS|Device: Sham Intervention	Cognitive Function|Inflammatory biomarkers|Genetic Biomarkers	Federal University of Paraíba	All	65 Years to 85 Years   (Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	CCL/Genes	June 2021	August 2021	April 2022	June 22, 2021		June 22, 2021			https://ClinicalTrials.gov/show/NCT04934423
769	NCT01725178	Train the Brain - Cognitive and Physical Training for Slowing Dementia	TTB	Unknown status	No Results Available	Mild Cognitive Impairment|Dementia|Memory Disorders	Behavioral: Cognitive and Physical training	Rate of cognitive decline, measured as score in neuropsychological tests|Modifications in brain activation during cognitive tasks, measured through functional magnetic resonance imaging|Rate of loss of grey and white matter in the cortex and the hippocampus, measured through Magnetic Resonance Imaging.|Recovery of normal frequency spectra in the electroencephalographic signal|Improvement in vascular function and structure, as variations in Flow Mediated Dilation, carotid intima-media thickness, arterial stiffness|Variations in brain vascular reactivity as flow and diameter response to CO2 inhalation	Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy	All	65 Years to 89 Years   (Older Adult)	Not Applicable	160	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	TTB-01	March 2012	December 2014	March 2016	November 12, 2012		March 30, 2016	Institute of Clinical Physiology - National Research Council, Pisa, Italy		https://ClinicalTrials.gov/show/NCT01725178
770	NCT03140865	Wake Forest Alzheimer's Disease Clinical Core	ADCC	Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Prediabetic State		Change in performance on cognitive measures.|Change in biomarker levels in cerebrospinal fluid (CSF).|Change in brain volumes on magnetic resonance imaging (MRI).	Wake Forest University Health Sciences	All	55 Years and older   (Adult, Older Adult)		850	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB00025540	January 2014	January 2025	January 2026	May 4, 2017		June 27, 2022	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03140865
771	NCT03419039	Anthocyanins as Dementia Prevention?	ACID	Unknown status	No Results Available	Dementia|Inflammation|Mild Cognitive Impairment|Coronary Artery Disease	Dietary Supplement: Anthocyanins|Dietary Supplement: Placebo	Quality of episodic memory.|Secondary endpoints from CogTrack|Blood outcome analysis|Cardiovascular parameters|Fecal analysis|Urine analysis|CSF measurements|MR-imaging/CT	Helse Stavanger HF	All	60 Years to 79 Years   (Adult, Older Adult)	Not Applicable	212	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	SUSID656	January 5, 2018	February 15, 2021	February 15, 2021	February 1, 2018		September 3, 2020	Stavanger University Hospital, Stavanger, Rogaland, Norway		https://ClinicalTrials.gov/show/NCT03419039
772	NCT04239079	Autoimmune Features of Neurodegenerative Disorders		Recruiting	No Results Available	Parkinson Disease|Alzheimer Disease|Mild Cognitive Impairment		Percentage of subjects with T-cell immune response	Columbia University	All	55 Years to 90 Years   (Adult, Older Adult)		120	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	AAAS1669|1R01NS095 435-01A1	May 1, 2019	June 2023	June 2023	January 23, 2020		March 22, 2022	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04239079
773	NCT05499767	HEPPI: Effectiveness of a Cognitive-Emotional Intervention for Homebound Older Adults	HEPPI	Recruiting	No Results Available	Mild Cognitive Impairment|Depressive Symptoms|Anxiety State	Behavioral: HEPPI	Changes in Episodic Memory|Changes in Depressive Symptomatology|Changes in Anxious Symptomatology|Changes in General Cognitive Function|Changes in Attentional Control|Changes in Subjective Memory Complaints|Changes in Perceived Quality of Life|Changes in Functional Status|Changes in Loneliness	University of Coimbra|Foundation for Science and Technology (FCT)	All	65 Years and older   (Older Adult)	Not Applicable	198	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	HEPPIEffectiv/CINEICC|SFRH/BD/146170/2019	September 1, 2021	March 2023	March 2023	August 12, 2022		August 12, 2022	Center for Research in Neuropsychology and Cognitive Behavioral Intervention (CINEICC), Coimbra, Portugal		https://ClinicalTrials.gov/show/NCT05499767
774	NCT02379156	Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia		Active, not recruiting	No Results Available	Tetraplegia|Hypothermia|Mild Cognitive Impairment	Drug: Midodrine Hydrochloride|Other: Cool Temperature	Core body temperature|Cognitive performance	James J. Peters Veterans Affairs Medical Center|The Craig H. Neilsen Foundation	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 4	30	U.S. Fed|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	HAN-14-045|315696|01589	April 2015	April 2021	December 2021	March 4, 2015		June 11, 2021	Center of Excellence for the Medical Consequences of SCI, James J Peters VAMC, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT02379156
775	NCT01699503	Indiana University Dementia Screening Trial	IU-CHOICE	Completed	Has Results	Dementia|Alzheimer's Disease|Mild Cognitive Impairment	Behavioral: Collaborative Dementia Care Program	Health Related Quality of Life (HRQOL)|Patient Health Questionnaire (PHQ-9)|Generalized Anxiety Disorder Scale (GAD-7)|Number of Participants With Health Care Utilization|Number of Participants With an Advance Directive at 12 Months	Indiana University|National Institutes of Health (NIH)|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	4005	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening	R01AG040220-01A1|1R01AG040220-01A1	October 2012	November 22, 2017	November 22, 2017	October 3, 2012	January 23, 2019	January 23, 2019	IU Health-Primary Care Clinics, Indianapolis, Indiana, United States|Wishard Health Services-Primary Care Clinics, Indianapolis, Indiana, United States|IU Health Arnett Primary Care Clinics, West Lafayette, Indiana, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01699503/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01699503
776	NCT01822535	Body Temperature in Persons With Tetraplegia When Exposed to Cold		Completed	Has Results	Tetraplegia|Hypothermia|Mild Cognitive Impairment	Drug: Midodrine hydrochloride	Visit 1: Percent Change in Core Body Temperature|Visit 2: Percent Change in Core Body Temperature With Midodrine|Visit 1: Percent Changes in Cognitive Performance - Stroop Interference|Visit 1: Percent Changes in Cognitive Performance - Delayed Recall	James J. Peters Veterans Affairs Medical Center	All	18 Years to 68 Years   (Adult, Older Adult)	Phase 4	30	U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)	01374	July 2011	October 2015	October 2015	April 2, 2013	March 4, 2016	March 4, 2016	Center of Excellence for the Medical Consequences of SCI, JJP VAMC, 7A-13, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT01822535
777	NCT03352557	Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease	TANGO	Terminated	No Results Available	Alzheimer's Disease	Drug: BIIB092|Drug: Placebo	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline Over Time at Week 78 on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Percentage of Participants With Anti-BIIB092 Antibodies in Serum Over Time up to Week 90	Biogen	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	654	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	251AD201|2017-002901-37	May 3, 2018	August 30, 2021	August 30, 2021	November 24, 2017		May 26, 2022	University of Alabama at Birmingham, Birmingham, Alabama, United States|Xenoscience Inc, Phoenix, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Dignity Health, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Advanced Research Center, Inc., Anaheim, California, United States|The Research Center of Southern California, Carlsbad, California, United States|Positron Research International, Fremont, California, United States|Neuropain Medical Center, Fresno, California, United States|V Royter, MD, APMC, Hanford, California, United States|Irvine Center for Clinical Research, Inc., Irvine, California, United States|Research Center for Clinical Studies West, Lancaster, California, United States|Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Stanford Hospital and Clinics, Palo Alto, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Invicro, New Haven, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Synexus Clinical Research US, Inc. - Orlando, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Synexus Clinical Research US, Inc. - The Villages, The Villages, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|McLean Hospital, Belmont, Massachusetts, United States|Tufts, Boston, Massachusetts, United States|Brigham and Women's Hospital Department of Neurology, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S. Marks, M.D., P.C., Plymouth, Massachusetts, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Enhancement Center of NJ, Toms River, New Jersey, United States|New York University Medical Center PRIME, New York, New York, United States|AD-CARE, University of Rochester, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|The Memory Clinic, Inc., Bennington, Vermont, United States|Cognition Health, Fairfax, Virginia, United States|Box Hill Hospital, Box Hill, Victoria, Australia|Caulfield Hospital, Caulfield, Victoria, Australia|Austin Hospital, Heidelberg West, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|CHU Strasbourg - Hôpital Hautepierre, Strasbourg Cedex, Bas Rhin, France|Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux Cedex, Gironde, France|Hôpital La Grave, Toulouse Cedex 9, Haute Garonne, France|Hopital Gui de Chauliac, Montpellier, Herault, France|CHU Rennes - Pontchaillou, Rennes cedex 2, Ille Et Vilaine, France|CHU Nantes - Hopital Nord Laënnec, Nantes cedex 1, Loire Atlantique, France|Hôpital Lariboisière, Paris cedex 10, Paris, France|Hôpital des Chapennes, Villeurbanne, Rhone, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|Studienzentrum fur Neurologie und Psychiatrie, Böblingen, Baden Wuertemberg, Germany|ISPG - Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Baden Wuerttemberg, Germany|Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg, Germany|Institut fuer Schlaganfall- und Demenzforschung (ISD), Muenchen, Bayern, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Hessen, Germany|Universitaetsklinikum Bonn AoeR, Bonn, Nordrhein Westfalen, Germany|Klinikum Altenburger Land GmbH, Altenburg, Thueringen, Germany|Charite - Campus Berlin Buch, Experimental and Clinical Research Center (ECRC), Berlin, Germany|IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo, Palermo, Italy|Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza, Roma, Italy|ULSS 6 Vicenza, Vicenza, Italy|Research Site, Obu-shi, Aichi-Ken, Japan|Research Site, Chiba-shi, Chiba-Ken, Japan|Research Site, Kawasaki-shi, Kanagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Kurashiki-shi, Okayama-Ken, Japan|Research Site, Suita-shi, Osaka-Fu, Japan|PALLMED Sp. z o.o., Bydgoszcz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Centrum Medyczne Senior, Sopot, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Mazowiecki Szpital Wojewódzki w Warszawie Sp z oo, Warszawa, Poland|CAE Oroitu, Getxo, Vizcaya, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Fundacio ACE, Barcelona, Spain|Hospital de Santa Maria, Lleida, Spain|Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|Hospital Victoria Eugenia, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Skånes Universitetssjukhus, Malmo, Sweden|Sahlgrenska Universitetssjukhuset, Mölndal Sjukhus, Molndal, Sweden|Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT03352557
778	NCT02353949	Investigating the Clinical Consequences of Flutemetamol-PET-scanning		Terminated	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease|Dementia	Drug: Flutemetamol (Vizamyl)	Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of ADCS-ADL score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of ADCS-CGIC score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.|Change of MMSE score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.	University of Zurich|ETH Zurich	All	Child, Adult, Older Adult	Phase 3	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Flutemetamol 2	May 2015	December 10, 2019	December 10, 2019	February 3, 2015		January 21, 2020	University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy, Schlieren, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT02353949
779	NCT04452864	Tablet-based Cognitive Training		Recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment	Device: Computerized Cognitive Training|Device: Documentaries with delayed Computerized Cognitive Training	Change in AD specific component score|MRI functional and structural	University of Bern	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	162	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-00630	July 1, 2020	December 1, 2024	April 1, 2025	July 1, 2020		September 13, 2021	University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland|Memory Clinic Zentralschweiz, Luzern, Switzerland		https://ClinicalTrials.gov/show/NCT04452864
780	NCT05480358	Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|Mild Dementia|Fasting-Mimicking Diet	Dietary Supplement: Fasting-Mimicking Diet ProlonADTM	Incidence of Treatment-Emergent Adverse Events|Percentage of patients able to achieve the designated diet regimen|Efficacy of the FMD in terms of conversion rate to AD|Efficacy of the FMD in terms of functional state|Efficacy of the FMD in terms of emotional state|Efficacy of the FMD in terms of nutritional state|Efficacy of the FMD in terms of caregiver stress' level|Efficacy of the FMD in terms of quality of life|Efficacy of the FMD in terms of prevention of Frailty|Efficacy of the FMD in terms of alzheimer and inflammatory biomarkers|Efficacy of the FMD in terms of episodic memory|Efficacy of the FMD in terms of general cognitive status	University of Genova	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	FMD AD	November 1, 2019	August 2023	August 2023	July 29, 2022		July 29, 2022	Alessio Nencioni, Genoa, GE, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera di Perugia, Perugia, Italy		https://ClinicalTrials.gov/show/NCT05480358
781	NCT03440840	Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV		Active, not recruiting	No Results Available	HIV-related Mild Neurocognitive Disorder	Procedure: Transcranial Direct Current Stimulation (tDCS)|Behavioral: Computer-based Cognitive Training|Behavioral: Watching Educational Videos	Psychomotor speed|Functional Status|Participant Assessment of Own Functioning (PAOF)|Center for Epidemiological Studies Depression scale (CES-D)	Nova Southeastern University	All	50 Years and older   (Adult, Older Adult)	Not Applicable	42	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	AG056256	January 16, 2018	October 15, 2019	November 2022	February 22, 2018		July 2, 2021	NSU Psychiatry Research Office, Fort Lauderdale, Florida, United States		https://ClinicalTrials.gov/show/NCT03440840
782	NCT03978650	Risk Factors for Falls and Fall-related Injuries Associated With Mild Neurocognitive Disorders		Active, not recruiting	No Results Available	Old Age|Fall Injury|Neurocognitive Disorders	Other: Observational	Fall Injury|Auditory verbal memory disorder|The Mental Alteration Test	Jewish General Hospital	All	65 Years and older   (Older Adult)		12000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-1804	July 23, 2019	August 1, 2022	January 1, 2023	June 7, 2019		August 24, 2021	Jewish General Hospital, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT03978650
783	NCT05014893	Neural Mechanisms of Cognitive Assessment and Rehabilitation for Mild Cognitive Dysfunction		Enrolling by invitation	No Results Available	Mild Cognitive Impairment (MCI)|Subjective Cognitive Decline (SCD)|Aging	Combination Product: multi-modal targeted intervention (e.g., cognitive training, exercise, games)	Change in Cognitive function (SCD-9)|Change in Cognitive function (MoCA)|Change in Cognitive function (AD8)|Change in Cognitive function (CDR)|Change in Physical capacity (TUG)|Change in Physical capacity (chair standing)	National Research Center for Rehabilitation Technical Aids	All	45 Years and older   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening	201900045	August 6, 2021	December 31, 2023	December 31, 2023	August 20, 2021		September 17, 2021	National Research Center for Rehabilitation Technical Aids, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT05014893
784	NCT01590706	A Study of Characterizing Cognitive Decline and Functional Cardiac Senescence in Healthy Korean Volunteers		Completed	No Results Available	Aging|Mild Cognitive Impairment|Angina Pectoris			Korea Institute of Oriental Medicine|Daejeon University	All	45 Years to 80 Years   (Adult, Older Adult)		116	Other	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	KC1101	November 2011	October 2012	March 2013	May 3, 2012		April 2, 2014	Dunsan Oriental Hospital of Daejeon Univ., Daejeon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01590706
785	NCT02488824	Effect of Heat Exposure on Cognition in Persons With Tetraplegia		Completed	Has Results	Tetraplegia|Hypothermia|Mild Cognitive Impairment	Procedure: Warm Temperature	Change in Core Body Temperature From Baseline to 120 Minutes Post Warm Challenge|Change in Cognitive Performance From Baseline to 120 Minutes Post Warm Challenge|Change in Distal Skin Temperatures From Baseline to 120 Minutes Post Warm Challenge|Change in Sweat Rate From Baseline to 120 Minutes Post Warm Challenge|Change in Thermal Sensitivity From Baseline to 120 Minutes Post Warm Challenge	VA Office of Research and Development|James J. Peters Veterans Affairs Medical Center	All	18 Years to 68 Years   (Adult, Older Adult)	Not Applicable	41	U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	D1734-P|HAN-15-013|01613	April 1, 2015	September 4, 2018	September 4, 2018	July 2, 2015	November 1, 2019	November 18, 2019	James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02488824/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02488824
786	NCT02267499	Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM Project	LLM	Completed	No Results Available	Mild Cognitive Impairment|Mild Dementia|Healthy	Other: LLM training	overall cognition|physical fitness|Episodic memory|working memory|executive function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Brain function	Aristotle University Of Thessaloniki|National and Kapodistrian University of Athens|University of Ulm|Greek Alzheimer's Association and Related Disorders	All	55 Years and older   (Adult, Older Adult)	Not Applicable	322	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	84171|238904	November 2010	April 2012	April 2013	October 17, 2014		October 20, 2014			https://ClinicalTrials.gov/show/NCT02267499
787	NCT03333096	Assessing Neurovisual Function in Patients With Cognitive Impairment		Unknown status	No Results Available	Glaucoma|Mild Cognitive Impairment|Glaucoma and Mild Cognitive Impairment|Healthy	Device: Ocusweep test battery|Diagnostic Test: Neuropsychological test battery	Perception speed|Evidence of cognitive impairment measured by MoCA-test|Evidence of impaired attentional ability - Cognitive profile|Evidence of impaired Executive Functioning - Cognitive profile 1/2|Evidence of impaired Executive Functioning - Cognitive profile 2/2|Evidence of impaired Visuoconstructive abilities - Cognitive profile|Evidence of slow reaction time - Cognitive profile|Evidence of impaired visual attention measured by UFOV-test - Cognitive Profile|Evidence of glaucomatous visual field defects 1/2|Evidence of glaucomatous visual field defects 2/2|Contrast Sensitivity - Ocusweep|Visual Acuity- Ocusweep|Visual Search - Ocusweep Neural|Memory guided saccades - Ocusweep Neural|Anti-saccades - Ocusweep Neural|Prosaccade - Ocusweep Neural	Turku University Hospital|Ocuspecto Oy|European Commission	All	65 Years and older   (Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	T212/2017	December 1, 2017	January 1, 2019	January 1, 2019	November 6, 2017		February 19, 2018	Turku University Hospital, Turku, Finland		https://ClinicalTrials.gov/show/NCT03333096
788	NCT01949376	Mild Cognitive Impairment in Breast Cancer Patients	HippoPCI	Completed	No Results Available	Breast Cancer|Cognitive Impairment		Rates of change in cognitive function from before treatment to after treatment initiation|Rates of change of brain structure from before treatment to after treatment initiation|Rates of change of brain function from before treatment to after treatment initiation	Northwestern University|National Institute of Nursing Research (NINR)	Female	40 Years to 70 Years   (Adult, Older Adult)		84	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	1R01NR014182-01	June 2013	December 31, 2019	December 31, 2019	September 24, 2013		April 3, 2020	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT01949376
789	NCT05189106	Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial	NADALS	Not yet recruiting	No Results Available	Amyotrophic Lateral Sclerosis|Alzheimer Disease|Mild Cognitive Impairment	Drug: Baricitinib	CSF Concentration of baricitinib|CSF CCL2 Concentration|CSF protein-kinase R (PKR) Concentration|CSF phospho-PKR (pPKR) Concentration|CSF pPKR/PKR ratio Concentration|CSF C-X-C motif chemokine ligand 10 (CXCL10) Concentration|CSF interferon gamma (IFNG) Concentration|CSF interleukin-6 (IL-6) Concentration|TAR DNA-binding protein 43 (TDP-43) Plasma Levels|CSF neurofilament light chain (NfL) Concentration|CSF tau Concentration|CSF phospho-tau (pTau)|Incidence of Adverse Effects	Massachusetts General Hospital	All	18 Years to 90 Years   (Adult, Older Adult)	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NADALS	September 14, 2022	July 1, 2024	October 1, 2024	January 12, 2022		September 6, 2022	Massachusetts General Hospital - ALS Site, Boston, Massachusetts, United States|Massachusetts General Hospital - AD Site, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT05189106
790	NCT04931459	A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD	INTERCEPT-AD	Recruiting	No Results Available	Alzheimer Disease	Drug: ACU193|Drug: Placebo	Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)|Change in Clinical Laboratory Tests|Changes in 12-Lead ECGs|Changes in the Columbia-Suicide Severity Rating Scale (C-SSRS)|Changes in Magnetic Resonance Imaging (MRI)|Estimate Blood Levels of ACU193|Estimate Maximum Blood Levels of ACU193|Estimate Time to Reach Maximum Blood Levels of ACU193|Estimate Clearance of ACU193|Estimate Volume of Distribution of ACU193	Acumen Pharmaceuticals|National Institute on Aging (NIA)	All	55 Years to 90 Years   (Adult, Older Adult)	Phase 1	62	Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ACU-001|3U01AG053247	June 21, 2021	March 2023	June 2023	June 18, 2021		September 6, 2022	Clinical Endpoints, Scottsdale, Arizona, United States|Orange County Research Institute, Anaheim, California, United States|Hoag Hospital Newport Beach, Newport Beach, California, United States|Velocity Clinical Research, Hallandale Beach, Florida, United States|Charter Research, Lady Lake, Florida, United States|Columbus Clinical Services, Miami, Florida, United States|Combined Research Orlando Phase I-IV, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Santos Research Center, Tampa, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Columbia University, New York, New York, United States|AMC Research, Matthews, North Carolina, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Kerwin Medical Center, Dallas, Texas, United States|Clinical Trials Network, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04931459
791	NCT04160299	Effectiveness of Alternative Therapy for Improving Cognition, Balance, and Physical Activity		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Older Adults|Neurological Injury	Behavioral: Dance-based exergaming	Feasibility of a 10-week Virtual reality-based dance training: questionnaire|Compliance rate of participants to a 10-week virtual reality-based dance training|Change in cognitive functions during single and dual tasks|Change in incidence of falls|Change in end point excursion|Change in Movement velocity|Change in maximum excursion|Change in directional control|Change in postural stability during reactive balance control (single and dual-task)|Change in step length|Change in gait speed|Change in cadence|Change in Blood pressure (mmHg)|Change in heart rate (beats per minute, bpm)|Change in physical activity level (step count)|Change in distance covered in Six-minute walk test (6MWT)|Change in time taken to complete Timed-Up and Go (TUG)|Berg Balance scale|Change in fall incidence in the home and community setting	University of Illinois at Chicago|National Institute on Aging (NIA)	All	65 Years to 90 Years   (Older Adult)	Not Applicable	20	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	2018-1074|P30AG022849	November 7, 2018	December 15, 2021	December 15, 2021	November 13, 2019		July 12, 2021	University of Illinois at Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT04160299
792	NCT03578991	Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease	DIALCAT	Completed	No Results Available	Patients Aged 65-85 (Both Included)|Diagnosed of Mild Cognitive Impairment|Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years	Device: Smart pillbox|Other: Interactive digital platform	Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).|Cardiovascular risk factor: Hypertension.|Cardiovascular risk factor: Obesity.|Cardiovascular risk factor: Dyslipidemia.|Degree of diabetes control.|Usal medication.|Presence of micro and macrovascular complications.|Presence and severity of hypoglycemia.|Lipid profile and renal and hepatic function.|Biomarkers (serum and DNA).|Short Physical Performance Battery test (SPPB).|Hachinski Scale (HS).|Blessed Dementia Rating Scale (BDRS).|Geriatric Depression Scale (GDS; 15-item short form).|Schwab and England Activities of Daily Living Scale (SE-ADL).|Montreal Cognitive Assessment (MOCA).|Mini-Mental State Examination (MMSE).|Memory failure in everyday life questionnaire (MFE).|The Functional Social Support Questionnaire (DUKE-UNC-11).|The Resource Utilization in Dementia (RUD).	Parc Sanitari Pere Virgili|Hospital Vall d'Hebron|Consorci Sanitari de Terrassa|Fundació Recerca Mútua Terrassa (FMT)|Clínica Universitària de la Fundació Universitària del Bages (FUB)|Althaia Xarxa Assistencial Universitària de Manresa|Fundació Privada Hospital Asil de Granollers (HAG)|Consorci Hospitalari de Vic|LambdaLoopers|Universitat Politècnica de Catalunya|Leitat|Mixestat|Meditecnologia	All	65 Years to 85 Years   (Older Adult)	Not Applicable	54	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	DIALCAT COMRDI-B64574221423350|COMRDI B64574221423350	July 1, 2019	April 15, 2020	April 15, 2020	July 6, 2018		August 14, 2020	Fundació Privada Hospital Asil de Granollers (HAG), Granollers, Barcelona, Spain|Fundació Althaia (FA), Manresa, Barcelona, Spain|Fundació Recerca Mútua Terrassa (FMT), Terrassa, Barcelona, Spain|Consorci Sanitari de Terrassa (CST), Terrassa, Barcelona, Spain|Consorci Hospitalari de Vic (CHV), Vic, Barcelona, Spain|Parc Sanitari Pere Virgili, Barcelona, Spain|LambdaLoopers, Barcelona, Spain|University Hospital Vall d'Hebron - Vall d'Hebron Institute of Research, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT03578991
793	NCT01979419	Korea Alzheimer's Disease Neuroimaging Initiative	K-ADNI	Unknown status	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease|Subcortical Vascular Dementia		Rate of dementia conversion or disease severity worsening, evaluated by neuropsychological, MRI, PET, biomarker indices.|Change from baseline in cognitive, neuroimaging, and biomarker assessments	Korean Alzheimers' Disease Neuroimaing Intitiative	All	50 Years to 80 Years   (Adult, Older Adult)		500	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	HI12C0713	November 2012	October 2020	October 2020	November 8, 2013		March 8, 2019	Seong Yoon Kim, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01979419
794	NCT01615666	A Composite MR Neuroimaging Marker for Alzheimer's Disease		Withdrawn	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Frontotemporal Dementia		To determine the sensitivity and specificity of the MRN Index as an AD biomarker.	Medical College of Wisconsin|National Institute on Aging (NIA)	All	50 Years to 90 Years   (Adult, Older Adult)		0	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	2R01AG020279-06A2	March 2009	January 2016	January 2016	June 8, 2012		January 14, 2016	Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT01615666
795	NCT03538522	A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Alzheimer Dementia|Dementia, Vascular|Dementia With Lewy Bodies|Cognitive Impairment|Tauopathies|Neurodegenerative Diseases|Neurocognitive Disorders|Cognitive Disorder	Drug: N-831(Traneurocin) 10 mg QD|Drug: NA-831 (Traneurocin) 20 mg QD|Drug: NA-831 (Traneurocin) 40 mg QD|Drug: Placebo oral capsule QD	Change from baseline in Clinical Dementia Rating Scale- Sum of Boxes (CDR-SB) score at Week 24|1. Mean difference between the last (Week 24) and first (Week 2) postdose using Clinical Dementia Rating Scale- Sum of Boxes (CDR-SB) assessment|Assess the change from baseline in ADCS-ADL MCI at Week 24	NeuroActiva, Inc.	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	126	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	NeuroActiva	September 15, 2018	September 30, 2019	October 30, 2019	May 29, 2018		June 30, 2020	NeuroActiva-Clinical Research Unit, Auckland, New Zealand|NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand		https://ClinicalTrials.gov/show/NCT03538522
796	NCT01876823	Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment		Completed	Has Results	Mild Cognitive Impairment|Major Depressive Disorder|Alzheimer's Disease	Drug: es-citalopram|Drug: Memantine	Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)|Change in Wechsler Memory Scale-III (WMS-III)|Change in Selective Reminding Test - Delayed Recall (SRT-DR)|Change in Trails B|Change in Trails A	New York State Psychiatric Institute	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2|Phase 3	60	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6277R	April 2006	March 2010	March 2010	June 13, 2013	October 24, 2014	October 24, 2014	New York State Psychiatric Institute, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01876823
797	NCT02650531	Norwegian COgnitive Impairment After STroke (NorCOAST) Study	Nor-Coast	Completed	No Results Available	Dementia|Mild Cognitive Impairment|Stroke		Score on the Montreal cognitive assessment (MOCA)|Time spent in upright position|Brain Imaging|Score on Short Physical Performance Battery (sppb)|Selfreported habits concerning smoking, alcohol, diet and medication using standardised questionnaires	Norwegian University of Science and Technology|Ullevaal University Hospital|Vestre Viken Hospital Trust|Haukeland University Hospital|University Hospital of North Norway	All	18 Years and older   (Adult, Older Adult)		816	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2015/171/REK nord	May 2015	October 8, 2018	October 8, 2018	January 8, 2016		February 23, 2022	Norwegian University of Science and Technology, Trondheim, Norway		https://ClinicalTrials.gov/show/NCT02650531
798	NCT03507257	Longitudinal Early-onset Alzheimer's Disease Study Protocol	LEADS	Recruiting	No Results Available	Early Onset Alzheimer Disease|Alzheimer Disease|Mild Cognitive Impairment	Drug: Flortaucipir|Drug: Florbetaben|Drug: Fluorodeoxyglucose	Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13)|Rate of change in cognition as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Change in tau deposition as measured by flortaucipir (18F-AV-1451) Positron Emission Tomography (PET) imaging|Change in amyloid deposition as measured by florbetaben using Positron Emission Tomography (PET) imaging|Neurodegeneration as measured by fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging compared to magnetic resonance imaging (MRI)|Change in brain structure using magnetic resonance imaging (MRI)|Change in cerebrospinal fluid (CSF) biomarkers|Change in plasma biomarkers	Liana Apostolova|Alzheimer's Therapeutic Research Institute|National Institute on Aging (NIA)|Alzheimer's Association|Indiana University	All	40 Years to 64 Years   (Adult)		700	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	ATRI-003|R56AG057195	April 30, 2018	August 31, 2023	August 31, 2023	April 25, 2018		September 7, 2022	Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center, Miami Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Houston Methodist Hospital, Houston, Texas, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03507257/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT03507257
799	NCT02266563	Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury		Completed	No Results Available	Traumatic Brain Injury|Chronic Traumatic Encephalopathy|Mild Cognitive Impairment	Drug: Amyvid PET Scan|Drug: T807 PET scan	Uptake of [18F]T807 in the brain|Uptake of [18F]AV-45 in the brain|Neuropsychological data composite score	Samuel Gandy|Icahn School of Medicine at Mount Sinai	Male	40 Years to 85 Years   (Adult, Older Adult)		46	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	GCO 14-0732	January 2015	December 21, 2017	December 21, 2017	October 17, 2014		May 2, 2019	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02266563
800	NCT03330587	Living Alone in Old Age With Cognitive Impairment		Recruiting	No Results Available	Living Alone|Alzheimer Disease|Mild Cognitive Impairment		Ethnographic interviews	University of California, San Francisco	All	55 Years and older   (Adult, Older Adult)		60	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	R01AG069147	March 1, 2016	February 20, 2023	May 31, 2025	November 6, 2017		July 11, 2022	Institute for Health & Aging, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03330587
801	NCT05122598	Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease		Recruiting	No Results Available	Mild Cognitive Impairment|Early Alzheimer's Disease|Memory Impairment	Drug: COT|Drug: Sham	Logical Memory II subscale (Delayed Paragraph Recall)|ADCS-PACC composite score|Olfactory Psychophysical Tasks scores|Changes in cortical thickness and grey matter volumes|Changes in subfield segmentations of the hippocampus and entorhinal cortex|Changes in the scores of Neuropsychological Test Battery (NTB)|Changes in the scores of Mini Mental State Examination (MMSE)|Changes in the scores of CDR scale (CDR)|Changes in the scores of Global Deterioration Scale(GDS)|Changes in the scores of Activities of Daily Living (ADCS-ADL)|Changes in the scores of Quality of Life scale (QOL)|Changes in odor discrimination scores|Changes in the grey matter volumes of other structures of the primary olfactory cortex|Changes in the cortical thickness of other structures of the primary olfactory cortex	Evon Medics LLC|Howard University|Family and Medical Counseling Service, Inc|Medical Home Development Group|National Institute on Aging (NIA)|Johns Hopkins University	All	55 Years to 95 Years   (Adult, Older Adult)	Phase 2	200	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	COTAG061981|2R44AG061981-03	November 15, 2021	April 1, 2023	April 30, 2023	November 17, 2021		May 17, 2022	Clinics of Dr. Edwin Chapman @ MHDG, Washington, District of Columbia, United States|Family and Medical Counseling Service, Inc, Washington, District of Columbia, United States|Howard University (HU), Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT05122598
802	NCT03333837	Improvisational Movement for People With Memory Loss and Their Caregivers	IMOVE	Completed	Has Results	Alzheimer's Disease (Incl Subtypes)|Dementia|Mild Cognitive Impairment	Behavioral: Dance Group|Behavioral: Non-Group Dance|Behavioral: Social Group|Behavioral: No Contact	Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD)|QOL-AD--PWD|Community Structure--PWD|Global Efficiency (eGlob)--PWD|Local Efficiency (eLoc)--PWD|Path Length--PWD|Fullerton Advanced Balance Scale (Overall Balance) PWD|Falls Efficacy Scale - International (FES) PWD|Neuropsychiatric Inventory Questionnaire (NPI-Q)|NPI-Q|Geriatric Depression Scale|Geriatric Anxiety Scale|Apathy Evaluation Scale--PWD|Expanded Short Physical Performance Battery (eSPPB)|Postural Sway--PWD|Gait Speed--PWD|Gait Variability--PWD	Wake Forest University Health Sciences|National Center for Complementary and Integrative Health (NCCIH)	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	104	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	IRB00042460|R01AT009444	February 6, 2018	May 26, 2021	May 26, 2021	November 7, 2017	July 27, 2022	July 27, 2022	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03333837/Prot_SAP_003.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03333837/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT03333837
803	NCT03665831	Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults		Recruiting	No Results Available	Major Depressive Disorder|Alzheimer Disease|Mild Cognitive Impairment	Device: Brainsway H1-Coil Deep TMS System	Change From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS)|Remission Rates Compared Within Treatment Group|Response Rates Compared Within Treatment Group|Change From Baseline on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)|Change From Baseline on the Neuropsychological Battery|Change in Functional Connectivity between PFC and Limbic Regions|Change in Perfusion within Prefrontal Cortex (PFC) and Posterior Cingulate Cortex (PCC)|Change in frontal theta power within the Anterior Cingulate Cortex (ACC)	Rotman Research Institute at Baycrest|Brainsway|Centre for Addiction and Mental Health	All	60 Years and older   (Adult, Older Adult)	Not Applicable	28	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CICP-2-00095	October 23, 2018	January 2022	April 2022	September 11, 2018		September 16, 2021	Rotman Research Institute at Baycrest, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03665831
804	NCT05004558	Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias		Not yet recruiting	No Results Available	Dementia|Alzheimer Disease|Dementia, Vascular|Lewy Body Disease|Frontotemporal Dementia|Mild Cognitive Impairment|Aging|Hypertension|Obesity, Abdominal|Obesity|Body Weight|Blood Pressure|Blood Glucose, High|Blood Glucose, Low|Dyslipidemias|Quality of Life|Cognitive Impairment	Other: Remote-based Resistance Exercise Training	Resting systolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure|Resting diastolic blood pressure, measured in mmHg from 0 and above with higher numbers indicating higher blood pressure|Height, red with a stadiometer in inches from 0 and above with higher numbers indicating taller height|Weight, ured with a physican scale in pounds from 0 and above with higher numbers indicating heavier weight|Body mass index, measured in meters squared, from 0 and above wiith larger values indicating a higher body mass index|Waist circumference, red in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference|Hip circumference, sured in inches with a Gulick tape measure from 0 and above with higher numbers indicating a larger waist circumference|Blood glucose, measured in mg/dL from 0 and above with larger values indicating a higher blood glucose concentration|High density lipoprotein cholesterol, ed in mg/dL from 0 and above with larger values indicating a higher high density lipoprotein concentrations, a desirable finding|Low density lipoprotein cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher low density lipoprotein concentrations, an undesirable finding|Triglycerides, measured in mg/dL from 0 and above with larger values indicating a higher triglyceride concentrations, an undesirable finding|Total cholesterol, measured in mg/dL from 0 and above with larger values indicating a higher total cholesterol concentrations, an undesirable finding|Cognitive Function as Measured by the Montreal Cognitive Assessment|Quality of Life as measured by the Short-Form (36) Health Survey	Drexel University|Mercy Health	All	55 Years and older   (Adult, Older Adult)	Not Applicable	36	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	THMA 2021-21	September 1, 2021	March 2022	June 2022	August 13, 2021		August 13, 2021			https://ClinicalTrials.gov/show/NCT05004558
805	NCT05484960	The Philippine Neurological Association One Database -Dementia	PNA1DB-Dem	Recruiting	No Results Available	Cognitive Impairment|Dementia|Mild Cognitive Impairment	Other: cognitive assessment	Frequency of dementia and mild cognitive impairment in the study population|F frequency of the different types of dementia in the study population|Frequency of risk factors for dementia in the study population|Demographic characteristics of patients with dementia or mild cognitive impairment|Dementia Severity|Diagnostic tests used at the time of the diagnosis|Pharmacologic and nonpharmacologic modalities used	Philippine Neurological Association|University of Santo Tomas Hospital, Philippines|Baguio General Hospital and Medical Center, Philippines|East Avenue Medical Center, Philippines|Jose R. Reyes Memorial Medical Center|Makati Medical Center|Quirino Memorial Medical Center, Philippines|St. Luke's Medical Center, Philippines|The Medical City, Philippines|University of the East- Ramon Magsaysay Memorial Medical Center, Philippines|University of the Philippines Manila - Philippine General Hospital|Chong Hua Hospital, Philippines	All	18 Years and older   (Adult, Older Adult)		73	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	PNA2020_0X	December 8, 2021	December 31, 2024	December 31, 2024	August 2, 2022		August 2, 2022	Baguio General Hospital and Medical Center, Baguio City, Baguio, Philippines|Chong Hua Hospital, Cebu City, Cebu, Philippines|Makati Medical Center, Makati City, Metro Manila, Philippines|The Medical City, Pasig City, Metro Manila, Philippines|East Avenue Medical Center, Quezon City, Metro Manila, Philippines|Quirino Memorial Medical Center, Quezon City, Metro Manila, Philippines|St. Luke's Medical Center, Quezon City, Metro Manila, Philippines|Jose R. Reyes Memorial Medical Center, Manila, Philippines|University of Santo Tomas Hospiatl, Manila, Philippines|University of the East- Ramon Magsaysay Memorial Medical Center, Manila, Philippines|University of the Philippines - Philippine General Hospital, Manila, Philippines		https://ClinicalTrials.gov/show/NCT05484960
806	NCT05522387	An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease		Recruiting	No Results Available	Alzheimer Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Tauopathies|Neurodegenerative Diseases|Neurocognitive Disorders|Mental Disorders|Mild Cognitive Impairment (MCI)	Drug: XPro1595	Number of participants who experience adverse events and serious adverse events|To evaluate the change in cognitive performance following administration of open-label XPro1595|To evaluate the change in cognition and global function following administration of open-label XPro1595|To evaluate the change in non-cognitive behavioral symptoms following open-label administration of XPro1595|To evaluate the change in Activities of Daily Living (ADL) following open-label administration of XPro1595|To evaluate the change on blood inflammatory and neurodegeneration biomarkers following open-label administration of XPro1595 (on blood inflammatory and neurodegeneration biomarker amyloid)|To evaluate the change on blood inflammatory and neurodegeneration biomarkers following open-label administration of XPro1595 (on blood inflammatory and neurodegeneration biomarker pTau)|To evaluate the change on imaging neuroinflammation following open-label administration of XPro1595|To evaluate the change on axonal integrity following open-label administration of XPro1595|To evaluate the change in Everyday Cognition (ECog) following open-label administration of XPro1595	Inmune Bio, Inc.	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	261	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XPro1595-AD-OLE	November 2022	December 4, 2025	December 4, 2025	August 31, 2022		August 31, 2022	INmune Bio Investigational Site, Macquarie Park, New South Wales, Australia		https://ClinicalTrials.gov/show/NCT05522387
807	NCT05081219	SNIFF - Combo INI+EMPA Trial		Recruiting	No Results Available	Mild Cognitive Impairment|Cognitive Impairment|Alzheimer Disease	Drug: Insulin (Humulin® R U-100)|Drug: Empagliflozin 10 MG|Device: Aptar Pharma CPS Intranasal Delivery Device|Drug: Placebo (Insulin Diluent)|Drug: Placebo (Capsules)	Number of Participants with Treatment-related Serious Adverse Events as Assessed by CTCAE v5.0|Change in the Preclinical Alzheimer Cognitive Composite 5 (PACC5) Z-Score|Change in the 14-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog 14) Score|Change in amyloid β-peptide (Aβ) 40 (Aβ40) in Cerebrospinal Fluid (CSF)|Change in amyloid β-peptide (Aβ) 42 (Aβ42) in Cerebrospinal Fluid (CSF)|Change in Cerebrospinal Fluid (CSF) Levels of Total Tau|Change in Cerebrospinal Fluid (CSF) Levels of Phospho-Tau 181|Change in Total Cerebral Blood Flow (CBF) Using MRI Pseudocontinuous Arterial Spin Labeling (ASL)	Wake Forest University Health Sciences	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00075245	October 14, 2021	October 2026	October 2028	October 18, 2021		November 12, 2021	Wake Forest University Health Sciences / Wake Forest School of Medicine, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT05081219
808	NCT05006599	SNIFF - 3-Week Aptar CPS Device		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Cognitive Impairment|Alzheimer Disease, Early Onset	Drug: Insulin (Humulin® R U-100)|Drug: Placebo|Device: Aptar Pharma CPS Intranasal Delivery Device	Percentage of Prescribed Dose Taken|Change in the Preclinical Alzheimer Cognitive Composite 5 (PACC5) Z-Score|Change in the 14-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog 14) Score|Change in Cerebrospinal Fluid (CSF) Insulin Levels|Change in amyloid β-peptide (Aβ) 40 (Aβ40) in Cerebrospinal Fluid (CSF)|Change in amyloid β-peptide (Aβ) 42 (Aβ42) in Cerebrospinal Fluid (CSF)|Change in Cerebrospinal Fluid (CSF) Levels of Total Tau|Change in Cerebrospinal Fluid (CSF) Levels of Phospho-Tau 181|Change in Cerebrospinal Fluid (CSF) Levels of Phospho-Tau 217	Wake Forest University Health Sciences	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00073876	May 2025	May 2029	May 2031	August 16, 2021		June 1, 2022			https://ClinicalTrials.gov/show/NCT05006599
809	NCT04555655	The Effects of Chicken Extract and a Peptide Supplement for the Prevention of Cognitive Decline in Non-demented Elderly Adults		Recruiting	No Results Available	Cognitive Decline|Mild Cognitive Impairment|Aging	Dietary Supplement: Chicken extract supplement|Dietary Supplement: Peptide Supplement|Other: Placebo	Cognitive Function assessed by Alzheimer's Disease Composite Score (ADCOMS)|Florbetaben (18F) PET Scan Imaging|Handgrip strength|Ratio of plasma tau protein and amyloid-beta 42|Alzheimer's Disease Composite Score (ADCOMS)|Blood myeloperoxidase (MPO) levels|Blood inflammation biomarker levels (hs-CRP, ESR, TNF-α, IL-6)|Fasting blood glucose level|Taiwanese Depression Questionnaire (TQD) score|Short Form-36 (SF-36) Component and Scale Scores|Athens Insomnia Scale (AIS)|Incidence of infections|Cerebral blood flow measured with sonography|Blood pressure (systolic blood pressure and diastolic blood pressure)	Brand's Suntory Asia|Taipei Medical University Shuang Ho Hospital|National Cheng-Kung University Hospital|Chang Gung Memorial Hospital	All	55 Years to 75 Years   (Adult, Older Adult)	Phase 2|Phase 3	276	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	BEC-CMI-003	December 11, 2020	December 2023	December 2023	September 21, 2020		February 21, 2021	Taipei Medical University Hospital Shuang Ho Hospital, New Taipei City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taoyuan Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT04555655
810	NCT04643327	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	TRIP	Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment|Memory Impairment	Drug: Levetiracetam|Drug: Placebo	Pattern separation performance (behavioural outcome)|Hippocampal DG/CA3 subfield activity	The University of Queensland|Queensland University of Technology|Johns Hopkins University|Cleveland Clinic Lou Ruvo Center for Brain Health|Royal Brisbane and Women's Hospital	All	Child, Adult, Older Adult	Phase 2	28	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HREC/2020/QRBW/69379	February 9, 2021	January 2023	December 2023	November 25, 2020		May 3, 2021	University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia		https://ClinicalTrials.gov/show/NCT04643327
811	NCT04601038	Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)	CORT-X	Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Memory Impairment	Drug: CORT108297|Drug: Placebo	Memory as assessed by pattern separation task performance after 2 weeks of treatment with CORT108297|Memory as assessed by the Hopkins Verbal Learning Test-Revised Edition (HVLT-R) after 2 weeks of treatment with CORT108297|Executive functioning as assessed by the Trail Making Test (TMT), part B after 2 weeks of treatment with CORT108297|Executive functioning as assessed by the Digit Span Task (digit span backwards) after 2 weeks of treatment with CORT108297	Johns Hopkins University	All	55 Years and older   (Adult, Older Adult)	Phase 2	52	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IRB00227116	June 28, 2021	June 30, 2023	January 1, 2024	October 23, 2020		June 27, 2022	Johns Hopkins School of Medicine, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT04601038
812	NCT04567745	Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Vascular Dementia	Diagnostic Test: Retinal fundus photography	retinopathy features identification	Mayo Clinic|Eyenuk, Inc.|Malavika Bhaskaranand PhD|Kaushal Solanki	All	18 Years and older   (Adult, Older Adult)	Phase 1	80	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	20-007289	September 29, 2020	September 30, 2021	September 30, 2021	September 28, 2020		November 1, 2021	Mayo Clinic Arizona, Scottsdale, Arizona, United States		https://ClinicalTrials.gov/show/NCT04567745
813	NCT04648735	Driving Evaluation and Fitness for Persons With Cognitive Impairments		Completed	No Results Available	Mild Cognitive Impairment|Dementia, Mild|Driving Impaired|Drive	Other: driving evaluation and practice	driving evaluation|control of steering wheel|control of speed	National Cheng Kung University	All	50 Years and older   (Adult, Older Adult)	Not Applicable	41	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other	National ChengKung University	August 1, 2015	July 31, 2018	July 31, 2018	December 1, 2020		December 4, 2020			https://ClinicalTrials.gov/show/NCT04648735
814	NCT04480112	Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults		Completed	No Results Available	Memory Disorders|Alzheimer Disease|Mild Cognitive Impairment	Behavioral: Technology based social interactions|Other: No research related technology based social interactions	Change in memory performance|Change in cognition|Change in phonemic fluency|Social isolation|Loneliness|Depressive symptoms|Misinformation about Covid-19	Boston University	All	Child, Adult, Older Adult	Not Applicable	196	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	H-26786	June 2, 2020	June 11, 2021	June 11, 2021	July 21, 2020		August 30, 2021	Boston University Alzheimer Disease Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04480112
815	NCT03954899	Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging		Recruiting	No Results Available	Mild Cognitive Impairment|Cognitive Decline|Healthy Aging	Dietary Supplement: melatonin|Other: placebo	Episodic memory|Overall cognitive function|p-tau/Aβ42 ratio|t-tau|Sleep Efficiency|Amplitude (Mesor) of rest-activity rhythm|Acrophase of rest-activity rhythm	Natalie Denburg|University of Iowa	All	56 Years to 85 Years   (Adult, Older Adult)	Not Applicable	230	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	201903824	November 12, 2019	October 2024	October 2024	May 17, 2019		February 28, 2022	University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States		https://ClinicalTrials.gov/show/NCT03954899
816	NCT04817176	MI-CBT Adherence Program for Lifestyle Interventions in Older Adults	MI-CBT KNAP	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Adherence, Patient|Ketosis	Behavioral: Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Other: Ketogenic Nutrition Program	Retention|Acceptability|Ketosis (adherence)|Clinical signal of effect	Florida State University	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1KL2TROO1429	September 24, 2021	July 1, 2023	July 1, 2023	March 26, 2021		September 9, 2022	Florida State University, Tallahassee, Florida, United States		https://ClinicalTrials.gov/show/NCT04817176
817	NCT00880555	Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)	CASL	Completed	Has Results	Alzheimer Disease|Dementia		FCI Score at Follow-up	VA Office of Research and Development|University of Alabama at Birmingham	All	50 Years to 89 Years   (Adult, Older Adult)		78	U.S. Fed|Other	Observational	Time Perspective: Prospective	E6553-W	April 2009	May 2014	May 2014	April 13, 2009	March 24, 2016	March 24, 2016	Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT00880555
818	NCT05107882	Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test	REPHRASE	Not yet recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Mild Dementia		Retinal beta-amyloid detection	Optina Diagnostics Inc.|Eastern Virginia Medical School|Cleveland Clinic Lou Ruvo Center for Brain|Ottawa Memory Clinic|Clinique Memoire de L'Outaouais|University of Washington	All	50 Years to 90 Years   (Adult, Older Adult)		500	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	DOC100464	November 2021	December 2022	December 2022	November 4, 2021		November 4, 2021			https://ClinicalTrials.gov/show/NCT05107882
819	NCT03772977	The Brain Health Champion Study	BHC	Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Dementia, Mild|Subjective Cognitive Decline|At Risk for Cognitive Decline	Behavioral: Brain Health Champion	Self-report adherence to Mediterranean diet|Self-report participation in cognitive and socially stimulating activities|Self-report exercise and physical activity|Quality of Life Self-Report|Neuropsychiatric status|Cognitive function|Sleep	Brigham and Women's Hospital	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	85	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017P000384	May 8, 2017	July 23, 2021	December 31, 2022	December 12, 2018		March 22, 2022	Brigham and Women's Hospital, Department of Neurology, Boston, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03772977/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03772977
820	NCT03234686	Deferiprone to Delay Dementia (The 3D Study)		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Prodromal Alzheimer's Disease|Mild Alzheimer's Disease	Drug: Deferiprone 600mg delayed release tablets|Drug: Placebo Oral Tablet	Efficacy of Deferiprone|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Brain Iron Levels	Neuroscience Trials Australia|The Florey Institute of Neuroscience and Mental Health	All	65 Years and older   (Older Adult)	Phase 2	171	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	DEF001	January 19, 2018	September 2022	September 2023	July 31, 2017		March 23, 2022	KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|Hunter New England Local Health District, Waratah, New South Wales, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|NeuroCentrix, Noble Park, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT03234686
821	NCT03351452	tES Effects on Associative Memory Performance		Completed	No Results Available	Healthy|Mild Cognitive Impairment|Alzheimer Disease	Device: real anodal transcranial direct current stimulation|Device: real transcranial alternating current stimulation|Device: sham transcranial electric current stimulation	Performance on immediate cued recall task|Performance on delayed cued recall task|task-dependent BOLD activity|resting-state BOLD activity	University of Bern	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	28	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	2017-01197	April 9, 2018	September 30, 2018	February 24, 2020	November 22, 2017		March 13, 2020	University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT03351452
822	NCT05225181	Effects of the Combining Physical Exercise and Cognitive Training for the Community-based Elderly		Not yet recruiting	No Results Available	Cognitively-normal|Mild Cognitive Impairment|Subjective Cognitive Decline	Behavioral: perform physical exercise|Behavioral: cognitive training|Behavioral: control group	Change scores of the Montreal Cognitive Assessment (MoCA).|Change scores of Wechsler Memory Scale (WMS)|Change scores of Stroop test|Change scores of Color trials test|Change scores of Verbal fluency tests|Change scores of Wechsler Adult Intelligence Scale; WAIS|Change scores of the short (12-item) form of the Everyday Cognition Scale (ECog-12)|Change scores of Dual-task tests|Change scores of Six-minute walk test,6MWT|Change scores of Timed up and go (TUG)|Change scores of 30 second chair stand test,CST|Change scores of International Physical Activity Questionnaires (IPAQ)|Change scores of Grip strength|Change scores of short physical performance battery,SPPB|Change scores of The Clinical Frailty Scale (CFS)|Change scores of Reported Edmonton Frail Scale (REFS)|Change scores of Amsterdam Instrumental Activity of Daily Living,A-IADL|Change scores of the World Health Organization Quality of Life-Old(WHOQOL-OLD)|Change scores of Geriatric Depression Scale,GDS|Change scores of Community Integration Questionnaire, CIQ	Chang Gung Memorial Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	202200014B0	March 1, 2022	December 31, 2023	December 31, 2023	February 4, 2022		February 24, 2022	Chang Gung Memotial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT05225181
823	NCT04127448	Exergaming Versus Aerobic Exercises on Mild Cognitive Impairment		Completed	No Results Available	Type 2 Diabetes|Cognitive Impairment	Other: Exergaming Training Group|Other: Aerobic Exercise Group	Change in Standardized Mini-mental State Examination (SMMSE) from baseline to 6th week.|Change in Montreal cognitive assessment scale (MOCA, Urdu version) from baseline to 6th week.|Change in Trail Making Test-A (TMT-A) from baseline to 6th week|Change in Trail Making Test-B (TMT-B) from baseline to 6th week|Change in Verbal fluency test (VFT) from baseline to 6th week|Change in Random Blood sugar (RBS) from baseline to 6th week	Riphah International University	All	50 Years and older   (Adult, Older Adult)	Not Applicable	33	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Riphah IU Raana Ali	March 1, 2017	August 1, 2017	August 1, 2017	October 15, 2019		October 15, 2019	Riphah International University, Islamabad, Federal, Pakistan		https://ClinicalTrials.gov/show/NCT04127448
824	NCT03227185	Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients		Terminated	No Results Available	Healthy|Mild Cognitive Impairment|Alzheimer Disease	Device: real anodal transcranial direct current stimulation (tDCS)|Device: sham transcranial direct current stimulation (tDCS)	Episodic memory performance - learning curve|Episodic memory performance - delayed recall 1|Episodic memory performance - delayed recall 2|Neurotransmitter levels	University of Bern	All	20 Years to 85 Years   (Adult, Older Adult)	Not Applicable	55	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	3351|2016-02175	October 1, 2017	October 18, 2019	October 19, 2019	July 24, 2017		February 28, 2020	University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT03227185
825	NCT02205710	Adaptive Cognitive Training in Healthy Older Adults		Completed	No Results Available	Mild Cognitive Impairment|Mild to Moderate Dementia|Alzheimer's Disease	Other: Computerized cognitive training|Other: Computerized games	Change in ratings on cognitive training survey|Change in neural activity|Change in performance on neuropsychological tests|Change in ratings of psychological wellbeing	Bruyere Research Institute|University of Ottawa	All	60 Years and older   (Adult, Older Adult)	Not Applicable	99	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other	M16-14-018	August 2016	August 2018	August 2018	July 31, 2014		August 2, 2019	Bruyere Continuing Care, Ottawa, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02205710
826	NCT04935372	β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline	β-AARC	Recruiting	No Results Available	Alzheimer Disease|Preclinical Alzheimer|Mild Cognitive Impairment	Other: Observational	CSF Aβ42/Aβ40 ratio|Cost effectiveness	Barcelonabeta Brain Research Center, Pasqual Maragall Foundation	All	55 Years to 80 Years   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	β-AARC_BBRC2021	May 25, 2021	August 31, 2022	August 31, 2025	June 23, 2021		June 23, 2021	BarcelonaBeta Brain Research Center, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT04935372
827	NCT05082883	Cognitive Screening Made Easy for PCPs		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Cognitive Decline	Diagnostic Test: Risk Assessment Cognitive Screening	Cognitive Performance score (under development)	University of Texas at Austin|Pennington Biomedical Research Center	All	60 Years and older   (Adult, Older Adult)		150	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	AG069780-01	August 13, 2021	December 2022	December 2022	October 19, 2021		June 10, 2022	Comprehensive Memory Center, UT Health Austin, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT05082883
828	NCT02062099	PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)	NIDeCo	Completed	No Results Available	Memory Complaint|Mild Cognitive Impairment|Alzheimer Disease	Drug: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment	Fixation and distribution of [18F]DPA-714 (Binding Potential BP)|[18F]AV-45 Standard Uptake Values ratio|Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline.	University Hospital, Tours	All	60 Years to 80 Years   (Adult, Older Adult)	Phase 1	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PHAO13-CH/ NIDeCo	January 2014	May 22, 2018	May 22, 2018	February 13, 2014		September 14, 2022	University Hospital of Tours, Tours, France		https://ClinicalTrials.gov/show/NCT02062099
829	NCT04656860	Juice Plus Supplement Clinical Trial		Recruiting	No Results Available	Cognitive Impairment|Alzheimer Disease, Early Onset|Mild Cognitive Impairment	Dietary Supplement: Juice Plus+	Change in Interleukin -5|Change in serum Amyloid A|Change in Interleukin 6|Change in C-reactive protein|Auditory Very Learning Test|Stroop Test|Trial Making task	University of Alabama, Tuscaloosa|University of North Texas Health Science Center	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	17-19-490	March 12, 2020	March 12, 2022	March 12, 2023	December 7, 2020		April 8, 2021	University of Alabama, North East Medical Building, Tuscaloosa, Alabama, United States|University of Alabama, Tuscaloosa, Alabama, United States		https://ClinicalTrials.gov/show/NCT04656860
830	NCT04168021	Remote Ischemic Conditioning of the Human Brain in Dementia Patients	RICBDE	Unknown status	No Results Available	Mild Cognitive Impairment|Dementia|Intermittent Claudication	Behavioral: Leg ischemia	Measurements to Assess General Cognitive Function|Neuropsychological Assessment|Changes in Functional Cognitive State|NeuroImaging|Neurophysiology|Electroencephalography recording	Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders	All	65 Years to 95 Years   (Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	BrainIRC	January 1, 2020	August 31, 2021	December 31, 2021	November 19, 2019		November 19, 2019			https://ClinicalTrials.gov/show/NCT04168021
831	NCT01951118	Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly		Completed	Has Results	Alzheimer Disease|Mild Cognitive Impairment|Delirium, Dementia, Amnestic, Cognitive Disorders	Drug: Donepezil	Change Over Time in Selective Reminding Test (SRT) Scores|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Clinician's Interview Based Impression (CIBIC-plus)|Pfeffer Functional Activities Questionnaire (FAQ)|Measurement of Everyday Cognition (Ecog)	New York State Psychiatric Institute|National Institutes of Health (NIH)|National Institute on Aging (NIA)	All	55 Years to 95 Years   (Adult, Older Adult)	Phase 4	121	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	6655|1R01AG041795	October 2013	May 2019	May 2019	September 26, 2013	July 13, 2020	July 13, 2020	New York State Psychiatric Institute, New York, New York, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01951118/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01951118/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01951118
832	NCT03933696	Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Type2 Diabetes	Device: Tailored Lighting Intervention	Sleep disturbance|Metabolic control|Depression|Cognition|Sleep disturbance using actigraphy|Light measurements|Melatonin Levels	Icahn School of Medicine at Mount Sinai	All	55 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment	GCO 17-2685-0002	January 2, 2019	August 31, 2023	August 31, 2023	May 1, 2019		April 26, 2022	Rutgers University, New Brunswick, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03933696
833	NCT04124029	Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)		Recruiting	No Results Available	Mild Traumatic Brain Injury|Moderate Traumatic Brain Injury|Mild Cognitive Impairment	Device: No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|Procedure: No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.	To better understand the contribution of mild Traumatic Brain Injury (mTBI) to neurodegeneration with the intent of detecting early behavioral, physiologic, anatomic, and protein evidence of neurodegeneration due to AD and CTE|Recognition Memory|EEG peak amplitude and latency|Cortical, quantitative MRI volume measurements|CSF Proteinopathy	VA Office of Research and Development|VA Boston Healthcare System	All	30 Years to 90 Years   (Adult, Older Adult)		800	U.S. Fed	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NURD-011-19F|I01-CX-19-008-CDA	July 1, 2021	June 30, 2026	June 30, 2026	October 11, 2019		August 23, 2022	VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04124029
834	NCT03162081	Medication Misuse and Dependence Among Elderly		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Elderly|Substance-Related Disorders	Diagnostic Test: Substance misuse screening|Diagnostic Test: EQ-5D|Diagnostic Test: Impulsivity screening|Diagnostic Test: Cognitive screening|Diagnostic Test: Functional tests|Diagnostic Test: Cognistat|Diagnostic Test: Neuropsychological profiling|Other: Clinical interview|Other: Medication use|Other: Comorbidity	Dependence y/n|Medication misuse y/n|MCI - Mild cognitive impairment|MMSE|COGNISTAT|EQ-5D|BIS-11|BIS/BAS score|TUG|SLB|Neuropsychological profiles|Use of addictive medication y/n|No of days of use of defined addictive medications/month|No. of possible side effects|No. of possible serious interactions|No.of inappropriate medications for elderly at admission|No.of inappropriate medications for elderly during in-hospital stay|No.of inappropriate medications for elderly at discharge|Substance use disorder	University Hospital, Akershus|King's College London|University of Oslo	All	65 Years to 90 Years   (Older Adult)		500	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	NRC256431WP2	May 3, 2017	February 1, 2021	December 2021	May 22, 2017		February 15, 2021	Akershus University Hospital, Lørenskog, Norway		https://ClinicalTrials.gov/show/NCT03162081
835	NCT05438147	Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms		Recruiting	No Results Available	Multiple Sclerosis|Mild Cognitive Impairment|Cancer	Other: CT-100 DiNaMo|Other: Care-as-Usual	PROMIS Item Bank v2.0 - Cognitive Function - Short Form 8a (PROMIS-CF)|Patient-reported Quality-of-Life (QoL) as measured by the PROMIS-29 in the Study App intervention group compared to a Care-As-Usual control group|Global Rating of Change (GRC-Cognition and GRC-Mood)|Changes in indication-specific measures of Symbol Digit Modalities Test (SDMT) in Multiple Sclerosis (only)|Changes in indication-specific measures of Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) in Cancer (Breast/Lung; only).	Click Therapeutics, Inc.	All	22 Years to 75 Years   (Adult, Older Adult)	Not Applicable	120	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CT-100-D-001	May 13, 2022	September 4, 2022	September 11, 2022	June 29, 2022		August 17, 2022	CCT Research, Mesa, Arizona, United States		https://ClinicalTrials.gov/show/NCT05438147
836	NCT05216315	tDCS and Cognitive Efficiency	FRtDCS	Enrolling by invitation	No Results Available	Aging|Mild Cognitive Impairment|Alzheimer Disease	Device: Transcranial direct current stimulation (tDCS)|Device: Sham stimulation	Complutense Verbal Learning Test (TAVEC)|Digits Wechsler Intelligence Scale for Adults-III (WAIS-III)|Experimental task - Recognition familiarity and false alarms|MMSE|Barcelona test (BT)	University of Valencia	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	H1526539449220	July 30, 2020	December 30, 2021	June 30, 2023	January 31, 2022		February 14, 2022	Juan C Melendez, Valencia, Spain		https://ClinicalTrials.gov/show/NCT05216315
837	NCT04171323	The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia		Active, not recruiting	No Results Available	Age-related Cognitive Decline|Mild Cognitive Impairment|Dementia	Behavioral: Cognitive Training|Behavioral: Computerized Cognitive Stimulation	Timed IADL performance score|ifunction performance efficiency index|Useful Field of View Test performance overall score|Graduated continuous performance test score|Examiner Executive Function Set shifting, Anti-Saccades, and Flanker performance composite score	University of South Florida|University of Florida|University of California, San Francisco|University of Minnesota|National Institute on Aging (NIA)	All	55 Years to 89 Years   (Adult, Older Adult)	Not Applicable	100	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	WIRB® Protocol #20192632|U01AG062368	March 3, 2020	December 30, 2022	December 30, 2022	November 20, 2019		February 17, 2022	University of California San Francisco, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04171323
838	NCT05457998	BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers		Not yet recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Dementia	Diagnostic Test: Flutemetamol F18 Injection|Diagnostic Test: [18F]-RO6958948 Injection|Diagnostic Test: [18F]-MK-6240 Injection|Diagnostic Test: [18F]-GTP-1 Injection	Rate of change in plasma biomarkers|Rate of change in cerebral amyloid pathology|Rate of change in Tau PET measures|Rate of cognitive decline as measured by traditional cognitive and behavioral assessments|Rate of cognitive decline as measured by digital cognitive assessments|Rate of change in retinal imaging metrics|Rate of change in psychological wellness as measured by the Geriatric Depression Scale	Butler Hospital|The Warren Alpert Foundation|Brown University|University of Rhode Island|Hoffmann-La Roche|Eli Lilly and Company|GE Healthcare	All	50 Years to 80 Years   (Adult, Older Adult)		200	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	1745146	September 1, 2022	September 1, 2027	September 1, 2027	July 14, 2022		July 14, 2022			https://ClinicalTrials.gov/show/NCT05457998
839	NCT04942184	STRATEGIES to Improve Memory in Alzheimer's Disease		Not yet recruiting	No Results Available	Alzheimer Disease|Dementia, Mild|Mild Cognitive Impairment	Behavioral: Memory strategies in Arm 1|Device: Electroencephalogram (EEG) headset in Arm 1|Other: Tablet in Arm 1|Behavioral: Memory strategies in Arm 2|Device: Electroencephalogram (EEG) headset in Arm 2|Other: Tablet in Arm 2	Change in performance in memory tasks over time|Change in electroencephalogram (EEG) early negative frontal component (N400)|Change in EEG Late Positive Parietal Component (LPC)|Change in EEG Late Positive Frontal Effect (LFE)|Neuropsychological assessment using the Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).|Generalization of strategies to daily life functioning|Quality of life with Alzheimer's disease|Subjective perception of memory performance	Boston University|National Institute on Aging (NIA)	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	H-40597|P30AG013846	October 2022	June 2023	June 2023	June 28, 2021		September 1, 2022			https://ClinicalTrials.gov/show/NCT04942184
840	NCT02781220	Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial	IMPACT2	Unknown status	No Results Available	Mild Cognitive Impairment|Dementia|Alzheimer's Disease		Percentage of change in care practices after amyloid PET scan|Percentage of change in drug management options after amyloid PET|Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan|Percentage of change in leading diagnosis after amyloid PET|Change in physician confidence in leading diagnosis|Change in care partner's confidence in diagnosis after amyloid PET|Change in care partner satisfaction with evaluation after amyloid PET|Change in care partner assessment of the quality of evaluation after amyloid PET|Proportion of care partners finding amyloid PET scan worthwhile|Proportion exhibiting increased behavior disturbance during amyloid scan visit|Percentage of change exhibiting increased behavior disturbance when the diagnosis is given|Care partner's sustained confidence in diagnosis received after amyloid PET scan|Care partner's sustained confidence in ability to adhere to management plan received after amyloid PET scan|Percentage of recommended care practices adhered to after amyloid PET scan|Percentage of recommended drug management adhered to after amyloid PET scan	University of Utah	All	65 Years and older   (Older Adult)		69	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	IMPACT-2	July 2016	July 2018	July 2021	May 24, 2016		January 28, 2020	Center for Alzheimer's Care, Imaging & Research, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT02781220
841	NCT02778971	Implications for Management of PET Amyloid Classification Technology	IMPACT	Unknown status	No Results Available	Mild Cognitive Impairment|Dementia|Alzheimer's Disease	Drug: [18F]Flutemetamol	Proportion of care practices changed after amyloid PET scan|Proportion of drug management options changed after amyloid PET|Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan|Proportion of change in leading diagnosis after amyloid PET|Change in physician confidence in leading diagnosis|Change in care partner's confidence in diagnosis after amyloid PET|Change in care partner satisfaction with evaluation after amyloid PET|Change in care partner assessment of the quality of evaluation after amyloid PET|Proportion of care partners finding amyloid PET scan worthwhile|Proportion exhibiting increased behavior disturbance during amyloid scan visit|Proportion exhibiting increased behavior disturbance when the diagnosis is given|Percentage of recommended care practices adhered to after amyloid PET scan|Percentage of recommended drug management adhered to after amyloid PET scan	University of Utah	All	45 Years to 90 Years   (Adult, Older Adult)		50	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	IMPACT-1	June 2016	June 2018	June 2021	May 20, 2016		January 28, 2020	Center for Alzheimer's Care, Imaging & Research, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT02778971
842	NCT04500847	Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD	LINE-AD	Recruiting	No Results Available	Alzheimer Disease, Early Onset|Mild Cognitive Impairment|Moderate Dementia	Drug: Emtriva Capsule|Drug: Placebo	Number of participants with treatment emergent adverse events (TEAE's) in the treatment group will be compared to the placebo group|Change from baseline in key inflammatory biomarkers; Tumor necrosis factor-alpha (TNF-α), Interleukin 1-beta (IL-1β), and Interferon-alpha (IFN-α)|Change in Mini Mental State Examination (MMSE) Total Scores|Change from baseline in Clinical Dementia Rating (CDR)|Change from baseline in Alzheimer's Disease Assessment Scale-cognitive (ADAS-Cog -13)|Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change from baseline in Free and Cued Selective Reminding Test (FCSRT+IR) with delayed recall|Change from baseline in cerebrospinal fluid (CSF) phosphorylated tau/amyloid beta 42 (pTau/Aβ42) ratios	Butler Hospital|Alzheimer's Association|Brown University|The Miriam Hospital	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 1	35	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	LINE-AD	December 17, 2021	March 31, 2023	August 2023	August 5, 2020		September 16, 2022	Memory and Aging Program, Butler Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT04500847
843	NCT02663531	Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Healthy	Device: DVA|Device: FDOCT|Device: Pattern ERG|Device: Optical Coherence Tomography	Flicker induced increase in retinal blood flow	Medical University of Vienna	All	50 Years and older   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	OPHT-180515	September 27, 2016	September 2023	September 30, 2023	January 26, 2016		April 7, 2022	Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria		https://ClinicalTrials.gov/show/NCT02663531
844	NCT04294888	TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Aging	Device: repetitive transcranial magnetic stimulation (rTMS)	Paired Associative Face Name Memory Test|Changes in intrinsic functional connectivity	Massachusetts General Hospital	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2019P003445	March 2, 2020	March 1, 2024	March 1, 2024	March 4, 2020		March 12, 2020	Massachuetts General Hospital, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04294888
845	NCT04277104	Does Acoustic Stimulation During Sleep Boost Slow Wave Sleep and Memory Performance?		Enrolling by invitation	No Results Available	Healthy|Mild Cognitive Impairment|Alzheimer Disease	Other: Closed loop acoustic stimulation|Other: Sham acoustic stimulation	Change from baseline episodic memory performance after three nights of intervention|Change from baseline performance in computer-based verbal new learning task (episodic memory) after three nights of intervention|Improvements in sleep physiology|Improvement in episodic memory performance at follow-ups|Improvement in new learning of episodic memory at follow-ups|Decreases in plasma amyloid-beta	University of Bern	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	72	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science	2018-01979	October 20, 2019	December 2022	December 2022	February 20, 2020		May 18, 2022	University Hospital of Old Age Psychiatry and Psychotherapy, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT04277104
846	NCT02910739	An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)		Completed	Has Results	Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease	Drug: MK-8931	Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-∞)|Maximum Observed Plasma Concentration of MK-8931 (Cmax)|Area Under the Concentration Versus Time Curve of MK-8931 From 0 to the Time of the Last Quantifiable (Above LLOQ) Sample (AUC0-last)|Area Under the Concentration Versus Time Curve of MK-8931 From 0 to 24 Hours (AUC0-24hr)|Plasma Concentration of MK-8931 at 24 Hours (C24hr)|Apparent Clearance of MK-8931 After Extravascular Administration (CL/F)|Time to Maximum Observed MK-8931 Plasma Drug Concentration (Tmax)|Apparent Terminal Half-Life of MK-8931 (t1/2)|Apparent Volume of Distribution of MK-8931 During the Terminal Phase After Extravascular Administration (Vz/F)|Number of Participants Experiencing an Adverse Event|Number of Participants Discontinuing Study Due to an Adverse Event	Merck Sharp & Dohme LLC	All	45 Years to 85 Years   (Adult, Older Adult)	Phase 1	16	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P08593|Celerion Project Number|Merck Protocol Number	October 11, 2016	April 3, 2017	April 12, 2017	September 22, 2016	October 1, 2018	October 1, 2018		"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02910739/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02910739
847	NCT04589182	Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson Disease		Recruiting	No Results Available	Parkinson Disease|Mild Cognitive Impairment|Huntington Disease	Device: MHSL- SleepBand|Device: Sham	Subjective sleep quality|Pilot study: feasibility of acoustic SWS enhancement|Vigilance|Sleep benefit on motor performance|Momentary sleepiness|Average sleepiness|Mood|Restorative effect of sleep|Slow wave enhancement|Auditory stimulation algorithm performance|Pilot study: changes in mood|Pilot study: changes in sleep quality|Pilot study: changes in sleepiness	Christian Baumann|ETH Zurich|University of Zurich	All	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	PDSL-EDS	October 20, 2020	October 31, 2022	October 31, 2022	October 19, 2020		July 6, 2021	University Hospital Zurich, Neurology department, Zürich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT04589182
848	NCT04790630	Cognitive Fitness for Depression in Older Adults		Recruiting	No Results Available	Depression Mild|Depressive Disorder, Major|Mild Cognitive Impairment	Other: Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|Other: Active Control	Change in attention / cognitive flexibility as measured by the Trail Making Part B test|Change in depression symptom severity as measured with the Montgomery Asberg Depression Rating Scale (MADRS)|Change in verbal learning as measured with the California Verbal Learning Test (CVLT) Total Learning|Change in attention processing speed as measured with the Flanker Test of Response Inhibition from the NIH Cognitive Toolbox|Change in self-reported depressive symptoms measured with the Carroll Depression Rating Scale|Change in problem solving/speed/spatial memory as measured with the NIH Toolbox fluid composite scales	UConn Health|National Institute of Mental Health (NIMH)	All	60 Years and older   (Adult, Older Adult)	Not Applicable	138	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	21-046-2|1K23MH118420-01A1	November 15, 2020	July 31, 2024	July 31, 2024	March 10, 2021		July 13, 2021	UConn Health, Farmington, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04790630
849	NCT02236416	Physical Exercise for Prevention of Dementia	EPD	Completed	No Results Available	Memory Disorders|Mild Cognitive Impairment|Aging	Behavioral: Intervention group|Behavioral: Control group	Change of Mini Mental State Examination (MMSE) score from baseline to 48 months|Change of neuropsychological test battery from baseline to 48 months|Change of Geriatric Depression Scale (GDS) from baseline to 48 months|Change of Short-form Health Survey (SF-36) from baseline to 48 months|Change of Memory Complaint Questionnaire (MAC-Q) from baseline to 48 months|Change of Physical Activity Scale for the Elderly (PASE) from baseline to 48 months|Change of AAHPERD (American Alliance for Health, Physical Education, Recreation and Dance) fitness test battery from baseline to 48 months	University of Molise	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	1000	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	21933_III/11	May 2011	July 2020	July 2020	September 10, 2014		July 21, 2021	Center for Research and Training in Medicine of Aging (CeRMA), Campobasso, Molise, Italy		https://ClinicalTrials.gov/show/NCT02236416
850	NCT01779310	Clinical Pathway for Alzheimer's Disease in China (CPAD)		Completed	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease|Dementia		Rate of cognitive assessment administration|Rate of anti-dementia prescription	Peking University|Beijing Novartis Pharma	All	45 Years and older   (Adult, Older Adult)		1024	Other|Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CENA731DCN01T	November 2012	April 2013	April 2013	January 30, 2013		July 25, 2017	The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Peking University Sixth Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Guangzhou Brain Hospital, Guangzhou, Guangdong, China|The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Union Hospital Tongji Mecial College, Huazhong University of Science and Technology, Wuhan, Hebei, China|Nanjing Brain Hospital, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Shandong Mental Health Center, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|Huadong Hospital Affiliated to Fudan University, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China|General Hospital, Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Huanhu Hospital, Tianjin, Tianjin, China|The First Teaching Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Ningbo Kangning Hospital, Ningbo, Zhejiang, China|The First Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT01779310
851	NCT03444181	ALzheimer and MUsic THerapy: Effects of Music Lessons on Brain Plasticity, Mood, and Quality of Life in Alzheimer Patients	ALMUTH	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|MCI With Increased Risk for Alzheimer Disease	Behavioral: Music lessons|Behavioral: Training intervention	Brain age|Depression symptoms|Living independently at home|Language abilities|Sensori-motor functions|Activities of daily living|Disease progression|Cognitive functioning|Integrity of fibre tracts|Resting-state functional connectivity|Working alliance	University of Bergen|NORCE Norwegian Research Centre AS|Bergen Municipality	All	18 Years and older   (Adult, Older Adult)	Not Applicable	135	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RCN 260576	April 11, 2018	June 2023	June 2023	February 23, 2018		October 13, 2021	Bergen Municipality, Bergen, Hordaland, Norway		https://ClinicalTrials.gov/show/NCT03444181
852	NCT03926702	Tau Imaging With JNJ067		Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Progressive Supranuclear Palsy	Drug: Radiopharmaceuticals	Positron-emission tomography (PET) scan results	University of California, Berkeley|University of California, San Francisco	All	50 Years and older   (Adult, Older Adult)	Early Phase 1	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	073H040	June 18, 2019	January 6, 2021	January 6, 2021	April 24, 2019		August 31, 2022	University of California, Berkeley, Berkeley, California, United States		https://ClinicalTrials.gov/show/NCT03926702
853	NCT05476302	Effect of Remote Cognitive Intervention in Patients With Parkinson's Disease During the COVID-19 Pandemic	TELEPARK	Completed	No Results Available	Parkinson Disease|COVID-19|Mild Cognitive Impairment	Other: Cognitive digital treatment	changes in cognitive status|changes in cognitive domains|changes in thymic state	Istituto Nazionale di Ricovero e Cura per Anziani	All	Child, Adult, Older Adult		18	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	INRCA_004_2022	January 1, 2020	October 31, 2020	October 31, 2020	July 27, 2022		July 27, 2022	IRCCS INRCA Hospital, Ancona, Italy		https://ClinicalTrials.gov/show/NCT05476302
854	NCT02592070	Activity & Cognition After Treatment for Breast Cancer	ACT	Completed	No Results Available	Breast Cancer|Mild Cognitive Impairment|Physical Activity	Behavioral: Walking	Change from baseline in cognitive function in breast cancer survivors immediately and one hour after an acute bout of exercise as assessed by a battery of cognitive functioning measures.|Change in relationship between exercise and cognitive function in breast cancer survivors as assessed by physical activity and fitness levels.|Physical activity guidelines in breast cancer survivors as assessed by graded exercise test.|Change from baseline in anxiety levels after one bout of exercise as assessed by HADS questionnaire.|Change in relationship between exercise and cognitive function in breast cancer survivors as assessed by psychosocial questionnaires.	University of Illinois at Urbana-Champaign	Female	30 Years to 60 Years   (Adult)	Not Applicable	31	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UIUC_IRB_15575	July 2015	April 2016	April 2016	October 30, 2015		February 10, 2020	Freer Hall, University of Illinois, Urbana, Illinois, United States		https://ClinicalTrials.gov/show/NCT02592070
855	NCT02997982	Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease	VALZ-Pilot	Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Herpes Simplex	Drug: Valaciclovir 500Mg Tablet	Cerebrospinal fluid (CSF) Total Tau|Cerebrospinal fluid (CSF) Neurofilament light chain (NFL)|Cerebrospinal fluid (CSF) phosphorylated Tau (p-Tau)|Cerebrospinal fluid (CSF) Amyloid beta 1-42|PET/CT: [18F]-FHBG accumulation within the central nervous system (CNS)|PET/CT: Location of [18F]-FHBG accumulation|PET/CT: [18F]-FHBG accumulation|Mini Mental State Examination - Swedish Revision (MMSE-SR)|Cerebrospinal fluid (CSF) acyclovir concentration|Cerebrospinal fluid (CSF) 9-carboxymethoxymethylguanine (CMMG) concentration|Serum acyclovir concentration|Serum 9-carboxymethoxymethylguanine (CMMG) concentration|Proportion completing the [18F]-FHBG-PET/CT investigations|Proportion completing the 28 days treatment with valaciclovir at specified doses	Hugo Lovheim|Umeå University	All	65 Years and older   (Older Adult)	Phase 2	33	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UmU-2016-390-31M|2016-002317-22	December 2016	March 4, 2020	March 4, 2020	December 20, 2016		April 3, 2020	Geriatric Centre, University Hospital in Umeå, Umeå, Västerbotten, Sweden|Memory Clinic, Uppsala University Hospital, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT02997982
856	NCT02320786	Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 1)	CoPILOT	Unknown status	No Results Available	Power Wheelchair|Mild Cognitive Impairment|Spinal Cord Injuries	Behavioral: CoPILOT	Change in Power-mobility Indoor Driving Assessment (PIDA)|Change in Wheelchair Skills Test Questionnaire (WST-P-Q)|Change in Wheelchair-use Confidence Scale (WheelCon-P )|Change in Health Utility Index Mark 3 (HUI3)|Change in The Wheelchair Outcome Measure (WhOM)|The Wheeling While Talking Test|Sensory data	University of British Columbia|Networks of Centres of Excellence of Canada|Alzheimer Society of Canada|Canadian Institutes of Health Research (CIHR)|Promobilia Foundation|Rick Hansen Foundation	All	19 Years and older   (Adult, Older Adult)	Phase 1	10	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	H14-01702	October 2016	May 2019		December 19, 2014		May 30, 2018	GF Strong Rehabilitation Centre, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT02320786
857	NCT05204940	Longitudinal Observational Biomarker Study	OPT-Neuro	Active, not recruiting	No Results Available	Depression|Dementia|Mild Cognitive Impairment	Behavioral: Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)|Behavioral: Neuropsychological Data|Behavioral: Clinical Scales	Persistent Depression Leading to Change in Cognition|Change in Neural Circuity	Centre for Addiction and Mental Health|National Institute of Mental Health (NIMH)|Patient-Centered Outcomes Research Institute	All	60 Years and older   (Adult, Older Adult)		750	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	080/2017|R01MH114970|R01MH114980|R01MH114969|R01MH114981|R01MH114966-01	September 27, 2017	February 2024	February 2025	January 24, 2022		April 28, 2022	UCLA Late-Life Mood, Stress, and Wellness Research Program, Los Angeles, California, United States|Washington University School of Medicine Healthy Mind Lab, Saint Louis, Missouri, United States|Columbia University Adult and Late Life Depression Clinic, New York, New York, United States|UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program, Pittsburgh, Pennsylvania, United States|Centre for Addiction and Mental Health, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05204940
858	NCT02521558	Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease	CTAD	Terminated	No Results Available	Memory Disorders|Mild Cognitive Impairment|Alzheimer's Disease	Behavioral: Intervention Group|Behavioral: Control Group	Changes in cognition as measured by the Mini Mental Status Exam|Changes in cognition as measured by the Montreal Cognitive Assessment|Changes in cognition as measured by the Consortium to Establish a Registry in Alzheimer's disease Word List Test|Changes in cognition as measured Letter and Category Fluency|Changes in cognition as measured by the Boston Naming Test (Short Form)|Changes in cognition as measured by the Trail Making Parts A & B|Changes in performance on cognitive rehabilitation tasks (composite measure of memory tasks)	Boston University|Wallace H. Coulter Foundation	Female	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-34203	September 2015	June 30, 2020	June 30, 2020	August 13, 2015		February 4, 2021	Boston University School of Medicine, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02521558
859	NCT05460143	Optical Neuroimaging in Dementia	ONID	Not yet recruiting	No Results Available	Dementia With Lewy Bodies|Alzheimer Disease|Mild Cognitive Impairment	Other: Near-infrared Spectroscopy scan|Other: Magnetic Resonance Imaging scan	Brain oxygenation|Brain metabolism|Cognitive behavioural data|Clinical scores	University of Cambridge|Cambridgeshire and Peterborough NHS Foundation Trust|The Gianna Angelopoulos Programme for Science, Technology and Innovation|The Newton Trust	All	18 Years and older   (Adult, Older Adult)		200	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	311930	September 1, 2022	September 1, 2025	September 1, 2025	July 15, 2022		July 15, 2022			https://ClinicalTrials.gov/show/NCT05460143
860	NCT02420470	The Early Warning System for the Diabetic Encephalopathy		Recruiting	No Results Available	Diabetes Mellitus Type 2|Mild Cognitive Impairment|Metabolic Syndrome X		Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations, and the changes in relationships and biomarkers at 2.5 years.|evaluation of obesity and the changes in the state of obesity at 2.5 years|metabolic characteristics and their changes at 2.5 years|Mental health and the changes in the scores of the scales at 2.5 years|Lifestyle and its changes at 2.5 years	Tang-Du Hospital	All	40 Years to 65 Years   (Adult, Older Adult)		300	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	TDLL-2014086	April 2015	November 2025	December 2026	April 17, 2015		July 13, 2022	Tangdu Hospital, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT02420470
861	NCT04466722	The A-LIST WMM Insights Series		Recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment		Phenotypical Characteristics of Patients and Caregivers	UsAgainstAlzheimer's	All	18 Years to 100 Years   (Adult, Older Adult)		10000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	A-LIST Protocol 1	August 15, 2018	December 31, 2023	December 31, 2023	July 10, 2020		June 15, 2022	UsAgainstAlzheimer's, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT04466722
862	NCT04426539	New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study		Recruiting	No Results Available	Alzheimer's Disease|Dementia|Mild Cognitive Impairment		Aim 1: Health outcomes in amyloid PET-positive versus amyloid PET-negative|Aim 2: Changes in patient management and health outcomes among various ethnoracial groups	American College of Radiology|Alzheimer's Association	All	18 Years and older   (Adult, Older Adult)		7000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	New IDEAS	December 17, 2020	December 2024	December 2024	June 11, 2020		June 6, 2022	Full list of Active Sites and Imaging Facilities, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04426539
863	NCT03583879	Using Gait Robotics to Improve Symptoms of Parkinson's Disease		Completed	No Results Available	Parkinson Disease|Dementia|Mild Cognitive Impairment	Other: Exoskeleton exercise|Other: Standard exercise|Other: No treatment	Change in cognitive function|Change in mood|Change in UPDRS Mentation score|Change in UPDRS Motor score|Change in functional balance|Change in self-report balance confidence (of not falling)|Change in gait speed|Change in dual-task gait cost index|Change in dual-task cognitive cost index|Change in six minute walk test score	Baycrest|Centre for Aging and Brain Health Innovation|University of New Brunswick	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	41	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KPD001	September 28, 2018	October 4, 2019	October 4, 2019	July 12, 2018		December 8, 2020	Assistive Technology Clinic, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03583879
864	NCT03390478	Promoting Independent Living in Frail Older Adults by Improving Cognition and Gait Ability and Using Assistive Products	MIND&GAIT	Completed	No Results Available	Frailty|Cognition|Mild Cognitive Impairment	Other: Combined Intervention Group	Change from Baseline in the participant's Cognition|Change from Baseline in the participant's Physical Frailty|Change from Baseline in the participant's Activities of Daily Living	Escola Superior de Enfermagem de Coimbra|Instituto Politécnico de Coimbra|Instituto Politécnico de Leiria|Instituto Politécnico de Santarém	All	65 Years and older   (Older Adult)	Not Applicable	62	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CT_MIND&GAIT	April 23, 2018	May 23, 2018	October 22, 2018	January 4, 2018		January 30, 2020	Health Sciences Research Unit: Nursing, Coimbra, Portugal		https://ClinicalTrials.gov/show/NCT03390478
865	NCT03761381	OCT Angiography and NRAI in Dementia		Recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment	Device: Optical Coherence Tomography Angiography (OCTA) Imaging|Device: Noninvasive Retinal Amyloid Imaging (NRAI)	Retinal amyloid protein detection|Decreased blood flow|Decreased retinal perfusion	Oregon Health and Science University	All	55 Years and older   (Adult, Older Adult)		20	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	IRB#00017045	September 14, 2018	December 2022	December 2022	December 3, 2018		March 26, 2021	Oregon Health & Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT03761381
866	NCT01550549	Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans		Completed	Has Results	Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases	Drug: florbetapir F 18	Inter-rater Reliability|Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)|Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)	Avid Radiopharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Not Applicable	151	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	18F-AV-45-PT01	August 2011	September 2011	September 2011	March 12, 2012	June 7, 2012	June 7, 2012			https://ClinicalTrials.gov/show/NCT01550549
867	NCT01815112	Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging		Terminated	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia	Other: Magnetic resonance imaging|Other: Positron emission tomography	Dynamic FDG (fluoro-deoxyglucose) PET|Aqueductal CSF flow|Follow-up MRI|Follow-up PET	Centre Hospitalier Universitaire, Amiens	All	65 Years and older   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	PI07-PR-MEYER1|2007-A01009-44	February 2008	April 2013	April 2014	March 20, 2013		March 10, 2015	CHU Rouen, Rouen, Haute Normandie, France|CHU Amiens, Amiens, Picardie, France		https://ClinicalTrials.gov/show/NCT01815112
868	NCT01518374	Clinical Evaluation of Florbetapir F 18 (18F-AV-45)		Completed	Has Results	Alzheimer Disease|Mild Cognitive Impairment|Neurodegenerative Diseases	Drug: Florbetapir F 18	Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration	Avid Radiopharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 2	1768	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18F-AV-45-A14	December 2009	May 3, 2017	May 3, 2017	January 26, 2012	June 14, 2018	July 18, 2018	Banner Health, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|UC Davis, Davis, California, United States|UC Irvine, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|UC Irvine, Orange, California, United States|UC San Francisco, San Francisco, California, United States|UC San Francisco Memory Center, San Francisco, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mt. Sinai Medical Center, Miami Beach, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Jefferson, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|University of Tennessee, Knoxville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|UTSW, Dallas, Texas, United States|UTSW, Dallas, Texas, United States|UTSW, Dallas, Texas, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01518374/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/74/NCT01518374/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT01518374
869	NCT04045990	Network Modulation in Alzheimer's Disease		Completed	No Results Available	Alzheimer Disease|Primary Progressive Aphasia|Mild Cognitive Impairment	Device: repetitive transcranial magnetic stimulation (rTMS)	Boston Naming Test|Western Aphasia Battery-repetition|Western Aphasia Battery-reading comprehension|Western Aphasia Battery-spelling|Controlled Oral Word Association Test|Cambridge Semantic Battery|The Northwestern Anagram Test|Picture Description Test|Changes in intrinsic functional connectivity	Brigham and Women's Hospital	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	11	Other	Interventional	Allocation: N/A|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2018P001362	September 1, 2018	January 31, 2022	March 1, 2022	August 6, 2019		March 17, 2022	Massachusetts General Hospital, Charlestown, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04045990
870	NCT02612376	Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study		Recruiting	No Results Available	Alzheimer Disease|Down Syndrome|Mild Cognitive Impairment		Longitudinal collection of biospecimens and data from participants with MCI, AD, DS, healthy controls, and parents of DS individuals.	University of Colorado, Denver	All	18 Years and older   (Adult, Older Adult)		800	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	15-1774	February 2016	January 2024	January 2024	November 23, 2015		June 28, 2021	University of Colorado, Denver, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT02612376
871	NCT02420756	Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study	IDEAS	Completed	No Results Available	Alzheimer's Disease|Dementia|Mild Cognitive Impairment	Device: PET Scan	To assess the impact of amyloid PET on the management of patients meeting Appropriate Use Criteria (AUC)|To assess the impact of amyloid PET on hospital admissions and emergency room visits in patients enrolled in the cohort (amyloid PET-known) compared to matched patients not in the cohort (amyloid PET-naïve) over 12 months	American College of Radiology|Alzheimer's Association|American College of Radiology Imaging Network	All	65 Years and older   (Older Adult)		18488	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IDEAS Study	February 2016	December 2017	December 2017	April 20, 2015		July 23, 2021	American College of Radiology Imaging Network, Philadelphia, Pennsylvania, United States|Https://Www.Ideas-Study.Org/Site-Locator/, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02420756
872	NCT03536975	Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology, Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases and Their Primary Caregivers	CAREGIVERSPRO	Unknown status	No Results Available	Cognitive Impairment, Mild|Dementia, Mild	Other: Platform	Burden of primary caregivers|Quality of life of patients|Quality of life of caregivers|Cognitive symptoms of patients|Psychological symptoms of caregivers (1)|Psychological symptoms of caregivers (2)|Instrumental Activities of Daily Living|Activities of Daily Living|Behavioural-psychological symptoms of patients (1)|Behavioural-psychological symptoms of patients (2)|Perceived Social Support|Relationships	University Hospital, Rouen|Centre Hospitalier Intercommunal Elbeuf-Louviers / Val de Reuil	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2016/369/HP	December 1, 2017	December 31, 2018	December 31, 2018	May 25, 2018		May 25, 2018	Centre Hospitalier Intercommunal Elbeuf Louviers, Elbeuf, France|Rouen University Hospital, Rouen, France		https://ClinicalTrials.gov/show/NCT03536975
873	NCT01705210	Functional MRI Biomarkers of Cognitive Decrements in Diabetes		Completed	No Results Available	Diabetes Mellitus, Type 2|Metabolic Syndrome X|Mild Cognitive Impairment		Functional and structural connectivity relationships of multiple brain regions and biomarkers of brain alterations|Anthropometrics|Mental health|Lifestyle|Cardiovascular risk factors	Maastricht University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Netherlands Organisation for Scientific Research	All	40 Years to 75 Years   (Adult, Older Adult)		106	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	NL34329.068.10 / METC 10-2-023|916.11.059	May 2012	April 2015	April 2015	October 12, 2012		April 10, 2015	Maastricht University Medical Center, Maastricht, Netherlands		https://ClinicalTrials.gov/show/NCT01705210
874	NCT01246804	The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)	GINGER	Completed	No Results Available	HIV Infections|Depression|Mild Cognitive Impairment	Drug: raltegravir single dose|Drug: ginkgo biloba multiple dose	raltegravir concentrations|adverse events	Radboud University Medical Center|Merck Sharp & Dohme LLC	All	18 Years to 55 Years   (Adult)	Phase 1	18	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other	UMCN-AKF 10.02	November 2010	March 2011	May 2011	November 23, 2010		November 30, 2020	CRCN, Radboud University Medical Centre, Nijmegen, Netherlands		https://ClinicalTrials.gov/show/NCT01246804
875	NCT05200572	Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers		Recruiting	No Results Available	Cancer, Advanced|Cognitive Impairment, Mild	Behavioral: Dyadic Life Review (DLR)	proportion of participants that complete the study|proportion of participants that consent who are approached for the study|proportion of participants who state the intervention is acceptable during a qualitative interview|mean change in the UCLA Loneliness Score for caregivers|mean change in Unidimensional Relationship Closeness Scale for caregivers|mean change in PROMIS29 domains|mean change in Perceived Stress Scale for caregivers|mean change in Caregiver Reaction Scale for caregivers|mean change in Geriatric Depression Scale for caregivers|mean change in Distress Thermometer and Problem list for caregivers|mean change in Dyadic Adjustment Scale-7 for caregivers|mean change in Dyadic Support Questionnaire|mean change in the correlation between caregiver and patient distress	University of Rochester|National Cancer Institute (NCI)|National Institute on Aging (NIA)	All	50 Years and older   (Adult, Older Adult)	Not Applicable	80	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	STUDY00006662|T32CA102618	March 28, 2022	September 1, 2023	November 1, 2023	January 20, 2022		June 21, 2022	University of Rochester Medical Center, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT05200572
876	NCT02417558	Cognitive/Physical Computer-Game Blended Training With Personalized Brain Network Activation Technology for the Elderly	AlterniityAR	Completed	No Results Available	Mild Cognitive Impairment, So Stated|Mild Dementia|Healthy	Behavioral: Alterniity Augmented Reality (AAR)|Behavioral: VideoGrade	Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC)|Physical Fitness|Episodic memory|Working Memory|Executive Function|World Health Organization Quality of Life (WHOQoL)|Instrumental Activities of daily living|Depressive symptoms|Overall brain function|Verbal learning and memory as assessed using California Verbal Learning Test (CVLT)|Verbal short-term memory as assessed using the Digit Span Test	XtremeVRI AG|Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders|Klinik Hirslanden, Zurich	All	50 Years and older   (Adult, Older Adult)	Not Applicable	607	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	84171-B	February 2015	September 2018	December 2018	April 15, 2015		February 8, 2022			https://ClinicalTrials.gov/show/NCT02417558
877	NCT02313935	Cognitive/Physical Computer-Game Blended Training of Elderly: Neuroscientific LLM Studies	LLM-AUTH	Completed	No Results Available	Mild Cognitive Impairment, So Stated|Mild Dementia|Healthy	Other: LLM|Other: FFA|Other: Brain Fitness|Other: VideoGrade	overall cognition|physical fitness|Episodic memory|working memory|executive function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Brain function	Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders	All	55 Years and older   (Adult, Older Adult)	Not Applicable	581	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	84171-A	November 2010	May 2012	April 2013	December 10, 2014		December 11, 2014			https://ClinicalTrials.gov/show/NCT02313935
878	NCT01055392	Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease		Unknown status	No Results Available	Cognitive Impairment|Alzheimer Disease	Drug: Lithium Carbonate|Drug: Placebo	effect of lithium to delay progression of cognitive deficits in patients with amnestic MCI|effect of lithium on CSF levels of Total Tau, Phosphorylated Tau and Amyloid-beta42|the effect of lithium on the activity of GSK3β in platelets and leukocytes drawn from peripheral blood.	University of Sao Paulo	All	60 Years to 80 Years   (Adult, Older Adult)	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	OVForlenza-Lithium|554535/2005-0	March 2007	March 2009		January 25, 2010		January 25, 2010	Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo, Sao Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT01055392
879	NCT03727386	The Effect of Vegetable Oil on Cognitive Functions of MCI Patients	DICe	Completed	No Results Available	Metabolic Ketosis|Cognitive Impairments, Mild	Other: Coconut oil|Other: Sunflower oil	Vegetable oil usage|Overall cognition|Quality of life of adults with Mild cognitive impairment measured by ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study Mild Cognitive Impairment- Activities of Daily Living)|Dietary intake assessed by four day food records using Nutritics software|Blood samples (beta hydroxyl butyrate):|Executive measure|Verbal Memory|Verbal Fluency|Processing Speed|Attention|Visual Spatial memory	Bournemouth University|Dorset HealthCare University NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Not Applicable	34	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	1718/IRASREZ/1	November 19, 2019	May 6, 2021	May 6, 2021	November 1, 2018		June 29, 2021	Bournemouth University, Bournemouth, Dorset, United Kingdom		https://ClinicalTrials.gov/show/NCT03727386
880	NCT02647645	Cognitive Training With and Without tDCS to Improve Cognition in HIV		Terminated	Has Results	HIV|Mild Neurocognitive Disorder	Device: Transcranial direct current stimulation|Procedure: Cognitive training|Device: Sham transcranial direct current stimulation	Working Memory: Participants' Rate of Improvement|Center for Epidemiological Studies Depression Scale (CES-D)|Patient's Own Assessment of Function (PAOF)	Nova Southeastern University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	21	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	1203142F	September 2015	May 2017	May 2017	January 6, 2016	October 15, 2018	June 22, 2021	NSU Psychiatry Research Office, Fort Lauderdale, Florida, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02647645/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02647645/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02647645
881	NCT03816644	5-Cog Battery for Detecting Cognitive Impairment and Dementia	5-Cog	Recruiting	No Results Available	Dementia|Cognitive Impairment|Mild Cognitive Impairment|Neurocognitive Disorders	Other: 5-Cog|Other: Health Literacy & Grip Assessment	Change in dementia care-A composite endpoint including new cognitive diagnoses, laboratory investigations related to cognitive impairment, new dementia prescriptions, and cognitive related referrals.|Change in health care utilization	Albert Einstein College of Medicine|National Institute of Neurological Disorders and Stroke (NINDS)	All	65 Years and older   (Older Adult)	Not Applicable	1200	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening	2018-9140|UG3NS105565	May 28, 2019	August 2022	August 2022	January 25, 2019		May 5, 2022	Albert Einstein College of Medicine, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT03816644
882	NCT00319891	Computer-Based Training for Mild Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease	Procedure: Computer-based Cognitive Training	The primary objective of this trial will be to assess the feasibility of using computer-based|cognitive training in an a population with early Alzheimer's Disease.|A standardized set of neuropsychological assessments will be conducted pre- and post-|compuer-based training.	Posit Science Corporation|University of California, San Francisco	All	60 Years to 90 Years   (Adult, Older Adult)	Phase 1	6	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OUT-109-2005	September 2004	October 2006	October 2006	April 27, 2006		May 15, 2013	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT00319891
883	NCT04867616	A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)		Recruiting	No Results Available	Alzheimer's Disease	Other: Placebo|Biological: Bepranemab	Change from Baseline to Week 80 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) total score|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent serious adverse events (TESAEs)|Incidence of TEAEs leading to discontinuation or death|Incidence of Drug-related TEAEs|Change from Baseline in suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change from Baseline to Week 56 and Week 80 on indices of tau burden in the brain as measured by [18F]Genentech tau probe 1 (GTP1) positron emission tomography (PET)|Change from Baseline to Week 56 and Week 80 in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14)|Change from Baseline to Week 56 and Week 80 in Amsterdam-Instrumental Activities of Daily Living (A-iADL)|Change from Baseline to Week 56 and Week 80 in Mini-Mental State Examination (MMSE) total score|Serum concentrations of bepranemab over the 80-week Double-blind Treatment Period	UCB Biopharma SRL|UCB Pharma	All	50 Years to 80 Years   (Adult, Older Adult)	Phase 2	450	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	AH0003|2020-005829-88	June 9, 2021	April 9, 2024	July 1, 2025	April 30, 2021		September 6, 2022	Ah0003 50305, Sun City, Arizona, United States|Ah0003 50428, Fresno, California, United States|Ah0003 50431, Fullerton, California, United States|Ah0003 50442, Irvine, California, United States|Ah0003 50458, Long Beach, California, United States|Ah0003 50450, Palo Alto, California, United States|Ah0003 50452, Pasadena, California, United States|Ah0003 50447, San Diego, California, United States|Ah0003 50434, Santa Ana, California, United States|Ah0003 50422, New Haven, Connecticut, United States|Ah0003 50467, New Haven, Connecticut, United States|Ah0003 50421, Stamford, Connecticut, United States|Ah0003 50465, Atlantis, Florida, United States|Ah0003 50449, Aventura, Florida, United States|Ah0003 50435, Boca Raton, Florida, United States|Ah0003 50437, Boynton Beach, Florida, United States|Ah0003 50430, Delray Beach, Florida, United States|Ah0003 50429, Fort Myers, Florida, United States|Ah0003 50436, Hialeah, Florida, United States|Ah0003 50426, Maitland, Florida, United States|Ah0003 50427, Miami, Florida, United States|Ah0003 50478, Naples, Florida, United States|Ah0003 50464, Ocoee, Florida, United States|Ah0003 50438, Pensacola, Florida, United States|Ah0003 50457, Port Orange, Florida, United States|Ah0003 50454, Tampa, Florida, United States|Ah0003 50444, West Palm Beach, Florida, United States|Ah0003 50476, West Palm Beach, Florida, United States|Ah0003 50446, Westchester, Florida, United States|Ah0003 50479, Decatur, Georgia, United States|Ah0003 50439, Lexington, Kentucky, United States|Ah0003 50445, Braintree, Massachusetts, United States|Ah0003 50453, Newton, Massachusetts, United States|Ah0003 50448, Saint Paul, Minnesota, United States|Ah0003 50420, Neptune, New Jersey, United States|Ah0003 50451, Cincinnati, Ohio, United States|Ah0003 50255, Columbus, Ohio, United States|Ah0003 50443, Portland, Oregon, United States|Ah0003 50423, East Providence, Rhode Island, United States|Ah0003 50455, Cordova, Tennessee, United States|Ah0003 50380, Houston, Texas, United States|Ah0003 50424, Fairfax, Virginia, United States|Ah0003 50432, Norfolk, Virginia, United States|Ah0003 50440, Bellevue, Washington, United States|Ah0003 40121, Brussels, Belgium|Ah0003 40123, Brussels, Belgium|Ah0003 40575, Brussels, Belgium|Ah0003 40576, Kortrijk, Belgium|Ah0003 40002, Leuven, Belgium|Ah0003 50463, Kelowna, Canada|Ah0003 50461, Ottawa, Canada|Ah0003 50520, Quebec, Canada|Ah0003 50045, Toronto, Canada|Ah0003 50291, Toronto, Canada|Ah0003 50462, Toronto, Canada|Ah0003 50522, West Vancouver, Canada|Ah0003 40129, Bordeaux, France|Ah0003 40580, Bron Cedex, France|Ah0003 40636, Dijon Cedex, France|Ah0003 40493, Marseille, France|Ah0003 40635, Nantes, France|Ah0003 40578, Paris, France|Ah0003 40201, Rennes, France|Ah0003 40131, Strasbourg, France|Ah0003 40581, Toulouse, France|Ah0003 40579, Villeurbanne, France|Ah0003 40028, Berlin, Germany|Ah0003 40590, Berlin, Germany|Ah0003 40430, Munich, Germany|Ah0003 40592, Siegen, Germany|Ah0003 40577, ULM, Germany|Ah0003 40371, Monza, Italy|Ah0003 40600, Parma, Italy|Ah0003 40597, Pavia, Italy|Ah0003 40497, Pozzilli, Italy|Ah0003 40438, Roma, Italy|Ah0003 40596, Rome, Italy|Ah0003 40598, Rome, Italy|Ah0003 40450, Amsterdam, Netherlands|Ah0003 40449, Den Bosch, Netherlands|Ah0003 40601, Zwolle, Netherlands|Ah0003 40603, Bialystok, Poland|Ah0003 40606, Bydgoszcz, Poland|Ah0003 40605, Katowice, Poland|Ah0003 40609, Katowice, Poland|Ah0003 40638, Scinawa, Poland|Ah0003 40608, Szczecin, Poland|Ah0003 40604, Warsaw, Poland|Ah0003 40607, Warsaw, Poland|Ah0003 40602, Warszawa, Poland|Ah0003 40611, Wroclaw, Poland|Ah0003 40159, Barcelona, Spain|Ah0003 40160, Barcelona, Spain|Ah0003 40267, Barcelona, Spain|Ah0003 40612, Barcelona, Spain|Ah0003 40105, Cordoba, Spain|Ah0003 40614, Donostia, Spain|Ah0003 40540, Madrid, Spain|Ah0003 40615, Madrid, Spain|Ah0003 40352, Pamplona, Spain|Ah0003 40280, Sant Cugat Del Valles, Spain|Ah0003 40617, Santander, Spain|Ah0003 40049, Sevilla, Spain|Ah0003 40453, Terrassa, Spain|Ah0003 40230, Valencia, Spain|Ah0003 40613, Valencia, Spain|Ah0003 40616, Zaragoza, Spain|Ah0003 40662, Birmingham, United Kingdom|Ah0003 40619, Bristol, United Kingdom|Ah0003 40639, Glasgow, United Kingdom|Ah0003 40622, Guildford, United Kingdom|Ah0003 40618, London, United Kingdom|Ah0003 40621, London, United Kingdom|Ah0003 40620, Motherwell, United Kingdom|Ah0003 40623, Plymouth, United Kingdom|Ah0003 40391, Southampton, United Kingdom|Ah0003 40691, Winchester, United Kingdom		https://ClinicalTrials.gov/show/NCT04867616
884	NCT05542953	[18F]APN-1607 PET in Subjects With AD Compared to HC		Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment Due to Alzheimer's Disease|Healthy Volunteers	Drug: [18F]APN-1607	Assessment of [18F]APN-1607 Uptake Patterns by Regional SUVR Values|Safety and Tolerability Profile Measured by Adverse Events (AEs)	APRINOIA Therapeutics	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	230	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	APN-1607-301	February 11, 2022	June 2023	June 2023	September 16, 2022		September 16, 2022	Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China		https://ClinicalTrials.gov/show/NCT05542953
885	NCT02450786	Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)		Unknown status	No Results Available	Parkinson's Disease	Drug: Donepezil	Rate of cognitive decline|changes of cognitive decline|changes of Parkinson's disease motor scale|Brain structure (cortical thickness and subcortical volume/shape) and Default mode network|brain functional connectivity|Comprehensive neuropsychological test	Yonsei University	All	40 Years and older   (Adult, Older Adult)	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4-2014-1089	June 2015	August 2019	August 2019	May 21, 2015		January 29, 2019	Severance Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02450786
886	NCT04141150	Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects		Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment Due to Alzheimer's Disease|Healthy Volunteers	Drug: [18F]APN-1607	Assessment of [18F]APN-1607 Uptake Patterns by Regional SUVR Values|Safety and Tolerability Profile Measured by Adverse Events (AEs)	APRINOIA Therapeutics, LLC|APRINOIA Therapeutics	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	130	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	APN-1607-201	August 19, 2019	January 2023	January 2023	October 28, 2019		April 28, 2022	Invicro, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT04141150
887	NCT05050604	A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients		Not yet recruiting	No Results Available	Vascular Cognitive Impairment	Drug: Choline Alfoscerate 400mg|Drug: Placebo of Choline Alfoscerate 400mg	The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baseline|The proportion of subjects reduced by more than or eual 0 points for modified ADAS-Cog score at 24 weeks compared to baseline|The proportion of subjects reduced by more than 2 points of modified ADAS-Cog score at 24 to 48 weeks compared to baseline|The proportion of subjects reduced by more than 4 points of modified ADAS-Cog score at 24 to 48 compared to baseline|The change of Modified ADAS-Cog score at 24 to 48 weeks compared to baseline|The proportion of subjects increased by more than 0 point of K-MMSE-2 score at 24 and 48 weeks compared to baseline|The change of K-MMSE-2 score at 24 to 48 weeks compared to baseline|The change of Modified K-MoCA score at 24 to 48 weeks compared to baseline|The change of CDR-SB score at 48 weeks compared to baseline	Chong Kun Dang Pharmaceutical|Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)	All	50 Years and older   (Adult, Older Adult)	Phase 4	418	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	INFINITE-V (B78_03VCI2004)	September 2021	November 2024	November 2024	September 20, 2021		September 20, 2021	Asan Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05050604
888	NCT01873664	Functional Magnetic Resonance Imaging Study of Jaw-tapping Movement on Memory Function		Unknown status	No Results Available	Memory Disturbances	Behavioral: Jaw-tapping	Brain activity of n-back task|Brain activity of jaw-tapping task	Kyunghee University Medical Center|Kyung Hee University Hospital at Gangdong	Female	50 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	NRF-2010-0017278	May 2009	July 2013	July 2013	June 10, 2013		June 10, 2013	Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01873664
889	NCT02457039	Acupuncture Prevents Chemobrain in Breast Cancer Patients		Completed	No Results Available	Chemo-brain|Drug-Related Side Effects and Adverse Reactions|Mild Cognitive Impairment|Breast Cancer	Procedure: Dense cranial electroacupuncture stimulation|Procedure: Body acupuncture|Procedure: Least acupuncture stimulation|Drug: Cytoxan-containing chemotherapy regimens	Changes in cognitive function (objective measurement)|Changes in cognitive function (subjective measurement)|Changes in quality of Life - composite measure|Changes in illness related fatigue measured by FACIT-Fatigue|Changes in chemo adverse effects - composite measure|Changes in subject perception of chemotherapy treatment measured by FACIT-TS-G	The University of Hong Kong|Chinese University of Hong Kong	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	93	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	UW 14-206	October 2015	December 2018	March 2019	May 29, 2015		May 20, 2019	Department of Chinese Medicine, The University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China|Department of Clinical Oncology, The University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China|The Nethersole School of Nursing, The Chinese University of Hong Kong, Sha Tin, N.t., Hong Kong|Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong|Department of Surgery, Queen Mary Hospital, Hong kong, Hong Kong|Department of Surgery, Tung Wah Hospital, Sai Ying Pun, Hong Kong		https://ClinicalTrials.gov/show/NCT02457039
890	NCT01327196	Cognitive Impairment and Cardiovascular Risk in Older	DECRIVAM	Completed	No Results Available	Cognitive Impairment|Cardiovascular Risk Factor		Prevalence of risk factors cardiovascular|neuropsychological assessment	Fundacion para la Investigacion y Formacion en Ciencias de la Salud|Grupo de Investigación de Atención Primaria de Castilla y León	All	65 Years and older   (Older Adult)		327	Other	Observational	Observational Model: Other|Time Perspective: Cross-Sectional	BIO39/SA04/10	June 2010	June 2012	December 2012	April 1, 2011		February 24, 2020	Fundacion INFOSALUD, Salamanca, Spain		https://ClinicalTrials.gov/show/NCT01327196
891	NCT00403520	Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers		Completed	No Results Available	Alzheimer's Disease	Drug: Experimental 1|Drug: Placebo Comparator	Evolution of the volume of the Hippocampi, measured by magnetic resonance imaging (MRI), between D0 and final visit (12 months ).|Evolution of the neuropsychological scores between Day 0 and final visit.	Eisai Inc.	All	50 Years and older   (Adult, Older Adult)	Phase 4	240	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	E2020-E033-415	November 2006	March 2008	August 2010	November 23, 2006		July 14, 2014	CHU Gui de Chauliac, Montpellier cedex, France		https://ClinicalTrials.gov/show/NCT00403520
892	NCT04171804	Efficacy of Transcranial Direct Current Stimulation In Parkinson's Disease MCI	PDMCIStim	Completed	No Results Available	Parkinson Disease	Device: Transcranial direct current stimulation	Changes in response conflict in the Stroop Test during the study period|Change in the verbal fluency performance during the study period|Changes in Trail Making A Test performance during the study period|Changes in digit span during the study period|Changes in delayed recall performance during the study period|Changes in verbal memory processes performance during the study period|Changes in face recognition performance during the study period|Changes in judgment of line orientation performance during the study period|Changes in the naming performance during the study period|Changes in amplitudes (in microvolts) for parameters from the ERP tests during the study period for parameters from the ERP tests during the study period|Changes in detection sensitivity from the behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period|Changes in reaction times from the behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period|Correlation between changes in behavioral measures and changes in amplitudes of ERP components	Istanbul University	All	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	26	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2018-055	January 1, 2019	June 10, 2021	June 10, 2021	November 21, 2019		March 31, 2022	Istanbul University, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT04171804
893	NCT02702817	Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia		Completed	No Results Available	Alzheimer Disease|Cognitive Decline Due to Alzheimer Disease|Mild Cognitive Impairment Due to Alzheimer Disease	Drug: Naproxen|Drug: Placebo	Trajectory of composite Alzheimer Progression Score (APS) from multiple cognitive and biomarker measures of pre-clinical Alzheimer's disease|frequency and severity of treatment-emergent adverse events|trajectory of cognitive abilities measured by global score on Repeatable Battery for Assessment of Neuropsychological Status|ratio of total and protein-bound naproxen concentrations as well as kinetics of drug accumulation and washout|biomarkers of inflammatory processes|CSF biomarkers of AD pathogenesis	Douglas Mental Health University Institute|McGill University|Johns Hopkins University	All	55 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	INTREPAD	August 1, 2012	March 31, 2017	July 15, 2017	March 9, 2016		August 1, 2017	Douglas Hospital Research Centre, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02702817
894	NCT02707458	Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration	DEPEND	Completed	No Results Available	Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease	Drug: Probucol	Plasma concentration of probucol following test dose|Apolipoprotein concentration in CSF before and after treatment with probucol at individualized dose	Douglas Mental Health University Institute|Weston Brain Institute|McGill University	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	23	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	DEPEND	April 2016	March 2017	March 2017	March 14, 2016		January 31, 2018	Douglas Hospital Research Centre, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02707458
895	NCT01565382	Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)		Completed	Has Results	Alzheimer's Disease	Drug: florbetapir F 18	Inter-reader Agreement - Median Kappa Statistic|Overall Inter-reader Agreement - Fleiss' Kappa	Avid Radiopharmaceuticals	All	50 Years and older   (Adult, Older Adult)	Phase 3	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic	18F-AV-45-A09	February 2011	February 2011	February 2011	March 28, 2012	June 27, 2012	August 16, 2022			https://ClinicalTrials.gov/show/NCT01565382
896	NCT03384069	CBT for African Americans With Cognitive Impairment		Completed	No Results Available	Alzheimer Disease	Behavioral: Group-based Cognitive Behavioral Therapy (CBT)|Behavioral: Phone-based Cognitive Behavioral Therapy (CBT)	Number of participants attending CBT sessions (participants retention)|Percentage of patients enrolled as per target (feasibility)|Change in attitudes of patients regarding a CBT intervention for Mild Cognitive Impairment (MCI)|Change in the Center for Epidemiological Studies-Depression (CESD-R) score|Change in Perceived Stress Scale (PSS) score|Change in the quality of life scale (36-Item Short-Form Health Survey (SF-36)) score	Emory University|Alzheimer's Association	All	50 Years and older   (Adult, Older Adult)	Not Applicable	31	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00099440	January 10, 2018	November 20, 2019	November 20, 2019	December 27, 2017		April 29, 2020	Emory Clinic, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT03384069
897	NCT01453127	DaTSCAN Imaging in Aging and Neurodegenerative Disease		Enrolling by invitation	No Results Available	Dementia|Parkinsonism|Mild Cognitive Impairment|REM Sleep Behavior Disorder	Drug: I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|Device: Single photon emission computed tomography (SPECT) scan	Correlate the DaTscan findings with clinical diagnosis|Safety of DaTscan imaging	Mayo Clinic	All	40 Years to 90 Years   (Adult, Older Adult)	Phase 4	500	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	11-001999	October 2011	December 2022	December 2022	October 17, 2011		April 29, 2022	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT01453127
898	NCT04267484	What Are my Options to Stay Safe at Home: Technology For Aging at Home	COORDINATEs	Unknown status	No Results Available	Memory Problems|Aging|Mild Cognitive Impairment|Shared Decision Making	Device: GPS and travel diary|Other: e-decision support platform	Autonomy and mobility assessment using GPS|Iterative assessment to tailor the e-decision support technology|User experience assessment of the newly adapted technology|Inform SDM processes about housing option|Open-ended questionnaire of participant global health status and their experience of using the GPS and filling the travel diary	CHU de Quebec-Universite Laval|Laval University|Dalarna University|University of Groningen|University of Alberta	All	65 Years and older   (Older Adult)		294	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	118792	November 28, 2018	August 2021	November 2021	February 13, 2020		February 17, 2020	CERSSPL, Québec, Quebec, Canada|University of Alberta, Edmonton, Canada|University of Groningen, Groningen, Netherlands|Dalarna University, Falun, Sweden		https://ClinicalTrials.gov/show/NCT04267484
899	NCT05373745	Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain		Recruiting	No Results Available	Chronic Pain|Mild Cognitive Impairment|Older Adults|Physical Activity	Behavioral: Active Brains 1|Behavioral: Active Brains 2	Change in PROMIS Physical Function|Change in PROMIS Pain Interference - Short Form 6b V1.0|Change in Step Count via the ActiGraph GT3XP-BTLE Accelerometer|Change in six-minute walk test (6MWT)|Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Montreal Cognitive Assessment (MoCA; audiovisual version)|Everyday Cognition Scale (eCog-12)|PROMIS Depression|PROMIS Anxiety|Numerical Rating Scale|Pain Catastrophizing Scale|Tampa Kinesiophobia Scale|Pain Self-Efficacy|Self-Compassion Scale|Measure of Current Status|Gratitude Questionnaire|Toronto Mindfulness Scale|PROMIS Loneliness|PROMIS Satisfaction with Social Roles and Activities|Memory Compensation Questionnaire|The Pain, Enjoyment of Life and General Activity (PEG) Scale|Global Cognitive and Social Engagement|Quota-Based Pacing|Pain Interference Weekly Measure	Massachusetts General Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	260	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2021P00281	June 20, 2022	December 31, 2025	December 31, 2026	May 13, 2022		June 30, 2022	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT05373745
900	NCT03867474	Mindfulness-Based Stress Reduction With Older Adults Living With Cognitive Impairment in Primary Care.		Unknown status	No Results Available	Feasibility Randomized Control Trial	Behavioral: Mindfulness-Based Stress Reduction (MBSR)	Canadian Occupational Performance Measure (COPM)|Geriatric Anxiety Inventory (GAI)|Patient Health Questionnaire-9 (PHQ-9)|Perceived Stress Scale (PSS)|Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)|Quality-of-Life-Alzheimer's Disease (QoL-AD)|Acceptance and Action Questionnaire (AAQ)	Women's College Hospital|Queen's University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	2017-0056-E	October 3, 2019	February 2020	August 2020	March 8, 2019		February 5, 2020	Womens College Hospital, Family Health Team, Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03867474
901	NCT04598178	Normative Data for the Qmci-TW in a Taiwanese Sample		Completed	No Results Available	Postoperative Cognitive Dysfunction		cognitive function by the Taiwan version of questionnaire Qmci (Qmci-TW)	National Taiwan University Hospital	All	20 Years and older   (Adult, Older Adult)		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	202002051RINA	August 4, 2020	February 27, 2021	February 27, 2021	October 22, 2020		May 6, 2021	NTUH, Taipei, Taiwan, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT04598178
902	NCT05178992	Use of Socially Assistive Robots for Long Term Care Older Adults With Cognitive Impairment and Apathy		Recruiting	No Results Available	Alzheimer Disease	Behavioral: Socially Assistive Robot Activity	Change in Apathy|Change in Trail Making Test (TMT)|Change in Animal Fluency Test	Vanderbilt University|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Phase 1|Phase 2	200	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	210386|R01AG062685	September 13, 2021	July 1, 2025	July 1, 2025	January 5, 2022		January 5, 2022	Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT05178992
903	NCT02847403	Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients	DRINN	Active, not recruiting	No Results Available	Dysglycemia|Cognitive Deficit	Drug: Exenatide|Other: placebo	Improvement of ADAS-cog Alzheimer's Disease Assessment Scale defined by ADAS-cog score at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Mini Mental State Evaluation test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Mini Mental State Evaluation quality test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Phonemic verbal fluency test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Semantic verbal fluency test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Geriatric Depression Scale (GDS) test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Clinical Dementia Rating Scale (CDR) test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Neuropsychiatric Inventory (NPI) test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Activities of Daily Living (ADL) test at 16 (V2) and at 32 weeks (V3) compared to baseline|Improvement of Instrumental Activities of Daily Living (IADL) test at 16 (V2) and at 32 weeks (V3) compared to baseline|changes in structural and functional connectivity of neural networks as assessed by functional MRI (fMRI) at 16 (V2) and at 32 weeks (V3)	Azienda Ospedaliero-Universitaria di Parma	All	51 Years to 79 Years   (Adult, Older Adult)	Phase 3	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015-001850-13	February 2016	July 2019	October 31, 2021	July 28, 2016		August 17, 2021	Endocrinology Unit, Parma, Italy|Center for Cognitive Disorders and Dementia AUSL of Parma and University of Parma, Parma, Italy		https://ClinicalTrials.gov/show/NCT02847403
904	NCT03439059	REducing SEDENTary Behaviour in Senior Living Facilities	RESEDENT	Completed	No Results Available	Cognitive Impairment|Physical Functioning|Quality of Life|Sleep	Behavioral: Reducing Sedentary Behaviour Group	Alzheimers Disease Assessment Scale- Cognitive (ADAS-cog)|Short Form 36 Health Survey|Timed Up and Go test	Western University, Canada	All	65 Years and older   (Older Adult)	Not Applicable	21	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Sedentary Behaviour in Seniors	June 1, 2018	December 31, 2018	December 31, 2018	February 20, 2018		January 10, 2019	Western University, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03439059
905	NCT04041895	Detecting Probable Alzheimer's Disease From Speech Using Linguistical Analysis		Unknown status	No Results Available	Alzheimer Disease|Dementia	Other: Audio speech recording	Analysis of speech audio recording describing the "Cookie-Thief Image" using proposed computational model designed by PI for determination of Alzheimer's disease|MMSE	East Tennessee State University	All	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	0218.16sw	August 13, 2018	August 2020	August 2020	August 1, 2019		August 1, 2019	East Tennessee State University, Johnson City, Tennessee, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04041895/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT04041895
906	NCT02013518	Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia		Unknown status	No Results Available	Alzheimers' Disease	Behavioral: Cognitive Behavioural Therapy	Number of participants reporting decrease in depression scores|Number of participants reporting increased Self-efficacy|Number of participants reporting increased Quality of Life|Number of participants reporting change in cognitive function|Number of participating caregivers reporting decreased burden of care	Oslo University Hospital|Sykehuset i Vestfold HF|Sykehuset Innlandet HF	All	Child, Adult, Older Adult	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2012/1943|12345	September 2013	December 2015	December 2016	December 17, 2013		December 17, 2013	Oslo University Hospital, Oslo, Norway		https://ClinicalTrials.gov/show/NCT02013518
907	NCT04693611	Prefrontal Cortex Dynamics of the Elderly During a Cognitive Stimulation Programme		Completed	No Results Available	Dementia|Neurocognitive Disorders|Cognitive Impairment|Cognitive Dysfunction|Cognitive Decline|Cognition Disorders in Old Age	Behavioral: Individual cognitive stimulation therapy (iCST)|Procedure: Functional near-infrared spectroscopy (fNIRS)	Cognitive functioning evaluated through Mini-Mental State Examination (MMSE)|Change in cognitive functioning evaluated through MMSE|Executive functions evaluated through Frontal Assessment Battery (FAB)|Change in executive functions evaluated through FAB|Prefrontal cortex activation pattern through a fNIRS|Change in prefrontal cortex activation pattern through a fNIRS|Depressive symptomatology assessed through the Geriatric Depression Scale-15 (GDS-15)|Change in depressive symptomatology assessed through the GDS-15	CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas	All	65 Years and older   (Older Adult)	Not Applicable	36	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	16122020	April 14, 2021	April 30, 2021	August 31, 2021	January 5, 2021		September 1, 2021	Cediara - Social Solidarity Association of Ribeira de Fráguas, Ribeira De Fráguas, Albergaria-a-Velha, Portugal		https://ClinicalTrials.gov/show/NCT04693611
908	NCT04466735	BRain Energy Activation With Ketones to Prevent Alzheimer's Disease	BREAK-AD	Recruiting	No Results Available	MCI	Dietary Supplement: Active group|Dietary Supplement: Placebo group	Acetoacetate brain uptake|Glucose brain uptake|Cognition|Plasma biomarkers|Structural and functional brain measures	Université de Sherbrooke|Alzheimer's Association|Nestlé Health Science SA	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 2	56	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2020-3448	October 15, 2020	July 2023	July 2023	July 10, 2020		November 3, 2020	Rearsh Centre on Aging, Sherbrooke, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04466735
909	NCT03824197	Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)	(AU-ROOAD)	Completed	No Results Available	Alzheimer Disease|Cerebral Amyloid Angiopathy	Other: EVOO|Other: OO	Effect of olive oil on the BBB intactness|Effect of olive oil on the brain activity|Cognitive function	Auburn University	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention	18-446 MR 1901	May 7, 2019	December 31, 2020	December 31, 2020	January 31, 2019		August 2, 2021	Auburn University, Auburn, Alabama, United States		https://ClinicalTrials.gov/show/NCT03824197
910	NCT05015803	Enhanced CBTi for Older Adult Sleep and Cognition	R44	Recruiting	No Results Available	Insomnia|Alzheimers Disease Related Dementias	Combination Product: CBTi with Application|Behavioral: CBTi|Behavioral: Sleep Hygiene Education	Change in Insomnia Severity Index|Change in Sleep Maintenance Efficiency|Change in Total Sleep Time	Penn State University|University of Arizona|Proactive Life Inc	All	60 Years to 90 Years   (Adult, Older Adult)	Phase 2|Phase 3	130	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	R44AG056250	December 14, 2021	March 2023	March 2023	August 20, 2021		July 14, 2022	The Pennsylvania State University, University Park, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT05015803
911	NCT03466177	Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease	RetAD	Unknown status	No Results Available	Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Dementia	Diagnostic Test: Non-invasive, multimodal retinal imaging|Diagnostic Test: Cerebral imaging|Diagnostic Test: Neuropsychiatric testing|Diagnostic Test: Venous blood sampling	Retinal biomarkers for AD: specificity|Retinal biomarkers for AD: sensitivity|Retinal biomarkers for AD: number needed to image|Retinal biomarkers for AD: area under the curve (AUC)|Retinal biomarkers for AD: receiver operating characteristic (ROC)|Retinal biomarkers for AD: quantification of cerebral Aβ load by non-invasive retinal imaging against the cerebral Aβ load measured by cerebral imaging|Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years	Universitaire Ziekenhuizen Leuven	All	50 Years to 85 Years   (Adult, Older Adult)		90	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	S60932	April 1, 2018	December 31, 2018	December 31, 2020	March 15, 2018		March 15, 2018	UZ Leuven, Leuven, Vlaams Brabant, Belgium	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03466177/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03466177
912	NCT05104593	An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Dementia	CAREPATH	Not yet recruiting	No Results Available	Comorbidities and Coexisting Conditions|Alzheimer Disease|Dementia|Malnutrition|Frailty|Sarcopenia|Stroke|Asthma|Chronic Obstructive Pulmonary Disease|Chronic Kidney Diseases|Heart Failure|Diabetes|Coronary Artery Disease|Hypertension|Behavioral Symptoms	Other: Intervention tested (CAREPATH)	Change in healthcare appointments|Quality of Life (QoL)|Change in unplanned care|Change in inappropriate prescription|Change in number of participants with advanced directives	Complejo Hospitalario Universitario de Albacete|ECLEXYS SAGL|FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.|Klinikum Bielefeld|University of Warwick|University Hospitals Coventry and Warwickshire NHS Trust|University of Castilla-La Mancha|CENTRUL IT PENTRU STIINTA SI TEHNOLOGIE|SRDC YAZILIM ARASTIRMA VE GELISTIRME VE DANISMANLIK TICARET ANONIM SIRKETI|OCTILIUM SAGL	All	65 Years and older   (Older Adult)	Not Applicable	204	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CAREPATH|945169	January 1, 2023	January 1, 2023	July 31, 2025	November 3, 2021		November 3, 2021	Complejo Hospitalario Universitario de Albacete, Albacete, Spain		https://ClinicalTrials.gov/show/NCT05104593
913	NCT04078724	Impact of Nutritional Supplementation on Sleep Quality and Gut Microbiome Composition in Older Adults		Completed	No Results Available	Sleep|Gut Microbiome	Dietary Supplement: 5-HTP|Other: Without 5-HTP	Change in sleep quality assessed by validated sleep questionnaires|Change in sleep quality assessed by electronic equipment|Change in fecal short chain fatty acid (SCFA) concentration as assessed by micromoles per gram (μmol/g)|Change in fecal microbiome composition|Change in Quality of Life: WHOQOL|Change in Cognitive function|Change in mood (depression)|Change in mood (anxiety)|Change in urinary melatonin levels as assessed by nanogram per milliliter (ng/mL)|Change in blood amino acids assessed by nanomole per milliliter (ng/mL)|Change in weight and height|Change in waist circumference as assessed by centimeter (cm)|Dietary assessment|Blood pressure as assessed by millimeter of mercury (mmHg)	National University, Singapore	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	33	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	S8	July 4, 2020	June 30, 2021	June 30, 2021	September 6, 2019		September 8, 2021	National University of Singapore, Singapore, Singapore|Hannah Seniors Activity Centre, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04078724
914	NCT04259827	On-line Cognitive Training for Parkinson's Disease		Unknown status	No Results Available	Parkinson Disease	Other: Neuronation|Other: Aspecific online games	Trial making B performance, total score (0-240 seconds)|Sum of total Z-score of cognitive assessment (-30 to 30)|Supervised gait performance normal gait|Supervised gait performance dual task gait|Parkinson´s disease Quality of life questionnire (PDQ-39) (0-117 points)|Quality of life - caregivers|Unified parkinson´s disease Rating Scale part 3 (0-132 points)|Instability measures|Turning performances|Dual task performance in circular walking (0-240 seconds)|Short Physical performance battery (SPPB), total time (0- 60 seconds)	Università degli Studi di Brescia	All	40 Years to 90 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	19/01	October 15, 2019	August 1, 2020	February 10, 2021	February 7, 2020		February 7, 2020	Department of Neurology ASST Spedali Civili Brescia, Brescia, Lombardia, Italy|Parkinson's disease Rehabilitation Centre, Trescore Balneario, Lombardia, Italy		https://ClinicalTrials.gov/show/NCT04259827
915	NCT04490733	Developing Risk Prediction Model and Testing the Effect of Dual Task Walking on Improving Cognitive Function in Patients With Colorectal Cancer		Recruiting	No Results Available	Colorectal Cancer	Behavioral: dual-task walking	Self-report Questionnaire|Neuropsychological battery test	National Taiwan University Hospital	All	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	355	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	201912231RINC	August 17, 2020	July 31, 2024	July 31, 2024	July 29, 2020		August 5, 2021	National Taiwan University, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT04490733
916	NCT02501876	Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease	DIACEA	Completed	No Results Available	Alzheimer´s Disease|Diabetes Mellitus Type 2	Other: There is a retrospectiv observational study. No intervention	The rate of conversion to Alzheimer's disease (AD)|The presence of common alleles for Alzheimer's disease (AD) and Diabetes mellitus type 2	Hospital Universitari Vall d'Hebron Research Institute	All	65 Years to 90 Years   (Older Adult)		202	Other	Observational	Observational Model: Case-Control|Time Perspective: Other	PR(AG)32/2015	May 2015	September 2015	May 2016	July 17, 2015		April 12, 2017	Vall d´Hebron University Hospital, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT02501876
917	NCT04779671	Effects of the Fully Immersive VR Cognitive Training Based on Leisure Activities for the Elderly With MCI and SCD.		Recruiting	No Results Available	MCI|SCD|Virtual Reality	Behavioral: VR cognitive training|Behavioral: Traditional cognitive training	Change scores of the Montreal Cognitive Assessment (MoCA)|Change scores of the Wechsler Memory Scale - Third Edition (WMS-III)|Change scores of Stroop Color-Word Test|Change scores of the Wechsler Adult Intelligence Scale (WAIS)|Change scores of the Everyday Cognition scales (ECog)-12 items|Change scores of the Lawton Instrumental Activities of Daily Living Scale (IADL)|Change scores of the WHOQOL-BREF Taiwan Version|Change scores of Geriatric Depression Scale (GDS)|Change scores of The Chinese Aging Well Profile (CAWP)	Chang Gung Memorial Hospital	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	190	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	202002283B0	October 2021	July 2024	July 2024	March 3, 2021		May 17, 2021	Chang Gung University, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT04779671
918	NCT03900936	Detecting Dementia Earlier	DDE	Unknown status	No Results Available	Alzheimer Disease|MCI|Aging	Diagnostic Test: Neuropsychological tests	Predicting progression|Social Characteristics and questionnaires	South Tees Hospitals NHS Foundation Trust	All	Child, Adult, Older Adult		20	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	207985	January 19, 2017	June 20, 2019	August 30, 2021	April 3, 2019		April 3, 2019	South Tees Hospitals NHS FT, Middlesbrough, Teesside, United Kingdom		https://ClinicalTrials.gov/show/NCT03900936
919	NCT04032626	MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients	MCLENA-1	Recruiting	No Results Available	Cognitive Impairment, Mild|Cognitive Dysfunction|Amyloid Plaque|Neurodegeneration|Inflammation, Brain	Drug: Lenalidomide 10 mg|Drug: Placebo	Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score|Change in cognition as assessed by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) total score|Change in cognition as assessed by the Clinical Dementia Rating - Sum of Boxes (CDR-SOB) total score|Change in cognition as assessed by the Mini Mental State Examination (MMSE) total score|Monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs)	St. Joseph's Hospital and Medical Center, Phoenix|National Institute on Aging (NIA)|The Cleveland Clinic	All	50 Years to 89 Years   (Adult, Older Adult)	Phase 2	30	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	19-658|R01AG059008|K01AG047279	July 22, 2020	September 2023	September 2024	July 25, 2019		April 22, 2022	St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Cleveland Clinic Lou Ruvo Center for Brain health, Las Vegas, Nevada, United States		https://ClinicalTrials.gov/show/NCT04032626
920	NCT03070821	Therapy of Alzheimer's Disease With Neurofeedback		Completed	No Results Available	Alzheimer Dementia (AD)|Elderly	Other: rtfMRI neurofeedback training|Device: 3T MRI	Visual and Verbal Memory Test (VVM)|Montreal Cognitive Assessment (MoCA)|Wechsler Memory Scale Revised (WMS-R)|Trail Making Test (TMT)|Visual Patterns Test (VPT)|Parahippocampal activation|Memory-related functional connectivity using Granger Causality Analysis (GCA)|Change of brain structure|Change of brain function	University Hospital, Aachen|Alzheimer Forschung Initiative e.V.	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	AFI 13812	January 30, 2013	June 30, 2016	June 30, 2016	March 6, 2017		March 6, 2017			https://ClinicalTrials.gov/show/NCT03070821
921	NCT00950430	Imaging of Brain Amyloid Plaques in the Aging Population		Enrolling by invitation	No Results Available	Alzheimer's Disease|Dementia With Lewy Bodies|Frontotemporal Dementia|Vascular Dementia	Drug: Pittsburgh Compound B (C-11 PiB)|Drug: F-18 FDG|Drug: Tau (18-F-AV-1451)	To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.|Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.|To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.|To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.|To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.	Mayo Clinic|National Institute on Aging (NIA)	All	30 Years to 100 Years   (Adult, Older Adult)	Phase 4	5000	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	08-005553|U01AG006786|R01AG011378	April 2008	April 2023	April 2023	July 31, 2009		October 7, 2021	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT00950430
922	NCT02761655	A Study of a Memory Intervention to Improve MA in PWMCI & FCG MA		Unknown status	No Results Available	Dementia	Behavioral: Memory Strategies	Medication adherence|Dementia Quality of Life (DQoL)|Family Caregivers Medication Administration Hassles (FCG-MAH)	Chang Gung University|Ministry of Science and Technology, Taiwan	All	65 Years and older   (Older Adult)	Not Applicable	200	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	NMRPD1E0811	August 2015	July 2016	July 2016	May 4, 2016		May 10, 2016	Chang Gung Memorial Hospital, Taoyuan Branch, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02761655
923	NCT04012866	Effects of Combined Cognitive Training With Aerobic Exercise in Stroke Patients With MCI		Unknown status	No Results Available	Stroke	Behavioral: Aerobic exercise training|Behavioral: Computerized cognitive training|Behavioral: Control training	Change scores of Mini-Mental State Exam (MMSE)|Change scores of the Montreal Cognitive Assessment (MoCA).|Change scores of Wechsler Memory Scale - Third Edition (WMS-III)|Change scores of Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)|Change scores of Useful Field of View (UFOV)|Change scores of Stroop Color-Word Test|Change scores of Dual-Task test|Change scores of Timed Up and Go Test (TUG)|Change scores of Six-Minute Walk Test (6MWT)|Change scores of Mobility Level|Change scores of International Physical Activity Questionnaires (IPAQ)|Change scores of Fugl-Myer Assessment (FMA)|Change scores of Rivermead Mobility Index (RMI)|Change scores of Muscle Strength|Change scores of Functional Independence Measure (FIM)|Change scores of Lawton Instrumental Activities of Daily Living Scale (Lawton IADL)|Change scores of Stroke Impact Scale (SIS)|Change scores of EuroQol-5D Questionnaire (EQ-5D)|Change scores of Community Integration Questionnaire (CIQ)|Change scores of Geriatric Depression Scale (GDS)|Task-based Electroencephalogram (EEG)|BDNF val66met genotype|Serum BDNF level|Total antioxidant capacity (TAC)|Glucose indicator|Plasma lipid level|Change scores of Caregiver Strain Index (CSI)|Change scores of Caregiver Burden Scale(CBS)	Chang Gung Memorial Hospital	All	20 Years to 90 Years   (Adult, Older Adult)	Not Applicable	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	107044-F	August 30, 2018	December 31, 2021	December 31, 2021	July 9, 2019		September 9, 2020	Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Far Eastren Memorial Hospital, New Taipei City, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT04012866
924	NCT01696019	Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders	SCIBHI	Completed	No Results Available	Cognitive Impairment|Dementia|Mild Cognitive Impairment|Alzheimer Disease	Other: Fast walking|Other: Tai Chi|Other: Intellectual stimulation|Other: Contact and testing only	Change in cognitive performance on battery of neuropsychological tests|Change in whole brain volume	University of South Florida|Fudan University	All	60 Years to 79 Years   (Adult, Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	Byrd-ARG2007	July 2008	September 2009	September 2009	September 28, 2012		September 28, 2012	Huashan Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT01696019
925	NCT05468905	China Longitudinal Aging and Cognitive Impairment Study	CLACIS	Recruiting	No Results Available	Aging|Mild Cognitive Impairment|Alzheimer Disease|Neurodegeneration	Other: None of intervention	Prevalence, incidence of cognitive impairment caused by neurological disease such as AD, VCI and other types of dementia|The conversion rate of normal aging to SCI, MCI and AD|The fluid biomarkers for normal aging, SCI, MCI and AD diagnosis|The imaging biomarkers for normal aging, MCI and AD diagnosis|Gut microbiota|Gait	Second Affiliated Hospital, School of Medicine, Zhejiang University|The Central Hospital of Lishui City|Zhejiang Rehabilitation Center	All	40 Years to 99 Years   (Adult, Older Adult)		4000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	wulab-CLACIS	January 10, 2021	December 2025	December 2026	July 21, 2022		July 21, 2022	Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Lishui central Hospital, Lishui, Zhejiang, China		https://ClinicalTrials.gov/show/NCT05468905
926	NCT01424436	Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient		Completed	No Results Available	Alzheimer's Disease	Biological: GSK933776	The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment|Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals.|To assess the safety and tolerability after single dose of GSK933776 administration.	GlaxoSmithKline	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1	19	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	113043	May 19, 2010	December 8, 2011	December 8, 2011	August 29, 2011		June 14, 2017	GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT01424436
927	NCT04875442	Safety and Performance Study of the Electroencephalographic Recording Device and Sound Emissions	MEMOWAVE	Not yet recruiting	No Results Available	Sleep Disorder	Device: Memowave emitting sounds|Device: Memowave not emitting sounds	accuracy of Electroencephalography signals of Memowave|Quality of the sleep|efficiency on mnesic consolidation	BioSerenity	All	40 Years to 85 Years   (Adult, Older Adult)	Not Applicable	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other	2020-A01806-33	August 30, 2021	March 30, 2022	June 30, 2022	May 6, 2021		May 6, 2021			https://ClinicalTrials.gov/show/NCT04875442
928	NCT01222351	Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172		Active, not recruiting	No Results Available	Late Onset Alzheimer Disease	Drug: BAY 94-9172 (Florbetaben)	Changes in amyloid plaque load in the brain of the course of 3 years	New York State Psychiatric Institute|Bayer|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	161	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	6045/7130R (Bayer)|IND 78868|R01AG037212-01	December 2010	January 2023	January 2029	October 18, 2010		February 14, 2022	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01222351
929	NCT00647478	System-IGF-1 Pathway and Alzheimer's Disease	SIGAL	Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Cognitive Function 1, Social|Control With Normal Activities of Daily Living		Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0).|Circulating IGF-I and IGFBP-3 levels|Genetic polymorphisms in IGF-I / IGFBP-3|Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function.	Assistance Publique - Hôpitaux de Paris	All	65 Years and older   (Older Adult)		693	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	P060224	October 2007	October 2010	July 2012	March 31, 2008		May 1, 2018	Broca Hospital Memory Clinic (CMRR), Paris, France		https://ClinicalTrials.gov/show/NCT00647478
930	NCT03575026	Effectiveness-Implementation Cluster RCT to Improve Community-dwelling Early Dementia Patients by Music Intervention		Unknown status	No Results Available	Dementia	Behavioral: Music-with-movement|Behavioral: Usual care	Changes in patients' anxiety|Changes in patients' depression|Changes in caregivers' stress and well-being|Changes in caregivers' stress|Changes in caregivers' well-being|Changes in caregivers' relationship with PWD|Changes in volunteers' satisfaction from volunteering|Changes in volunteers' expectation from volunteering|Changes in volunteers' knowledge towards dementia|Changes in volunteers' attitude towards dementia	The Hong Kong Polytechnic University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	5-ZH2P	April 18, 2018	July 2019	December 2019	July 2, 2018		July 2, 2018	School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03575026/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03575026
931	NCT01385033	[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)		Terminated	Has Results	Alzheimer's Disease	Drug: [18F]MK-3328	Area Under the Receiver Operating Curve (AUC of ROC) for Distinguishing Between AD and HE Participants Based on Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR)|Brain Cortical [18F]MK-3328 SUVR in AD Participants and HE Participants|Amyloid Plaque Burden Threshold Determined by the Trimmed HE Sample Mean and SD Brain Cortical [18F]MK-3328 SUVR	Merck Sharp & Dohme LLC	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 1	20	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	3328-002	August 19, 2011	May 15, 2012	May 15, 2012	June 29, 2011	February 20, 2014	November 8, 2018			https://ClinicalTrials.gov/show/NCT01385033
932	NCT02754830	A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)		Completed	No Results Available	Alzheimer's Disease	Drug: LY3303560 - IV|Drug: Saline Solution - IV|Drug: LY3303560 - SC	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (Serum): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-∞]) of LY3303560|Pharmacokinetics (Serum): Maximum Drug Concentration (Cmax) of LY3303560|Pharmacokinetics (Cerebrospinal Fluid): Area Under the Concentration Versus Time Curve (AUC) of LY3303560|Pharmacokinetics (Cerebrospinal Fluid): Maximum Drug Concentration (Cmax) of LY3303560|Mean Change from Baseline in QT/QT Corrected (QTc) Interval	Eli Lilly and Company	All	30 Years and older   (Adult, Older Adult)	Phase 1	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	16120|I8G-MC-LMDA	April 25, 2016	July 10, 2018	July 10, 2018	April 28, 2016		July 23, 2018	Parexel Early Phase Unit at Glendale, Glendale, California, United States|PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02754830
933	NCT02016560	Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects	MCI	Completed	Has Results	Alzheimer's Disease	Drug: florbetapir F 18|Drug: Flortaucipir F18|Procedure: Brain PET Scan	Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline|Exploratory Phase: Cross-sectional Flortaucipir Imaging Results|Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status|Confirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read|Exploratory Phase: Correlation Between Flortaucipir SUVr and Age	Avid Radiopharmaceuticals	All	20 Years and older   (Adult, Older Adult)	Phase 2|Phase 3	383	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	18F-AV-1451-A05	December 2013	July 28, 2017	July 28, 2017	December 20, 2013	August 24, 2020	September 22, 2020	Banner Alzheimer's Institute, Phoenix, Arizona, United States|Four Peaks Neurology, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|UC Irvine, Irvine, California, United States|Hoag Memorial, Newport Beach, California, United States|Norther California PET Imaging Center, Sacramento, California, United States|UC Davis, Sacramento, California, United States|UC San Francisco, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Molecular NeuroImaging, New Haven, Connecticut, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|21st Century Oncology, Fort Myers, Florida, United States|Sandlake Imaging, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|USF Health Byrd Alzheimer's Center, Tampa, Florida, United States|Independent Imaging, West Palm Beach, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Center for Clinical Imaging Research, Saint Louis, Missouri, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Center for Brain Health - NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02016560/Prot_000.pdf|"Statistical Analysis Plan: Confirmatory Phase SAP", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02016560/SAP_001.pdf|"Statistical Analysis Plan: Confirmatory Phase Addendum SAP", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02016560/SAP_002.pdf|"Statistical Analysis Plan: Exploratory Phase SAP", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02016560/SAP_003.pdf	https://ClinicalTrials.gov/show/NCT02016560
934	NCT01303744	Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074	CT04	Completed	Has Results	Alzheimer's Disease	Drug: CHF 5074 1x|Drug: CHF 5074 2x|Drug: CHF 5074 3x|Drug: Placebo	Differences in ∆sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point|Measurement of Trough CHF 5074 Plasma Levels|Changes in Plasma ΔTNFα Concentrations	CERESPIR	All	18 Years to 79 Years   (Adult, Older Adult)	Phase 2	96	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CCD-1014-PR-0053|2010-024270-19	March 2011	April 2012	April 2012	February 25, 2011	January 11, 2016	January 11, 2016	Comprehensive NeuroScience, Inc., St. Petersburg, Florida, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Memory Center of New Jersey, Inc., Monroe Twp, New Jersey, United States|Memory Enhancement Center of NJ, Inc., Toms River, New Jersey, United States|Senior Adults Specialty Research, Austin, Texas, United States|Clinica Santa Maria, Div Neurologia, Castellanza, Italy|Osp. Maggiore Policlinico, Clin. Neurol, Milano, Italy|Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze, Milano, Italy|Nuovo Osp Civ S. Agostino Estense, Dip di Neuroscienze, Modena, Italy		https://ClinicalTrials.gov/show/NCT01303744
935	NCT01264614	Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults		Completed	Has Results	Cognitive Decline|Dementia|Alzheimer's Disease|Mild Cognitive Impairment	Behavioral: Strengthening exercise	Stroop Test Performance From Pre- to Post-intervention|Digits Backwards Test Performance From Pre- to Post-intervention|Color Trails Test Performance From Pre- to Post-intervention|Fuld Test Performance From Pre- to Post-intervention|Figure Copy & Delayed Test Performance From Pre- to Post-intervention|Neurophysiological Function Pre- & Post- Intervention	Union College, New York|US Department of Veterans Affairs	All	55 Years and older   (Adult, Older Adult)	Not Applicable	22	Other|U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MIRB#00663	December 2010	April 2011	April 2011	December 22, 2010	March 11, 2015	March 11, 2015	Stratton VA Medical Center, Albany, New York, United States		https://ClinicalTrials.gov/show/NCT01264614
936	NCT01837641	A Study of LY3002813 in Participants With Alzheimer's Disease		Completed	No Results Available	Alzheimer Disease	Biological: LY3002813-IV|Biological: LY3002183-SC|Drug: Placebo-IV	Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813	Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Phase 1	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	15082|I5T-MC-AACC	May 3, 2013	August 24, 2016	August 24, 2016	April 23, 2013		December 26, 2017	Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Compass Research, Orlando, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|PRAHealthSciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sumida-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan		https://ClinicalTrials.gov/show/NCT01837641
937	NCT02624778	A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD		Completed	No Results Available	Alzheimer Disease	Biological: LY3002813|Drug: Placebo	Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)|Pharmacokinetics: Serum Concentrations of LY3002813|Change from Baseline in Incidence of Anti-Drug Antibodies	Eli Lilly and Company	All	50 Years and older   (Adult, Older Adult)	Phase 1	61	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science	16233|I5T-MC-AACD	December 22, 2015	August 28, 2019	August 28, 2019	December 8, 2015		June 12, 2020	Brain Matters Research, Delray Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Compass Research, The Villages, Florida, United States|SNBL Clinical Pharmacology Center Inc, Baltimore, Maryland, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Sumida-ku, Japan		https://ClinicalTrials.gov/show/NCT02624778
938	NCT05446584	Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History	PATH	Not yet recruiting	No Results Available	Mild Cognitive Impairment|Amnestic Mild Cognitive Disorder|Amnestic Mild Cognitive Impairment|Mild Traumatic Brain Injury|Concussion, Brain	Device: High Definition Transcranial Direct Current Stimulation	Changes in Rey Auditory Verbal Learning Test Score|Changes in Delis Kaplan Executive Function System (DKEFS) Trail Making Test|Changes in Delis Kaplan Executive Function System (DKEFS) Color-Word Interference Test	University of Texas Southwestern Medical Center	All	55 Years and older   (Adult, Older Adult)	Phase 2	75	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic	STU-2022-0591	January 1, 2023	May 31, 2026	August 31, 2026	July 6, 2022		July 6, 2022	University of Texas Southwestern Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT05446584
939	NCT02050464	Computational Tools for Early Diagnosis of Memory Disorders	ProsKuopio	Completed	No Results Available	Alzheimer Disease|Frontotemporal Dementia|Dementia, Vascular|Mild Cognitive Impairment		Sensitivity, specificity and accuracy of models for diagnosis of memory disorders	University of Eastern Finland|University of Sheffield|VTT Technical Research Centre of Finland|Klinik Hirslanden, Zurich|Sheffield Teaching Hospitals NHS Foundation Trust	All	50 Years to 85 Years   (Adult, Older Adult)		126	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	207094	December 2013	April 2017	April 2017	January 30, 2014		May 4, 2017	Department of Neurology and Brain Research Unit, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland|Kuopio University Hospital, Kuopio, Finland|VTT Technical Research Centre of Finland, Tampere, Finland		https://ClinicalTrials.gov/show/NCT02050464
940	NCT01548430	A Safety Study of TTP4000 in Subjects With Alzheimer's Disease		Completed	No Results Available	Alzheimer's Disease	Drug: TTP4000|Drug: Placebo	Number of participant with adverse events|Evaluation of participant plasma TTP4000 concentrations	vTv Therapeutics	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 1	8	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)	TTP4000-101	October 2011	February 2013	February 2013	March 8, 2012		February 12, 2015	Miami, Florida, United States|Durham, North Carolina, United States|High Point, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01548430
941	NCT01126424	A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability	SENIOR	Completed	Has Results	Cognition	Drug: Solifenacin|Drug: Oxybutynin|Drug: Placebo	Change From Baseline in Cognitive Function Composite Score - Power of Attention|Change From Baseline in Cognitive Function Composite Score - Continuity of Attention|Change From Baseline in Cognitive Function Composite Score - Quality of Working Memory|Change From Baseline in Cognitive Function Composite Score - Quality of Episodic Secondary Memory|Change From Baseline in Cognitive Function Composite Score - Speed of Memory|Change From Baseline in Postural Stability Test	Astellas Pharma Inc	All	75 Years and older   (Older Adult)	Phase 4	26	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)	905-EC-008|2008-005966-29	April 2010	December 2010	December 2010	May 19, 2010	October 15, 2012	October 15, 2012	Blackpool, Lancashire, United Kingdom|Manchester, Lancashire, United Kingdom|Bradford, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01126424
942	NCT03139799	Long-term Tablet-computer Based Casual Puzzle Video Game Intervention in Healthy Older and Cognitively Impaired Persons		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Acquired Brain Injury|Cognitive Impairment|Healthy	Behavioral: Experimental - Puzzle Video Game Intervention|Behavioral: Control - Tablet Newspaper Reading Intervention	Primary outcome measure - Attention: Visual Search|Additional attentional outcomes|Processing speed|Working memory|Spatial reasoning|Emotion and well-being 1|Emotion and well-being 2|Emotion and well-being 3|Self-efficacy|Intervention compliance|Game experience	University of Bern	All	21 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	2016-01281	July 15, 2020	December 1, 2023	December 1, 2023	May 4, 2017		May 3, 2021	ARTORG Center for Biomedical Engineering Research, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT03139799
943	NCT01687153	A Study of Brain Aging in Vietnam War Veterans	DOD-ADNI	Completed	No Results Available	Traumatic Brain Injury|Post Traumatic Stress Disorder|Alzheimer's Disease|Mild Cognitive Impairment		Rates of change in brain regions based on neuroimaging|Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers|Rates of change in neuropsychological measures of memory and general cognitive performance|Correlations within each group (TBI and PTSD) to assess whether baseline levels or rates of atrophy or cognitive decline are associated with severity of TBI or PTSD|Group differences in the patterns of amyloid deposition (from Florbetapir F 18) and brain atrophy|Group differences in white matter integrity as assessed with Diffusion Tension Imaging (DTI)|Rate of change of tau deposition as measured by 18F-AV-1451	University of Southern California|United States Department of Defense|Telemedicine & Advanced Technology Research Center|Northern California Institute of Research and Education|San Francisco Veterans Affairs Medical Center|Alzheimer's Therapeutic Research Institute	All	50 Years to 90 Years   (Adult, Older Adult)		289	Other|U.S. Fed	Observational	Observational Model: Cohort|Time Perspective: Prospective	ADC-044|W81XWH-12-2-0012|W81XWH-13-1-0259|W81XWH-14-1-0462	October 2012	September 21, 2021	September 21, 2021	September 18, 2012		November 29, 2021	Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Cornell Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Roper St Francis Healthcare, Charleston, South Carolina, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT01687153
944	NCT00483028	A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI		Completed	No Results Available	Alzheimer's Disease	Drug: donezepil (Aricept)	Neuropsychologic test scores: GMLT, DSST, Cog State TM including PAL test, RAVLT, ADAS-cog at baseline (pre-dose) 5 and 8 hours after the first dose and 2 and 6 weeks. (Continues in next bullet.)|MRS (Magnetic Resonance Spectroscopy) profile including but not limited to NAA (N-acetyl-aspartate), NAA/Cr (N-acetyl-aspartate/creatinine ratio), MI (Myoinositol) and MI/Cr (Myoinositol/creatinine ratio).	Pfizer	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	38	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	A9001134	June 2004		January 2007	June 6, 2007		February 5, 2008	Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Albany, New York, United States		https://ClinicalTrials.gov/show/NCT00483028
945	NCT01547754	Mild Neurocognitive Disorder in HIV Infection of the Brain		Terminated	No Results Available	HIV-Associated Cognitive Motor Complex		Brain uptake of [11C]dLop after pharmacological challenge with the P-gp inhibitor tariquidar.|Cerebrospinal fluid concentrations of antiretroviral drugs and inflammatory markers.	National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)	All	18 Years to 60 Years   (Adult)		8	NIH	Observational	Time Perspective: Prospective	120059|12-M-0059	January 9, 2012		August 25, 2014	March 8, 2012		December 16, 2019	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT01547754
946	NCT03672279	Validation of a Novel Self-Administered Cognitive Assessment Tool (CogCheck) in Patients With Mild and Major Neurocognitive Disorder Predominantly Due to Alzheimer's Disease	CogCheck-MC	Recruiting	No Results Available	Dementia Alzheimers|Mild Cognitive Impairment|Cognition Disorders|Neurocognitive Disorders	Diagnostic Test: CogCheck	CogCheck|Mini-Mental State Examination (MMSE)|Montreal Cognitive Assessment (MoCA)|Consortium to Establish a Registry for Alzheimer's Disease - Neuropsychological Assessment Battery (CERAD-NAB)|Basel Verbal Learning Test (BVLT)|Geriatric Depression Scale (GDS)|Beck's Depression Inventory (BDI)|Feedback questionnaire to assess the user-friendliness of CogCheck	University Hospital, Basel, Switzerland	All	65 Years and older   (Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CogCheck-MC-Validation	July 27, 2021	December 31, 2023	December 31, 2023	September 14, 2018		November 26, 2021	Memory Clinic, University Department of Geriatric Medicine FELIX PLATTER, Basel, BS, Switzerland		https://ClinicalTrials.gov/show/NCT03672279
947	NCT00597376	Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints		Completed	Has Results	Subjective Memory Loss in Older Persons	Other: Cerefolin NAC (a medical food)|Other: Cerefolin NAC placebo	Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only|Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only|Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only	Rush University Medical Center|Pamlab, Inc.	All	60 Years and older   (Adult, Older Adult)	Not Applicable	104	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	Pamlab-Cerefolin NAC-001-01	November 2007	May 2011	May 2011	January 18, 2008	May 23, 2013	May 23, 2013	Rush Alzheimer's Disease Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT00597376
948	NCT03192670	A Study of Low-level Light Therapy Using Photo-activated Modulation Ameliorates Cognitive Deficits		Unknown status	No Results Available	Mild Cognitive Impairment|Cerebral Blood Flow|Low-level Light Therapy|Brain Activity	Device: Low-level light therapy device	Neuropsychological Behavioral Assessment 1|Neuropsychological Behavioral Assessment 2|Neuropsychological Behavioral Assessment 3|ADL assessment 1|ADL assessment 2|Depression assessment|Quality of Life assessment|Gene test 1|Gene test 2|Neuroimaging Assessment 1|Neuroimaging Assessment 2	Yong-il Shin, MD|Samsung Medical Center|Pusan National University	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	168	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	PNUYH-03-2017-003, SMC-2016-1	June 20, 2017	December 31, 2018	December 31, 2019	June 20, 2017		June 20, 2017	Pusan National University Yangsan Hospital Yangsan, Yangsan, Gyeongnam, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03192670
949	NCT05347966	Brain Health Support Program	CTU: BHSP	Recruiting	No Results Available	Dementia Prevention|Mild Cognitive Impairment|Subjective Cognitive Impairment|Cognitive Change	Other: Brain Health PRO	Dementia Literacy|Self-efficacy|Change in attitudes toward dementia|Modifiable risk factors	Baycrest	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	350	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CTU: BHSP	April 1, 2022	November 2023	November 2023	April 27, 2022		May 27, 2022	University of British Columbia, Vancouver, British Columbia, Canada|University of New Brunswick, Fredericton, New Brunswick, Canada|Cognitive Clinical Research Group, Parkwood Research Institute, London, Ontario, Canada|Gait and Brain Laboratory, Parkwood Research Institute, London, Ontario, Canada|Baycrest, Toronto, Ontario, Canada|CRIUGM/ CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT05347966
950	NCT04250376	The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Mild Dementia|Parkinson Disease|Alzheimer Disease	Device: Focused Transcranial Ultrasound	Quick Dementia Rating Scale|Repeatable Battery Assessment for Neuropsychological Status (RBANS)|Montreal Cognitive Assessment (MoCA)|Quick Dementia Rating Scale (QDRS)	Neurological Associates of West Los Angeles	All	45 Years to 93 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	32222-1	November 27, 2017	December 2022	January 2023	January 31, 2020		September 1, 2021	Neurological Associates of West LA, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT04250376
951	NCT02350270	Gait, cOgnitiOn & Decline (GOOD)		Unknown status	No Results Available	Mild Cognitive Impairment|Mild Dementia|Moderate Dementia|Healthy	Other: gait and cognitive testing	Spatio-temporal gait parameters|Clinical assessment|Cognitive status	University Hospital, Angers|Biomathics	All	60 Years and older   (Adult, Older Adult)		2800	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	2014-17	January 2015	June 2015	December 2015	January 29, 2015		January 29, 2015	University Hospital, Angers, France		https://ClinicalTrials.gov/show/NCT02350270
952	NCT04954183	Development of an EEG Diagnostic for Alzheimer's Disease		Enrolling by invitation	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Dementia With Lewy Bodies|Normal Control APOE e4 Carriers and Noncarriers		Obtain electroencephalogram (EEG) data	Mayo Clinic|Spark Neuro Inc.	All	50 Years to 85 Years   (Adult, Older Adult)		30	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	21-000676	October 1, 2021	June 30, 2022	June 30, 2022	July 8, 2021		October 22, 2021	Mayo Clinic in Arizona, Scottsdale, Arizona, United States		https://ClinicalTrials.gov/show/NCT04954183
953	NCT05477056	Quality Improvement PrecivityAD Clinician Survey (QUIP I)	QUIP I	Enrolling by invitation	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Dementia|Cognitive Decline	Other: PrecivityAD blood test	evaluate patient selection for the blood test through analysis of clinician survey responses.|evaluate score interpretation for the Amyloid Probability Score (APS) through analysis of clinician survey responses.	C2N Diagnostics	All	60 Years and older   (Adult, Older Adult)		300	Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	C2N001	March 1, 2021	September 2, 2022	September 2, 2022	July 28, 2022		August 1, 2022	C2N Diagnostics, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT05477056
954	NCT03330470	Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease		Unknown status	No Results Available	Subjective Cognitive Impairment|Mild Cognitive Impairment|Parkinson Disease|Healthy Volunteers	Behavioral: exercise|Dietary Supplement: carnosine supplementation|Behavioral: stretching|Dietary Supplement: supplementation with placebo	glucose tolerance|learning/working memory|motoric functions - Berg Balance Scale|habitual physical activity|physical fitness	Slovak Academy of Sciences|Comenius University|University Hospital Bratislava|National Cheng Kung University	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	15-0253	January 1, 2017	December 31, 2020	December 31, 2020	November 6, 2017		September 17, 2018	University Hospital Bratislava, Comenius University, Bratislava, Slovakia|Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia|Laboratory of Cognitive Neurophysiology, Institute of Physical Education, Health & Leisure Studies, National Cheng Kung University, Tainan City, Tainan, Taiwan		https://ClinicalTrials.gov/show/NCT03330470
955	NCT02228187	Brain-Computer Interface System for Training Memory and Attention in Elderly		Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia	Device: Brain-Computer Interface	Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Sum of Scaled Score of the Rivermead Behavioral Memory Test-II|Number of Adverse Events/Serious Adverse Events Reported|Usability Measure of the Brain-Computer Interface training system	Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|National University, Singapore|Singapore Clinical Research Institute|Singapore General Hospital|Tan Tock Seng Hospital	All	60 Years to 80 Years   (Adult, Older Adult)	Phase 2	240	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	B-14-099	July 2015	June 2017	June 2017	August 28, 2014		August 2, 2017	Duke-NUS Medical School, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02228187
956	NCT05356611	Engage for Late-Life Depression and Comorbid Executive Dysfunction		Not yet recruiting	No Results Available	Depression in Old Age|Psychotherapy|Mild Cognitive Impairment|Executive Dysfunction	Behavioral: Engage	Hamilton Depression Rating Scale|World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)|Behavioral Activation for Depression Scale (BADS)|Social Problem-Solving Inventory Revised-Short Form	University of Nevada, Las Vegas	All	60 Years and older   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UNLV-2022-74	June 2022	December 2022	December 2023	May 2, 2022		May 2, 2022	University of Nevada, Las Vegas, Nevada, United States		https://ClinicalTrials.gov/show/NCT05356611
957	NCT03134963	Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study		Completed	Has Results	Mild Cognitive Impairment|Alzheimer Disease|Vascular Dementia|Healthy Controls	Other: Transcranial doppler ultrasonography|Other: Blood pressure monitoring|Other: Heart rate monitoring|Other: End tidal CO2 monitoring|Other: Addenbrooke's cognitive examination	Percentage of Recruited Subjects Able to Comply With the Protocol|Number of Participants With Rejected Measurements|Number of Participants in Which Percentage Change in CBFv Can be Derived|Number of Participants in Which the Change in the Autoregulation Index (ARI) Can be Derived	University of Leicester	All	18 Years to 100 Years   (Adult, Older Adult)		42	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	0613	May 5, 2017	December 1, 2017	December 1, 2017	May 1, 2017	November 25, 2020	October 5, 2021	University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom|Leicestershire Partnership Trust, Leicester, Leicestershire, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03134963/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03134963
958	NCT04492241	Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome		Recruiting	No Results Available	Motoric Cognitive Risk Syndrome|Mild Cognitive Impairment|Aging|Locomotive Syndrome	Drug: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|Drug: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution	Change of ADAS-Cog|Frequency of Falls|Change of each items from ADAS-Cog|Percentage of change of ADAS-Cog score 4 or more|TMT-A Score|TMT-B Score|Functional Activities Questionnaire score|Activities of Daily Living (ADLs) score|The Neuropsychiatric Inventory Questionnaire|Dementia Conversion Rate|Single-task gait speed test|Dual-task gait speed test-naming animals	Beijing Tiantan Hospital|Beijing Stroke Association	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	800	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	KY2020-052-03	July 5, 2021	December 31, 2023	December 31, 2024	July 30, 2020		December 9, 2021	Beijing Tiantan Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04492241
959	NCT02958670	Imaging Tau Deposition in the Brain of Elderly Subjects	Add-Tau	Active, not recruiting	No Results Available	Mild Cognitive Impairment|Healthy|Alzheimer Disease|Neurocognitive Disorders	Other: 18F-AV-1451 (Tau-PET tracer)	Volume of Interest (VOI) or Voxel based assessment of 18F-AV-1451-PET-signal	University of Zurich|Avid Radiopharmaceuticals|Swiss Federal Institute of Technology	All	50 Years and older   (Adult, Older Adult)	Not Applicable	141	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	KEK-ZH_Nr_2016-01079_V9.0	November 2016	December 2024	December 2029	November 8, 2016		December 22, 2021	Institute for Regenerative Medicine (IREM), Schlieren, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT02958670
960	NCT05427448	Validation of Blood Biomarkers for Alzheimer's Disease	ALZAN	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Dementia|Tauopathies	Diagnostic Test: Measurement of amyloid and pTau blood biomarkers	Diagnostic performance of blood biomarkers for Alzheimer's disease|Prediction of CSF profile|Diagnostic performance of blood biomarkers for FTD or LBD	University Hospital, Montpellier	All	18 Years and older   (Adult, Older Adult)	Not Applicable	342	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	21_0586	June 21, 2022	June 20, 2023	December 31, 2023	June 22, 2022		July 5, 2022	Montpellier University Hospital, Montpellier, Occitanie, France|Nîmes University Hospital, Nîmes, Occitanie, France|Perpignan Regional Hospital, Perpignan, Occitanie, France		https://ClinicalTrials.gov/show/NCT05427448
961	NCT05349318	Hyperbaric Oxygen Therapy for Prodromal Alzheimer´s Disease With Cerebrovascular Disease		Recruiting	No Results Available	Prodromal Alzheimer's Disease|Cerebral Vascular Disorder|Mild Cognitive Impairment|Vascular Cognitive Impairment	Device: Hyperbaric oxygen therapy|Device: Sham	Change from baseline of neurocognitive functions evaluation by Mindstreams cognitive battery test (Neurotrax)|Brain amyloid PET using Flumetamol (Vizamyl) tracer|Whole-brain quantitative perfusion imaging|Brain microstructure MRI evaluation|Brain volume MRI evaluation|Brain functional connectivity imaging	Assaf-Harofeh Medical Center	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	254-21-ASF	March 31, 2022	March 2024	March 2025	April 27, 2022		July 26, 2022	Shamir Medical Center (Assaf Harofeh), Zerifin, Israel		https://ClinicalTrials.gov/show/NCT05349318
962	NCT02931136	Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging		Not yet recruiting	No Results Available	Mild Cognitive Impairment|Biomarker|Diagnosis|Treatment	Drug: Huperzine A|Drug: Placebo	The average annual conversion rate in patients of MCI due to AD convert to the AD.	Shanghai Mental Health Center	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 4	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	Shanghai Mental Health Center	November 2019	December 2024	December 2025	October 12, 2016		April 16, 2019	Shanghai Mental Health Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT02931136
963	NCT02253732	Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs	Brain-Muscle	Completed	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Parkinson Disease|Healthy Volunteers	Behavioral: 3 months exercise intervention program	muscle microRNAs and myokines|whole body energy metabolism|cognitive function|motoric function|Muscle functional tests	Slovak Academy of Sciences|University Hospital Bratislava	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	UEE-SAS	September 2015	September 2017	March 2018	October 1, 2014		April 17, 2018	Univeristy Hospital in Bratislava, Bratislava, Slovakia|Inst. Exp. Endocrinology Slovak Acad Sci, Bratislava, Slovakia		https://ClinicalTrials.gov/show/NCT02253732
964	NCT05002699	Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia	IMPACT-AD BC	Active, not recruiting	No Results Available	Alzheimer Disease|Dementia|Cognitive Impairment|Mild Cognitive Impairment	Diagnostic Test: Alzheimer's disease CSF biomarkers	To assess the impact of Alzheimer's disease core CSF biomarker testing on the management of patients meeting the appropriate use criteria for lumbar puncture and testing.|To describe the participant's experience with Alzheimer's disease CSF biomarker testing.|To describe the study partner's experience with Alzheimer's disease CSF biomarker testing.|To assess changes in participant management among various clinical presentations.|To assess changes in participant management by clinical disease stage.|To assess the impact of Alzheimer's disease core CSF biomarker testing on the change in diagnosis and diagnostic confidence.	University of British Columbia|Brain Canada|Health Canada|Michael Smith Foundation for Health Research|Women's Brain Health Initiative|St. Paul's Foundation	All	40 Years and older   (Adult, Older Adult)		120	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	H17-01339	February 1, 2019	August 2022	March 2023	August 12, 2021		May 17, 2022	Northern Health, Prince George, British Columbia, Canada|Providence Health Care, Vancouver, British Columbia, Canada|Vancouver Coastal Health, Vancouver, British Columbia, Canada|Island Health, Victoria, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT05002699
965	NCT04323423	The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON.		Unknown status	No Results Available	Sedentary Behavior|Mild Cognitive Impairment|Glucose Intolerance|Overweight and Obesity	Behavioral: interrupting sedentary behaviour with light physical activity	Glycemic Variability|Cognition	Western University, Canada	All	65 Years and older   (Older Adult)	Not Applicable	12	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Glycemic variability & SB	January 1, 2021	December 1, 2021	December 1, 2021	March 26, 2020		August 18, 2020	The University of Western Ontario, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04323423
966	NCT03275363	The University of Hong Kong Neurocognitive Disorder Cohort		Unknown status	No Results Available	Neurocognitive Disorder|Mild Cognitive Impairment|Alzheimer Dementia|Vascular Dementia|Age-related Cognitive Decline	Diagnostic Test: Neurocognitive battery|Diagnostic Test: MRI|Biological: Blood tests|Diagnostic Test: EEG with event-related potential (ERP)|Diagnostic Test: Amyloid PET CT	Cognitive decline|Functional decline|Neuropsychiatric decline|Quality of life decline|Change in cognitive impairment status	The University of Hong Kong|Dementias Platform UK	All	65 Years and older   (Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	HKUNCDC	September 1, 2014	January 1, 2022	January 4, 2022	September 7, 2017		September 7, 2017	Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT03275363
967	NCT02875496	Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain	(BNA™)	Recruiting	No Results Available	Early Onset Alzheimer Disease|Mild Cognitive Impairment|Depression|Aging		Developing a BNA database for healthy aging population.	ElMindA Ltd	All	50 Years to 85 Years   (Adult, Older Adult)		2000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	ELM-26	August 2016	August 2022	December 2022	August 23, 2016		November 27, 2019	The Villages Health, The Villages, Florida, United States		https://ClinicalTrials.gov/show/NCT02875496
968	NCT04559789	Reducing Dementia Risk With Digital Health Coaching	DC-MARVEL	Active, not recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment|Cognitive Decline	Behavioral: MindMate + Health Coaching|Other: Health Education	Composite dementia risk|Rate of cognitive decline	Neurotrack Technologies, Inc.|National Institute on Aging (NIA)|University of Arkansas	All	45 Years to 75 Years   (Adult, Older Adult)	Not Applicable	200	Industry|NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention	1R44AG063672-01|R44AG063672	January 4, 2021	January 30, 2024	January 30, 2024	September 23, 2020		August 31, 2021	University of Arkansas, Fayetteville, Arkansas, United States		https://ClinicalTrials.gov/show/NCT04559789
969	NCT04100057	Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia		Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Neuropsychiatric Symptoms|Sleep Disturbance	Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral: Desensitization Therapy for insomnia (DT-I)	Fronto-limbic function|Neuropsychiatric Symptoms|Insomnia symptoms	Stanford University|National Institute of Mental Health (NIMH)	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	150	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	IRB-53039	October 30, 2021	August 30, 2024	August 30, 2024	September 23, 2019		September 27, 2021	Andrea Goldstein-Piekarski, PhD, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT04100057
970	NCT02986659	Genomic Outcomes of Metformin	GOMET	Completed	No Results Available	Coronary Artery Disease|Mild Cognitive Impairment|Obesity, Abdominal|Hypertension	Drug: Metformin|Drug: Placebo	Change in eigengene scores	Wake Forest University Health Sciences|National Institute on Aging (NIA)	All	65 Years to 79 Years   (Older Adult)	Phase 4	34	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research	IRB00034977	August 3, 2016	November 15, 2018	November 15, 2018	December 8, 2016		November 6, 2019	Wake Forest Health Sciences, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02986659
971	NCT05529277	Implementing Dementia Care Management Into Routine Care in the Region Siegen-Wittgenstein	RoutineDeCM	Not yet recruiting	No Results Available	Dementia|Dementia Alzheimers|Mild Cognitive Impairment|Care Management	Other: Dementia Care Management	unmet needs|Antidementia drug treatment|Neuropsychiatric Symptoms|Caregiver Burden	German Center for Neurodegenerative Diseases (DZNE)|University of Siegen|Gesundheitsregion Siegerland eG (GRS)|Alzheimer Gesellschaft Siegen-Wittgenstein eV|Kreisklinikum Siegen|Caritasverband Siegen-Wittgenstein eV	All	18 Years and older   (Adult, Older Adult)		60	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	GR025|ZMI1-2521FSB907|BB110/22	September 1, 2022	December 31, 2023	June 30, 2024	September 7, 2022		September 9, 2022	Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Greifswald, MV, Germany|University of Siegen, Siegen, NRW, Germany|Caritasverband Siegen-Wittgenstein eV, Siegen, NRW, Germany|Alzheimer Gesellschaft Siegen-Wittgenstein eV, Siegen, NRW, Germany|Kreisklinikum Siegen, Kliniken für Neurologie und Psychiatrie, Siegen, NRW, Germany|Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Witten, NRW, Germany		https://ClinicalTrials.gov/show/NCT05529277
972	NCT01661894	Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly	3ECog	Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Age-Related Cognitive Decline|Dementia	Device: BrainPalTM	Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Number of Adverse Events reported by participants on the Safety Measurement Form|Usability Measurement	Duke-NUS Graduate Medical School|Agency for Science, Technology and Research|National University, Singapore|Singapore Clinical Research Institute|Singapore General Hospital	All	60 Years to 70 Years   (Adult, Older Adult)	Phase 1	82	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-363	April 2012	April 2014	April 2014	August 10, 2012		July 25, 2014	Duke-NUS Graduate Medical School, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT01661894
973	NCT03875638	Treating Hyperexcitability in AD With Levetiracetam	LeAD	Recruiting	No Results Available	Alzheimer Dementia|Alzheimer Disease|Dementia of Alzheimer Type|Mild Cognitive Impairment	Drug: Levetiracetam|Drug: Placebo oral capsule	Neuropsychological Test Battery (NTB)|Transcranial magnetic stimulation (TMS) resting motor threshold|Transcranial magnetic stimulation (TMS)-evoked electroencephalogram (EEG) hypersynchrony|Resting-state electroencephalogram (EEG) beta band power|Resting-state electroencephalogram (EEG) beta band connectivity|Default-mode network resting-state functional magnetic resonance imaging (fMRI) functional connectivity|Change in motor evoked potential (MEP) amplitude|Change in beta power after theta-burst stimulation	Beth Israel Deaconess Medical Center	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 2	85	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	2019P000091	August 22, 2019	August 2023	November 2023	March 15, 2019		November 10, 2021	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03875638
974	NCT03847038	BarcelonaBeta Dementia Prevention Research Clinic: a Study on Risk Factors Disclosure		Active, not recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment|Subjective Cognitive Decline	Procedure: Preventive strategies advice and dementia risk estimate disclosure	Risk/benefit of disclosing dementia risk with a PERSONALISED and INDIVIDUALISED approach	Barcelonabeta Brain Research Center, Pasqual Maragall Foundation	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	306	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	BBRC-DemPrev-2018	July 16, 2018	February 3, 2022	December 31, 2022	February 20, 2019		April 21, 2022	Barcelonabeta Brain Research Center, Barcelona, Please Choose A State, Spain		https://ClinicalTrials.gov/show/NCT03847038
975	NCT05094817	Feasibility of an Online, Self-administered Cognitive Screening Tool in Older Patients Undergoing Ambulatory Surgery	FOCUS	Recruiting	No Results Available	Delirium in Old Age|Alzheimer Disease|Mild Cognitive Impairment|Neurocognitive Disorders	Other: Brain Health Assessment|Other: Demographics questionnaire|Other: PHQ-2|Other: AFT|Other: GAI-SF|Other: pain VAS|Other: IADL|Other: FAM CAM|Other: 4AT|Other: BHA Usability Survey|Other: Clinical Frailty Scale	Participants that completed BHA/total participants|Usability and acceptability of Cognitici's BHA|Percentage of patients who successfully complete Cogniciti's BHA|To estimate the incidence of pre-existing neurocognitive disorders (NCD) in older adults undergoing elective ambulatory surgery.	Women's College Hospital|University Health Network, Toronto	All	65 Years and older   (Older Adult)		220	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020-0155-E	February 11, 2022	August 2022	September 2022	October 26, 2021		March 25, 2022	Toronto Western Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05094817
976	NCT03483740	Psychosocial Intervention for Older HIV+ Adults With HAND	IN-HAND	Unknown status	No Results Available	HIV/AIDS|Aging|Mild Cognitive Impairment|Group, Peer	Behavioral: CRGT|Behavioral: HIV group therapy	Feasibility - participant attendance at group sessions|Acceptability - participant satisfaction with group sessions|Intervention fidelity - how closely facilitators adhere to intervention model	University Health Network, Toronto|CIHR Canadian HIV Trials Network|Unity Health Toronto|AIDS Committee of Toronto|Factor-Inwentash Faculty of Social Work, University of Toronto	All	40 Years and older   (Adult, Older Adult)	Not Applicable	16	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CTNPT 029	April 9, 2018	October 31, 2018	December 31, 2018	March 30, 2018		April 11, 2018	AIDS Committee of Toronto (ACT), Toronto, Ontario, Canada|St. Michael's Hospital Neurobehavioral Research Unit, Toronto, Ontario, Canada|University Health Network, Toronto General Hospital, Toronto, Ontario, Canada	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03483740/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03483740/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03483740
977	NCT01208675	The Swedish BioFINDER Study		Active, not recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer's Disease|Dementia With Lewy Bodies|Vascular Dementia		To compare the time to conversion to clinically probable AD in MCI subjects or healthy elderly subjects with normal and abnormal biomarkers (CSF, blood, MRI, PET)|Rate of cognitive decline as measured by various cognitive tests, Activities of Daily Living (FAQ) and Global Deterioration Scale.|Group differences for imaging and wet biomarker measurements.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on each specified biochemical biomarker|Correlations between biomarkers and biomarker change|Subgroups analyses: Abnormal CSF biomarkers, positive amyloid imaging, APOE genotype.	Skane University Hospital|Lund University	All	60 Years to 80 Years   (Adult, Older Adult)		1150	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	TiDiS-2010	September 2010	December 2022	December 2022	September 24, 2010		March 2, 2021	Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden		https://ClinicalTrials.gov/show/NCT01208675
978	NCT05475158	Comparison of OCTA Factors in Patients With or Without Amyloid Pathology: A Prospective Study		Completed	No Results Available	Alzheimer Disease|Amyloid Angiopathy|Macular Ischemia|Dementia|Mild Cognitive Impairment		SD-OCT imaging|SD-OCTA imaging|Diagnostic performance|Correlations	Pusan National University Hospital	All	50 Years to 90 Years   (Adult, Older Adult)		117	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	1908-004-081	September 1, 2019	July 31, 2021	July 31, 2021	July 26, 2022		July 26, 2022	Pusan National University Hospital, Busan, Korea, Republic of		https://ClinicalTrials.gov/show/NCT05475158
979	NCT02333942	Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia		Completed	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Frontotemporal Lobar Degeneration|Memory Disorders	Device: Nautilus NeuroWaveTM System	Sensitivity as a diagnostic aid in detecting Dementia (identified signatures as compared with the clinical assessment made by the PI)|Specificity as a diagnostic aid in detecting Dementia (Rate of false positives as compared with the clinical assessment made by the PI)|Sensitivity and specificity measures for MCI and Alzheimer's disease (Efficacy and rate of false positives as compared with the clinical assessment made by the PI)|Sensitivity and specificity measures between MCI and FTDL. (distinguish between MCI and FTDL using efficacy and rate of false positives from the identified signatures as compared with the clinical assessment made by the PI)|Sensitivity and specificity measures between FTDL and Alzheimer's disease (distinguish between FTLD and Alzheimer's disease using efficacy and rate of false positives from the identified signatures as compared with the clinical assessment made by the PI)	Jan Medical, Inc.|University of California, San Francisco	All	18 Years and older   (Adult, Older Adult)		41	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	082189	May 2014	February 2015	February 2015	January 8, 2015		September 13, 2019	University of Californa San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT02333942
980	NCT01370954	NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)		Completed	No Results Available	Early Memory Loss|Mild Cognitive Impairment|Alzheimer's Disease|Vascular Dementia	Other: CerefolinNAC®	To determine if CerefolinNAC® affects a subject's quality of life as measured by the Quality of Life-Alzheimer's Disease Scale (QOL-AD)|To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale	Pamlab, Inc.|InfoMedics, Inc.	All	50 Years to 80 Years   (Adult, Older Adult)		204	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	NAC-003	May 2011	November 2012	December 2012	June 10, 2011		May 9, 2013	Falls Neurology and Memory Center, Hickory, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01370954
981	NCT04385225	Effect of Hearing Loss and Vestibular Decline on Cognitive Function in Older Subjects	GECkO	Recruiting	No Results Available	Hearing Loss, Sensorineural|Bilateral Vestibulopathy|Alzheimer Disease|Mild Cognitive Impairment	Other: Longitudinal follow-up	Change in Repeatable Battery for the Assessment of Neuropsychological Status for Hearing Impaired Individuals total score	University Hospital, Antwerp|Universiteit Antwerpen	All	55 Years and older   (Adult, Older Adult)	Not Applicable	300	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	B300201938949	December 16, 2019	November 2022	November 2022	May 12, 2020		May 12, 2020	University Hospital Antwerp, Edegem, Antwerp, Belgium		https://ClinicalTrials.gov/show/NCT04385225
982	NCT01231971	Alzheimer's Disease Neuroimaging Initiative 2	ADNI2	Completed	No Results Available	Mild Cognitive Impairment (MCI)|Alzheimer's Disease (AD)|Significant Memory Concern (SMC)|Early Mild Cognitive Impairment (EMCI)|Late Mild Cognitive Impairment (LMCI)	Drug: Florbetapir|Drug: Flortaucipir	Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rate of conversion will be evaluated among all five groups|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by Florbetapir F 18|Group differences for each imaging and biomarker measurement|Correlations among biomarkers and biomarker change|APOE genotype, low CSF Aβ42, positive amyloid imaging with florbetapir F 18 (AV-45)|Rate of change of tau and extent of tau deposition as measured by flortaucipir (18F-AV-1451)|Rate of cognitive decline using computer based testing as measured by Cogstate Brief Battery (CBB)	University of Southern California|Northern California Institute of Research and Education|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute	All	55 Years to 90 Years   (Adult, Older Adult)		1182	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	ADC-039-ADNI2|U01AG024904	February 14, 2011	November 29, 2017	November 29, 2017	November 1, 2010		February 15, 2022	University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Martinez, California, United States|University of California, Irvine (Brain Imaging Center), Orange, California, United States|Stanford University / PAIRE, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Dartmouth Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurologic Institute, Amherst, New York, United States|New York University Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Clinic for Alzheimer's Disease and Related Disorders Program, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|St. Joseph's Health Center - Cognitive Neurology, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University / Jewish General Hospital Memory Clinic, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT01231971
983	NCT02699476	Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.		Unknown status	No Results Available	Traumatic Brain Injury|Concussion|Mild Cognitive Disorder	Behavioral: Psycho-Social Therapy|Device: Cognitive Behavioral Computer Training|Behavioral: Interactive Trainer-Subject Sessions|Device: Active Control Games	Composite performance score based on battery of neuropsychological tests of working memory, learning, memory, and executive function.|Participant reported outcomes|Working/school status|Exercise-base assessments|Functional assessments	Brain & Body Health Foundation	All	25 Years to 55 Years   (Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BBHF-001	February 2016	September 2017	December 2017	March 4, 2016		March 4, 2016	Brain & Body Health Institute, P.A., Lakeway, Texas, United States		https://ClinicalTrials.gov/show/NCT02699476
984	NCT04600726	Application of VR-based Working Memory Screening Test	VR	Not yet recruiting	No Results Available	Older Adults With Mild Neurocognitive Disorders|Older Adults With Non-communicable Diseases|Healthy Age-matched Older Adults	Other: no intervention	Delayed matching-to-place (DMP)|The Montreal Cognitive Assessment - Hong Kong Version|The Chinese Multiple Errands Test|Biological biomarkers for older adults with NCDs and Healthy Control	The Hong Kong Polytechnic University|Department of Neuroscience, Psychology and Behavior. The University of Leicester|School of Psychology, The University of Nottingham|The Alice Ho Miu Ning Nethersole Hospital	All	65 Years to 80 Years   (Older Adult)		160	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	VR_Clinical Trial	February 1, 2021	December 30, 2022	December 31, 2022	October 23, 2020		October 23, 2020			https://ClinicalTrials.gov/show/NCT04600726
985	NCT04951284	Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension	FUTURE-US	Recruiting	No Results Available	Alzheimer Disease|Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer's Disease (Incl Subtypes)|Mild Cognitive Impairment		The agreement between the change in the PACC5 composite between baseline and +12 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms, as measured by the coefficient of individual agreement (CIA).|The agreement between the change in the PACC5 composite between baseline and +24 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms, as measured by the coefficient of individual agreement (CIA).|The agreement between the change in the PACC5 composite between baseline and +36 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms, as measured by the coefficient of individual agreement (CIA).|The agreement between the change in the PACC5 composite between baseline and +12 months and the corresponding regression model, trained on baseline speech data, to predict it in the CN Arms (Arms 3 and 4), as measured by the CIA.|The agreement between the change in the PACC5 composite between baseline and +24 months and the corresponding regression model, trained on baseline speech data, to predict it in the CN Arms (Arms 3 and 4), as measured by the CIA.|The agreement between the change in the PACC5 composite between baseline and +36 months and the corresponding regression model, trained on baseline speech data, predicting it in the MCI Arms (Arms 1 and 2), as measured by the CIA.|The agreement between the PACC5 composite at +12 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms based on +12 month speech data, as measured by the coefficient of individual agreement (CIA).|The agreement between the PACC5 composite at +24 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms based on +12 month speech data, as measured by the coefficient of individual agreement (CIA).|The agreement between the PACC5 composite at +36 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms based on +12 month speech data, as measured by the coefficient of individual agreement (CIA).|The agreement between the PACC5 composite and the corresponding regression model, trained on baseline speech data and +12 month speech data, as measured by the coefficient of individual agreement (CIA).|The agreement between the PACC5 composite and the corresponding regression model, trained on baseline speech data and +24 month speech data, as measured by the coefficient of individual agreement (CIA).|The agreement between the PACC5 composite and the corresponding regression model, trained on baseline speech data and +36 month speech data, as measured by the coefficient of individual agreement (CIA).|The AUC of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +12 months.|The AUC of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +24 months.|The AUC of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +36 months.|The sensitivity of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +12 months.|The sensitivity of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +24 months.|The sensitivity of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +36 months.|The specificity of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +12 months.|The specificity of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +24 months.|The specificity of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +36 months.|The Cohen's kappa of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +12 months.|The Cohen's kappa of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +24 months.|The Cohen's kappa of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4); converters defined as having a CDR Global score of 0.5 or more at +36 months.|The AUC of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +12 months.|The AUC of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +24 months.|The AUC of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +36 months.|The sensitivity of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +12 months.|The sensitivity of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +24 months.|The sensitivity of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +36 months.|The specificity of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +12 months.|The specificity of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +24 months.|The specificity of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +36 months.|The Cohen's kappa of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +12 months.|The Cohen's kappa of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +24 months.|The Cohen's kappa of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +36 months.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		50	Industry	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NOV-0110-1	January 21, 2021	August 15, 2022	August 15, 2024	July 6, 2021		July 6, 2021	Syrentis Clinical Research, Santa Ana, California, United States		https://ClinicalTrials.gov/show/NCT04951284
986	NCT04928976	Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping	AMYPRED-US	Completed	No Results Available	Alzheimer Disease|Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer's Disease (Incl Subtypes)|Mild Cognitive Impairment		Area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms using speech recordings as input.|The sensitivity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The specificity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The sensitivity of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The specificity of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The AUC of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The sensitivity of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The specificity of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The AUC of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The sensitivity of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The specificity of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The Cohen's kappa of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The AUC of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The agreement between the PACC5 composite and the corresponding regression model predicting it in all four Arms, as measured by the coefficient of individual agreement (CIA).|For each classifier/regressor in outcome 1-16, the correlation between the AUC/CIA and each age group, gender and speech-to-reverberation modulation energy ratio group, as measured by the Kendall rank correlation coefficient.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		67	Industry	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	NOV-0110	January 22, 2021	July 30, 2021	July 30, 2021	June 16, 2021		September 5, 2021	Syrentis Clinical Research, Santa Ana, California, United States		https://ClinicalTrials.gov/show/NCT04928976
987	NCT04851496	Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension	AMYPRED-PAST	Recruiting	No Results Available	Alzheimer Disease|Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer's Disease (Incl Subtypes)|Mild Cognitive Impairment		The primary outcome measure is the area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.|The sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms using archival spoken or written language samples as input.|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifiers distinguishing between MCI and cognitively normal (CN) arms.|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		80	Industry	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	NOV-0100-2	November 19, 2020	August 30, 2022	August 30, 2022	April 20, 2021		April 7, 2022	Re:Cognition Health, Birmingham, United Kingdom|Re:Cognition Health, Guildford, United Kingdom|Re:Cognition Health, London, United Kingdom|Re:Cognition Health, Plymouth, United Kingdom		https://ClinicalTrials.gov/show/NCT04851496
988	NCT04846426	Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension	AMYPRED-FUTURE	Recruiting	No Results Available	Alzheimer Disease|Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer's Disease (Incl Subtypes)|Mild Cognitive Impairment		The agreement between the change in the PACC5 composite between baseline and +12 months and the corresponding regression model, trained on baseline speech data, predicting in all four Arms, as measured by the coefficient of individual agreement (CIA).|The agreement between changes in the PACC5 composite between baseline and +24, +36 months and the corresponding regression models, trained on baseline speech data, predicting in all 4 Arms, as measured by the coefficient of individual agreement (CIA).|The agreement between the changes in the PACC5 composite between baseline and +12, +24, +36 months and the corresponding regression models, trained on baseline speech data, to predict them in the CN Arms (3 and 4), as measured by the CIA.|The agreement between the changes in the PACC5 composite between baseline and +12, +24, +36 months and the corresponding regression models, trained on baseline speech data, predicting them in the MCI Arms (Arms 1 and 2), as measured by the CIA.|The agreement between the PACC5 composite at +12, +24, +36 months and the corresponding regression models, trained on baseline speech data, predicting in all four Arms based on +12, +24, +36 month speech data, as measured by the CIA.|The agreement between the PACC5 composite at +12, +24, +36 months and the corresponding regression models, trained on baseline speech data and +12, +24, +36 month speech data, as measured by the coefficient of individual agreement (CIA).|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between converters vs non-converters in the cognitively normal (CN) Arms (Arms 3 and 4).|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between fast decliners vs slow decliners in the MCI Arms (Arms 1 and 2) at +12, +24, +36 months.|The outcomes above where the model has access to speech data at 1 month, 3 month time points, in addition to baseline speech data.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		140	Industry	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NOV-0100-1	November 19, 2020	May 15, 2022	May 15, 2024	April 15, 2021		April 15, 2021	Re:Cognition Health, Birmingham, United Kingdom|Re:Cognition Health, Guildford, United Kingdom|Re:Cognition Health, London, United Kingdom|Re:Cognition Health, Plymouth, United Kingdom		https://ClinicalTrials.gov/show/NCT04846426
989	NCT04828122	Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech	AMYPRED	Completed	No Results Available	Alzheimer Disease|Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Alzheimer's Disease (Incl Subtypes)|Mild Cognitive Impairment		The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms using speech recordings as input.|The sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms.|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive cognitively normal (CN) (Arm 3) and amyloid negative cognitively normal (CN) (Arm 4) Arms.|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between amyloid positive MCI (Arm 1) and amyloid negative MCI (Arm 2) Arms.|The AUC, sensitivity, specificity and Cohen's kappa of the binary classifier distinguishing between the MCI (Arms 1 and 2) and the CN (Arms 3 and 4) Arms.|The agreement between the PACC5 composite and the corresponding regression model predicting it in all four Arms, as measured by the coefficient of individual agreement (CIA).|For each classifier/regressor in outcome 1-6, the correlation between the AUC/CIA and each age group, gender and speech-to-reverberation modulation energy ratio group, as measured by the Kendall rank correlation coefficient.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		141	Industry	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	NOV-0100	November 19, 2020	August 6, 2021	August 6, 2021	April 1, 2021		September 5, 2021	Re:Cognition Health, Birmingham, United Kingdom|Re:Cognition Health, Guildford, United Kingdom|Re:Cognition Health, London, United Kingdom|Re:Cognition Health, Plymouth, United Kingdom		https://ClinicalTrials.gov/show/NCT04828122
990	NCT05544201	Transcranial Alternating Current Stimulation for Sleep Disturbances in Neurocognitive Disorders Due to Alzheimer's Disease		Enrolling by invitation	No Results Available	Brain Stimulation|Alzheimer Disease|tACS|Sleep Disturbance|Aging|Cognitive Impairment, Mild	Device: High-definition transcranial current stimulation	Subjective sleep quality|Memory function|Attention function|Executive function|Saliva Aβ40 and Aβ42 levels	Chinese University of Hong Kong	All	60 Years to 90 Years   (Adult, Older Adult)	Not Applicable	99	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	RGC14111021	October 1, 2022	December 31, 2023	March 31, 2024	September 16, 2022		September 16, 2022	The Chinese University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT05544201
991	NCT01891383	Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel		Withdrawn	No Results Available	Dementia|Traumatic Brain Injury (TBI)|Mild Cognitive Impairment (MCI)|Chronic Traumatic Encephalopathy (CTE)|Post-traumatic Stress Disorder (PTSD)		Prevalence of dementia or MCI in the two groups (TBI versus no TBI)|Characterization of the types of dementia or MCI that occur in the two groups (TBI or no TBI)	Uniformed Services University of the Health Sciences|University of California, San Francisco	All	50 Years to 95 Years   (Adult, Older Adult)		0	U.S. Fed|Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	ERMS# 12lO9006|NEU-92-1855	July 2013	June 2016	August 2016	July 3, 2013		January 18, 2019	California Veterans Home-Yountville, Yountville, California, United States|Armed Forces Retirement Home, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT01891383
992	NCT03050385	Cognitive Rehabilitation During Transcranial Direct Current Stimulation		Completed	No Results Available	Transcranial Direct Current Stimulation|Neurocognitive Disorders	Device: transcranial direct current stimulation	Attrition rate due to adverse events|difference of Alzheimer Disease Assessment Scale -Cognitive subscale|difference of the mini mental state examination|difference of Clinical Dementia Rating scale - sum of boxes|difference of Mini Mental State Examination|Attrition rate for any reason|difference of Frontal Assessment Battery	National Center of Neurology and Psychiatry, Japan	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	A2016-048	October 2016	July 28, 2017	August 18, 2017	February 10, 2017		February 26, 2020	National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT03050385
993	NCT02265757	Behavioral Interventions to Prevent or Delay Dementia		Completed	No Results Available	Mild Cognitive Impairment|Memory Disorders|Mild Dementia|Impaired Cognition|Mild Cognitive Disorder|Amnestic Disorder|Dementia and Amnestic Conditions|Poor Short-term Memory|Memory Impairment	Behavioral: Cognitive Rehabilitation|Behavioral: Computer Brain Fitness Training|Behavioral: Support Group (patient and partner)|Behavioral: Wellness Education|Behavioral: Physical Exercise	Improvement in patient quality of life|improvement in patient memory based everyday functioning|improvement in caregiver mood and sense of burden	Mayo Clinic|Patient-Centered Outcomes Research Institute	All	50 Years and older   (Adult, Older Adult)	Not Applicable	272	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	14-000885	June 2014	March 31, 2018	March 31, 2018	October 16, 2014		February 22, 2019	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02265757/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02265757
994	NCT04606420	Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease		Active, not recruiting	No Results Available	Alzheimer Disease	Behavioral: Lifestyle medicine	Change from Baseline in Alzheimer Disease Assessment Scale cognitive section (ADAS-Cog) score|Change from Baseline in Clinical Global Impression of Change (CGIC) score|Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Changes from baseline in the microbiome|Changes from baseline in telomere length|Changes from baseline in biomarkers|Inflammatory biomarkers|Amyloid peptides|R-PLEX measures|Angiogenesis biomarkers|Vascular injury panel 2|Metabolic Panel: 1 Human 7-PLEX	Preventive Medicine Research Institute|University of California, San Francisco|Harvard Medical School (HMS and HSDM)|University of California, San Diego|The Cleveland Clinic|Renown Health	All	45 Years to 90 Years   (Adult, Older Adult)	Not Applicable	51	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	20172897	September 8, 2018	September 30, 2023	September 30, 2023	October 28, 2020		September 15, 2022	University of California, San Diego, San Diego, California, United States|Preventive Medicine Research Institute, Sausalito, California, United States|McCance Center for Brain Health, Harvard Medical School/Mass General Hospital, Boston, Massachusetts, United States|Renown Health Institute of Neurosciences, Reno, Nevada, United States		https://ClinicalTrials.gov/show/NCT04606420
995	NCT01481246	Neurocognitive Study for the Aging-a Longitudinal Study With a Greek Cypriot Cohort	NEUROAGE	Recruiting	No Results Available	Aging|Memory Impairment|Cognitive Decline|Mild Cognitive Disorder	Behavioral: Categorization training|Behavioral: Psychosocial and Psychoeducational Group training	Neuropsychological Tests	University of Cyprus	All	60 Years to 90 Years   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Humanities/Society/0308(ΒΕ)/07|SKEPSH|EXCELLENCE/1216/0404	July 2009	March 2023	March 2023	November 29, 2011		April 29, 2022	University of Cyprus, Nicosia, Cyprus		https://ClinicalTrials.gov/show/NCT01481246
996	NCT04134806	Gait Analysis by Induced Disorientation in a VR Environment		Unknown status	No Results Available	Mild Cognitive Impairment|Mild Dementia|Disorientation|Young Adults|Older Adults		Spatial disorientation|Gait variability|Spatial orientation ability|Heart rate variability|Skin conductance|Accelerometery|Apolipoprotein E4 status|Visuospatial function|Memory function|Executive function	University Medical Center Rostock|University of Rostock|German Center for Neurodegenerative Diseases (DZNE)	All	18 Years to 85 Years   (Adult, Older Adult)		80	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	A 2019-0062	March 1, 2019	December 31, 2021	December 31, 2021	October 22, 2019		May 8, 2020	Clinic and Polyclinic for Psychosomatics and Psychotherapeutic Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Western Pomerania, Germany		https://ClinicalTrials.gov/show/NCT04134806
997	NCT01534273	A Study of LY2886721 in Healthy Participants		Completed	Has Results	Healthy Volunteers	Drug: LY2886721|Drug: Placebo	Number of Participants With Clinically Significant Effects|Pharmacokinetics: Plasma Maximum Observed Concentration (Cmax) of LY2886721|Pharmacokinetics: Plasma Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of LY2886721|Pharmacokinetics: Plasma Maximum Observed Concentration at Steady State (Cmax,ss) of LY2886721|Pharmacokinetics: Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721|Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid 1-40 Concentration at Day 15|Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid 1-40 Concentration at 24 Hours Post-dose	Eli Lilly and Company	All	20 Years and older   (Adult, Older Adult)	Phase 1	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	14464|I4O-MC-BACJ	February 2012	July 2012	July 2012	February 16, 2012	August 28, 2019	August 28, 2019	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States		https://ClinicalTrials.gov/show/NCT01534273
998	NCT03551483	ArtontheBrain: An Inclusive Evidence-based Cognitive Health App for Older Adults to Promote Aging at Home		Unknown status	No Results Available	Cognitive Impairment|Mild Cognitive Impairment|Dementia|Age-related Cognitive Decline|Aging	Device: ArtontheBrain|Device: Seniors Online Victoria	EQ-5D-5L|Short Warwick-Edinburg Mental Well-Being Scale (WEMWBS)|Short-Form Health Survey (SF-36)|Stanford Health Care Utilization|Physical Activity Scale in the Elderly|Social Engagement Survey|Alternative Uses Task|Digit Span Test|Means-End Problem Solving|Art Engagement Survey|Life Space Questionnaire (LSQ)|Autobiographical Interview	Baycrest|University of Calgary|Sheridan College	All	60 Years and older   (Adult, Older Adult)	Not Applicable	110	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	#17-49	July 24, 2018	March 31, 2019	March 31, 2019	June 11, 2018		February 27, 2019	Baycrest Health Sciences, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03551483
999	NCT04387357	Multimodal Imaging in the Study of Disorientation in the Hospital		Unknown status	No Results Available	Mild Cognitive Impairment|Dementia|Disorientation|Older Adults|Magnetic Resonance Imaging		Spatial disorientation|Heart rate variability|Skin conductance|Accelerometry|Grey matter volume|White matter integrity|Resting-state functional connectivity|Interview responses	University Medical Center Rostock|German Center for Neurodegenerative Diseases (DZNE)|University of Rostock	All	50 Years and older   (Adult, Older Adult)		50	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	A-2012-0083	October 1, 2019	June 2021	June 30, 2021	May 13, 2020		May 13, 2020	Clinic and Polyclinic for Psychosomatics and Psychotherapeutic Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Western Pomerania, Germany		https://ClinicalTrials.gov/show/NCT04387357
1000	NCT05167045	A Pilot Study for the Brain Health Support Program	CTU BHSP-P	Completed	No Results Available	Dementia|Mild Cognitive Impairment|Subjective Cognitive Impairment|Pre-dementia|Dementia Prevention	Behavioral: Brain Health PRO	Functionality of the BHSP|User acceptance of the BHSP|Usability of the BHSP|To assess participant satisfaction with the organization, presentation and personalization of the BHSP content|To evaluate the feasibility of remote data collection	Baycrest	All	60 Years to 85 Years   (Adult, Older Adult)		20	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CTU BHSP-P	November 15, 2021	April 29, 2022	April 29, 2022	December 22, 2021		July 21, 2022	University of British Columbia, Vancouver, British Columbia, Canada|University of New Brunswick, Fredericton, New Brunswick, Canada|Baycrest, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05167045
1001	NCT03862222	Atlas of Retinal Imaging in Alzheimer's Study	ARIAS	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Mild Dementia|Aging|Cognitive Change	Other: Retinal Imaging|Other: Pupillometry|Other: Contrast Sensitivity|Diagnostic Test: Neuropsychological Evaluation|Genetic: APOE genotyping|Other: blood draw|Other: Gait Assessment|Other: Actigraphy	Structural retinal biomarkers assessed with OCT|Metabolic retinal biomarkers assessed with OCT|vascular retinal biomarkers assessed with OCT-A|general cognition|processing speed, attention|language|memory|physiological	University of Rhode Island|Stuart Sinoff, MD|Peter J Snyder, MD|BayCare Health System	All	55 Years to 80 Years   (Adult, Older Adult)		330	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	900-403-2	December 16, 2019	December 2021	June 2025	March 5, 2019		October 20, 2020	Morton Plant Hospital, Clearwater, Florida, United States|St. Anthony's Hospital, Saint Petersburg, Florida, United States|University of Rhode Island, Kingston, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT03862222
1002	NCT04537728	My Healthy Brain: Preserving and Promoting Brain Health Through Evidence-based Practices		Completed	No Results Available	Aging|Mild Cognitive Impairment|Dementia|Old Age; Dementia|Cognitive Decline	Behavioral: My Healthy Brain Version 2	Credibility and Expectancy Questionnaire (CEQ)|Client Satisfaction Questionnaire (CSQ-3)|Recruitment Feasibility|Program Acceptability|Treatment Fidelity|Assessment Feasibility|Adherence to Actigraph|Adherence to Lifestyle Behaviors|Change in Healthy Aging|Mindfulness: Cognitive and Affective Mindfulness Scale|Mindfulness: Homework log|Mindfulness: Five-Facet Mindfulness Questionnaire|Sleep: Pittsburgh Sleep Quality Index|Sleep: Jenkins Sleep Questionnaire|Sleep: Actigraph measures of sleep|Physical Activity: PROMIS Physical Function|Physical Activity: Godin Leisure Time Exercise Questionnaire|Physical Activity: Rapid Assessment of Physical Activity|Physical Activity: Actigraph measures of activity|Nutrition: Mediterranean Eating Pattern for Americans Screener|Nutrition: MIND Diet Adherence Checklist|Medication and Substance Use: Morisky Medication Adherence Scale|Medication and Substance Use: Alcohol Use Disorders Identification Test-Consumption|Medication and Substance Use: Fagerstrom Test for Nicotine Depedence|Stress and Emotional Functioning: Perceived Stress Scale|Stress and Emotional Functioning: PROMIS Depression|Stress and Emotional Functioning: PROMIS Anxiety|Stress and Emotional Functioning: Heart Rate Variability (Actigraphy)|Social Functioning: PROMIS Social Isolation|Social Functioning: PROMIS Emotional Support|Social Functioning: UCLA Loneliness Scale|Cognitive Functioning: Everyday Cognition Scale|Cognitive Functioning: PROMIS Cognition|Cognitive Functioning: Montreal Cognitive Assessment	Massachusetts General Hospital|Harvard Medical School (HMS and HSDM)|Brigham and Women's Hospital	All	60 Years and older   (Adult, Older Adult)	Not Applicable	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019P003657	September 1, 2020	August 31, 2021	December 31, 2021	September 3, 2020		September 1, 2022	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04537728
1003	NCT05138848	Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease	ALPS	Recruiting	No Results Available	Alzheimer Disease, Late Onset|Mild Cognitive Impairment|Sleep|Cognitive Change|Amyloid	Behavioral: Time in Bed Restriction|Behavioral: Sleep Schedule	Mean change in slow-oscillation activity assessed with electroencephalography|Mean change in Hippocampal Activation|Medial prefrontal-Hippocampal Connectivity|Change in mean Plasma amyloid-beta 1-42|Overnight memory retention on the AB paired associate task, preclinical Alzheimer's cognitive composite score|Amyloid positivity status|Mean change in delta activity during sleep|Mean change in Sleep Efficiency|Mean percent signal change in medial prefrontal activation|Mean change in medial temporal-Hippocampal Connectivity|mean change in plasma amyloid-beta composite score|Mean change in response time on executive function tasks|Mean change in accuracy on executive function tasks|Apolipoprotein (ApoE) e4 allele carrier status|Cognitive status based on neuropsychological adjudication|Clinical insomnia status	University of Pittsburgh|National Institute on Aging (NIA)	All	65 Years to 85 Years   (Older Adult)	Not Applicable	116	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	STUDY20110278|R01AG068001	January 3, 2022	May 31, 2026	May 31, 2026	December 1, 2021		March 8, 2022	UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT05138848
1004	NCT05532657	ACHIEVE Brain Health Follow-Up Study	ACHIEVE-BHFU	Not yet recruiting	No Results Available	Aging|Cognitive Decline|Mild Cognitive Impairment|Dementia|Hearing Loss	Other: Hearing intervention|Other: Successful aging/delayed hearing intervention	Change in global cognition|Mild cognitive impairment (MCI) / dementia|Change in cognition memory domain|Change in cognition executive function domain|Change in cognition language domain|Change in regional brain volumes|Change in white matter tract integrity	Johns Hopkins University|University of North Carolina|University of South Florida|University of Minnesota|University of Mississippi Medical Center|Wake Forest University|Mayo Clinic|National Institute on Aging (NIA)	All	73 Years to 89 Years   (Older Adult)	Phase 3	859	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	IRB00319430|R01AG076518	October 7, 2022	December 31, 2025	December 31, 2025	September 8, 2022		September 8, 2022	Johns Hopkins Comstock Center for Public Health Research and Prevention, Hagerstown, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Wake Forest University, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT05532657
1005	NCT03656107	The Cognition and Flow Study		Terminated	Has Results	Dementia|Alzheimer Disease|Mild Cognitive Impairment|Aging|Cognitive Impairment	Behavioral: Cognitive Training	Percentage of Participants Successfully Recruited|Percentage of Participants Able to Successfully Complete the Minimum (15 Mins, 3x Per Week, for 8 Weeks) and Maximum (30 Mins, 5x Per Week, for 12 Weeks) Criteria CT Program and Complete All Assessments|Percentage of Participants With Full Bilateral Data for Cerebral Blood Flow Velocity (CBFv)|Percentage of Control Participants Willing to be Randomised to Waiting List Control|Change in Cognition Score as Detected by the Addenbrooke's Cognitive Examination (ACE-III) From Baseline to Follow-up at 12 Weeks|Change in Functional Status - Lawton Instrumental Activities of Daily Living (IADL) From Baseline to Follow-up at 12 Weeks|Change in Mood - Geriatric Depression Scale (GDS-15) From Baseline to Follow-up at 12 Weeks|Change in Quality of Life Measure - Dementia Quality of Life Measure (DEMQOL) From Baseline to Follow-up at 12 Weeks|Percentage Increase in Cerebral Blood Flow Velocity (CBFv) From Baseline to Follow-up at 12 Weeks	University of Leicester|The Dunhill Medical Trust|University Hospitals, Leicester|Leicestershire Partnership Trust|University of Nottingham|Lumosity	All	50 Years and older   (Adult, Older Adult)	Not Applicable	56	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0677	January 14, 2019	September 4, 2020	September 4, 2020	September 4, 2018	May 27, 2022	May 27, 2022	University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom|Leicestershire Partnership Trust, Leicester, Leicestershire, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03656107/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03656107/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03656107
1006	NCT02524405	BEAM: Brain-Eye Amyloid Memory Study	BEAM	Recruiting	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Vascular Cognitive Impairment|Parkinson's Disease|Lewy Body Disease	Other: Pittsburgh Compound B [11C]-PIB	Retinal nerve fiber layer thickness|Amyloid Depostition|Retinal artery narrowing|Retinal venular widening	Sunnybrook Health Sciences Centre|Brain Canada|Weston Brain Institute|GE Healthcare|University Health Network, Toronto|Centre for Addiction and Mental Health|Baycrest|Unity Health Toronto|Kensington Eye Institute	All	50 Years to 90 Years   (Adult, Older Adult)		345	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	221-2013	February 2016	March 2023	December 2023	August 14, 2015		September 21, 2021	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02524405
1007	NCT03929302	Brain Energy Metabolism and Sleep in Adults		Active, not recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Cognitive Change|Energy Metabolism|Sleep Disturbance	Device: MyTAP oral appliance plus mouth shield	Sleep Improvement with MyTAP oral airway management intervention|Memory cognitive domain improvement after airway management intervention|Executive function cognitive domain improvement after airway management intervention	The University of Texas at Dallas|Texas A & M University Baylor College Of Dentistry|University of Texas, Southwestern Medical Center at Dallas	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	41	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	IRB 18-73	November 30, 2018	December 31, 2021	December 31, 2022	April 26, 2019		April 28, 2021	Center for BrainHealth, The University of Texas at Dallas, Dallas, Texas, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03929302/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03929302
1008	NCT04556305	Lifestyle Physical Activity and Cognitive Training Interventions: Preventing Memory Loss in Older Women With Cardiovascular Disease	MindMoves	Recruiting	No Results Available	Cognitive Decline|Cardiovascular Diseases|Cognitive Dysfunction|Cognitive Impairment|Mild Cognitive Impairment	Behavioral: Mind|Behavioral: Move	Change in East Boston Memory Test scores from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in Category Fluency Test scores from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in Digit Span Forwards and Backwards Test scores from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in Oral Trails A/B tests scores from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in Digit Ordering Tests scores from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in brain-derived neurotrophic factor (BDNF) levels from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in vascular endothelial growth factor A (VEGF) levels from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in insulin-like growth factor 1 (IGF-1) from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in GT3XE-Plus Triaxial Accelerometer activity minutes (light and moderate vigorous physical activity) from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in the two-minute step test of aerobic fitness score from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in self-reported physical activity as assessed by the Community Healthy Activities Model Program for Seniors (CHAMPS) survey from baseline to 24 weeks, 48 weeks, and 72 weeks|Change in self-reported cognitive activity from baseline to 24 weeks, 48 weeks, and 72 weeks	Rush University Medical Center	Female	65 Years and older   (Older Adult)	Not Applicable	254	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	18053104	October 5, 2020	November 1, 2023	November 1, 2023	September 21, 2020		February 9, 2022	Rush University Medical Center, Chicago, Illinois, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04556305/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04556305/SAP_001.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04556305/ICF_002.pdf	https://ClinicalTrials.gov/show/NCT04556305
1009	NCT04691102	Predictive Indices of Independent Activity of Daily-living in Neurorehabilitation		Recruiting	No Results Available	Stroke|Brain Injuries|Mild Cognitive Impairment|Parkinson Disease|Multiple Sclerosis		Inertial sensors-based assessment|Berg Balance Scale (BBS)|Dynamic Gait Index (DGI)|Balance Evaluation System Test (Mini-BESTest)|Electroencephalography (EEG)	I.R.C.C.S. Fondazione Santa Lucia	All	15 Years to 85 Years   (Child, Adult, Older Adult)		120	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	Prot. CE/PROG.877	May 1, 2021	June 30, 2022	October 1, 2022	December 31, 2020		March 17, 2022	Santa Lucia Foundation I.R.C.C.S., Roma, Rm, Italy		https://ClinicalTrials.gov/show/NCT04691102
1010	NCT03702907	DC Longitudinal Study on Aging and Specimen Bank	(DC LSOA)	Recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment|Aging|Aging Disorder		CDR	Georgetown University	All	45 Years and older   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2007-249	January 1, 2007	January 2027	January 2027	October 11, 2018		October 24, 2019	Georgetown University Memory Disorders Program, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03702907
1011	NCT02843906	Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?	BIPAGE	Unknown status	No Results Available	Senile Plaques|Tau Proteins|Alzheimer Disease|Bipolar Disorders|Mild Cognitive Impairment	Procedure: Lombar Punction|Radiation: Magnetic Resonance Imaging (MRI)|Radiation: Positron-Emission Tomography (TEP) /(FDG)|Other: Psychiatric tests|Other: Neuropsychological Tests|Genetic: Apolipoprotein (ApoE) detection	Functionnal/Cognitive evaluation|Psychatric evaluation|Brain MRI	University Hospital, Grenoble|University Hospital, Tours|Assistance Publique - Hôpitaux de Paris|University Hospital, Marseille|Hospices Civils de Lyon|Centre Hospitalier Universitaire de Besancon|Central Hospital, Nancy, France|University Hospital, Clermont-Ferrand|Versailles Hospital|University Hospital, Montpellier|Reims University Hospital|Centre Hospitalier Princesse Grace	All	60 Years to 80 Years   (Adult, Older Adult)	Not Applicable	180	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	38RC13.217	July 2015	July 2018	July 2018	July 26, 2016		July 26, 2016	University Hospital, Tours, Tours, France		https://ClinicalTrials.gov/show/NCT02843906
1012	NCT05514106	MIBG in Aging and Neurologic Disorders		Enrolling by invitation	No Results Available	Lewy Body Disease|Dementia|Parkinsonism|Mild Cognitive Impairment|REM Sleep Behavior Disorder	Drug: meta-iodobenzylguanidine (MIBG) (123I)|Diagnostic Test: 123I-MIBG scintigraphy	Correlate myocardial 123I-MIBG scintigraphy findings	Mayo Clinic	All	40 Years to 90 Years   (Adult, Older Adult)	Phase 4	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	21-012740	October 1, 2022	September 30, 2025	September 30, 2025	August 24, 2022		August 24, 2022	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT05514106
1013	NCT04680013	Genetic Studies in Familial Dementia		Recruiting	No Results Available	Dementia of Alzheimer Type|Alzheimer Disease, Late Onset|Alzheimer Disease, Early Onset|Mild Cognitive Impairment|Dementia		Correlation between genetic factors and Alzheimer disease, dementia, and related phenotypes.	University of Miami|Case Western Reserve University|Columbia University|Wake Forest University|National Institute on Aging (NIA)	All	18 Years and older   (Adult, Older Adult)		20000	Other|NIH	Observational	Observational Model: Other|Time Perspective: Retrospective	20070307|RF1AG054080|RF1AG054074|U01AG052410	June 1, 2007	November 1, 2025	November 1, 2025	December 22, 2020		August 30, 2021	University of Miami, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT04680013
1014	NCT05156073	Shared Decision Making About Medication Use for People With Multiple Health Problems		Recruiting	No Results Available	Polypharmacy|Dementia|Multiple Chronic Conditions|Deprescribing|Mild Cognitive Impairment	Other: Educational Materials	Feasibility as assessed by enrollment rate|Feasibility as assessed by net enrollment rate|Feasibility as assessed by the proportion of care partners who remember receiving the study materials|Feasibility as assessed by the number of patients with correct care partners identified in the Electronic Health Records (EHR)|Feasibility as assessed by participant retention|Feasibility as assessed by the number of safety concerns reported by participants|Acceptability as assessed by questionnaire administered to care partners|Acceptability as assessed by questionnaire administered to clinicians|Acceptability as assessed by visit length questionnaire reported by clinicians|Acceptability will be assessed from data from recorded primary care visits|Acceptability will be assessed from clinicians' responses to qualitative interview questions|Feasibility as assessed by number of discrepancies between Epic medication lists and patient-reported medication lists|Feasibility as assessed by measuring the Patient-level Medication Regimen Complexity Index (pMRCI)|Feasibility as assessed by the time to complete the Family Caregiver Medication Administration Hassles Scale (FCMAHS)	Johns Hopkins University|Reading Hospital Tower Health|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	IRB00253480|K23AG054742	May 19, 2022	March 2023	March 2023	December 14, 2021		May 27, 2022	Reading Hospital Family Health Care Center, Reading, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT05156073
1015	NCT01555411	Akershus Cardiac Examination (ACE) 1950 Study	ACE1950	Active, not recruiting	No Results Available	Atrial Fibrillation|Heart Failure|Mild Cognitive Impairment|Cardiovascular Diseases|Cerebrovascular Disorders		Outcomes related to CVD and CV-associated conditions|Specific CV endpoints; e.g. acute myocardial infarction, heart failure, atrial fibrillation, etc.|Specific CV-associated conditions, including renal, cerebrovascular, pulmonary, etc.|Specific clinical phenotypes; e.g. myocardial and arterial structure and function, lung function, etc.	Vestre Viken Hospital Trust|University Hospital, Akershus	All	62 Years to 65 Years   (Adult, Older Adult)		3706	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2011/1475 C|AFIA (initial study name)	September 2012	December 1, 2050	December 1, 2050	March 15, 2012		May 3, 2021	Akershus University Hospital, Lørenskog, Akershus, Norway|Vestre Viken HT, Baerum Hospital, Department of Medical Research, Sandvika, Akershus, Norway		https://ClinicalTrials.gov/show/NCT01555411
1016	NCT04733989	A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)		Recruiting	No Results Available	Alzheimer Disease|Alzheimer Disease, Early Onset|Mild Cognitive Impairment|Memory Loss|Memory Disorders|Memory Impairment	Other: Biomarker Data Collection	Measurement of each participant's blood-based biomarker (Beta-Amyloid, Phospho-Tau, Neurofilament Light Chain) levels will be collected through blood sampling.|Measurement of each participant's amyloid levels in the brain will be collected through amyloid PET brain scan imaging.	GAP Innovations, PBC	All	60 Years to 85 Years   (Adult, Older Adult)		1000	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	BIO-HERMES-001	April 21, 2021	September 2022	December 2022	February 2, 2021		August 2, 2022	Visionary Investigators, Aventura, Florida, United States|Charter Research - Lady Lake, Lady Lake, Florida, United States|JEM, Lake Worth, Florida, United States|ClinCloud, Maitland, Florida, United States|K2, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Charter Research - Winter Park, Winter Park, Florida, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Kansas University Alzheimer's Disease Center (KUADC), Fairway, Kansas, United States|Velocity Clinical Research - Syracuse, Syracuse, New York, United States|Kerwin Research Center, Dallas, Texas, United States|El Faro Health and Therapeutics, Rio Grande City, Texas, United States		https://ClinicalTrials.gov/show/NCT04733989
1017	NCT02159014	DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study	DanceFit	Completed	No Results Available	Cardiac Diseases|Stroke|Diabetes Mellitus|Dementia|Mild Cognitive Impairment	Behavioral: Facilitated group-based aerobic dance|Behavioral: Online, video prompted, individual aerobic dance|Behavioral: Facilitated group-based nutritional intervention|Behavioral: Self-paced online aerobic dance activity|Behavioral: Individual self-paced nutritional intervention	Recruitment and retention rates|Activity adherence rates|Level of physical activity participation|10 year risk of cardiac or cerebral ischaemic event|10 year risk of developing diabetes mellitus	North Essex Partnership NHS Foundation Trust|West Essex Clinical Commissioning Group|School for Social Entrepreneurs London and Lloyds TSB|University College, London	All	17 Years and older   (Child, Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	DanceFit Prime	August 2014	October 2015	October 2015	June 9, 2014		October 14, 2015	Chigwell Medical Centre, Chigwell, Essex, United Kingdom		https://ClinicalTrials.gov/show/NCT02159014
1018	NCT02463084	Macronutrient Effects on Alzheimer's Disease (MEAL-2)	MEAL-2	Completed	No Results Available	Prediabetic State|Insulin Resistance|Middle Age|Prehypertension|Mild Cognitive Impairment	Other: Low Diet|Other: High Diet	Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42)|Changes in brain structure|Changes in adipose tissue distribution (Change in dual energy x-ray absorptiometry (DEXA) scan and CT measures of central and subcutaneous body fat)|Changes in cognition (Change in delayed memory and executive function composites)|Change in brain function as measured by MRI|Change in brain perfusion	Wake Forest University Health Sciences	All	45 Years to 65 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention	IRB 00022512	March 2013	June 2016	June 2016	June 4, 2015		August 9, 2018	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02463084
1019	NCT02570997	Ascending Dose Study of CT1812 in Healthy Volunteers		Completed	No Results Available	Cognitive Impairment	Drug: CT1812|Drug: Placebo	Incidence and review of Treatment Emergent Adverse Events [Safety and Tolerability]	Cognition Therapeutics	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	Cog 0101	September 2015	May 2016		October 8, 2015		September 7, 2016	Nucleus Network Limited, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02570997
1020	NCT04937959	Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension	PAST-US	Recruiting	No Results Available	Alzheimer Disease|Alzheimer's Disease (Incl Subtypes)|Preclinical Alzheimer's Disease|Prodromal Alzheimer's Disease|Mild Cognitive Impairment|Normal Cognition		The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.|The sensitivity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms using archival spoken or written language samples as input.|The specificity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms using archival spoken or written language samples as input.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms using archival spoken or written language samples as input.|The AUC of the binary classifiers distinguishing between MCI and cognitively normal (CN) arms.|The sensitivity of the binary classifiers distinguishing between MCI and cognitively normal (CN) arms.|The specificity of the binary classifiers distinguishing between MCI and cognitively normal (CN) arms.|The Cohen's kappa of the binary classifiers distinguishing between MCI and cognitively normal (CN) arms.|The AUC of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.|The sensitivity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.|The specificity of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.|The Cohen's kappa of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) arms.	Novoic Limited	All	50 Years to 85 Years   (Adult, Older Adult)		40	Industry	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	NOV-0110-2	January 22, 2021	August 30, 2022	August 30, 2022	June 24, 2021		April 7, 2022	Syrentis Clinical Research, Santa Ana, California, United States		https://ClinicalTrials.gov/show/NCT04937959
1021	NCT04047485	Evaluation of the Effect of Cataract Surgery on Cognitive Function in Very Elderly Patients		Unknown status	No Results Available	Dementia|Mild Cognitive Impairment|Cataract Senile|Cataract|Delirium in Old Age|Delirium Confusional State|Post-Op Complication|Cataract in Old Age	Diagnostic Test: Visual Acuity|Diagnostic Test: CAM (Confusion Assesment Method)|Diagnostic Test: CATQUEST 9-SF|Diagnostic Test: OCT|Diagnostic Test: 6CIT|Diagnostic Test: Barthel Index|Diagnostic Test: Endothelial Microscopy - Cornea	Correlation between visual acuity and cognitive function at 3 months after Cataract Surgery.|Post operative delirium prevalence|Corneal endothelial cells density|Corneal pachymetry	University of Modena and Reggio Emilia	All	65 Years and older   (Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	1005/2018/OSS/AOUMO	February 2, 2019	February 28, 2020	March 30, 2020	August 6, 2019		August 6, 2019	Policlinico di Modena, Modena, Italy		https://ClinicalTrials.gov/show/NCT04047485
1022	NCT03472482	Optical Coherence Tomography in Cerebral Amyloidosis		Unknown status	No Results Available	Alzheimer Disease|Dementia Alzheimers|Dementia|Lewy Body Disease|Dementia, Lewy Body|Mild Cognitive Impairment	Diagnostic Test: non-invasive retinal imaging	Diagnostic performance of OCT measurements in dementia	Universitaire Ziekenhuizen Leuven	All	Child, Adult, Older Adult		85	Other	Observational	Observational Model: Case-Control|Time Perspective: Cross-Sectional	S59048	March 25, 2016	December 31, 2018	December 31, 2019	March 21, 2018		March 21, 2018	UZ Leuven, Leuven, Belgium	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03472482/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03472482
1023	NCT02492529	Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease	EPMR-MA	Completed	No Results Available	Alzheimer's Disease	Other: Neuropsychological tests|Device: A cranial MRI|Other: Experimental procedure	Improvement of recognition memory accuracy measures under the familiarity condition as compared with the novel condition in the AD-MCI group|Significant effect of the familiarity vs novelty condition on the pattern of % BOLD signal change in across the brain in the AD-MCI group|Significant group effect on the pattern of % BOLD signal change in across the brain|Predictive validity of the brain % BOLD signal change pattern for participants clinical status (i.e. controls vs. AD-MCI)|Significant interaction between the kind of familiarity condition (i.e. novel, experimental or pre-experimental) and the estimates of recognition memory processes efficiency (i.e. respective contributions of recollection and familiarity, % correct)	Rennes University Hospital	All	25 Years to 75 Years   (Adult, Older Adult)	Not Applicable	100	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	2014-A01123-44|35RC14_9777_EPMR-MA	July 21, 2015	December 31, 2017	December 31, 2017	July 8, 2015		January 23, 2018	Centre Hospitalier Universitaire, Rennes, France		https://ClinicalTrials.gov/show/NCT02492529
1024	NCT03975309	DHS MIND Metabolomics		Recruiting	No Results Available	Diabetes		Wide Range Achievement Test 4 (WRAT 4)|Rey Auditory Verbal Learning Test (RAVLT)|Modified Mini-Mental State Exam (3MSE)|Digit Symbol Coding Task (DSC)|Stroop subtests 1, 2 and 3|Category Fluency for Animals|Montreal Cognitive Assessments (MoCA)|Craft Story Recall (Immediate/Delayed)|Trail Making Test|Number Span Test (Forward/Backward)	Wake Forest University Health Sciences|National Institute on Aging (NIA)	All	18 Years and older   (Adult, Older Adult)		1000	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB00057194|1R01AG058921-01A1	September 9, 2019	February 2025	February 2025	June 5, 2019		February 7, 2022	Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03975309
1025	NCT04748666	PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia		Recruiting	No Results Available	Alzheimer Disease|Frontotemporal Degeneration (FTD)|Lewy Body Dementia (LBD)|Vascular Contributions to Cognitive Impairment and Dementia (VCID)|Mixed Etiology Dementias (MED)|Mild Cognitive Impairment (MCI)	Behavioral: Problem Solving Training	The Mean Change in Patient Health Questionnaire (PHQ-8) Score|The Mean Change in Zarit Burden Interview Score|The Mean Change in Family Caregivers Scale/Caregiver experience Score|The Mean Change in Client Satisfaction Questionnaire (CSQ-8) Score|Upstream Social Isolation Risk Screener (U-SIRS13)	University of Texas Southwestern Medical Center|University of Texas Rio Grande Valley|Texas A&M University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	232	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STU-2020-1276	June 14, 2021	June 14, 2023	June 14, 2023	February 10, 2021		September 22, 2021	University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas Rio Grande Valley, Edinburg, Texas, United States		https://ClinicalTrials.gov/show/NCT04748666
1026	NCT04111211	Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits	Memento-Plus	Recruiting	No Results Available	Alzheimer Disease		Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)|Mortality|Loss of autonomy based on functional activity assessment|Rate of cognitive decline based on change in cognitive performances|Incidence of neurovascular and cardiovascular events (Stroke and Coronary events)|Quality of life: EQ-5D (EUROQOL)|Incidence of prodromal AD (Pre-symptomatic dementia)|Incidence of institutionalization	University Hospital, Bordeaux	All	18 Years and older   (Adult, Older Adult)		2000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CHUBX 2019/16	December 3, 2019	June 2025	June 2025	October 1, 2019		May 18, 2022	CHU d'Amiens, Amiens, France|AP-HP - CHU Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHRU de Nice - Institut Claude Pompidou, Nice, France|CHU de Nice - Hôpital de Cimiez, Nice, France|AP-HP - Hôpital BROCA, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal, Paris, France|CHU de Bordeaux, Pessac, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France|Hospice Civil de Lyon, Villeurbanne, France		https://ClinicalTrials.gov/show/NCT04111211
1027	NCT05372172	Tennessee Alzheimer's Project	TAP	Recruiting	No Results Available	Aging|Alzheimer Disease|Biomarker|Cognitive Dysfunction|Mild Cognitive Impairment|Dementia|Cognition	Other: none, observational study	Cognitive status|APOE Genotype|White matter hyperintensities Volume|Grey Matter Volume|Cerebral Blood Flow|Lacunar infarcts|Microbleeds|Left ventricular ejection fraction|Cardiac output|Stroke volume|Heart rate|Biological markers for Alzheimer's disease|Blood based biological marker for Alzheimer's disease	Vanderbilt University Medical Center|National Institute on Aging (NIA)	All	60 Years and older   (Adult, Older Adult)		1000	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	211309|P20AG068082	October 27, 2021	December 31, 2025	December 31, 2025	May 12, 2022		May 19, 2022	Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT05372172
1028	NCT00009230	Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial		Completed	No Results Available	Memory Disorders	Drug: Celecoxib		University of California, Los Angeles|National Institute of Mental Health (NIMH)	All	40 Years to 90 Years   (Adult, Older Adult)	Phase 3		Other|NIH	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	IA0015|R01MH058156	June 2000	June 2005	August 2005	January 24, 2001		March 2, 2020	UCLA Neuropsychiatric Institute, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00009230
1029	NCT02264899	MEMENTO-VAScular COmponents of Dementia	VASCOD	Completed	No Results Available	Alzheimer's Disease (AD)|Alzheimer's Disease (AD) Related Disorders	Other: in Memento-VASCOD	Change in cognitive performances over|Progression to clinical dementia of Alzheimer's type according to standardized criteria|Change in CSF and blood amyloid biomarkers of AD|Change in brain atrophy and hippocampal volumes|Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)	University Hospital, Bordeaux|Ministry for Health and Solidarity, France	All	50 Years and older   (Adult, Older Adult)	Not Applicable	332	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CHUBX 2012/32	November 4, 2014	October 29, 2021	October 29, 2021	October 15, 2014		January 28, 2022	CHU d'Amiens, Amiens, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Dijon, Dijon, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|CHU de Strasbourg, Strasbourg, France		https://ClinicalTrials.gov/show/NCT02264899
1030	NCT02164643	Longitudinal Study of Brain Amyloid imaGing in MEMENTO	MEMENTOAmyGing	Completed	No Results Available	Alzheimer's Disease (AD) and Related Disorders	Drug: Flutemetamol (18F)|Drug: Florbetapir (18F)	Progression to clinical dementia stage according to standardized classifications (DSM-IV and NINCDS-ADRDA) as described in the MEMENTO protocol.|Longitudinal evolution of amyloid load measured through either Florbetapir (18F) or Flutemetamol (18F)|Speed of cognitive decline based on change in cognitive performances|Longitudinal evolution of biomarkers measured from blood, CSF, structural neuroimaging (MRI) and glucose metabolism molecular neuroimaging (18F-FDG PET).|Mortality|Loss of autonomy based on functional activity assessment|Institutionalization|Cardiovascular event (Stroke and Coronary events)|Quality of life|Prodromal AD (Pre-symptomatic dementia)|Etiology of dementia, when converted	University Hospital, Bordeaux|Fondation Plan Alzheimer|GE Healthcare|Avid Radiopharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Phase 3	448	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CHUBX 2010/47 A	June 10, 2014	October 9, 2019	October 9, 2019	June 16, 2014		February 3, 2022	CHU d'Angers, Angers, France|CHU de Besançon, Besancon, France|AP-HP - Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Bordeaux - Hôpital Xavier-Arnozan, Bordeaux, France|CHU de Brest, Brest, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nice, Nice, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne - Hôpital de la charité, Saint-etienne, France|CHU de Saint-Etienne - Hôpital Nord, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France		https://ClinicalTrials.gov/show/NCT02164643
1031	NCT01926249	A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders	MEMENTO	Completed	No Results Available	Alzheimer's Disease (AD) and Related Disorders		Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)|Mortality|Loss of autonomy based on functional activity assessment|Institutionalisation|Speed of cognitive decline based on change in cognitive performances|Cardiovascular event (Stroke and Coronary events)|Quality of life|Prodromal AD (Pre-symptomatic dementia)|Longitudinal evolution of biomarkers measured from blood, Cerebro-Spinal Fluid (CSF), structural neuroimaging (MRI) and molecular neuroimaging (18F-FDG PET)	University Hospital, Bordeaux|Fondation Plan Alzheimer	All	18 Years and older   (Adult, Older Adult)		2325	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CHUBX 2010/47	December 8, 2011	October 29, 2021	October 29, 2021	August 20, 2013		January 11, 2022	CHU d'Amiens, Amiens, France|CHU d'Angers, Angers, France|CHU de Besançon, Besancon, France|AP-HP - Avicenne, Bobigny, France|CHU de Bordeaux - Pellegrin, Bordeaux, France|CHU de Bordeaux - Hôpital Xavier-Arnozan, Bordeaux, France|CHU de Brest, Brest, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|Hôpitaux civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|Hospices civils de Lyon, Lyon, France|AP-HM, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|AP-HP - Hôpital BROCA, Paris, France|AP-HP - Hôpital LARIBOISIERE, Paris, France|Ap-Hp La Pitié-Salpêtrière, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne - Hôpital de la charité, Saint-etienne, France|CHU de Saint-Etienne - Hôpital Nord, Saint-etienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse - Hôpital Purpan, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU de Tours, Tours, France		https://ClinicalTrials.gov/show/NCT01926249
1032	NCT01465360	Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center		Completed	No Results Available	Alzheimer's Disease|Mild Cognitive Impairment|Vascular Dementia|Fronto-temporal Dementia|Primary Progressive Aphasia|Parkinson' Disease Dementia|Mixed Dementia		Sensitivity of AclarusDx™ in AD patients	Exonhit	All	21 Years and older   (Adult, Older Adult)		160	Industry	Observational	Observational Model: Case-Only|Time Perspective: Cross-Sectional	EHTAD/003	November 2011			November 4, 2011		July 6, 2012	Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Cleveland Clinic Center for Brain Health - Mellen Center, Cleveland, Ohio, United States|Cleveland Clinic Senior Care Assessment - Lakewood Hospital, Lakewood, Ohio, United States		https://ClinicalTrials.gov/show/NCT01465360
1033	NCT00267163	Brain Imaging and Mental Disorders of Aging Intervention		Completed	No Results Available	Cognition Disorders	Drug: donepezil|Drug: Placebo	Changes in cognition and brain metabolism measured by PET and MRI scans, and neuropsychological testing	National Institute on Aging (NIA)	All	40 Years to 90 Years   (Adult, Older Adult)	Phase 4	64	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention	IA0090|9R01AG018487-06	September 2000	July 2007	July 2007	December 20, 2005		August 29, 2008	UCLA, The Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00267163
1034	NCT04445831	A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease		Active, not recruiting	No Results Available	Alzheimer's Disease|Cognitive Impairment|Tauopathies|Mild Cognitive Impairment|Dementia|Brain Diseases|Central Nervous System Diseases	Biological: ACI-35.030|Other: Placebo|Biological: JACI-35.054	Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related)|Change from baseline in anti-phosphorylated Tau IgG titers in blood|Mean change from baseline in systolic and diastolic blood pressure (mmHg)|Mean change from baseline in heart rate (bpm)|Mean change from baseline in body temperature (degree Celsius)|Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS)|Number of participants with abnormal MRI results|Change from baseline in anti-Tau IgG titers in blood|Change from baseline in anti-phosphorylated Tau IgM titers in blood|Change from baseline in anti-Tau IgM titers in blood	AC Immune SA|Janssen Research & Development, LLC	All	50 Years to 75 Years   (Adult, Older Adult)	Phase 1|Phase 2	57	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ACI-35-1802|2018-004573-27	July 31, 2019	October 31, 2023	October 31, 2023	June 24, 2020		June 27, 2022	Clinical Research Services Helsinki, Helsinki, Finland|Itä-Suomen Yliopisto - Kuopion Kampus, Kuopio, Finland|Clinical Research Services Turku, Turku, Finland|Brain Research Center - Den Bosch, 's-Hertogenbosch, Netherlands|Brain Research Center - Amsterdam, Amsterdam, Netherlands|Minnesmottagningen - Sahlgrenska Universitetssjukhuset - Mölndal Sjukhus, Mölndal, Sweden|Kognitiv Mottagning - Karolinska Universitetssjukhuset - Huddinge, Stockholm, Sweden|Edinburgh Clinical Research Facility, Edinburgh, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04445831
1035	NCT03405675	Gerontology Research Programme: The Singapore Longitudinal Ageing Studies (SLAS I & II)	SLAS	Unknown status	No Results Available	Cognitive Changes Due to Organic Disorder (Finding)|Dementia|Mild Cognitive Impairment|Frailty|Depression|Healthy Ageing|Biological Ageing	Other: SLAS 1|Other: SLAS 2	Dementia and Mild Cognitive Impairment (MCI) Subtyping (Clinical diagnosis of different stages of Dementia)|Global and specific domain cognitive functioning ability (Measuring of Global and Specific domain of Cognitive functions)|Frailty (Measuring the physical and Cognitive Frailty)|Depressive symptoms and diagnosis (Measuring of Depressive symptoms and assessment of stages of Depression)|Successful ageing (Measuring the biological, psycho-social and lifestyle factors associated with Successful Ageing)|Self-reported independent functioning (Measuring the BADL and IADL)|Physical performance (Measuring the physical performance tests)|Health services utilization (Measuring cost and frequency of health services utilization)|Quality of life (Measuring the Quality of life SF 12)|Mortality (Measuring the risk factors related to mortality)|Post-bronchodilation spirometry (Measuring the lung functions tests)	National University, Singapore|Karolinska Institutet|Tan Tock Seng Hospital|Ng Teng Fong General Hospital|St Luke's Hospital, Singapore|St. Paul's Hospital, Canada|Singapore Institute of Technology|Duke-NUS Graduate Medical School|Melbourne Health|University of California|University Hospital, Basel, Switzerland|Université de Sherbrooke|University Hospital Tuebingen|National University Hospital, Singapore|Khoo Teck Puat Hospital|Shanghai Jiao Tong University School of Medicine|University of British Columbia	All	55 Years and older   (Adult, Older Adult)		6183	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NUS-IRB 04-140	July 1, 2003	December 31, 2020	December 31, 2020	January 23, 2018		March 14, 2019	National University of Singapore, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT03405675
1036	NCT03020381	Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study		Recruiting	No Results Available	Gait Apraxia|Mild Cognitive Impairment|Subjective Cognitive Impairment|Cerebral Atrophy|Alzheimer Disease|Dementia		Progression to Dementia|Type of Dementia|Development of Mobility Decline|Incidence of Falls|Brain anatomical changes (grey matter)|Brain anatomical changes (white matter)|Brain anatomical changes (ventricular volume)	Lawson Health Research Institute	All	60 Years to 85 Years   (Adult, Older Adult)		400	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	17200	December 2007	January 2023	January 2023	January 13, 2017		March 2, 2020	Gait and Brain Lab, Parkwood Institute, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03020381
1037	NCT02843529	Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)	AltoidaML	Completed	Has Results	Alzheimer Disease|Mild Cognitive Impairment|Memory Disorders|Cognitive Impairment|Dementia|Presymptomatic Disease	Other: Altoida: neuropsychological, MRI, EEG and CSF biomarkers	Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC)|Change From Baseline in Clinical Measure 1|Change From Baseline in Clinical Measure 2|Change From Baseline in Clinical Measure 3|Change From Baseline in Clinical Measure 4|Change From Baseline in Clinical Measure 5|Change From Baseline in Clinical Measure 6|Change From Baseline in Clinical Measure 7|Change From Baseline in Cognitive Measure|Secondary Resting State EEG Endpoints|Secondary Resting State Auditory Oddball ERP Endpoints|Total Abeta 1-42 (Aβ42) Amyloid Deposition|Change of Brain Amyloid Deposition|Change of CSF Biomarkers Tau and ptau181 Values|MRI (Optional)|Changes in Driving Breaking Force|Changes in Driving Acceleration Velocity|Changes in Driving Direction|Changes in Driving Violations	Altoida|Greek Alzheimer's Association and Related Disorders|University of Roma La Sapienza|IRCCS Centro San Giovanni di Dio Fatebenefratelli|Neuromed IRCCS|Scripps Health|Global Brain Health Institute (GBHI)|Takeda Pharmaceuticals International, Inc.|Research Center on Computational Biomarkers (RCCBM)|BiHELab - Bioinformatics and Human Electrophysiology Lab|Fundacion Clinic per a la Recerca Biomédica|University of Dublin, Trinity College|University of Barcelona|EIT Health|Klinik Hirslanden, Zurich|Center for BrainHealth - The University of Texas at Dallas	All	55 Years to 90 Years   (Adult, Older Adult)	Not Applicable	548	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	altoidaML01	October 17, 2016	February 18, 2020	February 21, 2020	July 26, 2016	December 16, 2020	January 26, 2021		"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02843529/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02843529
1038	NCT03657745	Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy	AlzLife	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Dementia|Cognition Disorders in Old Age|Cognitive Decline|Cognitive Deterioration	Device: Combination of 40Hz light and cognitive therapy (ALZLIFE)	In-app cognitive test|Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL)	Alzheimer's Light LLC	All	50 Years and older   (Adult, Older Adult)		2000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	AlzLife001	January 1, 2018	December 31, 2023	December 31, 2023	September 5, 2018		July 20, 2021	Andrey Vyshedskiy, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT03657745
1039	NCT02964221	Cognitive Changes After Major Joint Replacement	Cognigram	Completed	No Results Available	Postoperative Cognitive Dysfunction|Mild Cognitive Impairment|Delirium|Cognitive Deficit|Cognitive Change|Working Memory	Other: Cognitive Testing	Change in Cognitive Brief Battery (CBB) score from baseline to 4.5 months after surgery|Proportion of patients developing severe cognitive dysfunction at 4.5 months after surgery (defined as CBB score less than 80)|Proportion of patients developing mild cognitive impairment at 4.5 months after surgery defined as CBB score between 81 and 90|The effect of pre-operative mild cognitive impairment, pre-operative chronic inflammatory states, postoperative delirium, and postoperative complications on the incidence of mild cognitive impairment and severe cognitive dysfunction at 4.5 months	Dr. Stephen Choi|Sunnybrook Health Sciences Centre	All	50 Years and older   (Adult, Older Adult)		90	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	045-2015	June 15, 2016	May 1, 2017	May 1, 2017	November 16, 2016		May 10, 2017			https://ClinicalTrials.gov/show/NCT02964221
1040	NCT05175664	Novel Diagnostic and Disease Stage Biomarkers in AD	TRACK-AD	Not yet recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Neuro-Degenerative Diseases|Vascular Dementia|Dementia With Lewy Bodies|Healthy Controls	Other: Long-term study|Other: Short-term study|Other: Cross-sectional study	Changes in CDR|Changes in MMSE|Changes in MR brain scan|FDG-PET brain scan	Danish Dementia Research Centre	All	30 Years to 110 Years   (Adult, Older Adult)		350	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	H-21040317	January 1, 2022	January 1, 2025	January 1, 2025	January 4, 2022		January 4, 2022			https://ClinicalTrials.gov/show/NCT05175664
1041	NCT04503798	Online Cognitive Rehabilitation of Executive Dysfunction in Nonamnestic MCI		Unknown status	No Results Available	Nonamnestic Mild Cognitive Impairment|Cognitive Dysfunction|Cognitive Disorder|Neurocognitive Disorders|Mental Disorder|Cognitive Impairment, Mild	Behavioral: Online Goal Management Training	Change in dysexecutive functioning - participants' report|Change in cognitive failures|Change in dysexecutive functioning - carers' report|Change in Cambridge Brain Sciences online cognitive assessment|Change in associative memory	Baycrest|Centre for Aging and Brain Health Innovation	All	65 Years and older   (Older Adult)	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	#08-53	August 20, 2020	October 30, 2021	December 30, 2021	August 7, 2020		August 7, 2020	Baycrest Health Sciences, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04503798
1042	NCT00294307	Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers		Completed	No Results Available	Dementia|Dementia, Vascular|Alzheimer Disease|Delirium, Dementia, Amnestic, Cognitive Disorders|Lewy Body Disease|Mild Cognitive Impairment	Behavioral: Augmented Standard Care (ASC)|Behavioral: Resource Nurse Care (RNC)|Behavioral: Advanced Practice Nurse Care (APNC)	Patient - Function|Caregiver - Burden|Patient - Health Care Costs|Patient - Time to first rehospitalization or death; total rehospitalization days|Patient - Total rehospitalizations|Patient - Cognitive Function|Patient - Care Management|Patient - Symptoms (Physical and depressive symptoms)|Patient - Neuropsychiatric Behaviors|Patient - Quality of Life|Patient/Caregiver - Satisfaction with care|Caregiver - Depressive Symptoms	University of Pennsylvania|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)		814	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	R01AG023116	February 2006	July 2010	August 2012	February 20, 2006		February 5, 2019	Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn-Presbyterian Medical Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00294307
1043	NCT03550131	Innovations in Dementia Empowerment and Action	IDEA	Active, not recruiting	No Results Available	Alzheimer Disease|Dementia|Mild Cognitive Impairment|Parkinson Disease Dementia|Lewy Body Dementia|Vascular Dementia	Behavioral: Innovations in Dementia Empowerment and Action (IDEA)|Behavioral: Reducing Disabilities in Alzheimer's Disease (RDAD)	Change in Physical Activity of Care Recipient|Change in Physical Activity of Caregiver|Change in Physical Functioning of Care Recipient|Change in Physical Functioning of Caregiver|Change in Perceived Stress (PSS) of Caregiver|Change in Health-Related Quality of Life (HRQOL) of Care Recipient|Change in Health-Related Quality of Life (HRQOL) of Caregiver|Change in Quality of Life (QOL-AD) of Care Recipient|Change in Health-Related Quality of Life (QOL-AD) of Caregiver|Change in Rate of Care-Recipient Behavioral Disturbances	University of Washington	All	50 Years and older   (Adult, Older Adult)	Not Applicable	322	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	STUDY00003076	December 5, 2018	May 31, 2022	May 31, 2022	June 8, 2018		March 31, 2022	University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03550131
1044	NCT04916210	Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY	DISCOVERY	Recruiting	No Results Available	Ischemic Stroke|Intracerebral Hemorrhage|Subarachnoid Hemorrhage|Dementia, Vascular|Mild Cognitive Impairment|Vascular Cognitive Impairment		Change in post-stroke cognitive impairment and dementia (PSCID) diagnosis status|Change in cognitive function	Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS)	All	18 Years and older   (Adult, Older Adult)		8000	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	2020P001099|U19NS115388	March 5, 2021	November 30, 2025	November 30, 2025	June 7, 2021		June 7, 2021	University of Colorado, Denver, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT04916210
1045	NCT05019014	Olfactory Deficits in Neurologic Disease		Completed	No Results Available	Alzheimer Disease|Traumatic Brain Injury|Amyotrophic Lateral Sclerosis|Frontotemporal Dementia|Lewy Body Disease|Mild Cognitive Impairment		Selective loss of episodic odor memory (Poor POEM status) will correlate with imaging and neuropsychological signs of neurodegenerative disease.|Correct responses on the episodic memory of odor percepts measure will correlate with entorhinal cortical thickness, and neuropsychological test results.|Correct responses on the odor percept identification task will correlate with imaging and neuropsychological signs of neurodegenerative disease.|Correct responses on the odor discrimination task will correlate with imaging and neuropsychological signs of neurodegenerative disease.	Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)		201	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2011P001296	August 10, 2011	January 3, 2017	July 3, 2020	August 24, 2021		August 24, 2021	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT05019014
1046	NCT03653156	China Cognition and Aging Study	COAST	Recruiting	No Results Available	Mild Cognitive Impairment(MCI)|Alzheimer Disease, Late Onset|Familial Alzheimer Disease (FAD)|Vascular Dementia (VaD)|Normal Control|Non-Alzheimer Degenerative Dementia		The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design|The conversion rate of normal to MCI to AD in Chinese|The biomarkers for normal (pre-MCI), MCI and AD diagnosis|The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels|The effective non-pharmacologic treatment(NPT) intervention	Capital Medical University|Beijing Tiantan Hospital|Beijing Chao Yang Hospital|Fu Xing Hospital, Capital Medical University|Peking Union Medical College Hospital|Peking University First Hospital|Peking University Third Hospital|Chinese PLA General Hospital|China-Japan Friendship Hospital|Beijing Geriatric Hospital|The First Affiliated Hospital of Dalian Medical University|Fujian Medical University Union Hospital|Guangzhou Psychiatric Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Handan Central Hospital|Hebei General Hospital|First Hospital of Shijiazhuang City|Tangshan Worker's Hospital|Hunan Provincial People's Hospital|Kaifeng Central Hospital|People's Hospital of Zhengzhou University|Wuhan University Zhongnan Hospital|First Affiliated Hospital of Harbin Medical University|Tongji Hospital|People's Hospital Affiliated Hubei Medical University|The Third Xiangya Hospital of Central South University|Xiangya Hospital of Central South University|The First Hospital of Jilin University|China-Japan Union Hospital, Jilin University|Subei People's Hospital of Jiangsu|Nantong University Affiliated Hospital|Mineral General Hospital, Xuzhou|Jiangxi Provincial People's Hopital|Anshan Central Hospital|The Affiliated Zhongshan Hospital of Dalian University|First Hospital of China Medical University|Baotou Central Hospital|General Hospital of Ningxia Medical University|The People's Hospital of Ningxia|The Affiliated Hospital of Qingdao University|The 960th Hospital of PLA|Qilu Hospital of Shandong University|Qilu Hospital of Shandong University (Qingdao)|Shandong Provincial Hospital|Qingdao Municipal Hospital|The First Affiliated Hospital of Shanxi Medical University|Tang-Du Hospital|First Affiliated Hospital Xi'an Jiaotong University|Ruijin Hospital|RenJi Hospital|Shanghai Changzheng Hospital|Afﬁliated Hospital of North Sichuan Medical College|Tianjin Huanhu Hospital|Tianjin Medical University General Hospital|Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region|Ningbo Medical Center Lihuili Hospital|First Affiliated Hospital of Wenzhou Medical University|First Affiliated Hospital of Zhejiang University|Shao Yifu Hospital of Zhejiang Medical University|Zhejiang Provincial People's Hospital|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|The Second Affiliated Hospital of Chongqing Medical University|The First Affiliated Hospital of Anhui Medical University|People's Hospital of Chongqing|Dongfang Hospital Beijing University of Chinese Medicine|Zigong First People's Hospital	All	18 Years and older   (Adult, Older Adult)		100000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	SYXWJ001	January 10, 2007	January 1, 2038	January 1, 2038	August 31, 2018		June 1, 2022	The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Geriatric Hospital, Changping, Beijing, China|Beijing Chao Yang Hospital, Chaoyang, Beijing, China|China-Japan Friendship Hospital, Chaoyang, Beijing, China|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Fengtai, Beijing, China|Chinese PLA General Hospital, Haidian, Beijing, China|Fu Xing Hospital, Capital Medical University, Haidian, Beijing, China|Peking University Third Hospital, Haidian, Beijing, China|Peking Union Medical College Hospital, Xicheng, Beijing, China|Peking University First Hospital, Xicheng, Beijing, China|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Yuzhong, Chongqing, China|The Second Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China|Fujian Medical University Union Hospital, Fujian, Guangdong, China|Guangzhou Psychiatric Hospital, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan, Guangdong, China|First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China|Handan Central Hospital, Handan, Hebei, China|First Hospital of Shijiazhuang City, Shijiazhuang, Hebei, China|Tangshan Worker's Hospital, Tangshan, Hebei, China|Hebei General Hospital, Zhijiazhuang, Hebei, China|First Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|Kaifeng Central Hospital, Kaifeng, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|People's Hospital of Zhengzhou, Zhengzhou, Henan, China|People's Hospital Affiliated Hubei Medical University, Wuhan, Hubei, China|Tongji Hospital, Wuhan, Hubei, China|The Third Xiangya Hospital of Central South University, Wuhan, Hunan, China|Wuhan University Zhongnan Hospital, Wuhan, Hunan, China|Xiangya Hospital of Central South University, Wuhan, Hunan, China|Nantong University Affiliated Hospital, Nantong, Jiangsu, China|Subei People's Hospital of Jiangsu, Subei, Jiangsu, China|Mineral General Hospital, Xuzhou, Xuzhou, Jiangsu, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|China-Japan friendship Hospital of Jilin university, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|Changda Hospital, Anshan, Anshan, Liaoning, China|Affiliated Zhongshan hospital of Dalian university, Dalian, Liaoning, China|The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China|First Hospital of China Medical University, Shenyang, Liaoning, China|Baotou Central Hospital, Baotou, Nei Monggol, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|The People's Hospital of Ningxia, Yinchuan, Ningxia, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jining, Shandong, China|Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, China|QingDao Municipal Hospital, Qingdao, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|The 88th Hospital of PLA, Tai'an, Shandong, China|Shanghai Changzheng Hospital, Huangpu, Shanghai, China|Ruijin Hospital, Luwan, Shanghai, China|RenJi Hospital, Putong, Shanghai, China|The First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|First Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shanxi, China|Tang-Du Hospital, Xi'an, Shanxi, China|Afﬁliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China|Zigong First People's Hospital, Zigong, Sichuan, China|Tianjin Medical University General Hospital, Heping, Tianjin, China|Tianjin Huanhu Hospital, Jinnan, Tianjin, China|Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Urumqi, Xinjiang, China|First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Shao Yifu Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo, Zhejiang, China|First Affiliated Hospital of Wenzhou Medical Univeristy, Wenzhou, Zhejiang, China	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03653156/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03653156
1047	NCT00870974	A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions	FPEB	Completed	No Results Available	Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment	Drug: [18F]FPEB	Does FPEB reliably represent the known distribution of MGLUR5 in the brain?	Institute for Neurodegenerative Disorders	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 1	48	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)	FPEB	March 2009	October 2016	November 2016	March 27, 2009		January 6, 2017	Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT00870974
1048	NCT02267785	Exercise Targeting Cognitive Impairment in Parkinson's Disease		Unknown status	No Results Available	Parkinson's Disease	Other: Skill-Based Exercise|Other: Aerobic Exercise|Other: Social Contact	Change in Context Dependent Motor Learning (CDML)|Change in Dual Task Performance and Functional Magnetic Resonance Imaging (fMRI)|Change in D-KEFS Verbal Fluency Test|Change in Tower of London Test|Change in Wisconsin Card Sorting Test|Change in Parkinson Disease Questionnaire-39 (PDQ-39)|Change in Evaluation of PD Motor Symptoms with Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)|Change in Activity Specific Balance Confidence (ABC) Scale|Change in Confidence in ability to maintain an exercise program (CONF)|Change in Exercise Control Beliefs (BEL)|Change in Self-efficacy for Exercise Scale (EFFIC)|Change in Frontal Systems Behavior Scale (FrSBe)|Change in Motor Skill Fitness|Change in Cardiovascular Fitness|Change in Lifetime Total Physical Activity Questionnaire (LTPAQ)|Change in Global Physical Activity Questionnaire (GPAQ)|Change in Body Mass Index|Change in Body Fat Percentage|Change in Mattis Dementia Rating Scale|Change in Geriatric Depression Scale|Change in Geriatric Anxiety Inventory|Change in Apathy Scale|Change in Revised Activities of Daily Living Scale|Change in the Frontal Systems Behavior Scale (FrSBe)|Change in Adaptive Digit Ordering Test|Change in Hooper Visual Organization Test|Change in Benton's Judgment of Line Orientation|Change in D-KEFS Color Word Interference Test|Change in California Verbal Learning Test- 2nd Edition (CVLT-II)|Change in WMS-II Visual Reproduction Test|Change in WAIS-IV Similarities Test|Change in Boston Naming Test	University of Southern California|National Parkinson Foundation|University of California, Los Angeles	All	30 Years to 85 Years   (Adult, Older Adult)	Not Applicable	25	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	HS-14-00422	October 2014	December 2019	December 2019	October 17, 2014		May 31, 2019	University of Southern California, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT02267785
1049	NCT04335994	ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	ENCHANT	Active, not recruiting	No Results Available	Obstructive Sleep Apnea|Alzheimer Disease|Vascular Dementia|Mild Cognitive Impairment|Parkinsons Disease With Dementia|Dementia With Lewy Bodies|Mixed Dementia	Device: In-laboratory polysomnography|Device: Home Sleep Apnea Test	Proportion of patients who complete sleep testing|Proportion of patients diagnosed with OSA and treated using CPAP|Cognitive Outcomes (as assessed by the Montreal Cognitive Assessment)|Cognitive Outcomes (as assessed by the Psychomotor Vigilance Task)|Sleep-related quality of life (as assessed by the Functional Outcomes of Sleep Questionnaire)|Mood (as assessed by the Geriatric Depression Scale)|Daytime Sleepiness (as assessed by the Epworth Sleepiness Scale)|Health Related Quality of Life (as assessed by the EQ-5D-5L)|Patient satisfaction for each strategy and treatment (as assessed by a Likert scale)|Cost to deliver each management strategy and treatment	Sunnybrook Health Sciences Centre|Unity Health Toronto	All	Child, Adult, Older Adult	Not Applicable	122	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	090-2019	September 23, 2019	December 2023	June 2024	April 7, 2020		August 10, 2022	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT04335994
1050	NCT05081596	A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD	PATH-Pain	Recruiting	No Results Available	Depression|Pain|Cognitive Impairment	Behavioral: PATH-Pain	Change in cognitive functioning, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in cognition, as measured by the Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)|Change in depressive symptoms, as measured by the Montgomery-Asberg Depression Rating Scale (MADRS)|Change in pain-related disability, as measured by the Roland-Morris Scale	Weill Medical College of Cornell University|National Institute on Aging (NIA)	All	60 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21-01023108|R01AG070055	June 3, 2022	July 2026	July 2027	October 18, 2021		June 9, 2022	Weill Cornell Medicine, White Plains, New York, United States		https://ClinicalTrials.gov/show/NCT05081596
1051	NCT04925453	tDCS and Cognitive Training in Active Duty Service Members With Mild TBI: A Pilot Study		Recruiting	No Results Available	Brain Concussion|Brain Trauma|Attention Concentration Difficulty|Brain Injuries|Brain Injuries, Traumatic|Neurocognitive Dysfunction|Attention Impaired|Memory Impairment|Mild Traumatic Brain Injury|Mild Cognitive Impairment	Combination Product: active tDCS and cognitive training intervention|Combination Product: sham tDCS and cognitive training intervention	Symbol Digit Modalities Test (SDMT)|Neuropsychological Assessment Battery (NAB) Attention Module|Electroencephalogram (EEG)|Neurobehavioral Symptom Inventory (NSI)|Magnetic Resonance Imaging (MRI) w/out contrast (optional)|NIH Toolbox Quality of Life Assessment (NeuroQoL)|Insomnia Severity Index (ISI)|Fusion Task|tDCS Symptom Rating Questionnaire (SRQ)|BrainHQ Task Load Index (TLX)	United States Naval Medical Center, San Diego|The Defense and Veterans Brain Injury Center	All	18 Years to 55 Years   (Adult)	Not Applicable	60	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	NMCSD.2020.0016	January 19, 2021	October 2022	October 2023	June 14, 2021		June 14, 2021	Naval Medical Center San Diego, San Diego, California, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04925453/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04925453/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT04925453
1052	NCT03672448	The China Longitudinal Aging Study of Cognitive Impairment		Recruiting	No Results Available	Mild Cognitive Impairment|Alzheimer Disease|Dementia, Vascular|Dementia With Lewy Bodies|Dementia Frontal|Depression|Anxiety	Other: Naturalistic observation	Prevalence, incidence of neurocognitive disorder|Prevalence, incidence of mood disorder|conversion rate	Shanghai Mental Health Center	All	60 Years and older   (Adult, Older Adult)		10000	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CRC2017ZD02	September 1, 2018	November 30, 2023	November 30, 2023	September 14, 2018		January 10, 2020	Shanghai Mental Health Centre, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03672448
1053	NCT02428062	Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly	THE BRIDGE	Suspended	No Results Available	Post-operative Cognitive Dysfunction	Procedure: Hemodynamic target|Drug: Phenylephrine|Drug: Intravenous fluids|Procedure: Patient's positioning|Procedure: Reduction of depth of anesthesia|Drug: Ephedrine|Drug: Epinephrine|Drug: Norepinephrine|Drug: Dopamine	Post-operative cognitive dysfunction (POCD) at 3 months|Post-operative cognitive dysfunction (POCD) at 1 year|Post-operative delirium|Hearing loss at 3 months|Hospital length of stay|Mortality|Number of patients with at least one post-operative complication|Hearing loss at 1 year|Vestibular dysfunction at 3 months|Vestibular dysfunction at 1 year	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	All	75 Years and older   (Older Adult)	Phase 2|Phase 3	1812	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	TB-POCD	October 2014	December 2018	December 2019	April 28, 2015		April 13, 2018	Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; Via F. Sforza 35, Milano, Italy		https://ClinicalTrials.gov/show/NCT02428062
1054	NCT03556280	Multi-Center Study of Sensory Stimulation to Improve Brain Function	Overture	Active, not recruiting	No Results Available	Alzheimer Disease|Cognitive Impairment|Mild Cognitive Impairment|Dementia Alzheimers|Dementia, Mild|Dementia, Alzheimer Type|Dementia of Alzheimer Type|Dementia|Cognitive Impairment, Mild|Cognitive Decline	Device: GammaSense Stimulation System (Active Settings)|Device: GammaSense Stimulation System (Sham Settings)	Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Amyloid PET/CT	Cognito Therapeutics, Inc.	All	55 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	CA-0005	April 24, 2018	August 1, 2020	September 2021	June 14, 2018		August 24, 2021	Brain Matters Research, Delray Beach, Florida, United States|Brain Matters Research, Stuart, Florida, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States		https://ClinicalTrials.gov/show/NCT03556280
1055	NCT03608722	Video Games to Track Cognitive Health		Unknown status	No Results Available	Dementia|Mild Cognitive Impairment|Cognitive Impairment|Cognitive Decline|Cognitive Changes|Acute Changes in Cognition|Acute Head Injury|Concussion|Mild Traumatic Brain Injury	Other: SLUMS|Other: MMSE|Other: MoCA|Device: BrainCheck	Identification of cognitive function performance utilizing a BrainCheck score|Identification of cognitive function performance on BrainCheck compared to pen and paper tests	BrainCheck, Inc.	All	10 Years and older   (Child, Adult, Older Adult)	Not Applicable	2500	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	1MAY15-93	November 2015	August 2017	May 2020	August 1, 2018		July 16, 2019			https://ClinicalTrials.gov/show/NCT03608722
1056	NCT02767388	Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery	Chemobrain	Completed	Has Results	Myelodysplastic Syndrome|Effects of Chemotherapy|Mild Cognitive Impairment|Multiple Myeloma|Non-hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia		Change From Baseline Capture Task Performance at 1- and 3- Months|Change From Baseline N2pc Amplitude at 1- and 3- Months|Change From Baseline Filter Task Performance at 1- and 3- Months|Change From Baseline CDA Amplitude at 1- and 3- Months	University of Nebraska	All	19 Years to 80 Years   (Adult, Older Adult)		45	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	137-16-FB	September 1, 2016	December 11, 2017	March 15, 2018	May 10, 2016	September 6, 2019	September 6, 2019	University of Nebraska Medical Center, Omaha, Nebraska, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02767388/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02767388
1057	NCT03069391	The Interactive Physical and Cognitive Exercise System	iPACES™	Unknown status	No Results Available	Alzheimer Disease, Early Onset|MCI|Aging|Mild Cognitive Impairment|Neurocognitive Disorder|Cognitive Impairment|Cognitive Change	Behavioral: physical exercise alone (PES) first|Device: cognitive exercise alone (iCE) first|Device: interactive Physical and Cognitive Exercise (iPACES™)	executive function composite score|brain-derived neurotrophic factor (BDNF)|Sit-Stand Test	Union College, New York|1st Playable Productions|Albany Medical College|Skidmore College|University of Illinois at Urbana-Champaign|National Institute on Aging (NIA)	All	50 Years and older   (Adult, Older Adult)	Not Applicable	31	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16028|1R41AG053120-01	March 4, 2017	June 30, 2022	June 30, 2022	March 3, 2017		March 31, 2020	Healthy Aging & Neuropsychology Lab @ Union College, Schenectady, New York, United States		https://ClinicalTrials.gov/show/NCT03069391
1058	NCT01340885	Cognitive Decline in Non-demented PD		Completed	Has Results	Parkinson's Disease	Drug: Strattera|Drug: Exelon|Other: Placebo	Attention Network Effects|Quality of Life|Stroop Color Word Test|Fatigue|Depression|Daytime Sleepiness	Oregon Health and Science University|National Institute of Neurological Disorders and Stroke (NINDS)	All	18 Years and older   (Adult, Older Adult)	Phase 4	9	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PANUC - Lou|5P50NS062684-02	January 2011	January 2013	January 2013	April 25, 2011	July 7, 2020	July 7, 2020	Oregon Health & Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT01340885
1059	NCT05260515	Protecting Alzheimer Caregivers Using Technology Through Staying Sharp	PROACTS	Not yet recruiting	No Results Available	Mild Cognitive Impairment|Dementia Alzheimers|Old Age; Dementia|Caregiver Burden|Health Behavior|Social Behavior|Caregiver Burnout	Behavioral: Staying Sharp intervention	User experience|Physical activity|Socialization|Cognition|Caregiver Burden|Sleep Health|Dietary behaviors|Online engagement	Oregon Health and Science University|National Institute on Aging (NIA)	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 1|Phase 2	138	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	P30AG024978|5P30AG024978-18	August 15, 2022	December 31, 2023	June 30, 2024	March 2, 2022		June 14, 2022			https://ClinicalTrials.gov/show/NCT05260515
1060	NCT04437290	University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core		Not yet recruiting	No Results Available	Alzheimer Disease	Drug: investigational radiotracer [18F]MK6240	tau PET SUVR image	University of Washington|National Institute on Aging (NIA)|Ellison Foundation	All	55 Years and older   (Adult, Older Adult)		300	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	STUDY00009617|P30AG066509	September 2021	April 30, 2025	April 30, 2025	June 18, 2020		June 24, 2021			https://ClinicalTrials.gov/show/NCT04437290
1061	NCT03680664	Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS)		Completed	No Results Available	Anxiety Disorders|Mood Disorders|Transcranial Direct Current Stimulation|tDCS|Stress Reduction	Device: Active tDCS|Other: sham tDCS|Behavioral: MBSR	Change in cognitive and memory function|Change in depressive symptoms|Change in anxiety symptoms|Change in quality of life|Change in mindfulness	Centre for Addiction and Mental Health|University of Toronto	All	60 Years and older   (Adult, Older Adult)	Not Applicable	12	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	065/2017	November 8, 2018	July 4, 2019	July 4, 2019	September 21, 2018		January 6, 2020	Centre for Addiction and Mental Health, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03680664
1062	NCT04315337	Improving Everyday Task Performance Through Repeated Practice in Virtual Reality.	VKI	Recruiting	No Results Available	Alzheimer Disease|Mild Dementia|Mild Cognitive Impairment|Dementia|Dementia, Vascular|Dementia Alzheimers|Dementia, Mild|Dementia, Mixed|Dementia of Alzheimer Type	Behavioral: Virtual Kitchen Training	Real Trained Task Performance- Accomplishment|Real Trained Task Performance- Overt Commission Errors|Real Trained Task Performance- Micro-errors|Real Trained Task Performance- Completion Time|Virtual Reality Training Acceptability|Virtual Reality Training Usability	Temple University	All	65 Years and older   (Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	AG066771	January 12, 2021	October 31, 2022	March 31, 2023	March 19, 2020		August 2, 2022	Temple University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04315337
1063	NCT02860338	COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE		Completed	No Results Available	Mild Cognitive Impairment|Dementia|Hypoxia|Hyperhomocysteinemia|Vitamin B 12 Deficiency|Iron Deficiency|Anemia|TBI|Neurodegenerative Disorders|Alzheimer's Disease|Vascular Dementia|Brain Injuries|Tauopathies|Parkinson's Disease|Lewy Body Dementia|Frontotemporal Dementia|TDP-43 Proteinopathies		Cognitive testing - Memory Orientation Screening Test (MOST)|Resting and ambulatory pulse oximetry in office|Nocturnal pulse oximetry|Polysomnography in-lab and ambulatory ( in patient's residence)|Laboratory values: Chem 20, CBC/diff, BNP, CRP, iron, iron/TIBC, ferritin, homocysteine, methylmalonic acid, Vitamin D 25-OH, RPR/FTA-ABS/TPPA, IGF-1	Clionsky Neuro Systems Inc.	All	40 Years to 90 Years   (Adult, Older Adult)		900	Industry	Observational	Observational Model: Cohort|Time Perspective: Retrospective	CNS 2012-004	January 2009	December 2015	December 2015	August 9, 2016		August 9, 2016			https://ClinicalTrials.gov/show/NCT02860338
1064	NCT04939818	Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders	RHAPSODY	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Dementia With Lewy Bodies|Dementia, Vascular|Frontotemporal Dementia|Primary Progressive Aphasia|Parkinson Disease|Motor Neuron Disease|Major Depressive Disorder|Bipolar Disorder|Amyotrophic Lateral Sclerosis		The average length of speech elicitation for each speech task (in seconds) during the first week of self-assessments.|The intra-subject variance of length of speech elicitation for each speech task during the first week of self-assessments, as measured by Coefficients of Individual Agreement (CIA).|The inter-subject variance of length of speech elicitation for each speech task during the first week of self-assessments, as measured by Coefficients of Individual Agreement (CIA).|The subject average fraction of days during the first week of remote, self-assessment, where participants submitted at least one task response.|The average length of speech elicitation for each speech task, during the telemedicine video conference.|The AUC of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the Dementia with Lewy Bodies (LBD) diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the Frontotemporal Dementia and Vascular Dementia (FTD/VCI) diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The sensitivity of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the MND diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The specificity of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the AD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the LBD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the PD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the FTD/VCI diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the MDD diagnostic groups vs the applicable control group.|The Cohen's kappa of the binary classifier distinguishing between the BD diagnostic groups vs the applicable control group.|The AUC of the binary classifier distinguishing between the following diagnostic groups vs all other diagnostic groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|The sensitivity of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|The specificity of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|The Cohen's kappa of the binary classifier distinguishing between the following diagnostic groups vs the other groups (pooled): AD, LBD, PD, MND, FTD/VCI, MDD, BD.|For each classifier/regressor in the outcomes, the correlation between the AUC/CIA and each age group, gender and speech-to-reverberation modulation energy ratio group, as measured by the Kendall rank correlation coefficient.	Novoic Limited|King's College London	All	18 Years to 85 Years   (Adult, Older Adult)		250	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	NOV-0200	June 14, 2021	May 15, 2022	June 15, 2022	June 25, 2021		February 28, 2022	South London and Maudsley NHS Foundation Trust, London, Greater London, United Kingdom|King's College Hospital NHS Foundation Trust, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT04939818
1065	NCT04701177	Digitally-enhanced, Decentralized, Multi-omics Observational Cohort	ANANEOS	Enrolling by invitation	No Results Available	Presymptomatic Disease|Mild Cognitive Impairment|Memory Loss (Excluding Dementia)|Cognitive Change|Dementia|Alzheimer Disease|Parkinson's Disease and Parkinsonism	Diagnostic Test: AltoidaML	Establish standardized protocols for acquisition, transfer & analysis of clinical, digital, imaging, biologic and genetic data that can be used in the AD & PD research community.|Comprehensive and uniformly acquired dataset|Change in Diagnostic Area Under the Receiver Operating Characteristic Curve (ROC-AUC)|Establish the probability of phenoconversion to PD	Altoida|Ionio University, Greece|Greek Association Against Alzheimer's disease and related disorders	All	45 Years and older   (Adult, Older Adult)		100000	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	altoidaML02|GR-00546	March 15, 2021	October 30, 2026	November 30, 2026	January 8, 2021		May 11, 2022	Ionian University, Corfu, Greece		https://ClinicalTrials.gov/show/NCT04701177
1066	NCT04114994	Longitudinal Cognitive Assessment by BoCA	BoCA	Recruiting	No Results Available	Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia|Frontotemporal Dementia|Parkinson Disease|Multiple Sclerosis|TBI	Diagnostic Test: Boston Cognitive Assessment (BoCA)	Boston Cognitive Assessment (BoCA)	Alzheimer's Light LLC	All	50 Years and older   (Adult, Older Adult)		10000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	BoCA001	October 1, 2019	October 1, 2029	October 1, 2029	October 3, 2019		July 20, 2021	Andrey Vyshedskiy, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT04114994
1067	NCT05296239	SimpleC Wellness Platform With Social Robot Interaction		Completed	No Results Available	Engagement, Patient|Mood|Quality of Life|Aging|Mild Cognitive Impairment|Cognitive Impairment|Dementia	Other: SimpleC Wellness Platform with Social Robot Interaction	Facilitators to successful implementation|Barriers to successful implementation|Technology Acceptance Model Questionnaire. A 12-item scale with high scores indicating higher acceptance.|Technology acceptance and adoption|Robotic Social Attributes Scale (RoSAS). An 18-item scale with high scores indicating positive attitudes for dimensions of warmth and competency and a negative attitude for dimension of discomfort.|Robot Social Attributes|Usability and usefulness|Conversation quality|Value proposition/Economic Impact|Requirements|Affect|Guilt Scale. A 4-point scale with higher score indicating higher guilt.	SimpleC, LLC|University of Georgia|Advanced Medical Electronics	All	18 Years and older   (Adult, Older Adult)	Not Applicable	26	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	7645C	February 3, 2022	March 7, 2022	March 7, 2022	March 25, 2022		May 9, 2022	University of Georgia, Athens, Georgia, United States|SimpleC, LLC, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT05296239
1068	NCT03147937	Cognitive Changes After Major Joint Replacement - Full Trial (Cognigram 2)		Recruiting	No Results Available	Postoperative Cognitive Dysfunction|Cognitive Impairment|Mild Cognitive Impairment|Delirium|Cognitive Decline|Cognitive Change|Working Memory|Autoimmune Diseases|Inflammation	Other: Cognitive Testing	Proportion of patients with Cognigram score decreasing by > 2 SDs from baseline at 4.5|Proportion of patients with Cognigram score decreasing between 1 and 2 standard deviations from baseline at 4.5 months|Effect of pre-operative MCI on postoperative cognitive changes at 4.5 months|Effect of pre-operative chronic inflammatory states on postoperative cognitive changes at 4.5 months|Effect of postoperative delirium on postoperative cognitive changes at 4.5 months|Effect of postoperative complications on postoperative cognitive changes at 4.5 months	Dr. Stephen Choi|Sunnybrook Health Sciences Centre	All	50 Years and older   (Adult, Older Adult)		505	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	040-2017	May 1, 2017	December 2022	December 2022	May 10, 2017		September 22, 2021	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03147937
1069	NCT03661034	Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)		Active, not recruiting	No Results Available	Alzheimer Disease, Early Onset|Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Memory Disorders|Memory Loss|Memory Impairment|Memory Disorders, Age Related|Alzheimer Disease, Late Onset|Cognitive Impairment|Dementia, Mild|Dementia, Alzheimer Type|Cognitive Decline	Device: GammaSense Stimulation System (non-invasive, non-significant risk)	Change in Amyloid Positron Emission Tomography (PET) Scan|Adverse Events|Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)	Cognito Therapeutics, Inc.	All	50 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA-0004	May 31, 2018	May 1, 2021	March 1, 2022	September 7, 2018		August 24, 2021	Boston Center for Memory, Newton, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03661034
1070	NCT05531591	RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)	ONR	Active, not recruiting	No Results Available	Depression|Dementia|Mild Cognitive Impairment|Treatment Resistant Depression|Major Depressive Disorder|Treatment-Refractory Depression|Late Life Depression|Geriatric Depression	Drug: Aripiprazole Augmentation|Drug: Bupropion Augmentation|Drug: Switch to bupropion|Drug: Lithium Augmentation|Drug: Switch to nortriptyline	Change in Psychological Well-Being|Assessing the change in the Number of Participants With Remission From Depression|Safety Outcomes Assessment for Serious Adverse Events|To observe whether persistent (non-remitting) depression leads to greater cognitive decline (focusing on executive and episodic memory (EEM)-related cognitive domains	Centre for Addiction and Mental Health|National Institute of Mental Health (NIMH)	All	60 Years and older   (Adult, Older Adult)	Phase 4	600	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	080-2017, 086-2016 RCT|R01MH114970|R01MH114980|R01MH114981|R01MH114966-01	August 1, 2019	January 31, 2024	February 28, 2025	September 8, 2022		September 8, 2022	UCLA Late-Life Mood, Stress, and Wellness Research Program, Los Angeles, California, United States|Washington University School of Medicine Healthy Mind Lab, Saint Louis, Missouri, United States|Columbia University Adult and Late Life Depression Clinic, New York, New York, United States|Centre for Addiction and Mental Health, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT05531591
1071	NCT03926351	High Dose Omega 3 in People at Risk for Dementia		Unknown status	No Results Available	Dementia|Inflammation|Mild Cognitive Impairment|Cognitive Decline|SCD|Cognitive Dysfunction|Pathologic Processes|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Neurocognitive Disorders|Mental Disorder|Cognition Disorders	Dietary Supplement: Omega-3 capsules|Dietary Supplement: Olive oil	Cognitive function|Blood PBMC betaAmyloid mid-domain assay|CSF betaAmyloid 1-42|CSF TAU|CSF Phospho-TAU|MRI ASL|MRI WML|MRI DTI	University Hospital, Akershus|BASF AS|Pre Diagnostics AS	All	50 Years to 79 Years   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	REC: 2017/1364	October 1, 2018	October 2019	October 2020	April 24, 2019		April 24, 2019	Akershus university hospital, Sykehusveien 25, Lørenskog, Norway		https://ClinicalTrials.gov/show/NCT03926351
1072	NCT02726906	Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study		Active, not recruiting	No Results Available	Aging|Cognitive Ability, General	Behavioral: Moderate-aerobic walking|Radiation: Positron Emission Tomography (PET) scan|Behavioral: Healthy living education|Device: Physical activity monitor	Functional Magnetic Resonance Imaging (fMRI) brain scan as a measure of brain function|Mnemonic Similarity Test as a measure of memory (cognition)|Positron Emission Tomography (PET) scan as a measure of tracer binding|Single-stage treadmill test and modified physical function test as measures of physical function|Brain-derived neurotropic factor (BDNF) as a measure from blood	University of Southern California	All	55 Years to 80 Years   (Adult, Older Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	AG046928	July 2016	April 2022	April 2022	April 4, 2016		March 2, 2022	University of Southern California, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT02726906
1073	NCT05462977	Rhythmically Entrained Exercise in Community-Dwelling Older Adults	REECO	Enrolling by invitation	No Results Available	Exercise|Gait|Cognitive Decline|Caregiver Burden|Cognitive Impairment|Dementia|Alzheimer Disease|Mild Cognitive Impairment|Respite Care|Mental Health|Depression|Music Therapy|Psychosocial Intervention|Cognition|Geriatric Assessment|Cognitive Dysfunction|Cognitive Aging|Outcome Assessment, Health Care|Balance|Fall|Walking|Affect|Physical Exertion|Memory Deficit|Memory Disorders|Memory Impairment|Neuropsychological Tests|Executive Function|Middle Aged|Healthy Aging|Elderly	Behavioral: Group exercise program	Change of fall risks|Change of walking endurance|Change of balance control|Change of lower body strength|Change of cognitive function|Change of health-related quality of life	University of North Carolina, Greensboro	All	55 Years to 99 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	FY22-106	May 1, 2022	December 31, 2022	December 31, 2022	July 18, 2022		July 18, 2022	UNC Greensboro, Greensboro, North Carolina, United States		https://ClinicalTrials.gov/show/NCT05462977
1074	NCT02045056	Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease		Completed	No Results Available	Preclinical Alzheimer's Disease	Drug: Gemfibrozil|Drug: Placebo	Safety|microRNA-107 levels|beta-amyloid levels|Free and cued selective reminding test (FCSRT)|Paired associates learning (PAL)	Gregory Jicha, 323-5550|University of Kentucky	All	65 Years to 90 Years   (Older Adult)	Early Phase 1	72	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	R01AG042419	May 2014	June 30, 2018	June 2019	January 24, 2014		October 8, 2019	University of Kentucky, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT02045056
1075	NCT04313582	Feasibility of the SmartPrompt for Improving Everyday Function in Dementia	SmartPrompt	Recruiting	No Results Available	Dementia|Dementia, Vascular|Dementia Alzheimers|Dementia, Mixed|Dementia, Mild|Dementia of Alzheimer Type|Mild Cognitive Impairment|Mild Dementia	Behavioral: SmartPrompt smartphone application	Caregiver Task Completion Rating Sum of SmartPompt Condition|Caregiver Task Completion Rating Sum of Control Condition|Caregiver Task Burden Sum of SmartPompt Condition|Caregiver Task Burden Sum of Control Condition|Participant Activity Log Sum of SmartPompt Condition|Participant Activity Log Sum of Control Condition|Participant Frustration Sum of SmartPompt Condition|Participant Frustration Sum of Control Condition|Caregiver System Usability Scale (C-SUS)|Caregiver Problem Report Sum|Technical Support Log Total|Total Training Time|SmartPrompt Use Sum|Response Time (RT) to Alarm and Prompts Average|Participant Open-Ended Structured Interview|Caregiver Open-Ended Structured Interview	Temple University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	R21AG060422|24500	March 13, 2020	April 1, 2023	April 1, 2023	March 18, 2020		August 1, 2022	Temple University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04313582
1076	NCT02670161	Quality Improvement and Practice Based Research in Neurology Using the EMR		Enrolling by invitation	No Results Available	Brain Tumors|Epilepsy|Migraine|Mild Cognitive Impairment|Concussion|Multiple Sclerosis|Neuropathy|Parkinson's|Restless Legs Syndrome|Stroke	Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)	survival free of discontinuation or alternative prevention drug (migraine trial)|survival free of disability measured by FAQ score 9+ (memory trial)|survival free of discontinuation or alternative anti epileptic drug (epilepsy trial)	NorthShore University HealthSystem	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 4	3300	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EH14-355|1R01HS024057-01	May 2016	October 2021	December 2021	February 1, 2016		August 11, 2021			https://ClinicalTrials.gov/show/NCT02670161
1077	NCT02884492	Imaging Tau in Alzheimer's Disease and Normal Aging		Terminated	Has Results	Alzheimer's Disease	Drug: 18F-THK-5351|Procedure: Lumbar Puncture (optional)	18F-THK-5351 Standardized Uptake Value Ratio	William Charles Kreisl|National Institute on Aging (NIA)|Columbia University	All	50 Years and older   (Adult, Older Adult)	Phase 2	17	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AAAQ7868|1K23AG052633-01	July 2016	June 30, 2017	June 30, 2017	August 31, 2016	November 19, 2018	November 19, 2018	Columbia University Medical Center, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02884492/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02884492
1078	NCT02831283	Imaging Inflammation in Alzheimer's Disease		Enrolling by invitation	No Results Available	Alzheimer's Disease	Drug: 11C-PBR28|Drug: 18F-Florbetaben|Procedure: Lumbar puncture (optional)	11C-PBR28 binding (standardized uptake value ratio)|18F-Florbetaben binding (standardized uptake value ratio)|Cerebral spinal fluid (CSF) biomarkers	William Charles Kreisl|National Institute on Aging (NIA)|Columbia University	All	60 Years and older   (Adult, Older Adult)	Phase 2	100	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AAAO1151|1K23AG052633-01	June 2016	June 2022	June 2022	July 13, 2016		August 5, 2021	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02831283
1079	NCT01873794	Treating Cancer-Related Fatigue Through Systematic Light Exposure		Completed	No Results Available	Hematopoietic Stem Cell Transplantation|Breast Cancer|Fatigue|Mild Cognitive Impairment|Light|Quality of Life|Sleep	Device: Bright white light|Device: Dim red light	FACIT-Fatigue Scale|The Pittsburgh Sleep Quality Index|SF-36 Scale|CNS-Vital Signs|The Cognitive Failures Questionnaire|Brief Symptom Inventory-18|Actiwatch Spectrum	Icahn School of Medicine at Mount Sinai|National Cancer Institute (NCI)|University of California, San Diego|Hackensack Meridian Health	All	18 Years and older   (Adult, Older Adult)	Not Applicable	54	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	GCO 10-0864|5R21CA158954|HSM#11-01032	January 2012	July 2014	July 2014	June 10, 2013		April 11, 2017	Hackensack University Medical Center, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01873794
1080	NCT01198093	Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD)	CREDOS	Unknown status	No Results Available	Alzheimer's Disease			Samsung Medical Center|Ministry of Health & Welfare, Korea	All	Child, Adult, Older Adult		800	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2005-02-008	November 2005	August 2015	August 2015	September 9, 2010		September 28, 2012	Samsung Medical Center, Seoul, Kangnam-Ku, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01198093
1081	NCT04157244	The Music, Sleep and Dementia Study		Completed	No Results Available	Dementia|Alzheimer Disease|Circadian Rhythm Disorders|Circadian Rhythm Sleep Disorder|Insomnia|Hypersomnia|Cognitive Impairment|Cognitive Decline|Mild Cognitive Impairment|Frontotemporal Dementia|Neurocognitive Disorders|Vascular Dementia|Sleep Disorder|Memory Impairment	Behavioral: Tailored music listening intervention	Study Measures Completion|Acceptability of the study components|Objective sleep measures|The Quality of Life in Alzheimer's Disease Scale (QOL-AD)	University of Pennsylvania	All	18 Years to 110 Years   (Adult, Older Adult)	Not Applicable	32	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	829256	March 12, 2019	January 12, 2021	January 12, 2021	November 8, 2019		January 13, 2021	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04157244
1082	NCT02248649	Telemedicine Intervention to Improve Cognitive Function		Completed	Has Results	Parkinson's Disease	Behavioral: Structured physical activity|Behavioral: Health education	Change From Baseline on Cognitive Section of Alzheimer Disease Assessment Scale (ADAS-Cog) at Month 6|Change From Baseline on Cognitive Section of Alzheimer Disease Assessment Scale (ADAS-Cog) at Month 12|Change From Baseline on Cognitive Section of Alzheimer Disease Assessment Scale (ADAS-Cog) at Month 18	VA Office of Research and Development	All	40 Years and older   (Adult, Older Adult)	Not Applicable	160	U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	N1696-I	December 1, 2014	May 15, 2018	September 30, 2018	September 25, 2014	July 24, 2019	July 24, 2019	VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02248649/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02248649
1083	NCT00900770	Implications of Amyloid Pathology		Unknown status	No Results Available	Alzheimer's Disease		Pittsburgh Compound B (PiB) and F-18 fluorodeoxyglucose (FDG) PET Scan|Cognitive and functional assessments|Lumbar Puncture (optional)	National Institute on Aging (NIA)	All	60 Years to 90 Years   (Adult, Older Adult)		100	NIH	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	IA0158|2P50AG005134-268381|2P50AG005134	November 2008	March 2014	March 2014	May 13, 2009		December 29, 2009	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00900770
1084	NCT03682185	The Healthy Patterns Sleep Study		Completed	No Results Available	Dementia|Alzheimer Disease|Circadian Rhythm Disorders|Circadian Rhythm Sleep Disorder|Insomnia|Hypersomnia|Cognitive Impairment|Cognitive Decline|Mild Cognitive Impairment|Frontotemporal Dementia|Neurocognitive Disorders|Vascular Dementia|Sleep Disorder|Memory Impairment	Behavioral: Attention-Control Condition|Behavioral: Timed Activity Intervention	The Quality of Life in Alzheimer's Disease Scale (QOL-AD)|Neuropsychiatric Inventory (NPI)	University of Pennsylvania	All	18 Years to 110 Years   (Adult, Older Adult)	Phase 3	210	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	825000	May 1, 2016	May 31, 2021	May 31, 2021	September 24, 2018		July 2, 2021	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03682185
1085	NCT00178087	Determining Changes in Brain Structure Associated With Symptoms of Late-life Depression		Completed	No Results Available	Late-Life Depression		Changes in performance on a broad-based Neuropsychological Test Battery	University of Pittsburgh|National Institute of Mental Health (NIMH)	All	55 Years and older   (Adult, Older Adult)		331	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	R01MH072947|9512127|DATR A4-GPT	August 2005	August 2011	August 2011	September 15, 2005		April 7, 2015	UPMC Late-Life Evaluation and Treatment Center, Pittsburgh, Pennsylvania, United States|UPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00178087
1086	NCT03605381	MORbidity PRevalence Estimate In StrokE	MORe PREcISE	Unknown status	No Results Available	Stroke|CVA (Cerebrovascular Accident)|CVA; Sequelae|Stroke, Ischemic|Stroke Hemorrhagic|Hemianopia|Hemiplegia|Hemiparesis|Aphasia|Cerebral Infarction|Intracerebral Hemorrhage|Anxiety|Depression|Dysphagia|Dysarthria|Hemispatial Neglect|Mild Cognitive Impairment		Morbidity Secondary to Stroke	Aneurin Bevan University Health Board	All	18 Years and older   (Adult, Older Adult)		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	SP06|03 ABUHB	September 30, 2018	August 31, 2019	September 30, 2019	July 30, 2018		July 5, 2019	Ysbyty Ystrad Fawr, Ystrad Mynach, Caerphilly, United Kingdom|Royal Gwent Hospital, Newport, Gwent, United Kingdom|Prince Charles Hospital, Merthyr Tydfil, United Kingdom		https://ClinicalTrials.gov/show/NCT03605381
1087	NCT03174938	The Swedish BioFINDER 2 Study	BioFINDER2	Recruiting	No Results Available	Dementia|Alzheimer Disease|Parkinson Disease|Lewy Body Disease|Parkinson-Dementia Syndrome|Frontotemporal Degeneration|Semantic Dementia|Progressive Nonfluent Aphasia|Progressive Supranuclear Palsy|Corticobasal Degeneration|Multiple System Atrophy|Mild Cognitive Impairment	Diagnostic Test: Flutemetamol F18 Injection|Diagnostic Test: [18F]-RO6958948|Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau|Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau	Clinical diagnosis|Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Rate of cognitive decline as measured by MMSE.|Rate of cognitive decline as measured in ADL-function.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on cerebrospinal fluid AD biomarkers	Skane University Hospital|Lund University	All	20 Years to 100 Years   (Adult, Older Adult)	Not Applicable	1505	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	BioFINDER 2	May 15, 2017	December 31, 2028	December 31, 2028	June 5, 2017		March 2, 2021	Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden		https://ClinicalTrials.gov/show/NCT03174938
1088	NCT02655354	A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity	TSOS6	Completed	Has Results	Posttraumatic Stress Disorder|Depression|Alcohol-Related Disorders|Suicidal Ideation|Substance-Related Disorders|Mild Cognitive Impairment|Quality of Life|Pain|Wounds and Injury|Brain Injuries|Chronic Disease	Behavioral: Motivational Interviewing|Behavioral: Cognitive Behavioral Therapy Elements|Behavioral: Care Management|Drug: Fluoxetine|Drug: Fluvoxamine|Drug: Paroxetine|Drug: Sertraline|Drug: Citalopram|Drug: Venlafaxine|Drug: Duloxetine|Drug: Mirtazapine|Drug: Diphenhydramine|Drug: Trazodone|Drug: Prazosin	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury|Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury|Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury|Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury|Number of Participants With Suicidal Ideation|Number of Participants Endorsing a Single Item That Assesses Opioid Use|Cognitive Impairment Scale|Brief Pain Inventory|SF-36 Quality of Life|TSOS Patient Satisfaction: Overall Health Care|Number of Participants Endorsing a Single Item That Assesses Stimulant Use|Number of Participants Endorsing a Single Item That Assesses Marijuana Use|TSOS Patient Satisfaction: Mental Health Care	University of Washington|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	635	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	20150987|UH3MH106338	October 2015	November 2019	November 2019	January 14, 2016	July 2, 2021	July 2, 2021	Honor Health, Scottsdale, Arizona, United States|Cedars Sinai, Beverly Hills, California, United States|U.C. Davis, Sacramento, California, United States|Santa Clara Valley Medical Center, San Jose, California, United States|U.C.L.A. Harbor, Torrance, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Georgia Regents, Augusta, Georgia, United States|Eskenazi Health, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Louisiana State University, New Orleans, Louisiana, United States|Regions Hospital, Saint Paul, Minnesota, United States|Jacobi Medical Center, Bronx, New York, United States|University of Rochester, Rochester, New York, United States|Wake Forest, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Baylor Health Care System, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States|The University of Vermont, Burlington, Vermont, United States|Inova Trauma Center, Falls Church, Virginia, United States|The University of Wisconsin Madison, Madison, Wisconsin, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02655354/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02655354
1089	NCT00000180	AIT-082 Phase 1B Study		Completed	No Results Available	Memory Disorders	Drug: AIT-082		National Institute on Aging (NIA)	All	Child, Adult, Older Adult	Phase 1		NIH	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	IA0008|3U01AG010483-08S2		June 2005	June 2005	November 1, 1999		December 11, 2009	University of California, San Diego, San Diego, California, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University, St. Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT00000180
1090	NCT02335125	A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot	TSOS6	Completed	Has Results	Posttraumatic Stress Disorder|Depression|Alcohol-Related Disorders|Suicidal Ideation|Substance-Related Disorders|Mild Cognitive Impairment|Quality of Life	Behavioral: Motivational Interviewing|Behavioral: Cognitive Behavioral Therapy Elements|Drug: Psychotropic Drugs|Other: Care Management	Change From Baseline PTSD Checklist Civilian (PCL-C) at 1 Month|Change From Baseline Alcohol Use Disorders Identification at 1 Month|Change From Patient Health Questionnaire 9 Item Depression Scale at 1 Month|Change in Functional Status|Patient Health Questionnaire Item 9 Suicide Question|Number of Participants Endorsing a Single Item That Assesses Drug Use|Cognitive Impairment Scale	University of Washington|National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	STUDY00010782|UH2MH106338	February 2015	August 2016	August 2016	January 9, 2015	September 11, 2020	September 11, 2020			https://ClinicalTrials.gov/show/NCT02335125
1091	NCT04055532	Biomarkers in Neurodegenerative Diseases		Withdrawn	No Results Available	Mild Cognitive Impairment (MCI)|Alzheimer Disease (AD)|Dementia With Lewy Bodies (DLB)|Frontotemporal Lobar Degeneration (FTLD)|Parkinsons Disease With Dementia (PDD)|Transient Epileptic Amnesia (TEA)|Temporal Lobe Epilepsy (TLE)|Spinocerebellar Ataxias (SCA)|HIV Associated Neurocognitive Disorder (HAND)|Amyotrophic Lateral Sclerosis (ALS)|Primary Lateral Sclerosis (PLS)	Other: Neuraceq	Performance on Batteries of Cognitive Tests	University of Minnesota	All	18 Years and older   (Adult, Older Adult)		0	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	STUDY00007108	October 1, 2019	October 1, 2024	October 1, 2025	August 13, 2019		November 12, 2019	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT04055532
1092	NCT01515098	Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline	BERRY	Completed	No Results Available	Mild Cognitive Decline	Dietary Supplement: Freeze-dried blueberries|Dietary Supplement: Dextrose Placebo	Change in cognitive test performance|Change in brain activity (N200, P300) related to cognitive abilities as measured by event-related potentials (ERP)|Change in body mass distribution|Change in oxidative stress and inflammatory markers as measured in blood and urine	University of North Carolina, Chapel Hill	All	65 Years to 79 Years   (Older Adult)	Not Applicable	123	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	11-2075	January 2012	March 2015	March 2015	January 23, 2012		March 8, 2022	Nutrition Research Institute, Kannapolis, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01515098
1093	NCT01554475	Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction		Completed	No Results Available	Dementia|Cognitive Impairment		Number of patients taking alternative medicines|Numbers of potential and clinical relevant interactions|The patient's subjective experiences with alternative medicines	University Hospital of North Norway|Kløveråsen Center for dementia, Bodø	All	Child, Adult, Older Adult		151	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2011/1705(REK)	March 2012	October 2014	October 2014	March 15, 2012		February 18, 2015	Kløveråsen, Bodø, Norway		https://ClinicalTrials.gov/show/NCT01554475
1094	NCT00182832	e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems		Completed	No Results Available	Cognitive Impairment|Delirium	Behavioral: e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Behavioral: Standard Care	Use of potentially inappropriate medications, urinary catheter or physical restraints, and length of time in initiating a referral order, as recorded in the electronic medical record|Total number of hospital acquired complications recorded in the medical record that may be related to cognitive impairment (CI)|Length and cost of hospital stay from discharge records and billing system	Indiana University|National Institute on Aging (NIA)	All	65 Years and older   (Older Adult)	Not Applicable	424	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	IA0077|K23AG026770|K23AG026779-01	June 2006	December 2008	December 2008	September 16, 2005		April 13, 2016	Wishard Memorial Hospital, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00182832
1095	NCT04863378	Efficacy of a Multimodal Brain Health Intervention for Older African Americans	SHARP	Not yet recruiting	No Results Available	Cognitive Impairment, Mild|Cognitive Decline	Behavioral: Walking conversational reminiscence	Change from baseline in daily activity time recorded by actigraphy watch|Change from baseline in sleep time recorded by actigraphy watch and Emfit QS sleep sensor|Change from baseline in sleep movement recorded by Emfit QS sleep sensor|Change from baseline in weight recorded by digital scale and by Emfit QS sleep sensor|Change from baseline in global cognition	Oregon Health and Science University|National Center for Advancing Translational Science (NCATS)|Oregon Clinical and Translational Research Institute|University of California, Davis|Rush University	All	65 Years to 110 Years   (Older Adult)	Not Applicable	18	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	00022363|KL2TR002370	May 2021	May 2022	June 2022	April 28, 2021		April 28, 2021			https://ClinicalTrials.gov/show/NCT04863378
1096	NCT03035201	COcoa Supplement and Multivitamin Outcomes Study for the Mind	COSMOS-Mind	Completed	No Results Available	Cognitive Impairment|Dementia|Aging		Number of Participants that are not Hearing Impaired|Cocoa extract effects on global cognitive trajectory|Multivitamin effects on global cognitive trajectory|Treatment effects on incident cognitive impairment|Intervention effects on executive function and episodic memory	Wake Forest University Health Sciences|National Institute on Aging (NIA)|Brigham and Women's Hospital	All	65 Years and older   (Older Adult)		2262	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB00037753|1R01AG050657-01A1	September 2016	February 12, 2021	February 12, 2021	January 27, 2017		September 13, 2022	Wake Forest School of Medicine, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03035201
1097	NCT00355550	Tricaprilin In Age-Associated Memory Impairment		Completed	No Results Available	Age-Associated Memory Impairment	Drug: Tricaprilin|Other: Placebo	Changes in Psychologix and Cogscreen Test Batteries, RAVLT (Rey Auditory Verbal Learning Test)|Number of subjects with treatment related adverse events|Self-reported memory improvement	Cerecin	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	156	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	KET-06-003	July 2006	June 2007	June 2007	July 24, 2006		September 18, 2020	Meridien Research, Brooksville, Florida, United States|University Clinical Research-DeLand, DeLand, Florida, United States|Anchor Research Center, Naples, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|University Clinical Research Center, Pembroke Pines, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States		https://ClinicalTrials.gov/show/NCT00355550
1098	NCT04284449	Integrative Therapy for Holistic, Natural Cognition and Lifestyle Rehabilitation	ITHNCLR	Recruiting	No Results Available	Cognitive Dysfunction	Other: Whole-practice cognitive optimization	NIH Toolbox-Cognitive Battery|Quality of Life in Neurological Disorders questionnaire (Neuro-QoL)|Event-related potential (P300)|Peak alpha frequency|Physical activity|Sleep quantity|Number and type of Adverse Events	National University of Natural Medicine|North County Natural Medicine	All	60 Years and older   (Adult, Older Adult)		20	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	RB7102019	February 24, 2020	April 2022	April 2022	February 25, 2020		August 31, 2021	North County Natural Medicine, Encinitas, California, United States		https://ClinicalTrials.gov/show/NCT04284449
1099	NCT01459016	A Non-drug Methods Study in Participants With Alzheimer's Disease		Completed	Has Results	Alzheimer's Disease	Other: PET scan using florbetapir|Other: MRI Scan	Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)|Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)|Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir|Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)|Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T|Change From Baseline in the Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score|Change From Baseline in the Clinical Dementia Rating (CDR) Total Score	Eli Lilly and Company	All	55 Years and older   (Adult, Older Adult)	Phase 1	56	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	14162|I4O-MC-BACH	December 2011	December 2014	December 2014	October 25, 2011	February 13, 2017	June 28, 2018	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cahors, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Castres, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Foix Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lavaur, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Limoges, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Léon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montauban Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vic-En-Bigorre, France		https://ClinicalTrials.gov/show/NCT01459016
1100	NCT02899403	Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003	PharmacogWP3	Unknown status	No Results Available	Alzheimer Disease|ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1 (Disorder)	Other: Rapid Visual Information Processing (RVIP) test	EEG spectral power during RVIP task as compared to resting state|EEG spectral power during PRM task as compared to resting state|RVIP latency of responses|PRM number of errors|PRM latency of responses|difference between session 2 and session 1 EEG Spectral power during RVIP task	University Hospital, Lille	Male	18 Years to 30 Years   (Adult)	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	2013_45|2015-A00046-43	May 19, 2017	December 2020	December 2020	September 14, 2016		June 26, 2019	Hôpital Cardiologique, CIC, Lille, France		https://ClinicalTrials.gov/show/NCT02899403
1101	NCT04972019	Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study	TCIFCF	Recruiting	No Results Available	Cognitive Impairment, Mild	Device: Telerehabilitation Experimental Group|Other: Telerehabilitation Sham Control Group	Change in Montreal Cognitive Assessment (MoCA)|Change in Test of Pre-morbid Functioning|Change in NAB Attention Module|Change in NAB Functioning Word Module|Change in Trail Making Test|Change in Hopkins Verbal Learning Test Revised|Change in Brief Visuo-spatial Memory Test, Revised (BVMT-R)|Change in Quality of Life Patient/Cancer Survivor Version (QOL-CSV)|Caregiver Quality of Life-Cancer (CQOL-C)|Change in Beck Depression Inventory II|Change in Grasp strength (Jamar dynamometer)|Change in Shoulder strength (wrist weights)|Change in Range of motion (goniometer)|Change in Jebsen test of hand function|Change in Chedokee test (CAHAI-9)|Change in Game performance|Change in Subjective evaluation questionnaire|biosensor data|Change in Subjective Pain Rating Scale	Bright Cloud International Corp|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey	Female	20 Years to 65 Years   (Adult, Older Adult)	Not Applicable	40	Industry|NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Telerehab CH Feasibility|R43CA232936	February 9, 2022	September 30, 2022	September 30, 2022	July 22, 2021		May 2, 2022	Rutgers University Rober Wood Johnson Medical School, New Brunswick, New Jersey, United States|Bright Cloud Int'l Corp, North Brunswick, New Jersey, United States		https://ClinicalTrials.gov/show/NCT04972019
1102	NCT00146263	Computerized Cognitive Training in the Elderly	CogTrain	Withdrawn	No Results Available	Dementia	Behavioral: Savyon|Behavioral: Control	Computerized cognitive assessment using the Mindstreams battery	Beersheva Mental Health Center	All	60 Years and older   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BMHC-4018CTIL	September 2005	December 2007	December 2007	September 7, 2005		February 27, 2020	Beersheva Mental Health Center, Beersheva, Israel		https://ClinicalTrials.gov/show/NCT00146263
1103	NCT01202994	Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET		Unknown status	Has Results	Alzheimer's Disease	Drug: 18F-Flutemetamol	Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan.|Change in Participant Z-score	University of Utah	All	65 Years and older   (Older Adult)	Phase 2	27	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	43306	May 2011	May 2016	December 2018	September 16, 2010	January 11, 2018	February 7, 2018	University of Utah Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01202994
1104	NCT00094952	Biomarkers and Early Alzheimer's Disease		Unknown status	No Results Available	Alzheimer's Disease			National Institute on Aging (NIA)	All	60 Years to 80 Years   (Adult, Older Adult)		80	NIH	Observational	Time Perspective: Prospective	IA0054|AG022374	April 2003		March 2008	October 29, 2004		September 18, 2009	Center for Brain Health, Silberstein Institute, New York University School of Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00094952
1105	NCT03555292	11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes		Unknown status	No Results Available	Parkinson Disease	Drug: 11C-PiB	Amyloid burden range in all subjects|The cognitive scores in all patients	Oriental Neurosurgery Evidence-Based-Study Team	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	CPBD2018	July 12, 2017	May 12, 2021	October 12, 2021	June 13, 2018		June 13, 2018	Peking Tian Tan Hospital, Capital Medical University, Beijing, China|Tianjin Huanhu Hospital, Tianjin, China|Tianjin Medical University General Hospital, Tianjin, China		https://ClinicalTrials.gov/show/NCT03555292
1106	NCT03780621	Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects With Cognitive Impairment		Completed	No Results Available	Cognitive Impairment, Mild	Dietary Supplement: Andrographis and Withania|Dietary Supplement: Placebo	Change over time in neural electrical activity of the brain as measured by quantitative-topographic EEG for herbal treatment group versus placebo	EuroPharma, Inc.	All	60 Years to 75 Years   (Adult, Older Adult)	Phase 1	16	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	EP-1004	April 1, 2019	June 1, 2019	June 1, 2019	December 19, 2018		November 14, 2019	Clinical Labors of NeuroCode AG, Wetzlar, Germany		https://ClinicalTrials.gov/show/NCT03780621
1107	NCT03647384	Guilingji Capsule for Mild-to-moderate Cognitive Impairment		Unknown status	No Results Available	Cognitive Dysfunction	Drug: Gulingji capsules|Drug: Ginko Biloba Extract tablet	The Change From Baseline in Mini-Mental State Examination (MMSE) Total Score at Week 12 and 24|The Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 12 and 24|The Change From Baseline in Clinical Dementia Rating (CDR) Total Score at Week 12 and 24|The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 12 and 24|The Change From Baseline in Activities of Daily Living (ADL) Total Score at Week 12 and 24|The Change From Baseline in The Chinese Medicine Symptom Scale (CM-SS) Total Score at Week 12 and 24|The Change From Baseline in The Serum Level of Acetylcholine and Acetylcholinesterase at Week 24	Xiyuan Hospital of China Academy of Chinese Medical Sciences|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Beijing Xuanwu Traditional Chinese Medicine Hospital|Beijing Hospital|Beijing Shijitan Hospital, Capital Medical University|Peking University First Hospital|Huadong Hospital|Longhua Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Shandong University of Traditional Chinese Medicine|Shanxi Dayi Hospital|Shaanxi Hospital of Traditional Chinese Medicine	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 2	348	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other	2018XLA039-2	August 22, 2018	December 2019	December 2019	August 27, 2018		August 27, 2018	Li Hao, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03647384
1108	NCT00357227	Atrial Fibrillation and the Risk for Neurological Complications		Unknown status	No Results Available	Atrial Fibrillation			University Hospital Muenster|German Federal Ministry of Education and Research	All	50 Years to 85 Years   (Adult, Older Adult)		1000	Other	Observational	Observational Model: Defined Population|Time Perspective: Prospective	01 GI 0204	January 2004			July 27, 2006		April 19, 2007	University Hospital Münster, Dept. of Neurology, Münster, NRW, Germany		https://ClinicalTrials.gov/show/NCT00357227
1109	NCT00626210	Modafinil Treatment for Sleep/Wake Disturbances in Older Adults		Terminated	Has Results	Insomnia|Sleep Initiation and Maintenance Disorders|Alzheimer Disease	Drug: modafinil	Nocturnal Sleep Length at 1 Month|Improvement of Daytime Alertness and Quality of Life.	VA Palo Alto Health Care System	All	50 Years and older   (Adult, Older Adult)	Phase 4	2	U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8564	February 2008	April 2011	October 2012	February 29, 2008	October 30, 2014	October 28, 2019	VA Palo Alto Health Care System, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT00626210
1110	NCT04137913	Cognitive Health Research on Musical Arts	CHROMA	Unknown status	No Results Available	Cognitive Impairment|Creativity	Behavioral: Musical arts intervention	Change from baseline in functional resting state brain activity at follow-up visit.|Mean change from baseline in level of creativity using scores on Guilford's alternative Uses Divergent Thinking Test|Mean change in scores from baseline in perceived social support subscales of the Medical Outcomes Studies, including emotional support, tangible support, affectionate support, and positive social interactions.|Mean change from baseline in quality of life scores each subscale of the SF-36|Mean change from baseline in inhibition and inhibition/switching trials on the color-word interference test of the Delis Kaplan Executive Function System (DKEFS)|Mean change from baseline in cognitive scores (digit span forward, digit span backward, digit span sequencing, and total raw score) on the digit span test of the Wechsler Adult Intelligence Scale (WAIS).|Mean change from baseline in perseverative errors on the Wisconsin Card Sorting Test (WCST)|Mean change from baseline in affect scores on the Positive and Negative Affect Scale|Mean change from baseline in emotion regulation scores on the Emotional Regulation Scale|Mean change in inflammation from enrollment (baseline) to follow-up visit	William Marsh Rice University|Methodist Research Institute: Center for Performing Arts Medicine|National Endowment for the Arts, United States|Musiqa	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	60	Other|U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB-FY2019-355	May 29, 2019	April 30, 2021	April 30, 2021	October 24, 2019		October 24, 2019	Rice University Bioscience Research Collaborative, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04137913
1111	NCT03325699	Support Monitoring and Reminder Technology	SMART4MD	Unknown status	No Results Available	Mild Dementia|Cognitive Impairment, Mild	Device: SMART4MD Health Application	Health Related Quality of Life (HRQL) QoL-AD questionnaire (Thorgrimsen et al. 2003; Rebecca G. Logsdon et al. 2002; R. G. Logsdon et al. 1999)|Adherence to medication|Mini mental state examination (MMSE)|Attendance to health care appointments|Zarit Burden Interview (ZBI)	Johan Sanmartin Berglund|HealthBit|Andaluz Health Service|Blekinge Institute of Technology|Consorci Sanitari de Terrassa|DEX Innovation Centre|Anglia Ruskin University|University College Leuven - Limburg|Universidad Politecnica de Madrid|Athena ICT	All	55 Years to 120 Years   (Adult, Older Adult)	Not Applicable	1200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	643399	December 3, 2016	October 1, 2019	October 1, 2019	October 30, 2017		January 17, 2019	University College Leuven - Limburg, Genk, Belgium|DEX Innovation Centre, Praha, Czechia|Consorci Sanitaria de Terrassa, Terrassa, Barcelona, Spain|Servicio Andaluz Salud, Sevilla, Spain|Blekinge Institute of Technology, Karlskrona, Blekinge, Sweden		https://ClinicalTrials.gov/show/NCT03325699
1112	NCT00094939	Predictors of Cognitive Decline in Normal Aging		Unknown status	No Results Available	Alzheimer Disease|Dementia			National Institute on Aging (NIA)	All	60 Years to 80 Years   (Adult, Older Adult)		170	NIH	Observational	Time Perspective: Prospective	IA0056|R01AG012101	September 2003		August 2008	October 29, 2004		December 14, 2009	Center for Brain Health, Silberstein Institute, New York University School of Medicine, New York City, New York, United States		https://ClinicalTrials.gov/show/NCT00094939
1113	NCT03919162	A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD	VIVA-MIND	Recruiting	No Results Available	Alzheimer Disease	Drug: PQ912|Other: Placebo	2A Primary safety: proportion of participants who experience any adverse event of interest (AE-I).|2A Primary PK: derived mean values of varoglutamstat levels and corresponding calculated target occupancy (TO)|2A Primary efficacy: The within-participant change from baseline to week 24 in the composite sum of standardized scores from the ADNI Battery Composite (ABC, 9-item) compared between active arm and placebo.|2A Primary efficacy:The within-participant change from baseline to week 24 in quantitative EEG (global relative theta wave power)|2B Primary efficacy: The within-participant change from baseline to week 72 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score, compared between active arm and placebo.|Key secondary efficacy: CFC2, a cognitive-functional composite	Vivoryon Therapeutics N.V.|Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)	All	50 Years to 89 Years   (Adult, Older Adult)	Phase 2	414	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	PBD-01187|1R01AG061146-01	November 15, 2021	May 31, 2023	May 31, 2023	April 18, 2019		June 3, 2022	Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, California, United States|UCSD Alzheimer's Disease Research Center, La Jolla, California, United States|USF Health Byrd Alzheimer's Center and Research Institute, Tampa, Florida, United States|The University of Iowa Carver College of Medicine, Iowa City, Iowa, United States|The University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, United States|Northern Light Acadia Hospital, Bangor, Maine, United States|Upstate Medical University, Syracuse, New York, United States|Ohio State University, Columbus, Ohio, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT03919162
1114	NCT03748303	Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study	Allo-IM	Active, not recruiting	No Results Available	Alzheimer Dementia	Drug: Allopregnanolone	Safety - Adverse events|Safety - clinical laboratory measures|Safety - clinical assessment|Pharmacokinetic parameter - Cmax|Pharmacokinetic parameter - AUC|Pharmacokinetic parameter - Tmax|Pharmacokinetic parameter - Clearance|Pharmacokinetic parameter - Volume of distribution|Satisfaction and feasibility of home nurse survey	University of Arizona|University of Southern California|Alzheimer's Association	All	55 Years and older   (Adult, Older Adult)	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AlloPhase1-IM	October 1, 2019	December 1, 2022	June 2023	November 20, 2018		May 25, 2022	University of Southern California - Alzheimer Disease Research Center - Healthcare Consultation Center II, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03748303
1115	NCT04162990	Lifestyle Remodeling in Subjective Memory Complaint (SMC): Brain Imaging and Blood Biochemistry Study		Unknown status	No Results Available	Subjective Memory Complaint	Behavioral: Lifestyle remodeling Intervention|Behavioral: Does Comparator: regular treatment	Changes in Electroencephalogram (EEG) performance.|Concentration change from baseline in the blood biochemical indices. (Total Tau, Aβ1-40, Aβ1-42, IL-1b, TNF-a, IL-6, TGF-b, BDNF, insulin, and ApoE4)|Change score of the Chinese version Verbal Learning Test (CVVLT).|Change score of the WMS-III logical memory test part A.|Change score of the Taylor Complex Figure Test (TCFT).|Change score of the Digit Span Backward Test.|Subjective memory complaint survey.|Change scores of EuroQol-5 Dimension (EQ-5D).|Lifestyle activities survey.|Physiological parameter (Blood pressure and blood glucose) survey.|Change score of the Cognitive Abilities Screening Instrument (CASI).|Change score of the Boston Naming Test (BNT).|Change score of the category Verbal Fluency Test (VFT).|Performance changes of the Trail Making Test Form A/B (TMT-A/B).	Taipei Veterans General Hospital, Taiwan	All	50 Years and older   (Adult, Older Adult)	Not Applicable	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2019-06-002A	November 2019	July 2022	July 2022	November 14, 2019		November 14, 2019	Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan		https://ClinicalTrials.gov/show/NCT04162990
1116	NCT00329706	Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)		Completed	No Results Available	Dementia	Procedure: FDG-PET brain scan	change from baseline in neuropsychological (cognitive,functional) test results|utilization of healthcare resources|PET results, compared with working diagnoses made before and after time of PET|rates of prescription of AD-specific therapies	University of California, Los Angeles|Centers for Medicare and Medicaid Services	All	65 Years and older   (Older Adult)	Not Applicable	710	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic	02-10-079, 03-04-026	June 2006	January 2017	January 2017	May 25, 2006		May 2, 2017	Mayo Clinic, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Santa Monica-UCLA Medical Center, Santa Monica, California, United States|Gene E. Myers Cardiac and Vascular Consultants, Sarasota, Florida, United States|Lahey Clinic Hospital, Burlington, Massachusetts, United States|University of Buffalo, Buffalo, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT00329706
1117	NCT04579120	Neuroimaging in Healthy Aging and Senile Dementia (HASD IND)	HASD PIB IND	Recruiting	No Results Available	Alzheimer Disease	Drug: [11C]-Pittsburgh Compound B ([11C]PiB)|Drug: F 18 AV-1451 (Flortaucipir)	AD Biomarkers seen on Amyloid PET at Baseline and Years 1, 2, and/or 3|AD Biomarkers seen on Tau PET at Baseline and Years 1, 2, and/or 3|AD Biomarkers seen on MRI at Baseline and Years 1, 2, and/or 3|Compare and Correlate Predictive Ability of Biomarkers Seen with Different Imaging Variables for Onset of Symptoms|Compare and Correlate Predictive Ability of Biomarkers Seen with Other Types of Variables for Onset of Symptoms|Disparities for molecular biomarkers of AD in non-Hispanic white (NHW) and African American (AA) older adults	Tammie L. S. Benzinger, MD, PhD|Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)		650	Other	Observational	Observational Model: Other|Time Perspective: Prospective	201906009	September 1, 2021	November 2025	December 2025	October 8, 2020		April 7, 2022	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04579120
1118	NCT02414282	F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)	Protocol E	Completed	No Results Available	Alzheimer Disease|Progressive Posterior Cortical Dysfunction (PPCD)	Drug: F 18 T807	F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.	Tammie L. S. Benzinger, MD, PhD|Washington University School of Medicine	All	45 Years and older   (Adult, Older Adult)		20	Other	Observational	Observational Model: Other|Time Perspective: Prospective	IND 123119 Protocol E	March 2015	October 20, 2020	October 20, 2020	April 10, 2015		January 19, 2021	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT02414282
1119	NCT03816228	Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.	Protocol Z	Recruiting	No Results Available	Alzheimer Disease	Drug: F 18 T807 Flortaucipir	F 18 T807 Standard Uptake Value Ratios	Tammie L. S. Benzinger, MD, PhD|Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)		80	Other	Observational	Observational Model: Other|Time Perspective: Prospective	IND 123119 Protocol Z	September 1, 2022	January 2025	June 2025	January 25, 2019		April 15, 2022	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03816228
1120	NCT00000174	Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)		Completed	No Results Available	Alzheimer Disease|Cognition Disorders	Drug: Rivastigmine		Novartis|National Institute on Aging (NIA)	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 3		Industry	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Treatment	IA0012				November 1, 1999		June 24, 2005	Medici Research Centers, Peoria, Arizona, United States|University of California, Irvine, Orange, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Neuromedical Research Institute (Offices in Ft. Lauderdale, Miami Beach and Boca Raton), Ft. Lauderdale, Florida, United States|Miami Research Associates, Miami, Florida, United States|Center for Clinical Trials and Research, Venice, Florida, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|St. Louis University, St. Louis, Missouri, United States|Alzheimer's Research Corporation, Lakewood, New Jersey, United States|NYU Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Pahl Brain Associates, P.C., Oklahoma City, Oklahoma, United States|Clinical Studies, Ltd., Philadelphia, Philadelphia, Pennsylvania, United States|St. Paul Medical Center, Dallas, Texas, United States|University of Washington, Seattle, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00000174
1121	NCT00094913	PET Changes in Alzheimer's Disease (AD)		Unknown status	No Results Available	Alzheimer Disease			National Institute on Aging (NIA)	All	20 Years to 90 Years   (Adult, Older Adult)		105	NIH	Observational	Time Perspective: Prospective	IA0055|R01AG013616	May 2004		April 2005	October 29, 2004		May 27, 2009	Center for Brain Health, Silberstein Institute, New York University, New York City, New York, United States		https://ClinicalTrials.gov/show/NCT00094913
1122	NCT00921050	Subclinical Hypothyroidism and Mind in the Elderly		Completed	No Results Available	Subclinical Hypothyroidism	Drug: levothyroxine sodium|Drug: excipient without levothyroxine (placebo)	Change in cognitive ability measured by NEUROPSI increase of 10 points|ejection fraction, left ventricular diastolic capacity|Lipid profile and body composition by DEXA|clinical assessment v.g. significant changes in cardiac frequency and rhythm (if needed able to take EKG to confirm)|Free tiroxina and TSH (assessed by investigator other than treatment physician)|Changes in EKG	Universidad Autonoma de Nuevo Leon	All	60 Years to 95 Years   (Adult, Older Adult)	Phase 2|Phase 3	70	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	EN_LC_P136	June 2009	March 2012	March 2012	June 16, 2009		June 28, 2012	Endocrinology, Outpatient Hospital Clinic, Monterrey, Nuevo Leon, Mexico|Community Health Center (Fomerrey 19), Monterrey, Nuevo Leon, Mexico		https://ClinicalTrials.gov/show/NCT00921050
1123	NCT05315453	Brief Telehealth Cognitive Rehabilitation Following Mild TBI	On-TRACC	Recruiting	No Results Available	Mild Traumatic Brain Injury|Cognitive Impairment	Behavioral: Brief Cognitive Rehabilitation	Feasibility of administering the On-TRACC intervention to individuals with mTBI|Participant satisfaction with On-TRACC intervention|Preliminary effectiveness of On-TRACC intervention in decreasing post-concussive symptoms|Preliminary effectiveness of On-TRACC intervention at decreasing self-reported cognitive difficulties|Preliminary effectiveness of On-TRACC intervention at improving self-efficacy	University of Washington|VA Puget Sound Health Care System	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|U.S. Fed	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00013494	December 13, 2021	December 2022	December 2022	April 7, 2022		April 7, 2022	VA Puget Sound Health Care System, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT05315453
1124	NCT00106899	ADNI: Alzheimer's Disease Neuroimaging Initiative		Completed	No Results Available	Alzheimer's Disease	Procedure: Magnetic Resonance Imaging (MRI)|Procedure: Positron Emission Tomography (PET)|Procedure: Lumbar Puncture (LP)		Alzheimer's Disease Cooperative Study (ADCS)|Northern California Institute of Research and Education|National Institute on Aging (NIA)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Foundation for the National Institutes of Health|Alzheimer's Drug Discovery Foundation|Alzheimer's Association	All	55 Years to 90 Years   (Adult, Older Adult)		818	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	IA0068|1RC2AG036535|1U01AG024904	July 2005	June 2011	June 2011	April 1, 2005		September 16, 2014	University of Alabama, Birmingham, Alabama, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Sun Health / Arizona Consortium, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, Irvine - Brain Imaging Center, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami, Florida, United States|Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Neurological Group, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center/Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Schools of Medicine and Public Health, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Dent Neurological Institute, Orchard Park, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Neurological Care of CNY, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Vancouver, British Columbia, Canada|Parkwood Hospital, London, Ontario, Canada|Saint Joseph's Hospital, London, Ontario, Canada|Sunnybrook and Women's College, Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada|Jewish Hospital Memory Clinic, Quebec, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00106899
1125	NCT03237676	The Effect of Cognitive Rehabilitation Therapy in Improving Cognitive Function of Attention Following Mild Traumatic Brain Injury		Completed	No Results Available	Mild Traumatic Brain Injury|Cognitive Impairment	Other: Structured cognitive rehabilitation therapy|Other: Patient-centred cognitive therapy	Change in Neuropsychological Assessment Battery- Screening score|Change in Diffusion Tensor Imaging parameters|Change in Goal Attainment Scaling score	University of Malaya	All	18 Years to 60 Years   (Adult)	Not Applicable	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PO037-2015A	August 1, 2017	April 30, 2019	December 31, 2019	August 2, 2017		November 6, 2020	University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia		https://ClinicalTrials.gov/show/NCT03237676
1126	NCT04440969	Evaluation of Pilot Community-based Multi-domain Program Older Adults at Risk of Cognitive Impairment		Completed	No Results Available	Cognitive Decline|Cognitive Impairment, Mild	Behavioral: Multi-domain intervention	Change from baseline in cognition at Week 12 and Week 48|Change from baseline in quality of life at Week 12 and Week 48|Change from baseline in aerobic strength at Week 12 and Week 48|Change from baseline in leg strength at Week 12 and Week 48|Change from baseline in arm strength at Week 12 and Week 48	Geriatric Education and Research Institute|Ministry of Health, Singapore|Neeuro Pte Ltd|ProAge Pte Ltd|KKT Technology Pte Ltd (Holmusk)	All	55 Years and older   (Adult, Older Adult)	Not Applicable	199	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	GERI1613|MOH/NIC/COG02/2017	June 20, 2018	March 4, 2020	March 4, 2020	June 22, 2020		June 22, 2020	Geriatric Education And Research Institute, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT04440969
1127	NCT03230253	Effects and Mechanism of Two Hybrid Exercise-cognitive Trainings in Mild Ischemic Stroke With Cognitive Decline		Completed	No Results Available	Stroke Patients With Cognitive Decline	Behavioral: Sequential training|Behavioral: Dual training|Behavioral: Control training	fMRI (change is being assessed)|Serum BDNF level|Antioxidative marker|Glucose indicator|Plasma lipid level|Montreal Cognitive Assessment (MoCA)|Wechsler Memory Scale - Third Edition (WMS-III)|Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)|Useful Field of View (UFOV)|Stroop Color-Word test|Dual-task test|Time up and go test (TUG)|Six-minute walk test (6MWT)|International Physical Activity Questionnaires (IPAQ)|Fugl-Meyer Assessment (FMA)|Rivermead Mobility Index (RMI)|Muscle strength|Mobility level|Functional Independence Measure (FIM)|Lawton Instrumental Activities of Daily Living Scale (Lawton LADL)|Stroke Impact Scale (SIS)|Caregiver Burden Scale (CB scale)|EuroQol-5D questionnaire (EQ-5D)	Chang Gung Memorial Hospital	All	20 Years to 80 Years   (Adult, Older Adult)	Not Applicable	44	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	KMUHIRB-F(II)-20170040	April 19, 2018	July 3, 2020	July 31, 2020	July 26, 2017		October 26, 2020	Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT03230253
1128	NCT03860857	MRI and PET Biomarkers for Cognitive Decline in Older Adults		Recruiting	No Results Available	Alzheimer Disease|Cognitive Impairment|Cognitive Decline	Radiation: Amyloid PET scan|Drug: Tau PET scan using MK-6240|Behavioral: Neurocognitive testing|Other: MRI	Change in Clinical Dementia Rating - Sum of Box Score|Change in lure discrimination index - objects|Change in lure discrimination index - spatial|Change in lure discrimination index - temporal|Change in entorhinal cortical thickness|Change in perforant path integrity|Change in tau spatial distribution - advancing Braak stage	University of California, Irvine|National Institute on Aging (NIA)	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 3	200	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	2017-3832|R01AG053555-02	May 1, 2018	December 22, 2023	December 22, 2024	March 4, 2019		November 4, 2020	University of California, Irvine, Irvine, California, United States		https://ClinicalTrials.gov/show/NCT03860857
1129	NCT04971733	A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease		Active, not recruiting	No Results Available	Alzheimer Disease	Drug: E2814	Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Serious Adverse Events (SAEs)|Number of Participants With Markedly Abnormal Laboratory Values|Number of Participants With Clinically Significant Vital Signs Values|Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings|Change From Baseline in CSF Free and Bound MTBR-tau at 12 Weeks|Change From Baseline in Total MTBR-tau at 12 Weeks|Cmax: Maximum Observed Plasma Concentration for E2814 on Days 1 and 85|Tmax: Time to Reach the Maximum Plasma Concentration for E2814 on Days 1 and 85|AUC(0-672h): Area Under the Plasma Concentration-time Curve From Zero Time to 672 Hours for E2814 on Days 1 and 85|Cmax Serum: Maximum Observed Serum Concentration for E2814 on Days 1 and 85|Tmax Serum: Time to Reach the Maximum Serum Concentration for E2814 on Days 1 and 85|AUC(0-672h) Serum: Area Under the Serum Concentration-time Curve From Zero Time to 672 Hours for E2814 on Days 1 and 85|CSF Concentrations of E2814|Serum anti-E2814 Antibody Concentration|Plasma anti-E2814 Antibody Concentration|Change From Baseline in CSF Concentrations of Total tau (t-tau) and Phosphorylated tau (p-tau)|Change From Baseline in tau Positron Emission Tomography (PET) Signal	Eisai Inc.	All	18 Years to 80 Years   (Adult, Older Adult)	Phase 1|Phase 2	8	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E2814-G000-103|2020-005728-12	June 28, 2021	September 13, 2024	September 13, 2024	July 21, 2021		May 25, 2022	UC San Diego Altman Clinical and Translational Research Insititute Clinic, La Jolla, California, United States|Indiana University School of Medicine, Health Partners, Adult Neurology Clinic, Indianapolis, Indiana, United States|National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT04971733
1130	NCT04958512	Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill		Completed	No Results Available	Cerebrovascular Diseases	Drug: Yangxue Qingnao pill|Drug: Hydergotoxine mesylate tablets|Other: blank control group	Montreal Cognitive Assessment Scale (MoCA)	Peking University Third Hospital|Beijing Hospital	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	M2017154	August 30, 2017	January 31, 2018	March 31, 2018	July 12, 2021		July 12, 2021	Peking University Third Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT04958512
1131	NCT05463731	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)		Recruiting	No Results Available	Alzheimer's Disease	Drug: Remternetug (IV)|Drug: Remternetug (SC)|Drug: Placebo	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo|Mean Absolute Change from Baseline in Brain Amyloid Plaque on Amyloid PET Scan for Remternetug versus Placebo|Time to Reach Complete Amyloid Plaque Clearance on Remternetug versus Placebo|Pharmacokinetics (PK) Observed Trough Serum Concentration (Cmin) of Remternetug|Number of Participants with Treatment Emergent Anti-Drug Antibodies (TE-ADAs)	Eli Lilly and Company	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 3	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	18467|J1G-MC-LAKC	August 1, 2022	August 5, 2024	November 15, 2025	July 19, 2022		September 6, 2022	MD First Research - Chandler, Chandler, Arizona, United States|Hope Clinical Research, Inc., Canoga Park, California, United States|North County Neurology Associates, Carlsbad, California, United States|Wr- Pri, Llc, Encino, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Irvine Clinical Research, Irvine, California, United States|Kaizen Brain Center, La Jolla, California, United States|Anderson Clinical Research, Redlands, California, United States|Mountain Neurological Research Center, Basalt, Colorado, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Ki Health Partners, LLc, dba New England Institute for Clinical Research, Stamford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|VIN-Julie Schwartzbard, Aventura, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Finlay Medical Research, Greenacres City, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Charter Research - Lady Lake, Lady Lake, Florida, United States|ClinCloud - Maitland, Maitland, Florida, United States|K2 Medical Research, Maitland, Florida, United States|ClinCloud - Viera, Melbourne, Florida, United States|Merritt Island Medical Research, LLC, Merritt Island, Florida, United States|Optimus U Corporation, Miami, Florida, United States|VIN-Andrew Lerman, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Emerald Coast Neurology - Airport Boulevard, Pensacola, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Alzheimer's Research and Treatment Center, Stuart, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Tallahassee Neurological Clinic, Tallahassee, Florida, United States|Alzheimer's Research and Treatment Center, Wellington, Florida, United States|Palm Beach Neurology, West Palm Beach, Florida, United States|Conquest Research, Winter Park, Florida, United States|Charter Research - Winter Park, Winter Park, Florida, United States|Columbus Memory Center, PC, Columbus, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Covenant Medical Center, Waterloo, Iowa, United States|Cotton O'Neil Mulvane, Topeka, Kansas, United States|Care Access - Lake Charles, Lake Charles, Louisiana, United States|MedVadis Research Corporation, Waltham, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|Citizens Memorial Hospital District, Bolivar, Missouri, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Neurological Associates Albany, Albany, New York, United States|AMC Research, LLC, Matthews, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|NeuroScience Research Center, Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Summit Headlands, Portland, Oregon, United States|Center for Cognitive Health, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Keystone Clinical Studies, Plymouth Meeting, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|Gadolin Research, Beaumont, Texas, United States|Kerwin Medical Center, Dallas, Texas, United States|Neurology Consultants of Dallas, PA, Dallas, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|The University of Texas Health Science Center at Houston, Sugar Land, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Re:Cognition Health, Fairfax, Virginia, United States|National Clinical Research, Inc, Richmond, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Universal Research Group, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT05463731
1132	NCT05371639	Efficacy and Safety of Tian Ma Bian Chun Zhi Gan Tablets in Mild to Moderate Vascular Dementia		Not yet recruiting	No Results Available	Vascular Dementia|Cognitive Impairment	Drug: Tian Ma Bian Chun Zhi Gan Tablets|Drug: Placebo	Vascular Dementia Assessment Scale-cognitive subscale(VADAS-Cog)|Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Mini-Mental State Examination (MMSE)|Clock drawing test (CDT)|Activities of daily living (ADL)|Delayed story recall (DSR)	Dongzhimen Hospital, Beijing	All	55 Years to 80 Years   (Adult, Older Adult)	Phase 2	360	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	YHNK-XY-2-2021-01	June 2022	December 2024	June 2025	May 12, 2022		May 12, 2022			https://ClinicalTrials.gov/show/NCT05371639
1133	NCT05063539	A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease		Recruiting	No Results Available	Alzheimer Disease	Drug: LY3372689|Drug: Placebo	Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)|Change from Baseline to End Time Point in iADRS|Change From Baseline to End Time Point in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Change from Baseline to End Time Point in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)|Change from Baseline to End Time Point in Alzheimer's Disease Cooperative Study Instrumental Activities of Daily Living Inventory (ADCS-iADL)|Change from Baseline to End Time Point in Mini Mental State Examination (MMSE)|Change from Baseline to End Time Point in Brain Tau Deposition as Measured by Flortaucipir F18 PET scan|Change from Baseline to End Time Point in Volumetric Magnetic Resonance Imaging (vMRI) Measures|Pharmacokinetics (PK) Plasma Concentration of LY3372689	Eli Lilly and Company	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 2	330	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	18094|I9X-MC-MTAE|2021-000170-29	September 16, 2021	May 16, 2024	June 13, 2024	October 1, 2021		September 6, 2022	Hope Clinical Research, Inc., Canoga Park, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|VIN-Julie Schwartzbard, Aventura, Florida, United States|Neurology Offices of South Florida, Boca Raton, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Charter Research, Lady Lake, Florida, United States|K2 Medical Research, Maitland, Florida, United States|ClinCloud - Viera, Melbourne, Florida, United States|Merritt Island Medical Research, LLC, Merritt Island, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|VIN-Victor Faradji, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|VIN- Margarita Almeida El-Ramey, Pembroke Pines, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S. Marks M.D., P.C., Plymouth, Massachusetts, United States|MedVadis Research Corporation, Waltham, Massachusetts, United States|Adams Clinical, Watertown, Massachusetts, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|University at Buffalo - UBMD Neurology, Buffalo, New York, United States|NYU Langone Health, New York, New York, United States|Abington Neurological Associates, Ltd., Abington, Pennsylvania, United States|Keystone Clinical Studies, Plymouth Meeting, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Kerwin Medical Center, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|HammondCare, Sydney, New South Wales, Australia|Hornsby Ku-Ring-Gai Hospital, Sydney, New South Wales, Australia|KARA Institute for Neurological Diseases, Sydney, New South Wales, Australia|Central Coast Neurosciences Research (Tumbi Umbi), Tumbi Umbi, New South Wales, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Private Practice - Dr PL Morris, Southport, Queensland, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Box Hill Hospital Outpatients, Box Hill, Victoria, Australia|Delmont Consulting Suites, Glen Iris, Victoria, Australia|HammondCare, Malvern, Victoria, Australia|NeuroCentrix, Noble Park, Victoria, Australia|Bruyère Research Institute, Ottawa, Ontario, Canada|Ottawa Memory Clinic, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Clinique de la Mémoire de l'Outaouais, Gatineau, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|National Center for Geriatrics and Gerontology, Obu City, Aichi, Japan|Himeji Central Hospital Clinic, Himeji, Hyogo, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Memory Clinic Toride, Toride, Ibaraki, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Nozomi Memory Clinic, Mitaka-shi, Tokyo, Japan|Kikukawa Clinic, Nerima, Tokyo, Japan|Memory Clinic Ochanomizu, Tokyo, Japan|Oita University Hospital, Yufu, Japan|Wroclawskie Centrum Alzheimerowskie, Wroclaw, Dolnośląskie, Poland|Centrum Medyczne NEUROMED, Bydgoszcz, Kujawsko-pomorskie, Poland|Centrum Medyczne NeuroProtect, Warszawa, Mazowieckie, Poland|Diamond Clinic, Krakow, Małopolskie, Poland|Centrum Badan Klinicznych PI-House sp. z o.o., Gdansk, Pomorskie, Poland|Centrum Medyczne SENIOR, Sopot, Pomorskie, Poland|Nzoz Neuro-Kard Ilkowski i Partnerzy SPL, Poznan, Wielkopolskie, Poland|Centrum Medyczne Euromedis, Szczecin, Zachodniopomorskie, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Poland		https://ClinicalTrials.gov/show/NCT05063539
1134	NCT05059158	Amyloid-β Clearance Mechanisms in Alzheimer's Disease	AmyClearAD	Recruiting	No Results Available	Alzheimer's Disease (AD)	Radiation: positron emission tomography (PET)	Differences in the disruption of the brain-blood-barrier between the subgroups|Clearance mechanisms and glymphatic or cerebral lymphatic system|Connection between the structural/functional connectivity of the resting networks and the clearance mechanisms|Differences between sleep and activity in SCD, MCI and AD; Do they have a mediator role in association of the BBB disruption and Aß pathology?|Connection between clinical symptoms, Aß pathology and BBB disorder	Ludwig-Maximilians - University of Munich	All	50 Years to 85 Years   (Adult, Older Adult)		60	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	18-606|1081	June 1, 2021	June 2023	June 2023	September 28, 2021		September 28, 2021	Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums, München, Bayern, Germany		https://ClinicalTrials.gov/show/NCT05059158
1135	NCT04939961	Effects of Hericium Erinaceus on Microbiota and Cognition	HE	Active, not recruiting	No Results Available	Cognitive Decline, Mild	Dietary Supplement: Hericium erinaceus|Dietary Supplement: Placebo	Assessment of the microbial community composition in feces samples using next-generation sequencing|cognitive function|brain derived neurotrophic factor|neuropeptide Y	University of Primorska	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	Hericium erinaceus	June 18, 2021	September 20, 2021	December 20, 2022	June 25, 2021		March 2, 2022	University of Primorska, Faculty of Health Sciences, Izola, Slovenia		https://ClinicalTrials.gov/show/NCT04939961
1136	NCT00438347	Influence of Fitness on Brain and Cognition		Completed	No Results Available	Aging|Cognitive Ability, General	Behavioral: Aerobic Exercise|Behavioral: Stretching and toning	Behavioral measures|fMRI	University of Illinois at Urbana-Champaign|National Institute on Aging (NIA)	All	60 Years to 75 Years   (Adult, Older Adult)		179	Other|NIH	Observational	Time Perspective: Prospective	IA0102|5R37AG025667-02	April 2006	May 2012	May 2012	February 22, 2007		November 8, 2016	Beckman Institute, University of Illinois, Champaign, Illinois, United States|University of Illinois, Urbana, Illinois, United States		https://ClinicalTrials.gov/show/NCT00438347
1137	NCT01439555	Endothelial Facilitation in Alzheimer's Disease		Completed	Has Results	Alzheimer's Disease	Drug: Simvastatin|Drug: L-Arginine|Drug: Tetrahydrobiopterin	Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI)|Change in Cerebral Blood Flow as Measured by Arterial Spin Labeling During Magnetic Resonance Imaging (MRI)|Mini Mental State Examination (MMSE) Scores|Cognitive Assessment Screening Test (CAST)|Clinical Dementia Rating Scale (CDR)|Alzheimer's Disease Assessment Scale: Cognitive and Modified Version (ADAS-COG)|Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus)	University of Massachusetts, Worcester|The Glass Foundation	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13748	November 2011	November 2017	November 2017	September 23, 2011	July 30, 2019	July 30, 2019	UMass Medical School/ UMass Memorial Medical Center, Worcester, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01439555/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01439555
1138	NCT04727450	Effects of Multimodal Training of Combined Cognitive and/or Physical Training on Cognition and Fitness of Older Adults	MTCCP	Not yet recruiting	No Results Available	Cognitive Decline|Cognitive Impairment, Mild	Behavioral: Cognitive training|Behavioral: physical training|Behavioral: Combination of cognitive and physical training (CCPT)-BIGMAP	Cognitive Tests: for executive function (pre-test)|Cognitive Tests: for executive function (2nd test)|Cognitive Tests: for executive function (3rd test)|Cognitive Tests: for executive function (4th test)|Cognitive Tests: for attention (pre-test)|Cognitive Tests: for attention (2nd test)|Cognitive Tests: for attention (3rd test)|Cognitive Tests: for attention (4th test)|Cognitive Tests: for everyday memory (pre-test)|Cognitive Tests: for everyday memory (2nd test)|Cognitive Tests: for everyday memory (3rd test)|Cognitive Tests: for everyday memory (4th test)|Fitness Tests: BMI (pre-test)|Fitness Tests: BMI (2nd test)|Fitness Tests: BMI (3rd test)|Fitness Tests: BMI (4th test)|Fitness Tests: Senior physical fitness test battery (pre-test)|Fitness Tests: Senior physical fitness test battery (2nd test)|Fitness Tests: Senior physical fitness test battery (3rd test)|Fitness Tests: Senior physical fitness test battery (4th test)|Four square step test for dynamic balance (pre-test)|Four square step test for dynamic balance (2nd test)|Four square step test for dynamic balance (3rd test)|Four square step test for dynamic balance (4th test)	Hong Kong Baptist University|Jacobs University Bremen gGmbH|The Hong Kong Polytechnic University	All	60 Years and older   (Adult, Older Adult)	Not Applicable	228	Other	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	12607620	April 1, 2021	December 31, 2022	March 31, 2023	January 27, 2021		January 27, 2021	Hong Kong Baptist University, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT04727450
1139	NCT02286791	Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial	MAPRCT	Completed	No Results Available	Dementia	Behavioral: Mindful Awareness Program|Behavioral: Health Education Program	Change from baseline Mini-Mental State Examination (MMSE) at 3 months and 9 months|Change from baseline Clinical Dementia Rating (CDR ) at 3 months and 9 months|Change from baseline Rey Auditory Verbal Learning Test (RAVLT) at 3 months and 9 months|Change from baseline Digit Span Task at 3 months and 9 months|Change from baseline Colour Trails Tests (CTT) at 3 months and 9 months|Change from baseline Block Design at 3 months and 9 months|Change from baseline Semantic Verbal Fluency (Animals) at 3 months and 9 months|Change from baseline fMRI scan at 3 months|Change from baseline Biomarkers: blood sample at 3 months and 9 months|Change from baseline Biomarkers: urine sample at 9 months|Change from baseline Biomarker - fecal sample at 3 months and 9 months|Change from baseline Biomarker - saliva sample at 3 months and 9 months|Change from baseline Basic Health Screen at 3 months and 9 months|Change from baseline Activities of daily Living (ADL) at 3 months and 9 months|Change from baseline Instrumental Activities of Daily Living (IADL) at 3 months and 9 months|Change from baseline Geriatric Depression Scale (GDS) at 3 months and 9 months|Change from baseline Geriatric Anxiety Inventory (GAI) at 3 months and 9 months	National University, Singapore	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	55	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	B-14-110	September 2014	June 2015	June 2015	November 10, 2014		August 18, 2015	Training and Research Academy, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02286791
1140	NCT02707978	F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)		Withdrawn	No Results Available	Alzheimer Disease	Drug: F 18 T807	F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.	Tammie L. S. Benzinger, MD, PhD|Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IND 123119 Protocol C	September 30, 2017	September 2020	December 2020	March 14, 2016		July 10, 2020	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT02707978
1141	NCT02414178	F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)	AV ADAD	Recruiting	No Results Available	Alzheimer Disease	Drug: F 18 T807	F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.	Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)		130	Other	Observational	Observational Model: Other|Time Perspective: Prospective	IND 123119 Protocol D	March 1, 2021	March 2024	September 2024	April 10, 2015		July 1, 2021	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT02414178
1142	NCT03016741	Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer		Recruiting	No Results Available	Castration-Resistant Prostatic Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer|Hormone-Refractory Prostate Cancer	Biological: GnRH agonist/antagonist|Drug: Prednisone|Drug: Abiraterone Acetate|Drug: Enzalutamide	Cognitive function defined by overall Cogstate score and Cogstate module scores for each domain|Quality of life assessed using European Organization for Research and Treatment of Cancer quality of life questionnaire-C30 (EORTC QLQ C-30)|Fatigue assessed using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT- Fatigue)|Subjective measure of cognitive function by FACT-Cog|Depression by Patient Health Questionnaire (PHQ-9)|Instrumental activities of daily living by Texas Functional Living Scale	Northwestern University	Male	18 Years and older   (Adult, Older Adult)	Phase 4	100	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	NU 17U19|STU00206082|NCI-2016-01795	March 31, 2017	August 2022	August 2023	January 11, 2017		May 3, 2021	City of Hope Comprehensive Cancer Center, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03016741
1143	NCT03514524	Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.		Unknown status	No Results Available	Neuro-Degenerative Disease	Other: PET-MR imaging	changes in synaptic density with age or due to TBI, stroke or MCI/MBI|changes in tau-depositions with age or due to TBI, stroke or MCI/MBI|Monitoring capacities of these novel functional/structural imaging techniques|Relationship between synaptic density and tau deposition and cognitive/behavioral decline in normal ageing and in TBI, stroke and MCI/MBI.	Universitaire Ziekenhuizen Leuven	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	S60721	February 1, 2018	February 2019	September 2020	May 2, 2018		May 11, 2018	Division of nuclear medicine and molecular imaging, University Hospital Leuven, Leuven, Belgium		https://ClinicalTrials.gov/show/NCT03514524
1144	NCT02293915	An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease		Completed	No Results Available	Mild to Moderate Alzheimer Disease|Cognitive Impairment	Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo	Improvement of Alzheimer's Disease Assessment Scale-cognitive subscale(ADAS-cog)/12 of sodium oligo-mannurarate capsule|Improvement of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) of sodium oligo-mannurarate capsule|Improvement of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) of sodium oligo-mannurarate capsule|Improvement of Neuropsychiatric Inventory(NPI) of sodium oligo-mannurarate capsule|Glucose metabolism of bilateral temporoparietal cortex	Shanghai Greenvalley Pharmaceutical Co., Ltd.	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	818	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	971-III	April 1, 2014	June 29, 2018	September 28, 2018	November 19, 2014		October 10, 2018	Beijing, Beijing, Beijing, China|Chongqing, Chongqing, Chongqing, China|Fujian, Fuzhou, Fujian, China|Guangzhou, Guangzhou, Guangdong, China|Wuhan, Wuhan, Hubei, China|Changsha, Changsha, Hunan, China|Nanjing, Nanjing, Jiangsu, China|Suzhou, Suzhou, Jiangsu, China|Yangzhou, Yangzhou, Jiangsu, China|Jinan, Jinan, Shandong, China|Shanghai, Shanghai, Shanghai, China|Xi'an, Xi'an, Shanxi, China|Sichuan, Chengdu, Sichuan, China|Tianjin, Tianjin, Tianjin, China|Hangzhou, Hangzhou, Zhejiang, China|Wenzhou, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT02293915
1145	NCT03475446	The Effect of tES on a Cognitive Training		Completed	No Results Available	Memory Impairment	Device: real anodal tDCS healthy elderly|Device: real tACS healthy elderly|Device: sham tES healthy elderly|Device: real anodal tDCS MCI|Device: real tACS MCI|Device: sham tES MCI|Device: real anodal tDCS AD|Device: real tACS AD|Device: sham tES AD	Memory|Mood|QOL|AODL	University of Bern	All	60 Years to 85 Years   (Adult, Older Adult)	Not Applicable	65	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science	2017-02056	January 15, 2018	December 31, 2019	December 31, 2019	March 23, 2018		January 18, 2020	Klinik für Alterspsychiatrie und Psychotherapie UPD Bern, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT03475446
1146	NCT04808674	Remediation for Mild Cognitive Deficits After Cancer	EURECA	Not yet recruiting	No Results Available	Cognitive Remediation|Breast Cancer	Behavioral: Cognitive remediation program	Self-reported cognitive function|Neuropsychological function|Psychological distress|Quality of Life with FACT-B questionnaire|Fatigue	Hospices Civils de Lyon	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	69HCL20_1018|2021-A00798-33	May 16, 2021	July 20, 2021	September 16, 2024	March 22, 2021		March 22, 2021	Hospices Civils de Lyon - Groupement hospitalier sud - Hôpital Henry Gabrielle - Service de médecine physique et de réadaptation, Lyon, France|Hôpital Pontchaillou - Service de Médecine Physique et de Réadaptation, Rennes, France		https://ClinicalTrials.gov/show/NCT04808674
1147	NCT03170492	Does Computerized Cognitive Training Improve Executive Functioning in the Older Adult?	CCT	Unknown status	No Results Available	Cognitive Impairment, Mild|Executive Dysfunction	Other: RehaCom Computerized Cognitive Training for 480 minutes|Other: Pencil-and-Paper Cognitive Training for 480 minutes	Montreal Cognitive Assessment|Delis-Kaplan Executive Functioning System (Letter Fluency)|Trail Making Test Part A|Trail Making Test Part B|Executive Function Performance Test	University of the Sciences in Philadelphia|GenesisCAREs	All	55 Years and older   (Adult, Older Adult)	Not Applicable	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	947324	January 30, 2017	November 3, 2017	July 31, 2018	May 31, 2017		November 6, 2017	Mercy LIFE- West Philadelphia, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03170492
1148	NCT03025373	Virtual Reality Stimulation to Enhance Cognitive Function of Intensive Care Unit Patients		Completed	No Results Available	Cognitive Impairment, Mild|Quality of Life	Other: Visuo-acoustic stimulation	Attention measurement in patients in the intensive care unit|Quality of Life|Cognitive functioning	University Hospital Inselspital, Berne|University of Bern	All	18 Years and older   (Adult, Older Adult)		67	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	2016-01652	February 1, 2017	November 30, 2018	April 1, 2019	January 19, 2017		May 3, 2019	Universitätsklinik für Intensivmedizin, Inselspital, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT03025373
1149	NCT00321971	Prevention of Depression in Spouses of People With Cognitive Impairment		Completed	Has Results	Depression	Behavioral: PST-MCI/AD Caregiving|Behavioral: NT-MCI/AD Caregiving	Depressive Symptoms	University of Pittsburgh|National Institute of Mental Health (NIMH)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	73	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	K23MH070719	February 2007	December 2011	December 2011	May 4, 2006	March 7, 2018	April 3, 2018	University of Pittsburgh Alzheimer's Disease Research Center (ADRC), Pittsburgh, Pennsylvania, United States|Duquesne Univeristy, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00321971
1150	NCT02185222	Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint	D-COG	Completed	No Results Available	Memory Disorders|Age-Related Cognitive Decline	Drug: Cholecalciferol 100 000 UI|Drug: Placebo	Changes from baseline memory functions measured by the score of the total recall test from Free and Cued Selective Recall Reminding Test (Rappel Libre / Rappel Indicé 16 items : RL/RI 16) at one year and at two years|Changes from baseline global efficiency measured by the Mc Nair scale at one year and at two years|Evolution of anaemia evaluated by red blood cells count|Evolution of plasma calcium and albumin concentration|Evolution of urinary calcium and creatinine concentration|All adverse events|Serum level of 25-hydroxy vitamine D (25-OH D) measured to study observance|Changes from baseline global efficiency measured by the Mini Mental State Examination at one year and at two years|Changes from baseline global efficiency measured by the Montreal Cognitive Assessment at one year and at two years|Changes from baseline instrumental activity of daily living measured by 8 items at one year and at two years|Changes from baseline language measured by the "test de denomination orale d'images" (DO-80) at one year and at two years|Memory function measured by a visual test : delayed matching to sample 48 items (DMS-48)|Changes from baseline executive functions measured by the stroop test at one year and at two years|Changes from baseline executive functions measured by the verbal fluency at one year and at two years|Changes from baseline executive functions measured by the Trail Making Test part B at one year and at two years|Changes from baseline attention and speed processing measured by the Trail Making Test part A at one year and at two years|Changes from baseline attention and speed processing measured by the Digit symbol test at one year and at two years|Changes from baseline visuospatial study measured by the Rey figure (copy) at one year and at two years|Changes from baseline praxis at one year and at two years|Changes from baseline depressive symptoms measured by the Montgomery and Asberg Depression Rating Scale at one year and at two years	University Hospital, Tours	All	60 Years and older   (Adult, Older Adult)	Phase 3	68	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	SERC12-TC / D-COG|2013-005110-36	October 23, 2014	October 10, 2018	October 10, 2018	July 9, 2014		November 4, 2020	Chu Angers, Angers, France|CH BLOIS, Blois, France|CHU BREST - Hôpital de la Cavale Blanche, Brest, France|CHI ELBEUF Louviers Val-de-Reuil, Elbeuf, France|CHU NANTES - Hôpital Bellier, Nantes, France|CHU NANTES - Hôpital Laënnec, Nantes, France|Chr Orleans, Orléans, France|CHU POITIERS - Hôpital de la Milétrie, Poitiers, France|CHU RENNES - Hôpital Hôtel Dieu, Rennes, France|CHU ROUEN - Hôpital Charles Nicolle, Rouen, France|CHRU TOURS - Hôpital Bretonneau, Tours, France		https://ClinicalTrials.gov/show/NCT02185222
1151	NCT03092713	Combined Cognitive and Vocational Interventions After Mild-to-moderate TBI: a Randomized Controlled Trial		Completed	No Results Available	Brain Injuries, Traumatic|Cognitive Impairment	Behavioral: Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|Behavioral: Control Group	Return to work|Work stability|Rivermead post-concussion questionnaire|Euro-Qol - 5D (EQ-5D)|Quality of life after brain injury (Qolibri)	Oslo University Hospital|The Research Council of Norway|Sunnaas Rehabilitation Hospital|Oslo Metropolitan University|Norwegian Labour and Welfare Administration	All	18 Years to 60 Years   (Adult)	Not Applicable	121	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	2016/2038	January 2, 2017	December 31, 2020	June 30, 2021	March 28, 2017		October 19, 2021	Oslo University Hospital, Dept. of physical medicine and rehabilitation, Oslo, Norway		https://ClinicalTrials.gov/show/NCT03092713
1152	NCT04593290	Listen Carefully: An Exploratory Study of the Association Between Listening Effort and Cognitive Function		Completed	No Results Available	Cognitive Impairment, Mild|Hearing Loss	Device: Oticon Opn S 1 miniRITE hearing aid	Listening effort|The Stroop Color and Word test|Rey Complex Figure Test|Symbol-Digit Modalities Test|Trail Making Test A and B|Verbal Fluency Test (category and lexical)|Logical Memory Test A|Listening effort post-hearing aid use|Logical Memory Test A post-hearing aid use|Verbal Fluency Test (category and lexical) post-hearing aid use|Trail Making Test A and B - post-hearing aid use	Technical University of Denmark|Danish Dementia Research Centre	All	40 Years to 85 Years   (Adult, Older Adult)	Not Applicable	24	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	19042404	August 8, 2020	December 31, 2021	December 31, 2021	October 19, 2020		April 28, 2022	Copenhagen Memory Clinic, Rigshospitalet, Copenhagen, Region H, Denmark		https://ClinicalTrials.gov/show/NCT04593290
1153	NCT04381468	SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)	SIGNAL-AD	Recruiting	No Results Available	Alzheimer Disease	Drug: Pepinemab|Drug: Placebo	Number of subjects with treatment emergent adverse events (TEAEs)|Effects on brain metabolism|Alzheimer's Disease Assessment Scale- Cognitive subscale (ADAS-cog13)|Clinical Dementia Rating (CDR)|Mini Mental State Examination (MMSE)|Alzheimer's Disease Cooperative Study - Activities of Daily Living|Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (ADCS-CGIC)|Neuropsychiatric Inventory (NPI)|Immunogenicity of pepinemab in serum	Vaccinex Inc.|Alzheimer's Drug Discovery Foundation|Alzheimer's Association	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 1|Phase 2	40	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	VX15/2503-11	July 22, 2021	January 31, 2023	February 28, 2023	May 8, 2020		May 4, 2022	Pacific Research Network, Inc, San Diego, California, United States|Georgetown University, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|JEM Research Institute, Lake Worth, Florida, United States|Brain Matters Research, Stuart, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Memory Clinic, Newton, Massachusetts, United States|Columbia University Irving Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Re-Cognition Health, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT04381468
1154	NCT05372159	Vanderbilt Memory and Aging Project	VMAP	Recruiting	No Results Available	Alzheimer Disease|Aging|Aged, 80 and Over|Biomarkers|Brain|Case-Control Studies|Cognitive Dysfunction|Neuropsychological Tests	Other: none, observational study	White matter hyperintensities Volume|Grey Matter Volume|Cerebral Blood Flow|Lacunar infarcts|Small vessel microbleeds|Left ventricular ejection fraction|Cardiac output|Cardiac stroke volume|Pulse Wave velocity|Cardiac Strain|Biological marker for Alzheimer's disease|Blood based biological marker for Alzheimer's disease|APOE Genotype	Vanderbilt University Medical Center|National Institute on Aging (NIA)|National Institute of Neurological Disorders and Stroke (NINDS)	All	60 Years and older   (Adult, Older Adult)		1000	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	120158|K23AG045966|R01AG034962|F32AG046093|K24AG046373|R01NS100980|R01AG056534|F32AG058395|F31AG066358|IIRG-08-8873	September 17, 2012	December 31, 2026	December 31, 2026	May 12, 2022		May 12, 2022	Vanderbilt University Medical Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT05372159
1155	NCT04305210	Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination	PMPBB3/AV45	Unknown status	No Results Available	Alzheimer's Disease	Drug: F-18 PMPBB3|Drug: 18F-florbetapir	Tau Distribution	Chang Gung Memorial Hospital	All	45 Years to 90 Years   (Adult, Older Adult)	Phase 2	70	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	201802170A0	December 1, 2019	January 23, 2021	January 23, 2021	March 12, 2020		March 12, 2020	Chang Gung Memorial Hospital,Linkou, Taoyuan, Guishan Dist,, Taiwan		https://ClinicalTrials.gov/show/NCT04305210
1156	NCT04496778	Low Level Laser Therapy Impact on Cognitive Function and Quality of Life in Alzheimer Anemic Elderly Patients		Completed	No Results Available	Alzheimer Disease|Cognitive Impairment, Mild	Device: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|Other: aerobic exercise	change of cognitive function|changes of hemoglobin level|changes of balance|changes of quality of life|changes of body mass index|changes of waist hip ratio	Cairo University	All	65 Years to 75 Years   (Older Adult)	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	P.T.REC/012/0027772	January 3, 2020	July 28, 2020	August 1, 2020	August 3, 2020		August 25, 2020	Cairo, Giza, Dokki, Egypt		https://ClinicalTrials.gov/show/NCT04496778
1157	NCT04200911	Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway	(CARPE DIEM)	Active, not recruiting	No Results Available	Cognitive Impairment, Mild|Alzheimer Disease	Drug: Rapamune	Blood brain barrier penetration of RAPA|Adverse events|Target engagement of RAPA treatment in Alzheimer's Disease (AD)|Mini-Mental State Exam (MMSE)|Alzheimer's Disease Assessment Scale (ADAS-Cog) Word list Immediate and Delayed|Electronic Gait Mapping|Grip Strength|Clinical Dementia Rating (CDR)|Benson Figure Copy|Tablet-Based Cognitive Assessment (TabCat)|Global Deterioration Scale|Neuropsychiatric Inventory (NPI)|Functional activities questionnaire (FAQ)|Pittsburgh Sleep Quality Index (PSQI)	The University of Texas Health Science Center at San Antonio	All	55 Years to 85 Years   (Adult, Older Adult)	Early Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HSC20190850H	June 1, 2020	January 13, 2022	January 2023	December 16, 2019		February 4, 2022	UTHSA McDermott Clinical Sciences Building, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT04200911
1158	NCT01993836	Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care	MADCO-PC	Completed	Has Results	Alzheimers Disease|Postoperative Delirium|Post Operative Cognitive Dysfunction	Drug: Total intravenous anesthesia with propofol|Drug: General anesthesia with isoflurane	Correlation Between Perioperative Change in Cerebrospinal Fluid (CSF) Markers of Alzheimers Disease and Perioperative Cognitive Change|Correlation Between Perioperative Change in Ratios of Cerebrospinal Fluid (CSF) Markers of Alzheimers Disease and Perioperative Cognitive Change|Continuous Cognitive Index Score Change Difference Between Anesthetic Agent Groups|Change in CSF Markers of Alzheimers Disease by Anesthetic Agent Group|Change in Ratio of CSF Markers of Alzheimers Disease by Anesthetic Agent Group|Perioperative CSF Tau/Abeta Ratio Change	Duke University	All	60 Years and older   (Adult, Older Adult)	Phase 4	191	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic	Pro00045180	November 2013	January 10, 2019	January 10, 2019	November 25, 2013	May 5, 2020	May 5, 2020	Duke University Medical Center, Durham, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/36/NCT01993836/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01993836
1159	NCT02778581	Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment		Unknown status	No Results Available	Cognitive Impairments|Alzheimer Disease	Dietary Supplement: Lipidic Blend 1|Dietary Supplement: Lipidic Blend 2|Dietary Supplement: Placebo	Changes in Mini-Mental State Examination (MMSE) score|Changes in Global Clinical Dementia Rating (CDR) score|Changes in systemic oxidative parameters in periferic blood samples (Nitric Oxyde)|Changes in systemic oxidative parameters in periferic blood samples (Malondialdehyde (MDA))|Changes in beta-amyloid protein concentration|Changes in TAU-Protein concentration|Changes in regular treatment for the cognitive impairment|Changes in dietetic habits|Changes in Barthel score|Changes in Morisky-Green score|changes in weight|Number of adverse events	Team Foods Colombia S.A.|Biopolis S.L.	All	55 Years to 85 Years   (Adult, Older Adult)	Not Applicable	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	ALZ-OIL.01	March 2016	April 2017	July 2017	May 20, 2016		June 3, 2016	Hospital Universitario Vinalopó, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja,, Alicante, Spain		https://ClinicalTrials.gov/show/NCT02778581
1160	NCT03887455	A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease	Clarity AD	Active, not recruiting	No Results Available	Early Alzheimer's Disease	Drug: Lecanemab|Drug: Placebo	Core Study: Change from Baseline in the CDR-SB at 18 Months|Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Extension Phase: Change from Core Study Baseline in CDR-SB|Core Phase: Change From Baseline in Amyloid Positron Emission Tomography (PET) Using Centiloids at 18 Months|Core Study: Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale 14 (ADAS-cog14) at 18 Months|Core Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at 18 Months|Core Study: Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL) at 18 Months	Eisai Inc.|Biogen	All	50 Years to 90 Years   (Adult, Older Adult)	Phase 3	1906	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BAN2401-G000-301|2018-004739-58	March 27, 2019	September 15, 2025	September 15, 2025	March 25, 2019		July 13, 2022	Banner Alzheimer's Institute- Clinical Trials Department, Phoenix, Arizona, United States|Banner Sun Health Research, Sun City, Arizona, United States|Neurological Associates of Tucson dba Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Irvine Clinical Research, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|UCSF Memory and Aging Center, San Francisco, California, United States|Apex Research Institute, Santa Ana, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|North Bay Neuroscience Research Institute, Sebastopol, California, United States|ImmunoE Research Center, Centennial, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Advanced Clinical Research Network, Coral Gables, Florida, United States|Linfritz Research Institute, Inc., Coral Gables, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest FL, Fort Myers, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Charter Research, Lady Lake, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Clincloud, LLC, Maitland, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Gonzalez MD & Aswad MD Health Services, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|Rios Medical Center, Inc., Miami, Florida, United States|Vitae Research Center, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|Allied Biomedical Research (Clinical Trial), Miami, Florida, United States|Pharmax Research of South Florida, Inc, Miami, Florida, United States|Visionary Investigators Network, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States|Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Quantum Laboratories Inc., Pompano Beach, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Alzheimer's Research and Treatment Center, Stuart, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|USF Suncoast Gerontology Center, Tampa, Florida, United States|Bioclinica Research, The Villages, Florida, United States|Premiere Research Institute, West Palm, West Palm Beach, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|Columbus Memory Center, Columbus, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States|KU Wichita Center for Clinical Research, Wichita, Kansas, United States|Partners Population Health, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Donald S. Marks, MD. P.C., Plymouth, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|New York University Medical Center PRIME, New York, New York, United States|Neurological Institute of New York, New York, New York, United States|University of Rochester, Rochester, New York, United States|ANI Neurology, PLLC d/b/a Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, P.A. - Research Department, Raleigh, North Carolina, United States|PMG Research of Winston Salem, Winston-Salem, North Carolina, United States|OH Clinical Research Partners, Canton, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Columbs Neuroscience, LLC, Columbus, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Summit Research Network (OR) Inc., Portland, Oregon, United States|Neural Net Research, LLC, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Keystone Clinical Studies, LLC, Norristown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital - Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|Coastal Neurology, P.A., Port Royal, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Alliance for Multispecialty Research LLC, New Orleans Center for Clinical Research / Volunteer Research Group, an AMR company, Knoxville, Tennessee, United States|Senior Adult Specialty Research, Austin, Texas, United States|Texas Neurology, PA, Dallas, Texas, United States|Kerwin Research Center, Dallas, Texas, United States|Baylor College of Medicine AD and Memory Disorders Center, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|DBA The Memory Clinic, Bennington, Vermont, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Kingfisher Cooperative LLC, Spokane, Washington, United States|St Vincent's Hospital - Translational Research Centre, Darlinghurst, New South Wales, Australia|KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|The Prince Charles Hospital/Internal Medicine & Dementia Research Unit, Chermside Brisbane, Queensland, Australia|Central Adelaide Local Health Network, The Queen Elizabeth Hospital and the Royal Adelaide Hospital, Woodville South, Adelaid, South Australia, Australia|Austin Health - Medical and Cognitive Research Unit, Ivanhoe, Victoria, Australia|HammondCare Malvern Clinical Trials Unit, Malvern, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Health Research, West Vancouver, British Columbia, Canada|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc., Kentville, Nova Scotia, Canada|St. Joseph's HC- Parkwood Institute, London, Ontario, Canada|Recherches Neuro-Hippocampe, Inc., d/b/a Ottawa Memory Clinic, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais, Gatineau, Quebec, Canada|MoCA Clinic and Institute/NeuroSearch Developpements Inc., Greenfield Park, Quebec, Canada|Q&T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China|Xuanwu Hospital Capital Medical University, Beijing, Beijing, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China|Sun Yat-Sent Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Guangzhou Huiai Hospital, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Baotou Central Hospital, Baotou, Inner Mongolia Autonomous Region, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Nanjing Brain Hospital, Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China|The First Bethune Hospital of Jilin University, Changchun, Jilin, China|Qinghai Provincial People's Hospital, Xining, Qinghai, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Tongji Hospital, Shanghai, Shanghai, China|Renji Hospital Shanghai Jiaotong Universtiy School of Medicine, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, Shanghai, China|Tianjin Huanhu Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Hôpital de Hautepierre, Strasbourg Cedex, Bas Rhin, France|Hopital de la Timone, Marseille, Cedex 05, France|Hôpital Gui de Chauliac, Montpellier, Cedex 5, France|Hopital Guillaume et RenÃ LaÃnnec, Nantes, Cedex, France|Groupe Hospitalier Pitie-Salpetriere, Paris, Cedex, France|Centre de Recherche Clinique du Gérontopôle, Toulouse, Haute Garonne, France|Hôpital Lariboisière, Paris cedex 10, Paris, France|Hôpital neurologique Pierre Wertheimer, Bron Cedex, France|Eisai Trial Site #5, Günzburg, Baden Wuerttemberg, Germany|Eisai Trial Site #2, Mannheim, Baden-Wurttemberg, Germany|Eisai Trial Site #6, Berlin, Germany|Eisai Trial Site #1, Bielefeld, Germany|Eisai Trial Site #4, Erbach, Germany|Eisai Trial Site #3, Munchen, Germany|Ospedale "Card. G. Panico" -, Tricase, LE, Italy|Fondazione Istituto G.Giglio di Cefalù, Cefalu, Palermo, Italy|Clinica Neurologica, IRCCS Ospedale Policlinico San Martino, Genova, Genova, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico - U.O.S.D. Malattie Neurodegenerative, Milano, Italy|ASST-Monza, Ospedale San Gerardo, Monza, Italy|Prima Clinica Neurologica, Primo Policlinico AOU "L. Vanvitelli", Napoli, Italy|Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Fondazione Policlinico Agostino Gemelli - UCSC, Roma, Italy|Universita' Sapienza di Roma - Dipartimento di Neuroscienze Umane, Roma, Italy|Eisai Trial Site #4, Obu-shi, Aichi, Japan|Eisai Trial Site #15, Chiba-shi, Chiba, Japan|Eisai Trial Site #6, Yoshida-gun, Fukui, Japan|Eisai Trial Site #1, Fujioka-shi, Gunma, Japan|Eisai Trial Site #32, Otake, Hiroshima, Japan|Eisai Trial Site #30, Sapporo-shi, Hokkaido, Japan|Eisai Trial Site #28, Himeji-shi, Hyogo, Japan|Eisai Trial Site #19, Kobe-shi, Hyogo, Japan|Eisai Trial Site #24, Toride-shi, Ibaraki, Japan|Eisai Trial Site #9, Kahoku, Ishikawa, Japan|Eisai Trial Site #7, Atsugi-shi, Kanagawa, Japan|Eisai Trial Site #17, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site #20, Kawasaki-shi, Kanagawa, Japan|Eisai Trial Site #2, Yokohama-shi, Kanagawa, Japan|Eisai Trial Site #33, Higashimorokatagun, Miyazaki, Japan|Eisai Trial Site #22, Niigata-shi, Niigata, Japan|Eisai Trial Site #16, Kurashiki-shi, Okayama, Japan|Eisai Trial Site #8, Hirakata, Osaka, Japan|Eisai Trial Site #26, Suita-shi, Osaka, Japan|Eisai Trial Site #18, Saitama-shi, Saitama, Japan|Eisai Trial Site #31, Otsu-shi, Shiga, Japan|Eisai Trial Site #5, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site #29, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site #13, Hachioji-shi, Tokyo, Japan|Eisai Trial Site #12, Musashino-shi, Tokyo, Japan|Eisai Trial Site #23, Shinagawa-ku, Tokyo, Japan|Eisai Trial Site #25, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site #10, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site #3, Yamagata-shi, Yamagata, Japan|Eisai Trial Site #21, Hofu, Yamaguchi, Japan|Eisai Trial Site #14, Ube-shi, Yamaguchi, Japan|Eisai Trial Site #11, Osaka, Japan|Eisai Trial Site #27, Osaka, Japan|Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of|Chonnam National University Hospital, Gwangju, Jeolla-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Seoul, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Centro CAE Oroitu, Getxo, Bizkaia, Spain|Fundación CITA-alzheimer Findazioa, Donostia San Sebastian, Gipuzkoa, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Fundacion ACE, Barcelona, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Santa Cruz y San Pablo, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Complejo Hospitalario Ruber Juan Bravo, Madrid, Spain|Hospital de Salamanca, Salamanca, Spain|Hospital Victoria Eugenia - Cruz Roja, Sevilla, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Gothenburg, Västra Götalandslän, Sweden|Memory Clinic, Malmö University Hospital, Malmö, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Uppsala, Sweden|Re:Cognition Health, Plymouth, Devon, United Kingdom|Memory Assessment & Research Centre (MARC),, Southampton, Hampshire, United Kingdom|Sheffield Memory Service, Sheffield, South Yorkshire, United Kingdom|Re:Cognition Health Ltd, Birmingham, United Kingdom|Re:Cognition Health Ltd, Guildford, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|Re:Cognition Health Ltd, London, United Kingdom|Charing Cross Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03887455
1161	NCT00571025	Risk Evaluation and Education for Alzheimer's Disease	REVEAL I	Completed	No Results Available	Alzheimer's Disease	Behavioral: APOE Disclosure	Center for Epidemiological Studies-Depression Scale (CES-D)|Beck Anxiety Inventory (BAI)|Impact of Events Scale (IES)|Future Attitudes Scale (FAS)|Positive and Negative Affect Schedule (PANAS)	National Human Genome Research Institute (NHGRI)|National Institute on Aging (NIA)	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	301	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	IA0126|5R01HG002213	August 2000		April 2004	December 11, 2007		July 23, 2009	Boston University School of Medicine, Boston, Massachusetts, United States|Weill Medical College of Cornell University, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT00571025
1162	NCT03129269	Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults	COGFRAIL	Recruiting	No Results Available	Frail Elderly	Procedure: MRI and PET scan	Amyloid physiological parameter|Change in cognitive function with Clinical Dementia Rating Scale (CDR)|Changes in functional capacities with scales IADL|Changes in functional capacities with scales ADL|Changes in functional capacities with scales SPPB	University Hospital, Toulouse|MSDAVENIR	All	70 Years and older   (Older Adult)	Not Applicable	345	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	RC31/16/8753	January 2, 2017	January 2, 2026	December 31, 2026	April 26, 2017		October 7, 2021	Toulouse University Hospital (CHU de Toulouse), Toulouse, France		https://ClinicalTrials.gov/show/NCT03129269
1163	NCT04906863	Genetic Studies of Early-onset Dementia		Recruiting	No Results Available	Dementia, Early Onset	Genetic: Blood draw|Other: Neurocognitive testing|Other: Medical questionnaire	Genetic risk variants associated with early-onset dementia|Changes in blood biomarkers in early-onset dementia	Columbia University|University of Miami|National Institute on Aging (NIA)	All	18 Years and older   (Adult, Older Adult)		1000	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	AAAQ9793|1RF1AG054080-01	September 14, 2016	March 2022	March 2022	May 28, 2021		June 22, 2021	Columbia University Irving Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04906863
1164	NCT01345110	A Longitudinal Multidimensional Population Study on Brain Aging	InveCeAb	Completed	No Results Available	Dementia|Alzheimer Disease|Vascular Dementia		The proportion of the recruited persons who will develop Dementia syndrome, Alzheimer disease, Vascular dementia, Lewy Body dementia, frontotemporal dementia, Mild Cognitive Impairment, Cognitive Impairment No Dementia|The proportion of persons who will exhibit a performance decrease equal or more than of 1,5 standard deviation of the mean in the reference population in screening cognitive tests or in memory tests (verbal and visual memory) or in executive tests|Neuropsychological baseline features of the persons who will develop dementia or cognitive impairment|Clinical baseline features of the persons who will develop dementia or cognitive impairment|Social baseline features of the persons who will developed dementia or cognitive impairment|Genetic baseline features of the persons who will developed dementia and/or cognitive impairment	Fondazione Golgi Cenci|Alzheimer Federation Italy|Mario Negri Institute for Pharmacological Research|University of Pavia|Camillo Golgi Geriatric Institute	All	70 Years to 75 Years   (Older Adult)		1321	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	01	November 2009	December 2015	December 2015	April 29, 2011		December 11, 2015	Golgi Cenci Foundation, Abbiategrasso, Milan, Italy		https://ClinicalTrials.gov/show/NCT01345110
1165	NCT03279523	F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected		Completed	No Results Available	Alzheimer Disease|HIV	Drug: F 18 T807	Perform human in vivo tau imaging using F 18 T807 in 30 older (≥ 40 years old) HIV+ participants and 30 HIV- controls.|: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.	Tammie L. S. Benzinger, MD, PhD|Washington University School of Medicine	All	40 Years and older   (Adult, Older Adult)		60	Other	Observational	Observational Model: Other|Time Perspective: Prospective	IND 123119 Protocol G	May 3, 2016	May 23, 2018	May 23, 2018	September 12, 2017		September 22, 2020	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03279523
1166	NCT02414347	F 18 T807 Tau PET Imaging of Alzheimer's Disease	T807IND	Recruiting	No Results Available	Alzheimer Disease	Drug: F 18 T807	F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.	Tammie L. S. Benzinger, MD, PhD|Washington University School of Medicine	All	18 Years and older   (Adult, Older Adult)		900	Other	Observational	Observational Model: Other|Time Perspective: Prospective	IND 123119 Protocol A	October 2014	October 2024	December 2024	April 10, 2015		April 7, 2022	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT02414347
1167	NCT02956486	A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease	MissionAD1	Terminated	Has Results	Alzheimer's Disease	Drug: Elenbecestat|Drug: Placebo	Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score|Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS)|Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR)|Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6|Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6|Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24|Core Phase: Time to Worsening of CDR Score up to Month 24|Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24|Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score|Core Phase: Change From Baseline up to Month 24 in the MMSE Score|Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score|Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score|Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score|Core Phase: Change From Last Dose in the CDR-SB Score|Core Phase: Change From Last Dose in the ADCOMS|Core Phase: Change From Last Dose in the ADAS-cog11 Score|Core Phase: Change From Last Dose in the ADAS-cog14 Score|Core Phase: Change From Last Dose in the MMSE Score|Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in CDR-SB Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADCOMS|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in MMSE Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in FAQ Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score|Extension Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 12 of the Extension Phase	Eisai Co., Ltd.|Biogen|Eisai Inc.	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	2212	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	E2609-G000-301|2016-003928-23|2016-004128-42	October 20, 2016	January 15, 2020	January 15, 2020	November 6, 2016	February 3, 2021	February 3, 2021	Facility #1, Chandler, Arizona, United States|Facility #1, Colton, California, United States|Facility #1, Costa Mesa, California, United States|Facility #1, Fullerton, California, United States|Facility #1, Imperial, California, United States|Facility #1, Irvine, California, United States|Facility #1, Lemon Grove, California, United States|Facility #1, Oceanside, California, United States|Facility #2, Oceanside, California, United States|Facility #1, Oxnard, California, United States|Facility #1, Panorama City, California, United States|Facility #1, San Diego, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, Atlantis, Florida, United States|Facility #1, Aventura, Florida, United States|Facility #2, Aventura, Florida, United States|Facility #1, Boynton Beach, Florida, United States|Facility #1, Coral Gables, Florida, United States|Facility #2, Coral Gables, Florida, United States|Facility #1, Delray Beach, Florida, United States|Facility #1, Doral, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #2, Miami, Florida, United States|Facility #11, Miami, Florida, United States|Facility #9, Miami, Florida, United States|Facility #10, Miami, Florida, United States|Facility #4, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #6, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #7, Miami, Florida, United States|Facility #8, Miami, Florida, United States|Facility #2, Orlando, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #3, Orlando, Florida, United States|Facility #1, Palm Beach Gardens, Florida, United States|Facility #1, Pompano Beach, Florida, United States|Facility #1, Port Charlotte, Florida, United States|Facility #1, Port Orange, Florida, United States|Facility #1, Spring Hill, Florida, United States|Facility #1, Tampa, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, The Villages, Florida, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Suwanee, Georgia, United States|Facility #1, Meridian, Idaho, United States|Facility #1, Northbrook, Illinois, United States|Facility #2, Wichita, Kansas, United States|Facility #1, Boston, Massachusetts, United States|Facility #1, Farmington Hills, Michigan, United States|Facility #1, Chesterfield, Missouri, United States|Facility #1, O'Fallon, Missouri, United States|Facility #2, Saint Louis, Missouri, United States|Facility #1, Saint Peters, Missouri, United States|Facility #1, Mount Arlington, New Jersey, United States|Facility #2, Springfield, New Jersey, United States|Facility #1, West Long Branch, New Jersey, United States|Facility #1, Amherst, New York, United States|Facility #1, Brooklyn, New York, United States|Facility #1, New York, New York, United States|Facility #1, Canton, Ohio, United States|Facility #1, Centerville, Ohio, United States|Facility #1, Cleveland, Ohio, United States|Facility #1, Dayton, Ohio, United States|Facility #1, Lakewood, Ohio, United States|Facility #1, Westerville, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #1, Portland, Oregon, United States|Facility #1, Jenkintown, Pennsylvania, United States|Facility #1, Media, Pennsylvania, United States|Facility #1, Philadelphia, Pennsylvania, United States|Facility #1, East Providence, Rhode Island, United States|Facility #1, Providence, Rhode Island, United States|Facility #1, Port Royal, South Carolina, United States|Facility #1, Cordova, Tennessee, United States|Facility #2, Nashville, Tennessee, United States|Facility #1, Nashville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Dallas, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #3, San Antonio, Texas, United States|Facility #1, Salt Lake City, Utah, United States|Facility #1, Bennington, Vermont, United States|Facility #1, Hampton, Virginia, United States|Facility #1, Madison, Wisconsin, United States|Facility #2, Caba, Buenos Aires, Argentina|Facility #1, Caba, Buenos Aires, Argentina|Facility #4, Caba, Buenos Aires, Argentina|Facility #3, Caba, Buenos Aires, Argentina|Facility #1, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #3, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #2, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #1, Cordoba, Capital, Argentina|Facility #1, Rosario, Santa Fe, Argentina|Facility #4, Buenos Aires, Argentina|Facility #5, Caba, Argentina|Facility #2, Cordoba, Argentina|Facility #3, Cordoba, Argentina|Facility #1, Santa Fe, Argentina|Facility #1, Darlinghurst, New South Wales, Australia|Facility #1, Macquarie Park, New South Wales, Australia|Facility #1, Tumbi Umbi, New South Wales, Australia|Facility #1, Brisbane, Queensland, Australia|Facility #1, Caulfield, Victoria, Australia|Facility #1, Geelong, Victoria, Australia|Facility #1, Heidelberg, Victoria, Australia|Facility #1, Malvern, Victoria, Australia|Facility #2, Melbourne, Victoria, Australia|Facility #1, Parkville, Victoria, Australia|Facility #1, Nedlands, Western Australia, Australia|Facility #3, Melbourne, Australia|Facility #1, Vienna, Austria|Facility #1, Pleven, Bulgaria|Facility #1, Plovdiv, Bulgaria|Facility #1, Ruse, Bulgaria|Facility #4, Sofia, Bulgaria|Facility #3, Sofia, Bulgaria|Facility #1, Sofia, Bulgaria|Facility #2, Sofia, Bulgaria|Facility #1, Kamloops, British Columbia, Canada|Facility #1, Kelowna, British Columbia, Canada|Facility #1, West Vancouver, British Columbia, Canada|Facility #1, Halifax, Nova Scotia, Canada|Facility #1, Kentville, Nova Scotia, Canada|Facility #1, Ottawa, Ontario, Canada|Facility #1, Peterborough, Ontario, Canada|Facility #1, Montreal, Quebec, Canada|Facility #1, Sherbrooke, Quebec, Canada|Facility #1, Hradec Kralove, Czechia|Facility #1, Kladno, Czechia|Facility #1, Olomouc, Czechia|Facility #1, Praha 10, Czechia|Facility #1, Montpellier, Herault, France|Facility #1, Bordeaux, France|Facility #1, Bron Cedex, France|Facility #1, Marseille Cedex 05, France|Facility #1, Nantes, France|Facility #1, Paris, France|Facility #1, Rouen, France|Facility #1, Toulouse, France|Facility #1, Neuburg, Bayern, Germany|Facility #1, Hoppegarten, Brandenburg, Germany|Facility #1, Oranienburg, Brandenburg, Germany|Facility #1, Frankfurt, Hessen, Germany|Facility #1, Leipzig, Saxony, Germany|Facility #1, Berlin, Germany|Facility #2, Berlin, Germany|Facility #1, Gera, Germany|Facility #1, Homburg/Saar, Germany|Facility #1, Schwerin, Germany|Facility #5, Athens, Greece|Facility #4, Athens, Greece|Eisai Trial Site 1, Anjo-shi, Aichi, Japan|Eisai Trial Site 1, Nagoya-shi, Aichi, Japan|Eisai Trial Site 1, Obu-shi, Aichi, Japan|Eisai Trial Site 1, Yoshida-gun, Fukui, Japan|Eisai Trail Site 1, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 1, Omuta-shi, Fukuoka, Japan|Eisai Trial Site 1, Fujioka-shi, Gunma, Japan|Eisai Trial Site 1, Otake-shi, Hiroshima, Japan|Eisai Trial Site 2, Himeji-shi, Hyogo, Japan|Eisai Trial Site 1, Himeji, Hyogo, Japan|Eisai Trial Site 1, Kobe, Hyogo, Japan|Facility #1, Miki, Kagawa, Japan|Eisai Trial Site 3, Takamatsu City, Kagawa, Japan|Eisai Trial Site 1, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site 4, Kyoto City, Kyoto, Japan|Eisai Trial Site 1, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 2, Kyoto-shi, Kyoto, Japan|Eisai Trial site 5, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 1, Shimogyo-ku, Kyoto, Japan|Eisai Trial Site 1, Higashimorokatagun, Miyazaki, Japan|Eisai Trial Site 2, Okayama-shi, Okayama-ken, Japan|Eisai Trial Site 1, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 2, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 1, Okayama-shi, Okayama, Japan|Eisai Trial Site 1, Hirakata, Osaka, Japan|Eisai Trial Site 1, Naniwa-Ku, Osaka, Japan|Eisai Trial Site 1, Osaka-shi, Osaka, Japan|Eisai Trial Site 3, Osaka-shi, Osaka, Japan|Eisai Trial Site 2, Osaka-shi, Osaka, Japan|Eisai Trial site 2, Sakai-shi, Osaka, Japan|Eisai Trial Site 1, Suita-shi, Osaka, Japan|Eisai Trial Site 2, Suita-shi, Osaka, Japan|Eisai Trial Site 1, Suminoe-ku, Osaka, Japan|Eisai Trial Site 1, Kanzaki-gun, Saga, Japan|Eisai Trial Site 1, Otsu-shi, Shiga, Japan|Eisai Trial Site 2, Otsu, Shiga, Japan|Eisai Trial Site 1, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 1, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 2, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 1, Kodaira-shi, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Setagaya-ku, Tokyo, Japan|Eisai Trial Site 1, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Sumida-ku, Tokyo, Japan|Eisai Trial Site 1, Hofu-shi, Yamaguchi, Japan|Eisai Trial Site 1, Kumamoto, Japan|Eisai Trial Site 3, Kyoto, Japan|Eisai Trial Site 1, Osaka, Japan|Facility #1, Bucheon-si, Gyeonggi-do, Korea, Republic of|Facility #1, Seongnam, Gyeonggi, Korea, Republic of|Facility #1, Busan, Korea, Republic of|Facility #1, Incheon, Korea, Republic of|Facility #5, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #1, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #6, Seoul, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #1, Katowice, Poland|Facility #1, Kielce, Poland|Facility #1, Krakow, Poland|Facility #1, Poznari, Poland|Facility #1, Poznań, Poland|Facility #1, Siemianowice Śląskie, Poland|Facility #1, Warszawa, Poland|Facility #1, Guimarães, Portugal|Facility #1, Moscow, Russian Federation|Facility #1, Bratislava, Slovakia|Facility #1, Elche, Alicante, Spain|Facility #1, Sant Cugat Del Valles, Barcelona, Spain|Facility #1, Getxo, Bizkaia, Spain|Facility #1, Donostia/San Sebastian, Gipuzkoa, Spain|Facility #1, Palma de Mallorca, Illes Balears, Spain|Facility #1, El Palmar, Murcia, Spain|Facility #1, Barcelona, Spain|Facility #2, Madrid, Spain|Facility #1, Madrid, Spain|Facility #1, Valencia, Spain|Facility #2, Valencia, Spain|Facility #1, Cambridge, Cambridgeshire, United Kingdom|Facility #1, Chester, Cheshire, United Kingdom|Facility #1, Winwick, Warrington, Cheshire, United Kingdom|Facility #1, Plymouth, Devon, United Kingdom|Facility #1, Bournemouth, Dorset, United Kingdom|Facility #1, Crowborough, East Sussex, United Kingdom|Facility #1, Manchester, Greater Manchester, United Kingdom|Facility #1, Southampton, Hampshire, United Kingdom|Facility #1, Glasgow, Lanarkshire, United Kingdom|Facility #1, Blackpool, Lancashire, United Kingdom|Facility #1, Preston, Lancashire, United Kingdom|Facility #2, London, Middlesex, United Kingdom|Facility #1, Bath, North East Somerset, United Kingdom|Facility #1, Oxford, Oxfordshire, United Kingdom|Facility #1, Aberdeen, Scotland, United Kingdom|Facility #1, Sheffield, South Yorkshire, United Kingdom|Facility #1, Leatherhead, Surrey, United Kingdom|Facility #1, Birmingham, West Midlands, United Kingdom|Facility #1, Swindon, Wilts, United Kingdom|Facility #2, Glasgow, United Kingdom|Facility #1, Guildford, United Kingdom|Facility #1, London, United Kingdom|Facility #4, London, United Kingdom|Facility #3, London, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02956486/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02956486/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02956486
1168	NCT00611533	Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women		Completed	Has Results	Menopause|Cognitive Disturbances	Drug: atomoxetine|Drug: placebo	Brown Attention Deficit Disorder Scale|BADDS Total Score|Blood Pressure|Heart Rate|Weight	University of Pennsylvania|Eli Lilly and Company	Female	45 Years to 60 Years   (Adult)	Not Applicable	16	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	0403026533	May 2004	April 2008	April 2008	February 11, 2008	March 3, 2017	April 17, 2017	Yale University School of Medicine, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT00611533
1169	NCT01339130	Assessment of Social-emotional Functioning in Neurological Diseases	Emotion	Completed	No Results Available	Alzheimer Disease|Stroke|Parkinson's Disease|Lewy Body Dementia|Huntington Disease	Behavioral: Computerized tests and Electrophysiological measurements	Empathy ability|Empathy for pain|pattern of empathy disorders according to the disease (stroke, Mild cognitive impairment, Alzheimer disease and Parkinson disease	Centre Hospitalier Universitaire, Amiens	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	177	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PI09-PR-GODEFROY|2009-A00596-51	June 2009	June 2013	June 2013	April 20, 2011		September 7, 2015	CHU Amiens, Amiens, Picardie, France		https://ClinicalTrials.gov/show/NCT01339130
1170	NCT01582919	Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study	AMIMAGE 2	Completed	No Results Available	Dementia|Alzheimer Disease	Other: Neuroimaging	Measures of volume and diffusion parameters in the gray matter (hippocampus and cingular posterior cortex)|Performance on neuropsychological and daily life cognitive tests	University Hospital, Bordeaux	All	65 Years and older   (Older Adult)	Not Applicable	304	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CHUBX 2011/15	September 2012	June 2015	June 2015	April 23, 2012		April 4, 2017	Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux, Bordeaux, France		https://ClinicalTrials.gov/show/NCT01582919
1171	NCT00951197	Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects	AMIMAGE	Completed	No Results Available	Dementia|Alzheimer Disease	Other: Neuroimaging	FA (Fractional Anisotropy), MTR (magnetization transfer ratio) and T2 (Transverse relaxation time) measures in patients with dementia compared to controls, in left and right hippocampus, and posterior cingulum|FA, MTR and T2 measures in subjects with mild cognitive impairment no dementia|Performances in the 7 neuropsychological tests available in the AMI cohort|FA measures for the connexion Hippocampus-cingulum posterior	University Hospital, Bordeaux	All	65 Years and older   (Older Adult)		318	Other	Observational	Observational Model: Ecologic or Community|Time Perspective: Prospective	CHUBX2008/13	April 2009	March 2011	March 2011	August 4, 2009		April 30, 2012	Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux, Bordeaux, France		https://ClinicalTrials.gov/show/NCT00951197
1172	NCT02880956	A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease		Completed	Has Results	Alzheimer's Disease	Drug: ABBV-8E12|Drug: placebo for ABBV-8E12	Change From Baseline Over Time in CDR-SB Score|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Maximum Observed Serum Concentration (Cmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|Time to Cmax (Tmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|Serum Concentration at the End of a Dose Interval (Ctrough) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|Half-Life (T1/2) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|Area Under the Concentration-Time Curve From Dosing (Time 0) to Day 28 (AUC0-28) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|Cmax/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|AUC0-28/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses|Change From Baseline Over Time in Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) Total Score|Change From Baseline Over Time in ADAS-Cog-14 Comprehension of Spoken Language Score|Change From Baseline Over Time in ADAS-Cog-14 Constructional Praxis Score|Change From Baseline Over Time in ADAS-Cog-14 Commands Score|Change From Baseline Over Time in ADAS-Cog-14 Delayed Word Recall Score|Change From Baseline Over Time in ADAS-Cog-14 Ideational Praxis Score|Change From Baseline Over Time in ADAS-Cog-14 Maze Task Score|Change From Baseline Over Time in ADAS-Cog-14 Number Cancellation Score|Change From Baseline Over Time in ADAS-Cog-14 Naming Score|Change From Baseline Over Time in ADAS-Cog-14 Orientation Score|Change From Baseline Over Time in ADAS-Cog-14 Word Recall - Number of Words Not Recalled Score|Change From Baseline Over Time in ADAS-Cog-14 Remember Word Recognition Instructions Score|Change From Baseline Over Time in ADAS-Cog-14 Spoken Language Ability Score|Change From Baseline Over Time in ADAS-Cog-14 Word Find Difficulty Spontaneous Speech Score|Change From Baseline Over Time in ADAS-Cog-14 Word Recognition Score|Change From Baseline Over Time in Functional Activities Questionnaire (FAQ) Score|Change From Baseline Over Time in Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI) General Condition Score|Change From Baseline Over Time in ADCS-CGIC-MCI Cognition Score|Change From Baseline Over Time in ADCS-CGIC-MCI Behavior Score|Change From Baseline Over Time in ADCS-CGIC-MCI Functional Abilities Score|Change From Baseline Over Time in University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief) - Total Score|Change From Baseline Over Time in 24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients With Mild Cognitive Impairment (ADCS-MCI-ADL-24) Total Score|Change From Baseline Over Time in Repeatable Battery for Assessment of Neuropsychological Status (RBANS) - Total Scale Score|Change From Baseline Over Time in RBANS - Coding Total Score|Change From Baseline Over Time in RBANS - Digit Span Total Score|Change From Baseline Over Time in RBANS - Figure Copy Total Score|Change From Baseline Over Time in RBANS - Figure Recall Total Score|Change From Baseline Over Time in RBANS - List Recognition Total Score|Change From Baseline Over Time in RBANS - List Learning Total Score|Change From Baseline Over Time in RBANS - Line Orientation Total Score|Change From Baseline Over Time in RBANS - List Recall Total Score|Change From Baseline Over Time in RBANS - Picture Naming Total Score|Change From Baseline Over Time in RBANS - Semantic Fluency Total Score|Change From Baseline Over Time in RBANS - Story Memory Total Score|Change From Baseline Over Time in RBANS - Story Recall Total Score|Change From Baseline Over Time in Mini-Mental State Examination (MMSE) Total Score|Change From Baseline Over Time in Neuropsychiatry Inventory (NPI) Total Score|Change From Baseline Over Time in Alzheimer's Disease Composite Score (ADCOMS) Score	AbbVie	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	453	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	M15-566|2016-001634-10	January 26, 2017	March 30, 2021	July 28, 2021	August 26, 2016	August 26, 2022	August 26, 2022	Banner University of Arizona Medical Center Phoenix /ID# 151536, Phoenix, Arizona, United States|Banner Sun Health Res Inst /ID# 151895, Sun City, Arizona, United States|Irvine Clinical Research /ID# 162331, Irvine, California, United States|Ucsd /Id# 152467, La Jolla, California, United States|Ray Dolby Brain Health Center /ID# 154965, San Francisco, California, United States|Univ California, San Francisco /ID# 152053, San Francisco, California, United States|Brain Matters Research /ID# 147796, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida /ID# 162332, Fort Myers, Florida, United States|Mayo Clinic /ID# 151236, Jacksonville, Florida, United States|Synexus Clinical Research US, Inc. /ID# 147804, Orlando, Florida, United States|University of South Florida /ID# 151890, Tampa, Florida, United States|Synexus Clinical Research US, Inc /ID# 151633, The Villages, Florida, United States|Emory Midtown Infectious Disease Clinic /ID# 151492, Atlanta, Georgia, United States|Atlanta Center for Medical Research /ID# 151550, Atlanta, Georgia, United States|NeuroStudies.net, LLC /ID# 152746, Decatur, Georgia, United States|Great Lakes Clinical Trials /ID# 152754, Chicago, Illinois, United States|Advocate Lutheran General Hospital /ID# 152052, Park Ridge, Illinois, United States|Southern IL Univ School of Med /ID# 151769, Springfield, Illinois, United States|Indiana University /ID# 151861, Indianapolis, Indiana, United States|University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554, Fairway, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 152753, Lexington, Kentucky, United States|Johns Hopkins Bayview Med Cnt /ID# 151893, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 151770, Boston, Massachusetts, United States|Brigham and Women's Physicians /ID# 151882, Boston, Massachusetts, United States|Hattiesburg Clinic /ID# 202388, Hattiesburg, Mississippi, United States|Princeton Medical Institute /ID# 152934, Princeton, New Jersey, United States|Scott Research Inc. /ID# 151880, Laurelton, New York, United States|North Shore University Hospital /ID# 151632, New Hyde Park, New York, United States|Duke Cancer Center /ID# 147828, Durham, North Carolina, United States|Oregon Health and Science University /ID# 151690, Portland, Oregon, United States|Keystone Clinical Studies LLC /ID# 202305, Plymouth Meeting, Pennsylvania, United States|Rhode Island Hospital /ID# 151538, Providence, Rhode Island, United States|Vanderbilt University Medical Center /ID# 154547, Nashville, Tennessee, United States|Kerwin Research Center /ID# 147815, Dallas, Texas, United States|Houston Methodist Hospital /ID# 154810, Houston, Texas, United States|McGovern Medical School /ID# 204860, Houston, Texas, United States|University of Utah /ID# 151858, Salt Lake City, Utah, United States|Integrated Neurology Services /ID# 154863, Alexandria, Virginia, United States|The Kinghorn Cancer Centre /ID# 152632, Darlinghurst, New South Wales, Australia|Griffith University /ID# 152635, Southport, Queensland, Australia|Austin Health /ID# 152637, Heidelberg, Victoria, Australia|The Royal Melbourne Hospital /ID# 202633, Parkville, Victoria, Australia|Australian Alzheimer's Res Fou /ID# 152634, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research /ID# 152826, West Perth, Western Australia, Australia|UCL Saint-Luc /ID# 152847, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Universitair Ziekenhuis Leuven /ID# 152642, Leuven, Vlaams-Brabant, Belgium|Groupe Sante CHC - Clinique du MontLegia /ID# 152846, Liege, Belgium|Parkwood Institute /ID# 164204, London, Ontario, Canada|Toronto Memory Program /ID# 147863, Toronto, Ontario, Canada|Rigshospitalet /ID# 153192, Copenhagen Ø, Hovedstaden, Denmark|Clinical Research Services Turku /ID# 152845, Turku, Varsinais-Suomi, Finland|Ita-Suomen Yliopisto /ID# 152959, Kuopio, Finland|AOU di Modena /ID# 152394, Modena, Emilia-Romagna, Italy|Policlinico Agostino Gemelli /ID# 152396, Rome, Lazio, Italy|Duplicate_AOU Policlinico Umberto I /ID# 163144, Rome, Lazio, Italy|Azienda Ospedaliera di Perugia /ID# 152397, Perugia, Umbria, Italy|IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli /ID# 152395, Brescia, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 152391, Milano, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 152401, Milan, Italy|Universitair Medisch Centrum Utrecht /ID# 163576, Utrecht, Netherlands|CGM Research Trust /ID# 152827, Burwood, New Zealand|Fundacion CITA Alzheimer Fundazioa /ID# 152645, Donostia, Pais Vasco, Spain|Fundacio ACE /ID# 152643, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 152646, Barcelona, Spain|Hospital Clinico Universitario San Carlos /ID# 153703, Madrid, Spain|Hospital Universitario 12 de Octubre /ID# 152647, Madrid, Spain|Karolinska University Hospital Huddinge /ID# 156705, Stockholm, Stockholms Lan, Sweden|Sahlgrenska University Hospital Molndal /ID# 154465, Molndal, Vastra Gotalands Lan, Sweden	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02880956/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02880956/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02880956
1173	NCT01453569	Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease		Completed	Has Results	Alzheimer Disease|Cognitive Impairment	Drug: Sodium oligo-mannurarate 600mg|Drug: Sodium oligo-mannurarate 900mg|Drug: Placebo	Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule|Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule	Shanghai Greenvalley Pharmaceutical Co., Ltd.|Shanghai Mental Health Center	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 2	255	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	9712011-1	October 2011	August 2013	August 2013	October 18, 2011	January 27, 2015	January 27, 2015	Beijing Hospital, Beijing, Beijing, China|Chongqing Medical University Second Affiliated Hospital, Chongqing, Chongqing, China|The First Affliated Hospital of Third Military Medical University, Chongqing, Chongqing, China|The Third Affliated Hospital of Third Military Medical University, Chongqing, Chongqing, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Guangzhou Brain Hospital, Guangzho, Guangdong, China|The 251 Hospital of People's Liberation Army, Zhangjiakou, Hebei, China|The First Affliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Wuhan General Hospital of Guangzhou Military of People's Military Army, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The Central Hospital of Baotou, Baotou, Inner Mongolia, China|The Affliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Wuxi Mental Health Center, Wuxi, Jiangsu, China|The First Affliated Hospital of Chinese Medical University, Shenyang, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|The Ninth Hospital, Shanghai Jiao Tong University school of Medicine, Shanghai, Shanghai, China|Shanghai Mental Health Center , Shanghai Jiao Tong University school of Medicine, Shanghai, Shanghai, China|Tangdu Hospital of The Forth Military Medical University of PLA, Xi'an, Shanxi, China|West China Hospital, West China School of Medicine Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Sir Run Run Shaw Hospital, Medical college of Zhejiang University, Hangzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT01453569
1174	NCT03306979	Memory and Antioxidants in Vascular Impairment Trial		Recruiting	No Results Available	Vascular Cognitive Impairment no Dementia	Drug: N Acetylcysteine|Other: Placebo oral capsule	Change in executive function|Change in processing speed|Change in memory	Sunnybrook Health Sciences Centre	All	55 Years to 85 Years   (Adult, Older Adult)	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	241-2017	April 30, 2018	August 1, 2022	December 1, 2022	October 11, 2017		February 28, 2022	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03306979
1175	NCT00814346	Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions		Completed	Has Results	Alzheimer's Disease|Cognitive Impairment	Drug: EGb761®|Drug: Placebo	Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)|Change in Brain Glucose Metabolism in the MC and CNE Groups|Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups|Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups|Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups|Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups|Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)|Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups|Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups|Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)|Change in Cognitive Tests-CDR Score in MC and CNE Groups|Change in Cognitive Tests-GDS Score in MC and CNE Groups|Change in Cognitive Tests-MMSE Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT|Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups|Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups|Incidence of Adverse Events (AEs)|Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size	Ipsen	All	65 Years and older   (Older Adult)	Phase 2	49	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	2-39-00240-134|2007-005377-63	October 2008	July 2012	July 2012	December 24, 2008	March 28, 2016	February 8, 2019	Hôpital Corentin Celton 4 parvis Corentin Celton, Issy-Les-Moulineaux, France|Hôpital de Juvisy, Juvisy sur Orge, France|CMPI "Les Rives de Seine", Le Vesinet, France|Centre Hospitalier d'Orsay 4 place du Général Leclerc, Orsay, France|Private practice, Paris, France|Hôpital Broca 54-56 rue Pascal, Paris, France|Observatoire de l'âge, Paris, France|Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier, Villejuif, France		https://ClinicalTrials.gov/show/NCT00814346
1176	NCT02992327	Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)	BlacOut	Completed	No Results Available	Concussion, Mild|Neurocognitive Dysfunction		Results of neurocognitive testing|Symptom severity|SNTF plasma and serum levels	HealthPartners Institute|University of Pennsylvania	All	8 Years and older   (Child, Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	A15-085	August 30, 2015	August 6, 2018	August 6, 2018	December 14, 2016		September 7, 2018	Regions Hospital, Saint Paul, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02992327
1177	NCT03384043	Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease		Completed	No Results Available	Alzheimer Disease|Cognitive Impairment, Mild|Dementia, Mild	Behavioral: Smartphone Personal Assistant|Behavioral: Implementation Intention	Objective Prospective Memory Performance|Quality of Life - Positive Affect and Well-Being|Quality of Life - Ability to Participate in Social Roles and Activities|Quality of Life - Satisfaction with Social Roles and Activities|Quality of Life - Cognitive Function|Subjective Memory Performance Questionnaire|Perceived Memory Structured Interview|Use of Technology/Strategy|Instrumental Activities of Daily Living|Smartphone Acceptability/Usability Scale|Training Duration	Baylor University|National Institute on Aging (NIA)	All	Child, Adult, Older Adult	Not Applicable	52	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care	017-327|1R21AG053161-01A1	January 8, 2018	February 28, 2020	February 28, 2020	December 27, 2017		July 8, 2020	Baylor Scott & White Medical Center, Temple, Texas, United States		https://ClinicalTrials.gov/show/NCT03384043
1178	NCT04135872	Hypoalbuminemia in Mild Acute Stroke and Cognitive Impariment Post-stroke		Completed	No Results Available	Cognitive Impairment|Stroke|Albumin; Double	Other: strengthened nuitritional treatment	PSCI	Dongguan People's Hospital	All	40 Years to 80 Years   (Adult, Older Adult)		435	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	DongguanPeopleHospital	January 1, 2017	June 30, 2018	August 30, 2018	October 23, 2019		October 24, 2019	Dongguan Peoples' Hospital, Dongguan, Guangdong, China		https://ClinicalTrials.gov/show/NCT04135872
1179	NCT04576624	Brain-Health Lifestyle Restructuring Intervention		Recruiting	No Results Available	Lifestyle|Cognitive Decline|Aging	Behavioral: Lifestyle Intervention|Behavioral: social activity	Cognitive function|Activity participation|Change of activity participation|QOL (Quality of Life)|Physical function|Functional memory|Working memory|Complex attention|Processing speed	National Cheng Kung University|Ministry of Science and Technology, Taiwan	All	50 Years and older   (Adult, Older Adult)	Not Applicable	125	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	National Cheng-Kung University	August 1, 2020	July 31, 2023	July 31, 2023	October 6, 2020		October 6, 2020	National Cheng-Kung University, Tainan, Taiwan		https://ClinicalTrials.gov/show/NCT04576624
1180	NCT02810899	Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy		Completed	No Results Available	Brain Neoplasms	Drug: dexmedetomidine|Drug: normal saline	Intelligence Quotient|Time to anesthesia emergence|Time to extubation|Depth of sedation at the time of extubation|Emergence agitation	Peking University First Hospital|Beijing Tiantan Hospital	All	2 Years to 12 Years   (Child)	Phase 4	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	2015[969]|ChiCTR-IPR-15007085	September 2015	February 2016	June 2016	June 23, 2016		September 29, 2016	Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02810899
1181	NCT03552861	Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment		Unknown status	No Results Available	TMS Protocols in the Treatment of PD	Device: repetitive transcranial magnetic stimulation(rTMS)	Hamilton Depression Scale（HAMD）|Beck Depression Inventory（BDI）|Mini-mental State Examination（MMSE）|Montreal Cognitive Assessment Scale（MoCA）|Named test of the Aphasia Battery of Chinese|Similarity test|Symbol Digit modalities test（SDMT）|Verbal fluency test（VFT）|Logical memory test（LMT）|Delayed memory test（DMT）|Digit span test（DST）|Ten point clock test|Uniform Parkinson's Disease Rating Scale Ⅲ（UPDRSⅢ）|Modified Hoehn & Yahr scale（H-Y）|Time up and go test（TUG test）|Activity of Daily Living Scale（ADL）|Parkinson's Disease Questionnaire（PDQ-39）|Non-motor symptoms questionnaire(NMS-Q)|Pittsburgh Sleep Quality Index (PSQI)|Hamilton Anxiety Scale（HAMA）|Beck Anxiety Inventory（BAI）	Guangdong Provincial People's Hospital	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	252	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	GDREC2017083H（R1）	August 15, 2018	December 31, 2021	December 31, 2021	June 12, 2018		January 13, 2021	Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China|Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Affiliated Union Hospital of Fujian Medical University, Fuzhou, Fujian, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China|First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Huashan Hospital, Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03552861
1182	NCT05295966	Multisensory Physical Exercises in People With Cognitive Impairment		Recruiting	No Results Available	Dementia	Other: Cognitive therapy|Behavioral: Physiocognitive Integration	Speed of Gait at preferred pace|Cadence of Gait at preferred pace|Step Length of Gait at preferred pace|Speed during Dual task gait|Cadence during Dual task gait|Step Length during Dual task gait|Time up & go test	Universidad Rey Juan Carlos	All	Child, Adult, Older Adult	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	V1058	January 1, 2022	April 30, 2022	September 30, 2022	March 25, 2022		March 25, 2022	Universidad Rey Juan Carlos, Fuenlabrada, Madrid, Spain		https://ClinicalTrials.gov/show/NCT05295966
1183	NCT03554265	Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy		Active, not recruiting	No Results Available	Traumatic Brain Injury|Fatigue|Cognitive Impairment|COVID-19	Drug: Somatropin	Lean Body Mass as Measured by Dual Energy X-Ra Absorptiometry (DEXA) at Baseline|Lean Body Mass as Measured by Dual Energy X-Ra Absorptiometry (DEXA) at 6 months|Fat Mass as Measured by Dual Energy X-Ra Absorptiometry (DEXA) at Baseline|Fat Mass as Measured by Dual Energy X-Ra Absorptiometry (DEXA) at 6 months|Basal Metabolic rate as measured by Resting Energy Expenditure at baseline|Basal Metabolic rate as measured by Resting Energy Expenditure at 6 months	The University of Texas Medical Branch, Galveston	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 3	83	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-0313	August 6, 2018	December 21, 2022	June 1, 2023	June 13, 2018		August 23, 2022	University of Texas Medical Branch, Galveston, Texas, United States		https://ClinicalTrials.gov/show/NCT03554265
1184	NCT03558698	Are Cognition and Sleep Affected by Exposure to Carbon Dioxide and Bio Effluents During Sleep?		Completed	No Results Available	Cognitive Impairment, Mild|Sleep|Environmental Exposure	Other: Good ventilation|Other: Ventilation CO2|Other: Poor Ventilation	Reaction time (Simple)|CANTAB global composite score|Reaction Time (Five-Choice)|Sleep efficiency	University of Aarhus	All	10 Years to 12 Years   (Child)	Not Applicable	36	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	111017	January 23, 2018	June 22, 2018	June 22, 2018	June 15, 2018		October 11, 2018	Aarhus University, Department of Public Health, Section for Environment, Occupation and Health, Aarhus, Denmark		https://ClinicalTrials.gov/show/NCT03558698
1185	NCT01354691	Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease		Completed	Has Results	Alzheimer's Disease|Dementia|Memory Loss|Cognitive Impairment	Drug: ladostigil hemitartrate	ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale|Neuropsychiatric Inventory (NPI)|Cornell Scale for Depression in Dementia (CSDD)|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini-Mental State Examination	Avraham Pharmaceuticals Ltd	All	60 Years to 85 Years   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CR100101/CO15570	February 2011	September 2012	March 2013	May 17, 2011	July 30, 2020	July 30, 2020	Medizinische Univeritat Graz, Universitatsklinik fur Neurologie, Auenbruggerplatz 22, Graz, Austria|Privatordination Horn, HamerlingstraBe 15, Horn, Austria|Allgemeines Krankenhaus der Stadt Linz, KrankenhausstraBe 9, Linz, Austria|Privatordination, Lainzerstrasse 20, Wein, Austria|General Hospital Pula, Negrijeva 6, Pula, Croatia|General Hospital Zabok, Bracak 8, Zabok, Croatia|Clinical Hospital Center Zagreb, Kispaticeva 12, Zagreb, Croatia|Clinical Hospital Dubrava, Avenija Gojka Suska 6, Zagreb, Croatia|Polyclinic Neuron, Salata 12, Zagreb, Croatia|Psychiatric Hospital Vrapce, Bolnicka cesta 32, Zagreb, Croatia|Klinische Forschung Hamburg GmbH, Hoheluftaussee 18, Hamburg, Germany|Klinische Forschung Schwerin GmbH, FriedrichstraBe 1, Schwerin, Germany|Studienzentrum Nordwest, Lange StraBe 23-25, Westerstede, Germany|Military Medical Academy, Crnotravska 17, Belgrade, Serbia|Clinical Centre of Serbia, Dr. Subotica 6, Belgrad, Serbia|CAE Oroitu Centro Atencion Especializada C/Jata, 9, Algorta, Spain|Centro Geroinnova Barcelona, Calle Mandoni n 17, Barcelona, Spain|Fundacio ACE, Institut Catala de Neurosciencies Aplicadas, C/Margues de Sentmenat 35-37, Barcelona, Spain|Institud d' Assistencia Sanitaria de Girona, Edifici La Republica - C/Dr. Castany, s/n, Salt, Spain		https://ClinicalTrials.gov/show/NCT01354691
1186	NCT02868684	Imaging Biomarkers of Mild Traumatic Brain Injury: a Longitudinal Cohort Study		Completed	No Results Available	Mild Traumatic Brain Injury|Posttraumatic Stress Disorder|Affective and Somatic Complaints|Cognitive Impairments		Correlation between brain diffusion tensor imaging measures and Posttraumatic Stress Disorder symptom|Changes in post-concussive symptoms|changes in affective complaints|Changes in somatic complaints	First Affiliated Hospital Xi'an Jiaotong University|Second Affiliated Hospital of Wenzhou Medical University	All	18 Years to 75 Years   (Adult, Older Adult)		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NSFC81571752-1	August 2016	August 2020	September 2020	August 16, 2016		May 12, 2022	First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT02868684
1187	NCT04968041	KNA Proof-of-Concept		Completed	No Results Available	Adherence, Treatment|Retention|Cognitive Impairment, Mild	Behavioral: Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program	Adherence|Acceptability|Retention|Cognitive functioning	Florida State University	All	60 Years to 75 Years   (Adult, Older Adult)	Not Applicable	9	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	STUDY00000111	September 27, 2019	June 30, 2020	August 30, 2020	July 20, 2021		July 20, 2021	Florida State University, Tallahassee, Florida, United States		https://ClinicalTrials.gov/show/NCT04968041
1188	NCT01082965	Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease		Terminated	Has Results	Alzheimer's Disease	Drug: Donepezil|Drug: Placebo	Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1|Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8|Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8|Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8|Change From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8|Change From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8|Change From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8	Pfizer	All	50 Years and older   (Adult, Older Adult)	Not Applicable	18	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	A9001437	July 2010	July 2012	July 2012	March 9, 2010	September 12, 2013	September 12, 2013	Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01082965
1189	NCT03653351	Brain Stimulation and Enhancing Cognition in Older Adults		Completed	Has Results	Cognitive Impairment, Mild|Depressive Symptoms|Anxiety	Device: Active Transcranial Direct Current Stimulation (tDCS)|Device: Sham Transcranial Direct Current Stimulation (tDCS)	Cognitive and Memory Function	Washington University School of Medicine	All	60 Years and older   (Adult, Older Adult)	Not Applicable	26	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ID#201805097	June 27, 2018	April 22, 2019	April 22, 2019	August 31, 2018	June 29, 2021	July 8, 2021	Washington University in Saint Louis, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03653351/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03653351
1190	NCT04262206	Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults	PREVENTABLE	Recruiting	No Results Available	Cognitive Impairment, Mild|Dementia|Cardiovascular Diseases	Drug: Atorvastatin 40 Mg Oral Tablet|Drug: Placebo oral tablet	Number of patients without diagnosis of new dementia|Number of patients without of persistent disability|Cardiovascular mortality measured as a composite of CV death, hospitalization for myocardial infarction/unstable angina, heart failure, stroke/TIA, or coronary revascularization|Cognitive disability as measured as a composite of MCI or probable dementia	Duke University|National Institute on Aging (NIA)|National Heart, Lung, and Blood Institute (NHLBI)|Wake Forest University Health Sciences	All	75 Years and older   (Older Adult)	Phase 4	20000	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	Pro00103844|1U19AG065188-01	September 1, 2020	June 30, 2026	December 31, 2026	February 10, 2020		July 11, 2022	Birmingham VA, Birmingham, Alabama, United States|Southern Arizona VA Health Care System - Tucson, Tucson, Arizona, United States|Little Rock VA Medical Center, Little Rock, Arkansas, United States|Fresno VA Medical Center, Fresno, California, United States|Long Beach VA Medical Center, Long Beach, California, United States|VA Greater Los Angeles, Los Angeles, California, United States|VA Palo Alto Healthcare System, Palo Alto, California, United States|VA San Diego Medical Center, San Diego, California, United States|VA Connecticut Healthcare System, West Haven, Connecticut, United States|Bay Pines VA, Bay Pines, Florida, United States|Gainesville VA Medical Center, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Florida, Jacksonville, Florida, United States|Miami VA Medical Center, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Advent Health, Orlando, Florida, United States|Atlanta VA Medical Center, Atlanta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Chicago VA Medical Center/Jesse Brown VA, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|North Chicago VA Medical Center, North Chicago, Illinois, United States|Indianapolis VA Medical Center, Indianapolis, Indiana, United States|University of Iowa Healthcare, Iowa City, Iowa, United States|Kansas City VA Medical Center, Kansas City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|VA Eastern Kansas Healthcare System, Topeka, Kansas, United States|Louisville VA Medical Center, Louisville, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|VA Boston Healthcare System, Boston, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Essentia Health, Duluth, Minnesota, United States|Allina Health, Minneapolis, Minnesota, United States|Minneapolis VA Health Care System, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|VA Medical Center Jackson, Jackson, Mississippi, United States|University of Missouri Health System, Columbia, Missouri, United States|St. Louis VA Medical Center, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Omaha VA Medical Center, Omaha, Nebraska, United States|Reno VA/Sierra Nevada Health Care, Reno, Nevada, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Bronx VA Medical Center, Bronx, New York, United States|VA Hudson Valley Healthcare System, Montrose, New York, United States|VA New York Harbor Healthcare System, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville VA-Charles George VA Medical Center, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Salisbury VA Medical Center, Salisbury, North Carolina, United States|Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Dayton VA Medical Center, Dayton, Ohio, United States|Corporal Michael J. Crescenz VA Medical Center-Philadelphia VA, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Providence VA Medical Center, Providence, Rhode Island, United States|Charleston VA Medical Center, Charleston, South Carolina, United States|Columbia VA Health Care/Dorn VA Medical Center, Columbia, South Carolina, United States|Monument Health, Rapid City, South Dakota, United States|VA Medical Center Memphis, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center Dallas, Dallas, Texas, United States|Doctors Hospital at Renaissance, Edinburg, Texas, United States|San Antonio VA Medical Center, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|Intermountain, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|VA Salt Lake City Healthcare System, Salt Lake City, Utah, United States|Clarksburg VA Medical Center, Clarksburg, West Virginia, United States|VA Madison Healthcare System, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Milwaukee VA Medical Center, Milwaukee, Wisconsin, United States|VA Carribbean Healthcare, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT04262206
1191	NCT04273672	Speech, Linguistic and Acoustic Markers in Parkinson's Disease	SLAM-PD	Recruiting	No Results Available	Parkinson Disease|Cognitive Impairment, Mild|Speech	Diagnostic Test: Cognitive Battery|Behavioral: Voice, Speech and Language Analysis|Behavioral: Questionnaires and Clinical Assessments|Genetic: DNA Analysis	Detection of speech acoustic parameters that classify PD participants by cognitive status (mild cognitive impairment [MCI] vs. normal cognition)|Duration and location of pauses during speech in PD participants with and without mild cognitive impairment|Syntax processing efficiency score (percentage correctly understood sentences/processing time) in controls, and in PD with and without MCI	University of Massachusetts, Worcester|Massachusetts Institute of Technology, Lincoln Laboratories|Boston University|VA Puget Sound Health Care System|National Institute on Deafness and Other Communication Disorders (NIDCD)	All	18 Years and older   (Adult, Older Adult)		70	Other|U.S. Fed|NIH	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	H00011523|5K23DC016656	January 13, 2020	December 2022	March 2024	February 18, 2020		March 31, 2022	UMass Medical School/UMass Memorial Medical Center, Worcester, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04273672
1192	NCT03806478	Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease		Not yet recruiting	No Results Available	Dementia|Alzheimer Disease 1|Alzheimer Disease 2|Alzheimer Disease 3	Drug: APH-1105|Other: Placebo	Safety: Incidence of Treatment-emergent Adverse Events|Efficacy: Cognition Change|Efficacy: Change in Cognitive Functioning|Tolerability: [Pharmacokinetics] Cmax|Tolerability: [Pharmacokinetics] Tmax|Tolerability: [Pharmacokinetics] serum elimination half life|Tolerability: [Pharmacodynamics] protein kinase C activity|Change in Behavioral Functioning|Change in Behavioral Disturbance|Change in Dementia Symptom Severity|Evaluate the Quality of Life Status|Risk of Suicide	Aphios	All	50 Years and older   (Adult, Older Adult)	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment	APH-1105	June 2023	September 2024	December 2024	January 16, 2019		July 27, 2021			https://ClinicalTrials.gov/show/NCT03806478
1193	NCT00506415	Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline		Completed	Has Results	Alzheimer Disease	Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch	Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period|Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period|Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period|Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period|Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period|Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events	Novartis Pharmaceuticals|Novartis	All	50 Years to 85 Years   (Adult, Older Adult)	Phase 3	1584	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CENA713D2340	June 2007	May 2011	May 2011	July 25, 2007	September 19, 2012	September 19, 2012	Novartis investigative site, Birmingham, Alabama, United States|Novartis investigative site, Gilbert, Arizona, United States|Novartis investigative site, Phoenix, Arizona, United States|Novartis investigative site, Sun City, Arizona, United States|Novartis investigative site, Anaheim, California, United States|Novartis investigative site, Carson, California, United States|Novartis investigative site, Costa Mesa, California, United States|Novartis investigative site, Fullerton, California, United States|Novartis investigative site, La Habra, California, United States|Novartis investigative site, La Jolla, California, United States|Novartis investigative site, National City, California, United States|Novartis investigative site, Redlands, California, United States|Novartis investigative site, San Francisco, California, United States|Novartis investigative site, Fort Collins, Colorado, United States|Novartis investigative site, Longmont, Colorado, United States|Novartis investigative site, Boca Raton, Florida, United States|Novartis investigative site, Bradenton, Florida, United States|Novartis investigative site, Deerfield Beach, Florida, United States|Novartis investigative site, Delray Beach, Florida, United States|Novartis investigative site, Fort Lauderdale, Florida, United States|Novartis investigative site, Gainesville, Florida, United States|Novartis investigative site, Miami Beach, Florida, United States|Novartis investigative site, Pompano Beach, Florida, United States|Novartis investigative site, Port Charlotte, Florida, United States|Novartis investigative site, Sunrise, Florida, United States|Novartis investigative site, West Palm Beach, Florida, United States|Novartis investigative site, Atlanta, Georgia, United States|Novartis investigative site, Macon, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis investigative site, Chicago, Illinois, United States|Novartis investigative site, Springfield, Massachusetts, United States|Novartis investigative site, Flint, Michigan, United States|Novartis investigative site, Flushing, Michigan, United States|Novartis investigative site, Roseville, Michigan, United States|Novartis investigative site, Traverse City, Michigan, United States|Novartis investigative site, Hattiesburg, Mississippi, United States|Novartis investigative site, Ocean Springs, Mississippi, United States|Novartis investigative site, Columbia, Missouri, United States|Novartis investigative site, St. Louis, Missouri, United States|Novartis investigative site, Flemington, New Jersey, United States|Novartis investigative site, Nutley, New Jersey, United States|Novartis investigative site, Somerset, New Jersey, United States|Novartis investigative site, Albany, New York, United States|Novartis investigative site, Syracuse, New York, United States|Novartis investigative site, Greensboro, North Carolina, United States|Novartis investigative site, Morganton, North Carolina, United States|Novartis investigative site, Winston-Salem, North Carolina, United States|Novartis investigative site, Winston-Salem, North Carolina, United States|Novartis investigative site, Canton, Ohio, United States|Novartis investigative site, Columbus, Ohio, United States|Novartis investigative site, Corvallis, Oregon, United States|Novartis investigative site, Portland, Oregon, United States|Novartis investigative site, Beaver, Pennsylvania, United States|Novartis investigative site, Erie, Pennsylvania, United States|Novartis investigative site, Greensburg, Pennsylvania, United States|Novartis investigative site, Pittsburgh, Pennsylvania, United States|Novartis investigative site, Beaufort, South Carolina, United States|Novartis investigative site, Summerville, South Carolina, United States|Novartis investigative site, Brentwood, Tennessee, United States|Novartis investigative site, Nashville, Tennessee, United States|Novartis investigative site, Dallas, Texas, United States|Novartis investigative site, Fort Worth, Texas, United States|Novartis investigative site, Irving, Texas, United States|Novartis investigative site, Charleston, West Virginia, United States|Novartis investigative site, Huntington, West Virginia, United States|Novartis investigative site, Toronto, Ontario, Canada|Novartis investigative site, Calgary, Canada|Novartis investigative site, Edmonton, Canada|Novartis investigative site, Greenfield Park, Canada|Novartis investigative site, Halifax, Canada|Novartis investigative site, London, Canada|Novartis investigative site, Montreal, Canada|Novartis investigative site, Ottawa, Canada|Novartis investigative site, Peterborough, Canada|Novartis investigative site, Quebec, Canada|Novartis investigative site, Regina, Canada|Novartis investigative site, Toronto, Canada|Novartis investigative site, Vancouver, Canada|Novartis investigative site, Winnipeg, Canada|Novartis investigative site, Fains Veel, Alsace Lorraine, France|Novartis investigative site, Dijon, Burgundy, France|Novartis investigative site, Reims, Champagne-Ardenne, France|Novartis investigative site, Bordeaux, France|Novartis investigative site, Bourg en Bresse, France|Novartis investigative site, Caen, France|Novartis investigative site, Cherbourg, France|Novartis investigative site, Dijon, France|Novartis investigative site, Limoges, France|Novartis investigative site, Montpellier, France|Novartis investigative site, Nice, France|Novartis investigative site, Paris, France|Novartis investigative site, Rennes, France|Novartis investigative site, Rodez, France|Novartis investigative site, Bad Neustadt/Saale, Germany|Novartis investigative site, Berlin, Germany|Novartis investigative site, Bonn, Germany|Novartis investigative site, Burg, Germany|Novartis investigative site, Duesseldorf, Germany|Novartis investigative site, Frankfurt, Germany|Novartis investigative site, Giessen, Germany|Novartis investigative site, Koln, Germany|Novartis investigative site, Krefeld, Germany|Novartis investigative site, Leipzig, Germany|Novartis investigative site, Magdeburg, Germany|Novartis investigative site, Mannheim, Germany|Novartis investigative site, Marburg, Germany|Novartis investigative site, Muenchen, Germany|Novartis investigative site, Muenster, Germany|Novartis investigative site, Nuernberg, Germany|Novartis investigative site, Stralsund, Germany|Novartis investigative site, Stuttgart, Germany|Novartis investigative site, Wurzburg, Germany|Novartis investigative site, Milano, Milan, Italy|Novartis investigative site, Ancona, Italy|Novartis investigative site, Arcugnano, Italy|Novartis investigative site, Arezzo, Italy|Novartis investigative site, Bari, Italy|Novartis investigative site, Bologna, Italy|Novartis investigative site, Brescia, Italy|Novartis investigative site, Cagliari, Italy|Novartis investigative site, Catania, Italy|Novartis investigative site, Città di Castello, Italy|Novartis investigative site, Cremona, Italy|Novartis investigative site, Ferrara, Italy|Novartis investigative site, Firenze, Italy|Novartis investigative site, Foggia, Italy|Novartis investigative site, Genova, Italy|Novartis investigative site, La Spezia, Italy|Novartis investigative site, Milano, Italy|Novartis investigative site, Milan, Italy|Novartis investigative site, Modena, Italy|Novartis investigative site, Napoli, Italy|Novartis investigative site, Padova, Italy|Novartis investigative site, Pavia, Italy|Novartis investigative site, Perugia, Italy|Novartis investigative site, Pisa, Italy|Novartis investigative site, Rho, Italy|Novartis investigative site, Rome, Italy|Novartis investigative site, Torino, Italy|Novartis investigative site, Verona, Italy|Novartis investigative site, Barcelona, Spain|Novartis investigative site, Palma de Mallorca, Spain|Novartis investigative site, Basel, Switzerland|Novartis investigative site, Biel, Switzerland|Novartis investigative site, Mendrisio, Switzerland		https://ClinicalTrials.gov/show/NCT00506415
1194	NCT03352024	Impact of Hypno-analgesia on Pain During a Lumbar Puncture for Diagnosis of Alzheimer's Disease	PLHYMANEDE	Withdrawn	No Results Available	Cognitive Impairment|Alzheimer Disease	Other: Relational care|Other: Hypno-analgesia	Algoplus score of pain during the LP procedure|Rate of failure of the Lumbar Ponction|Evaluation of the anxiety|Evaluation of the pain|Evaluation of the pain by the patient	University Hospital, Montpellier	All	50 Years to 90 Years   (Adult, Older Adult)	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	9731	January 2018	November 2020	November 13, 2020	November 24, 2017		November 24, 2020			https://ClinicalTrials.gov/show/NCT03352024
1195	NCT05102201	Effect of the Group-based Paro Intervention on Physiological and Psychological Outcomes		Recruiting	No Results Available	Dementia, Mild|Dementia Moderate|Cognitive Impairment	Device: Paro (social robot) intervention	Oxytocin|Finger tapping test (FTT)|HRV measurements|The Chinese version of Mini-Mental State Examination (MMSE)|Core components of executive functions- WM and response inhibition|Core components of executive functions- WM(1) -Verbal WM task|Core components of executive functions- WM(2)-Visuo-spatial WM task|Core components of executive functions- response inhibition (1)-Color word Stroop task|Core components of executive functions- response inhibition (2)-Stop signal task|Core components of executive functions- response inhibition (3)-Go/no-go task|Geriatric Depression Scale - Short Form (GDS-SF)|The UCLA Loneliness Scale version 3 (UCLA-3)|Warwick-Edinburgh Mental Well-being Scale (WEMWBS)|Group atmosphere|Group satisfaction	National Tainan Junior College of Nursing	All	65 Years and older   (Older Adult)	Not Applicable	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research	Shu-Chuan Chen	March 22, 2022	May 24, 2022	May 30, 2022	November 1, 2021		June 1, 2022	National Cheng Kung University Hospital Dou-Liou Branch, Douliu, Taiwan	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/01/NCT05102201/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT05102201
1196	NCT05433493	Effect of Individual Cognitive Stimulation on Memory and Executive Function in Older Adults With Alzheimer's Disease		Recruiting	No Results Available	Dementia|Neurocognitive Disorders|Cognitive Impairment|Cognitive Dysfunction|Cognitive Decline	Behavioral: Cognitive stimulation	Cognitive functioning assessed through Mini-Mental State Examination (MMSE)|Change in cognitive functioning assessed through Mini-Mental State Examination (MMSE)|Cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)|Change in cognitive functioning assessed through Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-COG)|Memory function evaluated through Memory Alteration Test (MAT)|Change in memory function evaluated through Memory Alteration Test (MAT)|Memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)|Change in memory function evaluated through Free and Cued Selective Reminding Test (FCSRT)|Executive functions assessed through Frontal Assessment Battery (FAB)|Change in executive functions assessed through Frontal Assessment Battery (FAB)|Executive functions assessed through Trail Making Test (TMT)|Change in executive functions assessed through Trail Making Test (TMT)	Rsocialform - Geriatria, Lda|Aveiro University	All	65 Years and older   (Older Adult)	Not Applicable	150	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	20220621	July 1, 2022	September 1, 2022	March 31, 2023	June 27, 2022		August 2, 2022	Rsocialform - Geriatria, Lda, Mealhada, Aveiro, Portugal|Cediara - Associação de Solidariedade Social de Ribeira de Fráguas, Aveiro, Portugal|Santa Casa da Misericórdia da Horta, Açores, Portugal|Santa Casa da Misericórdia de Mirandela, Bragança, Portugal|Centro Social e Cultural S. Pedro de Bairro, Braga, Portugal|Centro Social Vale do Homem - Casa da Alegria, Braga, Portugal|Residência Sénior Don António, Castelo Branco, Portugal|Santa Casa da Misericórdia de Castelo Branco, Castelo Branco, Portugal|Associação de Promoção Social, Cultural e Desportiva de Fornos de Algodres, Guarda, Portugal|Fundação João Bento Raimundo, Guarda, Portugal|Associação Bem Estar para a Terceira Idade de Santiago de Litém, Leiria, Portugal|Santa Casa da Misericórdia de Alcobaça, Leiria, Portugal|Associação de Socorros da Freguesia de Turcifal, Lisboa, Portugal|Centro de Apoio Social de Oeiras - IASFA, Lisboa, Portugal|Inválidos do Comércio, Lisboa, Portugal|Associação de Apoio Social de Perafita, Porto, Portugal|Associação de Desenvolvimento da Vila de Paço de Sousa -Lar e Centro de dia Padre Américo, Porto, Portugal|ASSTIR - Associação de Solidariedade Social S. Tiago de Rebordões, Porto, Portugal|Centro Social e Paroquial de Recarei, Porto, Portugal|Santa Casa da Misericórdia de Santo Tirso, Porto, Portugal|Santa Casa da Misericórdia de Coruche, Santarém, Portugal|Santa Casa da Misericórdia de Ponte de Lima, Viana Do Castelo, Portugal|Associação de Solidariedade Social da Freguesia de Abraveses, Viseu, Portugal|Santa Casa da Misericórdia de Vouzela, Viseu, Portugal		https://ClinicalTrials.gov/show/NCT05433493
1197	NCT02042001	Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects	SWEAR	Completed	No Results Available	Impaired Cognition|Depression/Anxiety|Poor Quality Sleep|Quality of Life|HIV-1 Infection	Drug: Immediate switch to TDF/FTC/RPV|Drug: Switch to TDF/FTC/RPV after 24 weeks	Neuropsychiatric side effects|Neurocognitive side effects|Composite neuropsychiatric/neurocognitive|Symptoms|Quality of Life|Cognitive failure|Viral suppression|Viral failure|Virological efficacy|Safety & Tolerability	Azienda Ospedaliera San Gerardo di Monza|Gilead Sciences	All	18 Years and older   (Adult, Older Adult)	Phase 4	74	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IN-IT-264-1331	July 1, 2015	July 3, 2017	January 15, 2018	January 22, 2014		July 5, 2018	Clinic of Infectious Diseases, AO San Gerardo, Monza, MB, Italy|Spedali Civili - University of Brescia, Brescia, Italy|Clinica di Malattie Infettive, Ospedale San Martino, Genova, Italy|AO San Paolo - University of Milan, Milan, Italy|Ospedale Amedeo di Savoia - University of Turin, Torino, Italy		https://ClinicalTrials.gov/show/NCT02042001
1198	NCT01598532	Effects of LEDs on Memory in TBI Patients	LED	Completed	Has Results	Traumatic Brain Injury	Device: MedX Health Phototherapy (light therapy)	Stroop Test for Executive Function - Trial 3 - Inhibition|Stroop Test for Executive Function - Trial 4 Inhibition Switching|California Verbal Learning Test-II (CVLT-II) Total, Trials 1-5|California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall|Controlled Oral Word Association Test (FAS)|Digit Span, Forwards and Backwards	Spaulding Rehabilitation Hospital	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	22	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-P-001552	September 2009	March 2013	March 2013	May 15, 2012	August 22, 2016	September 30, 2016	Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01598532
